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Editorial
2013 European Multidisciplinary Cancer Congress
Education Book
Irving Taylor
1. Introduction
It is my pleasure to present, on behalf of the European Cancer
Organisation, the education book for the 2013 European Mul-
tidisciplinary Cancer Conference.
The comprehensive educational programme for the con-
ference has been developed as a result of the collaborative
work of both the scientific and educational committees of
ECCO.
Readers will note that the book covers a number of impor-
tant topics relating to common solid malignancies with the
overall theme of achieving an optimal approach and therefore
optimal results for our patients.
The topics covered are localised rectal cancer, early breast
cancer, resectable non-small-cell lung cancer, renal cancer
and melanoma. We have also included an extremely impor-
tant section on the mood disorders in cancer patients.
In each chapter relating to specific solid tumours, an ap-
proach to achieving optimal outcomes is discussed by a con-
sideration of the basic biological characteristics of the tumour
and its clinical management, as well as the integration of the
two. It is remarkable how similar the basic principles of man-
agement for each of the tumours are. For example, the impor-
tance of careful preoperative staging with modern imaging
and good, careful and fastidious surgical resection is crucial
and strongly emphasised. For this to be achieved, specialised
understanding of the biology of the tumour and its anatomi-
cal confines is essential. Accordingly surgical specialisation is
now amandatory requisite since outcome correlates with vol-
ume of patients treated.
The importance of a careful pathological examination is
emphasised, not only to determine prognosis but also to
determine the most effective adjuvant and in some cases,
neoadjuvant treatment that is required.
There is increasing emphasis on personalised treatment
determined by biological variables, and this is also empha-
sised in each chapter. In addition, the morbidity and indeed
mortality associated with the specific modalities of treatment
are documented so that risk–benefit analyses can be
assessed.
As clinicians, we must not ignore the importance of eco-
nomic consequences and resource implications of treat-
ments, and this societal concern is also discussed. Finally,
the importance of an integrated multidisciplinary approach
to the management of these tumours is emphasised by all
authors.
The authors of each chapter are to be congratulated for
providing excellent up-to-date reviews backed by detailed
and comprehensive lists of key references which include all
the major randomised clinical trials and meta-analyses for
the particular malignancy. Readers will find this particularly
useful in determining their decision-making.
I would like to thank all our authors and Chairs for their
hard work in providing chapters for this educational book,
and I hope our readers find their efforts worthwhile. I am par-
ticularly grateful to Samira Essiaf for her invaluable expertise
in preparing the book and dealing with all the administration.
I do hope you find the chapters helpful and of educational
benefit and enjoy reading them as much as I enjoyed editing
them.
1359-6349/$ - see front matter Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
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The optimal approach to early breast cancer
Lynda Wyld *
University of Sheffield, Academic Unit of Surgical Oncology, Royal Hallamshire Hospital, UK
Breast cancer outcomes continue to improve, with 5-year
survival rates having increased from 50% in the 1970s to
nearly 80% today. The reasons for the improvement are mul-
tifactorial, with major contributions made by the advent of
screening and improved systemic therapies such as anti-oes-
trogens, chemotherapy and trastuzumab. Running alongside
this improvement in breast-cancer-specific survival has been
an increasing realisation that preservation of the breast, with-
out compromise on rates of local control, is important for
quality of life. This has led to progress in techniques of breast
reconstruction and breast conservation, with oncoplastic
techniques to reshape the breast, minimising distortion and
asymmetry and increasing the use of primary systemic ther-
apy to enhance rates of conservation. Whilst surgery to the
breast itself is becoming more complex, surgery to the axilla
is becoming less extensive as there is an increasing realisa-
tion that the main value of identifying axillary disease is
not to enhance survival, or even local control, but to give
prognostic information to guide adjuvant therapies. This
drive has seen a move away from axillary clearance to senti-
nel-node biopsy, and perhaps eventually only axillary imag-
ing assessment, with the development of increasingly
sensitive tests such as magnetic resonance imaging (MRI)
and positron emission tomography (PET) [1].
The changes to practice have been driven by research evi-
dence, and the overarching theme is that of individualised
therapy. This is true of all the disciplines in the breast care
team. Surgery is now tailored to the woman’s disease, breast
shape and size and personal preferences, and in most cases
women may be offered surgery that will retain, restore or
even enhance her breasts should she so wish. Radiotherapy
is increasingly targeted to maximise the dose to the breast
whilst reducing the dose to the surrounding tissues using
highly complex computed-tomography-guided planning
(tomotherapy and intensity-modulated radiation therapy,
IMRT). Perhaps the most complex area of all is the interplay
between the molecular pathology of the tumour and the sys-
temic therapy which is offered. Tumour stage, grade and oest-
rogen receptor status have now been supplemented with
Her2 status, and increasingly the proliferation index, Ki67,
resulting in a new classification (luminal A, B, Her2+ and
basal-like) [2] which guides prognosis and predicts treatment
response. More detailed recurrence risk assessments may be
provided by multigene arrays such as Oncotype DxTM (Geno-
mic Health, United States of America (USA)) [3] and Mamma-
PrintTM (Agendia BV, The Netherlands) [4] which may further
aid decisions about chemotherapy benefits.
The future for breast cancer treatment will hold evenmore
individualised treatment plans than the complex schedules
on offer today. Next-generation sequencing opens up the pos-
sibilities for identification of even more complex gene signa-
tures [5], which may permit customised therapies with
some of the bewildering array of targeted molecular therapies
under development. Increasing rates of complete pathological
responses to primary systemic therapy may lead to ‘no sur-
gery’ options: something which is currently being trialled in
respect of both the axilla and the breast.
Central to all of the above is the close working relation-
ship of the breast multidisciplinary team. Each must have
not only expertise in their own discipline but awareness
of what their colleagues can (and cannot) achieve, so that
every patient receives an individualised treatment plan that
fits together like a perfect jigsaw, with every piece comple-
menting the others.
The following articles have been written by some of
the world leaders in the field of breast care, and exem-
plify these principles of individualised care and
multidisciplinarity.
Conflict of interest statement
None declared.
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Optimal approach in early breast cancer: Adjuvant
and neoadjuvant treatment
J. Ribeiro, B. Sousa, F. Cardoso *
Champalimaud Cancer Center, Breast Unit, Lisbon, Portugal
1. Introduction
The treatment of early breast cancer (EBC) is becoming
increasingly complex, but also more effective as a better
understanding of cancer biology is achieved with evolving re-
search. Longer follow-up of prospective trials is crucial to
evaluate the impact of current standard treatments in long-
term outcome and safety. In this review we will summarise
the current evidence for optimal treatment of EBC.
2. Which EBC patients can safely avoid
adjuvant chemotherapy?
In the 1980s there were substantial advances in the treatment
of breast cancer (BC), and the results of several large random-
ised trials indicated that adjuvant systemic therapy could de-
crease breast-cancer mortality by about 20%. In fact, the
widespread application of adjuvant systemic therapy is con-
sidered the main cause for the declining breast cancer mor-
tality observed in the Western world.
Treatment decisions are based on clinical (biological age,
comorbidities, performance status) and pathological variables
– tumour size, lymph-node status, histological grade, oestro-
gen receptor (ER), progesterone receptor (PR), HER2 and prolif-
eration – that can be combined in the form of algorithms (e.g.
Adjuvant!Online, Nottingham prognostic index) and form the
basis of treatment for guidelines such as the ones from the
European Society for Medical Oncology (ESMO), the National
Comprehensive Cancer Network (NCCN), and St Gallen. How-
ever, it is clear that still too many patients receive this therapy
with little likelihood of benefit and substantial toxicity.
In this section, available data on biomarkers and molecu-
lar tests related to prognostication will be reviewed. In the
first part we will address the evidence and utility for adjuvant
treatment decisions of biomarkers of proliferation (namely
Ki67) and urokinase plasminogen activator (uPA)/plasmino-
gen activator inhibitor (PAI-1). In the second part we will
assess the practical contribution of gene expression profiling
in breast cancer.
2.1. Biomarkers
2.1.1. Markers of proliferation – Ki67
Uncontrolled proliferation is a driver for cancer and is one of
the hallmarks of this disease. In general, markers of an ele-
vated proliferative rate correlate with a worse prognosis in
untreated patients and may add predictive information
regarding benefit from chemotherapy (CT) [1]. The most com-
monly used method to measure proliferation involves immu-
nohistochemical (IHC) detection of the nuclear non-histone
protein ki67, which is detected only in proliferating cells.
Ki67 expression is commonly assessed using the mindbomb
E3 ubiquitin protein ligase 1 antibody (MIB1) and reported as
a percentage of cells positive for Ki67.
2.1.2. Prognostic marker
Various studies have investigated the role of Ki67 as a prog-
nostic marker. In a meta-analysis of 40 studies, involving over
11,000 patients, baseline Ki67 was found to have a modest
prognostic value in multivariable analysis, which was more
evident in lymph-node-negative patients [2]. In another
meta-analysis of 46 studies including over 12,000 patients,
Ki67 positivity (using cut-offs defined by individual authors)
was associated with a higher risk of relapse and a worse sur-
vival in patients with EBC [3]. One must highlight several lim-
itations of these data: namely the facts that these are
retrospective studies, many include heterogeneous groups
of patients who were treated and followed in various ways
that are often incompletely documented, and ki67 methodol-
ogy and cutoff varied widely.
The clinical utility of Ki67 as a prognostic marker is more
apparent when it is considered within more narrowly defined
tumour subgroups and/or as part of a multiparameter panel
of biomarkers, as for example in the IHC4 [4]. Other investiga-
tors have reported that Ki67 is an important part of a prognostic
1359-6349/$ - see front matter Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
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algorithm for residual risk in EBC patients treated with letroz-
ole or tamoxifen [5].
2.1.3. Predictive marker
Studies have focused on the predictive value of this bio-
marker regarding benefit from CT or even from specific CT
agents. In the ER-positive BC the results are contradictory.
In the recently reported PACS 001 and BCIRG 001, high levels
of Ki67 were predictive of benefit from adding docetaxel to
fluorouracil, epirubicin and cyclophosphamide (FEC) CT as
adjuvant treatment [6]. However, these results contrast with
those from the International Breast Cancer Study Group Trials
(IBCSG) VIII and IX that found no predictive value of Ki67 lev-
els for the addition of cyclophosphamide, methotrexate and
fluorouracil (CMF) to endocrine therapy (ET) in endocrine-
responsive node-negative disease [7]. For ER-negative BC data
to suggest that Ki67 predicts adjuvant chemotherapy re-
sponse are scarce. However, taking into account all the avail-
able evidence that these tumours as a group are more
responsive to chemotherapy than ER-positive tumours [8,9],
one can hypothesise that higher chemotherapy sensitivity ob-
served in patients with ER-negative tumuors is at least par-
tially due to the consistently higher rates of proliferation of
these tumours. If so, Ki67 levels may be helpful in identifying
those patients most likely to benefit from chemotherapy [10].
In spite of consistent data on Ki67 as a prognostic marker
in early breast cancer, its role in breast cancer management
remains uncertain [11], mainly because of the lack of stan-
dardisation. In 2007 the ASCO Tumour Marker Guidelines sta-
ted that evidence supporting the clinical utility of Ki67 was
insufficient to recommend its routine use for prognostic pur-
poses in patients with newly diagnosed breast cancer [12].
However, in the St Gallen Consensus guidelines from 2011
[13] and 2013 most panelists recommend the use of Ki67 for
BC subtyping classification, prognostication and prediction
of response to CT, although there is no consensus on the best
cut-off to be used.
The limitations of this assay are largely related to the dif-
ficulty in interpreting the literature due to lack of standardisa-
tion of assay reagents, procedures and scoring. To overcome
these constraints in 2011 the International Ki67 in Breast Can-
cer Working Group published recommendations for Ki67
assessment in breast cancer [14]. These guidelines aim to
minimise pre-analytical and analytical variables in Ki67
assessment and harmonise scoring methodology and data
handling, facilitating its routine use in clinical practice.
2.1.4. Urokinase plasminogen activator/plasminogen
activator inhibitor
uPA and PAI-1 biomarkers are invasion biomarkers analysed
by a protein-based enzyme-linked immunosorbent assay (ELI-
SA). They can be used to determine the recurrence risk in pa-
tients with node-negative EBC with the aim of better refining
the decision to recommend CT in this patient population.
uPA is a serine protease with an important role in cancer
invasion and metastases [15]. When bound to its receptor
(uPAR), uPA converts plasminogen into plasmin and mediates
degradation of the ECM during tumour-cell invasion. PAI-1
levels are high in tumour tissue and plasma, and PAI-1 is inac-
tivated when bound to uPA.
Several retrospective studies [16,17] and a large pooled
analysis of individual patient data from 8377 women treated
in clinical trials by the European Organisation for the Re-
search and Treatment of Cancer (EORTC) [18], in which tu-
mour uPA and PAI-1 levels were determined in primary
tumour tissue extracts, proved that high levels of uPA, uPAR,
and PAI-1 are associated with shorter survival in women with
both node-negative and node-positive disease.
The Chemo N0 is a prospective, multicentre randomised
trial in which researchers stratified patients with node-nega-
tive BC into two groups according to the presence of low or
high uPA/PAI-1 values. Those with low values of both uPA
and PAI-1 received observation only, whereas those with high
uPA and/or PAI-1 values were randomised to receive either
CMF or observation. The 10-year follow-up updated analysis
showed that: low-risk N0 patients according to the uPA/PAI-
1, thus without any systemic therapy, had an excellent prog-
nosis, with a 10-year survival rate of almost 90% [19], while
the high-risk patients according to the uPA/PAI-1 had a 1.84-
fold higher disease recurrence risk (P = 0.017) than the low-
uPA/PAI-1. Additionally, the assay predicted, in the high-risk
population, the benefit from CT [20]. These results provide
for the first time long-term follow-up from a prospective bio-
marker-driven clinical trial in cancer.
The Node-Negative Breast Cancer (NNBC)-3 study is a pro-
spective multicentre phase III therapy trial, with the aim of
comparing risk assessment and clinical outcome on the basis
of tumour-biological factors uPA/PAI-1 with those based on
established, clinical and pathomorphological factors in
high-risk node-negative BC patients. It enrolled more than
4000 patients, stratified into low-risk and high-risk groups
according to the uPA/PAI-1 value or according to the clinical
pathological algorithm. Those classified as low risk did not re-
ceive CT, whereas those classified as high risk received either
six cycles of FEC or three cycles of FEC and three cycles of
docetaxel [21]. In the West German Study Group Plan B trial,
a prospective comparison of recurrence score (RS) – Onco-
typeDx – and independent central pathology assessment of
prognostic tools was performed. The study randomised 2361
patients; 18% had a recurrence score of 0–11 (low risk), 61%
had a recurrence score of 12–25 (intermediate risk), and 21%
had a recurrence score of >25 (high risk). A weak correlation
was found between uPA/PAI-1 and RS. These data showed
that high-risk status according to RS is well correlated with
high risk by uPA/PAI-1; however, there was substantial heter-
ogeneity in risk assessment in the low- and intermediate-risk
RS groups in which some patients are still considered to be
high risk according to uPA/PAI-1 [22].
2.2. Gene-expression-based assays
Gene expression profiling has identified several molecular sig-
natures that mostly have prognostic value and some predic-
tion value.
2.2.1. First-generation prognostic signatures – MammaPrintTM
MammaPrintTM is a microarray-based gene-expression-profil-
ing assay that measures the levels of expression of 70 genes
related to proliferation, invasion and angiogenesis. The assay
accurately categorises patients in poor and good prognosis
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groups on the basis of the development or not of distant
metastases within 5 years. Initially requiring fresh or frozen
samples, it can now be effectively performed in formalin-
fixed paraffin-embedded specimens (FFPE).
The initial data were derived from 78 patients with node-
negative BC, 65 cm, the vast majority of whom had ER-posi-
tive tumours and did not receive adjuvant systemic treatment
[23]. The validation cohort included 295 node-negative pa-
tients, of whom 61 were from the initial study, and confirmed
MammaPrintTM independent prognostic value beyond stan-
dard clinicopathological variables in this patient population
[24]. The TRANSBIG consortium carried out an independent
retrospective validation of MammaPrintTM using samples from
nine European countries, which further confirmed the prog-
nostic value of this tool [25]. Additional validation studies
were performed in node-positive EBC patients [26] and in
HER2+ EBC patients [27].
MammaPrintTM is the first FDA-approved gene-expression-
based assay to be used as a prognostic test in EBC patients.
The clinical utility of this assay is being prospectively evalu-
ated in the large, randomised MINDACT trial that enrolled
6690 EBC N0–N3 patients [28].
2.2.2. Oncotype DxTM recurrence score
Oncotype DxTM is a quantitative reverse transcriptase–poly-
merase chain reaction- (qRT–PCR-) based signature that mea-
sures the expression of 21 genes (16 cancer-related and five
reference genes), performed using RNA from FFPE tumour tis-
sues. With this multigene predictor assay a mathematical
function (named recurrence score, RS) aiming at predicting
the risk of distant relapse for patients with ER-positive,
lymph-node-negative breast cancer treated with tamoxifen
was developed based on the analysis of clinical samples from
the NSABP B-20 clinical trial [29]. The RS is a continuous var-
iable, ranging from 0 to 100, which translates into three risk-
group categories: low (RS < 18), intermediate (RS from 18 to
<31) and high (RS < 31).
OncotypeDxTM was then validated in a large cohort of ER-
positive, node-negative, tamoxifen-treated BC patients from
the NSABP-B14 trial [30]. The assay was able to stratify a gen-
erally good prognosis population into distinct subgroups (low,
intermediate, or high score) with different rates of distant
recurrence at 10 years (7%, 14% and 31% respectively. Onco-
typeDxTM RS was shown to be strongly associated with sur-
vival from breast cancer and independent from standard
clinicopathological variables [30,31]. Subsequent analysis re-
vealed that RS also seems to correlate with benefit from che-
motherapy in ER-positive BC [32]. The optimal management
of the intermediate-risk group is being addressed in the TAI-
LORx trial (NCT00310180) in which 11,248 patients with ER-
positive, node-negative breast cancer and intermediate risk
(RS 11–25) were randomly assigned to hormone treatment
either alone or in combination with chemotherapy.
Additional validation studies evaluated OncotypeDxTM in
EBC patients with ER-positive disease treated with AI [33]
and ER-positive node-positive BC patients [34].
The RxPONDER trial will randomise 4000 women with N1
disease and an RS of 625 to endocrine therapy with or with-
out chemotherapy [35].
While waiting for MINDACT and TAILORx results, interna-
tional recommendations support the selected use of Mamma-
PrintTM and Oncotype DxTM in the ER + EBC patients in whom
standard clinical/pathological factors are considered insuffi-
cient for adjuvant CT decisions.
2.2.3. PAM50
PAM50 assay provides a risk-of-relapse (ROR) score prognostic
of relapse-free survival for patients with node-negative BC
who did not receive adjuvant systemic therapy [36]. This as-
say is composed of 50 genes (derived from tumour samples
of 220 patients in the training set who had ER-positive or
ER-negative tumours and HER2+ or HER2-negative tumours)
related to proliferation, ER-regulated genes, HER2, and basal
and myoepithelial characteristics. It is compatible with
FFPE-derived RNA or qRT-PCR using FF tissue.
The prognostic ability of the PAM50 has been validated in
an independent test set of 786 patients with ER-positive dis-
ease treated only with adjuvant tamoxifen [37].
An ROR model containing a proliferation component (de-
rived using 11 genes associated with cell-cycle function)
was recently added to the original model.
2.2.4. Genomic grade index
The genomic grade index (GGI) is a gene expression signature
developed to better define histological grade assessment with
the ability to divide classic histological grade into low and
high risk. It was developed to overcome the limitation issues,
namely reproducibility, associated with the histological grade
assessment and was developed using a ‘‘bottom-up’’ ap-
proach whereby 97 genes associated with histological grade
were identified and subsequently related to clinical outcome
[38].
The intrinsic prognostic information of proliferation genes
seems to be better evaluated with the GGI than with classic
histological grade as shown in a population of 570 patients
for which complete recurrence-free survival (RFS) and histo-
logical grade was available [24,39,40]. The GGI was able to fur-
ther stratify the subset of histological grade 2 patients into
two subgroups: a grade 1 gene-like profile and a grade 3
gene-like profile with clearly different rates of relapse. Pa-
tients falling in the HG2-GGI3 category revealed a significantly
higher rate of relapse than the HG2-GG1 (HR = 3.61; confi-
dence interval (CI) 2.25–5.78; P < 0.001). In the overall popula-
tion the GGI was also able to stratify patients into two risk
categories with significant differences in RFS rates (high ver-
sus low risk; HR = 2.83; CI 2.13–3.77; P < 0.001).
In addition to prognostic prediction, the GGI ability to pre-
dict response neoadjuvant CT has also been evaluated [41]. In
a study with 229 tumour samples collected before the begin-
ning of CTwith docetaxel and to fluorouracil, doxorubicin and
cyclophosphamide (FAC) a high GGI was associated with
greater response than low-risk GGI (40% versus 12%;
P < 0.001).
2.2.5. Second generation prognostic signatures – genes related
to immune response
Several studies have recently analysed the prognostic role of
tumour-associated lymphocytes (TIL) in breast cancer, mainly
in the triple-negative subtype [42,43]. A link between increased
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lymphocytic infiltrate and reduced relapse rate and improved
survival has been suggested. The expression of genes related
to immune response has also been shown to provide important
prognostic information in ER-negative and in highly prolifera-
tive ER-positive BC [44–47]. Jointly there is evidence to suggest
that both the concentration of inflammatory infiltrate defined
by IHC and expression of B-cell or plasma-cell metagene de-
fined by microarray-based gene-expression profiling are likely
to provide important prognostic information.
2.2.6. Stroma-related prognostic gene signatures
The development of stroma-related prognostic gene signa-
tures is an evolving field of great scientific interest; however,
independent validation of their prognostic accuracy is still
needed before clinical application.
3. Which are the current major challenges
regarding neoadjuvant systemic therapy?
3.1. Advantages of neoadjuvant systemic treatment and
end-points for clinical trials
Neoadjuvant therapy (NT) is the standard of care for women
with locally advanced, inflammatory or inoperable primary
breast cancer (BC) [48–51]. Currently, based on the results of
landmark trials NSABP B-18 and NSABP B-27, NT is mainly
used in operable disease to improve the surgical options, to
determine the response to chemotherapy and to obtain
long-term DFS [52–56].
Pathological complete response (pCR) has been considered
predictive of long-term outcome in several neoadjuvant trials
[57], and this finding has been confirmed in two recent studies
[58,59]. The meta-analysis from the Collaborative Trials in Neo-
adjuvant Breast Cancer [58] included 12 randomised neoadju-
vant trials (n = 13,125) and results have shown that individual
patients who achieved a pCR (ypT0ypN0 or ypT0/isypN0) had
a more favourable long-term outcome. This effect was only
seen in HR+/grade 3, triple-negative and HER2+ tumours and
not in low-grade hormone-receptor-positive tumours. Simi-
larly, in the pooled analysis of seven prospective trials
(n = 6000) published by the German Group [59] pCR was associ-
ated with improved DFS in tumours luminal B/HER2-negative,
HER2+/nonluminal, and triple-negative. These recent data
establish pCR as a surrogate marker for survival but emphasise
that it is not an adequate endpoint for slow proliferative tu-
mours (grade 1 or 2, HR+). Additionally, it was not possible to
determine the magnitude of increase in pCR rates predictive
of superior long-term outcome of a specific therapy of a clini-
cally meaningful improvement in survival [60]. These findings
led the FDA to support certain drug development programmes
throughout NT trials using pCR for accelerated approval [61].
Neoadjuvant trials are also recognised as important research
tools, particularly in the field of biomarkers.
3.2. Which chemotherapy and targeted therapy regimens
in the neoadjuvant setting. Are there predictive markers?
Anthracycline/taxane-based CT regimens have been the most
extensively studied in the neoadjuvant setting, but so far no
specific regimen has been found to be clearly superior. Incor-
poration of taxanes has increased the response rates
[54,62,63] with large phase III trials reporting pCR rates of
15–20% [57,64,65]. The studies that have accessed tailoring
treatment to response [63,65–67] have not confirmed a clear
benefit from changing to a non-cross-resistant regimen.
In this regard efforts have been made to study biological
markers predictive of pCR. The integrated meta-analysis [68]
on individual data from the German Breast Group and the
AGO Breast Group, on 6402 patients enrolled in neoadjuvant
trials has shown that a greater chance of pCR was seen in
ER-negative patients (OR 3.2; P < 0.0001), HER2+ disease (OR
2.2; P < 0.0001), higher grade (OR 1.8; P < 0.0001), younger age
(OR 1.3; P = 0.0001), non-lobular type tumours (OR 1.7;
P = 0.001) and smaller tumour size (OR 1.5; P = 0.0006). Fur-
thermore, this group recently published a pooled analysis
assessing the prognostic impact of different definitions of
pCR and the outcome regarding the biological intrinsic breast
cancer subtypes [59]. It was found that pCR was associated
with improved DFS in tumours luminal B/HER2-negative
(P < 0.005), HER2+/nonluminal (P < 0.001) and triple-negative
tumours (P < 0.001) but not in luminal A (P = 0.39) or in lumi-
nal B/HER2+ (P = 0.45) tumours. Despite the fact that tumours
lacking expression of ER have higher pCR, exceeding 40% in
some studies, overall patient survival with this phenotype is
still shorter than in patients with hormone-receptor-positive
disease [9]. However, recent data show that patients with
HER2+/nonluminal and triple-negative disease who achieved
pCR have an excellent prognosis [58,59].
Mutations in p53 were shown not to be predictive of re-
sponse to taxanes in the large randomised multicentric neo-
adjuvant trial EORTC 10994/BIG 1-00 [69]. Some studies have
generated preliminary gene signatures with potential predic-
tive value for docetaxel and paclitaxel plus FAC [70,71] but
these signatures have not yet been validated in subsequent
studies and are not ready for use in clinical practice. More re-
cent studies suggest that prediction of response to a specific
CT agent is different among the different BC subtypes and is
more likely to be achieved by using multifactorial tools
[59,72–75]. HER2 over-expression/amplification predicts re-
sponse to treatment with the monoclonal antibody trast-
uzumab [76], and has also been associated with a better
response to anthracyclines [77,78]. It is uncertain whether
the latter effect is linked to the co-amplification of topoiso-
merase IIa as mixed results have been obtained [78,79]. The
association between HER2+ and response to taxanes sug-
gested in some studies [80] needs to be confirmed with fur-
ther research. In HER2+ disease the incorporation of
trastuzumab (H) into NT chemotherapy regimens is considered
standard of care [57]. The first reported randomised trial from
the MDACC showed a very high pCR rate of 65.2% in patients
treated with trastuzumab (versus 26%) [81,82] which led to a
premature closure of the study. Data from two randomised
phase III studies were subsequently available, the NOAH trial
[83] and the GeparQuattro trial [65,84]. The addition of trast-
uzumab to an anthracycline/taxane-based regimen led to an
improvement in event-free survival at 3 years (HR 0.59;
95%CI: 0.38–0.90) in the NOAH trial and a significant increase
in pCR rate in the GeparQuattro trial (31.7% in HER-2-positive
disease versus 15.7% in HER-2-negative disease).
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Lapatinib (L) has been tested in the NT setting, both as sin-
gle agent and in combination with trastuzumab in two phase
III studies. In the NeoALTTO study [85], 455 patients were ran-
domly assigned to L, H, or L plus H, given alone initially and
then combined with weekly paclitaxel before surgery. Combi-
nation of L and H yielded a significantly higher pCR rate than
the monotherapy arms. The dual combination was associated
with higher toxicity, mainly diarrhoea and a transient revers-
ible rise in transaminases. In the Geparquinto trial [84] 620
HER2+ patients with operable or locally advanced BC were
randomised to four cycles of epirubicin plus cyclophospha-
mide and four cycles of docetaxel 3 weeks, with either con-
current H or L. The H arm had a significantly higher pCR
(30.3%) compared with L (22.7%). Taken together, the results
of these two studies have led to the recommendation that
lapatinib should not be used as a single (neo)adjuvant anti-
HER2 target outside clinical trials. Furthermore, the lapatinib
monotherapy arm in the large adjuvant ALTTO trial has been
STOPPED and patients in that arm were informed and pro-
posed to receive adjuvant trastuzumab.
Dual-HER2 blockade has also been tested in the NeoSphere
trial [86], a phase II randomised trial designed to test the antitu-
mour activity and tolerability of the combination of docetaxel,
trastuzumab and pertuzumab (THP), compared with trast-
uzumab plus pertuzumab (HP), docetaxel and pertuzumab
(TP) and docetaxel and trastuzumab (TH). The pCR was signifi-
cantly higher (P = 0.014) for the combination of docetaxel with
both anti-HER2 target agents (THP), with good tolerability,
namely cardiac safety. These studies plus two trials in the met-
astatic setting [87,88] represent growing evidence that the dual
blockade of the HER2 receptor has superior efficacy and may
soon become standard of care. Still, it is not known which is
the optimal combination of anti-HER2 agents; the best chemo-
therapy regimen to use with these agents, the role of dual HER2
blockade in combination with endocrine therapy for HER2+
and HR+ BC are among other questions.
Triple-negative phenotype (TNBC) has higher response
rates to NT compared to non-triple-negative tumours in several
studies [59,72,89–91], but only if pCR is obtained can it be trans-
lated into a better prognosis. At the present time, CT is the only
proven therapy for TNBC and international guidelines recom-
mend the use of the same regimens as for non-TNBC, i.e. an
anthracycline/taxane-based regimen. Small studies have sug-
gested that platinums may be particularly effective in this sub-
set, with pCR rates of 54.6% for docetaxel and carboplatin [92],
40% for epirubicin, cisplatin, and fluorouracil followed by
weekly paclitaxel [93], and 80% with cisplatin in a BRCA1 muta-
tion patient population [94]. However, pCR rates of 20% have
also been reported with neoadjuvant cisplatin monotherapy
[95]. These results need further validation in large randomised
studies, especially in the non-BRCA population.
4. What is the optimal adjuvant chemotherapy
regimen?
4.1. State-of-art regimens according to breast cancer
subtype
So far available data do not allow for different regimen recom-
mendations according to BC subtype. Therefore, the consider-
ations below apply to all subtypes of BC when CT is deemed
necessary, with some specific points for HER2+ EBC.
The rationale and support for adjuvant CT for patients
with BC are derived from many large, randomised trials and
from the Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) meta-analysis. In the last update analysis [96] the
use of adjuvant CT, with either an anthracycline-based or a
CMF regimen, was shown to be superior to no treatment in
terms of risk of recurrence, breast cancer, or overall mortality
(Table 1). The application of adjuvant CT translated to an
absolute benefit of 5.0%.
There is no single standard adjuvant chemotherapy regi-
men in the treatment of EBC.
When choosing a particular regimen various factors must
be taken in account: namely the recurrence risk, co-morbid
illness and patient preference. The following discussion is
organised along the lines of debate concerning CT regimens:
anthracyclines versus CMF and anthracyclines versus
taxanes.
4.2. Anthracyclines versus CMF
Several randomised trials and the EBCTCG overview (Table 2)
support the superior efficacy of anthracycline-based regimens
over CMF with level I based evidence. However, some caveats
must be highlighted. In the 2011 Oxford Overview anthracy-
cline-based regimens were divided into standard doses (e.g.
cumulative doses of 240 mg/m2 of doxorubicin) or higher
doses (i.e. cumulative doses > 240 mg/m2 of doxorubicin or
360 mg/m2 of epirubicin) [96]. The improvement in the risk
of recurrence, breast cancer or overall mortality was present
only with the use of higher cumulative doses of anthracy-
clines (Table 2). This suggests that a real difference between
these regimens exists but is limited to anthracycline regi-
Table 1 – Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) overview results comparing adjuvant chemotherapy (CT)
with no CT in early breast cancer (EBC).
Risk of recurrence Breast cancer mortality Overall mortality
Anthracycline-based regimen versus no CT
RR: 0.73, 95% confidence interval (CI)
Absolute gain: 8%
RR: 0.79, 95%CI
Absolute gain: 6.5%
RR: 0.84, 95%CI
Absolute gain: 5%
Cyclophosphamide, methotrexate and
fluorouracil (CMF) regimen versus no CT
RR: 0.70, 95%CI
Absolute gain: 10.2%
RR: 0.76, 95%CI
Absolute gain: 6.2%
RR: 0.84, 95%CI
Absolute gain: 4.7%
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mens containing three agents (e.g. CEF, CAF) and given for at
least six cycles. Standard dosing of anthracycline-based ther-
apy (four cycles of a two-drug regimen, e.g. 4AC) seems to be
equivalent to CMF.
4.2.1. Anthracyclines versus Anthracylines + taxane based
therapy
The role of taxane-base CT as adjuvant treatment of EBC is an
extensively studied but still controversial issue. We currently
have 21 clinical trials of first-generation taxanes, several
pooled analyses, meta-analyses, and since 2012 the role of
these agents is also evaluated in the analysis of the EBCTCG
overview.
Some of the key first-generation taxane trials are pre-
sented in Table 3. When analysing the 12 first-generation tri-
als using low-strength anthracycline reference regimens,
eight suggest a benefit in terms of DFS for the taxane regimen
(CALGB 9344; NSABP B-28; the MD Anderson Neoadjuvant
Trial; FinHER; BCIRG 001; HORG; GEICAM 9805; US Oncology
Group 9735) and only three of the 10 trials that reported sur-
vival showed a benefit in OS (CALGB 9344, BCIRG 001, and
US Oncology 9735).
Several pooled analyses and meta-analyses have been
undertaken aiming to clarify the benefit of taxane-based ther-
apy (Table 3). Overall they support a modest improvement in
DFS and overall survival (5% and 3% absolute benefit,
respectively) when taxane-based regimens are compared
with standard anthracycline polychemotherapy, irrespective
of the type of taxane, schedule of administration, extent of
nodal involvement and hormone-receptor expression status
[97].
In the EBCTCG 2012 meta-analysis the incorporation of a
taxane into an anthracycline CT regimen resulted in reduc-
tion in the recurrence risk, risk of breast cancer and overall
mortality (Table 3) independently of age, nodal status, tumour
size, tumour grade or ER status.
However, we must underscore that treatment compari-
sons varied greatly, which complicates the analysis. In this re-
gard, the effect of taxanes was analysed taking into account
how the CT regimen in the control group compared with the
non-taxane CT in the taxane group (same, doubled or inter-
mediate). The major effect of these agents was seen in the tri-
als where the same control regimen was used in both arms
(n = 11,167 women) with a reduction in the risk of recurrence,
breast cancer and overall mortality that translated into an
absolute gain of 4.6%, 2.8% and 3.2%, respectively [96]. When
considering this benefit we must acknowledge that in these
trials a ‘week’ anthracycline-based regimen was used and
greater treatment duration was obtained with the additional
four cycles of a taxane to the anthracycline regimen. As a
matter of fact, when the number of cycles in the control
anthracycline regimen was doubled (to mirror the addition
of four cycles of taxanes to anthracyclines in the experimen-
tal arm) there was little difference in recurrence, breast can-
cer or overall mortality (Table 3).
4.2.2. HER2 positive breast cancer
The optimal anti-HER2 adjuvant treatment will be addressed
belowT
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4.3. Should anthracyclines be avoided in the adjuvant
setting?
Anthracyclines are amongst the most active chemotherapeu-
tic agents for the treatment of breast cancer. Multiple trials in
the past two decades demonstrated that anthracycline-based
chemotherapy was associated with lower rates of breast can-
cer recurrence and improved survival when compared with
non-anthracycline chemotherapy regimens, such as CMF
[96]. However, these agents are associated with increased risk
of cardiovascular complications, dependent on cumulative
dose and schedule, and are often irreversible.
The benefit of taxanes when incorporated into the adju-
vant setting for women with newly diagnosed breast cancer
was analysed in several trials and has been discussed above.
It is, however, unknown whether the benefit seen from add-
Table 3 – Adjuvant taxane trials in early breast cancer (EBC).
Study Population Median
follow-up
(months)
Treatment DFS (P-value) OS (P-value)
‘‘Low-strength’’ sequential anthracycline
CALGB 9344 Node-positive EBC
(n = 3170)
69 AC · 4 versus AC · 4 –
Pac · 4
7 years: 64% versus
58% (HR: 0.83;
P = 0.001)
7 years: 74% versus
68% (HR: 0.82,
P = 0.01)
NSABP B-28 Node-positive EBC
(n = 3060)
34 AC · 4 versus AC · 4 –
Pac · 4
5 years: 76% versus
72%; (HR: 0.83;
P = 0.002)
5 years: 85% versus
85% (HR: 0.93;
P = 0.46)
MDACC EBC (n = 524) 60 FAC · 8
Pac · 4 – AC · 4
86% versus 83% (HR:
0.70; P = 0.009)
NR
NSABP B-27 T1–T3 operable BC
(n = 2411)
102 S! AC! Doc versus
S! AC
AC! S! Doc versus
S! AC
71% versus 68% (HR:
0.92; P = 0.29)
70% versus 68% (HR:
0.92; P = 0.29)
83% versus 82% (HR:
0.93; P = 0.46)
82% versus 83% (HR:
0.97; P = 0.7)
‘‘Low-strength’’ concurrent anthracyclinea
BCIRG-001 Node-positive EBC
(n = 1491)
124 DAC · 6
FAC · 6
62% versus 55%,
P = 0.0043
76% versus 69%,
P = 0.002
GEICAM 9805 Node-negative EBC
(n = 1060)
77 DAC · 6
FAC · 6
87.8% versus 81.8%
(HR: 0.68; 95%CI;
P = 0.01)
95.2% versus 93.5%
(HR: 0.76; 95%; P = NS)
‘‘Standard strength’’ sequential anthracycline*
GEICAM 9906 Node-positive EBC
(n = 1246)
66 FECq3w · 6
FEC · 3 – Pac · 8w
78% versus 72% (HR:
0.74; P = 0.006)
90% versus 87% (NR;
P = 0.11)
PACS 01 Node-positive EBC
(n = 1999)
60 FECq3w · 6
FEC · 3 – Doc · 3w
78% versus 73% (HR:
0.82;
P = 0.034)
91% versus 87% (HR:
0.73; P = 0.014)
WGSG/AGO
EC-Doc Trial
1–3 Positive lymph
node (n = 2011)
41 4 · EC – 4 · Doc
6 · FEC100
6 · CMFb
Estimated 5 years EFS
91% versus 85% (HR:
0.58, P = 0.004)
Estimated 5 years OS
95% versus 91%
(P = 0.03)
Meta-analysis
Meta-analysis 13 Studies EBC
(n = 22,903)
– – HR: 0.83 (95%CI, 0.79–
0.87; P < 0.00001)
HR: 0.85 (95%CI, 0.79–
0.91; P < 0.00001)
EBCTCG overview – taxane-plus-anthracycline
versus anthracycline-based regimen
Results for all trials that test taxane
effect (n = 44,000)
Distant recurrence RR: 0.87
Any recurrence RR: 0.86
(P = 0.00001)
BC mortality RR: 0.87
(P = 0.00001)
Other mortality RR: 0.99
Overall mortality RR: 0.89
(P = 0.0001)
Unconfounded trialsa
(taxane versus control group)
8-year recurrence:
30.2% versus 34.8%
(absolute gain 4.6%)
8-year BC mortality:
21.1% versus 23.9%
(absolute gain 2.8%)
8-year overall mortality
23.5% versus 26.7%
(absolute gain 3.2%)
Counfounded trialsa
(taxane versus control group)
8-year recurrence:
19.2% versus 22%
(absolute gain 2.9%)
8-year BC mortality:
10.1% versus 11.5%
(absolute gain 1.4%)
8-year overall mortality
11.2% versus 12.4%
(absolute gain 1.2%)
FEC, cyclophosphamide, epirubicin, and fluorouracil; AC, doxorubicin and cyclophosphamide; Pac, paclitaxel; FAC, fluorouracil, doxorubicin
and cyclophosphamide; Doc, docetaxel; S, surgery; DAC, docetaxel, doxorubicin, cyclophosphamide; EC, epirubicin and cyclophosphamide;
CMF, cyclophosphamide, methotrexate, and fluorouracil.
a Anthracycline-based adjuvant breast cancer regimens are categorized into ‘standard-strength’ and ‘low-strength’ regimens based on
cumulative doses of doxorubicin >240 mg/m2 and epirubicin >360 mg/m2. Example: standard strength: FEC100; FEC90; CEF; CAF:A75 or E100
followed by CMF; reduced strength: FEC75; FEC60; FEC50; FAC; AC; EC.
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ing a taxane in the adjuvant setting will obviate the need for
anthracyclines in a subset of patients, since the great major-
ity of studies evaluated the addition of a taxane to an anthra-
cycline regimen and not its replacement. A phase III
randomised trial, the US Oncology Research Trial 9735 [98],
enrolled 1016 women with stages I–III HER2-negative breast
cancer and randomly assigned therapy with four cycles of
AC or four cycles of docetaxel plus cyclophosphamide (TC).
With a median follow-up of 7 years, TC resulted in a signifi-
cantly higher DFS (81% versus 75%) and OS (87% versus
82%). However, how the TC regimen compares with stronger
anthracycline-based regimens such as FEC/FAC and with
third-generation regimens, which incorporate both an
anthracycline and taxane, is still unknown. Therefore, most
international guidelines continue to recommend an anthra-
cycline- and taxane-containing regimen for most women,
particularly those with higher-stage tumours, and for those
with triple-negative or HER2+ BC, unless there are clear con-
traindications for the use of anthracyclines [13].
The role of anthracycline regimens in the HER2+BC is also
a matter of intense research. Several CT regimens used with
trastuzumab have been evaluated in large prospective stud-
ies, and historically anthracyclines have been considered crit-
ical for the management of HER2+ BC. A number of studies
from the pre-trastuzumab era support this concept. Retro-
spective subset analyses of anthracycline-based adjuvant CT
studies have suggested that the major benefit for these regi-
mens is seen in HER2-over-expressing tumours [99]. The value
of HER2 and TOP2A as predictive markers of response to
anthracycline-based therapy has been extensively studied.
In the meta-analysis by Di Leo et al., although HER2 amplifica-
tion and combined TOP2A amplification and deletion had
some value in prediction of responsiveness to anthracy-
cline-based therapy, the overall findings did not support the
routine use of TOP2A to select the adjuvant CT regimen in this
patient population [78].
With the advent of trastuzumab, concerns have been
raised regarding the use of anthracycline-based regimens in
HER2+ early BC due to potential cardiotoxicity. Previous or
concurrent anthracyclines are a risk factor for trastuzumab-
related cardiotoxicity. Notwithstanding the increased inci-
dence of cardiac events, these still remain in very acceptable
ranges for all types of CT regimens used in the adjuvant set-
ting. Rates of severe congestive heart failure in adjuvant trials
ranged between 0.4% and 3.5%, depending on the regimen
and schedule used.
Combining trastuzumab with a non-anthracycline-con-
taining CT regimen was evaluated in the BCIRG 006 trial with
the aim of investigating whether the association of trast-
uzumab, carboplatin and docetaxel could be better tolerated
and superior in terms of efficacy compared with an anthracy-
cline-based schedule [79]. At a median follow-up of
65 months, the differences in DFS and OS between ACTH
and TCH, although not statistically significant, were numeri-
cally different, with a trend favouring the anthracycline-con-
taining regimen. The trial hypothesis that TCH was superior
to ACTH was not proven and, since the study was not pow-
ered to detect equivalence between ACTH and TCH, this con-
clusion cannot be drawn. With respect to adverse events, the
differences were significantly lower rates of severe (grade )
neutropenia (66% versus 63%) and leucopaenia (48% versus
60%) but significantly higher rates of anaemia (6% versus
3%) and thrombocytopenia (6% versus 2%) for TCH and a
higher incidence of congestive heart failure (2% versus
0.4%), subclinical and sustained loss of mean left ventricular
ejection fraction (18.6% versus 9.4%) for ACTH. Based on this
trial alone, TCH can only be considered an alternative treat-
ment for patients with contraindications to anthracyclines
(pre-existing cardiac conditions, borderline ejection fraction
at baseline, or prior anthracycline exposure) while anthracy-
cline-based regimens remain the standard of care.
Findings suggest that the more dramatic risk reduction
when adding trastuzumab to CT is observed when using some
concurrent CT and trastuzumab, and employing both anthra-
cycline and a taxane.
4.4. Dose-dense adjuvant chemotherapy
The introduction of granulocyte-colony-stimulating factors
has allowed the administration of CT in the dose-dense ap-
proach, thought to have higher efficacy based on mathemat-
ical models of human breast cancer growth [100]. The
pivotal trial CALGB9741 [101] has shown significant improve-
ment in DFS and OS with dose-dense concurrent AC followed
by paclitaxel in women with node-positive EBC. Several trials
with dose-dense regimens have shown similar results, as
shown in a systematic review and meta-analysis of these
studies [102] with HR of death 0.85 (95%CI = 0.77–0.93) and
HR of relapse or death 0.81 (95%CI = 0.75–0.88). Another
important finding was that the benefit was seen only in hor-
monal-receptor-negative disease. There was no statistically
significant increase in adverse events. The concern about
these results is related to the design of these trials that did
not evaluate the same agents and doses in the conventional
arm as in the investigational arm. Further prospective data
will help to clarify which patients should be selected for this
approach. At the moment these regimens have been mainly
used in high-risk disease with features of aggressive biology.
4.5. Sequential versus combination regimens
Sequential single-agent doxorubicin and cyclophosphamide
did not improve outcome compared with combination AC
[103]. Sequential versus concurrent use of anthracyclines
and taxanes in EBC has been evaluated in three studies: CAL-
GB 9741, BIG 2-98 and NSABP B-38.
The first study, CALGB 9741 [101], randomised 2005 female
patients, with node-positive disease, to sequential
A · 4! T · 4! C · 4, every 3 weeks; A · 4! 3 T · 4! C · 4,
every 2 weeks with filgrastim; concurrent AC · 4! T · 4,
every 3 weeks or AC · 4! T · 4, every 2 weeks with filgrastim.
Dose-dense treatment was associated with improved DFS and
OS, with no increase in toxicity.
In the BIG-2-98 [104] study 2887 patients, also with node-
positive disease, were randomised to sequential A · 4!
CMF · 3 (sequential control); concurrent AC · 4! CMF · 3
(concurrent control); sequential A!T · 4! CMF · 3 (sequen-
tial experimental); concurrent AT · 4! CMF · 3 (concurrent
experimental). The updated analysis [105] revealed that
sequential docetaxel was associated with significant
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improvement of DFS compared with control arms and with
concurrent AT.
Preliminary results of NSABP B-38 were recently presented
[106]. The trial randomised 4894 women (65% node-positive)
to dose-dense ACT, dose-dense AC followed by the combina-
tion of paclitaxel and gemcitabine (ACTG), or TAC. Five-year
DFS and OS were similar between groups, but the TAC regi-
men was associated with more grade 3/4 toxicity, namely feb-
rile neutropenia and diarrhoea. Based on the tolerability
profile, and on the possible higher efficacy, sequential anthra-
cycline–taxane-based regimens are preferred to combination
regimens.
4.6. Are there predictive biomarkers to help select the
optimal regimen?
Identification of markers that predict chemosensitivity in BC
is a research priority. Several approaches and technologies
have been used to identify these predictive markers. The
aim is to answer two questions: (a) can we use gene signa-
tures to identify tumours, which are more likely to respond
to chemotherapy? and (b) when chemotherapy is indicated,
what is the optimal chemotherapy regimen for a specific tu-
mour or group of tumours?
4.6.1. Markers predicting general chemosensitivity
Since patients with poor prognosis disease defined by first-
generation signatures have tumours with high expression of
proliferation-related genes, and cytotoxic agents target the
proliferating fraction of tumours, the finding that first-gener-
ation prognostic signatures also predict benefit from conven-
tional multidrug CT regimens is not surprising [45,107–110].
With respect to OncotypeDx, two retrospective studies
have reported its predictive value for chemosensitivity
[32,111]. In the NSABP trial B-20, 651 patients with node-neg-
ative, hormone-receptor-positive tumours were randomised
to tamoxifen alone (n = 227) or tamoxifen plus CT (methotrex-
ate–fluorouracil or CMF) (n = 424) [32]. A high recurrence score
predicted benefit from CT [hazard ratio (HR) = 0.26; 95%
CI = 0.13–0.53], with little or no benefit from CT in the low
and intermediate recurrence score groups. The predictive va-
lue of the OncotypeDx was also assessed in a subset of pa-
tients more than 50 years old with node-positive hormone-
receptor-positive tumours included in the SWOG 8814 trial
[111]. In this trial, patients were randomised to receive either
tamoxifen alone (n = 361); CAF followed by tamoxifen for
5 years (n = 566); or concurrent CAF and tamoxifen (n = 550).
The 21-gene recurrence score was assessed in 367 of these pa-
tients. The addition of CT to tamoxifen resulted in no differ-
ence in DFS or OS in the low recurrence score group, but a
clear benefit in DFS and OS in the high recurrence score
group. There appeared also to be a benefit for patients in
the intermediate recurrence score group, but the confidence
intervals were wide due to the small sample size.
This signature was assessed in a series of 167 patients with
tumours >5 cm or clinically positive nodes and has also been
suggested to predict the response to neoadjuvant CT [112].
Pathological complete response (pCR) after neoadjuvant CT
was used as a surrogate for chemosensitivity and in this trial
only patients with a bad signature achieved a pCR of 20% (29/
144). None of the patients with a good signature (n = 144)
achieved a pCR (0/23). The authors concluded that patients
with a good signature would be unlikely to respond to CT.
4.6.2. Markers predicting drug-specific chemosensitivity
There are currently no biomarker predictors of response to
specific cytotoxic agents. There are several reasons for the
apparent inability to develop these predictive factors, namely:
(a) resistance or response to therapies may be caused by a
functional alteration in only a few genes and this may not
manifest itself as a detectable signal in the complex tran-
scriptomic landscape of a tumour; (b) tumours are often com-
posed of a mosaic of genetically heterogeneous clonal
subpopulations harbouring numerous private genetic aberra-
tions (that is, aberrations found in a single clone of a tumour
[31,113]. These private genetic aberrations may be the drivers
of resistance to therapy in a subpopulation and would not be
detected by microarrays that survey the average expression
profile of the entire tumour.
The Topoisomerase II Alpha Gene Amplification and Pro-
tein Overexpression Predicting Efficacy of Epirubicin (TOP)
trial (NCT00162812) led to the development of the anthracy-
cline-based score (A-score), which combines three predictive
signatures: a TOP2A gene signature and signatures related
to tumour invasion and immune response [74]. Analysis of
the predictive power of the A-score was performed in the
EORTC 10994/BIG (Breast International Group) 00-01
(NCT00017095) trial and from ER-negative patients from the
Randomised Clinical Trial to Evaluate the Predictive Accuracy
of a Gene Expression for Stage I–II Breast Cancer
(NCT00336791). Both studies revealed its high negative predic-
tive value (0.98, 95%CI 0.90–1.00) [74] suggesting, if validated,
its potential clinical use for identification of patients who
are unlikely to benefit from anthracyclines.
5. What is the optimal adjuvant endocrine
treatment?
5.1. Tamoxifen 5 years
Endocrine therapy (ET) is one of the most effective treatments
in women with endocrine responsive breast cancer. Tamoxi-
fen has been the mainstay endocrine agent for both pre-
and postmenopausal women. Updated analyses [114] of the
EBCCTG overview assessed long-term outcomes among
21,475 women with EBC in trials of 5 years of tamoxifen com-
pared with observation or placebo. In oestrogen-receptor- (ER-
)positive disease, 5 years of tamoxifen significantly reduced
recurrence rates throughout the first 10 years, independently
of progesterone receptor status, nodal status, or use of CT: rel-
ative risk (RR) 0.53 during years 0–4 and RR 0.68 during years
5–9 [both 2P < 0.00001]. For marginally ER-positive disease
there was also an important risk reduction (RR 0.67). More
importantly there was a reduction in breast cancer mortality
by about a third throughout the first 15 years (RR 0.71 during
years 0–4, 0.66 during years 5–9, and 0.68 during years 10–
14; P < 0.0001).
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5.2. Ovarian suppression and aromatase inhibitors for
premenopausal patients
The standard adjuvant hormonal therapy in premenopausal
women with ER-positive disease remains tamoxifen alone
for 5 years, but benefit has also been shown with the use of
luteinising-hormone-releasing (LHRH) agonists specifically
in the absence of CT. Several studies have been conducted
testing LHRH agonists alone, combined with tamoxifen, che-
motherapy or both. In the EBCTCG overview [115] 8000 pa-
tients randomised to ovarian function suppression (OFS) or
ablation by surgery/radiation had reduced recurrence and
breast cancer mortality, but the benefit was seen mainly in
the absence of other systemic treatments. An individual pa-
tient data meta-analysis [116] of 16 trials using LHRH identi-
fied 9022 women with ER+ disease and assessed recurrence
rate, breast cancer mortality and overall mortality. While
LHRH agonists alone did not have a significant effect, adding
these agents to CT, to tamoxifen or both, significantly reduced
recurrence by 12.7% (P = 0.02) and death after recurrence by
15.1% (P = 0.03). Furthermore, the benefit of LHRH agonists
after CT was seen in women younger than 40 years, but not
in older premenopausal women. However, the data do not an-
swer the question of whether LHRH agonist is useful only
when amenorrhoea is not achieved with CT, an event that
has been associated with worse outcome in some trials
[117,118].
Recently a guideline from Cancer Care Ontario was pub-
lished and endorsed by ASCO [119] conducting a systematic
review of available literature. The guideline does not recom-
mend the routine use of OFS added to chemotherapy, tamox-
ifen or a combination of both. It does acknowledge as a major
difficulty in assessing its efficacy the fact that ovarian sup-
pression has not been compared with current CT regimens
(e.g. anthracyclines or anthracyclines/taxanes), which deems
the benefit of these agents unclear. For chemical suppression
the guideline does suggest the use of monthly injections.
The role of aromatase inhibitors (AIs) in premenopausal
women was assessed in the ABCSG-12 trial [120] which ran-
domised 1803 patients to receive goserelin monthly plus
tamoxifen or anastrozole, with or without zoledronic acid
for 3 years. There was no significant difference in DFS be-
tween the anastrozole and tamoxifen groups (HR = 1.10; CI
0.78–1.53), but the trial was relatively small to answer this
secondary objective. Till now AIs combined with OFS are only
recommended in premenopausal patients if tamoxifen is
contraindicated. To better understand the role of aromatase
inhibitors, as well as OFS in this setting, results from the stud-
ies TEXT, SOFT and PROMISE are eagerly awaited.
5.2.1. Aromatase inhibitors
For postmenopausal patients the aromatase inhibitors anas-
trozole, letrozole and exemestane have been extensively
studied in adjuvant setting as upfront therapy for 5 years,
‘‘switch’’ strategy of initial tamoxifen for 2–3 years followed
by an AI 2–3 years, the reverse sequence, or as an extended
treatment after 5 years of tamoxifen (see Table 4) [121–129].
The meta-analysis of the adjuvant trials [130] analysed a co-
hort of 9856 patients where AI upfront therapy was compared
with standard tamoxifen treatment, showing a significant
2.9% absolute decrease in recurrence and a non-significant
absolute 1.1% decrease in breast cancer mortality. A second
cohort comprising 9015 patients compared the switch strat-
egy with standard tamoxifen treatment and showed a signif-
icant absolute decrease in recurrence and in breast cancer
mortality of 3.1% and 0.7%, respectively. Current ASCO [131]
and European Guidelines [132] recommend the incorporation
of AIs in the endocrine treatment plan as switch (2–3 years) or
upfront therapy strategy (5 years). For patients who have
completed 5 years of tamoxifen the addition of an AI for a fur-
ther period of 2–5 years is recommended, especially for pa-
tients with node-positive disease. On the other hand,
5 years of tamoxifen alone is still a viable option for certain
patients at very low risk of recurrence.
The choice of endocrine treatment and the timing for AI
treatment is nowadays based on the toxicity profile of these
drugs compared with tamoxifen, general health issues of
each individual and the risk of relapse. A recent meta-analy-
sis [133] on safety reports from major adjuvant trials found
that AI therapy was associated with a higher risk for cardio-
vascular disease (HR, 1.2) and bone fracture (HR, 1.48) than
tamoxifen, but a lower risk for venous thromboembolism
(HR, 0.53) and uterine cancer (HR, 0.32). Overall these risks
were low, around 2% of patients, and fractures only occurred
in fewer than 10% of all patients. Additional data from a pop-
ulation-based study [134] evaluating 44,000 women with
breast cancer and age-matched women without breast can-
cer, have shown that breast cancer patients on ET had a lower
risk for both myocardial infarction and ischaemic stroke than
those who did not have breast cancer. No differences were
seen between AI therapy and tamoxifen therapy in the risk
for myocardial infarction or stroke, but AI therapy was asso-
ciated with a higher risk for any fracture (mainly hip frac-
tures). Guidelines [131,132] recommend surveillance of bone
mineral density during AI treatment, and calcium and vita-
min D supplementation or a bisphosphonate depending on
the result.
5.3. Extended ET treatment
Because the risk of recurrence in hormone-receptor-positive
disease still remains after the first decade [135], clinicians
and researchers have been questioning the benefit of ex-
tended tamoxifen treatment beyond 5 years. Three prospec-
tive trials addressed this question, randomising patients
after 5 years of tamoxifen treatment to additional 5 years of
treatment or placebo (NSABP-B14 [136], aTTom trial [137]
and ATLAS trial [138]). Except for the NSABP B14 trial, these
studies together with EBCCTG [114] have shown benefit for
extended tamoxifen. However, balance with side effects has
to be considered as extended treatment is associated with in-
creased incidence of endometrial cancer, which is 2.3-fold
with 5 years of tamoxifen and 4-fold with 10 years [114]. On
the other hand, there is some evidence that tamoxifen has
a favourable effect in lipid profile [139–141]. ATLAS results
suggest some protection against ischaemic heart disease
and certainly no increase in stroke deaths. In the EBCCTG
overview the non-significant excess of stroke deaths was bal-
anced by a non-significant shortfall in cardiac deaths with lit-
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Table 4 – Trials of adjuvant endocrine therapy.
Study Treatment arms/
population (n)
Median follow-up Recurrence Mortality
Tamoxifen 5 years
Overview 2011 (W164) TAM 5 years versus
no
TAM 10,645 ER+
15 years RR = 0.53 [SE 0.03]
years 0–4
RR = 0.68 [SE 0.06]
years 5–9
2P < 0.00001
RR = 0.97 [SE 0.10]
years 10–14
RR = 0.71 [SE 0.05]
years 0–4
RR = 0.66 [SE 0.05]
years 5–9
RR = 0.68 [SE 0.08]
years 10–14
P < 0.0001
OFS
Overview 2005 [115] 8000 ER+/ER
unknown, <50 years,
OFS
LHRH– 3408
5 years 15 years gain 4.3% (SE
1.9)
2P < 0.00001
15 years gain 3.2% (SE
2.0)
2P = 0.04
Meta-analysis [164] 11,906
Premenopausal
6.8 years No systemic treatment
versus LHRH:
HR 0.72 (95%CI 0.49–
1.04), P = 0.08
CT versus LHRH:
HR 1.04 (95%CI 0.92–
1.17), P = 0.52
CT versus
LHRH + TAM:
HR 0.90 (95%CI 0.75–
1.08), P = 0.25
Addition to TAM:
HR 0.85 (95%CI 0.67–
1.09), P = 0.20
Addition to CT ± TAM:
HR 0.88 (95%CI 0.77–
0.99), P = 0.04
No systemic treatment
versus LHRH:
HR 0.82 (95%CI 0.47–
1.43), P = 0.49*
CT versus LHRH:
HR 0.93 (95%CI 0.79–
1.10), P = 0.40a
CT versus
LHRH + TAM:
HR 0.89 (95%CI 0.69–
1.15), P = 0.37a
Addition to TAM:
HR 0.84 (95%CI 0.59–
1.19), P = 0.33a
Addition to CT ± TAM:
HR 0.85 (95%CI 0.73–
0.99), P = 0.04*
AIs 5 years
ATAC [164] TAM 5 years versus
ANA 5 years
3116/3125
120 months HR = 0.91 (95%CI 0.83–
0.99)
P = 0.04
0.97 (95%CI 0.88–1.08)
P = 0.6
BIG 1.98 [164] TAM 5 years versus
LET 5 years
2459/2463
76 months HR = 0.88 (95%CI 0.78–
0.99)
P = 0.03
HR = 0.87 (95%CI 0.75–
1.02)
P = 0.08
TEAM [164] EXE 5 years versus
TAM 2–3 years
followed EXE 2–
3 years
4868/4898
5.1 years HR = 0.97 (0.88–1.08)
P = 0.60
HR = 1.00 (0.89–1.14)
P > 0.9
Meta-analysis [164] Cohort 1
AIs initial
monotherapy versus
TAM
9856
5.8 years 9.6% AI versus 12.6%
TAM
2.9% absolute
decrease (SE 0.7%)
2P < .00001
4.8% AI versus 5.9%
TAM
1.1% (SE = 0.5%)
absolute decrease
2P = 0.1
MA.27 [6] EXE 5 years versus
ANA 5 years
7576
4.1 years HR = 1.02 (95%CI 0.87–
1.18)
P = 0.85
HR = 0.93 (95%CI 0.77–
1.13)
P = 0.46
AIs and tamoxifen in switching strategies
BIG 1.98 [129] LET 5 years
TAM 2 years followed
by LET 3 years
LET 2 years followed
by TAM 3 years
1546/1548/1540
71 months HR = 1.05 (95%CI 0.84–
1.32)
HR = 0.96 (95%CI 0.76–
1.21)
HR = 1.13 (95%CI 0.83–
1.53)
HR = 0.90 (95%CI 0.65–
1.24)
ABCSG-8/ARNO 95 [125] TAM 5 years versus
Tam f 2 years
followed by ANA for
3 years
28 months HR = 0.60 (0.44–0.81)
P = 0.0009
P = 0.16
(continued on next page)
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tle net effect on overall vascular mortality. Interestingly, a re-
cent study [142], with a median follow up of 10.1 years, as-
sessed the long-term benefits of 5 years versus 2 years of
tamoxifen use in a large randomised trial of EBC women more
than 50 years of age. Follow-up strategies included matching
trial subjects with death data from the British National Health
Service Information Center. Besides the well-known positive
efficacy of tamoxifen, this study revealed a nearly statistically
significant reduction in cardiovascular deaths (HR, 0.79;
P = 0.08) with longer tamoxifen, and in women of 50–59 years
there was an even greater reduction in cardiovascular events
(HR, 0.65; P = 0.005; P = 0.046 for interaction between age and
treatment groups).
In postmenopausal women extended use of AIs after
5 years of tamoxifen has shown improvement in DFS (see Ta-
ble 4), and in one study, the MA-17 trial [143], an improvement
in OS was also seen in node-positive patients. It is not known
if longer use of AIs (more than 5 years) will increase outcomes
without compromising safety, and it is not recommended un-
til mature data from MA.17R and NSABP B-42 trials are avail-
able. The best regimen of ET for postmenopausal patients and
the duration of ET treatment are still unanswered questions.
Table 4 – (Continued)
Study Treatment arms/
population (n)
Median follow-up Recurrence Mortality
ITA [122] TAM 5 years versus
Tam f 2 years
followed by ANA
128 months HR = 0.64 (0.44–0.94)
P = 0.023
HR = 0.72 (0.44–1.17)
P = 0.3
IES [124](164)(164) (164) TAM 5 years versus
Tam f 2–3 years
followed by EXE 2–
3 years
55.7 months HR = 0.76 (95%CI 0.66–
0.88)
P = 0.0001
HR 0.85 (95%CI 0.71–
1.02)
P = 0.08
Meta-analysis [130] Cohort 2
AIs T after 2–3 years
of TAM versus TAM
9015
3.9 years 5.0% AI versus 8.1%
TAM
3.1% absolute
decrease (SE 0.6%)
2P < .00001
1.7% AI versus 2.4%
TAM
0.7% (SE = 0.3%)
absolute decrease
2P = 0.2
Extended treatment beyond 5 years
ATLAS [138] TAM 5 years versus
TAM 10 years
3428/3418
NR RR = 0.90 (95%CI 0.79–
1.02) 5–9 years
RR = 0.75 (95%CI 0.62–
0.90) later years
RR: 0.84, 95%CI 0.76–
0.94; P = 0.002 in ER+
RR = 0.97 (95%CI 0.79–
1.18) 5–9 years
RR = 0.71 (95%CI 0.58–
0.88) later years
639 deaths versus 722
deaths, P = 0.01 in ER+
NSABP-B14 [136] TAM 5 years versus
TAM >5 years
579/593
7 years DFS = 82% TAM
5 years versus 78%
TAM >5 years
P = .03
OS7Y = 94% TAM
5 years versus 91%
TAM >5 years
P = .07
aTTOM [137] TAM 5 years versus
TAM 10 years
6934
4.2 years 415 TAM 5 years
versus 442
recurrences TAM
10 years
RR = 0.94 (95%CI 0.81–
1.09)
P = 0.4
NA
MA.17 [143] TAM 5 years followed
LET 5 years
versusTAM 5 years
2594/2593
30 months HR = 0.58 (95%CI 0.45–
0.76)
P < .001
HR = 0.82(95%CI 0.57–
1.19)
P = 0.03
NSABP-B33 [164] TAM 5 years followed
EXE 5 years versus
TAM 5 years
779/786
30 months DFS 4 years 91%
versus 89%
RR = 0.68 (P = 0.07)
16 deaths versus 13
P = 0.1
ABCSG-6a [165] TAM 5 years followed
ANA 3 years versus
TAM 5 years
469/387
62 months HR = 0.62 (95%CI 0.40–
0.96)
P = 0.031
HR = 0.89 (95%CI 0.59–
1.34)
P = 0.57
AI, aromatase inhibitor; DFS, disease-free survival; ER+, estrogen-receptor-positive patients; HR, hazard ratio; RR, event rate ratio; OS, overall
survival; TAM, tamoxifen; LET, letrozole; EXE, exemestane; ANA, anastrozole; LHRH, luteinizing-hormone-releasing agonists; OFS, ovarian
function suppression.
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5.4. Compliance to hormonal therapy and predictors of
response to treatment
Adherence to ET is a concern in patients with EBC as it is be-
lieved to impact on the outcome; however, the association be-
tween non-adherence and breast cancer mortality is not
proven. In ET studies patients are considered to be adherent
to treatment if P80% of prescribed doses are taken, but the
best tool for measurement of adherence is not yet defined,
and has varied among studies. It has been reported that
adherence to tamoxifen falls to 50% during the course of ther-
apy [144]. Non-adherence to anastrozole has been reported to
occur in 1/3 of patients [145]. In a recent population-based
study of 8769 patients with BC [146], 32% discontinued treat-
ment with tamoxifen or an AI over the 4.5-year follow-up per-
iod, and among those who continued 28% were non-adherent.
Younger women were at high risk of non-adherence being
50% more likely to discontinue therapy and 40% more likely
to be non-adherent (P < 001).
Among patients taking AIs the musculoskeletal toxicities
are the main reason for treatment discontinuation/non-
adherence [147–149]. Predictive factors of these adverse ef-
fects have been studied, but have not been consistent among
studies. A retrospective exploratory analysis from the ATAC
trial has shown that previous hormone replacement therapy,
previous CT and obesity were risk factors for the development
of joint symptoms. A recent exploratory analysis from a pro-
spective study, the Exemestane and Letrozole Pharmacoge-
netics (ELPh) clinical trial [150], found that younger age and
prior taxane-based CT were associated with a greater likeli-
hood of treatment discontinuation, but prior tamoxifen ther-
apy, prior hormone replacement therapy and body mass
index were not predictors. One third of patients prematurely
discontinued adjuvant AI therapy in this study, but it was also
seen than more than one third of patients who switched
drugs tolerated the second AI, confirming previous results
[151].
There is no evidence to demonstrate differences in efficacy
and toxicity among AIs. Anastrazol has shown efficacy simi-
lar to that of letrozol in the MA.27 trial [152]. The results from
the FACE trial comparing two non-steroidal AIs, letrozole and
anastrozole, are awaited.
The main predictors of response to hormonal treatment
are oestrogen and progesterone receptors [114]. There is no
Table 5 – Phase III trials of adjuvant trastuzumab in patients with HER2-positive early breast cancer (EBC)
Study Population Median
follow-up
(months)
Treatment DFS (P-value) OS (P-value) Cardiac
dysfunction
(%)
HERA [156] Node-positive or
node-negative
high-risk EBC
after completion
of standard CT
(n = 5.090)
96 No additional
therapy
H 1 year
H 2 year
HR = 0.76,
P < 0.0001
HR = 0.76,
P = 0.0005
0.8
3.7
NSABP B-31/
NCCTG N9831
[157]
Node-positive
Node-negative
high-risk EBC
(n = 4046)
100.8 AC!Pac
AC!Pac!H
62.2%
73.7% (P < 0.001)
HR = 0.6
75.2%
84.0%
(P < 0.0001)
HR = 0.63
NCCTG
N9831 [161]
Node-positive
Node-negative
high-risk EBC
(n = 1.944)
63.6 AC!PacH
AC!Pac!H
84% (5 years)
80% (P = 0.0216)
HR = 0.77
NR
NR
17
14
BCIRG 006 [79] Node-positive
Node-negative
high-risk EBC
(n = 3,222)
65 AC!Doc
AC!Doc-H
Doc–Carb–H
75%
84% HR = 0.64
(P < 0.001 versus
CT)
81% HR = 0.75
(P < 0.04 versus
CT)
87%
92% HR = 0.63
(P < 0.001
versus CT)
87%
HR = 0.77
(P < 0.038
versus CT)
9.0
18.1
8.6
PACS-04 [159] Node-positive
EBC
47 FEC or Epi–Doc
FEC or Epi–Doc!H
1 year
78% (3 years)
81% (P = 0.41)
96% (3 years)v
95% (P = 2.38)
2.2
4.2
FinHER [158] Node-positive
Node-negative
high-risk EBC
(n = 232)
62 Doc or Vin !FEC
Doc or Vin !FEC–H
73.3%
83% HR = 0.65
(P = 0.12)
82.3%
91.3% (5 years)
HR = 0.55
(P = 0.094)
Meta-analysis
2012 [160]
All trials included HR: 0.60; 95%
P < 0.00001
HR: 0.66; 95%
P < 0.00001
FEC, cyclophosphamide, epirubicin, and fluorouracil; AC, doxorubicin and cyclophosphamide; Pac, paclitaxel; Doc, docetaxel; S, surgery; H,
herceptin; Carb, Carboplatin; Vin, vinorelbin; Epi, epirubicin.
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evidence to support HER2 status as predictive of different re-
sponses to tamoxifen or AIs [129,153]. New genomic tools
such as Oncotype DX and PAM50 [30,154] have been predictive
of tamoxifen treatment, but their use in clinic has been
mainly as a prognostic tool.
Recently an exploratory analysis from the BIG 1-98 trial
[155] of 2599 patients treated with tamoxifen monotherapy
or letrozol monotherapy, with a 12-year follow-up, showed a
significant interaction effect between histology subtype and
degree of benefit to letrozole over tamoxifen, with greater
benefit being seen with letrozol in women with lobular carci-
nomas compared with invasive ductal carcinomas. Although
these data need further validation, it restores confidence in
the use of AI in high-risk lobular tumours.
6. What is the optimal adjuvant anti-HER2
treatment?
For patientswith HER2+ early BC the use of trastuzumab and CT
is well established and evaluated in six adjuvant trastuzumab
randomised clinical trials (Table 5) involving more than
13,000 women: the Herceptin Adjuvant trial (HERA) [156], the
National Surgical Adjuvant Breast and Bowel Project (NSABP)
B-31 trial and the North Central Cancer Treatment Group
(NCCTG) N9831 trial [157], the Breast Cancer International Re-
search Group (BCIRG) 006 trial [79], the Finland Herceptin trial
(FinHER) [158] and the Protocol Adjuvant dans le Cancerdu Sein
(PACS-04) trial [159], and in a 2012 meta-analysis [160].
All trials except PACS-04 yielded an improved DFS (HR be-
tween 0.6 and 0.77) and OS (HR between 0.55 and 0.77) with
the administration of trastuzumab (Table 5).
Cardiac toxicity data from these trials indicate that the
rate is higher when anthracyclines are used and with concur-
rent regimens. Nevertheless, the rates are always low and
clinically acceptable.
The 2012 meta-analysis of eight studies, involving 11,991
patients, assessed the benefits of adding trastuzumab to adju-
vant CT in patients with HER2+ BC [160]. The inclusion of
trastuzumab resulted in an improvement in DFS with an
HR = 0.60 (95%CI 0.50–0.71), regardless of trastuzumab treat-
ment duration or administration schedule (i.e. concurrently
or sequentially with CT) and an improvement in OS with an
HR = 0.66 (95%CI 0.57–0.77).
6.1. Timing of trastuzumab initiation
The decision about whether trastuzumab should be adminis-
tered concurrently or sequentially after the completion of
adjuvant CT as been addressed directly in the N9831 trial.
The second planned interim analysis, with a median follow-
up of 6 years, indicates that although trastuzumab added
sequentially to CT improves DFS, there is a strong trend to-
wards a better outcome with concurrent trastuzumab relative
to sequential administration [161].
In the 2012 meta-analysis the benefit in OS was associated
with concurrent administration [HR 0.64 (95%CI 0.53–0.76)]
but not with sequential treatment of CT followed by single-
agent trastuzumab [HR 0.85 (95%CI 0.43–1.67)] [160]. BCIRG-
006 also support the use of trastuzumab administered concur-
rently with CT in the adjuvant setting [79].
6.2. Duration of trastuzumab treatment
One year of trastuzumab is the standard of care in adjuvant
therapy. In the HERA trial a comparison between 1 and 2 years
of adjuvant trastuzumab after CT concluded that 2 years of
treatment was not better than 1 year [162]. The PHARE trial
recruited over 3380 HER2+ patients and randomly assigned
them to receive either 6 months or 1 year of adjuvant trast-
uzumab. The trial results were reported as unable to prove
the non-inferiority hypothesis of 6 months versus 1 year of
adjuvant trastuzumab [163]. In the 2012 meta-analysis trast-
uzumab administered for 12 months was associated with an
improvement in OS [HR 0.67 (95%CI 0.57–0.80)]; although
trastuzumab treatment for 66 months also showed a trend
towards an improvement in OS, it did not reach statistical sig-
nificance [HR 0.55 (95%CI 0.27–1.11)] [160].
Several trials are still ongoing evaluating the optimal dura-
tion and regimen of adjuvant trastuzumab; these might lead
to a different conclusion in the future. The relative benefit
of 6 months versus 1 year of trastuzumab is being evaluated
in the PERSEPHONE trial (which also evaluates sequential ver-
sus concurrent trastuzumab) and the HELLENIC trial (using
only concurrent therapy). The SHORT-HER and SOLD trials
are evaluating 9 weeks versus 12 months of trastuzumab gi-
ven concomitantly with a taxane, similar to the FinHER trial.
7. Conclusions and future perspectives
(Neo)adjuvant systemic therapy has dramatically changed the
natural history of EBC. Together with screening and early
detection, it is responsible for the 30% decrease in mortality
observed since the 1990s.
The stronger effects are seen with biologically targeted
agents such as endocrine and anti-HER2 therapies. Similar
advances are still lacking for the heterogeneous groups of tri-
ple-negative EBC.
Prognostication has been greatly improved in the last dec-
ade, but advances in prediction have been only minimal and
remain a research priority.
New technologies and a better knowledge of the biology of
the different subtypes of BC, as well as an in-depth under-
standing of the mechanism of cancer resistance, will hope-
fully enable us to achieve a true individualised/personalised
medicine in the near future
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1. Introduction
During the last two decades the pathological classification of
breast carcinoma has evolved rapidly. Starting from the pure
assessment of conventional morphology, it has gradually
been integrated with immunophenotypic evaluation of the
hormone receptor, HER2, and Ki67 status. In addition, molec-
ular genetic testing (mostly by fluorescence in situ hybridisa-
tion, FISH) for Her2 immunohistochemically ‘equivocal’ cases
has become a standard. Pathological evaluation of breast
specimens has shifted rapidly from a mere diagnostic pro-
cess, aimed at establishing the biological potential of a breast
‘lump’, to a far more complex integration of diagnostic, prog-
nostic and predictive parameters. The current landscape has
been further complicated by the relatively recent introduction
of a ‘molecular’ classification of breast cancer [1]. Since then
pathologists and clinicians have struggled in the attempt to
translate (or maybe to force) the classic morphological ap-
proach into a molecularly based scheme (Table 1).
Whatever the approach, the role played by the pathologist
in the clinical decision-making process has never been so
central. Establishing the correct diagnosis, as well as accu-
rately evaluating key prognostic/predictive biomarkers, repre-
sent the core of the breast cancer pathology report. Even
acknowledging the current complexity of personalised treat-
ments, it is broadly accepted that the information mandatory
for inclusion in the pathology report represents a milestone
for optimal therapeutic planning.
2. Pathological diagnosis
The pathological diagnosis of breast carcinoma still repre-
sents the key step. Before considering the complex integra-
tion of predictive and prognostic markers, it should not be
overlooked that the diagnosis of breast cancer is not always
straightforward. The presence, within the breast cancer mul-
tidisciplinary team, of a skilled breast pathologist represents
a fundamental prerequisite in order to achieve optimal thera-
peutic planning.
The World Health Organisation (WHO) has recently up-
dated its breast cancer classification, separating invasive
breast carcinoma into two broad categories: invasive carci-
noma of no special type (formerly known as invasive ductal
carcinoma) and special subtypes (Table 2). The recognition
of special subtypes is relevant as distinct morphologies often
correlate with distinct clinical outcomes [2].
Once the correct diagnosis of invasive carcinoma is made,
pathologists are asked to provide a set of morphological
parameters representing important clues to prognostic strat-
ifications. These include the size of the lesion, the presence of
lymphatic and blood vessel invasion, the status of lymph
nodes and the histological grading (Table 3). The currently
adopted grading system is that devised by Elston and Ellis,
and represents a powerful prognostic tool that represents a
key factor in clinical decision-making [3]. The so-called Not-
tingham system is based on the evaluation of differentiation
(as expressed by the amount of tubule formation), nuclear
pleomorphism (by comparing neoplastic cell nuclei with adja-
cent normal breast epithelial cells) and mitotic activity (as ex-
pressed by number of mitoses counted per 10 high-power
fields). Of course the dimension of a ‘high-power field’ de-
pends on the size of the microscope. The WHO, in its most re-
cent classification, has therefore provided a conversion table
aimed at minimising inter-observer variability [2].
As shown, pathological evaluation of haematoxylin-and-
eosin-stained slides still represents the cornerstone of breast
cancer diagnosis. Even though molecular testing is playing an
increasingly key role in several fields of cancer, it is extremely
important that morphological expertise is not lost, and that
educational efforts are supported in order to maintain diag-
nostic skills to the highest possible standard.
3. Evaluation of predictive/prognostic markers
The three main biomarkers used in the routine clinical man-
agement of invasive breast carcinoma are represented by the
oestrogen receptor (ER), progesterone receptor (PR) and HER2.
More recently, the evaluation of the Ki67 labelling index has
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been added as a further element in clinical decision-making
[4]. The ER and PR play central roles in defining the hormone
responsiveness and therefore in the selection of patients for
endocrine therapy. In the past, ER expression has been vari-
ably measured; however there is a broad consensus on the
fact that immunohistochemical evaluation of ER expression
is both sensitive and specific. Immunohistochemical mea-
surement of the ER can be effectively (and relatively inexpen-
sively) performed on formalin-fixed, paraffin-embedded
(FFPE) tissue [5]. Both the proportion and the intensity of ER
expression are evaluated microscopically, with or without
the help of digital imaging tools. Approximately 80% of inva-
sive breast carcinoma variably expresses the ER. Any cut-off
of expression has been abolished as even 1% of positive cells
would still define the tumour as hormone-responsive [5]. Still,
there is a direct correlation between level of expression of the
ER and response to both tamoxifen and aromatase inhibitors
[6,7]; however, even tumours expressing extremely low levels
of ER may benefit from hormonal therapies when compared
to ER-negative ones (8).
The PR is also routinely evaluated immunohistochemically
[8]. The ER regulates PR expression, and therefore the pres-
ence of the latter gives testament to the functional integrity
of the ER pathway [9]. Expression of the PR is detected in
approximately 60–70% of invasive breast cancers, and as with
the ER there is direct correlation between its level of expres-
sion and response to hormonal therapy [8,10].
The best estimation of response to hormone therapy is
generated by the combination of both ER and PR expression
[11]. The combination ER+/PR+ accounts for approximately
70% of invasive breast cancers and correlates with the best
anti-oestrogen response (60%). Approximately 25% of patients
exhibit an ER/PR phenotype which predicts unresponsive-
ness to hormone therapy. The ER+/PR cases are associated
with intermediate levels of response, whereas the very exis-
tence of true ER/PR+ cases is still the source of sharp debate.
HER2 (ERBB2) represents a proto-oncogene located on
chromosome 17 and is amplified in approximately 15% of
breast invasive carcinomas [12]. HER2 amplification strongly
correlates with protein over-expression that can therefore
be detected immunohistochemically. HER2 represents both a
prognostic and a predictive biomarker. HER2 amplification
not only correlates with poorer outcome [13] but also predicts
response to molecular targeted therapies aimed specifically
against HER2 (i.e. trastuzumab and lapatinib) [14,15]. HER2
status is primarily determined immunohistochemically on
FFPE tissue and scored according to broadly accepted guide-
lines [16]. Cases with strong complete membrane staining in
more than 30% of neoplastic cells (so-called 3+) are candi-
dates for anti-HER2 therapy. Negative or weakly positive cases
(so called 0 and 1+) are generally excluded, whereas cases
with continuous but less strong than 3+ membrane staining
undergo FISH to assess the presence of HER2 gene amplifica-
tion that, if present, would also qualify the patients for anti-
HER2 targeted therapy. The best response is seen in cases
showing strong HER2 over-expression and/or HER2 gene
amplification. Lack of accuracy in HER2 testing represents a
major obstacle to correct selection of patients and (analo-
gously to ER/PR testing inaccuracy) may impact on clinical
outcomes [17].
4. Towards a molecular classification of breast
carcinoma
Molecular analysis of breast carcinoma using a gene expres-
sion array approach has led to the recognition of several
genetically distinct forms [1]. Gene expression profile assays
measure quantitatively in tumour samples the expression of
each gene harboured on the array. These techniques generate
great amounts of data that need to be analysed with bioinfor-
matic techniques. Two main approaches are most often used:
unsupervised hierarchical cluster analysis and supervised
classification. Unsupervised approaches analyse gene expres-
sion within a series of tumours without using the clinical
and/or pathological information available. Hierarchical clus-
ter analysis then subclassifies tumours into distinct sub-
groups. If the aim of analysis is to identify gene expression
patterns predictive of clinical behaviour then a supervised ap-
proach seems to be more appropriate. This technique in fact
Table 2 – WHO classification of breast cancer.
Invasive carcinoma of no special type
Special types:
• Invasive lobular carcinoma
• Tubular carcinoma
• Cribriform carcinoma
• Carcinoma with medullary features
• Metaplastic carcinoma
• Carcinoma with apocrine differentiation
• Salivary gland/skin adnexal type tumours
• Adenoid cystic carcinoma
• Mucoepidermoid carcinoma
• Polymorphous carcinoma
• Mucinous carcinoma (including signet ring variant)
• Carcinoma with neuroendocrine features
• Invasive papillary carcinoma
• Invasive micropapillary carcinoma
• Inflammatory carcinoma
• Exceptional rare types and variants
Table 1 – Molecular classification of breast cancer.
Subtype Clinico-pathological
definition
Luminal A ER- and/or PR-positive
HER2-negative
Ki67 low (<14%)
Luminal B Luminal B (Her2-negative)
• ER- and/or PR-positive
• HER2-negative
• Ki67 high
Luminal B (Her2–positive)
• ER- and/or PR-positive
• HER2-positive
• Any Ki67
HER2-positive
(non-luminal)
HER2-positive
ER- and PR-negative
Basal-like Triple-negative (no special type)
• ER- and PR-negative
• HER2-negative
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specifically correlates gene expression with key clinical
parameters such as overall or disease-free survival as well
as response to a given therapy.
The unsupervised hierarchical cluster analysis of breast
carcinoma has led to a broad division into ER+ and ER cases
[18,19]. If the set of genes expressed by the two categories is
examined closely, ER+ cases are linked to breast luminal cells,
whereas ER cases are associated with myoepithelial cells.
The next step is the correlation of these subgroups with clin-
ical outcomes. This approach has led to the definition of the
entities (intrinsic subtypes) listed in Table 1: namely types
luminal A and B, HER2 and basal-like [1,20].
The attempt to correlate gene expression profiles with
clinical outcome has generated several gene signatures. The
most popular is represented by a 70-gene signature that
may determine prognosis in stage-1 or -2 node-negative pa-
tients affected by breast carcinomas smaller than 5 cm. The
70-gene signature separates patients into two groups with
good and poor prognoses, and appears to work as an indepen-
dent predictor of metastatic spread [1]. The 70-gene signature
has been popularised with the commercial label Mammaprint
which has been cleared by the FDA as an in vitro diagnostic
multivariate index assay.
An alternative approach is represented by the 21-gene
recurrence score [21]. This is a qRT-PCR-based signature com-
mercially named Oncotype DX, that predicts the likelihood of
recurrence at 10 years for ER-positive, lymph-node-negative
patients. The test provides a continuous recurrence score
(RS) and risk category: low (RS < 18), intermediate (RS 18–30)
and high (RS > 30). The 21-gene recurrence score apparently
may also correlate with benefit from chemotherapy in ER-po-
sitive breast cancer patients [21].
The clinical utility of gene expression profiling in breast
cancer has generated a lively and still ongoing debate. Even
if there is a strong pressure (particularly in the US, United
States) towards a broader use of such approaches, their po-
tential benefit seems until now to be restricted to a minority
of breast cancer patients. Nonetheless, also in consideration
of the rapid evolution (and cost reduction) of molecular genet-
ic techniques, it has to be expected that molecular assays will
be implemented increasingly in clinical practice.
5. Conclusions
Pathological evaluation of breast cancer specimens plays a
key role in planning the best therapeutic options. In addition
to accurate diagnosis of malignancy and cancer subtype,
pathologists are central in helping clinicians in the selection
of patients for both endocrine therapy as well as for anti-
Her2 targeted approaches. Precise evaluation of breast cancer
biomarkers still represents a key issue not yet entirely re-
solved, and it has been shown to impact on clinical deci-
sion-making as well as on patient outcome. It is vital that
pathology laboratories systematically implement External
Quality Control policies aimed at achieving and maintaining
the highest diagnostic standard.
The rapid evolution of molecular techniques has in part
changed the landscape of breast cancer prognostic biomark-
ers. The advent of genomic signatures certainly represents a
step forward, but their clinical utility is being still debated;
complete agreement regarding their clinical as well as their
cost-effectiveness is still to be achieved.
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Optimal approach in early breast cancer: Radiation
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A R T I C L E I N F O
Radiation therapy significantly reduces by at least 70% the relative risk of local and regional
recurrences for breast cancer after surgery. A positive influence on overall survival has been
clearly demonstrated, especially for patients with a high absolute risk for locoregional
recurrences. However, this is partially counterbalanced by late toxicity (dependent upon
the radiation dose) especially to cardiac structures. Apart from this toxicity, a clear influ-
ence of radiation-therapy-related factors on functional and cosmetic outcome has also
been demonstrated. Over time, technical improvements have led to a marked reduction
in dose to the neighbouring organs, with a consequent drop in acute and late toxicity. This
has also allowed the introduction of shorter radiation schedules, lowering the burden of
treatment to the patient and the hospital. Several tools, techniques and guidelines have
been developed to optimise the balance between the desired reduction in recurrence rates
and side effects.
The multidisciplinary team should discuss all available treatment options for every individ-
ual breast cancer patient. Individualisation of the selection of the optimal combination of
treatments, depending on patient and tumour-related factors, is of utmost importance.
Apart from direct tumour-related outcomes, cosmesis and potential side effects have to
be taken into account. Counselling should include known risk factors for survival and com-
plications, including comorbidity.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
1. Introduction
Radiation therapy (RT) forms an integral component of the
managementofearly-stagebreast cancer.Over theyears, signif-
icant progress – accelerating over time – has resulted from our
growing knowledge of the biology and the natural behaviour of
breast cancer as well as from technical improvements in RT.
While initially research focused on optimising locoregional
disease control by combining surgery with RT, the introduction
of breast-conserving therapy (BCT) initiateda periodof research
aimed at lowering the burden of treatment [1,2]. At the
same time, adjuvant systemic treatment became widely used,
resulting in a reduced risk ofmetastases and thereby improving
overall survival. The interaction between the benefits fromboth
locoregional andsystemic treatmentsopenedtheway to further
improving the clinical outcome for breast cancer patients in
terms of survival aswell as quality of life.
The 21st century started with a number of developments,
including fine-tuning of the indications for RT for each indi-
vidual target volume (intact breast, post-mastectomy chest
wall, axillary, internal mammary and supraclavicular lymph
nodes) depending on the clinicopathological features of an
individual patient’s disease, as well as hypofractionation
and accelerated partial breast irradiation.
2. Prognostic factors influencing locoregional
treatment
Several prognostic factors determine the risk of recurrence at
local, regional and distant sites. On the basis of this, recom-
1359-6349/$ - see front matter Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
http://dx.doi.org/10.1016/j.ejcsup.2013.07.028
* Tel.: +31 (0)135947765.
E-mail address: Poortmans.ph@bvi.nl.
mendations for both local and systemic treatments for pa-
tients with breast cancer are defined.
Factors influencing the risk of recurrence include tumour
size, tumour grade, margin status, lymph-node involvement,
oestrogen and progesterone receptor status, HER-2/neu status
and patient age. Whereas the relative benefit of locoregional
and systemic therapy remains largely independent of these
factors, they greatly determine the absolute benefit that can
be expected. For systemic therapy they also determine the
selection of its type (endocrine therapy, chemotherapy, trast-
uzumab, or a combination of these).
Age may also influence treatment recommendations as it
helps to predict the relative risk for death related to cancer
compared to death from other causes. In general, treatment
tolerability, especially for chemotherapy, tends to decrease
with increasing age.
Patients who are BRCA1 or BRCA2mutation carriers should
receive extensive counselling to discuss the possible ap-
proaches, including BCT and mastectomy, and even including
prophylactic contralateral mastectomy given their increased
risk of developing a second primary breast cancer in either
breast in the future [3,4].
3. Breast conserving therapy
3.1. Lumpectomy with or without radiation therapy
It is well recognised that up to 80% of patients with invasive
breast cancer may benefit from BCT, which offers rates of dis-
ease control and survival similar to those of mastectomy. This
was confirmed by the meta-analyses of the Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG) [5]. Candidates
for BCT include patients with unicentric disease that can be
removed with negative margins and with acceptable cosmetic
results.
The size of an invasive breast cancer, in relation to overall
breast size, in a patient considering BCT will determine
whether neoadjuvant chemotherapy or endocrine therapy is
required to reduce the size of the primary tumour prior to
definitive surgery. Patients with multicentric tumours and
inflammatory breast cancer are not considered candidates
for BCT. Patientswithmultifocal tumourswithin a single quad-
rant of the breast –which can be removed in a single segmental
resectionwith clearmargins and a cosmetically acceptable re-
sult – may be considered candidates for segmental resection
followed by whole-breast RT. Oncoplastic surgical techniques
that are becoming more widely used clearly extend the range
of possibilities for BCTwith acceptable cosmetic outcomes in
patients that were offered mastectomy in the past.
Excision alone without RT may occasionally be considered
for patients at low risk of recurrence. In these cases, it is rec-
ommended that the negative margins be wide (P10 mm). For
instance, patients older than 70 years with oestrogen-recep-
tor-positive T1 primary tumours may choose to forgo whole
breast RT, if they accept receiving 5 years of endocrine ther-
apy, because of their lower risk of local recurrence in the
breast. However, whole breast irradiation in this setting does
reduce the risk of local recurrence by at least two thirds [6].
Moreover, adjuvant hormonal treatment – which also carries
side effects – can be avoided if RT is given.
3.2. Boost
The purpose of the boost is to deliver additional radiation to
the area at the highest risk of harbouring microscopic resid-
ual disease: namely, the primary tumour bed and immedi-
ately surrounding breast parenchyma. Multiple studies have
shown that this area has the highest risk of recurrence in
the breast [7,8].
While the EORTC trial 10801 comparing mastectomy and
BCT demonstrated equivalent overall survival rates for up to
20 years after treatment, a significant difference in local con-
trol was seen between the participating centres, and the high
boost dose of 25 Gy that was used resulted in a significant
proportion of the patients with severe fibrosis and a poor cos-
metic outcome [9]. The next EORTC ‘‘boost’’ trial 22881/10882
paid special attention to quality assurance, fibrosis and cos-
metic scoring. The boost dose was lowered from 25 Gy to
16 Gy, which was randomised against no boost at all. This
trial and two other prospective randomised trials showed that
delivering a boost dose to the tumour bed after whole breast
irradiation significantly reduces the local recurrence rate
[7,10,11]. Young age appears to be the most significant inde-
pendent patient factor related to local recurrence. The abso-
lute effect of the boost – reducing the local recurrence rate
relatively by 41% overall – was much more marked for youn-
ger patients (Fig. 1) [7,12]. The cosmetic results were scored as
excellent to good in 86% of patients receiving no boost and in
71% of patients receiving a boost. Apart from the boost dose,
other predictors for cosmetic outcome included whole breast
dose and megavolt energy, type of boost, energy of electrons,
and use of adjuvant chemotherapy or hormonal therapy [13].
An inhomogeneous dose distribution of whole breast RT neg-
atively influenced the risk for developing fibrosis, similar to
the findings of Donovan and colleagues [14]. Based on this
trial, nomograms have been developed to predict in individual
patients the impact of a boost dose of 16 Gy on the rate of ipsi-
lateral breast relapse (http://research.nki.nl/ibr) and fibrosis
[13,15].
To evaluate the need for a further increase in the boost
dose from 16 Gy to 26 Gy for patients up to 50 years of age,
the ‘‘Young Boost Trial’’ (NCT00212121) was run in The
Netherlands, Germany and France between 2004 and 2011.
Early analysis of the results, without splitting up for the ran-
domisation arm, shows that the estimated local recurrence
rate remains far below the results obtained in trials, despite
the much younger age in the population investigated.
3.3. Accelerated partial breast irradiation
As previously mentioned, after lumpectomy with surgical ax-
illary staging, the standard of care is whole breast irradiation
with or without a boost dose. However, accelerated partial
breast irradiation (APBI) is rapidly emerging as a treatment
option for early-stage invasive breast cancer in certain clinical
scenarios. It may be considered in women who areP50 years
of age, with tumours that are pathologically 3 cm or smaller,
and node-negative. Ideally, these patients should be treated
in the framework of clinical trials because of the more limited
long-term data for APBI comparedwith those for whole breast
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irradiation [16–18]. It is expected that in the near future, after
completion of the prospective randomised clinical trials com-
paring APBI with standard whole breast irradiation, a precise
definition of the place of APBI will become available.
3.4. Young patients
It is important to see the clear decrease in local recurrence
rates over time in the EORTC 10801, EORTC 22881–10882 and
Young Boost trials (Fig. 2) [19]. The explanation of this contin-
uous improvement is multifactorial and includes technical
and diagnostic factors and the increasing use of adjuvant sys-
temic treatment. It is well established that chemotherapy and
hormonal treatment reduce local recurrence rates by about
35–50%. Indeed, according to the consensus at the time, virtu-
ally no patient who participated in the EORTC 10801 trial, and
only 31% of the patients participating in the EORTC 22881–
10882 trial, received adjuvant systemic treatment, while in
the Young Boost trial nearly all patients received systemic
treatment, often combined chemotherapy and hormonal
treatment [12]. Therefore, results from the past after BCT in
young patients should not be considered as a contraindica-
tion for offering this treatment today to patients <50 years
of age. Some caution might remain for very young patients
(635 years of age) in view of the relative scarcity of data and
the possibly different aetiological factors in these patients. In-
deed, in two large Dutch population-based cohort studies of
young breast cancer patients, conflicting results were found
on comparing BCTwith mastectomy [20,21].
3.5. Ductal carcinoma in situ
For non-invasive disease (ductal carcinoma in situ, DCIS),
treatment options depend on the extent of the disease. For
mammographically detected unifocal lesions, which can be
removed in a single lumpectomy specimen with good cos-
metic results, BCT is an excellent option. Clear surgical mar-
gins of at least 2 mm are recommended [22]. Postoperative
radiation therapy is indicated to eliminate potential residual
Fig. 1 – Cumulative incidence of breast cancer recurrence according to age group. Reproduced with permission from [7].
Fig. 2 – Local breast recurrence rate in three consecutive
trials. Reproduced with permission from [19].
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microscopic disease. Whole breast irradiation is considered
the standard of care after lumpectomy, as it reduces the risk
of recurrence in the breast by approximately 50–60% at
10 years of follow-up [23]. Half of the recurrences are invasive
cancer and half are DCIS, with a similar risk reduction for
both after radiation therapy. A boost dose to the primary tu-
mour bed might further reduce the local recurrence rate
[24]. Axillary surgical lymph node evaluation is not required
for patients with pure DCIS because it is associated with an
extremely low risk of nodal involvement. Sentinel-node
biopsy may be considered in the presence of extensive or
high-grade DCIS, especially if a mastectomy is performed.
For patients with more extensive DCIS, or for those wishing
to avoid radiation therapy, total mastectomy with or without
breast reconstruction is the preferred option.
4. Mastectomy
4.1. Chest wall irradiation
If mastectomy with surgical axillary staging is selected as the
primary surgical treatment option, recommendations for
post-mastectomy radiation therapy (PMRT) are based on the
risk of locoregional failure in the chest wall or in the undis-
sected regional lymphatics (upper part of the axilla including
the infraclavicular region, supraclavicular region, and inter-
nal mammary region). Available data are essentially based
on comprehensive locoregional treatment, making it cur-
rently impossible to define clear recommendations for chest
wall irradiation only.
If the primary tumour is <5 cm in diameter and if there is
no axillary nodal involvement, the risk of locoregional failure
is <10% without PMRT, so RT is not recommended in this clin-
ical scenario [25]. Clinicopathological factors associated with
a high risk (>20%) of locoregional recurrencewithout PMRT in-
clude four or more involved lymph nodes,P20% involvement
of the number of axillary lymph nodes, T4 tumours, and T3
tumours combined with axillary nodal involvement [25,26].
One to three positive lymph nodes after primary chemother-
apy are also associated with a higher risk of locoregional
recurrence. Therefore, PMRT is recommended in all these
clinical settings [27]. If mastectomy with surgical axillary
staging is performed prior to chemotherapy, the current Na-
tional Cancer Comprehensive Network guidelines strongly
suggest that post-chemotherapy radiation be considered to
the chest wall and undissected regional lymphatics, also in
the setting of one to three positive lymph nodes. Other tu-
mour- and patient-related factors that are associated with a
higher risk of locoregional recurrence without PMRT include:
T3, tumour size of P4 cm with involved lymph nodes, age
<40 with involved lymph nodes, grade 3, lobular histology,
lymphovascular invasion and involved lymph nodes, largest
axillary node P2 cm, gross extranodal extension of P2 mm,
involved lymph nodes with fewer than ten axillary lymph
nodes dissected, and premenopausal status with lymphovas-
cular space invasion [28,29]. As the debate on the use of PMRT
in intermediate-risk patient groups continues, most guide-
lines refer to a combination of risk factors [30,31].
Nowadays, most patients presenting with risk factors will
receive adjuvant systemic treatment. Especially in locore-
gionally advanced disease (the typical indication for mastec-
tomy), primary systemic treatment is becoming
progressively more popular. In general, the indications for
PMRT remain the same, although the pathological stage is
not reliably known and the response to systemic treatment
might be used for adjusting the recurrence risks. In general,
patients presenting with clinical stage III disease (4 or more
suspicious or confirmed positive lymph nodes on pretreat-
ment ultrasound, cT3N1 disease, or cT4 disease) prior to che-
motherapy should undergo PMRT. Patients presenting with
clinical stage IV disease who experience a complete response
to systemic therapy or those being treated with curative in-
tent should be considered for PMRT as well. In patients with
close or positive margins and clinical T3, N0 disease, PMRT
to at least the chest wall should be considered. PMRT should
also be considered in patients presenting with T1–2, N1
disease and one or more of the following clinicopathological
features: residual tumour size >2 cm, residual lymph-node-
positive disease after chemotherapy, age <40 years and
lymphovascular invasion.
4.2. Radiation therapy and breast reconstruction
The number of women requesting breast reconstruction after
mastectomy is increasing. In particular, immediate breast
reconstruction (IBR) is becoming more popular for breast can-
cer patients who are not good candidates for breast-conserving
therapy. Uncertainty exists about the preferred type (using
implanted material, autologous tissue, or a combination) of
IBR in patients requiring PMRT to minimise the complication
and reoperation rates and to optimise cosmetic outcome.
Other concerns are the safety and efficacy of IBR, the possible
risk of a delay in starting adjuvant systemic treatment and
the influence on the quality of RT delivery in terms of dose
homogeneity and target volume coverage [32,33].
In general, PMRT is associated with a higher rate of capsu-
lar contracture following IBR using an implant. However, good
results can be obtained in the majority of these patients [34].
Fewer data exist on PMRT following IBR using autologous tis-
sue, although most authors report that the outcome in terms
of complication rates and cosmetic results is better when
compared with implant reconstruction only [32,35,36]. Surgi-
cal intervention, including free fat grafting, can be used to im-
prove – if needed – long-term results after IBR and PMRT. Most
data confirm that IBR is not associated with a significant delay
in starting adjuvant therapy. A homogeneous dose of radia-
tion to the chest wall with/without the regional lymph nodes
can be delivered with acceptable heart and lung doses if opti-
mised modern RT techniques – including procedures for
adjustment of respiratory movement, highly conformal 3D
and IMRT – are appropriately used (Fig. 3) [37,38].
Few data are available on the influence of pre-reconstruc-
tion PMRT on tissue expander breast reconstruction. In
general, a higher frequency of capsular contracture and a
slightly higher reoperation rate for procedures using implants
are seen, leading to worse patients’ and surgeons’ subjective
evaluations. On the other hand, a history of PMRT alone
should not dictate the type of reconstruction [39]. Patients
who develop neither severe skin changes nor subcutaneous
fibrosis may still be considered for implant-based breast
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reconstruction [35,40–42]. Pre-reconstruction RT seems not to
influence the overall success rate of reconstruction using
autologous tissue, nor to contribute to postoperative compli-
cations. However, it increases the rate of vascular complica-
tions in free flap breast reconstructions, seen mostly during
surgery itself. In general, the cosmetic outcome and satisfac-
tion in women reconstructed with autologous tissue is higher
than in those with implant-based reconstruction. The opti-
mal timing for breast reconstruction after PMRT is unclear.
Often, an interval of 12 months between PMRT and recon-
struction is advised, but some state that breast reconstruction
with autologous tissue can potentially be performed earlier
[43,44].
5. Regional radiation therapy
The indications for regional RT are independent of the type of
surgery to the breast (BCTor mastectomy). Therefore, most of
what was stated in the subsection ‘‘chest wall irradiation’’ is
also applicable to this chapter.
The EBCTCG overview confirmed that PMRT and RT in the
framework of BCT improves specific and overall survival in all
breast cancer patient subgroups with involved axillary lymph
nodes as well as in node-negative patients treated with BCT
[45]. In most older trials, comprehensive locoregional RTwas
used. Based on this, a division into three risk categories for
locoregional relapse is made with a proposal for selecting
the target volumes for RT (Tables 1 and 2) [46].
The clinically most relevant drainage of the breast tissue is
to the ipsilateral lower axilla. Therefore, staging most often
includes at least a sentinel-node biopsy to estimate the de-
gree of axillary lymphatic involvement by the tumour; this
provides the most important single prognostic factor for pa-
tients with breast carcinoma. In general, nodal involvement
occurs in an orderly fashion [47]. The other major route of
lymphatic spread is via the ipsilateral internal mammary
chain (IMC). They are primarily found in the first three
intercostal spaces. Internal mammary chain drainage is cor-
related with tumour location in the breast [48]. The identifica-
tion rate for IMC disease with sentinel node procedures
depends on the technique of the procedure itself, being high-
est with an intra-tumoural injection of tracer followed by a
peri-tumoural injection, and lowest with a subdermal or
peri-areolar injection [49].
Supraclavicular nodal involvement generally represents
stages of advanced regional disease and carries a poorer prog-
nosis. The major route of cancer spread to the supraclavicular
lymph nodes is via the axillary lymph nodes [50].
Since the publication of the ACOSOG Z0011 trial – showing
that axillary surgery is probably not required for patients with
a positive sentinel-node biopsy and treated with BCT, includ-
ing tangential field irradiation to the whole breast – uncer-
tainty exists about RT to a positive axilla without further
axillary clearance [51]. A proposal based on the combination
Fig. 3 – Individualised treatment plan using multiple electron beams for chest wall irradiation in a patient with an immediate
breast reconstruction with an implant (a) axial slice; (b) sagittal slice).
Table 1 – Risk categories for locoregional relapses after
mastectomy and axillary clearance. Ax LN +, involved
axillary lymph nodes. Reproduced with permission from
[47].
Risk category Low Intermediate High
Tumor stage T1-2 T1-2 T3-4
Number of Ax LN + 0 1-3 > 3
Grade 1-2 3
Vascular invasion - +
Histology ductal lobular
Risk < 10% 10-20% > 20%
Table 2 – Indication for irradiation of the different target
volumes after mastectomy and axillary clearance as well as
for regional radiation therapy (RT) in the framework of
breast-conserving therapy (BCT). Yes, evidence and gener-
ally accepted; Yes?, evidence but not generally accepted;
No?, limited evidence, however advocated by some authors;
No, no evidence. Reproduced with permission from [47].
Risk category Low Intermediate High
Thoracic wall No? Yes? Yes
Supraclavicular No? Yes? Yes
Internal mammary No Yes? Yes?
Axilla No No No
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of several treatment- and tumour-related factors is being
developed in the Netherlands.
6. Radiation related toxicity
There is ample evidence to suggest that cardiac irradiation is
detrimental, although cardiac consequences of RT of the
breast have long latencies estimated to become detectable
onlyP15 years after treatment. The EBCTCG overview of ran-
domised trials demonstrated that the gain in locoregional
control was not fully translated into an improvement in over-
all survival, suggesting that survival benefit with RT becomes
at least partially offset by increased cardiovascular deaths [5].
In particular, radiation techniques that have incorporated
large volumes of the heart have been shown to negatively im-
pact on overall survival [52].
Therefore,minimising cardiac irradiation is a critical aspect
of treatment planning. Depending on the individual case,
changing the gantry angle, the collimator angle, or shaping –
with small cardiac blocks or MLC leaves – the borders of the
medial and/or lateral tangential fields can result in adequate
coverage of the primary tumour site and most of the breast
while excluding the heart from the high-dose region. These
treatment fieldmodifications should be customised to the nor-
mal tissue anatomy of the individual patient, the location of
the primary tumour bed and the contour of the breast. In addi-
tion, in cases where the tumour bed is very close to the heart,
treatment at deep inspiration can be advantageous [53–55].
Further research is warranted to understand the dose–re-
sponse relationship leading to radiation-induced cardiovas-
cular disease. Current research focuses on the one hand on
optimising the radiation therapy techniques to limit the expo-
sure of cardiac structures and lung tissue to radiation, and on
the other hand on examining which cardiac substructures are
most related to the induction of late toxicity and mortality
[52,56–58]. Of importance is also the requirement to conduct
proper follow-up, which is indispensable for evaluation of
long-term treatment effects after radiation therapy and to ad-
vise patients on how to adapt their life style in the case of an
elevated risk of cardiovascular toxicity [59].
7. Technical developments
Donovan and colleagues were among the first to confirm on a
clinical level the advantages of optimisation of RT dose distri-
bution. In a randomised prospective trial they investigated
the influence of dose homogeneity on late adverse effects
after BCT to evaluate whether the additional costs in infra-
structure and staffing are justified [14]. With forward-planned
IMRT, they minimised dose inhomogeneity in the breast
significantly. Of great importance is that they were able to
associate this with the change in breast appearance during
follow-up as scored by photographic as well as by clinical
assessment. These results confirm the sensitivity of late
normal tissue effects to fraction size [60]. Therefore, 3D dose
planning should be routinely implemented, even more with
hypofractionated RT schedules.
A broad spectrum of RT techniques are described in the lit-
erature, ranging from low complexity (conventional, wedge-
based approaches using limited beam angles) to highly mod-
ulated, multiple-angle photon techniques [61–63]. As some of
the highly complex techniques might lead to a higher dose to
the organs at risk (heart, lungs, contralateral breast), their
implementation should be carefully considered and coupled
with other technological improvements [64].
A rapidly increasing number of RT departments are using
hypofractionated RT schedules, especially after the publica-
tion of the long-term results of large prospective trials
[65–67]. With this, whole breast RT duration can be reduced
from the conventional 5 weeks to 3 weeks. Adding to this
obvious advantage to the patients, a boost dose for BCT is
becoming more selectively applied to only those patients with
a high risk of local recurrence, reducing the treatment by
1–1.5 weeks and decreasing the risk of fibrosis.
The use of electrons and brachytherapy as boostmodalities
is gradually being replaced by 3D-CRT photon beam tech-
niques. Interest in this technique has recently been stimulated
with the introduction of the simultaneous integrated boost
(SIB) technique, in which the dose to the whole breast is com-
bined with a simultaneous boost to the primary tumour bed
[68]. Apart from logistical advantages for the RT department,
it significantly reduces the boost field sizes thanks to both im-
proved conformality and electronic equilibrium [69].
Patients with large pendulous breasts may be treated in
the prone position to minimise skin folds in the breast, such
as the infra-mammary fold. Placing the patient in the prone
position also allows the surgical bed to fall farther away from
the rib cage, increasing the distance between the cardiac
structures and the lumpectomy site.
Breathing-adapted treatment reduces the impact of respi-
ratory motion on the motion of the target volume. Treatment
delivery under deep inspiration also increases the distance
between the breast and the heart for left-sided breast cancer
patients, reducing the RT dose to the heart [53–55,70].
8. Challenges
8.1. Target volume delineation
The primary objective of radiation therapy is to eradicate
microscopic residual disease after surgery. The areas at high-
est risk of recurrence after mastectomy are the chest wall and
the undissected lymph-node regions. In the case of BCT, the
entire breast can contain residual or potential multicentric
disease as well. On the basis of the work by Holland et al.,
the highest residual tumour cell density is expected to be
adjacent to the original tumour site [71]. This explains why
at least 80% of the early failures after BCT occur in the same
quadrant as the original primary tumour.
The regions to be treated constitute the clinical target vol-
umes, to which an additional margin needs to be included to
account for internal motion, patient motion, and setup uncer-
tainty, resulting in the planning target volume that will be
used for RT planning. The transition from clinically set-up
1D treatments to fully virtually prepared 4D RT plans is highly
dependant on proper target volume delineation, which is con-
sidered by most radiation oncologists as currently being the
weakest link in the quality chain of breast cancer RT, with a
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high inter-observer variation [72]. These variations appear to
be clinically significant both in terms of dosimetric target cov-
erage as well as exposure of the organs at risk [73]. To improve
consistency in target volume delineation, a number of initia-
tives have been undertaken, after which it has been demon-
strated that training as well as the availability of clearly
written guidelines decreases inter- and intra-observer vari-
ability [72]. ESTRO has given a high priority to increasing its
online educational and professional services. Within this re-
source, a multifunctional platform for volume delineation
has been created. This will also be used to facilitate the orga-
nisation of teaching courses and the writing of internationally
accepted guidelines.
8.2. Individualisation
To properly individualise, we should take into account several
factors, including prognosis, risk-to-benefit ratios, patient
expectations and specific anatomy. Therefore we should con-
sider every single patient as a unique combination of per-
sonal, disease and anatomical factors. Based on this we can
discuss proper decision-making in a multidisciplinary setting
and with the patient.
As for RT, treatment planning – based on a complete 3D
dataset – can now be fully individualised to the patients’ anat-
omy and the delineated target volumes, taking into account
the dose to normal structures. In general, a standard set-up
RT technique will fit most patients, and every department
should accrue experience with a standard approach that best
fits their own way of working. However, individualisation of
techniques should be done on the basis of the anatomy of
each single patient. As an example, the entire chest wall
may sometimes be treated with electron-beam fields [57].
With a five-field technique a homogeneous dose to the tho-
racic wall (and the IMC if indicated) can be delivered with a
much lower dose to the underlying lungs and heart compared
with tangential photon fields, especially in patients with a
markedly curved thoracic wall [74]. Also, a partially wide tan-
gential approach, including the IMC lymph-node region to-
gether with the chest wall or breast in a single pair of fields,
can be used when a separate IMC field cannot be employed
due to the patients’ anatomy.
8. Future perspectives
The future lies in a multidisciplined approach and a coming
together of the indications for all types of treatment, includ-
ing surgery, RT and systemic treatment. At present, few treat-
ments are clinically linked (such as lumpectomy combined
with whole breast RT). However, we can no longer neglect
the interactions within the therapeutic spectrum. Therefore,
we should focus more on treatment packages instead of sim-
ply adding one treatment to another.
As an example, the management of the axilla is expected
to change markedly in the coming years. Even the standard
use of the sentinel node procedure is challenged in some pa-
tient categories where the need (or lack of need) for systemic
treatment can be estimated on the basis of other prognostic
information. Use of axillary clearance as a routine procedure
is rapidly decreasing andmight even become extinct when re-
sults from trials such as the EORTC AMAROS trail become
known [75].
Another example is the issue of the patient at very low risk
who might be offered years of hormonal treatment or a short
course of whole or partial breast RT, with the challenge of
demonstrating the added value of combining both ap-
proaches together. This fits well into the drive to optimise
the cost/benefit ratio of cancer treatment, especially in times
of limited financial resources [76].
The response to systemic treatment can be used in high-
risk patients as a predictor for improved survival. It is likely
that these high-risk patients might benefit most in terms of
overall survival from optimal locoregional treatment [77]. Per-
haps a proportion of these patients might even be treated
without surgery.
Another issue that will only be solved after the presenta-
tion of data from recent prospective trials is the selection of
the areas to be treated. While irradiation of the IMC lymph-
node area is the most strongly debated, an early analysis
did not show an increased level of toxicity [78].
New biological targeted agents should be tested in combi-
nation with RT. Similar to chemotherapy, several studies test-
ing the prognostic and predictive value of genomic and
proteomic tests are being conducted.
The duration of RT for breast cancer has reduced from 6–
7 weeks to 3–4 weeks over the last few years. Further reduc-
tion to even fewer fractions in a shorter time period is the
subject of recent and ongoing trials [79]. This should help to
end the discussion about the sequence of RT and systemic
treatments by decreasing the possible postponement of the
latter with a shorter RT course.
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Introduction
Optimal approach for localised rectal cancer
CJA Punt *
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Rectal cancer remains one of the most challenging tu-
mours in respect of local treatment. The many disciplines in-
volved, the development of new insights and novel treatment
strategies, and the close correlation between quality of care
and outcome provides a fascinating scenario. In this educa-
tional session several of these aspects are discussed, and will
be of interest to surgeons, radiotherapists, medical oncolo-
gists, radiologists and pathologists.
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Optimal imaging staging of rectal cancer
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1. Clinical significance of imaging
A patient diagnosed with rectal cancer is managed by a mul-
tidisciplinary team in which the radiologist nowadays partic-
ipates as a full sparring partner. His/her imaging findings can
influence the treatment decision-making. The local staging
work-up consists of endorectal ultrasound and/or magnetic
resonance imaging (MRI). The distant staging work-up de-
pends on the local policy but often consists of ultrasound or
computed tomography (CT) of the liver and chest X-ray or
chest CT. While previously all patients underwent a standard-
ised resection, nowadays there is evidence that imaging can
identify the high risk patients with locally advanced rectal
cancer whose tumour is threatening or invading the mesorec-
tal fascia and needs preoperative treatment. This article dis-
cusses the role of the different imaging modalities for local
staging and restaging of rectal cancer and their accuracies
for identifying the risk factors for local recurrence and for
assessing response to preoperative chemoradiotherapy. The
chapter ends with future perspectives in rectal cancer
imaging.
2. Staging modalities
2.1. Endorectal ultrasound (EUS)
The main strength of endorectal (or endoluminal) ultrasound
(EUS) is its excellent spatial resolution, particularly for tissues
that are located near the ultrasound probe. For tissues that
are at a greater distance from the probe, the performance of
EUS is limited. As a result, EUS is accurate mainly for the
assessment of tumour ingrowth in the bowel wall and hence
for the discrimination between tumours that are limited to
the submucosa (T1) versus tumours showing ingrowth in
the muscularis externa (T2). For the evaluation of tumour
penetration into the perirectal fat (i.e. T3 tumours), EUS
reaches results similar to those of MRI and experiences the
same interpretation difficulties; these are related to problems
in distinguishing desmoplastic stranding in T2 tumours from
tumour stranding in T3 tumours (see section on tumour stag-
ing). Because of its limited field of view, EUS is less suitable for
the assessment of tumour infiltration into the mesorectal fas-
cia (MRF), tumour extension to the high dorsal pelvic wall and
evaluation of lymph nodes – in particular those in the high
mesorectum along the superior rectal vessels. Furthermore,
it is often difficult to position the ultrasound probe and visu-
alise high and/or stenosing tumours, resulting in inconclusive
results in >10% of patients [1]. Another drawback of EUS com-
pared to cross-sectional imaging techniques is that it is highly
operator-dependent and requires a learning curve before opti-
mal diagnostic performance can be obtained [2]. A potential
benefit of EUS compared to CTand MRI is that it allows for tis-
sue biopsies within one single examination, so that histopa-
thological confirmation can immediately be obtained.
2.2. Computed tomography (CT)
Multislice CT (MSCT) is often considered the modality of first
choice for the distant staging of colorectal cancer (e.g. the
detection of metastatic spread to the liver and/or lungs).
Although it has been proposed by some authors that
simultaneous staging of the rectal tumour using CT as a
‘one-stop-shop’ imaging tool may be beneficial, there are
several drawbacks to the use of CT for assessing the local
tumour status. First of all, the soft tissue contrast of CT is
limited, making it more difficult to distinguish between
tumours limited to the bowel wall and those which have
penetrated the wall. For the assessment of an involved
mesorectal fascia, MSCT is reported to have moderate to poor
accuracy (54–66%). Interestingly, CT can reach fairly good
diagnostic performance for assessing the MRF in tumours
that are located in the mid–high rectum with reported
positive predictive values (PPVs) and negative predictive
values (NPVs) of 86% and 94%, respectively. It is particularly
in low rectal tumours where the limited soft tissue contrast
of CT hampers a reliable differentiation between the tumour
and surrounding structures, resulting in a PPV and NPV of
only 53% and 73% in assessing an involved MRF [3]. For the
evaluation of lymph nodes, CT experiences the same difficul-
ties as MRI and EUS, which are discussed in detail below.
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2.3. Positron emission tomography (PET)
PET allows for the detection of metabolically active tissues
(e.g. malignant tumours) using tumour-tracing radiopharma-
ceuticals, of which in oncology the glucose analogue 18F-fluo-
rodeoxyglucose (18F-FDG) is the most widely adopted. FDG-PET
can be performed in combination with computed tomography
(CT). This hybrid PET–CT allows for a simultaneous assess-
ment of tumour morphology together with the functional
information from PET. The role of PET(–CT) for the primary
staging of colorectal cancer is limited. Because PET is known
to miss small metastatic lesions in the liver – due to its
limited spatial resolution – it is not recommended as the
staging modality of first choice. However, in patients with
known liver metastases scheduled for liver surgery, PET(–CT)
is very accurate in excluding the presence of extrahepatic le-
sions such as lymph-node and bone metastases. In this con-
text, the use of PET can significantly decrease the number of
futile laparotomies [4]. A second clinical application of PET(–CT)
is the detection of recurrent tumours in patients with a
suspected recurrence after primary surgical treatment for
colorectal cancer. In this setting PET has advantages over
CT, MRI and EUS in differentiating between recurrent tumour
and postoperative scar tissue. Recently there is a growing
interest in the use of PET(–CT) as a tool to predict treatment
response in patients with locally advanced rectal cancer trea-
ted with chemoradiotherapy. Assessment of the decrease in
the standardised uptake value (SUV) during chemoradiation
has been reported by several authors to be a strong indicator
for therapeutic efficacy [5]. Although at present these findings
will not yet impact the treatment plan, in the future early re-
sponse prediction using functional imaging methods such as
PET may be of great clinical value as this may allow for early
treatment adaptations to enhance the chance of a good ther-
apeutic response.
2.4. Magnetic resonance imaging (MRI)
MRI using modern phased-array external coils offers the
advantages of an excellent soft tissue contrast, high spatial
resolution and a large field of view. This makes MRI an invalu-
able technique for detailed morphological information on
both the tumour and its extension into the surrounding mes-
orectal compartment and neighbouring organs. MRI is the
recommended imaging method for staging and restaging of
rectal cancer in most European countries. The following sec-
tions will elaborate on aspects of MRI relevant for rectal can-
cer imaging, including the optimal MR protocol.
3. MRI protocol for the staging of rectal cancer
3.1. Patient preparation
MRI using phased array external coils has become the stan-
dard technique for state-of-the-art imaging of rectal cancer.
MRI using an endorectal coil, although similar in performance
to EUS for the assessment of superficial (T1 and T2) tumours,
has not gained worldwide acceptance. First, endorectal MRI is
more cumbersome in application and less patient-friendly
than EUS and does not allow for simultaneous tumour biop-
sies, which is an added advantage of EUS. Furthermore, coil
positioning for endorectal MRI can be very difficult, particu-
larly in high and/or stenosing tumours. For phased array
MRI routine use of spasmolytics or bowel preparation is not
required. Nevertheless, occasional use of spasmolytics may
be helpful when severe bowel movement artefacts are already
visible on the (sagittal) planning scan, particularly in patients
presenting with tumours situated high in the rectum and
thus nearer to adjacent small bowel loops. Use of endorectal
contrast or filling (for example using ultrasonography gel) is
not recommended as part of standard clinical routine. The
main argument for applying endorectal filling is to allow a
more confident assessment of the exact tumour location
within the lumen, particularly in smaller-sized tumours [6].
However, given the fact that information on the tumour loca-
tion is given during endoscopy, the use of intraluminal filling
does not outweigh its potential disadvantages. Apart from the
patient burden, the introduction of endorectal contrast
causes stretching of the rectal wall which in turn compresses
the mesorectal compartment. Hence, rectal distension may
hamper the assessment of lymph nodes in the mesorectal
compartment and can also result in overestimation of tumour
invasion of the mesorectal fascia [7], which are in fact two of
the principal important factors that need to be evaluated with
MRI (see also section below on assessing risk factors for local
recurrence).
3.2. Imaging sequences
A standard rectal MR protocol should consists of multiplanar
T2-weighted Fast Spin Echo (T2W FSE) sequences, since these
offer an optimal soft tissue contrast between the tumour, the
mesorectal fat and the mesorectal fascia surrounding the
mesorectal compartment. The optimal slice thickness of the
T2W sequences ranges between 1 and 3 mm and should not
exceed 5 mm. A sagittal T2W sequence should be first ob-
tained in order to localise the tumour and allow for proper
angulation of the axial and coronal planes. It is of the utmost
importance that the axial and coronal planes are angled ex-
actly perpendicular and parallel to the longitudinal tumour
axis (as identified on the sagittal scan) so that the relationship
of the tumour with the surrounding organs and structures
can reliably be assessed. In very low rectal tumours the coro-
nal sequences should be angled parallel to the anal canal to
establish the relation of the tumour to the pelvic floor and
anal sphincter musculature. There is no solid evidence yet
for the routine use of additional sequences other than T2W
sequences in three planes. Fat-suppression sequences are
not recommended since they do not allow a proper apprecia-
tion of the mesorectal fascia. A (non-enhanced) T1-weighted
sequence may be useful for the evaluation of coincidental
findings in other pelvic organs, but is not required for the
staging of rectal cancer. There is no solid indication for the
administration of intravenous contrast agents. Gadolinium
contrast was shown not to be beneficial for T-stage and
CRM evaluation [8]. Although experimental studies have
investigated the use of dynamic contrast-enhanced MRI and
lymph-node-specific contrasts, at the time of writing these
techniques are not yet recommended for daily clinical
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practice [9–11]. Similarly, diffusion weighted imaging (DWI)
sequences have so far been obtained mainly in research pro-
tocol settings, although there is growing evidence that the
addition of DWI may be valuable, especially in the restaging
setting after chemoradiation to re-evaluate the primary tu-
mour (see also section on diffusion-weighted MRI below).
4. Assessing the risk factors for local
recurrence using MRI
There are four main risk factors for developing a local recur-
rence, which are used to determine treatment planning: (1)
the tumour height (low, middle or upper third of the rectum),
(2) the local extent of the tumour (T-stage), (3) involvement of
the mesorectal fascia and (4) nodal involvement (N-stage).
4.1. Tumour height
Tumour height is an important parameter as low rectal tu-
mours (e.g. within the first 5 cm above the anal verge) are
known to have a worse prognosis than tumours situated
higher in the rectum. As a result of the distal tapering of
the mesorectum and consequent decrease of the thickness
of the fat plane surrounding the rectum, low tumours have
a relatively close relationship with the mesorectal fascia,
the pelvic floor muscles and the anterior pelvic organs (pros-
tate/seminal vesicles in men and vagina/uterus in women)
and have a higher risk of invasion.
Although the tumour height can be accurately measured
on MRI (often using the anorectal junction as a reference
point) the surgeon is generally already aware of the tumour
location from his endoscopic assessment, so often this is
not one of the strong arguments to perform imaging. In the
United States, the location of the tumour in relation to the
peritoneal reflection is often used as an additional landmark
to determine whether a patient requires neoadjuvant treat-
ment (if the tumour is below the peritoneal reflection) or
not (if the tumour is above the peritoneal reflection). The level
of the tumour in relation to the peritoneal reflection can be
accurately assessed using MRI [12].
4.2. Tumour (T-)stage
The overall reported accuracy for T-stage prediction with
phased array MRI varies between 67% and 83% [13]. The main
strength of MRI is the evaluation of large T3 tumours that
penetrate the muscular rectal wall and T4 tumours invading
adjacent organs, for which MRI has been reported to achieve
sensitivities and specificities of 74% and 76% (in T3 tumours)
and 82% and 96% (in T4 tumours), respectively [14]. MRI, how-
ever, is known to have difficulties in differentiating between
superficial T1 and T2 tumours. As opposed to EUS, with MRI
it is not possible to separately appreciate all three layers of
the rectal wall. The submucosal layer of the rectal wall is
not visualised on phased-array MRI (except when there is oe-
dema). Hence, differentiation between a T1 tumour limited to
the submucosa and a T2 tumour penetrating the muscularis
propria is not feasible. Consequently, EUS remains the corner-
stone technique for the selection of superficial T1 tumours
that can be considered for local excision. Another limitation
of MRI (as well as EUS) is the differentiation between T2 and
borderline T3 tumours. Desmoplastic strands into the meso-
rectal fat in a T2 tumour without actual tumour infiltration
cannot be discriminated from desmoplastic reactions con-
taining tumour nests indicating a T3 tumour. In practice, this
results in the over-staging of a considerable number (up to
40%) of T2 tumours because radiologists tend to err ‘on the
safe side’ rather than risk under-staging [15,16]. Only when
the bowel wall on T2-weighted MR images is visualised as a
completely intact hypointense line around the tumour does
this indicate an intact muscular bowel layer, which can be
used as a reliable predictor for the tumour being limited to
the bowel wall (T1–2) with a PPV of 86–91% [17].
4.3. The mesorectal fascia (MRF)
Preoperative knowledge of tumour involvement of the MRF is
critical in order to determine whether it will be possible to ob-
tain a complete resection of the tumour. Assessment of the
MRF is only relevant in the case of a T3 or T4 tumour. When
it is established that the tumour is surrounded by an intact
bowel wall (indicating a T1–2 tumour) the MRF will never be
involved [13]. In the case of a PT3 tumour, the relation be-
tween the tumour and the MRF should be evaluated (i.e. the
circumferential resection margin at TME). When the tumour
invades the MRF or extends within a margin of <1 mm, the
MRF is involved. It is well known that MRI is very accurate
in evaluating tumoural involvement of the MRF. In a large pa-
tient cohort the MERCURY study group found an overall accu-
racy of >90% for MRI in predicting tumour involvement of the
MRF [18]. In a meta-analysis of seven individual reports
(including the MERCURY cohort) sensitivities and specificities
for MRI ranged between 60% and 88% and between 73% and
100% respectively [19].
4.4. Lymph nodes and extramural venous invasion (EMVI)
In addition to MRF involvement, lymph-node status com-
prises one of the main factors that determine the necessity
for the addition of neoadjuvant radiotherapy and/or chemo-
therapy. Unfortunately, so far MRI, EUS and CT have not
proved to be sufficiently accurate to determine the nodal sta-
tus. Themain problem is that imaging relies on nodal size (i.e.
short axis diameter) as the main criterion to discriminate be-
tween benign andmetastatic nodes. In rectal cancer in partic-
ular it is known that size is not a reliable predictor because
metastases frequently occur in small (<5 mm) nodes [20]. As
a result there is no reliable size threshold, and cut-off sizes
have been reported ranging from ‘any visible node’ to
>1 cm. In practice, the chosen size threshold depends mainly
on the desired balance between sensitivity and specificity,
more often favouring the former. Two meta-analyses that
analysed the pooled data from nodal imaging studies using
size criteria on EUS, CTor MRI showed similarly poor sensitiv-
ities and specificities in the range of 55–78% [14,19]. Some
authors have shown that the use of morphological criteria
in addition to size can improve the diagnostic performance
of imaging in assessing the lymph nodes with reported sensi-
tivities of 36–85% and specificities of 95–100% [21,22]. Nodes
with a sharply delineated border and homogeneous signal
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intensity tend to be benign. In contrast, nodes with an irreg-
ular border and heterogeneous signal pattern are more likely
to be involved. These criteria have not, however, been widely
implemented into clinical practice, probably partly because
these features are quite difficult to evaluate in very small
nodes (62–3 mm). Apart from nodes within the lower and
mid mesorectal compartment, a report on rectal cancer
should also mention any suspicious nodes that are located
high in the mesorectum, along the superior rectal vessels,
as well as outside the mesorectum below the internal iliac
bifurcation at the root of the medial rectal vessels (the lateral
nodes), as involvement of these nodes harbours a higher risk
for distant and local recurrence and will need to be included
in the radiation field and/or removed with surgery.
Extramural venous (or vascular) invasion (EMVI) is the
presence of tumour invasion in the veins in the vicinity of
the tumour. EMVI, as established at histology, is known to
be associated with an increased risk of local and distant
recurrence and an impaired overall survival [23]. As such,
EMVI is considered an important prognostic marker at histo-
pathology. It has been shown that the presence of EMVI can
be assessed on MRI based on the presence of tumoural signal
intensity within vessels surrounding the rectum, or the pres-
ence of a nodular expansion or irregular vessel contour as cri-
teria [24]. It has furthermore been suggested that the
presence of EMVI may be related to the presence of nodular
disease, since lymphatic vessels run parallel to blood vessels
and may therefore be simultaneously invaded by the tumour.
In one report, a high EMVI score had been shown to predict
the presence of N2 disease with low to moderate sensitivity
(56%) and relatively high specificity (81%) [25]. The exact cor-
relation between EMVI and the presence of nodal metastases,
however, is not well established.
5. Restaging after neoadjuvant treatment
Traditionally, restaging with MRI after neoadjuvant treatment
had only a limited role, since the surgeon would proceed with
the original surgical treatment plan as determined on the ba-
sis of the primary staging MRI, regardless of the response
after chemoradiotherapy. Nowadays the role of restaging with
imaging is emerging as surgeons recognise its value for plan-
ning the surgical approach. For example, if a tumour is shown
to have downsized and retracted from initially invaded organs
and/or the MRF, a standard total mesorectal excision (TME) in-
stead of a more extended pelvic resection can be considered.
Retraction from the anal canal may allow for sphincter-
preserving surgery. Although still controversial, alternative
treatments such as a local, transanal excision or deferral from
surgery (a so called ‘wait-and-see policy) in the selected group
of very good or complete responding patients have been re-
ported by several groups with very promising results [26,27].
This paradigm shift in treatment puts the relevance of a
restaging with imaging into a whole new perspective.
Although the importance of a restaging MRI is acknowledged,
there is no clear consensus on what should be the time inter-
val between the completion of the neoadjuvant treatment
and the response evaluation with imaging. It is believed that
a longer interval (i.e. at least 6 weeks) provides better insight
into the final treatment response.
5.1. Residual tumour versus fibrosis
Basically, a report of a restaging MRI should include an
assessment of the same items as during primary staging
(i.e. T-stage, MRF and N-stage). However, an important addi-
tional challenge in the restaging setting is the interpretation
of post-treatment fibrosis. As a result of the chemoradiother-
apy the tumour and nodes shrink and become fibrotic. On
post-treatment T2W MRI this fibrosis is visualised as a hypo-
intense bowel thickening at the previous site of the primary
tumour or in the nodes. It is extremely difficult to differenti-
ate between mere fibrosis and fibrotic tissues still containing
(small) islets of residual tumour. Because radiologists will
tend to over-stage rather than under-stage, relatively high
over-staging rates (up to 50%) as compared with primary stag-
ing have been reported. Overall accuracies for determining
the T-stage after chemoradiotherapy (the yT-stage) range be-
tween 43% and 60% [28,29]. More favourable results have been
suggested for the selection of patients with a ‘good’ tumour
response (i.e. tumour down-staging to yT0–2). It has been
shown that post-CRT MRI can accurately predict tumours that
are confined to the bowel wall (ypT0–2) with PPVs of 86–91%
and NPVs of 70–75% [17]. However, for the specific selection
of patients with a complete tumour response (yT0) results –
in particular PPV – are much poorer, and up to 80% of patients
with a complete response are over-staged as having residual
tumour [15,30]. This suggests that, using standard MRI, it will
be very difficult to select patients for a ‘wait-and-see’ policy.
5.2. Tumour regression from the MRF
Similar to restaging of the tumour, the reassessment of the
MRF is hampered mainly by difficulties in interpreting post-
treatment fibrosis. In the case of residual fibrotic involvement
of the mesorectal fascia, it is difficult to determine whether
there is still actual tumour involvement and a substantial
number of patients will be over-staged. However, there are
some patterns that can help radiologists in confidently
assessing tumour clearance from a previously involved MRF.
If a fatpad of >2 mm reappears between the tumour and
MRF, we can be confident that the MRF will be free of tumour.
If there is only some residual (fibrotic) stranding into the MRF,
the MRF will also be likely to be free of tumour [31]. NPVs in
the range of 91–100% have been reported for reassessment
of MRF involvement after CRT indicating that the patients
with a free MRF can be reliably selected. PPVs, however, are
much lower (ranging between 44 and 68%), reflecting the
over-staging problems described above [18,28,31]. Park et al.
suggested that the evaluation of tumour clearance from the
MRF after CRT may be improved by the addition of diffu-
sion-weighted imaging, although these results have not (yet)
been confirmed by other studies [32].
5.3. Lymph nodes and EMVI after chemoradiation
As a result of chemoradiation treatment the majority of the
lymph nodes will decrease in size or even completely disap-
pear. Hence, the median number and size of lymph nodes
after CRT is significantly lower than at primary staging. The
main aim of re-evaluating the nodal stage after CRT is to
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establish whether there are remaining metastatic nodes left
inside but also outside the mesorectum, or if all initially sus-
picious nodes have become sterilised. In the latter case, a pa-
tient with a concomitantly good response of his primary
tumourmay be a candidate for organ-saving treatments (local
excision or wait-and-see), yet at the time of writing this is still
within the scope of clinical trials and not clinical routine. A
careful comparison of nodes before and after chemoradiation
is of crucial importance when interpreting nodes on post-CRT
MRI. Also, a re-evaluation of any initially suspicious extra-
mesorectal nodes should be performed in order to determine
whether a lateral lymph-node dissection will be required. The
diagnostic performance of post-chemoradiation MRI for
restaging of the nodes is reported to be equal or slightly better
than with primary staging MRI, with accuracies varying from
64% to 88% [28,33,34]. The criteria used for the restaging of
nodes are similar to those used for primary nodal staging
(size and, to a lesser extent, the nodal border and signal inten-
sity), but it has been suggested by some authors that size cri-
teria work better in the restaging setting. A possible
explanation for this is that many irradiated nodes disappear,
and of the remaining small nodes over 80% are sterilised [35].
Hence, nodes that remain large in size after CRT are more
likely to be malignant.
There is no evidence (yet) to support the benefit of the re-
evaluation of EMVI after CRT. In currently available literature
EMVI has been assessed mainly in patients undergoing
immediate surgery (without preoperative treatment). In the
reports where patients undergoing neoadjuvant treatment
were included, no subset analyses were performed to specif-
ically investigate the value of assessing EMVI after preopera-
tive CRT.
6. Future perspectives
The time has passed when imaging was used to only provide
information on tumour morphology. Functional imaging
techniques give more comprehensive information on tumour
morphology and underlying tissue characteristics. Some of
these imaging biomarkers have already been implemented
into clinical protocols, others are still under investigation.
Multiparametric imaging in rectal cancer patients will signif-
icantly improve the radiologist’s performance, in particular
for treatment response evaluation. Apart from that, technical
developments in MR scanner hardware allow for innovative
moving table techniques which generate whole-body MR
images complementary to whole-body PET. The clinical intro-
duction of hybrid PET–MR scanners combining both morpho-
logical and functional whole-body imaging within one single
examination is the beginning of a new era.
6.1. Diffusion-weighted MRI (DWI)
One of the most promising functional MR techniques for
oncological imaging is diffusion-weighted MRI (DWI).
Although originally used for the assessment of brain ischae-
mia, body applications of DWI are now also increasingly
beginning to set the pace. DWI uses differences in the move-
ment (‘diffusion’) of water protons between tissues with a
different cellular density to differentiate between tumoural
and non-tumoural tissues. Moreover, DWI can provide quan-
tifiable data reflecting a tissue’s cellular structure, referred to
as the apparent diffusion coefficient (ADC). Both the visual
assessment of diffusion images, as well as the quantitative
measurement of ADC, have shown great potential for rectal
cancer imaging, in particular for the evaluation of the thera-
peutic response of rectal tumours after chemoradiotherapy.
It has been shown by several authors that, compared with
standard MRI, DWI offers significantly better diagnostic per-
formance for the selection of patients with a good or com-
plete response of their primary tumour after CRT, with
reported AUCs up to 0.88 [30,36,37]. Although at present
DWI is being investigated mainly in research settings and
its true clinical potential has yet to be proven, DWI sequences
are already frequently implemented into clinical protocols.
6.2. Dynamic and lymph node contrast-enhanced MRI
Measurements of tumour microvascular perfusion are known
to be valuable for cancer detection and treatment monitoring.
Dynamic contrast-enhanced (DCE) or ‘perfusion’ MRI tech-
niques could be a promising adjunct to morphological MRI
in early response prediction. A pre-treatment measured Ktrans
perfusion parameter has been shown in early studies to be
valuable in distinguishing between patients with good or poor
responses. Another potentially interesting topic in the field of
lymph node imaging is the use of ‘lymph-node-specific’ MR
contrast agents. Very promising results have been shown for
the use of ultrasmall particles of iron oxide (USPIO), but this
contrast has so far not been approved by the Food and Drug
Administration for clinical use. Other MR contrasts such as
gadofosveset-trisodium are currently being investigated.
Although initial results seem very encouraging, these will
need to be confirmed in large multicentre studies to warrant
implementation into clinics.
7. Conclusions and recommendations
Since the treatment for rectal cancer has emerged from a
‘one-size-fits-all’ strategy towards a personalised treatment
plan based on a patient’s individual tumour risk profile, the
role of the radiologist within the multidisciplinary team has
changed. The radiologist now plays a full consulting role,
and his imaging findings can influence treatment manage-
ment. The current role of CTs (and PET–CTs) is mainly for
the assessment of distant tumour spread. For local tumour
staging MRI and EUS are the main players. EUS remains the
best technique for the evaluation of low-risk, superficial tu-
mours (T1–2) that may primarily be treated with (local) exci-
sion. For the evaluation of larger tumours, in particular for
the assessment of large tumours that have a risk for invasion
of the mesorectal fascia and neighbouring pelvic organs, MRI
is the technique of first choice. Although lymph-node status
is an important determinant for treatment, none of the cur-
rently available imaging modalities (CT, MRI or EUS) is suffi-
ciently accurate to reliably assess the nodes.
The role of imaging for restaging after neoadjuvant che-
moradiotherapy is rapidly advancing. While previously the
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surgical treatment plan was established on the basis of the
findings of primary staging, this plan may now be altered
on the basis of the response of the tumour to CRT and the
new findings at restaging imaging. The main difficulty after
chemoradiotherapy is the differentiation on imaging between
small residual disease and post-radiation fibrosis. Together
with the dilemma of accurate nodal staging, these two chal-
lenges need to be addressed in the coming years. New hybrid
and versatile MRI techniques, however, are on the horizon
that may be able to offer a solution.
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Neoadjuvant therapy before surgical treatment
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A R T I C L E I N F O
Neoadjuvant treatment in terms of preoperative radiotherapy reduces local recurrence in
rectal cancer, but this improvement has little if any impact on overall survival. Currently
performed optimal quality-controlled total mesorectal excision (TME) surgery for patients
in the trial setting can be associated with very low local recurrence rates of less than 10%
whether the patients receive radiotherapy or not. Hence metastatic disease is now the pre-
dominant issue. The concept of neoadjuvant chemotherapy (NACT) is a potentially attrac-
tive additional or alternative strategy to radiotherapy to deal with metastases. However,
randomised phase III trials, evaluating the addition of oxaliplatin at low doses plus preop-
erative fluoropyrimidine-based chemoradiotherapy (CRT), have in the main failed to show a
significant improvement on early pathological response, with the exception of the German
CAO/ARO/AIO-04 study. The integration of biologically targeted agents into preoperative
CRT has also not fulfilled expectations. The addition of cetuximab appears to achieve rel-
atively low rates of pathological complete responses, and the addition of bevacizumab
has raised concerns for excess surgical morbidity. As an alternative to concurrent chemo-
radiation (which delivers only 5–6 weeks of chemotherapy), potential options include an
induction component of 6–12 weeks of NACT prior to radiotherapy or chemoradiation, or
the addition of chemotherapy after short-course preoperative radiotherapy (SCPRT) or che-
moradiation (defined as consolidation chemotherapy) which utilises the ‘‘dead space’’ of
the interval between the end of chemoradiation and surgery, or delivering chemotherapy
alone without any radiotherapy.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
1. Rectal cancer: neoadjuvant therapy before
surgical treatment
Rectal cancer is a very heterogeneous disease with different
prognostic implications and varying outcomes. Historically,
a high local recurrence rate has dominated decision-making.
The need for radiation treatment has become deeply in-
grained in surgical and radiation oncology culture, prompted
by an imperative to avoid local pelvic recurrence at all costs.
Local recurrence can be associated with intractable pelvic
pain, tenesmus, mucinous discharge and intestinal obstruc-
tion, and few patients can be saved [1]. However, recent data
suggest that metastases are now the predominant problem
[2]. In a pooled analysis of 2795 patients recruited in five Euro-
pean randomised controlled trials, the 5-year distant metas-
tasis rate was 30.8% [3].
Initially, because of the lack of reliable preoperative imag-
ing, attempts to improve outcomes centred on postoperative
chemoradiation according to pathological staging. With the
emergence of more sophisticated imaging, this strategy has
been extrapolated to the neoadjuvant arena, and validated
by further phase III trials. Management has therefore moved
from a solely surgically treated disease to the current wide-
spread use of neoadjuvant radiation or combined chemother-
apy and radiation therapy.
Over the past 3 decades the neoadjuvant management
philosophy has also evolved independently in different re-
gions of the world. The individual phase III studies performed
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in each country have driven the precise patterns of care. In
the United Kingdom refinements in surgical technique – i.e.
total mesorectal excision (TME) and extralevator abdomino-
perineal excision (ELAPE) [4,5] coupled with improvements
in the quality of such surgery [6] – and the use of MRI and uni-
versal multidisciplinary team (MDT) discussion, have ensured
that isolated local recurrence is now a rare event in 2012, if
the surgeon can perform a good quality TME, even without
radiotherapy [6]. However, even with expertly performed
TME, the rate of distant recurrence has been documented as
18% in stage II patients and 37% in stage III patients in one
important retrospective series [7].
Recently there has been enthusiasm for integrating more
active systemic chemotherapy to increase down-staging and
response and to lessen the risk of metastatic disease. In
stage III colon cancer adjuvant chemotherapy based on
5-fluorouracil (5FU) reduced the risk of recurrence and pro-
longed survival, and hence has been firmly established and
recommended as adjuvant treatment in patients following
a curative resection [8]. More recent studies have confirmed
that the addition of oxaliplatin to 5FU-based chemotherapy
improves disease-free survival (DFS) [9,10] and overall sur-
vival (OS) [10] in patients with stage III colon cancer
(although rectal cancers within 12 cm of the anal verge were
excluded from these studies). FOLFOX is now considered an
international standard as adjuvant chemotherapy for colon
cancer in stage III disease, although there is still controversy
regarding its use in high-risk stage II colon cancer. Yet the
role of adjuvant chemotherapy in rectal cancer is not as
clear-cut as in stage II and stage III colon cancer, and the
validity of this standard has been questioned in a recent
meta-analysis [11].
In Northern Europe short-course preoperative radiation
therapy (SCPRT) (25 Gy in five fractions) followed by immedi-
ate surgery was evaluated as an adjunct to surgery [12,13].
Early trials showed an improvement in survival [12], and there
have been subsequent consistent reports of lower local recur-
rence rates in randomised trials [14,15]. Yet integration into
routine practice in other parts of the world has always been
slightly tempered by early reports of severe acute and long-
term toxicity [12,13,16].
When directly compared with standard chemoradiother-
apy (CRT), SCPRT shows similar efficacy [17,18]. The recent
TROG 01.04 trial in clinical stage T3 rectal cancer compared
SCPRTwith long-course preoperative CRT [18]. The trial con-
firmed similar outcomes for SCPRT and CRT for distant recur-
rence, overall survival and late effects. After a minimum
follow-up period of 3 years cumulative incidences of local
recurrence at 5 years were 7.5% for SCPRT and 5.7% for CRT
respectively (P = 0.51). For distal tumours, six of 48 SCPRT pa-
tients and one of 31 CRT patients had a local recurrence
(P = 0.21).
In the landmark German l CAO/ARO/AIO – 94 Trial [19] a to-
tal of 823 patients were randomised between preoperative
CRT and postoperative CRT (patients received postoperative
adjuvant chemotherapy in both arms of this trial). Acute
and late toxicities were significantly reduced with the preop-
erative approach, although it should be recognised that a
higher radiation dose was mandated for the postoperative
regimen. Loco-regional failure was only 6% in the preopera-
tive arm versus 13% in the postoperative arm. There was,
however, no difference observed in the distant metastases
rate, DFS or OS. This advantage is also supported to some ex-
tent by the National Surgical Adjuvant Breast and Bowel Pro-
ject (NSABP R-03) trial results [20] which showed a statistically
significant improvement in 5-year DFS (65% versus 53%,
P = 0.011) for preoperative therapy (although it included an
additional 6 weeks of neoadjuvant chemotherapy). Both trials
have therefore served to validate the benefit of neoadjuvant
5FU-based chemoradiotherapy for locally advanced rectal
cancer compared with postoperative therapy.
Hence, randomised controlled trials have unequivocally
demonstrated that preoperative radiotherapy or chemoradia-
tion [12,13,20–23] is more effective than postoperative chemo-
radiation therapy in terms of reducing local recurrence, and
with less acute and late toxicity than postoperative therapy.
Yet the risk of dying from rectal cancer is linked mainly to
the development of distant metastases, and to experience a
late local recurrence as described by Sauer et al. [23] the pa-
tient needs to survive 5 years. As an alternative setting to con-
current chemoradiation (which only delivers 5–6 weeks of
chemotherapy), potential options are an induction compo-
nent of 6–12 weeks of neoadjuvant chemotherapy (NACT)
prior to radiotherapy or chemoradiation [20,24–27], adding
chemotherapy after SCPRTor chemoradiation (defined as con-
solidation chemotherapy) which utilises the ‘‘dead space’’ of
the interval between the end of chemoradiation and surgery
[28–30], or delivering chemotherapy alone without any radio-
therapy [31,32].
In Valentini’s recent pooled analysis of seven chemoradi-
ation trials, the most effective predictive model for
developing local recurrence was based on ypT stage, cT
stage, age, ypN stage and concomitant delivery of adjuvant
chemotherapy. Hence the only preoperative data available
were age and cT status. The best model for predicting
distant metastases used ypN stage, ypT stage, surgical
procedure and delivery of adjuvant chemotherapy (in order
of relevance). Hence these nomograms are unhelpful in the
preoperative setting [3].
More recently, outcomes have been shown to vary accord-
ing to predicted (i.e. clinical) T stage of disease (Table 1), and
other prognostic factors (mainly extramural vascular invasion
and tumour extent in relationship to the circumferential
resection margin), which can be determined by preoperative
magnetic resonance imaging (MRI). Hence a more individua-
lised approach to treatment selection is now feasible accord-
ing to the relative risk of local recurrence versus metastatic
disease. However, the consistently accurate parallels between
clinical imaging and pathological staging obtained in the
MERCURY study have not been easily reproduced. Both the
technical aspects and the immediate demands of the pres-
ence of a specialist radiologist for optimal MRI imaging, and
the interpretation of the scans, mean there is a significant de-
gree of individual variation between andwithin centres. All of
these factors have contributed to a variable acceptance of the
technique worldwide.
In this article for the ESMO educational symposium we
discuss the various available options for neoadjuvant therapy,
their rationale and the results obtained. We consider the dif-
ferent approaches of long-course CRT and SCPRT: the intensi-
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fication of preoperative radiation and chemoradiation with
dose-escalation of external-beam radiotherapy (EBRT), using
brachytherapy, intraoperative radiotherapy (IORT), hyperfrac-
tionation and various available techniques such as intensity-
modulated radiotherapy (IMRT). We make recommendations
as to which clinical or imaging features require preoperative
CRT or SCPRT to be delivered, and where it could possibly be
avoided. The strategies of neoadjuvant, concurrent, consoli-
dation (i.e. immediately following chemoradiation and prior
to surgery) chemotherapy with cytotoxic agents are explored.
We speculate on the initial attempts to integrate biological
agents as future potential strategies of treatment with and
separate from radiation.
The current era of precision imaging offers many options
for conformal external-beam radiotherapy, such as IMRT,
volumetric arc therapy (VMAT), brachytherapy and a pleth-
ora of systemically active cytotoxic and biological agents.
Practice has also been driven more recently by meticulous
refinements in surgical technique, in which all the sur-
rounding mesorectal fat are removed in a neat anatomical
package (total mesorectal excision and extralevator abdom-
inoperineal excision), the availability and quality of preoper-
ative MRI to determine potential risks, an increasing value
placed on histopathology and assessments/metrics of the
quality of surgery. TME is associated with much lower rates
of local recurrence and improved survival [4], but all these
advances have contained and driven down the local recur-
rence rate.
In 2005, investigators from Hong Kong challenged the ac-
cepted wisdom and questioned whether low-risk stage II pa-
tients benefit from neoadjuvant therapy [33]. With a median
follow up of 43 months, they reported a 6% local recurrence
rate at 5 years for patients undergoing anterior resection
(with a median level of tumour at 8 cm from the anal verge).
Recent population-based data [34] and retrospective series
exploiting these advances further undermine the approach
of a blanket use of radiotherapy/chemoradiation by exploring
the omission of radiotherapy when MRI suggests the tumour
is easily resectable and the circumferential resection margin
(CRM) is not threatened [35–38]. Others have also recently
questioned the routine use of chemoradiation for rectal can-
cer [39,40].
The current high clinical and pathological response rates
[41] observed from chemotherapy in small clinical trials also
offer an alternative option to chemoradiation. So the ratio-
nale for selecting patients suitable and appropriate for neoad-
juvant preoperative radiotherapy/chemoradiotherapy needs
reconsidering.
For patients with resectable rectal cancer prior to the cur-
rent TME era, trials of CRT or SCPRT demonstrate a reduction
in loco-regional failure (LRF), but without extending DFS or
OS.
More recent randomised trials in locally advanced rectal
cancer (LARC) suggest that the high historical local recurrence
rate of the 1990s has been reduced to <10% with CRT and/or
SCPRT. In the main, local recurrence in rectal cancer has been
replaced by an even larger risk of metastatic disease as the
current predominant problem. Hence many oncologists have
recommended both intensifying chemotherapy in the neoad-
juvant setting, and also integrating other cytotoxic drugs, in
addition to 5FU, into CRT schedules as the logical next steps
to improve outcome in rectal cancer.
In the UK and Northern Europe patients with rectal cancer
are selected for preoperative treatment on the basis of clinical
staging. Many multidisciplinary teams categorise patients
into ‘‘the good, the bad and the ugly‘‘, which allows the defi-
nition of three different clinical settings for rectal cancer
[42]. Early cT1/T2 tumours are not usually treated with radio-
therapy; more advanced T3 tumours in which the patient is
considered at risk of local recurrence [15,43] are advised to re-
ceive SCPRT followed by TME; and thirdly patients, with clin-
ically unresectable cancers – where MRI suggests a
threatened/ breached CRM (10–15% of cases), or the levators
are potentially involved, or in cancers which require surgical
resection beyond the conventional TME plane – then radiation
as a component of CRT is clearly necessary for down-staging.
MRI assessment forms the basis of the recent UK 2011
NICE clinical colorectal guidelines on colorectal cancer
(http://guidance.nice.org.uk/CG/Wave16/2) which defines
three different risk groups of patients with rectal cancer,
according to the risk of local recurrence. MRI is sufficiently
sophisticated to allow accurate prediction of mesorectal sur-
gical margin involvement by tumour (within a tolerance of
1 mm) preoperatively, and can also demonstrate macro-
scopic extramural vascular invasion (EMVI). Both a positive
CRM and EMVI carry a high risk of subsequent metastatic
disease.
Few patients in any of the randomised phase III
studies had standardised staging with MRI. Few had primary
rectal cancers staged as T4 or, by MRI criteria, were
encroaching on, or extending beyond total mesorectal exci-
sion planes, which are considered to require preoperative
chemoradiation (and sometimes surgical resection beyond
conventional TME planes). Such poor-prognosis patients have
an even higher risk of metastatic disease even after success-
ful surgery.
Table 1 – Japanese-style surgery with laparoscopic pelvic lymph-node dissection (LPLND). Risk of local recurrence and distant
metastases. Cut-off for depth of mesorectal involvement 64 mm.
Stage IIA Stage IIIB All Stage III
64 mm Local recurrence 12/295 (4.1%) 14/204 (6.9%) 21/245 (8.6%)
Distant metastases 21/295 (7.1%) 36/204 (17.6%) 47/245 (19.2%)
>4 mm Local recurrence 13/295 (7.7%) 23/218 (10.6%) 34/267 (12.7%)
Distant metastases 28/168 (16.7%) 58/218 (26.6%) 75/267 (28.1%)
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2. Radiotherapy as neoadjuvant treatment
2.1. SCPRT
Several trials with more than 6000 patients support the bene-
fit of SCPRT in reducing local recurrence. The rationale for
SCPRT is based on the short overall treatment time (OTT),
which allows surgery to take place before the radiation reac-
tion is expressed, but does not allow sufficient time for tu-
mour shrinkage.
The Swedish Rectal Cancer Trial [13] randomly assigned
patients with cT1–3 rectal cancer to SCPRT and immediate
surgery versus surgery alone (not TME). A significant improve-
ment in both local recurrence and survival was observed in
the SCPRT arm. The Dutch group performed the Commissie
Klinisch Vergelijkend Onderzoek (CKVO) 95-04 trial, which
used the same design but trained and mandated surgeons
to perform TME. Both early [43] and more mature long-term
reports [44] confirmed a significant improvement in local con-
trol with SCPRT, although no difference in overall survival was
observed.
The MRC CR07 trial [6,15] randomised 1350 rectal cancer
patients to either SCPRT (5 · 5 Gy) followed by immediate sur-
gery or selective postoperative chemoradiation (25 · 1.8 Gy
with concurrent 5-fluorouracil) administered only for patients
with histologically involved (61 mm) resection margins. The
majority of resections were considered TME, but only 51%
were good quality TME in the mesorectal plane [6]. Overall,
clinically significant absolute risk reduction in the 3-year local
recurrence rate of 6.2% was observed (4.4% for SCPRT versus
10.6% for selective postoperative CRT), corresponding to a rel-
ative risk reduction of 61%. At 3 years, disease-free survival
was 6% better for SCPRT, but there was no improvement in
overall survival. The CR07 trial suggests SCPRT reduces the
risk of local recurrence for all tumour locations, all patholog-
ical stages, and good, average or poor quality surgery.
SCPRT may also only partially compensate for a positive
CRM [45,46] if this threat to the mesorectal fascia (MRF) was
not detected on preoperative MRI. This strategy has aims dif-
ferent from those of long-course CRT, where we hope to
shrink/down-stage the tumour and facilitate an R0 resection
to be performed, or to increase the chances of performing
sphincter-sparing surgery.
Other advantages of SCPRT include high compliance, even
in the elderly, and low cost. Two large randomised trials have
each reported that in resectable cancers, SCPRT and CRT are
equivalent in terms of outcomes such as local recurrence, dis-
ease-free survival (DFS) overall survival (OS) and toxicity
[16,17] (Table 2). In the UK, SCPRT is increasingly being used
with an interval to surgery or as a radical treatment ± high
dose rate brachytherapy (HDRBT). SCPRT is considered to
have the advantage of rapid delivery and high compliance
for patients who are frail, elderly and with cardiac and renal
co-morbidities which preclude 5FU-based chemotherapy.
However, there is a price to pay. Long-term data from ran-
domised trials of SCPRT versus surgery alone demonstrate al-
most twice the prevalence of bowel dysfunction after SCPRT
[47–50]. The CR07 data suggest that SCPRT caused a signifi-
cant increase in unintentional release of stools [51]. More
recent retrospective analyses suggest that frequency, urgency,
evacuatory difficulties and faecal incontinence – i.e. the low
anterior resection syndrome (LARS) – are common. Effects
on sexual functioning [52] and urinary incontinence [49] have
also been documented after SCPRT.
With modern MRI, metabolic imaging with positron emis-
sion tomography/computed tomography (PET/CT) and indi-
vidual biomarkers it should be possible to be more selective
for risk of local recurrence. It is therefore difficult to support
the current widespread advocacy for routine adjuvant radio-
therapy as used in the treatment arms of recent trials. Alter-
natively for this same reason, efforts have been made to limit
the radiation dose to normal rectum.
The histology is only minimally corrupted by the radio-
therapy changes, allowing accurate pathological staging in
terms of the nodal status, extramural vascular invasion and
perineural invasion. Patients treated with SCPRT or HDRBT
will undergo surgical resection and receive postoperative
adjuvant chemotherapy many weeks earlier than with con-
ventional CRT. Hence selection for and delivery of postopera-
tive adjuvant chemotherapy with systemically active
schedules (e.g. FOLFOX) can usually start within 6–10 weeks
of diagnosis.
2.2. SCPRT and surgery after an interval
Two retrospective studies [53,54] reported safety and efficacy
of SCPRTwith an interval of several weeks to allow response.
Both reported similar curative resection rates and local con-
trol as after preoperative long-course CRT. Although the pop-
ulations of these studies varied, a pathological complete
response (pCR) was observed in 4/37 patients (11%) and 2/24
patients (8%), respectively, who underwent surgery after an
interval of a few weeks.
A randomised Polish study of 154 patients with locally ad-
vanced rectal cancer who were operated using TME between
1999 and 2006 examined the influence of the time interval be-
tween SCPRT and surgery on long-term OS and recurrence
rate [55]. Patients were randomised between SCPRT (5 · 5 Gy)
followed by surgery either 7–10 days or 4–5 weeks later after
completion of RT [55]. With approximately 4 years minimum
follow-up, 5-year survival rates were 63% and 73% for imme-
diate and later surgery respectively (P = 0.24). The longer time
interval between RT and surgery resulted in a greater down-
staging rate (44.2% versus 13%), but did not increase sphinc-
ter-saving procedures or curative resections.
A further small randomised trial of 83 patients with resect-
able (stage II and III) rectal cancer [56] compared the clinical
and pathological down-staging from SCPRT and long-course
CRT followed by surgery after an interval of 6 weeks in both
groups. The preliminary results suggested improved tumour
down-sizing from CRT compared to SCPRT. Pathological com-
plete response was observed in one patient (2.7%) in the
SCPRT group versus six patients (13.1%) in the CRT group.
Postoperative morbidity and R0 resection rates were similar.
The ongoing Stockholm III trial – which is randomising be-
tween three arms: SCPRT proceeding to immediate surgery
within a week, SCPRT and delayed surgery after 4–8 weeks,
and 50 Gy in 25 fractions with surgery after a similar interval
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[57] – will also provide additional information on allowing an
interval for response after SCPRT. However, current data sug-
gest that it is feasible to use SCPRT and delay for several
weeks, opening the opportunity to fill this gap with chemo-
therapy. This strategy has been successfully employed in pa-
tients with synchronous metastases [58].
2.3. Chemoradiation
The rationale for long-course chemoradiation is to achieve
additive effects from the combination of chemotherapy and
radiation, both locally and systemically, with a concurrent
fluoropyrimidine, thereby inducing down-staging/downsiz-
ing, and in some cases facilitating sphincter-sparing proce-
dures, while at the same time reducing distant metastases
and in a small group of patients (approximately 10–15%)
achieving tumour sterilisation. The current shortcoming of
this approach is that we have only managed to integrate sin-
gle-agent fluoropyrimidines (intravenous 5FU or capecita-
bine/UFT) at suboptimal, sub-systemic doses into everyday
practice.
In ultrasound-staged resectable cancers (i.e. presumably
where the preoperative MRI would now suggest the CRM/
MRF is not potentially involved), or where down-staging is
not required, then SCPRT and CRT have been shown to be
equivalent in terms of outcomes such as local recurrence,
DFS and OS [17,18]. For more advanced cases, where the sur-
geon assesses the tumour as unresectable and/or the CRM/
MRF is recognised to have been breached or threatened
according to the MRI appearances, long-course CRTwith the
addition of 5FU to radiation has favourable effects on re-
lapse-free survival (RFS) and cancer-specific survival with a
trend to improve overall survival [59].
Concerns also remain that the delivery of adjuvant chemo-
therapy in the postoperative setting has frequently been com-
promised by delays because of surgical morbidity, slow
recovery and healing, poor tolerance, and marked dose reduc-
tions, with patient compliance being approximately 50%
[19,60,61]. These three studies showed that 20%, 23% and
25%, respectively, failed to start postoperative 5FU-based
adjuvant chemotherapy. The observation from Biagi et al.
[62] that even a few weeks delay following curative surgery
before implementing systemic chemotherapy impacts on sur-
vival provides a rationale to administer chemotherapy
preoperatively.
Despite the above controversies, consensus guidelines
from European groups [63,64], Canada [65] and the United
States of America [66] recommend preoperative chemoradia-
tion for the majority of patients with stage II and stage III rec-
tal cancer. This approach has narrowed to the conventional
use of 45–50.4 Gy at 1.8 Gy per fraction, irrespective of the
stage, size, site and molecular biology of the cancer [67].
There are also significant long-term late effects, including
an increased risk of insufficiency fractures in the pelvis
[68,69], and an increased risk of second malignancies from
CRT even within 10–12 years. Tubiana [70] warns that large
target volumes treated with moderate doses carry a high risk
of second malignancy. The incidence of second malignancy
has probably been underestimated because, with a median
age of 65–70 years, patients in rectal cancer trials had a rela-
tively short life-expectancy after treatment, and follow-up is
usually short. With recent gains in survival, longer follow-
up, cancer registries and end-result programmes, the cumula-
tive incidence of secondmalignancies could reach as much as
20% of patients treated by radiotherapy [70].
2.4. Intensity-modulated radiotherapy (IMRT)
Clinical trials of SCPRT or CRT have almost invariably used
three- or four-field techniques. Acute gastrointestinal toxicity
is the commonest dose-limiting toxicity in many chemoradi-
ation trials, and provides the main dose-limiting factor for the
radiotherapy. In the German CAO/ARO/AIO-94 trial, preopera-
tive chemoradiation led to a 12% rate of G3–4 acute toxicity in
terms of diarrhoea, and a 9% rate of gastrointestinal G3–4 late
toxicity. Total doses of between 45 and 50 Gy probably lead to
a 5% risk of late toxicity for the small bowel at 5 years, and
there is a significant association between 6G3 acute small
bowel toxicity and the volume of small bowel irradiated [71–
74]. Acute toxicity in trials which have integrated oxaliplatin
have even higher rates of G3/G4 diarrhoea at approximately
25%, and might be expected to be associated with a greater
risk of late damage to the small bowel. None of the random-
ised phase III trials to date in rectal cancer have used IMRT.
Table 2 – Trials comparing shortcourse preoperative radiotherapy (5X5 Gy) with preoperative chemoradiation.
Trial No Stage chemo Adjuvant
chemotherapy
Local
recurrence
RFS/DFS 5 year OS
Polish SCPRT 155 cT3-T4 none Optional Crude 9% 4 year DFS 58% 4 year OS 67%
Polish CRT 157 cT3-T4 5FU/FA Optional Crude 14% 4 year DFS 56% 4 year OS 66%
TROG SCPRT 163 II-III none Mandated
FUFA 6/12
3 years 7.5% 5 year RFS 64% 5 year 74%
TROG SCPRT 163 II-III PVI 5FU 225mg/m2 Mandated
FUFA 4/12
3 years 4.4% 5 year RFS 61% 5 year 70%
Latkauskas SCPRT 37 II-III none Not stated Not stated Not stated Not stated
Latkauskas CRT 46 II-III 5FU/FA Not stated Not stated Not stated Not stated
Pach 2012 SCPRT
immediate 7-10 days
77 I-III none Not stated 1.5% Not stated 63%
Pach 2012 SCPRT
delayed 4-5 weeks
77 I-III none Not stated 7% Not stated 73%
SCPRT = short course preoperative radiotherapy; CRT = chemoradiation; RFS/DFS relapse free survival/disease free survival; OS = overall
survival; FUFA = 5FU and folinic acid.
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Highly conformal planning using multi-leaf collimators
(MLCs) which can be adjusted during the treatment may limit
the radiation dose to the bowel and other normal structures,
thereby potentially reducing acute and late gastrointestinal
side effects [75–77]. A recent retrospective review demon-
strated a significant decrease in gastrointestinal toxicity
grade P2 for patients receiving IMRT [78]. We clearly need
to evaluate the precise mechanisms that are responsible for
the late functional effects of radiotherapy, as some patients
could either forego radiotherapy completely, or the radiother-
apy fields could be more tailored to avoid say the lumbarsa-
cral plexus or the sphincter mechanisms themselves.
Alternatively, IMRT/IGRT may facilitate EBRT dose-escala-
tion of radiotherapy protocols and more aggressive combina-
tions of radiotherapy with cytotoxic chemotherapy and/or
novel systemic agents. The downside is increased low-dose
exposure of the surrounding healthy tissue circumferentially
around the tumour, potentially leading to an increase in the
volume of normal tissues exposed to low doses of radiation.
IMRT with capecitabine and oxaliplatin is being tested in a
phase II study (RTOG 08-22) for cT3-4N0-2 patients with rectal
cancer. The preliminary results, presented in abstract form
only, appear to show that IMRT is feasible with a high rate
of contouring and planning compliance and less gastrointes-
tinal gradeP2 toxicity compared with other RTOG rectal can-
cer chemoradiation studies such as RTOG 0247 [79].
More recently several other strategies have been used to
increase the radiation dose to the primary with brachyther-
apy or contact boost, with intraoperative radiotherapy using
electrons.
3. Brachytherapy
High-dose-rate intraluminal brachytherapy (HDRBT) is highly
conformal; the rapid fall-off in dose allows a high dose of radi-
ation to be delivered at themucosal surface of the rectumover-
lying the tumour and reduces doses to surrounding normal
structures compared to conventional radiotherapy tech-
niques. Publications are sparse for resectable rectal cancer,
and rely mainly on a single institution (McGill University in
Montreal) which has reported significant tumour regression
in over 300 patients, over 29% of the patients achieving a com-
plete pathological response at surgery [80–82]. Because of the
rapid dose fall-off, HDBRT may treat the pelvic lymph nodes
less adequately. Preoperative HDRBT (26 Gy over 4 days) fol-
lowed by surgery after 4–8 weeks compares favourably in
terms of complications and outcomes with SCPRT in a recent
matched retrospective analysis from Canada and Sweden
[83]. Brachytherapy also appears as effective as long-course
conventional CRT butmay be associatedwith less severe acute
toxicity. However, many radiation oncologists remain uncer-
tain about the late sequelae from use of higher dose rates.
There is a significant dose–response relationship for
tumour regression after preoperative CRT [84]. Recent reports
describe a 31% pCR and 83% achieving an R0 resection in 34
patients treated with 10 Gy HDRBT boost following down-
staging of potentially resectable rectal cancers with long-
course chemoradiotherapy [85]. For inoperable tumours,
HDBRT has been used to dose-escalate after chemoradiation
to achieve a greater tumour response and facilitate a curative
resection [86]. A small randomised study (Lyon 96–02) sug-
gests that a higher dose achieves a higher rate of complete
clinical response, and hence increases the chance of sphinc-
ter preservation from 44% to 76% [87,88].
4. Integration of cytotoxic agents into the
neoadjuvant setting
The intentions of integrating oxaliplatin into the multimodal-
ity treatment are, first, to assess additional effects from pre-
operative neoadjuvant using oxaliplatin as a radiosensitiser,
to achieve greater tumour response, and to reproduce some
of the gains in survival achieved by cisplatin in chemoradia-
tion schedules in cervix cancer/head and neck cancer. Sec-
ond, the hope is to achieve systemic effects, since in
metastatic disease the addition of oxaliplatin to the combina-
tion of 5FU and folinic acid (FOLFOX) offers response rates in
the range of 50% [89]. Oxaliplatin also has a proven role in the
adjuvant setting in CRC.
There are two distinct philosophical approaches for inte-
grating oxaliplatin in rectal cancer. Radiation oncologists
aim to integrate oxaliplatin during radiotherapy as a radio-
sensitiser to increase response (usually at sub-systemic doses
for tolerability). In contrast, medical oncologists are designing
phase II/randomised phase II trials using systemically active
high-dose chemotherapy outside chemoradiation to reduce
micrometastases outside the pelvis.
Four randomised phase III studies – Action Clinique
Coordonne´es en Cance´rologie Digestive (ACCORD), STAR-01
and NSABP R04 and CAO/ARO/AIO-04 and PETACC-6 studies
– (Table 3) have compared preoperative chemoradiotherapy
using a combination of a fluoropyrimidine and oxaliplatin
with preoperative chemoradiotherapy using an intravenous
or oral fluoropyrimidine alone [91–95]. Early results from
these randomised phase III trials have not shown any
significant impact on early pathological response with the
exception of the German CAO/ARO/AIO-04 study.
The ACCORD trial, which compared capecitabine plus
oxaliplatin with capecitabine alone, showed no difference
in the pCR rate, which (unusually for a phase III) formed
the primary end-point (19.2% versus 13.9%, P = 0.09) [92,93].
The STAR-01 trial also showed no difference in the pCR rate
(15% versus 16%, P = 0.982.). Yet the percentage of patients
with pathological M stage was significantly lower in the
5FU-plus-oxaliplatin group (2% versus 11%, P = 0.014), sug-
gesting that addition of oxaliplatin to preoperative CRT
might have influenced the development of distant metasta-
ses. In contrast, the CAO/ARO/AIO-04 study showed an im-
proved pCR rate in patients receiving oxaliplatin (17%
versus 13%, P = 0.038) [96]. In addition, the PETACC-6 trial
randomised patients between preoperative RT (50.4 Gray in
25 fractions) with capecitabine alone and the same radiation
schedule with capecitabine + oxaliplatin (50 mg/m2). The
trial has completed accrual and results are awaited.
4.1. Irinotecan
Several phase II trials have suggested a potential benefit for
the addition of irinotecan to preoperative CRT. The random-
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ised phase II RTOG-0012 trial showed no benefit [97,98]. The
current national trial in the UK (ARISTOTLE) is examining
the utility of the incorporation of irinotecan into preoperative
CRT in MRI-defined unresectable/borderline resectable rectal
cancer (www.controlled-trials.com/ISRCTN09351447).
4.2. Integration of biologicals
Standard chemotherapy regimens for CRC have integrated
molecularly targeted agents (cetuximab, panitumumab, bev-
acizumab and aflibercept) to improve response rates or extend
PFS and OS. The approach of using epidermal growth factor
receptor (EGFR) and vascular endothelial growth factor (VEGF)
inhibitors has been extrapolated to the treatment of locally
advanced rectal cancer to avoid overlapping toxicities. Yet
the reader should be mindful that there is only a single phase
III study in any disease site demonstrating an advantage to
combined biological agents and radiotherapy compared with
radiation alone [99]. Also these agents have not been shown
to have activity in the adjuvant setting [100,101].
Bevacizumab added to standard cytotoxic chemotherapy is
associated with improved survival and higher pathological re-
sponse rates in patients undergoing resection of colorectal li-
ver metastases [102], but may not affect response rates
defined by RECIST (response evaluation criteria in solid tu-
mours) [103]. Bevacizumab may be safely administered in the
preoperative setting for the treatment of liver metastases
[104], without increasing post-surgical complications [105,106].
A phase I clinical study of bevacizumab prior to and con-
currently with 5FU-based CRTreduced tumour perfusion, vas-
cular volume, microvascular density, interstitial pressure and
viable endothelial cells [107]. Willett and colleagues continued
into a phase I/II study and reported a pCR rate of 16%, and an
additional 72% of patients who had only microscopic foci
remaining after treatment with bevacizumab and 5FU plus
RT in patients with T3/T4 tumours [108].
In another small phase I study in patients with metastatic
(four) or locally advanced rectal adenocarcinoma (seven), the
combination of bevacizumab, oxaliplatin and capecitabine
chemoradiation was active with a pCR of 22%, but with signif-
icant acute toxicity [109].
In a phase II study in patients with T3/4, N1, or recurrent
disease, administration of capecitabine and bevacizumab con-
comitant with preoperative RT resulted in a pCR rate of 32%
and amicroscopic residual disease rate of 24% [110]. A slightly
lower pCR rate of 24% was observed in a phase II study of pa-
tients with T3/4N0 or T1-4N1-3 rectal cancer who received
induction CT comprising only two cycles of 5FU/LV + oxalipla-
tin (FOLFOX6) plus bevacizumab, followed by concomitant RT
plus FOLFOX and bevacizumab [111]. In this study 9/25 pa-
tients (36%) also developed postoperative complications [111].
The more recent AVACROSS study selected 47 patients
according to MRI criteria, and used four cycles of induction
chemotherapy using capecitabine, oxaliplatin and bev-
acizumab, followed by chemoradiation with concurrent cape-
citabine and bevacizumab [112]. Results are impressive, with
98% having an R0 resection and 36% achieving a pCR, while
a further 23% were down-staged to ypT1/T2N0. There was
one sudden death during the induction, and surgical morbid-
ity appears prominent, since 26/45 patients (58%) experienced
at least one postoperative complication and 11/45 (24%)
required surgical re-intervention (even though the median
time from the last dose of bevacizumab to surgery was
2 months).
A phase II trial evaluated preoperative capecitabine, oxa-
liplatin and bevacizumab with radiation therapy followed by
surgery and postoperative 5FU, leucovorin, oxaliplatin (FOL-
FOX) and bevacizumab for locally advanced rectal cancer in
57 patients [113]; 17% achieved a pCR, but 47% of patients
who underwent surgery experienced a surgical complication.
A Canadian study achieved a pCR of 18%, but four patients
(11%) required re-operation due to complications [114].
A further study evaluating bevacizumab/chemoradiation in
thepreoperativeandadjuvant settings in66patientswithstage
II/III rectal cancer [115] achieved a pCR rate of 29%, but again
showed frequent grade 3/4 toxicity and surgical morbidity.
None of these studies showed a consistent definitive signal
of improved efficacy. Yet, since the eligibility criteria in the
AVACROSS study, which achieved a pCR of 36%, were similar
to those of the GEMCAD study [116], where a pCR of only 14%
was observed with induction Xelox and capecitabine and oxa-
liplatin chemoradiation, it is possible that the addition of bev-
acizumab offers greater efficacy. However, several studies
raise concerns that the combination of bevacizumab and
radiation may impact on surgical morbidity. Future studies
need either to leave a longer interval following the comple-
tion of bevacizumab before surgery or to drop the bev-
acizumab from the chemoradiation component.
Preliminary results of chemoradiation clinical trials with
cetuximab, on the early clinical endpoint of pCR, are at best
Table 3 – Short-term outcomes from randomised studies integrating oxaliplatin (OXA) as radiosensitiser.
outcomes STAR-01 ACCORD- 0405 CAO/ARO/AIO-04 NSABP R04 PETACC-6a
5FU379 OXA352 Cape293 OXA291 5FU624 OXA613 5FU/cape622 OXA631 5FU/cape547 OXA547
G3/G4
diarrhoea
4% 15% 3% 13% 8% 12% 7% 15% Not stated Not stated
ypCR 16% 16% 14% 19% 13% 17% 19% 21% 11% 13%
Ypn0 74% 71% 70% 72% 70% 72% Not stated Not stated Not stated Not stated
Ypn+ 26% 29% 30% 28% 30% 28% Not stated Not stated Not stated Not stated
CRM <1mm 7% 4% 13% 8% 6% 5% Not stated Not stated Not stated Not stated
R0 resection 94% 97% Not
stated
Not
stated
92% 90% Not stated Not stated 92% 86%
5FU, 5-fluorouracil; CRM, circumferential resection margin.
a Ref. [90]
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disappointing. A large multinational randomised phase II
study EXPERT-C (NCT00383695) has compared neoadjuvant
therapy comprising oxaliplatin, capecitabine and chemora-
diotherapy with or without cetuximab in 164 patients.
Kras status (mutant or wild-type) does not appear to be
predictive for pCR in rectal cancer when EGFR inhibitors are
integrated into chemoradiation regimens [117,118]. In the
more recent Expert C study, in the group of patients with
wild-type Kras, who received capecitabine, oxaliplatin and
cetuximab, the overall survival at 3 years was 96% [119].
5. Chemotherapy additional to SCPRT or CRT
As an alternative setting to concurrent chemoradiation
(which only delivers 5–6 weeks of chemotherapy) potential
options are either an induction component of 6–12 weeks of
NACT prior to radiotherapy or chemoradiation [24–26], adding
chemotherapy after SCPRT or chemoradiation as consolida-
tion, which utilises the ‘‘dead space’’ of the interval between
the end of chemoradiation and surgery [28,30], or delivering
chemotherapy alone without any radiotherapy [31,32].
5.1. Neoadjuvant/induction chemotherapy prior to
chemoradiation
The most popular method of integrating chemotherapy is as
induction prior to chemoradiation, which achieves high rates
of symptomatic improvement (65%) [120]. Clinical response
rates with induction chemotherapy vary between 28% [120],
41% [27] and 59% [119] when cetuximab was added, with no
patients observed to have progressive disease.
Phase II randomised studies [25,116,119,121] suggest that
neoadjuvant chemotherapy prior to chemoradiation is feasi-
ble, and can be delivered with minimal compromise of either
the radiation or subsequent surgery.
The EXPERT phase II study of 78 patients used a 12-week
induction phase of capecitabine and oxaliplatin followed by
chemoradiation with capecitabine with chemoradiation (total
dose 54 Gy) in locally advanced rectal cancer. The radiological
response rate was 81% (two CRs and 50% PRs). The early out-
come results of this study appear impressive, but it is not pos-
sible to determine the relative contributions of the induction
chemotherapy and the concurrent CRT schedule or the high
dose of pelvic radiotherapy (54 Gy); however, when compared
to the group’s subsequent study, with an identical eligibility
and chemotherapy schedule but a lower RT dose (50.4 Gy),
the pCR fell from 23% to 14% [119]. Mature results of the EX-
PERT trial in 105 patients [25] demonstrated a 3-year PFS
and OS of 68% and 83% respectively. The 3-year RFS for the
93 patients who had a R0 resection was 74%.
A Spanish study (GCR-3 study) compared a conventional
schedule of chemoradiation followed by TME and postopera-
tive adjuvant chemotherapy using capecitabine and oxalipla-
tin, against induction chemotherapy using capecitabine and
oxaliplatin followed by CRT and TME [116]. The pCR rate
was similar in both arms, 14% versus 13%, but significantly
more patients in the postoperative adjuvant arm had grades
3/4 acute toxicity than in the induction arm (54% versus
19%; P = 0.0004, respectively). In the postoperative adjuvant
arm, 25% of patients did not begin treatment, and only 51%
received all four cycles, whereas 100% of patients in the
induction arm began treatment, and 92% received all four
(P = 0.001). The relative dose intensity for both capecitabine
and oxaliplatin were significantly higher in the induction
arm, with no differences in radiotherapy compliance between
the two arms (P = 0.001). Despite the high compliance in the
induction arm, 3-year DFS was not increased [121].
The NASBP-R-03 (National Surgical Adjuvant Breast and
Bowel Project R-03) is the only phase III trial to have inte-
grated neoadjuvant chemotherapy at systemic doses. The
trial randomised 267 patients to either preoperative 5FU
based CRT (n = 130) or postoperative CRT (n = 137) [20]. In addi-
tion, the preoperative arm utilised up-front weekly bolus 5FU/
leucovorin (LV) for 6 weeks prior to starting concurrent CRT
(5FU/LV for 5 days during the first and fifth weeks of radiation
to a total dose of 45 Gy with a 5.4 Gy boost). Thus the trial
mandated 3 months of neoadjuvant 5FU/LV in the preopera-
tive arm, followed by postoperative adjuvant weekly 5FU/LV.
The accrual was lower than expected (267 of the planned
900 patients). The preoperative treatment arm failed to dem-
onstrate an improvement in local recurrence. The 5-year
cumulative incidence of locoregional recurrence was 10.7%
for both treatment arms (HR = 0.86; 95%CI, 0.41–1.81;
P = 0.693), but had a statistically improved DFS with a hazard
ratio of 0.629 (P = 0.011) and a trend towards improved overall
survival. These findings suggest an effect of the neoadjuvant
chemotherapy on systemic disease.
In the CONTRE trial, patients received eight cycles of FOL-
FOX as NACT followed by CRT and surgery. Preliminary data
presented at the Gastrointestinal American Society of Clinical
Oncology (GI ASCO) 2013 meeting from the first 32 patients re-
ported a 33% pCR rate and >90% compliance [122].
A recent study with induction FOLFOX and bevacizumab
[111] provoked grade 3/4 toxicity during chemoradiation in
19 of 25 patients (76%). In some of these phase II studies the
authors do not clearly report the toxicity profiles separately
for concomitant chemoradiation and when used as full-dose
chemotherapy alone [28]. However, studies of neoadjuvant
chemotherapy raise concerns regarding the high rate of toxic
deaths. Patients with the more advanced and larger pelvic tu-
mours appear to have a particularly high risk of thromboem-
bolic and cardiac effects [25,123], less so if T4 tumours are
excluded [31].
5.2. Consolidation chemotherapy (neoadjuvant
chemotherapy following chemoradiation)
Consolidation chemotherapy does not compromise compli-
ance to and delivery of chemoradiation. Retrospective data
from the Memorial Sloane Kettering Cancer Center [124] and
others [125,126] suggest that increasing the interval between
CRT and surgery might enhance the rate of pathological com-
plete responses, although other studies partly contradict this
[127,128].
Habr-Gama reported that extending the duration of the
chemotherapy post-chemoradiation increased the complete
clinical response rate (cCR) of 48%, achieving an overall com-
plete response rate (i.e. including cCR and pCR) of 65% [27].
Recent studies have tested the hypothesis that by delaying
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Table 4 – Phase II/phase III trials of neoadjuvant chemotherapy in progress.
Study Preoperative treatment Entry criteria Status RT/CRT Comments
BACCHUS
NCRI Randomised phase II
(recruiting)
60 patients
FOLFOX + bevacizumab for 5
courses, then final FOLFOX,
then surgery versus
FOLFOXIRI bevacizumab for 5
courses ,then final
FOLFOXIRI then surgery
MRI-defined entry Yet to open SCPRT or CRT only for
progression/lack of response
Primary
endpoint: pCR
RAPIDO
Phase III
EudraCT number 2010-
023957-12
885 patients
SCPRT (5 · 5 Gy) followed by
Oxaliplatin/capectabine 6
cycles versus
Control capecitabine + CRT
MRI-defined entry Yet to open CRT 50.4 Gy/28# with
capecitabine
Primary
endpoint: 3-year
DFS
COPERNICUS
NCRI stratified phase II
NCT01263171
80 patients
Panitumumab/FOLFOX
for 4 courses
for Kras WT then SCPRT
FOLFOX for 4 courses
for Kras WT then SCPRT
MRI defined entry Yet to open SCPRT for all patients Primary endpoint:
proportion of
patients who
commence
neoadjuvant
chemotherapy and
radiotherapy and
then undergo
surgical resection
French
phase II
NCT00865189
91 patients
FOLFOX + bevacizumab
for 6 courses then CRT(with
bevacizumab/5FU) versus
CRT alone
No Ongoing not
recruiting
Primary endpoint
: pCR
Chinese randomised phase II
NCT01211210
495 patients
FOLFOX (4 cycles) then
surgery versus
FOLFOX CRT
Versus 5FU CRT (control)
No Recruiting Primary endpoint
3-year DFS
SWOG study
NCT00070434
Up to 65 patients
Multiple regimens T4 rectal cancer Ongoing not
recruiting
CRTwith capecitabine Primary endpoint
: response
Polish Study
NCT00833131
540 patients
SCPRT (5 · 5 Gy) followed by
FOLFOX (3 cycles) then
surgery versus
5FU/capecitabine CRT (50 Gy)
as control
Unresectable rectal
cancer
Recruiting SCPRT versus CRT Primary endpoint
: the rate of R0
resection
Beth Israel Study
NCT00831181
22 patients
Six cycles of modified
FOLFOX 6 followed by TME
followed by an additional six
cycles of FOLFOX 6
MRI
T3N0M0 or T1–3N1M0
Recruiting Primary endpoint:
pathological response and
complete response
Continued on next page
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surgery or increasing the interval between CRT and surgery,
and allowing more time for response or even administration
of two additional cycles of FOLFOX chemotherapy, it may be
feasible to increase down-staging and achieve a higher rate
of pCR [29,122].
The ‘Timing of Rectal Cancer Response to Chemoradiation
Consortium’ phase II multicentre trial used NACT as consoli-
dation chemotherapy in the interval following CRT prior to
surgery, with pCR as the primary endpoint. An initial cohort
preserved the standard 6–8 week interval between comple-
tion of CRT and surgery, which achieved a pCR of 18%.
Sequential cohorts added further cycles of consolidation FOL-
FOX after CRT prior to surgery, increasing the pCR rates to 25%
and 30%, respectively [29]. Postoperative adjuvant FOLFOX
chemotherapy was also administered to achieve a total of
6 months of systemic chemotherapy.
The delay in surgery by leaving the primary in situ could
potentially increase the chance of metastatic disease. A fur-
ther question remains as to whether FOLFOX is as effective
at preventing metastatic disease if the primary (with pre-
sumed stem cells) remains in situ when the chemotherapy
is interrupted and attenuated by delivery in a few cycles
rather than as a continuous 3–6-month treatment.
5.3. Neoadjuvant chemotherapy without chemoradiation
Neoadjuvant chemotherapy may achieve better access to
malignant cells when the tumour has an intact blood supply,
and may offer better compliance to treatment [116]. Systemic
doses of chemotherapy can be delivered at an early stage of
the diagnosis rather than after a delay of up to 18 weeks asso-
ciated with standard CRT. Two studies from the Memorial Slo-
an-Kettering Cancer Center support the feasibility of
neoadjuvant chemotherapy alone in rectal cancer [31,32].
This feasibility study in patients with clinical stage II–III [31]
rectal cancer (but not T4 tumours) used FOLFOX (oxaliplatin
and 5-flourouracil) with bevacizumab [31] The R0 resection
rate was the primary outcome. They reported a pCR in 8/29
patients (27%).
6. Trials in progress (Table 4)
A Polish study (NCT00833131) in unresectable rectal cancer
addresses the question of whether SCPRT (25 Gy in 5 frac-
tions) followed by consolidation chemotherapy using FOL-
FOX4 can increase the rate of R0 resection compared with
the standard of conventionally fractionated chemoradiation
(50.4 Gy total dose in 28 fractions of 1.8 Gy over 5.5 weeks with
FULV or capecitabine).
A similar study (RAPIDO) is a collaboration of Dutch and
Swedish study groups and compares chemoradiation
followed by delayed surgery and postoperative adjuvant che-
motherapy with 5 · 5 Gy SCPRT followed by chemotherapy
and then followed by surgery.
The present authors are participating in a randomised
phase II neoadjuvant study (BACCHUS (Bevacizumab and
Combination Chemotherapy in Rectal Cancer until Surgery)
in resectable rectal cancer where preoperative MRI suggests
adverse features such as EMVI, but the CRM is not threatened.T
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The study aims to evaluate the efficacy, toxicity and feasibility
of FOLFOX/ bevacizumab versus FOLFOXIRI/ bevacizumab.
7. The future
Many questions regarding the role of neoadjuvant chemother-
apy remain. In CRC, as in other malignancies, combination
cytotoxic chemotherapy is more effective in improving sur-
vival, so is the current standard of 5FU or capecitabine the
optimal partner to radiotherapy in preoperative CRT? Is the
theoretical benefit of additional agents such as oxaliplatin
outweighed by the increase in acute toxicity, or disguised/di-
luted by the short-term duration of weeks rather than
months and the failure of current regimens to achieve sys-
temically active doses? Is there a role for altered fractionation
in conjunction with concurrent chemotherapy? Should we
integrate targeted therapies into CRT or will we find antago-
nism as with the combination of EGFR and VEGF inhibition
and chemotherapy? Can we reduce the acute and late toxicity
of CRT with improvements in RT delivery such as IMRT/
VMAT?
Finally, is disease stage (i.e. cTN) the best way to select for
SCPRT/ CRT treatment? Can we identify patients more or less
likely to benefit from preoperative CRT, in terms of defining
either patients with a particularly low risk of local recurrence
who do not require RT, or patients with a particularly high risk
of metastatic disease for whom pelvic RT is probably irrele-
vant [43].
8. Conclusion
There is strong evidence for the role of radiotherapy in reduc-
ing the risk of local recurrence. Radiotherapy remains an
important component of the multimodal treatment of rectal
cancer, particularly if the CRM is threatened. The two current
routinely administered (and evidence-based) different ap-
proaches (SCPRTand neoadjuvant CRT) are supported by large
randomised phase III trials, and are now endorsed and widely
used for resectable rectal cancer (T3–T4 or N+). However, rou-
tine use and support for both approaches is not universal.
Individual radiation oncologists often favour one or other of
these approaches. Arguments usually address the risk of local
recurrence, enabling a curative resection and facilitating
sphincter-sparing surgery, rather than the integration of sys-
temic chemotherapy and the high risk of metastatic disease.
However, CRT has found favour because of the opportunity
for response and down-staging and even complete patholog-
ical response.
To increase tumour resectability, there is scope for escalat-
ing the dose of radiation – particularly to the area where the
CRM is threatened on MRI – either with HDRBT or the
opportunity for dose-painting with IMRT. For less advanced
cases, where the CRM is not threatened, the risk of metastatic
disease now predominates over the risk of local recurrence.
To reduce metastases, systemically active cytotoxic chemo-
therapy with or without biological agents is clearly required.
Chemotherapy at systemically effective doses is therefore a
logical way to improve survival in patients with locally ad-
vanced rectal cancer. Concurrent, induction, and consolida-
tion chemotherapy prior to surgery are all potential
strategies for improving outcome. Trials are required to as-
sess the role of chemotherapy both with and without
radiotherapy.
Increasing surgical precision and a greater recognition of
the long-term functional effects of radiotherapy and the risks
of second malignancy have reduced local recurrence, and
prompted a more selective use of neoadjuvant radiotherapy
treatment based on MRI-derived risk. Treatment choices for
the individual should now reflect the surgeon’s and multidis-
ciplinary team’s views on a more realistic balance between
the relative importance of preventing local recurrence, the
adverse impact of radiotherapy on function and quality of life,
the avoidance of a permanent stoma and the more predomi-
nant risks of metastastic disease.
In the future imaging and biomarkers will increasingly
predict the risk of local recurrence, metastatic disease, and
those patients more likely to suffer severe late effects from
radiotherapy, and thus help to individualise treatment.
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1. Introduction
On a worldwide scale, colorectal cancer is one of the leading
causes of cancer deaths, affecting millions of people every
year. One third of colorectal cancer concerns the rectum. In
more than two thirds of the cases rectal cancer is still local-
ised to the pelvis without detectable metastases. In these
cases surgical resection is the cornerstone for a curative ap-
proach. Since the introduction of the combined abdomino-
perineal resection by Miles and Que´nu around the beginning
of the 20th century [1], rectal cancer became a curable dis-
ease. However, for many decades the results of surgery have
been disappointing, as it was often spoiled by a local recur-
rence rate of up to 40% or even higher. Uncontrolled progres-
sive local recurrences, hardly palliated by irradiation or
chemotherapy, have brought a miserable death to tens of mil-
lions of patients.
This situation lasted till the end of the last century when
the anatomical basis of rectal cancer surgery was revived by
Heald and Quirke [2,3]. Quirke demonstrated that the radial
margin between the tumour border and the surgical resection
margin was a strong prognosticator for local recurrence. He
pointed out that both tumour progression and surgical quality
were important for a safe margin. Poor surgery with incom-
plete mesorectum or tears into the mesorectal fat or muscu-
lar tube of the rectum could reduce this margin and
consequently lead to local recurrences. Heald introduced
the principle of total mesorectal excision (TME). In doing so
he defined the optimal quality of surgery.
Worldwide surgeons have accepted as standard of care that
optimally the rectum has to be removed within its enveloping
mesorectal fascia. TME emphasises the importance of an ana-
tomical resection in the planes between the mesorectal fascia
and the surrounding pelvic fascias. However, the principle of
resection of the rectum within its mesorectal fascia seems to
fail when analysing low rectal cancer. From the early random-
ised controlled trials it was learned that patients requiring an
abdomino-perineal excision (APE) still had high positive cir-
cumferential resection margins [4–7]. The lower rectum and
anorectum are not surrounded by a protecting layer of meso-
rectal fat. Instead, already in an early stage, progressing tu-
mours reach and possibly infiltrate the pelvic floor muscles,
which are continuous with the external sphincter more dis-
tally. Compared with patients undergoing low anterior resec-
tion (LAR) APE patients have tumours located lower and more
advanced, therefore new principles of surgery had to be devel-
oped [8]. Results of lower rectal cancer surgery improved when
the principle of the extra levator approach was introduced [9–
12]. This involves removal of the lower rectum during an abdo-
mino-perineal excision en bloc with the external sphincter and
levator ani muscles. In the lower rectum the role of complete
removal of the mesorectal fascia is replaced by removal of
the levator ani muscles. Again, the quality of the surgery can
be judged by the completeness of this resection.
Modern rectal cancer surgery can be tailored to the specific
topographical relationships of the tumour. In proximal tu-
mours the mesorectal fascia acts as the guiding structure.
Transection of the specimen can be performed 4–5 cm distally
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from the lower tumour border or at the pelvic floor when the
mesorectum terminates higher. More distal tumours can be
removed by either intersphincteric resection – if the tumour
is confined within the smooth muscle tube of the muscularis
propria, sometimes even allowing for a colo-anal anastomosis
– or extralevator resection if the pelvic floor is threatened or
already involved by tumour progression. The third option
for an abdomino-perineal excision is to take an even wider
approach, taking out the ischiorectal fat en bloc with the leva-
tor muscles, if the tumour has perforated or fistulated
through the pelvic floor muscles into this fatty area. However,
this will be the case only in extremely rare circumstances.
Modern rectal cancer surgery is part of a multidisciplinary
approach. Preoperative imaging with magnetic resonance
imaging (MRI) is able to delineate the tumour very accurately
and helps to select those patients requiring downsizing and
down-staging, optimising the chances of a good tumour
resection [13–15]. The pathologist plays an important role in
the feedback to the surgeon, which is necessary to improve
surgical outcome [16].
The first step in integration of optimal imaging, treatment
modalities and pathology is taken is several countries. The
next step will be to optimise treatment for the individual pa-
tient, who is interested not only in the oncological outcome
but also in functional results and subsequent quality of life.
Avoiding and decreasing morbidity, especially in the elderly,
will require the development of new innovative strategies.
2. Contribution of pathology to the anatomical
approach
It may seem odd to start a discussion on modern surgical ap-
proaches to localised rectal cancer with the findings of the
pathologist. However, it was a pathologist who demonstrated
the importance of the distance of the radial tumour border to
the mesorectal fascia, which is called the circumferential
resection margin (CRM) in TME surgery [3].
In 2002 Nagtegaal analysed the data of the Dutch TME
study, and she confirmed that in 44% of the patients the in-
volved circumferential resection margin was the result of
poor-quality surgery. It was also shown that, after incomplete
mesorectal excision, the overall recurrence rate was almost
doubled, which could be attributed mainly to the excess of lo-
cal recurrences [16]. Nagtegaal and Quirke performed a meta-
analysis on the importance of the CRM in more than 17,500
patients and concluded that CRM involvement predicts not
only local recurrence but also distant metastasis and subse-
quent overall survival. Failure to achieve a negative CRM after
neoadjuvant treatment leads to a poorer prognosis compared
with no neoadjuvant treatment. Possibly the explanation for
this is the selection of patients with tumours more resistant
to therapy. This finding could be an argument for restaging
after neoadjuvant therapy, and to consider more prolonged
neoadjuvant treatment, or to refer to a specialised centre
for more extended resection or additional boosting of the area
at risk [17].
Thus, the actual feedback of the pathologist to the surgeon
should contain information on the CRM and quality of sur-
gery [18]. Another important issue, which will be discussed la-
ter in this paper, is the evaluation of the effectiveness of the
chosen neoadjuvant treatment. Preferably, macroscopic
images of the resected specimens, as well as the microscopic
images, should be available for internal audit and continued
education and improvement of all member decisions during
the multidisciplinary tumour board meetings.
Quirke proposed a 3-point grading system for the evalua-
tion of the macroscopic specimen for both low anterior and
abdomino-perineal resections. Good surgery would be quali-
fied by an intact mesorectal fascia with only minor irregular-
ities, or in the case of APE, a specimen with levator ani and
external sphincters without any defects deeper than 5 mm
and the levator ani attached to the mesorectal fascia [19,20]
(see Figs. 1–3).
After moderate-quality surgery the bulk of the mesorec-
tum is removed but shows an irregular surface, however still
without exposing the muscularis propria or perforations. In
the case of an APE, a specimen which shows waist formation,
indicative for a less complete levator ani covering at the ano-
rectal junction, but with intact sphincters, signifies a moder-
ate quality of surgery.
Poor surgery would be characterised by severe irregulari-
ties on the surface of the specimen, exposing the muscularis
propria or internal sphincter or even showing perforations to
the lumen.
Very essential for the grading of the APE specimen is the
question of whether the levator ani muscle is still attached
to the mesorectum. Thus, waist formation is avoided and
the result is a more cylindrical resection. In order to achieve
optimal feedback, pathology reports should be standardised,
not only regarding the reporting of the TNM status, but also
on the quality of surgery [19].
3. The importance of MRI for the surgical
treatment of rectal cancer
Magnetic resonance imaging (MRI) is a reliable diagnostic tool
for clinical staging of rectal cancer, but other imaging meth-
ods for the pelvis are also being used for this purpose. Com-
puted tomography (CT) is able to identify enlarged lymph
nodes, although it is not accurate for assessing the morphol-
ogy of these nodes. Furthermore, the contrast resolution of
CT is insufficient to reliably assess involvement of the surgical
resection plane in mid and lower rectal cancer. CT, however, is
indicated for distant staging of metastatic disease and, if
there is no easy access to an MRI, for assessment of resect-
ability of high rectal tumours [21–23]. Endorectal ultrasound
(EUS) cannot visualise the mesorectal fascia, but is the modal-
ity of choice to differentiate between T1 and T2 lesions for the
selection of local therapies. EUS has a high sensitivity to stage
depth of submucosal involvement [24]. However, MRI is the
king of kings of all imaging modalities in its tissue contrast
resolution and provides the necessary detailed anatomical
information on pelvic fascias and dissection planes between
pelvic soft tissues, which sets the scene for the planning of
the resection.
Without the anatomical topographical information of an
MRI, the surgeon has to rely on ad hoc decisions when unex-
pected problems occur during the actual surgical procedure
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and in a worst-case scenario these problems may even go
unnoticed, or have become irreversible. With the anatomical
information from MRI critical sites of resection can be
anticipated and addressed before surgery: i.e. use of neoadju-
vant treatment or referral to a centre specialised in extended
extra anatomical pelvic resection if TME surgery is not justified.
Fig. 1 – Rectal extralevator abdomino-perineal excision specimen. The solid yellow lines indicate the intact mesorectum. The
red lines demonstrate the extralevator muscles attached to the specimen covering widely the anorectal junction (white
arrow) where the mesorectum ends and the internal sphincter starts (dotted yellow line). Even advanced T3 or T4 tumours at
the anorectal junction and below can be safely removed when covered by the extralevator muscle layer. Typically a
cylindrically shaped specimen. Mesorectum intact. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
Fig. 2 – ‘Standard’ abdomino-perineal excision specimen, demonstrating waist formation at the anorectal junction or just
above (white arrow). Only marginal coverage by the external sphincters of the distal mesorectum. Will suffice for less
advanced tumours of the anorectum or anorectal junction. Specimen characterised by ‘waist’ formation. Mesorectum intact.
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The Mercury study group reported the reliability of MRI
on predicting extramural depth of tumour invasion. Very
good correlation of extramural spread on MRI and histopa-
thology was found: the 95% confidence interval being
<0.5 mm. The TNM classification lacks specificity in the
T3 stage [25]. A T3 tumour with limited extramural spread
(outside the muscularis propria) has a different prognosis
to a T3 tumour with more extended spread. Merkel et al
demonstrated that a cut-off point of 5 mm spread divided
patients into groups with good and poor prognoses, pro-
vided that a safe CRM was obtained [26]. For the surgeon
it is important that patients with limited extramural
spread can be treated as T2 patients, and in most cases
will not require neoadjuvant treatment with its associated
adverse effect on surgical morbidity and functional
outcome.
Even more important from the surgical technical point of
view is the fact that MRI can reliably anticipate an involved
circumferential resection margin. MRI differentiates between
high-risk (<1 mm) and low-risk (>1 mm) patients for local
recurrence. MR CRM margins >1 mm and <2 mm, >2 and <5
and >5 mm carried a similar risk for local recurrence of
around 7%, in contrast to the 20% risk of patients with an
anticipated margin of <1 mm [27]. The ability to predict a 1-
mm free margin was recently confirmed by a German group
[28].
The ability of MRI to discriminate between positive and
negative lymph nodes is quite disappointing. Like other
imaging modalities, conventional MRI without any MR con-
trast lacks both sensitivity and specificity to identify or rule
out positive nodes, and cannot reliably be used for treatment
stratification [29,30]. Size has been an unreliable variable to
predict nodal involvement [31,32]. Several contrast agents
have been and are under investigation, but at the time of
writing results are still inconclusive [33–35]. Diffusion-
weighted MRI imaging (DWI) shows a high signal in both be-
nign and malignant nodes and therefore cannot differentiate
between the two. A restaging MRI, including DWI, has a high
negative predictive value (NPV) for the detection of nodal
metastases and can be more reliably used for nodal restag-
ing after neoadjuvant treatment [36]. The most reliable vari-
able seems to be the evaluation of nodal morphology, such
as roundness, irregular border or heterogeneous texture.
However, this is difficult and subject to large inter-observer
variability, especially in nodes <6 mm and in patients with
only small nodes of limited value in clinical practices
[31,37]. MRI plays an important role in the evaluation of re-
sponse to neoadjuvant treatment (NT) and the consequences
for the final surgical resection. NT is able to downsize the tu-
mour. In particular, large tumours may have been over-
staged at the initial MRI.
Sometimes a pushing tumour border seen on primary
staging MRI may be mistaken for an infiltrating one.
Restaging with MRI after NT may reveal surgical dissection
planes which were obscured at the primary staging MRI. As
a consequence, surgical planning can be more
conservative.
Clinical T and N stage may also alter after NT and allow a
change in surgical approach. MRI is furthermore accurately
correlated with histopathological down-grading of the tu-
mour. Apart from opening new possibilities for a minimal
invasive surgical approach for the very good responders,
non-responders can be identified who may require intensifi-
cation of the treatment plan [38–44].
Fig. 3 – Poor specimen after abdomino-perineal excision. Deep indentations and even perforation in mesorectum. Very little
coverage of the external sphincter and showing tears in the external sphincter.
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In order to understand the consequences of NT, it is of cru-
cial importance that radiologists and pathologists participate
in the multidisciplinary treatment team.
4. Role of neoadjuvant treatment for the
surgeon
The primary objective in rectal cancer surgery is to achieve a
free surgical resection margin. The purpose of NT is twofold:
first, to sterilise the potential tumour-cell-bearing volume in
the pelvis, which is not removed during surgery, more specif-
ically the lateral zones of lymphatic spread; and second, to
change the size and stage of the primary rectal cancer in or-
der to facilitate surgical resection and even to allow for more
limited surgery. In Japan the lateral lymph nodes are removed
as standard procedure during rectal cancer surgery. By doing
so, NT can be safely omitted according to the Japanese work-
ers. Comparison between the Japanese results with extended
lymphadenectomy and the Dutch TME study (which random-
ised between TME surgery with and without 5 · 5 Gy preoper-
ative radiotherapy) showed that 5 · 5 with standard TME
surgery was as effective as extended lateral lymphadenec-
tomy for the prevention of local recurrences [45].
The Swedish Rectal Cancer Trials, the Dutch TME study
and the British CRO7 study have clearly demonstrated that
preoperative 5 · 5 Gy followed by immediate surgery (prefera-
bly within 1 week) yields excellent oncological results in pa-
tients in whom a CRM-negative margin can be achieved [46–
49]. A recent update of the third Swedish Rectal Cancer Trial
shows that a waiting period after 5 · 5 Gy short-course radio-
therapy effectively reduces postoperative morbidity, while
also a down-staging effect was noticed [50].
In contrast, advanced tumours, invading the mesorectal
fascia or even penetrating into the surrounding pelvic struc-
tures, would inevitably lead to positive surgical margins if
the surgeon sticks to the principle of dissection along the
mesorectal fascia. These patients require a more extended
resection, peripheral to the mesorectal fascia. In the pelvis
with organs packed tightly together these extended resec-
tions often result in loss of autonomic nerves, other pelvic
supporting structures (sacrum, pelvic floor muscles) or organs
(bladder, genital organs and ureters). Preoperative treatment
with radiotherapy and concomitant chemotherapy can effec-
tively downsize and even down-stage locally advanced tu-
mours and thus take away the threat of an involved margin,
allowing for a more preservative approach [51–53]. Whereas
the lateral margin is influenced by NT, it is not evident that
the distal margin moves upwards, or that it is possible or even
wise to perform a low anastomosis in a previously irradiated
part of the (ano-)rectum [54,55].
SystemicchemotherapymayalsobeincorporatedintoanNT
scheme. In metastasised patients it helps to select the respond-
ers, who may be good candidates for metastasectomy aswell as
resection of the primary from those patients who are progres-
sive and would not benefit from extended surgery [56]. The
Dutch Colorectal Cancer Group initiated the international RAP-
IDO study, which seeks to find answers for the question of
whether upfront systemic chemotherapy as part of NT can re-
ducetheoccurrenceofmetastasesinlocalisedrectalcancer[57].
5. The anatomical surgical approach to
localised rectal cancer
The surgical approach is based on the preoperative MRI image
and may also take into account the response to neoadjuvant
treatment. The resection itself follows anatomical principles
and is based on removal of the rectum within its covering
mesorectal fascia. In proximal tumours, the distal rectum
may be preserved, provided that at least 4–5 cm of the meso-
rectum is removed distally from the tumour [58]. In low rectal
cancers at the anorectal junction or below, depending on the
infiltration depth of the tumour, the pelvic floor muscles and
external sphincter often need to be removed en bloc with the
rectum to assure a complete resection with a CRM of more
than 1 mm [10,11].
A secondary objective is to avoid damage to the nerve
system as little as possible. The pelvic autonomic nerves
consist of a fine network originating around the aorta,
which descends as a fine mesh lining the mesorectal fascia.
The hypogastric nerves condense and split into two lateral
bundles which can easily be identified and followed to the
inferior hypogastric plexus. In this area innervation, lym-
phatic drainage and blood supply mingle in the lateral pil-
lars of the rectum. The nervi erigentes also join the
inferior hypogastric plexus from the dorsolateral and also
lie in close approximation to the dorsolateral mesorectal
fascia. The somatic levator ani and pudendal nerves are
protected by the pelvic fascia and are less at risk than the
autonomic nerves [59].
The anterior mesorectum distally to the peritoneal
reflection is thin, but, similarly to the rest of the mesorec-
tum, is also covered with a fascia-like structure (fascia of
Denonvilliers), which allows for dissection of the anterior
mesorectal fascia from the prostate/vesicles or posterior
vaginal wall [60,61]. More distally, this layer ends and is re-
placed by intertwining bundles of somatic perineal muscles
joining with the smooth muscular layer of the muscularis
propria of the anorectum. This organisation of muscle fibres
anchors the anorectum to the pelvis. More laterally and
dorsally at the level of the sphincters, the adherence of
the smooth muscles to the surrounding external sphincter
muscles is much more loosely organised. The external
sphincter may be considered the distal part of the funnel
shaped pelvic floor muscles enveloping the smooth-muscu-
lar layer of the internal sphincter. As mentioned above, lat-
erally and dorsally the adherence between internal and
external sphincters is low and allows for the development
of an intersphincteric resection plane. On the anterior side
the somatic pelvic floor muscles, which distally join in a
tendinous perineal body, are very adherent to the anterior
part of the anal rectum. Therefore no such thing as an
intersphincteric dissection plane is present on the anterior
side of the distal rectum [62]. This is a very important ana-
tomical fact which influences the way low rectal tumours
can be dissected. An abdomino-perineal excision (APE) can
be performed in three dissection planes: (1) the intersphinc-
teric plane which is close to the internal sphincter and suit-
able only for tumours which are confined to the muscularis
propria of the rectum; (2) the extralevator plane which
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follows the external fascia of the external sphincter contin-
uously along the external fascia of the levator ani muscles
and transects these muscles as laterally as possible before
entering the abdomen; and (3) the ischiorectal plane which
also removes the ischiorectal fat and which follows the
external fascia of the pelvis, removing the ischiorectal fat
en bloc with the levator ani muscles. Again, the abdomen
is entered as laterally as possible at the level of the attach-
ment of the levator ani muscles to the pelvic wall see
(Fig. 4).
In most distal rectal carcinomas the extralevator abdomi-
no-perineal excision (ELAPE) is recommended to achieve a
complete resection with a negative CRM [63]. Either the pa-
tient may be operated in a supine position with the legs in
movable stirrups, or the patient may be turned to prone posi-
tion for the perineal resection [64]. When the operation is per-
formed in the supine position the patient does not need to be
turned and the procedure can start with either the perineal
phase or the abdominal phase.
In the supine position the dissection starts with an inci-
sion around and subsequent closure of the anus [10,19]
(Fig. 5). The external perineal fascia which covers the external
sphincter can be followed up to the lateral attachment of the
levator ani to the pelvic sidewall. At this level the levator ani
can be cut, exposing the mesorectum. Dorsally, the anococ-
cygeal ligament has to be transected. Depending on the loca-
tion of the tumour, the presacral space may be entered
ventrally to the coccyx, or in dorsally located tumours, the
coccyx may be removed to enter the presacral space. After
transection of the levator on both sides, exposing the meso-
rectum and opening the presacral space exposing the dorsal
part of the distal mesorectum, the anterior dissection may
commence. The anterior part of the levator ani muscle en-
closes the internal genital organs and needs to be transected
at the level of Denonvilliers’ fascia. After exposing Denonvil-
liers’ fascia the dissection continues distally; retracting the
specimen dorsally helps to identify the somatic perineal mus-
cles, which are closely adherent to the anorectum. The tran-
section takes place in the somatic muscles, avoiding a
fausse route into the bowel. If the operation was not started
with the abdominal phase, the abdomen is opened now. Dis-
section is according to TME principles, avoiding nerve dam-
age. As the pelvic floor muscles are already transected,
taking out the specimen is a relatively uncomplicated
procedure.
If the operation is performed in prone position, the proce-
dure most often starts with the abdominal phase, with the
patient lying in supine position [65] (Fig. 6). Again, care must
be taken not to push the dissection too deep down because of
the risk of coning in, resulting in dissection of the pelvic floor
off the mesorectum and subsequent waist formation. How-
ever, it is important to develop the presacral space until the
os coccygis is exposed. On the lateral side the low hypogastric
plexus has to be dissected off the mesorectum and the lateral
pillars also have to be transected. Denonvilliers’ fascia has to
be exposed before the abdominal phase can be ended and the
patient can be turned into prone position for the perineal
phase.
In prone position a teardrop like incision is made around
the anal skin and extended proximally above the ano-coccy-
geal joint. After closure of the anus, the deep perineal fascia
is followed from the external sphincter to the lateral attach-
ments of the levator ani. After the coccyx has been cut, the al-
ready opened presacral space is entered and the lateral
Fig. 4 – Early 19th century anatomical lithography demonstrating the intense autonomous nerve network in the abdomen,
illustrating the high risk of surgery to damage the nerves. Furthermore the levator ani muscle can be seen as an envelope
around the distal rectum.
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attachments of the levator ani can be cut. After arriving at the
level of Denonvilliers’ fascia, the specimen can be everted
through the perineal wound and the dissection of the anterior
plane of the specimen commences under direct vision. First,
the puborectal sling has to be cut, as also the deep perineal
muscles which are closely adherent to the anterior part of
the anorectum. Again the dissection is carried out proximally
to distally. Cutting the perineal body is the last part of the
operation before the specimen is taken out. Care must be ta-
ken not to damage the urethra and the neural bundles of
Walsh, which are very close to this dissection plane.
In both positions a complete extralevator abdomino-peri-
neal excision can be performed. In prone position visibility
of the perineal operating field is better at the cost of a wider
incision, which requires closure with a (biological) mesh or
musculo-cutaneous flap [9]. In the supine position simulta-
neous access to the tumour from the abdomen and perineum
may be an advantage in more advanced tumours. An inter-
sphincteric or ischiorectal approach is more commonly per-
formed in supine position. In both positions, the abdominal
phase may also be performed laparoscopically.
6. Future perspectives
6.1. Registry
On a population-based level, outcome of rectal cancer treat-
ment differs not only widely among countries, but also within
countries among hospitals and even within hospitals among
individual surgeons [18,66–68]. But in the end, the chain of
treatments given to an individual patient can be traced back
to each individual link of the chain. If the quality of pathology
is excellent, it will enable one to unravel the different prog-
nostic variables which apply to an individual patient. Not only
can the biology of the tumour be ascertained but also the
quality of surgery and the effect of neoadjuvant treatment.
Furthermore the anatomical information from the MRI may
be linked to the outcome and quality of the surgical
procedure.
Registration of these variables will identify the weak links
and will allow better quality of the complete chain, improving
outcome and reducing the burden of treatment costs for
avoidable poor results [69] (Fig. 7).
Fig. 5 – Perineal phases of an extralevator abdomino-perineal excision in supine position. mr, mesorectum; pb, perineal body.
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Localised rectal cancer – but also metastasised rectal can-
cer – must be treated by a multidisciplinary team. In order to
achieve the best quality of treatment, the planning of the
treatment and the sequence of the different treatment
modalities have to be decided upon before any treatment is
given. During a multidisciplinary team meeting (MDT), after
the results of imaging and histopathological biopsies have be-
come available, the specific problems of a rectal cancer can be
identified and the best approach for the individual patient
may be selected, depending on the presence/exclusion of
metastatic disease, local extent of the tumour and the pa-
tient’s condition. It is important for the patient to know
who has the role of the director of the treatment. In most
cases this responsibility lies with the surgeon, who is respon-
sible not only for the surgery but for all components involved
in the treatment planning.
On a local level the use of standard protocols, the registra-
tion of the MDT meetings and the registration of the impor-
tant outcome parameters can help to identify blind spots.
These data can constitute the basis for a larger – possibly na-
tional – registry [70]. These national registries can be used to
compare countries. In Norway, Sweden, Denmark, the UK and
the Netherlands mandatory registration has led to almost
100% coverage of the population.
EUROCARE collects colorectal cancer data from all Euro-
pean countries and was able to show large differences in out-
come in Europe [66].
A limitation on the overall use of the EUROCARE database
is the wide spread in coverage of their populations between
the European countries. It is difficult to compare results be-
tween countries with coverage of less than 50% and countries
with coverage of 100%. Furthermore, the completeness of
important clinical data such as stage distribution and cancer
subsites varies widely between registries. For example, the
United Kingdom had poorer oncological results than France
and Germany; however, the UK has coverage of 100% com-
pared with coverage of 18% and 1% respectively for France
and Germany. Explaining difference in outcome between
countries with different coverage is difficult, particularly
when it is unclear whether coverage of less than 50% is repre-
sentative for the country as a whole.
But then again, there is no need to create a scale of the
outcome of different countries. It is more relevant to identify
the best practice and to set European guidelines based on the
Fig. 6 – Perineal phases of an extralevator abdomino-perineal excision in prone position. La, levator ani muscle; vs, vesiculea
seminales; zb, nerve bundles of Walsh.
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best knowledge available [71,72]. The EURECCA colorectal pro-
ject, which promotes registry based on consensus and subse-
quent sharing of data, can lead to a better outcome for rectal
cancer patients all over the world [66,73–76].
6.2. Centralisation
With the improvement in care during the last decades and the
introduction of MDT meetings, the oncological outcome of
rectal cancer has greatly improved. Another more recent
development and improvement in cancer care is the introduc-
tion of centralisation of care for advanced cases and major
surgery. In rectal cancer this also plays an important role. In
advanced cases the cancer grows through its surrounding fas-
cia into other organs and structures. In those advanced cases,
when an exenteration is needed, the resection could consist
of an orthopaedic, gynaecological and urological en bloc
resection combined with the rectal resection. It is not desir-
able that such a procedure is performed by multiple surgeons.
Therefore the rectal cancer surgeon has to be a complete pel-
vic surgeon. However, normally these advanced cases have a
low incidence in a normal regional hospital. The small num-
bers increase the risk of performing an irradical resection as
the experience with these cases is limited. Centralisation of
advanced rectal cancer cases will not only result in less irrad-
ical resections but also in better postoperative care. As a hos-
pital treats more advanced cases, all specialties involved in
rectal cancer care gain more experience. Furthermore postop-
erative complications are seen sooner, radiological imaging is
interpreted better by the radiologist and pathologists gain
more experience with large specimens and the influence of
neoadjuvant treatment. All this will result in lower mortality
rates and better oncological outcome. Specialisation has led
to improved outcome in rectal cancer treatment; how much
more this will be true for locally advanced cases requiring
more individualised surgery [77–79].
6.3. Patient reported outcome measures
Due to the major improvements in therapy and oncological
outcome in the last decades, the influence of treatment on
the individual patient has become more and more important.
Particularly in the last decade, where outcome of a disease is
not the only measurement of adequate treatment, there is an
increasing interest in the influence of treatment on patients’
quality of life (QOL). Most of the studies published on quality
of life and rectal cancer use generally used questionnaires
such as the sf-36, EORTC QLQ-C30 OR EORTC QLQ-C38. These
questionnaires are reliable, valid and responsive, but have not
been developed to assess treatment on an individual level
[80–82].
The modern rectal cancer patient is confronted with a
combination of treatments, all of which will to a certain ex-
tent influence his way of living. The patient would probably
like to be informed about alternatives in their treatment sche-
dule and about the consequences of their choice.
It is important for future research to focus on different and
more interesting patient groups, such as frail and elderly pa-
tients. In these patients, it is more likely that the assumed
benefits of survival give an increase in morbidity and could
have an adverse effect on QOL. Future studies on rectal cancer
have not only to focus on the effect of additional treatments
on survival, but also the influence of the treatment on QOL.
If the treatment results in increase in QOL, is the possible
Fig. 7 – Good collaboration of radiologist, surgeon and pathologist enables continuous quality improvement. Good
registration is an indispensable prerequisite (http://www.virtualpathology.leeds.ac.uk)
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consequent decrease in QOL worthwhile? It is likely that
these studies will make the decision process easier for the in-
volved specialties in the treatment of rectal cancer and will
result in a more patient-tailored treatment.
7. Conclusion
Surgery is still the cornerstone of rectal cancer treatment for
the time being. Therefore, the surgeon should take the role of
the director of the treatment plan, and should realise that sur-
gery is an integral part of a comprehensive multidisciplinary
approach. The basis for quality assurance is registration. A
modern anatomical surgical approach requires also a modern
attitude towards quality assurance and an obligation to keep
the patient well informed about the choices which have been
made and to allow the patient to have his/her own say in the
matter.
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Adjuvant chemotherapy
B. Glimelius *
Oncology and Radiation Science, Uppsala University, Dept. of Radiology, Uppsala, Sweden
1. Rectal cancer – less scientific evidence than
for colon cancer
In rectal cancer there is much less scientific evidence for clin-
ically relevant gains from postoperative chemotherapy than
there is for colon cancer. The large adjuvant trials that re-
vealed the gains in disease-free survival (DFS) and overall sur-
vival (OS) included either patients with colon cancer only or a
limited number of patients with rectal cancer. In comparison
with colon cancer, combination chemotherapy with a fluoro-
pyrimidine and oxaliplatin has not been explored at all in rec-
tal cancer, whereas three large randomised trials in colon
cancer all showed improved DFS and possibly OS in patients
randomised to combination therapy [1–3].
Incoloncancer, the loco-regional therapyhasnot changed to
anymajor extent during recent decades. This has been the case
for rectal cancer,where thequality of surgery has beensubstan-
tially improved with the introduction of the total mesorectal
excision (TME) concept. Furthermore, a great majority of rectal
cancerpatientsnowreceivepreoperative therapy, at least if they
belong to the intermediateor locallyadvancedgroups, andpost-
operative radiotherapy or chemoradiotherapy is seldom given
as it oftenwas in recent decades [4–6]. Thismore complex treat-
ment scenario, and the improvements over time of the loco-
regional treatment strategies, have made it difficult to evaluate
the effects of adjuvant chemotherapy in rectal cancer.
Two opposing views can be considered when giving rec-
ommendations for whether or not to give adjuvant chemo-
therapy to rectal cancer patients. One is to extrapolate from
colon cancer, applying the knowledge achieved from the large
trials to rectal cancer under the assumption that they all
come from the same organ and all are adenocarcinomas.
The other view is to look at the trials in detail, explore what
types of loco-regional treatment have been given and then
evaluate whether we have randomised evidence for favour-
able effects in the different clinical situations.
2. Do rectal and colon cancers respond
similarly to chemotherapy?
In metastatic disease, the primary location of the colorectal
cancer appears to be irrelevant on the basis of numerous
studies which have analysed the relevance of the tumour site
(colon versus rectum), e.g. Ko¨hne et al [7]. Thus, a possible
reason for the apparently greater effect of adjuvant chemo-
therapy with modulated 5-fluorouracil (5-FU) in colon than
in rectum cancer is probably not due to different chemosensi-
tivities. No study has explored the value of capecitabine or a
combination regimen with a fluoropyrimidine and oxaliplatin
as adjuvant therapy in rectal cancer, whereas these treat-
ments have been extensively used in metastatic disease [8],
with no detectable differences according to site.
Detectable metastases do come from tumour cells/cell
deposits that once have been subclinical and present at the
time of diagnosis. Thus, the lack of difference in the meta-
static setting strongly argues against lower chemosensitivity
of rectal cancer cells compared with colon cancer cells. How-
ever, colon cancer differs in some aspects relevant to tumour
biology, and thus potentially chemosensitivity, from rectal
cancer [9–11]. The molecular characteristics, however, also
differ between parts of both colon and rectum [12]. These dif-
ferences may not materialise in the metastatic setting, but
may be relevant when the disease is only subclinical.
3. Evidence for effects of adjuvant
chemotherapy in rectal cancer
A Cochrane report [13], based upon 21 clinical trials including
9221 patients, concluded that significant gains are present in
both DFS and OS (Table 1). These patients have been treated
over several decades. During this extended time period, both
surgery and the use of additional (chemo)radiotherapy have
evolved considerably [6]. The hazard ratios (HRs) for gains in
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Table 1 – Summary of the cochrane meta-analysis and of the major randomised clinical trials on the role of systemic adjuvant chemotherapy after curative loco-regional
treatment of rectal cancer.
Treatment setting Study/Ref. No. of pts Study features Results Comments
All Cochrane analysis
[13]
9221 from
21 trials
All stages, all treatments, all
settings
HR for OS 0.88 (0.76–0.91), for
DFS 0.75 (0.68–0.83)
Trials running during several
decades, great heterogeneity
between the trials
Adjuvant
chemotherapy after
surgery alone
Sakamoto/Japanese
meta-analysis [41]
2310 from
three old trials
Stages I–III, 5FU, UFT or
carmofur 6 m,
mitoC 6 m added in two
trials
HR for OS 0.86 (P = 0.049), for
DFS 0.77 (P = 0.0003)
No gain in colon cancer
(n = 2380)
JSCCR/Japanese
meta-analysis [42]
2385 from
three trials
Stages I–III, UFT or carmofur
12 m, mitoC 6 m
HR for OS 0.92 (P = 0.04), for
DFS 0.83 (NS)
Two trials probably included
in the above study
Sakamoto/Japanese
meta-analysis [43]
2091 from
five trials
Stages I–III, UFT or
carmofur12–24 m, mitC 6 m
added in three
trials
HR for OS 0.82 (P = 0.02), for
DFS 0.73 (P < 0.0001) and for
LRFS 0.68 (P = 0.003)
Some trials overlapping with
the above two meta-analyses
NSAS-CC [44] 274 Stage III, surgery w/wo UFT
12 m
HR for OS 0.60 (P = 0.034), for
DFS 0.66 (P = 0.033)
No gain in colon cancer
(n = 334), HR 0.82, P = 0.4).
Included in the above meta-
analysis, updated results
Nordic trials [45] 691 Stages II–III, 5FU 4–12 m OS at 5 y 73% versus 81% for
AC in stage II (P = 0.09) and
51% versus 48% for AC in
stage III (P = 0.91)
Various 5FU regimens. A
numerical gain was seen in
colon cancer stage III
(n = 708, OS at 5 y 48 versus
55%, P = 0.15), however,
dependent upon the time
from surgery to start of AC
[33]
NSABP-R01 [46] 371 Stage II–III, 5FU, semustine
and vincristine
OS and DFS improved (43%
versus 53% for AC at 5 y,
P = 0.05 and 30% versus 42%
for AC, 0.006, respectively
Postop RTalone had no effect
on OS or DFS
QUASAR uncertain
[18]
549 Stage II, III. 5FU 6 m HR for OS approx 0.85 (NS),
for DFS approx 0.75 (NS)
Subgroup analysis from the
trial. In all 948 RC patients
included, HR for OS was 0.77
(95% CI 0.54–1.00), for DFS
0.68 (0.48–0.96). 86% of all pts
included had stage II
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Table 1 – continued
Treatment setting Study/Ref. No of pts Study features Results Comments
Adjuvant
chemotherapy after
postop RT/CRT
Hellenic group [47] 220 Stage II, III, postop CRT alone
or with 5FUFA 4 cycles
AC NS improved DFS at 5 y
from 68 to 70% and OS from
73 to 77%
Cafiero et al [48] 218 Stage II, III, postop RTw/wo
5FU/Leva 6 m
HR for OS 1.04 (P = 0.9), for
DFS 1.12 (P = 0.6)
Low compliance with
adjuvant chemotherapy, NS
improvement in compliant
pts
Dutch group [49] 299 Stage II, III, postop RTw/wo
5FU/Leva 12 m
HR for OS approx 0.95, for
DFS approx 0.90 (NS)
Approx 75% of pts had at
least 6 m treatment.
Significant effect seen in
colon cancer in the same
trial
ECOG Est 4276 [50] 237 Stages II–III, postop RT, CT or
CRT
5-yr OS RT 46%, CT 47%, CRT,
50% (NS)
Abstract only
QUASAR uncertain
[18]
201 Stage II, III, postop RTw/wo
5FU 6 m
HR for OS approx 0.80 (NS),
for DFS approx 0.65 (NS)
See comment on QUASAR
above
Adjuvant
chemotherapy after
preop RT
EORTC 22921 [19] 505 cT3, T4, preop RTw/wo 5FU
3 m postop
HR for OS for AC versus no
AC 0.85 (0.68–1.04) and for
DFS 0.87 (0.72–1.04). LR at 5 y
was 17 and 10% in the RTand
RT/AC groups, resp
Represents 2 of the 4 arms in
this trial. Results not
separated for preop RT and
CRT (see below) groups. 27%
of pts scheduled for AC never
started. Difference in LR
between preop RT only and
the other 3 groups, P = 0.002
QUASAR uncertain
[18]
198 Stage II, III. preop RTw/wo
5FU 6 m
HR for OS and DSF approx
0.55 (NS)
See comment on QUASAR
above
Adjuvant
chemotherapy after
preop CRT
EORTC 22921 [19] 506 cT3, T4, preop CRTw/wo 5FU
3 m postop
See above. LR was 9% and 8%
in the CRT and CRT/AC
groups, respectively
See above
Italian Group [51] 635 Fixed/tethered RC. Preop CRT
w/wo 5FU 4.5 m
postop
OS 64% for CRT only and 68%
when AC added (NS). No
difference in LR
Preliminary data, median
follow-up 25 m. Abstract
only
Fernandez-Martos
et al [52]
108 CRT + surg + AC 4 m XELOX
versus 4m XELOX +
CRT + surg
No difference Randomised phase 2, preop
CT tolerable
Adjuvant
chemotherapy before
and after preop CRT
Expert-C [53] 164 High risk operable RC,
neoadjuvant Cape/Oxali
3 m, CRT, postop Cape/Oxali
3 m or same
treatment with cetuximab
HR for OS 0.27 (P = 0.035), for
DFS 0.81 (P = 0.668)
Results for K-ras wild-type
pts only
Preop, preoperative; Postop, postoperative; AC, systemic adjuvant chemotherapy; RT, radiotherapy; CRT, chemoradiotherapy; pts, patients; UFT, uracil–tegafur; carmofur, 1-hexylcarmobyl-5-fluo-
rouracil; m, months; HR, hazard ratio; OS, overall survival; DFS, disease-free survival; LRFS, local relapse-free survival; JSCCR, Japanese Society for Cancer of the Colon and Rectum; HCFU, 1-
hexylcarbomoyl-5-fluorouracil; NS, not statistically significant; 5FU, 5-fluorouracila; mitoC, mitomycin C; y, year; w/wo, with or without; Leva, levamisole; approx, approximately; CI, confidence
interval; Cape, capecitabine, Oxali, oxaliplatin; resp, respectively.
a5FU was modulated with folinic acid in most trials.
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rectal cancer are, according to the Cochrane report, for stages
II + III: 0.75 for DFS and 0.89 for OS. No heterogeneity was seen
between stages II and III. These HRs appear rather similar to
the ones seen in colon cancer stage II but are less than those
seen in colon cancer stage III [14–16]. Whether the relative
gains differ between colon cancer stages II and III is uncer-
tain, however, since they are to a large extent based upon in-
ter-trial comparisons. The trials predominantly including
stage III patients are generally older than those including
stage II patients. Furthermore, the estimates for stage II are
from a Cochrane report probably including all trials and pa-
tients, whereas no such report has been completed for stage
III. The large ACCENT (Adjuvant Colon Cancer Endpoints)
(Adjuvant Colon Cancer Endpoints) database gives important
information as it includes the majority of the large trials [16]
but then also tends to overestimate the gains, since all posi-
tive trials were included but not necessarily all negative trials.
Itmay thus bepossible to conclude that adjuvant treatment
for rectal cancer should be given as for colon cancer, based
upon the Cochrane analyses. Otherswould argue that the het-
erogeneity between the trials is so extensive that no firm con-
clusions can be drawn. An entirely different view was also
expressed in a recent systematic review [17] where the differ-
ent rectal cancer trials were scrutinised according to whether
the patients were pretreated, with radiotherapy only or with
chemoradiotherapy, or if they received (chemo)radiotherapy
postoperatively. These trials are summarised in Table 1.
4. Discussion of selected individual trials and
of an analysis of pooled data
4.1. QUASAR uncertain study
This trial [18] included 984 rectal cancer patients (and 2345 co-
lon cancer patients) in whom the doctors were uncertain
about the value of adjuvant chemotherapy. In the group of
rectal cancer patients, 5-year OS was increased from 74% in
the control group to 78% (HR 0.77, P = 0.05) in the group of
patients who were randomised to surgery and adjuvant
5-FU + calcium folinate. This gain was numerically the same
in those rectal cancer patients who had surgery alone
(n = 549) or preoperative (n = 198) or postoperative
(chemo)radiotherapy, albeit not statistically significant. This
is probably due to limited patient numbers in the subgroups.
This study provides the strongest individual proof that adju-
vant chemotherapy has at least some efficacy in rectal cancer.
4.2. EORTC 22921/FFCD9203 (Fe´de´ration Francophone de
la Cance´rologie Digestive)
These two trials [19–21] chiefly tested the value of concomi-
tant chemotherapy and radiotherapy in intermediate rectal
cancer, although the European Organisation for Research
and Treatment of Cancer (EORTC) trial, having a 2 · 2 design,
also explored the value of adjuvant 5-FU/leucovorin. The tri-
als (n = 1011 and 756 patients, respectively) showed that the
addition of chemotherapy decreased local recurrence rates
(HR 0.54; 0.41–0.78) but not distant progression or OS, even if
analysed together to increase power [21]. Although subgroup
analyses according to ypT stage indicated that a survival gain
was seen in the group of patients whose tumours appeared to
respond to the (chemo)radiotherapy [22], the EORTC trial ar-
gues against any relevant gain from adjuvant chemotherapy
in pretreated rectal cancer patients.
4.3. PROCTOR/SCRIPT/Chronicle (Preoperative Radiotherapy
and/oradjuvantChemotherapy combinedwithTME-Surgery in
Operable Rectal cancer/Simply Capecitabine in Rectal cancer
after Irradiation Plus TME)
Due to the scientific lack of firm evidence for benefit from
adjuvant chemotherapy in rectal cancer properly operated
and pretreated with (chemo)radiotherapy, trials with a
surgery-alone group were initiated by researchers in the
Netherlands, Sweden and the United Kingdom (UK). These trials
have unfortunately been prematurely closed for patient inclu-
sion because of poor accrual. The PROCTOR study included
patients who had preoperative 5 · 5 Gy and TME and random-
ised the patients to surgery alone or 6 months of 5-FU/leuco-
vorin. It was later changed (to SCRIPT) to capecitabine instead
of 5-FU/leucovorin. In addition, patients who had received
preoperative chemoradiotherapy could be included. In total,
over 500 patients were included in these Dutch/Swedish trials
until December 31, 2012. The UK Chronicle trial randomised
110 patients who had preoperative chemoradiotherapy to a
control group or adjuvant 5-FU/leucovorin and oxaliplatin.
There are no mature data from the trials, although an interim
report presented at a scientific meeting when 470 patients
had been included could not see any gain (van de Velde, per-
sonal communication). The trials illustrate the ambitions
from scientists to create good scientific evidence and rely on
extrapolated data as little as possible [23].
4.4. Other recent trials
In a Finish trial, 278 patients in clinical stage II + III were ran-
domised between TME alone or preoperative 5 · 5 Gy, TME
and adjuvant 5-FU/leucovorin [24]. The trial results will again
be confounded by radiotherapy, but early and late toxicity of
the combined treatment can be properly evaluated against
modern surgery alone. No increase in serious surgical compli-
cations was seen. Wound infections and perineal wound
dehiscence were, as expected, more common after irradia-
tion. If the trial turns out to be negative, it will argue against
the value of adjuvant chemotherapy since any survival gains
from 5 · 5 Gy with TME is at best limited [6]. The limited num-
ber of patients and inclusion also of patients with early stages
may prevent firm conclusions.
In two parallel identically designed German trials in colon
(n = 855) and rectal (n = 796) cancer, respectively, adjuvant 5-
FU/leucovorin was superior to 5-FU alone in colon cancer
[67% (95% CI 59–73) versus 54% (95%; CI 97–61)] – but not in
rectal cancer – [56% (95% CI 99–63) versus 51% (95% CI 43–
58)] [25]. The authors speculate that the chemosensitivity of
colon and rectal cancer differs.
4.5. Nomogram
Valentini et al. [26] collected information from a total of 2795
patients included in five European clinical trials with the aim
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 7 2 –7 9 75
of allowing the selection of patients who might benefit from
adjuvant chemotherapy. The trials were heterogeneous in
many relevant aspects, and only two of them randomised
patients between adjuvant chemotherapy or not [19] (Cionini
et al, unpublished). The other three trials either planned to
give adjuvant chemotherapy to all patients [20,27] or did not
specify this in the protocol [28]. Neither of the two individual
trials exploring the value of adjuvant chemotherapy revealed
any significant gain in recurrence-free survival, whereas a
small gain was seen when all trials were pooled together.
Pooling of data from different trials may, however, easily
introduce bias. Nomograms were developed for prediction of
local recurrence, distant metastases and OS. The pathological
stage (ypTN) after preoperative treatment (most patients had
chemoradiotherapy to 45–50 Gy) was most important,
although the use of adjuvant chemotherapy gave some addi-
tional value to the models. This added value was numerically
smaller for distant metastases [HR ± 95% CI; 0.90 (0.83–0.97)]
than for local recurrence [HR ± 95% CI; 0.81 (0.72–0.92)] and
OS [HR ± 95% CI; 0.82 (0.76–0.88)]. The proposed nomogram
was considered to have reliable concordance indices (0.73
for distant metastases) and could thus be useful for clinical
assistance. The nomogram – which did not account for com-
peting risk of death for recurrence prediction, therefore
slightly overestimating the risk – indicated that any gains
from adjuvant chemotherapy were minimal (1–2%) for
responding patients, whereas the gains were larger for those
who did not respond well to the preoperative chemoradio-
therapy. The opposite conclusion was reached, as described
above, when one of the included trials [19] was analysed ret-
rospectively [22].
5. Recommendations
5.1. High rectal cancers
It is reasonable to conclude that tumours arising in the upper
peritonealised third of the rectum should be treated as if aris-
ing from the colon. This means that most stage II patients
should not have any adjuvant chemotherapy, some high-risk
stage II patients should have adjuvant fluoropyrimidine and a
few with several or very high-risk features an oxaliplatin
combination. Most stage III patients should have an oxalipla-
tin combination, although some with low-risk features, par-
ticularly if they are older than 70 years, should rather be
offered a fluoropyrimidine alone. These patients seldom have
had preoperative (chemo)radiotherapy, although this may
have been used in locally advanced, ugly tumours [6].
5.2. Non-irradiated low and medium-high rectal cancer
Adding 5FU-based adjuvant chemotherapy after surgery
alone seems to provide meaningful benefits in terms of OS
and DFS and perhaps also local recurrence rates, also in rectal
cancers from the lower two-thirds. In practice, this is not of-
ten clinically relevant since very few patients with a tumour
below about 10 cm from the anal verge with adverse histolog-
ical features have been treated with surgery alone. Clinical
and radiological imaging is not perfect, with a tendency for
over-staging being more common than under-staging. What
could be discussed in these patients is whether adjuvant che-
motherapy then should be given alone or whether they
should rather have adjuvant chemotherapy with chemoradio-
therapy given either upfront or sometime during the treat-
ment period. There are no data from modern trials to rely
upon. If the local recurrence risk is reasonably high, for exam-
ple if the surgery was non-radical (R1 + R2 or crm+), chemora-
diotherapy is probably more relevant than if the risk of local
recurrence is limited but the risk of systemic relapse is higher.
Extensive lymph-node involvement (N2) and extramural
vascular invasion (EMVI+) increase the risk particularly of
systemic dissemination but also to some extent of local
recurrence. However, it appears as if trial data taken together
indicate that adjuvant chemotherapy seems more relevant
for most patients than chemoradiotherapy, although this
conclusion is controversial due to the lack of good trial data.
5.3. Pretreated rectal cancer
The ability to give solid recommendations based upon good
evidence is limited when radiotherapy and particularly che-
moradiotherapy have been given prior to surgery. Often a time
period has been present between the end of chemoradiother-
apy and surgery, and during that time period substantial
tumour regression may have been seen. Most evidence,
although based upon retrospective or pooled data, indicate
that the patients then are best treated according to the path-
ological stage. If a pCR or a good regression is seen the value
of adjuvant chemotherapy may be minimal, chiefly because
the risk of recurrence is small (<15%). The study which devel-
oped the nomogram [26] indicates that patients with poor tu-
mour regression benefit from adjuvant chemotherapy. This
author is uncertain about its value, and would have preferred
to see a randomised study completed. Still, adjuvant oxalipl-
atin-based therapy is often given, chiefly because the risk of
recurrence is high. In a United States (US) national compre-
hensive cancer network analysis [29] it was seen that a size-
able minority of the patients (about 20%) who preoperatively
received chemoradiotherapy did not receive adjuvant chemo-
therapy, as recommended. Strategies to facilitate the ability to
complete the third and final component of curative treatment
were considered necessary.
Adjuvant chemotherapy is also provided in the control
group of the ongoing RAPIDO trial (Clin Trials Gov,
NCT01558921) where locally advanced, ugly rectal cancers
are randomised between chemoradiotherapy, surgery and op-
tional adjuvant capecitabine–oxaliplatin (XELOX) for
6 months or 5 · 5 Gy, 5 months of XELOX and surgery [30].
Due to the scientific uncertainty, some countries (centres)
have chosen not to give adjuvant chemotherapy in the control
group.
6. Timing of chemotherapy
Sensitivity of the subclinical tumour cells potentially present
after surgery to the given drug(s) is for obvious reasons crucial
for an increase in recurrence-free survival, and hence DFS
and OS. However, since the currently available drugs in colo-
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rectal cancer have rather limited tumour cell kill effects, the
number of tumour cells to be killed is also relevant. The tu-
mour cells have left the primary tumour prior to diagnosis,
between the diagnosis and the surgery (or start of a treatment
that at least temporarily prevents the tumour cells from being
clonogenic) and at the latest during the surgery to remove the
primary. The number of cells in the deposits to be killed is
also influenced by the delay from surgery to initiation of the
adjuvant therapy. The relevance of this delay has been the fo-
cus of many retrospective studies and meta-analyses of the
studies in colon cancer [31–33]. Most studies have reported
poorer survival in groups of individuals who started adjuvant
therapy later rather than earlier. The start of treatment is not
random (a randomised trial comparing different times is not
possible for ethical reasons) but may be caused by many fac-
tors that negatively influence particularly survival but also
risk of and time to recurrence. The analyses may thus be sub-
ject to severe bias. All trials that have shown a benefit from
adjuvant therapy in colon cancer had a requirement that it
should be initiated within 4–6 weeks. In later trials, the max-
imum allowed time has been much longer, up to 12–13 weeks,
actually diminishing the ability to detect a difference between
two treatments. Several national guidelines also permit a de-
lay up to 12 weeks (e.g. [34]). In a survey among 679 out of 1151
patients who received chemotherapy, only 72% met the 12-
week benchmark. This proportion was lower in rectal cancer
(67%) than in colon cancer (79%).
For many reasons, the time from diagnosis to start of adju-
vant therapy is longer in rectal cancer than in colon cancer.
The surgery is generally more extensive, with more complica-
tions and longer postoperative recovery. The preoperative
radiotherapy – which probably efficiently decreases the clono-
genic capacity of the tumour cells in the primary, but not in
the subclinical distant metastases – is another reason for a
longer delay during which tumour cell growth occurs. The
chemotherapy given concomitantly with the radiotherapy is
not very dose-efficient compared with that when it is used
alone, and probably has marginal influence on the risk of dis-
tant recurrence. The tendency to prolong the interval be-
tween the end of (chemo)radiotherapy and surgery to see
more pCRs and down-sizing [35] further prolongs the interval
and may cause survival to deteriorate. One apparently posi-
tive aspect of likely no benefit for the patients (the treatment
has already been given) may be counterbalanced by another
aspect. This also relates to the increased use of 5 · 5 Gy with
a delay of 6–8 weeks (as explored in the randomised Stock-
holm III trial [36]) outside of trials in intermediate (bad) rectal
cancers (designated by most as locally advanced) [6]. The
Stockholm III completed patient accrual in January 31, 2013,
so survival data will not be available for many years.
7. Conclusions
In many countries the use of adjuvant chemotherapy for rec-
tal cancer is not an issue, meaning that it is recommended
and given as for colon cancer. There are no good studies
describing how often it is an issue, but several centres in sev-
eral countries have expressed concerns about the value of
adjuvant chemotherapy in rectal cancer [37]. This is not the
case for colon cancer, where treatment recommendations
are probably very similar to the guidelines presented by the
European Society for Medical Oncology (ESMO) [38]. These
recommendations are based upon firm evidence when they
relate to the entire group of patients with colon cancer, but
must be questioned in the different substages. The surgery
performed today for colon cancer is of higher quality than it
was when the trials were run. Furthermore, and possibly even
more relevant, is higher quality of the pathology investiga-
tions. This has caused stage migration. The extent of this
has not been quantified. However, if we follow the recom-
mendations [38], we treat groups of patients with very low
risks of recurrence (even less than 10% with an oxaliplatin
combination), gaining very few individuals. When analysed,
population data indicate that the use in colon cancer follows
the present recommendations (e.g. [39]), whereas greater var-
iability has been reported for rectal cancer (e.g. [40]). The
available literature-based documentation from the trials has
been briefly summarised here. No one can object to the much
less scientific evidence for sufficient gains in rectal cancer
compared with colon cancer. However, interpretations differ
considerably between different researchers and clinicians,
particularly when the surgery has been preceded by
(chemo)radiotherapy.
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Introduction
Optimal approach for melanoma
Martin Gore
The Royal Marsden NHS Foundation Trust, London, UK
The incidence of cutaneous melanoma is rising faster than that
of any other malignancy, and in some parts of Europe it is now
the commonest cancer outside of ‘‘the big four’’ common
malignancies: i.e. breast, lung, colorectal and prostate cancers.
There is little doubt that the major factors in the development
of melanoma are skin type, racial origin and sun exposure.
Short sharp bursts of sunlight leading to sunburn are danger-
ous, especially when they occur in children and adolescents.
Ten percent of melanomas are familial in origin, and as
with other cancers, the biology associated with such tumours
has helped us to develop an understanding of the molecular
genetics of sporadic melanoma. A number of mutations have
been described, including those found in CDKN2A, CDK4, RB1,
p14ARF, NRAS and particularly BRAF. BRAF mutations are
found in approximately 50% of patients with cutaneous mel-
anoma, and the development of targeted agents against
mutations in BRAF has been responsible for one of the most
dramatic examples of molecular medicine in oncology.
Adjuvant therapy for patients at high risk of relapse
following treatment for primary melanoma or locoregional
disease remains an area of uncertainty. The use of adjuvant
interferon, at various doses and schedules, has been the sub-
ject of many randomised trials over 25 years. It is of note that
some large trial groups such as those in Europe still feel that
there is enough uncertainty as to the efficacy of interferon
that randomised trials of adjuvant therapy should still be per-
formed with a no-treatment control arm. The one indisput-
able fact about adjuvant interferon is that it is associated
with a relapse-free survival benefit, but some argue that, un-
like treatment in the metastatic setting, the purpose of adju-
vant therapy is to improve overall survival. A number of
meta-analyses of the randomised trials involving interferon
have been published, and it appears that the maximum abso-
lute benefit to overall survival is in the order of 2–3% and
again, some argue that this is below the threshold of useful
clinical utility. Randomised trials of the newer melanoma
therapies are now being brought into the adjuvant arena.
Vemurafenib is a BRAF inhibitor, and the results of the
first randomised trial of vemurafenib against standard of care
– namely, dacarbazine (DTIC) – were dramatic in terms of
response rates, progression-free survival and overall survival.
The hazard ratio for overall survival at the time of the first
analysis was unprecedented in solid tumour oncology. The
therapeutic momentum has continued with the development
of MEK inhibitors and their combination with BRAF inhibitors.
Other targeted therapies are being developed for uveal and
acral melanomas, e.g. against c-KIT mutations in the latter.
The most important recent development in immunotherapy
has been the targeting of inhibitors of the immune system, e.g.
CTLA-4, PD-1 and its ligand PD-L1. Ipilimumab targets CTLA-4
and is the first immunotherapy to have shown an overall survival
benefit in melanoma within the context of a randomised trial.
The magnitude of benefit can be very great in some patientswith
prolonged complete remissions; however, it is only a minority of
patients that benefit. Early results targeting PD-1 and PD-L1 are
particularlyexcitingbecausetheyappear tochallengethe dogma
that immunotherapy only impacts a minority of patients. Early
results suggest that the majority of patients show some benefit
without necessarily achieving a complete remission.
The new immunotherapeutic landscape means that our
previous view of follow-up needs to change rapidly. We now
know that there is an important immunotherapy that is
associated with a survival advantage, but that, as with most
immunotherapies, it can take some time before the host
response becomes effective. This time-frame may be 2–
4 months, and therefore it is completely illogical to wait for
a patient to become symptomatic from their metastatic dis-
ease before investigating and treating them.
Patients must have their metastatic disease diagnosed
early, otherwise there is little prospect of a successful out-
come to immunotherapy, and therefore patients at high risk
of relapse need regular imaging, and treatment should be
instituted before high volumes of disease are seen.
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1. Introduction
Melanoma is a cancer arising from the malignant transforma-
tion of melanocytes. These pigment-producing cells derive
embryologically from pluripotent neural crest stem cells. Dur-
ing foetal development they not only predominantly migrate
to and differentiate within the epidermis, but also to other ex-
tra-cutaneous pigment-containing sites such as the eyes,
meninges, oesophagus and mucous membranes. Three sub-
types of melanoma can therefore be characterised: cutaneous
melanoma (the most common) arising from melanocytes in
the epidermis, mucosal melanoma from melanocytes resid-
ing in the mucous membranes and uveal melanoma from
melanocytes residing in the ocular stroma. In this chapter
we will consider each of these melanoma subtypes in turn,
highlighting the differences in epidemiology, biology and
prognosis between them.
2. Cutaneous melanoma
2.1. Epidemiology
Cutaneous melanoma is by far the most common melanoma
subtype, accounting for in excess of 90% of cases of mela-
noma [1]. Melanoma is reported as the 19th most common
cancer worldwide, with estimated age-standardised inci-
dence rates of 2.8–3.1 per 100,000 [2]. There is considerable
variation in incidence between countries, with the highest
rates reported in Australia (37 per 100,000) and the lowest in
South-Central Asia (0.2 per 100,000). This trend is attributed
to variations in racial skin phenotype, as well as differences
in sun exposure around the world; in the United States (US),
for example, 98.2% of cases are reported amongst white-
skinned individuals [1].
Europe lags behind Australia and the United States in
terms of incidence rates, but the statistics demonstrate that
even within Europe incidence rates vary widely [3]; Switzer-
land has the highest rates (19.2 cases per 100,000) with Greece
recording the lowest (2.2 cases per 100,000). There is also evi-
dence of clear North–South and East–West incidence gradi-
ents across the continent. The reason for such marked
intra-continental variation in incidence is unclear and may
well be associated with differences in affluence and conse-
quent recreational sun exposure. However, it is also likely to
be (at least in part) related to discrepancies in cancer registra-
tion [4] between different countries, in particular in Eastern
Europe.
Unfortunately the incidence of cutaneous melanoma
around the world has been rising annually [5–7], at a rate fas-
ter than that of any other malignancy. This is of particular
concern given the unusual age demographics of the disease.
Unlike other solid malignancies, where the majority of cases
are diagnosed at over the age of 65, melanoma affects a high-
er proportion of younger patients, with a median age of diag-
nosis of 57 years. Age-specific incidence rates increase
steadily from the third to the ninth decades of life. There is
a female preponderance in younger age groups (4:10 in 20–
24-year-olds) which changes to a male preponderance (16:10
in >85-year-olds) after a sharp increase in incidence amongst
males from the age of 55 onwards [8]. Estimates from the Uni-
ted States [9] quote a lifetime risk of melanoma as 1 in 56 for
women and 1 in 37 for men, with UK estimates at 1 in 60 for
women and 1 in 61 for men [10], further highlighting global
differences. Australia/New Zealand has the highest global
melanoma mortality rate (3.5/100,000) followed by North
America (1.7/100,000) and then Europe (1.5/100,000) [3]. Over-
all, mortality rates are higher amongst men than women
[11], perhaps because of the later presentation of disease.
Several risk factors thought to be significant in the devel-
opment of cutaneous melanoma have been identified by epi-
demiological studies. These can be grouped into
environmental factors and genetic factors, but there is clearly
interplay between both genetics and the environment to ac-
count for such a wide variation in disease demographics.
Pigmentation has an indisputable and significant influ-
ence on skin susceptibility to malignant change. The melano-
cortin 1 receptor (MC1R) is a melanocyte cell-surface receptor
that induces pigment production (via the signalling cascade
recruitment of MITF) following activation by its ligand, al-
pha-melanocyte-stimulating hormone (MSH) [12]. There are
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many polymorphisms of the MC1R gene, resulting in the
numerous skin-colour phenotypes seen in humans; variants
such as the red hair, fair-skinned phenotype express low pig-
mentation, with a consequent increased sensitivity to ultravi-
olet (UV) light and associated increased melanoma risk [13].
As implied above, the main environmental factor impli-
cated in the development of cutaneous melanoma is UV radia-
tion. The incidence of melanoma is highest in equatorial
regions, and decreases with increasing distance from the equa-
tor [14,15]. This directly corresponds with UV light exposure,
particularly UV-B levels [16–18], and occurs regardless of skin
type. Although a direct causal link has not been established,
epidemiological studies [17,19] have repeatedly demonstrated
an association between the pattern and timing of sun exposure
and melanoma. The majority of cutaneous melanomas arise
on sporadically (rather than chronically) sun-exposed skin, in
sites and individuals more prone to sunburn. The highest rates
are seen in individuals with repeated intense sun exposure.
This theory is further strengthened by the observation that pa-
tients with melanoma who actively reduce their sun exposure
after initial diagnosis are consequentlyat reduced risk of devel-
oping a second primary melanoma [20]. On the contrary, indi-
viduals with dark skin, or skin that darkens easily in response
to sunlight but does not burn, have demonstrably lower rates
of melanoma [17]. Patients with xeroderma pigmentosum
(XP) commonly develop cutaneous (and conjunctival) melano-
mas [21]; these individuals have a genetic inability to repair UV-
induced DNA damage, providing further support for the signif-
icance of UV radiation in melanomagenesis.
The age at which sun exposure and/or sunburn occurs also
appears to be important. Systematic review [19,22,23] has
strongly associated intermittent childhood or adolescent
sun exposure with a higher risk of melanoma. In particular,
individuals experiencing more than five episodes of severe
sunburn had a two-fold increased risk of melanoma [24,25].
Although the melanomagenic effects of UV-B exposure are
well evidenced, UV-A exposure is not without risk [26]. Long-
term follow-up of psoriasis patients has demonstrated that
those receiving UV-A therapy are at increased risk of develop-
ing melanoma [27]. Sunbeds emit UV-A radiation; a meta-
analysis of studies [28] exploring melanoma incidence follow-
ing sunbed use reported a 75% increase in risk in individuals
under 35 with a history of sunbed use. Further studies sup-
port this finding, drawing clear associations between mela-
noma risk and the amount of sunbed usage, particularly
from a young age [29–31]. The association was felt to be suffi-
ciently conclusive for UV light from sunbeds to be formally
classified as a human carcinogen [28,32]; unfortunately, de-
spite this evidence and consequent public health warnings,
sunbed tanning remains popular.
No other conclusive environmental risk factors – including
(unusually) smoking – have been identified. Smoking, a com-
mon carcinogen, has not been independently associated with
melanoma [33]. Interestingly, however, there is an association
between melanoma and comorbidities: for example, individu-
als who are immunosuppressed (due to organ transplanta-
tion) are at demonstrably higher risk of melanoma,
including recurrence in individuals with resected primary
melanomas prior to transplantation [34,35]. Also, patients
who have other skin malignancies (basal- or squamous-cell
carcinomas) are at higher risk of melanoma development
[36] and subsequent disease-related death [37].
It is also important to consider individual genetics when
determining personal risk. Clearly genetic factors such as
race and skin phenotype affect risk, as discussed earlier, but
it has also been estimated that approximately 10% of melano-
mas are familial in origin [38]. Some of these occur in specific
syndromes – such as familial atypical multiple mole and mel-
anoma syndrome (FAMMM) or dysplastic naevus syndrome
(DNS) – wherein individuals have multiple and phenotypically
variable moles at high risk of malignant transformation,
thereby presenting an almost guaranteed lifetime melanoma
risk. Many individuals will not meet the diagnostic criteria for
these syndromes but still have numerous naevi, often a
reflection of cumulative sun exposure. Observational studies
suggest a strong association between high naevus counts
and melanoma [39,40]. A personal history of cutaneous mela-
noma is also a known risk factor for further melanoma
primaries [41–43].
2.2. Biology
Aside from these familial syndromes, advances in gene anal-
ysis technology have allowed the investigation of less com-
mon but high-risk alleles that also appear to contribute to
cancer risk in individuals. Linkage studies focused on families
with a high incidence of melanomas [44–46] identified a mel-
anoma susceptibility locus on chromosome 9p21, subse-
quently found to represent the gene locus for CDKN2A
[47,48]. This gene locus undergoes complex transcription
(from alternate reading frames) and thus encodes two pro-
teins, p16 and p14ARF; the majority of mutations affect the
former protein [49,50].
p16 normally interacts with and inhibits cyclin-dependent
kinase 4 (CDK4). During the normal cell cycle, CDK4 com-
plexes with cyclin D, resulting in phosphorylation of the reti-
noblastoma (Rb1) protein, in turn releasing E2F-1 and thus
allowing it to induce S-phase gene synthesis; p16 therefore
acts as a negative regulator of the cell cycle [47,50]. Mutations
affecting this important protein disrupt its inhibitory func-
tion, thus deregulating the cell cycle. They are therefore
thought to prime melanocytes for malignancy. Evidence [51–
53] also exists for a pro-melanomagenic effect of germline
mutations affecting CDK4 and Rb1 directly. p14ARF also has
an important role in down-regulating p53 activity (through in-
creased activation of MDM2), thus also acting as a tumour
suppressor; disruption of this activity through mutations
could also be tumourigenic [54].
The actual prevalence of CDKN2A mutations is difficult to
quantify. In melanoma family studies estimates have ranged
from 20% to 57% [50], but in the general population are
thought to be considerably lower, in the region of 1.2–2.9%
[55]. Gene penetrance estimates are further complicated by
the knowledge that the environmental factors discussed ear-
lier further modulate risk in individuals with CDKN2A. Estab-
lishing the relative risk contribution from genes is therefore
more challenging. There may also be interaction between ge-
netic mutations to modulate melanoma risk further; for
example, some MC1R gene variants can increase the pene-
trance of CDKN2A mutations, thus increasing risk further
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[56,57]. A link between CDKN2A melanoma and other malig-
nancies (e.g. pancreatic cancer) has also been demonstrated
[58–60].
BRCA2 is well associated with increased risk of breast
malignancies, but its role in melanoma is not fully estab-
lished. Given that some studies [61] suggest an increased risk
of melanoma in the presence of mutations in this gene,
whereas others [62] have been unable to demonstrate this,
no sound conclusions can be drawn regarding this gene.
Other genes are also being investigated; genome-wide associ-
ation studies [63–65] have identified several loci that may cor-
relate with increased melanoma risk, but the biological
mechanism of many of these has not yet been established.
Genetic mutations affecting protagonists of the mitogen-
activated protein kinase (MAPK) pathway have been found
in many tumour types. This key cell signalling pathway is
activated by ligand binding to a cell-surface receptor tyrosine
kinase (RTK), which in turn activates RAS. The RAS family of G
proteins consists of three isoforms, the most important of
which is NRAS. NRAS activation results in further pathway
signal transduction through phosphorylation (and conse-
quent activation) of the RAF proteins BRAF and CRAF [66].
Homo- or hetero-dimer formation of RAF molecules ulti-
mately leads to the activation of extracellular signal-regu-
lated kinase (ERK) which in turn acts on numerous targets
to promote cell growth and survival, as well as controlling fur-
ther MAPK pathway signalling by inducing the expression of
negative regulators [67], and directly inhibiting proteins such
as CRAF [68].
Mutations affecting this pathway are present in the vast
majority of cutaneous melanomas, predominantly affecting
the NRAS (approximately 20%) [69] or BRAF (approximately
40–50%) proteins [70]. In the case of BRAF, the vast majority
of mutations constitute a single amino acid substitution from
valine to glutamic acid at codon 600 (V600E), resulting in a
constitutively active BRAF protein that is consequently able
to signal in a continuous and unopposed fashion down the
MAPK pathway, thus promoting melanomagenesis and pre-
venting apoptosis [71,72]. Interestingly, a similar proportion
of naevi also contain BRAF mutations, implying that these
alone are not sufficient for malignant transformation [73].
It is hypothesised that whilst melanocyte acquisition of a
BRAF mutation is not the founder event for oncogenesis, it oc-
curs early in the development of invasive melanoma and fur-
ther enhances the effects of other oncogenic stimuli; thus it
facilitates malignant transformation, rather than initiating
it. BRAF mutations are more commonly seen in melanomas
arising in intermittently sun-exposed sites, implying that
UV light (as described earlier) may be one such stimulus.
Additionally, as there is significant interaction between intra-
cellular signalling pathways, further genetic aberrations
affecting the PI3 kinase pathway, for example, may also be
sufficient to induce melanoma development. Once developed,
however, there is clear tumour dependency on persistent acti-
vation of the MAPK pathway [72].
2.3. Prognosis
Prognostic factors in cutaneous melanoma have been closely
studied; they include histopathological characteristics, pa-
tient characteristics, biochemical measures and most re-
cently genetic mutations. Each of these will be considered
in turn.
The American Joint Committee on Cancer (AJCC) staging
system [74] is globally acknowledged as an invaluable tool
in predicting outcomes for patients diagnosed with mela-
noma. It is based on data derived from analysis of tens of
thousands of cutaneous melanoma patients; the current sev-
enth edition was introduced early in 2010 and incorporated
new factors not previously used in the estimation of mela-
noma prognosis.
Histopathological features logically form the main criteria
for determining prognosis. Increasing thickness of the cuta-
neous primary correlates with worsening survival outcomes,
dropping from 96% 10-year survival for lesions <1 mm, to
54% for lesions >4 mm; even for lesions <1 mm in thickness,
there is further deterioration in outcome between lesions
<0.25 mm thickness and those >0.75 mm [75]. Moreover, at
each tumour thickness it has been demonstrated that the
presence of epithelial ulceration in the primary results in a
worse prognosis than if there is no ulceration [76,77]. These
two features (tumour thickness and ulceration) are arguably
the most powerful independent prognostic factors for cutane-
ous melanoma [76,78,79]. A third significant pathological fea-
ture is the mitotic rate [80,81]; a rate of >20 mitosis/mm2
results in a 10-year survival of approximately 48% relative to
93% in those individuals with <1 mitosis/mm2. Other features
of the primary associated with higher risk of relapse or
metastases are high tumour vascularity (i.e. new vessel for-
mation at the base of an invasive melanoma) [82,83] and lym-
phovascular invasion (tumour invasion of the dermis
microvasculature) [84]; the evidence for these factors is not
as conclusive as that for those discussed earlier.
The site of the primary also has important prognostic
implications; those arising centrally (trunk, head and neck)
tend to carry a worse prognosis than those arising on the
limbs (lower < upper) [76,85,86]. Additionally, cutaneous mel-
anoma can metastasise to lymph nodes. The presence of
lymph-node disease has adverse prognostic implications,
with further variation depending on the burden of nodal dis-
ease – both in terms of micrometastatic versus macroscopic
disease – and the number of lymph nodes involved. The pres-
ence of microscopic lymph-node disease results in 10-year
survival rates of 63%, but if macroscopic disease is present
this drops to 47% [76,87]. Similarly, there is a 10% 5-year sur-
vival deterioration with an increase in the number of nodes
involved (from 1 to 3) [87]; for those with macroscopic metas-
tases this increased risk is independent of other primary tu-
mour characteristics. Metastases to other sites have adverse
prognostic implications. Satellite cutaneous lesions reduce
survival by a similar proportion to lymph-node metastases
[88], with worsening prognosis with metastases to the lung
and further deterioration with any other organ involvement
[74,76].
In terms of patient characteristics, it is well established
that age is an independent prognostic factor, with worsening
outcome associated with increasing age [76,89,90]. Interest-
ingly, for early-stage (I–II) melanoma, female gender also
has positive prognostic implications [78,91–93], possibly re-
lated to the higher number of thin, non-ulcerated, extremity
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lesions diagnosed in women. The histopathological factors
previously discussed are more prognostically significant than
gender.
With regard to biochemical features, serum lactate dehy-
drogenase (LDH) is well recognised as an independent prog-
nostic factor in cutaneous melanoma; in multivariate
analysis [74,94] a raised LDH level predicts approximately
50% lower survival rates in patients with distant metastases.
Other serum prognostic biomarkers have also been studied;
the most promising, S100 protein levels, correlate with sur-
vival in patients with resected locoregional disease [95,96],
with high levels predicting a significantly worse outcome
than with normal levels.
The increased use of gene expression profiling is also pro-
viding further genetic prognostic clues. The BRAF gene muta-
tion – which as previously described is integral to melanoma
pathogenesis – has been investigated as a prognostic marker
too. It appears to be linked to known prognostic factors such
as age and site of primary, whilst also being unrelated to fac-
tors such as site of metastasis and LDH [97]. In advanced dis-
ease, meta-analyses have demonstrated that the presence of
a BRAF mutation is independently associated with a worse
survival outcome [97–99]. The data in this area continue to
evolve.
3. Uveal melanoma
Uveal melanoma is the most common primary ophthalmic
malignancy in adults and is associated with resistance to
available treatments and poor prognosis. The incidence of
uveal melanoma in Europe has been estimated as between
2 and 8 per million [100] and the median age at presentation
ranges from 55 to 60 years of age [101,102]. Both US [103] and
European [100] studies report that the incidence rate has been
stable since the 1970s, and disappointingly there has been no
improvement in survival over this time period. There is regio-
nal variation within Europe with an increase in incidence
from South to North, leading to the hypothesis that ocular
pigmentation may be protective [100]. Other incidence studies
support this hypothesis.
In the USA the majority of cases occur in the white popu-
lation [103]; there is a low incidence in South African black
populations [104] and in Far East Asian populations [105].
Case–control studies provide further supportive evidence that
lighter skin [106] and iris [107–109] colours are a risk factor for
the development of uveal melanoma. The role of UV-B radia-
tion in the pathogenesis of uveal melanoma is less clear as
studies rely on self-reported retrospective data on exposure
to sunlight. Some case–control studies have reported a weak
positive relationship between lifetime UV-B exposure and
uveal melanoma [106,110], whereas others have reported no
relationship [111,112]. Despite this the use of sunlamps is
recognised as a significant risk factor for the development
of uveal melanoma [106,109].
3.1. Biology
Disruptions in a number of tumour suppressor genes and/or
activation of oncogenes have been implicated in the develop-
ment of uveal melanoma. Disruption of the activity of the ret-
inoblastoma (Rb) tumour suppressor gene leads to
uninhibited progression of melanocytes through the G1–S
phase of the cell cycle, resulting in deregulated cell prolifera-
tion. Cyclin D4, either by over-expression [113] or lack of inhi-
bition by the tumour suppressor gene INK4a [114],
phosphorylates Rb resulting in its inactivation [113]. The p53
tumour suppressor gene is often functionally inhibited by
the over-expression of HDM2 resulting in the inhibition of
apoptosis [115]. Also PTEN, a negative regulator of the PI3K-
AKT pathway, is frequently inactivated or down-regulated in
uveal melanoma leading to increased cell proliferation and
survival [116].
More recently mutually exclusive mutations in GNAQ and
GNA11, genes encoding the alpha subunit of heterotrimeric
cell surface G proteins, have been reported. These alpha sub-
units are involved in mediating signals between G-protein-
coupled receptors and downstream effectors such as protein
kinases A and C [117]. Mutations in codon 209 of GNAQ and
GNA11 have been reported in approximately 46–49%
[118,119] and 32% [120] of patients, respectively, and lead to
constitutive activation of the G protein alpha subunit and
activation of the MAPK signalling pathway (in human mela-
nocyte cell lines), driving cell proliferation [118]. The majority
of substitutions at codon 209 of GNAQ and GNA11 involve
substitutions of glutamine by leucine or glutamine by proline
[118,120]. Mutations at codon 183 of GNAQ and GNA11 also
occur, although less frequently, and involve the substitution
of cytosine by thymine [118,120] which is characteristic of
ultraviolet-radiation-induced mutations [121], thereby sup-
porting the role of UV-B radiation in the pathogenesis of a
minority of uveal melanomas. As mutations in GNAQ and
GNA11 are common in uveal melanoma, targeting these or
downstream effectors such as protein kinase C [122] or mem-
bers of the MAPK signalling [123] pathway are promising po-
tential therapeutic options. However, the presence of these
mutations is not correlated with the development of meta-
static disease.
Inactivating somatic mutations of the gene coding for
BRCA1-associated protein-1 (BAP1) have been found in up to
85% of metastasising uveal melanomas [124]. BAP1 is a de-
ubiquitinating enzyme (DUB) encoded at the 3p21.1 locus
[125]. It regulates cell growth by mediating ubiquitination of
the nuclear transcription regulator, host cell factor 1 (HCFC1)
[126], and stabilises the BRCA1–BARD1 tumour suppressor
complex [127]. Also families with germ-line mutations of
BAP1 have been identified with an increased incidence of both
uveal and cutaneous melanoma, as well as other malignan-
cies [128–130].
Vascular endothelial growth factors (VEGFs) are a family of
five proteins which bind to VEGF receptors (VEGF-Rs) on endo-
thelial cells and promote angiogenesis. Increased VEGF
expression is involved in the pathogenesis of a number of so-
lid malignancies. The expression of VEGF is increased in hyp-
oxic environments [131], and raised VEGF-A levels have been
found in the aqueous humour of eyes with uveal melanoma
[132,133]. Significantly increased levels of VEGF-A have been
reported by some groups in patients with metastatic disease
[134], although not consistently [135]. The role of VEGF in
the pathogenesis of uveal melanoma requires further clarifi-
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cation, but trials of anti-angiogenic agents of patients with
melanoma, including uveal melanoma, are underway.
3.2. Prognosis
Major aberrations in karyotype are frequently observed in
uveal melanoma [136]. Monosomy 3 is the most common
and is reported in approximately 50% of cases treated with
enucleation [137]. It has been found to correlate with clinical
features of poor survival – such as large tumour size, tumours
of the ciliary body [138] and epithelioid cytology [139] – and is
also closely associated with the development of metastatic
disease [140]. Such patients with monosomy 3 uveal mela-
noma have a poor 5-year survival [141]. This may be due to
loss of tumour suppressor genes located on chromosome 3,
including BAP-1. It is likely that loss of chromosome 3 is an
early event in tumourigenesis, predisposing to other cytoge-
netic aberrations such as gain of 8q [142]. This is found in
around 40% of cases and corresponds to the locus for the
MYC proto-oncogene [143]. Together these cytogenetic abnor-
malities are more common in ciliary body tumours [144] and
are associated with the development of metastatic disease
[143]. Gain in chromosome 6p is associated with a better prog-
nosis. It has been observed in approximately 25% of tumours
and exclusively in tumours without monosomy 3 [143].
More recently gene expression profiling has identified two
distinct molecular subtypes (classes 1 and 2) of primary uveal
melanoma using a three-gene signature, with significant dif-
ferences in prognosis [145]. This signature identifies genes
which are involved in apoptosis, cell growth and angiogene-
sis. Class 1 tumours are associated with gain of chromosome
6 and are less likely to metastasise, whereas class 2 tumours
are associated with monosomy 3 and demonstrate a propen-
sity to metastasise. Consequently the 92-month survival for
class 1 and class 2 subtypes differed significantly at 95% and
31% respectively.
4. Mucosal melanoma
Given that the primary function of melanocytes is pigmenta-
tion and protection of the skin and eyes against UV radiation,
their presence in unexposed sites such as mucous mem-
branes is not fully understood. There is accumulating evi-
dence that melanocytes function as antigen-presenting cells
[146,147], and as mucous membranes form a critical antimi-
crobial barrier, melanocytes at this site may have a role to
play as part of the innate immune system [148]. At leptome-
ningeal sites there is even evidence of a neuroendocrine role
[149]. Regardless of their function, mucosal membrane mela-
nocytes are susceptible to malignant transformation in a sim-
ilar fashion to their cutaneous and uveal counterparts.
4.1. Epidemiology
Mucosal melanoma is the least common of the three mela-
noma subtypes, accounting for less than 1.5% of all melano-
mas [1,150]. The incidence rate is similar around the world
[151] and estimated at 2.2 [150] and 2.6 [152] cases per million
per year in the USA and Europe respectively. Significant regio-
nal variation in incidence across Europe has been reported,
with the highest rate (2.7 cases per million per year) noted
in Northern Europe, and the lowest (0.88 cases per million
per year) in Eastern Europe [152], but this may simply reflect
differences in classification and reporting of this rare malig-
nancy. Interestingly, unlike cutaneous melanoma (which
demonstrates an annual increase in incidence), the annual
incidence of mucosal melanoma has remained relatively sta-
ble over several decades [1,150,153].
The incidence of mucosal melanoma varies with both gen-
der and age [150]. The median age at diagnosis is 70, with the
exception of oral cavity melanomas which tend to occur in
younger patients. Incidence increases with age; over 65% of
cases are diagnosed in patients over 60. The incidence in wo-
men is almost twice as high as in men, possibly because of
the higher rates of genital tract melanomas [1,154,155]
amongst women. The absolute incidence of mucosal mela-
noma in white populations is higher (2:1) than in non-whites
[1,150,155,156].
Mucosal melanomas arise most often in the head and neck
region, female genital tract and anorectal region [150]. No
clear risk factors for mucosal melanoma are known. As mu-
cous membranes are not exposed to the sun, UV radiation
is not considered an important aetiological factor. The role
of viruses – such as human papillomavirus (HPV) or human
herpes virus (HHV) implicated in other oral malignancies –
has not been substantiated [157–159]; however, a role for the
human immunodeficiency virus (HIV) has been postulated
[160,161] for anorectal mucosal melanomas. Inhaled chemical
irritants such as formaldehyde [162] are also not thought to be
significant carcinogens for this malignancy. It has been re-
ported that smoking is associated with a greater prevalence
of pigmented oral lesions [163]. Oral mucosal melanoma is
thought to be preceded by oral melanosis in one third of cases
[157,164,165], but no clear link to smoking has been identified,
particularly at other mucosal sites.
4.2. Biology
The advent of next-generation genomic sequencing has en-
abled detailed investigation of the molecular biology of this
rare melanoma subtype, and provided an insight into its
pathogenesis. Unlike cutaneous melanoma, V600E BRAF or
NRAS mutations are rare in mucosal melanoma [166,167]. In-
stead a distinct molecular mutation pattern exists, further
differentiating mucosal melanomas biologically from their
cutaneous and uveal counterparts.
The proto-oncogene, KIT, is a type III transmembrane
receptor tyrosine kinase (RTK) that dimerises upon extracel-
lular binding of its ligand stem-cell factor (SCF), activating
its intracellular tyrosine kinase domain and thus the receptor.
The activated protein, c-KIT, leads to phosphorylation of a
downstream intracellular signalling cascade and the activa-
tion of MAPK and phosphoinositide 3-kinase (PI3K) pathways
crucial for proliferation, migration, differentiation and sur-
vival in many cell types, including melanocytes [168,169].
Although the exact mechanism of KIT signalling in mela-
nocytes is not fully understood, studies have demonstrated
that inactivating mutations in KIT can lead to amelanotic dis-
orders [170,171] and prevent normal melanocyte development
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 8 1 –9 1 85
and survival [172]. Loss of KIT expression in melanocytes also
results in abnormal proliferation and melanocyte mobility
[173]. A loss/lack of KIT expression is often seen in progressive
melanoma [174,175]. Early studies on the genetic alterations
in mucosal melanoma led to the identification of chromo-
somal aberrations, such as gain of 1q, 6p and 8q [176–178].
Subsequently, detailed studies [179,180] comparing melano-
mas derived from different anatomical sites demonstrated
gain-of-function mutations (such as K642E, D816H and
V559A), amplifications or over-expression of c-KIT in 39% of
mucosal melanomas. This frequency is reported to vary
markedly by site of melanoma; in one study 88% of oral
mucosal melanomas were reported as expressing aberrant
c-KIT [181], while others [180] reported their highest rates
(35%) amongst genital tract melanomas. It was also noted
that mutations of KIT did not occur alongside mutations in
NRAS or BRAF [180].
Exon 11 mutations (including point mutations, in-frame
deletions and insertions) are the most common KIT muta-
tions; the L576P mutation in particular is found in approxi-
mately one third of these melanomas [166,179,180]. This
region encodes the juxtamembrane domain of the KIT recep-
tor, which performs an auto-inhibitory role. Mutations in this
region lead to constitutive receptor activation and consequent
abnormal intracellular growth signals, predominantly via the
PI3K pathway [182]. Experimental evidence suggests that such
activation alone is insufficient for mucosal melanoma gene-
sis, requiring further triggers within the cellular microenvi-
ronment (such as hypoxia) in order to induce malignant
transformation [182].
There is clearly still much to learn about the biology of
mucosal melanoma, but the knowledge gained thus far about
KIT mutations is encouraging further research in this area, fo-
cused particularly on exploiting this mutation in the pursuit
of effective treatment options for this condition. KIT muta-
tions have been successfully targeted in the treatment of
other malignancies such as gastrointestinal stromal tumours
(GIST), which also demonstrate an increased prevalence of
KIT mutations.
4.3. Prognosis
Mucosal melanoma has the poorest prognosis of all the mel-
anoma subtypes considered. Five-year survival estimates
range from 25% to 40% [1,152]. Interestingly, patients with
KIT mutations appear to have a poorer prognosis than wild-
type patients [183].
The site of these melanomas is often occult; early malig-
nant lesions are usually asymptomatic, and any subsequent
symptoms are non-specific, resulting in significant diagnostic
delay and enabling the lesion to grow and metastasise. Even
supposedly early-stage disease deemed to be fully surgically
resectable (and thus curable) often has a poor outcome. This
is most likely due to the presence of occult metastatic disease
at diagnosis. The lack of knowledge regarding disease risk
factors means that, in contrast with cutaneous melanoma,
strategies to improve mucosal melanoma outcomes must fo-
cus on early detection of the disease rather than avoidance of
risk factors and prevention of development.
5. Conclusion
The socio-economic burden of melanoma is disproportionate
as its incidence is highest amongst younger, economically ac-
tive individuals. Both inherited, genetic and lifestyle factors
have been shown to affect the malignant transformation of
melanocytes. More recently it has become clear that cutane-
ous, mucosal and uveal melanomas are each distinct disease
entities with unique clinical behaviours and characteristic
molecular abnormalities. This improved understanding has
led to the development of new treatment strategies which
have started to improve outcomes. However, there is still a
long way to go as melanoma, for now, remains an assortment
of diseases with a common poor prognosis – particularly for
those with advanced disease.
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Targeted therapy in melanoma – the role of BRAF,
RAS and KIT mutations
Simone M. Goldinger, Carla Murer, Pascale Stieger, Reinhard Dummer *
University Hospital, Department of Dermatology, Zurich, Switzerland
Melanoma today is considered as a spectrum of melanocytic malignancies characterised by
clinical and molecular features, including targetable mutations in several kinases such as
BRAF or c-KIT. The successful development of therapies targeting these mutations has
resulted in new specific treatment options. These include vemurafenib, dabrafenib, tramet-
inib, imatinib and other kinase inhibitors that are selected when the respective mutation is
present.
The BRAF inhibitor vemurafenib has resulted in improved survival in patients with BRAF-
mutated advanced melanoma. Dabrafenib has shown similar efficacy. The MEK inhibitor
trametinib also improved overall survival. In addition, the MEK inhibitor MEK 162 was
investigated in a phase II clinical trial and showed promising efficacy in terms of response
rate and progression-free survival (PFS) in NRAS-mutated melanomas. After this first suc-
cess in the treatment of advanced melanoma, there is expectation that combinations of
kinase inhibitors will additionally improve overall survival rates and PFS in advanced
melanoma.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
1. Introduction
Melanoma is the most common lethal cutaneous malignancy.
It arises from melanocytes that have their origin in the neural
crest. The genetic events and their relationship to the complex
interaction with the microenvironment transforming normal
melanocytes intomelanoma are under intensive investigation.
2. Molecular dissection of melanoma
In the last decade melanoma was dissected into several
molecular subgroups on the basis of genomic alterations,
including mutations, deletions and amplifications, in addition
to clinical features. These subgroups include BRAF, NRAS and
KIT mutated melanomas.
First, up to 50% of melanomas derived from the skin with-
out chronic sun damage (intermittently exposed to ultraviolet
(UV)) contain mutations in the gene encoding the serine–thre-
onine protein kinase BRAF. BRAF together with ARAF and
CRAF activates a second protein known as mitogen-activated
protein kinase kinase (MEK), which in turn activates extracel-
lular signal-regulated kinase (ERK).
Second, 20% of melanomas present with RAS mutations.
Most of the NRAS mutated melanomas are superficial,
spreading melanomas (intermittently exposed to UV). How-
ever, NRAS seems also to be involved in melanomas deriving
from giant congenital nevi. A recently published model for
congenital nevi [1] used a melanoma mouse model over-
expressing NRAS under the control of a tyrosinase promoter
in combination with loss of INK4a. The phenotype of these
mice closely resembles giant congenital nevi. In this model,
haplo-insufficiency of the transcription factor SOX10 pre-
vented melanoma formation.
Finally, minor percentages have activating mutations in
the KIT gene, most common in mucosal melanomas derived
from the genital regions [2,3] or mutations in GNA11 or GNAQ
genes in uveal melanomas [4,5]. Some of the targetable muta-
tions in the KIT gene are also found in acral and other muco-
sal (for example, penile or anal) melanomas but with lower
frequency. The KIT receptor protein tyrosine kinase is a trans-
membrane protein consisting of extracellular and intracellu-
lar domains. Most KIT mutations are located in exon 11,
which codes for the juxtamembrane domain, and in exon
13, which codes for a kinase domain.
Recently, deep exome sequencing shed further light on the
genomic landscape of melanoma [6,7]. Both publications
impressively demonstrated that UV light is responsible for
most mutations inmelanomas derived fromUV-exposed skin.
1359-6349/$ - see front matter Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
http://dx.doi.org/10.1016/j.ejcsup.2013.07.011
* Corresponding author. Address: Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland. Tel.:
+41 44 255 25 07; fax: +41 44 255 89 88.
E-mail address: reinhard.dummer@usz.ch (R. Dummer).
Hodis et al. reported that more than 80% of all non-silent cod-
ing mutations are UVB-dependent. Similar observations were
also reported by Krauthammer et al. In addition, both papers
provide evidence that RAC1 might be another driver mutation
for melanoma in addition to BRAF and NRAS. RAC1 is a mem-
ber of the Rho family of GPTases and therefore shares some
features with the RAS oncogenes. Interestingly these investi-
gations also identified deactivating mutations in phospha-
tases. These molecules might contribute as a feedback
mechanism during the activation of signalling pathways, and
defects in their function may contribute to tumour initiation
and progression. Obviously there aremany genetic alterations
inmelanoma. Itwill be crucial to identify drivermutations that
are promising targets for therapy in this huge landscape of ge-
netic alterations. These genetic alterations are definitely not
restricted to exomes. There are also relevant mutations in
non-coding DNA sequences such as promoter regions. Huang
et al. described two independent mutations in the promoter
of telomerase reverse transcriptase (TERT) [8]. Keeping these
data inmind, we can expectmanymore surprising discoveries
using these powerful techniques in the near future.
3. Breakthrough with kinase inhibitor therapy
in melanoma subgroups
The best-validated targeted drugs in melanoma are the selec-
tive BRAF inhibitors vemurafenib (PLX4032, ZelborafTM) and
dabrafenib (GSK2118436, TafinlarTM) as well as the LGX818
(Novartis) compound [9] that appears to have the highest
affinity for the catalytic domain of the kinase. All of them
are relatively selective for their intended target V600E BRAF,
with little cross-reactivity for wild-type BRAF and CRAF
[10,11]. A few other kinases are inhibited with 10- to 100-fold
of the concentration needed to inhibit V600 BRAF. These mol-
ecules selectively inhibit the growth of cells that harbour a
V600 BRAF mutation. In phase I clinical trials, where patients
were selectively enrolled on the basis of the presence of a tu-
mour BRAFV600E or BRAFV600K mutation, vemurafenib and dab-
rafenib both demonstrated evidence of tumour regression
early in the course of therapy in the majority of patients
[11–13]. Subsequent phase II and III trials designed to evaluate
overall disease control and survival in comparison with stan-
dard chemotherapy have documented the durability of re-
sponse in larger cohorts. In a phase II trial, vemurafenib
produced objective responses in 53% of 132 patients with
metastatic melanoma harbouring a BRAFV600E or BRAFV600K
mutation [14,15]. The median duration of response was
6.7 months. In a phase III trial with single-agent dacarbazine
as the control arm, overall survival (OS) was significantly im-
proved amongst 337 patients with BRAFV600E mutant meta-
static melanoma receiving vemurafenib compared with 338
patients who received dacarbazine (hazard ratio (HR) 0Æ37;
95% confidence interval (CI): 0.26–0.55; P < 0.001) [16]. Progres-
sion-free survival (PFS) was also significantly improved (haz-
ard ratio 0.26; 95% CI: 0.20–0.33; P < 0Æ001) and the response
rate was superior in the vemurafenib arm (48% objective re-
sponse rate versus 5%; P < 0Æ001). The benefit of vemurafenib
was maintained in an updated overall survival (OS) analysis
with approximately 10 months median follow-up, as demon-
strated by the median OS with vemurafenib of 13.2 months
compared with 9.6 months with dacarbazine and a hazard ra-
tio (HR) for death of 0.62 (95% CI 0.49–0.77) in favour of vemu-
rafenib [17]. These data led to approval of vemurafenib in the
United States (US), European community and Switzerland.
Dabrafenib was compared with dacarbazine (random ratio
3:1) in a phase III trial in patients with previously untreated
stage IV or unresectable stage III melanoma harbouring the
BRAFV600 mutation. Median PFS was 5.1 months for dabrafe-
nib (187 patients) and 2.7 months for dacarbazine (63 pa-
tients), with an HR of 0.30 (95% CI: 0.18–0.51; P < 0.0001) [18].
This drug was recently approved by the Food and Drug
Administration (FDA) in the US.
In summary, vemurafenib and dabrafenib have both dem-
onstrated impressive clinical efficacy with response rates in
the region of 50% in V600 BRAF mutated advanced melanoma
[11,12,19]. Although the response duration is highly variable,
as shown by these phase II and phase III trials, these results
are a breakthrough in melanoma treatment.
Furthermore, multiple in vitro studies have demonstrated
that mutated BRAF signalling is mediated via MEK and ERK
[20]. Thus, selective MEK inhibitors have also shown efficacy
in patients with BRAF mutant metastatic melanoma. Selu-
metinib was the first allosteric, selective MEK inhibitor to be
evaluated in a phase II clinical trial in patients with meta-
static melanoma [21]. This agent produced an objective re-
sponse rate in patients with BRAF mutant tumours, whereas
no response was observed in wild-type tumours, reinforcing
the importance of selecting a specific patient population.
The addition of selumetinib to dacarbazine has resulted in
prolonged PFS in BRAF mutated metastatic melanoma [22]
and was the first agent to show clinical activity in uveal mel-
anoma when compared to temozolomide [23]. Trametinib is
another, orally available selective inhibitor of MEK1 and
MEK2. It demonstrated a reasonable objective response rate
and an improved survival compared to chemotherapy in BRAF
mutant melanoma. The median PFS was close to 5 months
using the MEK inhibitor in comparison to 1.5 months in the
chemotherapy group. After 6 months, there was an improve-
ment in the overall survival rate in the trametinib group of
81% (versus 67% in the chemotherapy group). Trametinib
(MekinistTM) was recently approved by the FDA for the treat-
ment of patients with unresectable or metastatic melanoma
with BRAF V600E or V600K mutation.
The combination of these kinase inhibitors clearly shows
further encouraging data. The combination treatment with
dabrafenib and trametinib was analysed with different
dosages in 247 BRAF V600 mutated melanoma patients. Med-
ian PFS was significantly improved at 9.4 months for the pa-
tients treated with 150 mg dabrafenib twice daily and 2 mg
trametinib daily, as compared with 5.8 months for the pa-
tients treated with dabrafenib alone (HR for progression or
death, 0.39; 95%CI, 0.25–0.62; P < 0.001). The rate of complete
or partial response in the combination group was 76% (com-
pared with 54% with monotherapy (P = 0.03) [24]. In other
words, the combination of BRAF and MEK inhibitors results
in an increased response rate and prolonged PFS [24]. Today,
there are several phase III clinical trials that compare the re-
sponse rates and the PFS in BRAF mutated patients for mono-
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therapy with a BRAF inhibitor versus combination of BRAF
and MEK inhibitors.
Lito et al. have investigated the ERK-dependent feedback
mechanism during BRAF inhibition using a selective inhibitor.
They could clearly show that a BRAF inhibitor blocks RAF
monomers, resulting in RAF dimer formation. These dimer
feedback mechanisms are decreased. The addition of a MEK
inhibitor can overcome this problem and enhance the inhibi-
tion of the pathway and antitumour efficacy [25].
In vitro investigations using NRAS mutant melanoma cell
lines have suggested that MEK inhibitors may be useful in this
genetic background. A recent clinical trial using the MEK1/2
inhibitor MEK 162 in a phase II clinical trial has confirmed
that advanced NRAS mutant metastatic melanoma can be
successfully treated in patients. A response rate of approxi-
mately 25% was found, with a PFS similar to that observed
using MEK inhibitors in BRAF mutant metastatic disease
[26]. Other MEK inhibitors have been investigated in NRAS
mutated melanomas with some promising results.
Until recently, most clinical trials investigating immuno-
modulation, chemotherapy or targeted therapy have excluded
patients with brain metastasis due to concerns about drug
penetration through the blood–brain barrier and symptoms
such as intracranial bleeding resulting in life-threatening
consequences. Lately, the urgent need for medical treatment
of this patient population led to a trend change. There are re-
cent data [27] using the anti-CTLA-4 antibody ipilimumab at a
dose of 10 mg/kg every 3 weeks for four cycles in melanoma
patients with brain metastasis, with a response rate of 16%
in asymptomatic and 5% in symptomatic patients. A recently
reported trial [13] on dabrafenib in asymptomatic patients
with BRAF-mutated melanoma and at least one measurable
brain metastasis between 5 mm and 40 mm in diameter has
further demonstrated clinical activity. Moreover, in a pilot
study [28] of 24 symptomatic, very advanced melanoma pa-
tients with brain metastasis and harbouring a BRAF V600
mutation were treated safely and effectively with vemurafe-
nib, improving patients’ performance status and quality of
life. Further clinical trials – including combined therapies
with other inhibitors, with immunotherapy and with stereo-
tactic radiosurgery – are needed in the near future.
Both BRAF and MEK inhibitors have a very peculiar side-ef-
fect profile. As recently reported, BRAF inhibitors are charac-
terised by activating germline mutations of RAS and lead to
cutaneous side effects recently defined as RASopathic [29].
They involve both epidermis and adnexa and include inflam-
matory disorders such as maculopapular exanthema, follicu-
lar rash or pruritus, hair and nail changes, as well as
keratinocytic proliferations such as keratosis pilaris, palmopl-
antar hyperkeratosis, acanthopapilloma, keratoacanthoma
and squamous-cell carcinoma [30]. Melanocytic disorders
and proliferations have also been observed. In particular,
vemurafenib causes an important UVA-dependent phototox-
icity [31] that needs adequate UV protection. Dabrafenib, on
the other hand, does not seem to cause phototoxicity reac-
tions [30]. Its most common adverse events include skin-re-
lated toxic effects, fever, fatigue, arthralgia, and headache [18].
MEK inhibitors can cause papulopustular rashes, xerosis
cutis (often associated with fissured finger tips), diarrhoea,
nausea, vomiting, fatigue and blurred vision [32]. Moreover,
self-limiting retinopathy-like dose-dependent retinal disor-
ders with early onset have been described [33]. Only one of
the seven described patients was symptomatic. The retinal
disorders were transient and resolved even during continua-
tion of MEK therapy. However, a close monitoring of the retina
with a specific mark on sub-retinal exudates is highly recom-
mended. The cutaneous side effects during MEK inhibition
are similar to those observed with epithelial growth factor
receptor (EGFR) inhibitors [34]. Notably, in a recently con-
ducted trial, cutaneous adverse events were observed in over
85% of the patients [35]. This emphasises the importance of
regular dermatological follow-up examinations. Thus, regular
skin examination andmanagement by experienced dermatol-
ogists, as well as continuous prophylactic photo-protection,
including a UVA optimised sun screen, are mandatory.
The combination of BRAF and MEK inhibitors interestingly
seems to reduce the common cutaneous side effects [24].
The impressive progress observed with the use of kinase
inhibitors is unfortunately limited by the development of
resistance that is observed after 6 months on average using
BRAF inhibitor monotherapy and after 9–10 months using
BRAF–MEK inhibitor combination therapy. There is intensive
research ongoing to understand the mechanisms behind this
clinically very relevant phenomenon. Most investigations
have been performed in vitro [36]. It remains unclear which
resistance mechanisms are the most frequent in vivo in hu-
mans. A recent study using human melanoma xenografts in
a nude mouse model has shown that melanoma cells can
transcriptionally up-regulate the BRAF molecule in order to
compensate the inhibition by vemurafenib. If vemurafenib
is removed from the system, there is an over-stimulation of
the pathway resulting in decreased proliferation, probably re-
lated to oncogene-driven senescence. As a consequence,
resistance can be delayed by pulsed therapy with vemurafe-
nib rather than continuous dosing [37]. This observation is
interesting and needs to be further investigated in the clinical
setting in the near future.
In contrast to BRAF mutated melanoma, the kinase
inhibitor imatinib has proven efficacy in patients with ad-
vanced melanoma harbouring KIT mutations [38]. KIT muta-
tions are found at low frequencies (610%) in melanomas
arising from mucosal or acral lentiginous surfaces [39]. As
the vast majority of patients with metastatic melanoma suf-
fer from primary tumours on glabrous skin (trunk, extremi-
ties, and head/neck), the number of patients in the
metastatic setting with mutated KIT is small. Durable re-
sponses were observed in 16% of a 51-patient cohort with
either mutations or amplifications in KIT [40]. In a phase II
trial, in which 43 patients with KIT mutations or amplifica-
tion were enrolled, 23% of patients had objective responses
[41]. In both studies, certain mutations in exon 11 and 13
of c-KIT (particularly L576P mutation in exon 11) were asso-
ciated with the highest response rate. In addition Nilotinib,
a tyrosine kinase inhibitor used in imatinib-resistant
chronic myelogenous leukaemia (CML), seems another
promising agent in the treatment of KIT mutated metastatic
melanoma and is currently under clinical investigation.
Thus, sensitivity to KIT inhibition exists in metastatic mela-
noma [21] but it is confined to a subset of this already small
subpopulation of patients.
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After decades of standstill, progress in understanding the
biology of melanomas has resulted in powerful targeted thera-
pieswith impact on progression-free and overall survival. Ongo-
ing research is focusedon resistancemechanismsandstrategies
to overcome them [36]. In order to further improve the outcome
in this still poor-prognosis population, patients should be
encouraged to participate in well-designed clinical trials.
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A R T I C L E I N F O
Melanoma is considered one of the immunogenic – if not the most immunogenic – malig-
nancies. This is based on several observations.
1. Spontaneous remissions occur occasionally.
2. In about 5% of melanomas no primary tumour is found. The genetic aberrations of these
tumours closely resemble those of cutaneous melanomas, and therefore are suggestive
of spontaneous regressions of the primary tumours.
3. Both primary tumours and metastases often have brisk lymphocytic infiltrates, a phe-
nomenon that is correlated with better outcome.
4. Studies of isolates of these tumour-infiltrating T lymphocytes have revealed that a pro-
portion of these cells recognise melanoma antigens.
5. Melanomas respond to immunotherapy.
These observations have led to over 30 years of research on immunotherapy for melanoma;
many of these efforts have failed, with only a few exceptions: interleukin-2 (IL-2) and to a
lesser degree interferon-a (IFN-h). Recently, new developments in immunotherapy have rev-
olutionised this treatment modality. Anti-CTLA4 has received approval from the Food and
Drugs Administration (FDA) and the European Medicines Agency (EMA) for the treatment of
stage IV melanomas based on the improvement in overall survival in phase III trials, and
more recently blockade of PD1/PDL1 interactions has shown objective clinical responses
in a stage IV melanoma in early-phase clinical trials. In addition, several independent sin-
gle-institution phase I/II trials using adoptive cell therapy have shown a consistently high
response rate, including durable complete remissions in a substantial percentage of treated
patients.
Now, for the first time, immunotherapy has moved beyond the treatment of melanoma as
both CTLA4 and PD1 blockade have been shown to induce objective responses in other
tumour types as well.
This chapter will discuss the mechanism of action, clinical efficacy and side effects of IL-2,
the novel treatments consisting of the immune checkpoint blockade drugs anti-CTLA4 and
anti-PD1 and adoptive cell therapy.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
1. Introduction
Of all treatments for malignancies, immunotherapy has been
the most extensively studied in metastatic melanoma. These
often experimental, immunotherapeutic interventions can be
divided into: (1) biologicals such as cytokines, including inter-
leukin-2 (IL-2), interferons and granulocyte–monocyte colony-
stimulating factor (GM-CSF); (2) vaccination strategies such as
peptide vaccines, whole-protein vaccines, virus-based vac-
cines, DNA vaccines and dendritic-cell-based vaccines; (3)
adoptive cell therapy with lymphokine-activated killer cells
(LAKs), tumour-infiltrating lymphocytes (TILs), peripheral-
blood-derived melanoma-specific T cells and gene-modified
T-lymphocytes and (4) immune checkpoint inhibitors, includ-
ing anti-CTLA4, anti-PD1 and anti-PDL1 and immune co-
stimulatory molecules, including anti-CD137. These
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experiments were initiated because of the observations that
not only primary melanomas – especially primary superficial
spreading skin melanomas, but also metastatic disease – can
spontaneously regress [1]. In addition, about 5% of patients
present with melanoma metastases, often lymph-node
metastases, and sometimes also visceral metastases, without
any sign of primary melanoma on dermatological inspection.
Recently, it was shown that the genetic make-up (BRAF and
NRAS mutations) of these unknown primary melanomas is
very similar to that from non-chronic sun-damaged
(non-CSD) skin melanomas, suggesting that the primary
melanomas may have spontaneously regressed [2].
Little is known about the exact frequency of spontaneous
regressions in melanoma, but it is considered to be low
(around 3%), although some reviews have mentioned fre-
quencies above 15%. In a review from 2009, describing 76
cases from 1866 and onwards, the proposed mechanisms
for spontaneous regressions are thought to involve immune,
endocrine, inflammatory and tumour environmental nutri-
tional factors [3]. Although all of the above are probably in-
volved, the focus of this review is on immune factors.
The role of lymphocytic infiltrates in melanoma was first
described by Clemente et al., showing that brisk infiltration
by tumour-infiltrating lymphocytes (TILs) into primary mela-
nomas was correlated with better survival [4,5]. Later this was
also shown for TILs in metastatic lesions [6], suggesting a cau-
sal role for TILs in tumour control. In addition, in the past
20 years many tumour antigens have been discovered that
we now know are recognised by TILs. T cells derived from TILs
were shown to recognise melanocyte differentiation antigens
gp100, tyrosinase and MART-1/Melan-A. Other genes were
discovered in the 1990s, such as melanoma-associated genes
(MAGE) and NY-eso-1 [7–16]. In contrast to proteins that be-
long to the melanocyte differentiation antigens, these gene
products are derived from aberrantly expressed genes by tu-
mours, which play a physiological role during foetal develop-
ment, are silenced thereafter, but are still present mainly in
the testis. Thus, these genes have been named cancer/testis
genes. Very recently, it was demonstrated that TILs can also
recognise mutated antigens (van Rooij et al., J Clin Oncol, in
press). Melanoma has the highest frequency of mutations of
all cancers [17,18]. The vast majority of these mutations carry
a typical ultraviolet light signature. Using next-generation
DNA sequencing and RNA sequencing of tumours from paired
tumour and TIL samples, many mutations that potentially
carried a new T-cell epitope were found. Using major histo-
compatibility complex (MHC) tetramers, TILs from these tu-
mours were screened for the presence of T cells specific for
these mutated or neo-antigens. Within four tumour–TIL
pairs, four mutated antigen-specific T-cell populations could
be detected, some at high frequencies.
On the basis of these studies and clinical responses ob-
served in patients treated with immunotherapy, melanoma
can be considered one of the immunogenic types of cancer
– perhaps even the most immunogenic cancer.
In the past 30 years many trials focusing on immunother-
apy have been performed: in the early days with cytokines,
combinations of chemotherapy and cytokines, peptide vac-
cine trials, other vaccine trials (including DNA vaccines, viral
vaccines, whole-protein vaccines, tumour-cell vaccines and
dendritic-cell vaccines) and adoptive cell therapy with LAK
cells, melanoma-specific T-cell clones or peripheral-blood-de-
rived melanoma-specific T cells. With the exception of high-
dose IL-2, many trials failed, including the combination of
chemotherapy and cytokines, the LAK cell therapy and many
vaccine trials. Others showed responses in a minority of pa-
tients, some of which were very durable, but many strategies
were not taken to phase III trial level because of lack of activ-
ity. In the past decade, immunotherapy has become much
more successful, and ipilimumab is the first therapy to show
an improvement in overall survival (OS). It is likely that also
new developments such as anti-PD1/PDL1 will change the
survival of patients. Adoptive cell therapy has become a po-
tent therapy and will hopefully be investigated in randomised
controlled trials (RCTs) as well. This review focuses on the
therapies that have impacted on the lives of stage IV mela-
noma patients.
2. Clinical immunotherapy of metastatic
melanoma
2.1. Immunotherapy by infusional high-dose IL-2 boluses
High-dose interleukin-2 was tested in murine models of sar-
coma and melanoma and shown to lead to regression of
established transplantable pulmonary metastases and
subcutaneous tumours. The idea was that infusion of
high-dose IL-2 led to the activation of lymphocytes, generat-
ing lymphokine-activated killer cells in vivo, since infusion
of in vitro activated lymphocytes was highly active in murine
tumour models. In 1985, based on the observations in
mouse models, the first patients with metastatic cancer
(mostly melanoma) were treated with purified IL-2, given
as bolus infusions intravenously (i.v.) every 8 h. In some pa-
tients with melanoma objective partial clinical responses
were seen [19]. Toxicity in these patients consisted of fever,
chills and gastrointestinal tract symptoms such as nausea
and diarrhoea, hypotension, severe weight gain, anaemia,
leucocytopaenia and thrombocytopenia [20]. In Europe,
studies with continuous high-dose IL-2 i.v. infusion led to
even more toxicity; many patients required admission to
the intensive care unit (ICU) and some patients succumbed
to this treatment. In many studies, especially in patients
with either metastatic melanoma or metastatic renal cell
carcinoma, lower doses of IL-2 have been tested. Although
clinical responses were observed in a minority of patients,
the durability of these responses has been short. On the ba-
sis of consistent achievement of durable complete remis-
sions in 5–10% of patients with high-dose bolus IL-2
infusions in phase II trials, this treatment was Food and
Drugs Administration (FDA)-approved for the treatment of
metastatic melanoma in 1998, because of an unmet need
in this patient population [21]. High-dose IL-2 still is one
of the treatment options for stage IV melanoma (and for
metastatic renal-cell carcinoma) in the United States (US).
In particular, patients with good performance status and
M1a or M1b disease may benefit from this treatment. In Eur-
ope, high-dose IL-2 for these indications has not been ap-
proved and is therefore hardly used.
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High-dose bolus IL-2 is given in a dose of 600,000–
720,000 IU/kg as an i.v. bolus (15 min infusion), every 8 h for
no more than 15 boluses, followed by about 10 days of rest,
followed by another 15 infusions. This is considered one
course. Patients are followed every 2–4 months for prolonged
periods of time.
The exact mechanism of action of high-dose IL-2, despite
its presence in the clinic for over 20 years, remains elusive.
IL-2, discovered as a T-cell growth factor in 1976 [22], is a
133-amino-acid protein which binds to the IL-2 receptor (IL-
2R) present on T cells, B cells and NK cells. The IL-2R can con-
sist of two or three chains, the IL2Ra, IL-2Rb and IL-2Rc
chains. The IL-2Ra and b chains form the low-affinity IL-2R
and all three chains form the high-affinity IL-2R. Both recep-
tors can deliver signals upon binding IL-2. Since the IL-2R is
widely expressed on cells from the adaptive immune system,
the presence of IL-2R (on subpopulations of cells) is not a pre-
dictive biomarker for response to treatment. In fact, so far no
biomarker of response has been found for high-dose IL-2
treatment. Recently, in a retrospective study, a non-statisti-
cally greater objective response rate was found for patients
with melanomas harbouring an NRAS mutation (compared
to BRAF mutation or wild-type tumours) [23]. Wang et al.
studied the molecular patterns associated with response to
treatment and observed that high-dose IL-2 has immense im-
pact on gene profiles of peripheral-blood mononuclear cells
(PBMCs), while the molecular changes within the tumours
were small and differed between lesions [24]. Analyses of
transcriptional profiles pre- and post-treatment with high-
dose IL-2 in PBMCs did not reveal a statistically significant sig-
nature. Interestingly, within the same tumours analyses on
pre- and post-fine-needle aspirates did not show important
changes within genetic profiles; however, an immune re-
sponse signature present pre-treatment was associated with
better prognosis: complete remission (CR), partial remission
(PR) and stable disease SD versus progressive disease PD.
These results suggest that response to immune therapy with
IL-2 is predetermined and can be measured by the presence of
an immune response genetic signature within the tumour.
However, the study was small, and validation in a larger study
is warranted before gene profiling can be used to select pa-
tients for high-dose IL-2 treatment.
Clinical biomarkers that are associated with response re-
sult from pooled retrospective analyses of metastatic mela-
noma patients treated with high-dose IL-2 in several trials.
Durable responses were almost only observed in patients with
Eastern Cooperative Oncology Group (ECOG) 0–1 performance
status and pulmonary, lymph-node and subcutaneous metas-
tases (M1a and M1b) [25].
Despite the lack of knowledge on the mechanism of action
of high-dose IL-2, this treatment remains one of few that
gives rise to durable CRs. Probably a large proportion of these
CRs are cured from melanoma [26].
In the past years, IL-2 has been combined with other ther-
apies. These combined modalities consisted of IL-2 with or
without gp100 peptide vaccination [27], IL-2 combined with
stereotactic radiotherapy (RT) [28], IL-2 combined with anti-
CTLA4 antibody ipilimumab [29] and IL-2 combined with infu-
sion of ex vivo expanded tumour-infiltrating lymphocytes [30].
The only randomised controlled study was performed by Sch-
wartzentruber et al., which illustrated an improved response
rate and progression-free survival for the combined modality
arm consisting of gp100 peptide vaccine + high-dose IL-2
compared with high-dose IL-2 alone [27]. Combinations of
stereotactic RT and IL-2 or ipilimumab and IL-2 were tested
in small single-arm phase I/II studies [28,29]. Both combina-
tions showed an unexpectedly high response rate, including
complete remissions.
Taken together, high-dose IL-2 has been the oldest ap-
proved form of immunotherapy for metastatic melanoma.
Despite the development of new immunotherapies, high-
dose IL-2 remains a valid treatment option, especially in the
US.
2.2. Immunotherapy by immune checkpoint blockade
For T-cell activation a dual signalling step is required. The first
essential step is binding of the T-cell receptor to its cognate
antigen, the major histocompatibility complex (MHC) peptide
complex presented by antigen-presenting cells (APCs). The
second step is binding of the co-stimulatory molecule CD28
to CD80/CD86 (B7.1/B7.2) on the APC. The combined signalling
leads to full T-cell activation, resulting in up-regulation of IL-2
and IL-2R gene expression and cell division. Next to CD28, T
cells also express cytotoxic T-lymphocyte antigen-4 (CTLA4),
a co-inhibitory molecule, which binds the same ligands as
CD28 but with higher affinity [31,32]. Due to differences in
both spatial and timely expression of CD28 and CTLA4, CTLA4
will appear at the cell surface later during the immune re-
sponse and will then out-compete CD28 signalling [33]. Sig-
nalling through CTLA4 will stop IL-2 and IL-2R gene
transcription and cell proliferation. Its key role as a regulator
of immune responses was well established in CTLA4-deficient
mice that, upon exposure to environmental antigens after
birth, develop a severe and lethal lymphoproliferative disease
due to uncontrolled and persistent T-cell activation, prolifera-
tion and infiltration in peripheral tissues [34]. Blockade of
CTLA4 signalling by monoclonal antibodies has demonstrated
anti-tumour activity in murine models. In the case of immu-
nogenic tumours, single-agent CTLA4 blockade was enough
to induce tumour shrinkage, whereas in other models anti-
CTLA4 synergised with other treatment modalities to induce
efficacious antitumour immune responses (reviewed in [35]).
In the B16 melanoma model, the combination of vaccination
with irradiated GM-CSF gene transduced tumour cells and
CTLA4 blockade was successful in eradicating the tumour
[36]. These animals developed autoimmune depigmentation
or vitiligo, which was dependent on CD8 T cells, indicating
breaking of immune tolerance in these animals. CTLA4 is ex-
pressed not only by CD8 T cells, but also by CD4 T cells and
even high by CD4 FoxP3 regulatory T cells. Whether anti-
CTLA4 works through the blockade of CTLA4 on CD4 and
CD8 T cells, or through another mechanism involving regula-
tory T cells, has still not been revealed [37].
Two fully human monoclonal antibodies were developed
for use in humans, ipilimumab (MDX-010) and tremelimumab
(CP-675,206). Ipilimumab was the first monoclonal antibody to
be tested in patients with metastatic melanoma [38]. In these
early studies, which enrolled only a few patients, tumour
regressions and autoimmune adverse events were observed.
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Tremelimumab was tested in a classical dose-escalating
phase I trial [39]. Comparable to ipilimumab, tremelimumab
also leads to tumour regression, and also to uncommon tox-
icities, including dermatitis, colitis, hepatitis and hypophysi-
tis, indicating that immunological tolerance was broken in
some patients treated with CTLA4 blockade. Originally, an
association between the incidence of immune-related ad-
verse events and clinical response were thought to be present
[40]; however, this could not be confirmed in the randomised
controlled trials that have been performed with these agents.
Ipilimumab was studied in two large randomised controlled
trials [41,42]. The first trial was a second-line study in stage
IV melanoma; 676 HLA-A*0201-positive patients were ran-
domised in a 3:1:1 ratio between the combination of ipi-
limumab and gp100 vaccine, ipilimumab (+ placebo) and
gp100 vaccine (and placebo). In this study ipilimumab was gi-
ven in a dose of 3 mg/kg every 3 weeks four times. The pri-
mary endpoint of the study was overall survival. With a
median follow-up of between 17 and 28 months, a statistically
significant difference in median survival was observed in
both ipilimumab arms (10.0 and 10.1 months) compared to
gp100 vaccine alone (6.4 months). The objective response rate
for ipilimumab plus vaccine was 5.7% and for ipilimumab
alone 10.9% compared with 1.5% for the gp100 vaccine group.
At 1 year 43.6% and 45.6% of patients in the ipilimumab arms
and 25.3% in the vaccine arm were alive, also at 2 years 21.6%,
23.5% and 13.7% respectively. Grade 3–4 immune-related ad-
verse events were experienced by 10–15% of the patients,
and seven deaths (1%) were associated with immune-related
side effects. Although preclinical data and an early clinical
trial suggested synergy between gp100 vaccine and CTLA4
blockade [38], this could not be confirmed in this large RCT.
Based on the statistically significant improvement in overall
survival, ipilimumab was approved as first- (US) or second-
line (European Union (EU)) treatment for patients with stage
IV melanoma. In the second phase III trial ipilimumab com-
bined with dacarbazine was compared with dacarbazine
alone. Here ipilimumab was given in a dose of 10 mg/kg every
3 weeks four times, followed by maintenance every 3 months.
Comparably to the second-line ipilimumab trial, this trial also
found a statistically significant improvement in overall sur-
vival in the patients treated with ipilimumab plus DTIC
(11.2 months) compared with DTIC plus placebo (9.1 months).
At 3 years, 20.8% of patients in the ipilimumab arm were still
alive compared with 12.2% in the DTIC alone arm. In 56.3% of
patients grade 3–4 adverse events were observed. Whereas in
the MDX-010-20 trial gastrointestinal adverse events were
most frequent, only 36% of patients received in the second
trial all four doses of ipilimumab treatment, mostly because
of liver toxicity. This unexpected observation of hepatotoxic-
ity was attributed to the combination of DTIC plus
ipilimumab. Hence, the combination of DTIC plus ipilimumab
is not recommended.
Tremelimumab was tested in a classical phase I design and
the recommended dose for phase II studies was 15 mg/kg
every 3 months [43]. Subsequently tremelimumab was stud-
ied in a randomised controlled phase III trial in stage IV mel-
anoma patients as first-line therapy compared with
dacarbazine [44]. Although a trend towards improved overall
survival was seen in this study, this difference was not statis-
tically significant. In part this may have been due to the fact
that patients with lactate dehydrogenase levels more than
twice the upper limit of normal were excluded from the study,
whereas these patients were included in the ipilimumab piv-
otal trials. Therefore, the survival in the control arm may
have been better and the difference in overall survival (OS) be-
tween the two arms smaller. In addition, at least 16% of pa-
tients in the dacarbazine arm were treated with ipilimumab
upon failure, which may also have contributed to a better
OS in the control arm. Patients with an objective response
to tremelimumab had a considerably longer duration of this
response (35.8 months) compared with patients responding
to dacarbazine (13.7 months).
Recently, in a series of 752 patients who were treated with
ipilimumab for stage IV melanoma, 120 adverse events were
described [45]. These adverse events ranged from drug reac-
tions – sometimes severe and accompanied with eosinophilia
and systemic symptoms (DRESS syndrome), small bowel per-
foration, ischaemic gastritis, hepatitis, pancreatitis, nephritis,
hypophysitis, aseptic meningitis, alveolitis and even cardiac
fibrosis. Others had already described rare conditions such
as Guillain–Barre´ syndrome and sarcoidosis [46,47]. Algo-
rithms have been developed to treat patients that develop ad-
verse events. Most patients will require immediate
corticosteroid therapy, and sometimes other immunosup-
pressive agents such as infliximab in the case of severe colitis
that does not respond promptly to high-dose steroid therapy,
and mycophenolate mofetil or even anti-thymocyte globulin
(ATG) in the case of fulminant hepatitis.
In summary, CTLA4 blockade is an aspecific immunother-
apeutic strategy which was the first therapy to show a statis-
tical significant improvement in median overall survival in
melanoma in two phase III trials. About 20–25% of patients
will experience durable, mostly partial remissions, some even
complete remissions. Ipilimumab is the only approved immu-
notherapeutic drug. Toxicity of ipilimumab occurs in about
50–70% of patients, with 10–20% being serious, mostly im-
mune-related adverse events. Preferably, ipilimumab should
be administered to patients by experienced clinicians. Ipi-
limumab has been approved for first- or second-line therapy
in the US and as second-line treatment in Europe. Patients
with absolute lymphocyte count >1 · 109/L or with an in-
crease in ALC at the second infusion are more likely to benefit
[48,49]. However, validated predictive biomarkers are still
lacking.
Next to CTLA4, programmed death-1 (PD1) protein is an-
other cell-surface molecule that has inhibitory properties
[48,49]. In contrast to CTLA4, PD1 expression is involved in
inhibition of T cells in peripheral tissues during inflammation
[37,50]. Upon activation, PD1 is expressed on CD4+ and CD8+ T
cells and B cells, which results in the inhibition of e.g. T-cell-
receptor- (TCR-)mediated signalling, probably through activa-
tion of phosphatase SHP2 [51]. The ligands of PD1 are PD-L1
(B7-H1) and PD-L2 (B7-CD) on APCs [52]. However, PD-L1
expression may also be induced on tumour cells [53,54]. Inter-
action between PD1-positive T cells and PD-L1-expressing
tumour cells was therefore suggested to hamper proper T-cell
function and appears to be one of the immunosuppressive
mechanisms executed by tumours to escape an initially ongo-
ing immune control [54,55]. Similarly to CTLA4 expression on
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regulatory T cells, also PD1 is highly expressed on these FoxP3+
CD4 T cells. Therefore the blockade of PD1 by anti-PD1 anti-
bodies may work through breaking the inhibitory interaction
between PD1+ CD4 and CD8 T cells and PD-L1-expressing
tumour cells, or by decreasing the number or function of reg-
ulatory T cells. Similarly, antibodies specific for PD-L1 can re-
store the function of tumour-specific PD1+ CD4 and CD8 T
cells.
Both anti-PD1 and anti-PD-L1 antibodies are now in clini-
cal trials. Nivolumab (MDX-1106; BMS 936558; ONO-4538)
was the first anti-PD1 antibody to be tested in a phase I study
(n = 39) as a single agent in several tumour types, including
melanoma, renal cell carcinoma and non-small-cell lung can-
cer (NSCLC) [56]. Based on its mechanism of action, similar
toxicity as had been seen in anti-CTLA4 treatment was ex-
pected; however, anti-PD1 – given in doses ranging from 0.3
to 1, 3 and 10 mg/kg – was quite safe. After one dose no
dose-limiting toxicity was observed. Grade 3 toxicity con-
sisted of CD4 lymphopaenia, fatigue and musculoskeletal
problems. As far as immune-related adverse events were con-
cerned, one patient developed colitis and one patient hypo-
thyroidism. The first responded to corticosteroids and
infliximab, the other was treated by thyroid hormone replace-
ment. Since anti-PD1 treatment was well tolerated, the max-
imum tolerated dose (MTD) could not be determined from
this study.
Recently, the results from the extension phase of this
phase I study – involving 296 patients with either melanoma,
renal-cell carcinoma (RCC) or NSCLC – were published [57].
Objective response rate in melanoma was 28%, and the
majority of these responses were durable, lasting longer than
1 year. Interestingly, the authors found a strong correlation
between cell-surface expression of PD-L1 on tumour cells
and response to anti-PD1 treatment. So far an objective re-
sponse was observed in none of the patients lacking tumour
PD-L1 expression, indicating that PD-L1 expression may be
an important predictive biomarker for treatment with anti-
PD1.
Brahmer et al. published the results from a phase I study
with anti-PD-L1 (MDX-1105) [58]. In total, 207 patients were
treated, of whom 52 had metastatic melanoma; 17% of the
melanoma patients developed an objective response. Only a
minority of patients developed grade 3–4 toxicity (9%). Im-
mune-related adverse events were also observed during this
study, but were manageable. Also for anti-PD-L1 the MTD
could not be defined. Apart from MDX-1105 and MDX-1106,
several other antibodies are currently in development: CT-
011 and MK-3475 are both anti-PD1 antibodies, RG7446 and
MEDI4736 are anti-PD-L1 antibodies, while MP-224 is an Fc-
fused PD-L2, a molecule that inhibits PD-1 signalling.
In summary, blockade of PD1/PD-L1 interaction at the tu-
mour site by inhibitory antibodies appears to be another
promising immunotherapeutic strategy for the treatment of
melanoma. These drugs seem less toxic than anti-CTLA4
and appear to induce a higher objective response rate, of
which a large proportion appears to be durable. Large ran-
domised controlled trials with these drugs are ongoing. So
far, on the basis of extended phase I trial results, the toxicity
profile of anti-PD1 appears to be better compared with ipi-
limumab. In addition, the response rate of anti-PD1 appears
to be higher in patients with metastatic melanoma. Random-
ised controlled trials comparing ipilimumab directly with
anti-PD1 or the combination of ipilimumab and anti-PD1 are
ongoing and should reveal which patients will benefit most
from anti-PD1 treatment and when.
3. Immunotherapy by adoptive cell therapy
3.1. Tumour-infiltrating lymphocytes (TILs)
In the 1980s, adoptive cell therapy was tested in clinical trials
based on the observation in murine models that infusion of
in vitro IL-2-activated lymphocytes was highly effective in
the eradication of tumours. The infusion of these so-called
lymphokine-activated killer (LAK) cells in melanoma patients
was compared with high-dose IL-2 alone and was not shown
to be statistically significantly superior in response rate, pro-
gression-free survival or other outcomes of the trial [59]. It
took until early 2000 before the infusion of T cells led to
impressive response rates in substantial numbers of patients
with metastatic melanoma. Dr. S. Rosenberg and colleagues
showed that infusion of in vitro cultured TILs derived from a
large melanoma metastasis was able to induce regression of
bulky metastatic disease and even complete remissions in
some patients [30,60]. From previous experiments and mouse
models, it became apparent that prior depletion of host lym-
phocytes greatly improved the in vivo survival of the infused
TILs, and a short in vitro culture time was important for sur-
vival, in vivo expansion and efficacy. Based on these observa-
tions, heavily pre-treated metastatic melanoma patients were
treated with lympho-depleting chemotherapy, consisting of
high-dose cyclophosphamide and fludarabin, followed by
infusion of large numbers of TILs (around 1 · 1011 cells) fol-
lowed by bolus infusion of high-dose IL-2 (up to 15 boluses)
[30,60]. This conditioning regimen results in short but deep
leukopaenia, including neutropenia and lymphopaenia, but
is non-myeloablative and thus does not require peripheral
haematopoietic stem cell (HSC) support. Mouse models
showed that depletion of the lymphocytic compartment not
only results in the creation of physical space for the infused
TILs, but also results in much less competition from host lym-
phocytes for the homeostatic cytokines IL-7 and IL-15, giving
a head start to the infused cells [61]. Secondly, lympho-deple-
tion also diminishes the immunosuppressive cell popula-
tions, such as regulatory T cells from the circulation. Based
on the results from the first trial, in later studies lympho-
depleting regimens were intensified to combination of che-
motherapy with total body irradiation (TBI) up to 12 Gy [62].
Naturally, this heavy conditioning regimen necessitated
bone-marrow rescue by HSC support. In small phase I/II stud-
ies each with 25 patients, escalation of TBI combined with
cyclophosphamide plus fludarabin resulted in further
improvement in response rates to up to 72%, with 10–20% of
patients acquiring a durable complete response. Not surpris-
ingly, the treatment was harsher on the patients, resulting
in more acute adverse events and prolonged organ dysfunc-
tion [62]. In the early studies cultured TILs were selected for
reactivity against autologous melanoma cell lines, and if not
present HLA-matched allogeneic melanoma cell lines. The
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process of selection, however, required extra culture time,
since the final dose of infused T cells was around 1 · 1011 cells.
In subsequent studies, this selection step was deleted from
the protocol, which simplified the production process sub-
stantially. Importantly, this did not harm the objective re-
sponse rate, which remained around or above 50%,
including the occurrence of complete responses [63]. The sim-
plified protocol of non-selected TILs was subsequently
adopted by several laboratories in the US and in Israel [64–
66]. By now several studies using this protocol, but without
the addition of TBI to the non-myeloablative chemotherapy
regimen, have shown a highly consistent objective response
rate of 40–50% of treated patients. In order to widely distribute
TIL treatment over Europe, a randomised controlled trial is
required.
3.2. Gene-modified T cells
Because TIL therapy is not always feasible, and because of the
complexity of the treatment, alternatives for adoptive cell
therapy with TILs have been developed. One of the most
promising new strategies is the use of tumour-specific anti-
gen receptors [67]. These tumour-specific receptors can be de-
rived from a tumour-specific T-cell clone with a high-affinity
T-cell receptor (TCR) that recognises a human MHC/tumour-
derived peptide complex, or from a high-affinity antibody
specific for a cell-surface tumour antigen. These antibody-
based receptors, called chimeric antigen receptors (CARs),
are genetically fused to proteins of the T-cell receptor signal-
ling machinery (CD3f, CD28 and others), so that T lympho-
cytes genetically changed to express these receptors upon
antigen binding will be properly activated [68].
For the genetic transfer of TCR or CAR genes to T cells sev-
eral options exist; however, the most widely used is transfer
by retroviral infection. These retroviruses and lentiviruses
are genetically modified to contain the genes for a specific
CAR/TCR. In addition, these viruses have been crippled to pre-
vent replication. Upon infection of the T lymphocytes these
viruses place the genes encoding the CAR/TCR more or less
randomly into the host-cell genome. Thus, these receptors
can be genetically transferred into peripheral-blood T lym-
phocytes, thereby creating an army of tumour killer cells.
So far tumour-specific T-cell receptors have been used only
for diseases other than melanoma; for example, a high-affinity
CD19 binding antibody has been used successfully in B-cell
lymphomas/leukaemia [69–71].
For melanoma, patients have been treated with TCR-
transduced T cells specific for MART-1, NY-eso-1 and more re-
cently also for MAGE-A3 [72–75]. In all three trials, objective
responses have been observed. So far, gene therapy with the
NY-eso-1-specific TCR was most effective and safest. In the
trials with the MART-1-specific TCR, a substantial portion of
patients developed on-target toxicity due to T-cell attack on
MART-1-positive cells in the body, leading to severe dermatitis
and vitiligo, uveitis and hearing loss (Kogt–Koyanagi–Harada
disease). In most instances these side effects were transient
and responsive to topical corticosteroids.
Apart from on-target toxicity – which is more likely to oc-
cur for TCRs specific for over-expressed gene products or dif-
ferentiation antigens, as normal tissues often also express
these antigens – off-target toxicity is another potential dan-
ger of this treatment. The most important reason for this
type of toxicity is cross-reactivity of the introduced TCR with
an unknown antigen. Since TCRs recognise MHC peptide
complexes, and since most individuals have six different
MHC class I alleles, the chance of a TCR having affinity for
one of these plus an unknown peptide is not just theoretical.
Choice of target and knowledge about tissue expression of
the antigen for which the TCR is specific is going to be
crucial.
Taken together, adoptive cell therapy is still at the level of
early clinical trials; however, the efficacy of this treatment is
promising, with establishment of durable remissions in some
patients. With more centres performing these trials, the expe-
rience with this complex therapy is rapidly increasing. There-
fore, this treatment should be taken to the next level:
randomised controlled trials.
4. Conclusion
In conclusion, immune therapy of melanoma is by 2013 an
established and expanding strategy that can induce durable
responses in advanced-stage melanoma patients, some of
whom may be cured for life. Immunotherapy, however, comes
with a price. New and unexpected toxicities may develop dur-
ing the course of the treatment or after cessation of treatment
and requires experience in order to properly manage these
therapies. In addition, these therapies are costly and some-
times highly complex (TIL and TCR/CAR gene therapy). There-
fore research focused on finding biomarkers that predict
response to treatment, such as PDL1 tumour expression for
response to anti-PD1, will be one of the most important chal-
lenges for the coming years.
Apart from immunotherapy as a novel treatment option for
patients with stage IV melanoma, targeted therapy has also re-
cently changed the outcome of these patients. Drugs such as
vemurafenib, dabrafenib and trametinib have been shown to
prolong survival of metastatic melanoma patients harbouring
the common BRAF V600 mutation. With all these new thera-
pies now available, studies on selecting the best patient popu-
lation for each therapy, and on the optimal sequence of
treatments, will be key to most effectively prolonging the lives
of metastatic melanoma patients, also on the use of these ther-
apies in the most cost-effective manner.
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Adjuvant therapy for high-risk melanoma
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Thus far the development of adjuvant therapies in mela-
noma has suffered greatly from the lack of effective drugs
for stage IV melanoma. This has led to adjuvant therapies
that are not uniformly used because of rather marginal
benefits.
1. Adjuvant therapies other than with
interferon
1.1. Early trials with immune stimulants
More than 25 randomised trials have been conducted in stage
II/III melanoma with non-specific immune stimulants – such
as BCG (bacillus Calmette–Guerin), Corynebacterium parvum,
levamisole or combinations of these agents with dacarbazine
– without identifying clear benefits [1].
1.2. Adjuvant vaccine trials
Adjuvant vaccine trials in melanoma thus far have failed, re-
sults ranging from ineffective (three randomized controlled
trial (RCTs) [1]) to harmful (three RCTs [2–4]). Two large trials
with Canvaxin ended early because of a detrimental outcome
for the vaccine arm. Two large trials with the GMK vaccine
(ganglioside GM2/KLH/QS-21) were also stopped early because
of inferior outcome in the vaccine arms compared with high-
dose interferon (HDI) in the Eastern Cooperative Oncology
Group (ECOG) 1694 trial [3] and compared with observation
in stage II patients (European Organisation for Research and
Treatment of Cancer (EORTC) 18961 trial) [4], evoking fears
that prolonged, multiple administrations of vaccines could
be harmful [5].
Regarding the adjuvant use of granulocyte–monocyte col-
ony-stimulating factor (GM-CSF), a recent report of the ECOG
E4697 trial failed to demonstrate a significant impact on sur-
vival [6]. In two randomised trials the GM-CSF-containing
arms did worse than the vaccine-alone arms [7,8], again indi-
cating that multiple vaccinations might be harmful.
New vaccine trials are ongoing. The MAGE-A3 protein
combined with the immunostimulant AS15 is being evaluated
in an RCT in stage III patients after encouraging results were
obtained in a randomised phase II EORTC trial [9]. Moreover,
a potentially predictive gene profile, characterising mostly
immunomodulatory factors, is used to stratify and analyse
the results of the RCT [10]. Also a study of an oncolytic herpes
simplex virus vector encoding GM-CSF is ongoing in stage III/
IV patients after interesting results in phase II patients were
obtained [11,12].
1.3. Adjuvant therapy with interferon
Twenty-five years of RCTs in melanomawith interferon-alpha
(IFNa) are a testimony that efficacy of adjuvant therapy with
IFN is modest at best. Meta-analyses of phase III trials demon-
strated that IFN has a consistent effect on relapse-free sur-
vival (RFS) but no or only a marginal effect on overall
survival (OS) [13–15]. No relationship between dose or dura-
tion of treatment and outcome has been demonstrated. These
findings suggest that only a minority of patients are sensitive
to IFN, and demand that we identify these patients. Based on
the EORTC 18991 trial in 1256 patients, the US Food and Drug
Administration (FDA) approved pegylated interferon a-2b
(PEG-IFN; SylatronTM) in 2011 for stage III melanoma patients
[16]. The EORTC 18952 trial in 1388 stage IIB/III melanoma pa-
tients compared intermediate doses of interferon a-2b (IFN)
with observation [17].
These EORTC RCTs stratified patients by SN-staging
(microscopic involvement only: stage III-N1) or gross macro-
scopic relapse (stage III-N2) as well as by presence or absence
of ulceration in the primary tumour. Both stage and ulcera-
tion are key prognostic factors [32]. Patients with only
micrometastases have a much better prognosis than patients
with palpable node metastases [18]. Palpable nodal disease
may represent more aggressive disease from the onset or by
acquisition of additional mutations over time. Regarding
ulceration, for the same Breslow thickness, patients with an
ulcerated primary have a 10–25% lower survival probability
at 10 years, indicating a distinct biological entity [19]. Also,
ulcerated primaries have (a) a distinct gene profile [20]; (b) a
severely immunosuppressed status of sentinel nodes [21]
and (c) a different stromal response [22].
The meta-analysis of the two largest adjuvant IFN/PEG-IFN
RCTs involving 2644 patients demonstrated that both tumour
load in the lymph nodes and ulceration of the primary are
independent predictive factors for adjuvant IFN therapy [23].
Patients with favourable stage (IIb/III-N1) and/or ulcerated
primary tumour benefited significantly from IFN/PEG-IFN
treatment (hazard ratios (HRs) 0Æ56–0Æ69) with regard to RFS,
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distant-metastasis-free survival (DMFS), and OS, whereas pa-
tients with stage III-N2 disease or non-ulcerated primary tu-
mour did not. Ulceration of the primary was the
overridingly important predictive factor for IFN sensitivity.
In a meta-analysis of 1393 patients with ulcerated melano-
mas – reported in a variety of trials that did not include
EORTC 18991 – Wheatley et al reported a hazard ratio (HR)
of adjuvant IFN therapy for OS of 0.77 (99% confidence inter-
val (CI) 0.63–0.93), whilst there was no impact of adjuvant
IFN therapy in the 2118 patients without ulceration (HR 0.98;
99% CI 0.87–1.17) [23]. Treatment interaction between ulcera-
tion and IFN has been investigated retrospectively in the Sun-
belt and the Nordic trials [24,25]. In the Sunbelt trial, which
enrolled SN-positive patients only, a significant treatment
benefit occurred only in patients with ulcerated primaries
[24]. In the Nordic trial, almost all patients had palpable nodal
involvement and, consistently with the EORTC trials, no sig-
nificant benefit was conferred by the presence of ulceration
[25]. The role of ulceration is currently being evaluated pro-
spectively in the adjuvant PEG-IFN trial EORTC 18081 in 1200
patients with stage II ulcerated primary melanomas.
Research on tissue samples to identify gene profiles and
cytokine profiles potentially predictive for IFN sensitivity is
ongoing [26]. In contrast to findings by Gogas and Kirkwood
[27], the prognostic and potentially predictive value of the
presence of autoimmune antibodies in the EORTC and Nordic
trials was evaluated and found not to be a strong prognostic
factor, neither did it have predictive value [28,29].
In 2012, the results of the adjuvant phase III trial of
adjuvant biochemotherapy (CVD + IL2 + IFN) demonstrated a
significant improvement in RFS but no improvement in
OS. These results are interesting but not practice-changing
[30].
2. New adjuvant trials with novel agents
2.1. Immunomodulators
For patients with advanced stage III melanoma, a double-
blind RCT comparing adjuvant ipilimumab versus placebo re-
cently completed accrual of 950 patients (EORTC 18071; Clin-
icalTrials.gov, number NCT00636168) [31]. Preliminary data
from another small trial suggest adjuvant ipilimumab activity
in advanced resected stage III/IV disease [32]. New adjuvant
trials evaluating anti-PD-1 are being prepared.
2.2. BRAF inhibitors and MEK inhibitors
New adjuvant trials in lymph-node-positive melanoma pa-
tients have been launched involving BRAF inhibitors either
alone or in combination with MEK inhibitors [33,34]. The basis
for these trials is their success in stage IV patients. Trials
are ongoing, and design and pros and cons will be
discussed.
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Introduction
Optimal approach for upfront resectable
non-small-cell lung cancer
Jan P. van Meerbeeck *
Antwerp University Hospital, Thoracic Oncology /MOCA, Edegem, Belgium
Approximately one third of patients with non-small-cell
lung cancer (NSCLC) present with resectable disease, defined
as clinical stages I and II and some borderline stage III exten-
sions (e.g. T3N0–1). Although radical resection is the corner-
stone of treatment in adequately staged patients, its
outcome is not always curative, as some patients might be
functionally inoperable, refuse surgery, have an unexpected
non-radical resection or stage upgrading, or relapse locally
or with distant metastases. The following reviews address
the current state of the art in the peri- and intra-operative
management of patients with resectable NSCLC.
As disease extent is an important predictor of prognosis
and determines treatment choices, accurate staging is of
prime importance. The 10 modifications and the mediastinal
lymph-node map – adopted by the American Joint Committee
on Cancer (AJCC) and the Union for International Cancer Con-
trol (IUCC) in their respective seventh revision of the tumour-
node-metastasis (TNM) system – are considered a quality indi-
cator for disease extent, initial treatment allocation and the
reporting of treatment results. Difficulties arise in accurate
prognosis owing to the role of stagemigration and the increas-
ing number of biological factors interfering with disease ex-
tent. There are many tumour-related pathological factors,
but only one is actually routinely used in clinical practice.
Most factors probably lack potential clinical usefulness.
Surgical resection remains the standard of care for func-
tionally operable early-stage NSCLC and resectable stage IIIA
disease. The role of invasive staging and restaging techniques
is currently under debate, but they provide large biopsy spec-
imens which allow for precise mediastinal staging. Different
operative procedures are currently available to the thoracic
surgeon, and some can be performed by video-assisted tho-
racic surgery (VATS) with oncological results equal to those
of open thoracotomy.
The new multidisciplinary adenocarcinoma classification
has profound surgical implications. The role of limited or
sublobar resection comprising anatomical segmentectomy
andwidewedgeresectionareconsideredforearly-stage lesions
which are more frequently encountered with the recently
introduced screening programmes. Large databases are cur-
rently collectingmanysurgical parameters, allowingmorepre-
cise calculation of mortality and morbidity according to
predefined risk factors. Centralisation of care has been shown
to improve results. Quality-of-life evaluation is becoming
increasingly important and should be consideredwhen decid-
ing on a specific treatment, especially in a multimodality
setting.
In the situation of totally resected NSCLC patients, the role
of post-operative chemotherapy is now established for stages
II and IIIA and remains debatable in stage IB. Various at-
tempts to identify prognostic biomarkers for selecting pa-
tients for adjuvant chemotherapy have failed so far. Patient
selection for adjuvant therapy should be based upon more
discriminatory pathological data than a crude assessment
such as stage, but only if supported by evidence. The present
recommendations for resected NSCLC from the European
Society for Medical Oncology (ESMO) are to deliver a cis-
platin-based chemotherapy for stages II and III. The role of
post-operative radiation therapy (PORT) in this group of pa-
tients remains controversial. In a meta-analysis, the conclu-
sions were that PORT was detrimental to patients with
early-stage completely resected NSCLC, but the role of PORT
in the treatment of tumours with N2 involvement was un-
clear, and further research was warranted. Recent retrospec-
tive and non-randomised studies – as well as subgroup
analyses of randomised trials evaluating adjuvant chemo-
therapy – provide evidence of possible benefit of PORT in pa-
tients with mediastinal nodal involvement.
In summary, these are exciting times for the treatment of
early-stage lung cancer as prevalence, classification, staging
and treatment have changed, although proof of better out-
come has still to be delivered.
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Surgical resection remains the standard of care for functionally operable early-stage non-
small-cell lung cancer (NSCLC) and resectable stage IIIA disease. The role of invasive stag-
ing and restaging techniques is currently being debated, but they provide the largest biopsy
samples which allow for precise mediastinal staging. Different types of operative proce-
dures are currently available to the thoracic surgeon, and some of these interventions
can be performed by video-assisted thoracic surgery (VATS) with the same oncological
results as those by open thoracotomy. The principal aim of surgical treatment for NSCLC
is to obtain a complete resection which has been precisely defined by a working group of
the International Association for the Study of Lung Cancer (IASLC). Intraoperative staging
of lung cancer is of utmost importance to decide on the extent of resection according to
the intraoperative tumour (T) and nodal (N) status. Systematic nodal dissection is generally
advocated to evaluate the hilar and mediastinal lymph nodes which are subdivided into
seven zones according to the most recent 7th tumour-node-metastasis (TNM) classifica-
tion. Lymph-node involvement not only determines prognosis but also the administration
of adjuvant therapy.
In 2011, a new multidisciplinary adenocarcinoma classification was published introducing
the concepts of adenocarcinoma in situ and minimally invasive adenocarcinoma. This
classification has profound surgical implications. The role of limited or sublobar resection,
comprising anatomical segmentectomy and wide wedge resection, is reconsidered for
early-stage lesions which are more frequently encountered with the recently introduced
large screening programmes. Numerous retrospective non-randomised studies suggest
that sublobar resection may be an acceptable surgical treatment for early lung cancers, also
when performed by VATS.
More tailored, personalised therapy has recently been introduced. Quality-of-life parame-
ters and surgical quality indicators become increasingly important to determine the
short-term and long-term impact of a surgical procedure. International databases currently
collect extensive surgical data, allowing more precise calculation of mortality and morbid-
ity according to predefined risk factors. Centralisation of care has been shown to improve
results. Evidence-based guidelines should be further developed to provide optimal staging
and therapeutic algorithms.
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1. Introduction
Thoracic surgery remains a major diagnostic and therapeutic
modality for patients with non-small-cell lung cancer
(NSCLC). However, many controversial issues remain regard-
ing its precise role and application. Invasive staging and
restaging procedures are applied more selectively with the
introduction of endosonographic techniques. When discuss-
ing the different types of operative procedures that are avail-
able to the thoracic surgeon, a distinction has to be made
between early-stage disease (stages IA/B and IIA/B), locore-
gionally advanced disease (stages IIIA/B), and metastatic dis-
ease (stage IV). Indications for surgical treatment of NSCLC
are tailored according to the most recent 7th tumour-node-
metastasis (TNM) classification, taking into account that sur-
gery for locoregionally advanced disease remains a highly
controversial topic. Intraoperative staging of lung cancer is
extremely important to determine the extent of resection
according to the intraoperative tumour (T) and nodal (N) sta-
tus. Systematic nodal dissection is generally advocated to
determine the precise nodal involvement. In 2011, a new ade-
nocarcinoma classification was published with adenocarci-
noma in situ and minimally invasive adenocarcinoma as
new categories. The surgical implications of this relate mainly
to the role of limited, sublobar resection. Especially when part
of a combined modality regimen, surgical resection has a pro-
found influence on quality of life. Prospective data on short-
and long-term effects have recently become available, allow-
ing better counselling of our patients.
In this review invasive mediastinal staging and restaging
are discussed, as well as indications for surgical resection,
intraoperative staging, the new adenocarcinoma classifica-
tion and its surgical implications, quality of life after lung
resection, and finally surgical quality indicators, including
the relationship between volume and outcome.
2. Invasive mediastinal staging and restaging
of lung cancer
2.1. Importance of lymph-node staging
In the absence of distant metastases, the prognosis of a pa-
tient with lung cancer largely depends on locoregional
lymph-node involvement. Pathological staging remains the
gold standard in quantifying the extent of locoregional and
mediastinal lymph-node involvement. Patients with ipsilat-
eral hilar or intrapulmonary lymph-node metastases (N1) are
not precluded from surgery as complete resection provides a
good long-term outcome when combined with adjuvant che-
motherapy. Patients with ipsilateral mediastinal lymph-node
metastases (N2) are currently treatedwith combinedmodality
therapy, mostly chemoradiation. Only patients with limited
N2 disease, in whom down-staging is obtained after induction
therapy, may be considered for surgical resection. Patients
with contralateral mediastinal or supraclavicular lymph-node
involvement (N3) are currently considered unsuitable candi-
dates for surgery due to poor long-term prognosis with mul-
timodality therapy, including surgery.
Currently available invasive staging techniques are sum-
marised in Table 1. Due to refinements in non-invasive and
minimally invasive, endosonographic staging techniques,
the role of surgical invasive staging and restaging has been
redefined.
2.2. Invasive mediastinal staging
Mediastinoscopywas introduced by Carlens in 1959 as ameth-
od for inspection and tissue biopsy in the superior mediasti-
num; it still holds true today [1]. With the routine use of
mediastinoscopy, the rate of exploratory thoracotomies could
be drastically reduced. Mediastinoscopy is associatedwith low
morbidity (2%) and lowmortality (0.08%) but remains an inva-
sive procedure requiring general anaesthesia [2].With the sub-
sequent advent of new imaging techniques – initially
computed tomography (CT), later on positron emission
tomography (PET) and integrated PET–CT followed by themin-
imally invasive endosonographic techniques, endoscopic
ultrasound (EUS) and endobronchial ultrasound (EBUS) – the
precise role ofmediastinoscopy is amatter of constant debate.
The different staging techniques that belong to the surgi-
cal armamentarium are listed in Table 1. Comparison of
mediastinal lymph-node stations that can be reached by
endosonography and invasive surgical staging is given in Ta-
ble 2. Mediastinoscopy provides a thorough exploration of the
superior mediastinum, allowing not only large biopsy sam-
ples of the different nodal stations in the superior mediasti-
num, but also evaluation of possible mediastinal extension
of a primary lung cancer. In this way, sufficient tissue be-
comes available for detailed molecular analysis.
Anterior mediastinoscopy, which is called anterior medi-
astinotomy when a rib cartilage has to be removed, provides
access to the anterior mediastinum and lymph-node stations
5 and 6 on the left side. Some centres have experience with
extended mediastinoscopy which is a combination of cervical
and anterior mediastinoscopy by the same cervical incision
[3]. Also evaluation of the supraclavicular lymph-node station
1 is possible by the latter incision. In many centres anterior
mediastinoscopy is now replaced by thoracoscopy or video-
assisted thoracic surgery (VATS), allowing a complete explora-
tion of the ipsilateral pleural cavity.
The reported positive predictive value (PPV) and negative
predictive value (NPV) of mediastinoscopy for staging of
NSCLC are 100% and 96%, respectively [4]. When an extensive
lymph-node dissection is performed by video-assisted medi-
Table 1 – Invasive mediastinal staging and restaging
techniques.
Cervival mediastinoscopy
Repeat mediastinoscopy, remediastinoscopy
Anterior mediastinoscopy (mediastinotomy)
Extended mediastinoscopy (combination cervical + anterior)
Scalene lymph-node biopsy
Video-assisted mediastinal lymphadenectomy (VAMLA)
Transcervical extended mediastinal lymphadenectomy
(TEMLA)
Video-assisted thoracic surgery (VATS), thoracoscopy
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 1 0 –1 2 2 111
astinal lymphadenectomy (VAMLA) or transcervical extended
mediastinal lymphadenectomy (TEMLA) procedures, the rate
of false negatives becomes extremely low [5–7].
Combination of EBUS and EUS – so-called ‘medical medi-
astinoscopy’ – provides access to a larger number of lymph-
node stations than classical cervical mediastinoscopy. Both
EBUS and EUS can be performed under local anaesthesia,
which is a major advantage. Rapid on-site examination
(ROSE) by the pathologist definitely increases accuracy. When
a positive result is obtained, surgical invasive staging is
avoided. For this reason EBUS and EUS are currently the pre-
ferred examinations after non-invasive tests, and in experi-
enced hands a high accuracy is reported.
In the randomised Assessment of Surgical Staging versus
Endosonographic Ultrasound in Lung Cancer: a Randomized
Clinical Trial (ASTER) study, 241 patients with resectable, sus-
pected or proven NSCLC, in whom mediastinal staging was
indicated on the basis of CT or PET findings, were enrolled
into a randomised controlled multicentre study comparing
different strategies for mediastinal lymph-node staging [8].
Nodal metastases were found in 35% by surgical staging
alone, 46% by endosonography (EBUS and EUS) and 50% by
endosonography followed by surgical staging. NPVs were 86,
85 (P = 0.47) and 93% (P = 0.18), respectively [8].
In a prospective study of 153 patients, Yasufuku and col-
leagues chose EBUS as the initial investigation for mediastinal
lymph-node staging followed by mediastinoscopy [9]. If both
were negative, a thoracotomy was performed. Prevalence of
N2/N3 disease was 35%. EBUS had an NPVof 91% and medias-
tinoscopy of 90%, so the conclusion of this study was that
EBUS may replace mediastinoscopy. In a recent retrospective
study from the same centre, the sensitivities and NPVs of
EBUS in evaluating clinical N0 or N1 disease were 76% and
96%, respectively [9]. The role of endobronchial ultrasound-
guided transbronchial needle aspiration for differentiating
stage I from stage II lung cancer: poster presentation at the
49th Annual Meeting of the Society of Thoracic Surgeons,
Los Angeles, California, January 26–30, 2013). However, it
should be mentioned that this group comprises thoracic sur-
geons having a large experience with endosonographic and
invasive staging techniques. Can these results from a high-
volume dedicated centre be duplicated in everyday practice?
Cerfolio published a retrospective review of 234 patients
with NSCLC who were staged by EBUS or EUS for suspected
N2 disease on CT or PET–CT [10]. Mediastinoscopy was per-
formed when EBUS/EUS were negative. NPVs for detecting
N2 disease by EBUS, EUS and mediastinoscopy were 79%,
80% and 93%, respectively. EBUS was found to be falsely neg-
ative in 28%, and EUS in 22% of the cases. In a retrospective
study from a single institution by Defranchi, 494 patients, sus-
pected of lung cancer, underwent EBUS [11]. A negative result
was followed by mediastinoscopy. Of the patients with suspi-
cious mediastinal lymph nodes, 28% still had N2 disease con-
firmed by mediastinoscopy despite a negative EBUS. In this
way, negative EBUS/EUS results should still be confirmed by
mediastinoscopy.
The current indications for surgical mediastinal staging
are a matter of judgment and precise knowledge of the vari-
ous staging modalities and their results. None of the available
techniques can be expected to provide perfect results. The
main question becomes what false-negative rate one is will-
ing to accept. In patients with suspected mediastinal
lymph-node involvement by non-invasive techniques, evalu-
ation by EBUS/EUS followed by mediastinoscopy in cases
where no positive lymph nodes are found by endosonograph-
ic techniques has produced excellent results, with a reported
increase in sensitivity for detection of mediastinal nodal dis-
ease of up to 93% [8]. In concordance with the European Soci-
ety of Thoracic Surgeons (ESTS) guidelines, positive CT, PETor
PET–CT findings should be cytologically or pathologically con-
firmed [12]. EBUS and EUS are complementary to surgical
invasive staging techniques with a high specificity but low
NPV. Therefore, an invasive surgical technique is still indi-
cated if EBUS/EUS yield a negative result. Fig. 1 provides a flow
chart of mediastinal staging of NSCLC that is currently used
at the Antwerp University Hospital in Belgium.
2.3. Invasive mediastinal restaging
Most patients with pathologically proven N2 disease detected
during preoperativework-up will be treated by induction ther-
apy. Themediastinum can be principally restaged by the same
techniques as applied in primary staging. At the present time,
CT, PETand PET–CTare not accurate enough to make final fur-
ther therapeutic decisions after induction therapy. The accu-
racy of CT in restaging after induction therapy is only 58%
[13]. PET scanning is more accurate than CT for mediastinal
restaging, with a reported PPV to detect persisting nodal dis-
ease of 73% [14]. In detecting residual N2 disease, however,
PPVwas less than20%.Theuse of PET–CT fusion images signif-
icantly increases the accuracy throughbetter localisationof fo-
cal isotope uptake in mediastinal nodes [15]. However, 20%
false-negative and 25% false-positive rates have been reported
[16]. In caseswhere there is a suspicion of residualmediastinal
disease, invasive biopsies are still required.
Endosonographic techniques are also used for restaging.
However, their false-negative rates remain high, ranging be-
tween 20% and 30% [17,18]. Therefore, negative findings
should still be confirmed by surgical restaging.
Table 2 – Mediastinal staging.
LN EBUS EUS Cervical
mediastinoscopy
VAMLA
TEMLA
VATS
L R
1 + + + + – –
2R + – + + – +
2L + + + + – –
4R + – + + – +
4L + + + + – –
5 – – – + + –
6 – – – + + –
7 + + + + + +
8 – + – + + +
9 – + – – + +
EBUS, endobronchial ultrasound; EUS, oesophageal ultrasound; LN,
lymph-node station, L, left; R, right; TEMLA, transcervical extended
mediastinal lymphadenectomy; VAMLA, video-assisted mediasti-
nal lymphadenectomy; VATS, video-assisted thoracic surgery.
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Results of recent series of repeat mediastinoscopies after
induction therapy are summarised in Table 3 [15,19–24].
Remediastinoscopy offers the advantage of providing patho-
logical evidence of response after induction therapy. In this
way, it remains a valuable tool to select patients for surgical
resection [25]. Survival clearly depends on the findings of
remediastinoscopy, patients with a positive repeat mediasti-
noscopy having a poor prognosis compared to those with a
negative remediastinoscopy [21]. In a combined series of 104
patients, nodal status was the only significant factor related
to survival in multivariate analysis [22].
An alternative approach consists of the use of minimally
invasive, endosonographic procedures to obtain an initial
proof of mediastinal nodal involvement. Mediastinoscopy is
subsequently performed after induction therapy to evaluate
response [26]. In this way, a technically more difficult remedi-
astinoscopy can be avoided.
Only one study has reported the results of VATS for restag-
ing after induction therapy [27]. In this Cancer and Leukemia
Group B (CALGB) 39803 trial a negative result of VATS was de-
fined as negative lymph-node biopsies from at least three
lymph-node stations, whereas a positive result consisted of
a pathological proof of persisting N2 disease in the mediasti-
num or the demonstration of pleural carcinomatosis. Sensi-
tivity, specificity and NPV of VATS for restaging were 67%,
100% and 73%, respectively.
In the restaging guidelines published by the ESTS an inva-
sive technique providing cytological or histological informa-
tion is also recommended [12]. Endoscopic or surgical
invasive procedures may be utilised, the precise choice
depending on the availability of the technique and expertise
of the centre [12]. This policy was confirmed in a recent sys-
tematic review on restaging after induction therapy for stage
IIIA NSCLC [26].
Current restaging algorithms used at the Antwerp Univer-
sity Hospital are depicted in Fig. 2.
3. Surgery for non-small cell lung cancer
(NSCLC)
3.1. Complete R0 resection
The final aim of surgical treatment for non-small-cell lung
cancer (NSCLC) is complete (R0) resection. In this respect,
specific criteria have been established by a working group
of the International Association for the Study of Lung Can-
cer (IASLC) [28]. Complete resection is defined as complete
removal of the primary tumour with no residual macro-
scopic or microscopic tumour left behind; moreover, a sys-
tematic or lobe-specific nodal dissection must have been
performed, and the highest mediastinal lymph node must
be negative.
Table 3 – Results of remediastinoscopy after induction therapy.
Author, year Ref. n IT Morbidity (%) Mortality (%) Sensitivity (%) Negative
predictive
value (%)
Accuracy (%)
Pitz, 2002 19 15 CT 0 0 50 71 78
Stamatis, 2005 20 165 CT–RT 2.5 0 74 86 93
De Waele, 2006 21 32 CT (n = 26) CT–RT (n = 6) 3.1 0 71 75 84
De Leyn, 2006 15 30 CT 0 0 29 52 60
De Waele, 2008a 22 104 CT (n = 79) CT–RT (n = 25) 3.9 1 70 73 84
Marra, 2008b 23 104 CT–RT 1.9 0 61 85 88
Call S, 2011c 24 84 CT (n = 49) CT–RT (n = 35) 4.0 1 74 79 87
Ref., reference; n, number of patients; IT, induction therapy; CT, chemotherapy; CT–RT, chemoradiotherapy.
a Combined, updated series.
b Subset of patients of Stamatis, 2005 [20].
c Results of restaging after induction therapy.
Fig. 1 – Flow chart for mediastinal staging of non-small-cell lung cancer (NSCLC) in the Antwerp University Hospital. ES,
endosonographic technique (endobronchial or endoscopic ultrasound); MS, mediastinoscopy; MMT, multimodality
treatment; PET–CT, integrated positron emission tomography and computed tomography.
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Although no prospective, randomised trial exists to com-
pare surgery versus radiotherapy in the treatment of early-
stage NSCLC, surgical resection has traditionally been consid-
ered the treatment of choice. Markedly improved survival
rates are reported in surgical series in comparison to patients
who did not undergo surgical resection for a variety of rea-
sons [29]. Early-stage disease and T3N1 NSCLC are considered
definite indications for surgery.
Resectability and operability of a primary NSCLC depend
not only on the clinical and intraoperative staging of the tu-
mour, but also on the functional capacity of the patient. So,
detailed cardiopulmonary evaluation to determine the func-
tional status is equally important as this might impact on
the extent of resection [30]. After definitive pathological
examination, a distinction can be made between R0 resec-
tions when there is no residual tumour, R1 with micro-
scopic residual tumour and R2 with macroscopic residual
tumour.
3.2. Types of lung cancer resection
Lung cancer resections can be divided into three major groups
(Table 4).
Group 1 – standard resections: standard resections include
lobectomy (removal of a lobe), bilobectomy (removal of two
lobes on the right side) and pneumonectomy (removal of an
entire lung). Pneumonectomy was initially considered as the
treatment of choice in the years 1940–1950, whilst lobectomy
was reserved for patients with diminished pulmonary or car-
diac reserve. In later years, lobectomy was found to provide a
similar survival rate as pneumonectomy if the lesion could be
totally resected by lobectomy.
Group 2 – lung parenchyma saving operations: these opera-
tions can be divided into proximal and distal procedures.
The proximal interventions comprise all bronchoplastic and
tracheoplastic operations. The most frequently performed
bronchoplastic procedure is a sleeve resection of the right
upper lobe for a lung cancer invading the upper lobe orifice.
The very first sleeve resection was performed in 1947 for a
carcinoid tumour in the right upper-lobe orifice in an Air
Force cadet to avoid a pneumonectomy which would have
precluded his career as a pilot [31]. Distal procedures include
segmentectomies and wedge resections.
Regarding the extent of resection, lobectomy is generally
considered the procedure of choice in cancers confined to a
Table 4 – Types of operative procedures
Standard:
Lobectomy
Bilobectomy
Pneumonectomy
Lung-parenchyma-sparing operations:
Proximal Bronchotomy
Rotating bronchoplasty
Bronchial or tracheal wedge excision
Bronchial or tracheal sleeve resection
Distal Anatomical segmentectomy
(wide) Wedge excision
Extended procedures (lung + other structure):
Pericardium (intrapericardial pneumonectomy)
Diaphragm
Chest wall (ribs, vertebrae)
Superior sulcus (Pancoast tumour)
Fig. 2 – Flow chart for mediastinal restaging of non-small-cell lung cancer (NSCLC) in the Antwerp University Hospital
depending on whether a minimally invasive procedure or mediastinoscopy was initially performed. ES, endosonographic
technique (endobronchial or endoscopic ultrasound); MS, mediastinoscopy; PET–CT, integrated positron emission
tomography and computed tomography; RT, radiotherapy; ReMS, repeat mediastinoscopy
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single lobe. This attitude resulted from a prospective random-
ised trial from the Lung Cancer Study Group comparing lobec-
tomy to lesser resections for peripheral clinical T1N0 lesions
[32]. Patients were randomised to standard lobectomy or les-
ser resection during thoracotomy. Noteworthy in this study
was that nearly half of the patients had a contraindication
to randomisation, mostly because of location of the tumour
or unexpected N1 or N2 disease. Patients who underwent a
limited resection were found to have a tripling of local recur-
rence rate, a 30% increase in overall death rate and a 50% in-
crease in cancer-related death rate in comparison to
lobectomy patients. However, these results were only signifi-
cant at a P-value level of 0.10.
The role of sublobar resection, anatomical segmentectomy
or wide-wedge resection is being reconsidered for very early
lung cancer following large screening programmes for lung
cancer. This is due to the findings of non-solid or part-solid
ground glass opacities, so-called GGOs [33]. This will be fur-
ther discussed with the newly introduced adenocarcinoma
classification.
Group 3 – extended operations: extended operations involve
resection of lung parenchyma with an adjacent organ or
structure invaded by the tumour. Examples include resection
of the chest wall, diaphragm, pericardium, left atrium, supe-
rior vena cava and apex of the chest in superior sulcus tu-
mours. En bloc resection of the locally involved
extrapulmonary structure is advised to avoid tumour spillage
and to ensure a complete R0 resection with negative
margins.
3.3. Different thoracic approaches
A posterolateral thoracotomy incision is the classical inci-
sion performed for lung cancer resection. If feasible, a mus-
cle-sparing thoracotomy is preferred to preserve the
latissimus dorsi muscle. Sternotomy may be used in patients
requiring bilateral procedures, especially bilateral upper-lobe
lung cancers. An extended incision such as a hemi-clam-
shell incision is utilised in selected patients requiring an ex-
tended resection. At the present time, VATS is increasingly
being used as specific access to the thoracic cavity. In a ser-
ies of 1100 VATS lobectomies, excellent results were re-
ported, with an operative mortality of 0.8% [34]. Morbidity
generally appears to be lower with the VATS approach,
although in a nationwide database of 13,619 patients who
underwent lobectomy by thoracotomy or VATS, patients
who underwent VATS lobectomy were 1.6 times more likely
to have intraoperative complications [35]. A recent system-
atic review and meta-analysis of randomised and non-ran-
domised trials concluded that VATS lobectomy is an
appropriate procedure for selected patients with early-stage
NSCLC [36]. Currently, VATS has become a standard ap-
proach for peripheral wedge resections and lobectomy for
stage I tumours. VATS segmentectomy is much less widely
performed and its potential benefits and limitations still re-
quire further evaluation [37,38].
Although VATS seems to be equal or even beneficial in
terms of morbidity, length of stay and survival in comparison
to an open approach, further evaluation in large, prospective
randomised trials is necessary [39].
3.4. Intraoperative staging – systematic nodal dissection
Detailed intraoperative systematic lymph node dissection is
important to provide an accurate pathological TNM staging.
The different intrathoracic lymph-node stations were origi-
nally described by Naruke et al. in 1978 [40] and were recently
updated in the 7th TNM classification where the concept of
nodal zones was introduced [41]. The nodal zones and sta-
tions are listed in Table 5 [41,42].
Thoracotomy provides the final investigation and determi-
nation of resectability.
Non-resectable tumours include T4 tumours with invasion
into important adjacent structures or tumours with extensive
mediastinal metastases. These include involvement of vital
mediastinal structures or extracapsular N2 and N3 diseases.
For resected N2 disease, invasion of the highest mediastinal
lymph node heralds a poor prognosis. Massive involvement
of hilar structures is generally a contraindication unless an
intrapericardial pneumonectomy can be performed. Pleural
metastases are also a contraindication to resection due to a
poor long-term survival.
When deciding on the type of operation to be performed,
the surgeon should first perform a careful intraoperative
exploration, taking into account several strategic points. He/
she should determine whether the tumour is peripheral or
central, which lymph nodes are involved, and whether or
not there is transgression of the fissure. Frozen-section anal-
ysis of suspicious lymph nodes or margins can be helpful in
determining the extent of resection. Whenever possible,
lobectomy remains the procedure of choice. Pneumonectomy
is considered ‘a disease in itself’ due to its profound respira-
tory and haemodynamic implications and associated higher
Table 5 – Regional lymph-node mapping into zones and
stations according to the 7th tumour-node-metastasis
(TNM) edition [41].
Supraclavicular zone:
1. Low cervical, supraclavicular and sternal notch
Upper zone:
2. Upper paratracheal
3. a. Prevascular
b. Retrotracheal
4. Lower paratracheal
Aortopulmonary (AP) zone:
5. Subaortic or Botallo’s
6. Para-aortic (ascending aorta or phrenic)
Subcarinal zone:
7. Subcarinal
Lower zone:
8. Para-oesophageal (below carina)
9. Pulmonary ligament
Hilar/interlobar zone:
10. Hilar
11. Interlobar
Peripheral zone:
12. Lobar: upper, middle and lower lobe
13. Segmental
14. Subsegmental
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 1 0 –1 2 2 115
complication rates in comparison to lobectomy. Most pa-
tients, however, have adapted to living with just one lung
[43]. A sleeve lobectomy should be considered as an alterna-
tive whenever technically feasible, providing that a complete
resection can be obtained [44].
In a large series of 334 patients operated for lung cancer
invading the chest wall, 5-year survival rate was 32% in pa-
tients who underwent a complete resection, in contrast to
only 4% for incomplete resections, and 0% for exploration
only [45]. Long-term survival was mainly dependent on nodal
involvement and complete resection, and less dependent on
the depth of chest wall invasion.
For precise N staging during thoracotomy, a systematic no-
dal dissection is performed as advocated by Graham et al.
[46]. In this technique, dissection of the mediastinal, hilar
and lobar lymph nodes proceeds in a systematic fashion. In
their classical paper Graham et al. reviewed 240 patients with
clinical T1–3 N0–1 NSCLC [46]. Preoperative mediastinoscopy
was performed when lymph nodes larger than 1.5 cm were
present on chest CT. The rate of exploratory thoracotomy
without further resection was only 3%. Following surgical
resection pathological N2 disease was found in 20% of pa-
tients. There was no subgroup with 0% incidence of N2
involvement and skip metastases were found in 34% of pa-
tients with N2 disease. Peripheral tumours less than 2 cm
had a 24% incidence of lymph-node metastases. Systematic
lymph-node dissection is currently considered the gold stan-
dard for the accurate staging of nodal (N) disease and should
be routinely performed, also when a minimally invasive ap-
proach is chosen.
In a non-randomised study of 373 patients, complete
mediastinal lymph-node dissection identified more levels
of N2 disease in patients with stages II and IIIA NSCLC,
and was associated with improved survival in comparison
to systematic nodal sampling but only for right-sided lesions
[47]. A survival advantage of complete mediastinal lymph-
node dissection has only been demonstrated in one prospec-
tive randomised trial [48]. In a recently published multicen-
tre prospective clinical trial, patients with intraoperatively
staged T1-2N0-non-hilar N1 NSCLC were randomised to
lymph-node sampling versus systematic nodal dissection.
The latter identified occult disease in 3.8% of patients but
was not associated with a benefit in overall survival [49].
However, all patients in this trial were carefully staged with
invasive, pathological analysis of four lymph-node stations.
These results should not be generalised to higher-stage
tumours.
The technique of systematic lymph-node dissection on the
right side includes the dissection of the upper (level 2R) and
lower (level 4R) paratracheal nodes, subcarinal (level 7),
para-oesophageal (level 8R) and inferior pulmonary ligament
(level 9R) lymph-node stations. On the left side, the aortopul-
monary, para-aortic and lower paratracheal nodes (levels 5, 6,
4L), and levels 7, 8L and 9L should be resected.
N1 disease also represents a heterogeneous group of dis-
eases. This was demonstrated by Riquet et al., who reported
a series of 1174 patients with NSCLC; 22% of the patients
had N1 disease, with a 5-year survival of 47.5% [50]. A dis-
tinction was made between intralobar N1 (levels 12 and
13) and extralobar hilar N1 (levels 10 and 11) diseases.
Five-year survival rate for intralobar N1 was 54% and for hi-
lar N1 39%. This difference was highly significant. The prog-
nosis of intralobar N1 is similar to N0 disease, and
extralobar N1 is more closely related to N2 with single-sta-
tion involvement.
4. Surgical implications of the new
adenocarcinoma classification
4.1. New categories
In early 2011, a new adenocarcinoma classification was pub-
lished by a common working group of the IASLC, the Ameri-
can Thoracic Society (ATS) and the European Respiratory
Society (ERS) [51–53]. This classification is listed in Table 6.
Of special interest to thoracic surgeons are the new cate-
gories adenocarcinoma in situ (AIS) which represents small
(63 cm) solitary adenocarcinomas consisting purely of lepidic
growth without invasion, and minimally invasive adenocarci-
noma (MIA) with 60.5 cm invasion. AIS and MIA were intro-
duced because the 5-year disease-free survival approaches
100% if the tumours are completely resected. The term bron-
chioloalveolar carcinoma (BAC) is no longer utilised as it ap-
plies to five different categories in the new classification,
which gave rise to much confusion [51].
With the advent of helical CT and screening trials in high-
risk populations, there is a renewed interest in small nodules,
especially those with ground-glass opacity (GGO). Recently,
results of the National Lung Screening Trial were published
Table 6 – IASLC/ATS/ERS classification of lung adenocarci-
noma in resection specimens [51–53]. Table reproduced with
permission from Wolters Kluwer Health.
Preinvasive lesions:
Atypical adenomatous hyperplasia
Adenocarcinoma in situ (63 cm, formerly BAC)
- non-mucinous
- mucinous
- mixed mucinous/non-mucinous
Minimally invasive adenocarcinoma (63 cm lepidic
predominant tumour with 65 mm invasion):
- non-mucinous
- mucinous
- mixed mucinous/non-mucinous
Invasive adenocarcinoma:
Lepidic predominant (formerly non-mucinous
BAC pattern, with >5 mm invasion)
Acinar predominant
Papillary predominant
Micropapillary predominant
Solid predominant with mucin production
Variants of invasive adenocarcinoma
Invasive mucinous adenocarcinoma (formerly mucinous
BAC)
Colloid
Foetal (low and high grade)
Enteric
BAC, bronchioloalveolar carcinoma.
116 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 1 0 –1 2 2
[54]. In this trial, 53,454 people at high risk for lung cancer
were randomised between screening with low-dose CT or
chest radiography. In the CT group, there was a relative reduc-
tion in mortality from lung cancer of 20.0% and a reduction in
death from any cause of 6.7% [54].
Whether some of these lesions can be treated by limited
resection – so-called sublobar resection comprising anatomi-
cal segmentectomy or wedge excision – is currently the sub-
ject of intensive investigation [53]. For a limited resection to
be oncologically valid, a precise pre- and intraoperative diag-
nosis becomes imperative. In terms of preoperative diagnosis,
specific criteria on chest CT as percentage GGO, tumour sha-
dow disappearance rate and histogram analysis have been
shown to have a high predictive value [55]. The role of PET
and integrated PET–CT scanning and specific tumour markers
is currently being evaluated [56].
4.2. Sublobar (limited) resection for lung cancer
The detection rate of smaller lung cancers in recent times is
increasing, and therefore the appropriateness of lobectomy
for stage I lung cancer, especially those tumours 62 cm (clin-
ical T1a disease), is again being questioned [33,57]. Recently,
there have been numerous publications suggesting that sub-
lobar resection for early lung cancers may be an adequate sur-
gical treatment. Many of these studies are retrospective and
not randomised [58–60]. Most reports showed no difference
in survival or in locoregional recurrence between lobectomy
and sublobar resection for tumours 62cm in size. Patients
with GGO tumours on CT have been reported to have a
100% survival at 5 years after resection [61–64]. However, pos-
sible delayed cut-end recurrences have been described after
limited resection of GGO lesions [65].
Two recent reviews and one meta-analysis of sublobar
resection concluded that the well-selected use of sublobar
resection, especially for pure AIS 62 cm, yielded survival
and recurrence rates comparable to those of lobectomy [66–
68]. Thus, sublobar resection is generally considered accept-
able for GGO lesions or adenocarcinomas with minimal inva-
sion. Lobectomy is still considered the standard surgical
treatment for tumours 62 cm in size that have a solid appear-
ance on CT because such tumours are invasive carcinomas.
Definite recommendations can only be made when the re-
sults of large randomised trials such as Japan Clinical Oncol-
ogy Group (JCOG) 0802 in Japan, CALGB 140503 in North
America and European Institute of Oncology (IEO) S638/311
in Italy become available. These trials randomise patients
with tumours 62 cm between lobectomy and sublobar
resection.
Whether a purely anatomical segmentectomy provides a
similar or better result to a wide-wedge resection has not
yet been clearly determined. When correlating CT findings
of GGO with histopathology, many of these lesions corre-
spond to non-invasive forms of neoplastic growth. [61–
64,69,70]. In a recent prospective study from Japan (JCOG
0201), radiological non-invasive peripheral lung adenocarci-
noma was defined as an adenocarcinoma 62.0 cm with
60.25 consolidation [71].
Recent guidelines and a large, randomised screening trial
state that small nodules 610 mm or 6500 mm3 that are
clearly 100% pure GGO lesions on chest CT, which are sus-
pected to be AIS or MIA, be considered for close follow-up
rather than immediate surgical resection [72,73]. Specific CT
characteristics to be considered are size, attenuation, shape
and growth rate.
4.3. Systematic lymph-node dissection for early-stage
adenocarcinoma
In some specific subsets of very early-stage adenocarcinoma,
especially pure GGO lesions, systematic lymph-node dissec-
tion may not always be required [74]. Recent analysis of the
Italian COSMOS screening study showed that systematic no-
dal dissection can be avoided in the early stage – clinically
N0 lung cancer when the maximum standardised uptake va-
lue on PET scanning is <2.0 and the pathological nodule size is
610 mm – as the risk of nodal involvement is very low in this
subset of patients [75].
In a Japanese prospective study, a specific treatment algo-
rithm has been proposed [76]. Lesions 610 mm of any type or
pure GGO nodules were initially observed and discussed with
each specific patient. When size or density increased, they
were subsequently resected. GGO lesions 11–15 mm were
treated by segmentectomy and lymph-node sampling. Solid
lesions of 11–15 mm and GGO lesions of 16–20 mm were re-
moved by segmentectomy combined with lymph-node dis-
section. Solid lesions of 16–20 mm were resected by
lobectomy with lymph-node dissection. Applying this algo-
rithm, an excellent 5-year disease-free survival rate of 98%
was observed for limited resection [76].
5. Quality of life after lung cancer resection
Although mortality and major morbidity rates offer a patient
valuable information, these data alone are inadequate in
meeting the growing needs for detailed comparison of surgi-
cal approaches and rising expectations of patients. Patients
may regard immediate postoperative complications as an
acceptable risk, but are not prepared to accept significant
postoperative quality of life (QoL) impairments [77]. Several
publications focus on predictors of QoL after early-stage lung
cancer resection. Extent of resection [78–80], surgical ap-
proach [81,82], age [83–85] and smoking status [86–88] are con-
sidered to be significant.
The extent of resection has a significant influence on the
QoL evolution. Several publications evaluated QoL after lobec-
tomy and pneumonectomy [78–80]. Literature data agree that
the initial limitations in the physical QoL component ob-
served after both resections are more pronounced after pneu-
monectomy. Depending on the specific publication, both
resections yielded comparable results after 3–6 months. Sub-
lobar resections, indicated in stage IA patients with a tumour
located in the periphery of the lung and <2 cm in diameter,
are currently often performed. Although these procedures im-
ply a parenchyma-sparing intent, QoL has rarely been re-
ported after sublobar resections. Pompeo et al. evaluated
patients with severe emphysema undergoing a sublobar
resection for stage I lung cancer [89]. Significant improve-
ments were reported in the domains of the physical QoL com-
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ponent, presumably because of a lung volume reduction ef-
fect. Saad prospectively described the evolution in QoL after
different lung resections [90]. A comparable improvement in
the physical QoL was seen after lobectomy as well as after
sublobar resection.
The effect on QoL not only of the muscle-sparing versus
the non-muscle-sparing thoracotomy, but also of minimally
invasive thoracic surgery was recently evaluated. The effect
of the muscle-sparing thoracotomy is mostly seen on the
physical QoL component, with improved shoulder function
and less thoracic pain compared to the non-muscle sparing
thoracotomy [91]. The advantages of VATS over thoracotomy
in terms of QoL are found in the immediate postoperative per-
iod. After postoperative day 4, no significant differences in
QoL are seen [92]. After a VATS procedure Landreneau et al.
found that patients experienced significantly less pain only
on the first 2 days in comparison to a muscle-sparing thora-
cotomy [93].
Conclusions of QoL research in younger patients cannot be
transferred blindly to septuagenarians. Several authors pro-
spectively evaluated QoL after lung-cancer surgery in an el-
derly patient population. In general, age >70 years is an
important risk factor for impairment of the physical QoL com-
ponent, and recovery is not guaranteed until P24 postopera-
tive months [78]. After lobectomy as well as pneumonectomy,
the emotional component returns to baseline the first
3 months after surgery in elderly patients and may reflect a
so-called response shift whereby patients adapt their stan-
dards and perceptions to their expectations and rate their
personal situations better than would otherwise be expected
[94].
Several authors compared QoL between patients aged less
versus more than 70 years. Salati et al. compared QoL after
lobectomy [83]. Preoperatively, elderly patients scored worse
on the physical component of QoL, but scored higher values
on the emotional component. At 3 months after surgery, no
significant differences were seen between the two patient
groups. Burfeind et al. evaluated the effect of lobectomy on
patients who were younger versus older than 70 years [84].
Both groups demonstrated a similar decrement in QoL with
a parallel return to baseline. The one notable exception was
in the physical QoL component, which had returned to base-
line by 6 months in young patients and stayed impaired in pa-
tients P70 years at 6 and 12 months postoperatively.
The effect of smoking habits on postoperative QoL at
6 months was evaluated by Myrdal et al. [87]. Patients who
continued smoking after lung-cancer surgery had signifi-
cantly lower scores for the emotional QoL component than
former smokers and those who had never smoked. In con-
trast, Sarna et al. could not withhold the smoking status
as predictive for postoperative QoL [88]. In a recent study,
we concluded that smoking cessation is beneficial at any
time point prior to lung-cancer resection [86]. Current smok-
ing at the time of surgery is associated with a longer impair-
ment of QoL functioning as well as symptom scores. Since
smoking status is one of the few prognostic factors in the di-
rect control of the patient, this study offers valuable infor-
mation to promote smoking cessation before lung-cancer
surgery.
There is an ongoing debate on the effect of induction and
adjuvant chemotherapy or radiotherapy on QoL after lung-
cancer surgery [95–97]. Several authors evaluated the effect
of chemotherapy on the QoL of lung-cancer patients, in both
non-surgical and surgical patients. In non-surgical patients,
chemotherapy was associated with worse QoL, unless the pa-
tient responded to treatment [98]. Paull et al. reported that
exposure to postoperative chemotherapy was a risk factor
for poor QoL after surgery for early-stage lung cancer [97].
These results are not consistent with the study of Fiedler
et al. who evaluated QoL after pneumonectomy comprising
early- as well as advanced-stage lung cancer [96]. Adjuvant
chemotherapy had no significant influence on QoL at
6 months.
Although many questions remain concerning QoL evolu-
tion after lung-cancer surgery, QoL data are essential in prop-
er patient counselling and may create realistic postoperative
objectives for patients. The real challenge in the management
of lung-cancer patients consists not only in improving prog-
nosis but also in maintaining or increasing QoL.
6. Surgical quality control
Thoracic surgery comprises a large variety of different proce-
dures which may prove to be technically challenging, such as
extended resections of the superior sulcus, sleeve resections,
intrapericardial procedures and extensive operations after
induction therapy. For this reason uniform judgment of surgi-
cal quality is difficult to perform. Overall mortality is only a
crude parameter and risk stratification is necessary. More-
over, dedicated anaesthesiological, intensive-care and nurs-
ing management is required to obtain the best
postoperative results; thus team management will not only
determine the short-term results but also long-term outcome.
This also implies that hospital volume may be a critical
determinant.
Is there a clear relationship between surgeon or hospital
volume and final outcome? In a seminal paper Luft et al. dem-
onstrated that mortality after open-heart surgery, vascular
surgery and prostatectomy decreases with increasing number
of procedures performed [99]. When analysing data from uni-
versity reports, Hillner et al. showed a relationship between
volume and outcome for complex intra-abdominal and
lung-cancer interventions [100]. When looking at the specific
number of pulmonary resections, mortality was lower in
those centres performing more than 24 interventions on a
yearly basis. Mortality of lobectomy was significantly lower
when performed by a thoracic surgeon compared to a general
surgeon. The latter finding was confirmed in a more recent
study [101]. In another analysis of more than 2000 pulmonary
resections, low-volume centres were compared to high-vol-
ume institutions. Morbidity was lowest and survival highest
in those centres performing more than 67 resections per year
[102]. Also in a Flemish, multicentre, hospital-based lung-can-
cer registry, mortality decreased when hospital volume in-
creased [103]. The same holds true for oesophagectomy
[104]. In the latter paper, mortality after lung resection was
not related to technical factors but mainly to severe postoper-
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ative complications, underlining the importance of a dedi-
cated multidisciplinary team in taking care of this patient
population.
Are results different in teaching hospitals with specific
thoracic surgical residents? In a recent analysis of 498,099
lung resections a superior outcome was found in hospitals
with a thoracic surgery residency programme [105]. The odds
ratio of death in patients undergoing pneumonectomy was
reduced by more than 30% compared with hospitals providing
training in general surgery.
Although evidence-based minimal volume standards are
currently lacking, a recent systematic review and meta-anal-
ysis concluded that hospital volume and surgeon specialty
are important determinants of outcome in lung-cancer resec-
tions [106].
So, centralisation of care seems to be the logical conse-
quence in improving short-term and long-term results. How-
ever, most of the presented data come from North America
with established training programmes in thoracic and cardio-
thoracic surgery. What is the current situation in Europe?
In many European countries, general thoracic surgery cur-
rently exists as a separate specialty. However, the precise
number of centres performing thoracic surgical procedures
is unknown and accurate figures on the total number of inter-
ventions are not currently available. Certification in thoracic
surgery is not uniform throughout Europe. As an example,
thoracic surgery is not a specifically defined entity in Belgium,
where it falls within the discipline of general surgery together
with abdominal, cardiac, vascular, paediatric and trauma
surgery.
There is also no uniform European training programme in
thoracic or cardiothoracic surgery. To establish a more precise
structure of general thoracic surgery a working group has
been established by the European Association for Cardio-tho-
racic Surgery (EACTS) and the ESTS. Recently, the Union
Europe´enne des Me´decins Spe´cialistes (UEMS) has created a
specific thoracic surgical division related to the general and
cardiothoracic surgical sections. Specific criteria for training
and accreditation in thoracic surgery are currently being
developed.
To obtain more precise data on the number of general tho-
racic surgical procedures in Europe, several large databases
have been created. The ESTS created a voluntary database
for general thoracic surgery. In 2011 a total of 24,574 lung
resections were reported, including all diagnoses. Lobectomy
represented 57.5% of cases, and pneumonectomy 9.5%. A to-
tal of 16,710 cases of primary lung cancer were reported,
lobectomy and bilobectomy being performed in 76% of cases.
In this database mortality and morbidity are calculated
according to specific risk scores, allowing benchmarking be-
tween different units and countries.
To ensure high-quality patient care in thoracic surgery, the
EACTS/ESTS working group felt that it should be performed
within the logistical and economical framework of specialised
units. These units should be designed to allow patient care
and treatment according to recommended standards, as well
as education of surgical trainees, continuous development
and research in thoracic surgery. The working group proposed
two types of thoracic surgical centres: highly specialised cen-
tres within or associatedwith a university, performing at least
250 major thoracic procedures per year, and standard units
which are free-standing or combined with cardiac, vascular
or general surgery. In a standard unit at least 100 major inter-
ventions should be performed annually. Lung transplantation
and its alternative procedures should be performed only in
centres with special interest and with cardiac surgical facili-
ties. According to well-defined criteria in combination with
an on-site visit, dedicated thoracic units can obtain an insti-
tutional quality certification in general thoracic surgery.
In order to raise the profile of thoracic surgery in Europe,
further harmonisation is necessary. Unified databases should
become available, detailing not only mortality but also spe-
cific outcome measures related to morbidity, survival and
quality of life. Postgraduate education remains necessary to
ensure a high quality of thoracic surgical interventions as
has recently been demonstrated by a study from the Nether-
lands evaluating completeness of lymph-node dissection in
dedicated thoracic surgical centres [107,108].
Thoracic surgeons should be further involved in random-
ised clinical trials comparing newly introduced treatment
modalities – such as stereotactic radiotherapy or radiofre-
quency ablation – to classical surgical procedures. They
should also be prepared to adapt to a new, constantly chang-
ing environment. Multidisciplinary collaboration and large-
scale prospective studies are necessary to update current
diagnostic and therapeutic algorithms ensuring optimal pa-
tient care in thoracic surgery [109].
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Role of adjuvant radiotherapy in completely
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Most long-term survivors of non-small-cell lung cancer (NSCLC) are patients who have had
a completely resected tumour. However, this is only achievable in about 30% of the patients.
Even in this highly selected group of patients, there is still a high risk of both local and dis-
tant failure. Adjuvant treatments such as chemotherapy (CT) and radiotherapy (RT) have
therefore been evaluated in order to improve their outcome. In patients with stage II and
III, administration of adjuvant platinum-based chemotherapy is now considered the stan-
dard of care, based on level 1 evidence. The role of postoperative radiation therapy (PORT)
remains controversial. In the PORT meta-analysis published in 1998, the conclusions were
that if PORTwas detrimental to patients with stage I and II completely resected NSCLC, the
role of PORT in the treatment of tumours with N2 involvement was unclear and further
research was warranted. Thus at present, after complete resection, adjuvant radiotherapy
should not be administered in patients with early lung cancer. Recent retrospective and
non-randomised studies, as well as subgroup analyses of recent randomised trials evaluat-
ing adjuvant chemotherapy, provide evidence of the possible benefit of PORT in patients
with mediastinal nodal involvement. The role of PORT needs to be evaluated also for
patients with proven N2 disease who undergo neoadjuvant chemotherapy followed by sur-
gery. The risk of local recurrence for N2 patients varies between 20% and 60%. Based on cur-
rently available data, PORT should be discussed for fit patients with completely resected
NSCLC with N2 nodal involvement, preferably after completion of adjuvant chemotherapy
or after surgery if patients have had preoperative chemotherapy. There is a need for new
randomised evidence to reassess PORT using modern three-dimensional conformal radia-
tion technique, with attention to normal organ sparing, particularly lung and heart, to
reduce the possible over-added toxicity. Quality assurance of radiotherapy as well as qual-
ity of surgery – and most particularly nodal exploration modality – should both be moni-
tored. A new large multi-institutional randomised trial Lung ART evaluating PORT in this
patient population is needed and is now under way.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
1. Introduction
Most long-term survivors of non-small-cell lung cancer
(NSCLC) are patients having had a complete surgical resec-
tion. However, this is only achievable in about 30% of the
patients. Even in this highly selected group of patients,
there is still a high risk of both local and distant failure.
Adjuvant treatments such as chemotherapy (CT) and
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radiotherapy (RT) have therefore been evaluated in order to
improve their outcome. For years, the use of adjuvant CT
and/or RT was a controversial issue, as neither seemed to
have any impact on survival in individual trials that were of-
ten under-powered. However, the meta-analysis including tri-
als comparing surgery alone to surgery + adjuvant CT
published in 1995 showed a modest survival benefit of 5%
in completely resected patients having received postopera-
tive cisplatin-based adjuvant CT compared with patients
without CT [1]. The beneficial effect of adjuvant CTwas con-
firmed in large trials initiated after the meta-analysis. It var-
ies between 4% and 15% at 5 years in favour of surgery plus
adjuvant chemotherapy [2–8]. Furthermore, the meta-analy-
sis published in 2010 including 8447 patients with updated
data from the old trials, and data from all recent trials show
an absolute increase in survival of 4% at 5 years (from 60%
to 64%, P < 0.0001) [9]. Thus, most clinicians now consider
adjuvant CT as standard treatment in patients with stages
II and III completely resected lung cancer. Updated survival
analysis of two individual trials has also been published
with contrasting results as to the persistent long-term ben-
eficial effect of adjuvant chemotherapy [10,11]. On the other
hand, concerning adjuvant RT, an individual data-based
meta-analysis evaluating the role of postoperative radiother-
apy (PORT) after surgery for NSCLC was also undertaken in
the 1990s: it showed that adjuvant RT could be deleterious
in patients with early lung cancer (i.e. stages I and II) but
that in more advanced lung cancer (i.e. stage IIIA) it should
be better explored in new studies, especially in patients with
mediastinal involvement [12]. At the current time, adjuvant
treatment is focused on chemotherapy and the risk of dis-
tant metastases rather than on postoperative radiotherapy
which may also have an impact on disease control. It seems,
however, that 20–60% of patients may be at risk for loco-re-
gional recurrence. In view of the high proportion of patients
still suffering from local failure after a complete resection
and adjuvant chemotherapy, a new interest in PORT has
been generated, even though PORT remains a controversial
issue. We have therefore reviewed the evidence regarding
adjuvant radiotherapy in completely resected NSCLC in
2013. Assessing the patterns of failure after surgery and
the possible PORT-related toxicity is helpful in evaluating
the benefit/risk ratio of postoperative therapy. Even if the
risk of local recurrence in early lung cancer is generally con-
sidered to be small in comparison with the risk of distant
recurrence, the rates of local failure are highly variable in
the literature, ranging from 6% to 45% in stage I and from
7% to 55% for stage II disease. There are various reasons
for this: problem of definition, and local failures often not
reported when they occur at the same time as distant
metastases or after distant failure.
An additional difficulty in the decision to administer adju-
vant treatment may be the new tumour-node-metastasis
(TNM) classification [13,14]. Five-year rates of locoregional
recurrence (LRR) for stages IA, IB, IIA, IIB and IIIA disease
using TNM-6 were 16%, 26%, 43%, 35% and 40%, respectively.
Using TNM-7, corresponding rates were 16%, 23%, 37%, 39%
and 30%, respectively, and there about 10–15% ‘stage shifters’
[14,15].
2. Studiesevaluatingmediastinalpostoperative
radiotherapy
Several retrospective studies, contemporaneous to the studies
included in the meta-analysis, have shown that the risk of lo-
cal recurrence could be reduced by PORT (25–35%) in historical
comparisons [16–22]. However, this finding was not corrobo-
rated by most randomised trials.
In this review article, we will focus on randomised trials
and on the meta-analyses on PORT [12,23–29]. Several of the
trials are old, conducted in the era before computed tomogra-
phy (CT) scan and positron emission tomography (PET), with
patients treated with cobalt 60 (Co60) or even orthovoltage
therapy; this resulted in a higher risk of both morbidity and
mortality [30,31]. Furthermore, irradiated volumes were often
large, fractionations often superior to 2 Gy daily, all these fac-
tors contributing to a higher morbidity; other technical fac-
tors such as the absence of CT-based planning in most trials
or the use of spinal cord blocks which potentially block medi-
astinal disease may explain several LRRs. As previously sta-
ted, the rates of local failures at 5 years vary according to
stage, and in several studies patients at low risk for LRR were
included, possibly obscuring a radiation-induced benefit in
higher-risk patients.
3. Randomised trials of adjuvant radiotherapy
in stage I resected NSCLC
Van Houtte et al. [23] conducted a randomised trial in 175 pa-
tients who had a complete resection and had no lymph-node
involvement. The 5-year survival rate was 24% in the RT arm
versus 43% in the control arm. PORTwas significantly delete-
rious, especially after pneumonectomy (16% in the PORT arm
versus 43% in the control arm). They concluded that TRT
should not be recommended in N0 patients. A more recent
Italian randomised trial compared PORT at the dose of 50.4
Gy to no PORT in 104 patients with pathological stage I disease
[24]. The patients included in this study benefited from more
modern radiotherapy: all patients had a CT-planned treat-
ment, linear accelerators were used and treatment volumes
– including the bronchial stump and ipsilateral hilum – were
small. Radiotherapy significantly decreased the risk of local
recurrence from 23% in the control group to 2.2% in the PORT
group (P = 0,002) but there was no significant difference in
terms of 5-year overall survival (67% in the PORT group and
58% in the control group). There was no over-added toxicity
in the PORT group. However, it may be argued that patients
with pathological stage I NSCLC have such a low risk of local
recurrence, that routine PORT is generally not recommended
except for patients with R1 or R2 resections.
4. Randomised trials of adjuvant radiotherapy
in stages II and III resected NSCLC
The Lung Cancer Study Group conducted a randomised study
including 230 patients with stage II and III squamous-cell car-
cinoma to evaluate postoperative PORT at the dose of 50 Gy
[25]. PORT significantly decreased the risk of local recurrence:
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1% versus 41% in the control arm (P = 0.001). But this effect did
not translate into a demonstrable overall survival benefit (5-
year survival rate around 40% in both arms), since most recur-
renceswere outside the radiation field orwere distant failures.
However a subgroup analysis suggested that PORT could pro-
long disease-free interval in patients with N2 disease. The de-
sign of the Medical Research Council study was quite similar
but also included patients with adenocarcinoma [26]. Patients
with pathologically staged T1–2, N1–2 NSCLC were randomly
assigned to receive either surgery alone or surgery and PORT
at the dose of 40 Gy in 15 fractions. The results confirmed pre-
vious studies: therewas no advantage for survival in the PORT
group over the control arm, but in the N2 subgroup analysis
there was a non-significant trend towards improved survival
and local control. Thus, the authors concluded that there
was no indication for PORT in N1 disease, but the question re-
mained open for N2 patients. The largest trial evaluating PORT
included 728 patients (221 with stage I, 180 with stage II and
327 with stage III disease) [27]. It demonstrated that PORT
had a detrimental effect on survival: the 5-year survival rate
was 43% for the control group and 30% for the RT group
(P = 0.002). In terms of 5-year rate without local recurrence,
there was a trend in favour of PORT among N2 patients. The
excess mortality rate in the radiotherapy group was due to
an increase in intercurrent deaths. In a Chinese randomised
study of 366 completely resected patients with N1 or N2 nodal
disease, PORT significantly reduced the rate of local relapses:
the local failure rate was 12.7% versus 33.2% in the control
group (P = 0.01), but this had no impact on survival [28].
In conclusion, before the meta-analysis was published, the
role of PORTwas unclear as the individual trials showed con-
flicting and inconclusive results. They did not have the statis-
tical power to detect moderate survival differences. Thus the
PORT meta-analysis group gathered individual data on 2128
patients from nine randomised trials [12]. Its results indicated
that PORT had a significant detrimental effect on survival,
with an absolute decrease of 7% at 2 years, reducing the over-
all survival from 55 to 48% (P = 0.001). Subset analyses sug-
gested that PORT could be deleterious in terms of overall
survival, predominantly among patients who had a complete
resection and no mediastinal involvement (either pN0 or
pN1). However, than authors could observe a 24% relative
reduction in local recurrence rate (all stages together), so that
the question of PORT in pN2 patients who have a high local
recurrence rate remained valid and could warrant further re-
search. This overview was updated in 2005 and included an
additional trial by Trodella et al. in the analysis; it still showed
PORT to be detrimental, with an 18% relative increase in the
risk of death [32]. A very recent letter updating the results of
the meta-analysis was published using different statistical
methods, confirming that PORT should not be routinely used
unless there is supporting evidence from new trials of mod-
ern PORT [33]. Unfortunately no phase III trial evaluating
more modern PORT versus no PORT has been published since
1998. However, there have been studies on adjuvant chemo-
therapy as well as chemoradiotherapy. The already men-
tioned meta-analysis on the role of adjuvant chemotherapy
in completely resected patients also comprised a second anal-
ysis based on 13 trials and 2660 patients, mostly stage III pa-
tients, and compared surgery plus radiotherapy versus
surgery plus radiotherapy and chemotherapy [9]. It showed
a significant improvement in survival of 4% at 5 years (from
29% to 33%). It should be outlined that a similar 4% absolute
benefit was observed in the analysis of trials comparing sur-
gery with surgery and chemotherapy that included mainly
patients with stages I and II NSCLC. Thus the effect of chemo-
therapy was similar irrespective of which loco-regional treat-
ment was used: surgery alone or surgery plus PORT. The
authors concluded that, as this meta-analysis was not de-
signed to study the effect of PORT, randomised trials were
needed to assessmodern radiotherapy as adjuvant treatment.
5. Studies on adjuvant chemoradiotherapy in
stage II and III patients
Until 1998, PORT was considered the standard treatment by
many clinicians in stage II and stage III patients; thus the East-
ern Cooperative Group (ECOG) completed a prospective trial
comparing PORTat the dose of 50.4 Gy in 1.80 Gy fractionswith
PORT and concomitant chemotherapy combining etoposide
and cisplatin [34]. The 3-year survival rate was, respectively,
52% in the PORT arm and 50% in the combined treatment
arm (P = 0.56). The loco-regional recurrence rate within the
radiotherapy field was about 13% in both arms and was there-
fore smaller than the rates reported in the literature. A better
standardised surgical treatment may explain these results in
terms of local control, as well as the use of more modern
radiotherapy using CT-scan-based planning. The protocol re-
quired a thoroughmediastinal lymph-node dissection or sam-
pling according to the American Thoracic Society lymph node
definitions [35,36]. There was a significant difference (P < 0.05)
between the recurrence rate of patients with mediastinal dis-
section (50%) and those with mediastinal sampling (60%) [37].
Thus the authors concluded that cisplatin and VP-16 adminis-
tered concomitantly with PORT did not prolong survival or
modify local failures compared to PORT alone. Other phase II
trials have evaluated adjuvant concomitant chemoradiation
in stage II and IIIA patients [38,39]. In the RTOG 9705 phase II
trial, where 86 patients had concurrent paclitaxel/carboplatin
and PORT at the dose of 50.4 Gy, the 3-year progression-free
and overall survival ratewas respectively 50% and 61%, and lo-
cal failure was a component of first failure in 15% of patients
[38]. In another phase II study that included 42 patients (40%
of pN1 and 60% of pN2 patients) treated with a similar regi-
men, the 2- and 5-year Kaplan–Meier estimates of local regio-
nal control were 92% and 88%, whereas the 2- and 5-year
overall survival rate was 72% and 44%, respectively [39]. Even
if these results seemed better that those reported in the Inter-
group trial, no randomised trial was undertaken, so that adju-
vant concomitant chemoradiation after complete surgery
cannot be considered as a standard treatment.
6. Postoperative radiotherapy (PORT): toxicity
issues
The excess of toxicity (mostly cardiac and pulmonary) and
non-cancer-related deaths observed after PORT in the meta-
analysis trials can probably be explained by old radiation 2D
techniques, excessive volumes of radiation, too large doses
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and fraction sizes and no CT-scan-based planning. Unfortu-
nately, the authors could not collect data on toxicity or causes
of intercurrent deaths in the different studies. Late cardiac
complications that are described after mediastinal radiother-
apy are linked to the total dose, the fraction size, the irradi-
ated volume, the technique of irradiation, as well as
comorbidities (tobacco use, overweight) [40,41]. Pulmonary
complications such as pneumonitis and lung fibrosis can also
be observed, but they occur earlier; there are strong volume
and fractionation effects [42]. In a recent prospective study
of 291 patients, cardiopulmonary functions as well as quality
of life were evaluated prospectively at baseline and at 2 years
among 171 pN2 patients who had PORT and 120 pN1 patients
who did not have PORT. The authors found no significant dif-
ference in terms of cardiopulmonary morbidity among pa-
tients alive at 2 years [43]. The administration of certain
radiosensitising drugs such as gemcitabine may increase this
risk. In the phase II trial RTOG 9705 evaluating adjuvant con-
comitant chemo-radiotherapy, a 6% crude incidence of late
pulmonary toxicity and similarly a 5% rate of late cardiac tox-
icity of grade 3 or over were observed [38]. Miles et al. elabo-
rated a mathematical model to describe the tumour stage-
and field-size-dependent risks/benefits of postoperative
radiotherapy and showed that RT-induced mortality was
strongly dependent on field size [44]. In the largest published
randomised trial, Dautzenberg could determine that the use
of fraction sizes >2 Gy resulted in a high risk of late toxicity
[27]. The risk of non-cancer-related death was, respectively,
7% in the control group, 16–18% among patients who had dai-
ly RT fractions 62 Gy and 26% among those who had higher
doses per fraction. Several studies reported reduced toxicity
and mortality with more modern PORT. A retrospective study
focusing on toxicity issues showed that PORT could be admin-
istered safely if patients were treated with more modern
treatment techniques, more limited volumes of irradiation,
daily fraction sizes 62 Gy and total doses 654 Gy [45]. The
4-year actuarial rate of death from intercurrent disease
(DID) for patients treated with PORT within the E3590 trial
was 12.9%: not significantly different from the 10.1% expected
rate of DID observed in a control population matched for age
and gender and corrected for smoking status [46]. A Surveil-
lance, Epidemiology and End Results (SEER) data-based study
analysed deaths from heart disease in a group of 6148 pN1 or
pN2 patients operated between 1983 and 1993 who were fol-
lowed up until 2005 [47]. Amongst them, 58% had PORT. PORT
delivery was associated with an increase in the hazard for
heart disease. However, this increase was only significant in
patients treated between 1988 and 1993. For the authors, this
could reflect the impact of more modern radiotherapy tech-
niques utilised in the second half of the 1990s on morbidity.
7. Should PORT be considered for patients
with mediastinal involvement?
Lally et al. have reported on PORT in a population-based co-
hort of 7465 patients with stage II and III non-small-cell lung
cancer who had surgery [48]. They selected from the SEER
database patients treated between 1988 and 2002, out of
which 47% received PORT. Patients who had PORT were pre-
sumably treated with more modern radiotherapy techniques
than patients included in the meta-analysis. The 5-year sur-
vival rate was 20% in the no-PORT versus 27% in the PORT
group (P = 0.0036). The authors concluded that PORT offered
a significant survival benefit for patients with N2 nodal dis-
ease, but that there was a detrimental effect for patients with
N0 or N1 nodal disease. However, as with any retrospective
study using a large database, one should be cautious with
the results. Another recently published trial by Douillard
et al. also suggested the possible impact of PORT on survival
in patients included in the adjuvant Navelbine International
Trialist Association (ANITA) randomised trial [5,49]. In a sub-
group analysis according to nodal status, survival was im-
proved in patients with pN2 disease who received PORT,
both in the chemotherapy (MS 23.8 versus 47.4 months) and
observation arms (median 12.7 versus 22.7 months). The
authors concluded that their retrospective evaluation sug-
gested a positive effect of PORT administered after CT in
pN2 disease, and that these results supported further evalua-
tion of PORT in prospectively randomised studies. They also
could show as in the meta-analysis that PORT seemed to be
deleterious in pN1 patients. However, most studies do not
specify the exact location of locoregional recurrence. In a
large retrospective study of 406 patients with pN2 nodal
involvement, the local recurrence rate among the 332 evalu-
ated patients was 39.2% and most of these recurrences oc-
curred in the mediastinum [50]. Some additional interesting
issues concerning local control have been outlined by retro-
spective studies. Kelsey observed that left-sided tumours
tended to recur in the contralateral mediastinum more fre-
quently than right-sided tumours, and this could be ex-
plained by lymph node exploration techniques as left
lymph-node exploration is considered more difficult than
right-sided lymph-node exploration [37,51]. Sawyer et al. have
tried to divide pN2 patients into three different subgroups
according to their respective risk of failure: high-risk (in cases
of multiple distant mediastinal nodes involved), intermedi-
ate-risk (in cases of involvement of inferior nodes or superior
nodes with eventual invasion of hilar nodes). and low-risk (if
there is no hilar node involvement) [22]. Several recent mono-
institutional studies have evaluated PORT retrospectively in
patients with pN2 involvement and they show positive results
not only in terms of local recurrence but also in terms of sur-
vival [52–55]. Furthermore, most patients had no adjuvant
chemotherapy, no staging according to today’s standards
and this delineates the importance of a new randomised
study comparing PORT to no PORT in such a frequent cancer
as NSCLC.
Another issue is whether patients with provenmediastinal
involvement and who have neoadjuvant chemotherapy
should have PORT after a complete resection. Many clinicians
treat patients with clinical N2 involvement with preoperative
chemotherapy. Several studies, as well as a meta-analysis
based on literature, have indeed suggested a benefit in terms
of survival in favour of preoperative chemotherapy [56–60].
Mediastinal down-staging has been shown to be an important
prognostic factor [57,59]. However, the recurrence rate can be
quite high as seen in the updated results of a phase II trial of
neoadjuvant chemotherapy where at 5-year follow-up, 60% of
patients had local relapse [61]. Another recently published
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trial also showed a high incidence of local failure in stage IIIA
N2 patients down-staged after neoadjuvant chemotherapy.
The 5-year local-regional failure (LRF) rate was 31%, and most
locoregional recurrences appeared in the mediastinal (92%)
and hilar lymph nodes (23.7%), the risk being particularly high
in case of N1 disease [62]. In another retrospective study, the
5-year actuarial local control rate was 82% among patients gi-
ven PORT versus 35% who had no PORT. Thus even if PORT
after neoadjuvant chemotherapy followed by surgery may re-
duce local recurrence as reported in small retrospective stud-
ies, this remains to be proven [63,64] Thereby the question of
PORT is also valid among patients who have histologically
proven N2 disease before preoperative chemotherapy, what-
ever their response is: persistent mediastinal involvement
or mediastinal down-staging (from N2 histologically proven
to pN0 or pN1). No randomised study has been published on
this issue.
8. Importance of surgery and preoperative
staging in the perspective of modern adjuvant
radiotherapy
New data concerning PORT should take into consideration the
quality of surgery and the progress made in terms of preoper-
ative staging or re-staging after neoadjuvant chemotherapy.
At present most patients considered for surgery are much
better selected on the basis of a PET scan and brain imaging.
PET–CT is highly sensitive and specific in detecting mediasti-
nal nodal spread and extracranial metastases [65,66]. After
induction chemotherapy for patients with N2 involvement,
repeated FDG-PET may select surgical candidates among pa-
tients with mediastinal down-staging or persistent minor dis-
ease [67].
In the past years there has been an important collaborative
effort of thoracic surgeons to define lymph-node exploration
and complete resection. The European Society of Thoracic
Surgeons (ESTS) has proposed guidelines for appropriate
intraoperative and preoperative lymph-node staging [68,69].
The International Association for the Study of Lung Cancer
(IASLC) staging committee has proposed a definition of com-
plete resection [70]. All resection margins – including bron-
chial, venous and arterial stumps and peribronchial soft
tissue – should be microscopically free of disease. Systematic
nodal examination should comprise at least three intrapul-
monary and hilar nodes and at least three nodes from the fol-
lowing mediastinal nodal stations according to the location of
the primary tumour. There is no consensus about whether
the highest mediastinal node that has been explored and re-
moved should be negative. It is also unclear whether the ex-
tent of mediastinal exploration can affect long-term
survival. Even if randomised trials have been performed com-
paring these two mediastinal approaches, there still is a de-
bate between advocates of radical mediastinal node
dissection who claim not only a potential prognostic benefit
but a better tumour staging and treatment, and opponents
of the radical approach because of higher morbidity and mor-
tality and possibly a negative effect on survival because of im-
paired local immunity [71–73].
Considering resected patients, an exploratory analysis of
the IASLC database studied survival after complete resection
in relation to the extent of node involvement using the zonal
concept [74,14]. Three groups were identified, with significant
differences in terms of survival. Group 1 with single-zone N1
disease had a 5-year survival rate of 48%. Group 2 consisting
of patients with multizone N1 and single-zone N2 disease
had 5-year survival rates around 35%. Group 3 comprised pa-
tients with multizone N2 disease, and the 5-year survival rate
did not exceed 20%. More recently, two large retrospective
studies have tried to question whether the number of lymph
nodes involved were of added prognostic significance com-
pared with the pathological nodal stage (pN category)
[75,76]. However, among the 2538 pathologically staged N1
and N2 cases in the IASLC database, such results were not ob-
served [77]. The importance of mediastinal node involvement
seems therefore the best and most consensual prognostic
factor.
9. Implications for a new trial evaluating PORT
At present, based on level 1 evidence, patients who have had a
complete resection of the primary tumour with mediastinal
lymph-node dissection showing no mediastinal involvement
(pN0 and pN1) should not have PORT. The issue of PORT is
not as clear among patients with N2 mediastinal involve-
ment. Indication of PORT is currently debated for each indi-
vidual patient with mediastinal involvement. A new trial is
needed addressing PORT in stage IIIA patients. Conforma-
tional radiotherapy should be mandatory so as to reduce tox-
icity and improve outcome [78–80]. The irradiation volume
should take into account the data of thoracic CT scan and
the eventual PET scan data before surgery, as well as the
description of mediastinal exploration and histopathological
results. A recent study has shown there are wide variations
in target volume definition for PORT [81]. Based on previous
studies, it seems reasonable to treat only involved lymph-
node stations and uninvolved stations at high risk to better
protect surrounding normal structures and consequently
minimise treatment-related mortality [82–85]. An atlas of
CT-based definition of thoracic lymph-node stations may be
helpful [86].
In the ongoing study LungART, the irradiation volume in-
cludes the lymph-node stations involved according to the
pathological report as well as lymph-node stations consid-
ered at high risk of involvement according to tumour location
[87].
Among pN2 patients included in the PORT overview, the
high rate of distant metastases diluted any real effect of local
control on overall outcome. As the standard treatment for pa-
tients with mediastinal involvement has changed in the last
10 years from surgery plus adjuvant radiotherapy to surgery
plus chemotherapy, and selection of surgical candidates has
evolved with PET–CT as well as minimally invasive staging
procedures, it is of utmost importance to evaluate whether
modern adjuvant radiotherapy can improve survival in pa-
tients after complete resection and adjuvant chemotherapy.
Lung ART is a randomised trial evaluating modern PORT in
patients with mediastinal involvement. Patients may have
chemotherapy in the neoadjuvant setting or adjuvant setting.
It is an inter-group study involving the Intergroupe Franco-
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phone de Cancerologie Thoracique (IFCT 0503), a United King-
dom group (UK 11/NW/0075) and the EORTC (EORTC 22055-
08053) (NCT00410683). Another trial is ongoing in China com-
paring adjuvant chemotherapy followed by PORT to adjuvant
chemotherapy alone (NCT00880971). Such studies could re-
sult into an optimisation of standard care in operable stage
III patients.
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1. Introduction
Adjuvant use of chemotherapy has established efficacy in
several solid human tumours – breast, colon and lung cancers
being among the most frequent. The role of adjuvant treat-
ment – either locoregionally or systemically after local treat-
ment, allowing a complete resection of the primary tumour
and locoregional lymph nodes – is to improve cure rates.
The goal of adjuvant chemotherapy is to eradicate micro-
metastases that may already be established but are undetect-
able as well as to destroy possible circulating tumour cells.
The benefit, however, is hypothetical, and patients are gener-
ally selected on the basis of the pTNM staging obtained at sur-
gery. One has to keep in mind that most of the patients who
will be disease-free at 5 years have already been cured by sur-
gery. The benefit of adjuvant chemotherapy is always limited
in terms of magnitude to low percentages, and the risk/bene-
fit ratio for a given patient is low. In addition, adjuvant che-
motherapy has its own toxicity that may be acute but also
long-lasting even after termination. Taking these consider-
ations into account, the use of chemotherapy and the choice
of cytotoxic agents should be based on properly conducted
clinical trials, with a well-defined population and a follow-
up long enough to assure a real benefit with time. Data from
efficacy in metastatic settings should not simply be applied to
adjuvant use without results of randomised trials in this situ-
ation and a proven level of evidence. Tumour cell biology
shows that a given tumour evolves with time, and that meta-
static disease is quite a different disease from the adjuvant
setting.
The purpose of this Educational Lecture is:
• To review the data on adjuvant chemotherapy for NSCLC.
• To analyse how the concept has evolved with time.
• To present the results of meta-analysis.
• To provide an update on the most recent trials.
• To examine the impact on special populations.
• To look at possible prognostic/predictive biomarkers.
• To provide recommendations for routine practice.
2. The first signal of a possible effect of
adjuvant chemotherapy in resected NSCLC
During the last 4 decades of the 20th century, numerous trials
of various sample sizes and chemotherapy combinations
have been performed in various settings worldwide. Despite
an effort to accrue about 10,000 patients in 50 clinical trials,
none of them individually has been convincing enough to
establish adjuvant chemotherapy as a standard of care. In
1995, the Non-Small Cell Lung Cancer Collaborative Group
under the joint auspices of the Medical Research Council
(MRC) in the United Kingdom, Institut Gustave Roussy in
France and Istituto Mario Negri in Italy published a meta-
analysis looking at the impact of adjuvant chemotherapy in
resected non-small-cell lung cancer (NSCLC) [1]. They re-
viewed updated data on individual patients from randomised
trials performed between 1965 and 1991. All types of treat-
ment were analysed, including adjuvant chemotherapy, radi-
ation therapy and advanced disease. Among these trials, 14 –
including a total of 4357 patients – were performed in the
postoperative setting and compared surgery to surgery + che-
motherapy. The drugs used were heterogeneous, as were the
doses, and overall no benefit on overall survival was shown.
The analysis was refined on the basis of the heterogeneity be-
tween categories of regimen used, and that was statistically
significant. Therefore, chemotherapy regimens were grouped
into three categories: (1) long-term alkylating agents, (2) other
drugs, and (3) cisplatin-based. No heterogeneity was found
within each category, and a separate meta-analysis was per-
formed for each of the three groups. The hazard ratios (HRs)
of death showed differences among the groups, already sug-
gesting that the choice of chemotherapy was important: (1)
long-term alkylating agents: HR 1.15 (1.04–2.20), P 0.005; (2)
other drugs: HR 0.89 (0.72–1.11) P 0.30; and (3) cisplatin-based:
HR 0.87 (0.74–1.02) P 0.08.
These initial results showed a highly significant detrimen-
tal effect of long-term alkylating agents, with a 15% increase
in the risk of death from alkylating agents. On the contrary, in
the cisplatin-containing regimen group, the benefit, although
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not significant, showed a 13% reduction in the risk of death,
translating into an improved 5% survival at 5 years; however,
this survival benefit was not significant, and in practice cis-
platin-based adjuvant chemotherapy is not a standard of care
for resected NSCLC at this time.
Based on the results of the meta-analysis, further random-
ised trials were performed taking advantage of the ‘‘signal’’
seen earlier with cisplatin-based chemotherapy.
3. Evolution of the concept of adjuvant
chemotherapy for resected NSCLC
After the initial meta-analysis of adjuvant chemotherapy in
resected NSCLC by the Non-Small Cell Lung Cancer Collabora-
tive Group, additional randomised trials were performed and
meta-analysed by Hotta and other Japanese investigators [2].
This second meta-analysis included 11 trials with a total of
5716 patients, performed in Japan but also in the rest of the
world. Among these randomised trials six had UFT, an oral
fluoropyrimidinewidely used in Japan, either as a single agent
or in combination with cisplatin. The remaining five were
more in agreement with what is used in the western world,
including etoposide, mitomycin C, vindesine, vinorelbine or
vinblastine in combination with cisplatin. Sample sizes were
sometime small, trials having 100 patients or fewer. Most of
these trials individually showed no significant benefit on the
5-year survival rate, but overall the meta-analysis obtained
an HR of 0.87 at a significant P value of 0.001. When only
the cisplatin-containing regimens were considered, the HR
was 0.89 with a P value of 0.012. In Japanese patients treated
in UFT single-agent trials, the risk of death was reduced by
20% (HR 0.799, P value 0.015).
Additional trials based on platinum-containing regimens
have also been performed in the western world and will be
summarised individually below.
3.1. IALT
The International Adjuvant Lung Cancer Trial (IALT) Collabo-
rative Group [3,4] conducted a pragmatic randomised trial,
started in 1995, evaluating the impact of a cisplatin-based
chemotherapy in resected NSCLC (stages I–III according to
the 1986 AJCC classification). The experimental arm offered
three or four cycles of various cisplatin-containing regimens
to be compared by observation. Companion drugs associated
with cisplatin included one of four drugs (vindesine, vinblas-
tine, vinorelbine or etoposide), the dose of cisplatin was left to
the discretion of each centre (ranging from 80 to 120 mg/m2),
as was the number of cycles (three or four) or the use of adju-
vant radiotherapy. A total of 14 regimens were therefore pos-
sible. The trial was planned for 3300 patients, but it
discontinued early with 1867 patients because of low accrual
due to the emergence and recent results of neoadjuvant che-
motherapy. The most frequent chemotherapy regimens used
(in 76% of patients) were cisplatin–etoposide and cisplatin–
vinorelbine. Additional radiation was delivered in 20–25% of
patients. The patient population included 36% stage I (10%
IA), 24% stage II and 40% stage III. At the date of publication
[3], after a median follow-up of 56 months, a significant over-
all survival benefit was seen with a 14% reduction in the risk
of death and a P value of 0.03, translating into a 4.1% survival
benefit at 5 years. No subgroup analysis was reported, but G.
Strauss [4] in a separate paper concluded that only stage III
patients were benefiting from adjuvant chemotherapy.
The results of IALTwere later updated in 2010 [5]. The ini-
tial benefit seen with a median follow-up of 56 months was
not confirmed when more events were observed after a med-
ian of 7.5 years of follow-up. The HR for overall survival
moved up from 0.86 to 0.91, with a no-longer-significant P va-
lue of 0.10. The analysis of the cause of death showed a slight
increase in non-cancer-related death in the chemotherapy
arm, possibly reflecting long-term adverse effects of adjuvant
chemotherapy (HR 1.36, P value 0.06), the incidence of local
recurrences or distant metastases remaining lower in the
adjuvant chemotherapy population. This emphasises the
need for a sufficiently long follow-up for adjuvant trials.
3.2. Big Lung Trial
The Big Lung Trial [5,6] was a pragmatic, UK-based trial to
evaluate the impact of cisplatin-containing chemotherapy in
NSCLC in all settings: early, locally advanced and metastatic.
In the adjuvant situation, cisplatin could be combined
with several drugs, including mitomycin–ifosfamide (MIC),
mitomycin–vinblastine (MVP), vindesine (CV) or vinorelbine
(NP). The trial started in 1995 and stopped in 2001. It accrued
in the surgical setting only 381 patients out of 1394 planned. It
is therefore difficult to draw conclusions from such a small
sample size. With a median follow-up of 35 months the HR
of 1.02 (P value 0.90) showed no benefit at all.
3.3. ALPI
The Adjuvant Lung Project Italy (ALPI) [6] along with the Euro-
pean Organisation for Research and Treatment of Cancer
(EORTC) performed an adjuvant chemotherapy trial in re-
sected stages I, II and III (UICC/AJCC 1986) NSCLC. Surgery fol-
lowed by adjuvant chemotherapy with mitomycin, vindesine
and cisplatin (MVP) was compared with surgery alone. Three
cycles of chemotherapy were planned after randomisation.
The study accrued 1209 patients between January 1994 and
January 1999. After a median follow-up of 65 months, the
overall survival HR was 0.96 (P = 0.589), showing no benefit
from adjuvant chemotherapy. This negative trial had several
weaknesses: 108 patients from a single centre were excluded
from the analysis, only 69% of randomised patients received
the three planned cycles of chemotherapy and half of them
required dose reduction. The toxicity of MVP was prohibitive
with an excess of toxic death during the first year. However,
even though the study was negative, the 3.4% overall survival
benefit at 5 years was not that different from that of the IALT
(4.1%).
3.4. CALGB 9633
In the United States, CALGB 9633 [7,8] evaluated the use of
three or four cycles of paclitaxel–carboplatin in the adjuvant
setting for resected stage IB only (T2N0 TNM 6 classification).
This study planned to accrue 500 patients starting in Septem-
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ber 1995, but stopped at 344 in November 2003. Results were
presented first at ASCO 2004 [7] with 34 months of follow-
up, and full mature data were published in 2008 [8] with a
median follow-up of 74 months. At the initial ASCO 2004 pre-
sentation, the outcome was in favour of adjuvant paclitaxel–
carboplatin, with an overall survival HR of 0.62 (P = 0.028) and
a 4-year survival rate of 71% versus 59% in the control arm.
This was the first study to demonstrate a benefit in early stage
IB. However, the updated publication with a much longer fol-
low-up did not confirm the initial, preliminary results. With
time and more events, the overall survival HR went up to
0.83 (P = 0.12), a 2% improvement on the 5 year-survival rate.
Similarly, as seen in the IALT discussed above, in CALGB
9633 the benefit of adjuvant faded with time and emphasised
the need for prolonged follow-up to establish the proof of
benefit in adjuvant setting.
Interestingly enough, a subgroup exploratory analysis was
performed in CALGB 9633 according to tumour size P or
<4 cm [8]. In the updated analysis with a 74 month follow-
up the overall survival in stage IB was not improved in the in-
tent-to-treat population, but an overall survival benefit was
seen for patients with a tumour P4 cm with an HR of
death = 0.69 and a P value = 0.043, a median overall survival
of 99 months compared with 77 months in the surgery only
arm. On disease-free survival the magnitude of the benefit
was similar for tumoursP4 cm. These data support the adju-
vant use of paclitaxel–carboplatin in patients with resected
stage pIB P4 cm NSCLC.
3.5. NCIC JBR 10
From July 1994 to April 2001, the National Cancer Institute of
the Canada Clinical Trials Group (NCIC-CTG) [9,10] accrued
482 NSCLC patients in the JBR-10 phase III randomised trial
of adjuvant cisplatin–vinorelbine versus surgery alone for R0
resected stages pIB (45%) and pII (except T3N0, TNM 6 classi-
fication). Patients were randomised to receive four cycles of
cisplatin–vinorelbine over 16 weeks in the chemotherapy
arm versus observation in the control arm. The results were
published after median follow-up of 5.1 years [9] and updated
after 9.3 years.
Overall survival was improved after 5 years of follow-up
with an HR of death of 0.69, P = 0.009, reflecting a 15% benefit
at 5 years (69 versus 54%) and medians of 94 versus
73 months. Similarly, disease-free survival was extended in
the chemotherapy group (HR 0.60, P < 0.001). The updated sur-
vival data after 9.3 years showed that the benefit was pre-
served with time with an HR of death = 0.78 (P = 0.04) [10].
Subgroup analysis according to stage IB versus II did not show
a statistically significant benefit in stage IB. The benefit was
restricted to stage II (HR 0.59, P = 0.004). In the updated anal-
ysis with 9.3 years of follow-up, similar findings were re-
ported. Based on the tumour size effect reported in CALGB
9633, this parameter was examined in JBR-10 with a cut-off
value of 4 cm in stage IB. Similarly, in JBR-10 a difference
was noted, with a potential detrimental effect of adjuvant cis-
platin–vinorelbine in stage IB <4 cm (HR 1.73, P = 0.56) and a
potential benefit in tumours P4 cm (HR 0.66, P = 0.133).
In an attempt to find a predictive biomarker of efficacy, the
RAS mutational status (including H, N and KRAS) was evalu-
ated in 451/482 patients. Ras mutational status was not asso-
ciated with a differential effect of chemotherapy.
Chemotherapy compliance in JBR-10 showed that 45% of
patients randomised to cisplatin–vinorelbine received the
planned four cycles, 55% three cycles and 64% two cycles.
The median number of delivered cycles was three. The most
frequent adverse event was neutropenia. Dose of vinorelbine
was reduced from 30 to 25 mg/m2 weekly after 18 patients
were treated initially.
The JBR-10 trial established the benefit of adjuvant cis-
platin–vinorelbine (the first third-generation drug combined
with cisplatin) in stage II R0 resected NSCLC, and possibly in
stage IB P4 cm.
3.6. ANITA 1
ANITA (Adjuvant Navelbine International Trialists Associa-
tion) [11] is an international randomised phase III trial evalu-
ating on overall survival the benefit of 4 cycles of cisplatin–
vinorelbine in R0 resected p stages IB (T2N0), II and IIIA
NSCLC (TNM 6). From December 1994 to December 2000, a to-
tal of 840 patients were accrued, with 407 randomised to che-
motherapy. The use of adjuvant radiation therapy – after
surgery in the control arm or after chemotherapy in the
experimental arm – was allowed, neither randomised nor
mandatory but left to the decision of the investigators.
With a median follow-up of 70 months, the primary overall
survival end-point was met on the intent-to-treat population
(HR of death 0.79, P = 0.013), a benefit of 8.6% at 5 years con-
firmed at 7 years. Relapse-free survival was also significantly
improved (HR of relapse 0.76, P = 0.002). No difference was
seen with the surgery alone arm in stage IB (62% versus 64%
survival at 5 years). The benefit was actually restricted to
stages II and IIIA. In stage II, the 5-year survival rates were
52% versus 39% in the chemotherapy arm versus control
arm respectively (HR of death 0.71), in stage IIIA 42% versus
26% (HR of death 0.69). These results do not allow a definitive
conclusion, however, since the test of interaction was not sig-
nificant and no P values were calculated. The impact of the N
stage was reported independently of T stage: for pN0 patients
median overall survival was 99.6 versus 95.5 months in the
control arm and chemotherapy arm respectively. In patients
with pN1 disease, median overall survivals were respectively
31.2 versus 65.7 months in favour of adjuvant chemotherapy
and 20 versus 32.6 months in patients with pN2 stages. No
conclusion can be reached from adjuvant radiation since its
use was not randomised, but it showed a potential detrimen-
tal effect in pN1 disease after adjuvant chemotherapy and a
benefit in pN2 disease [12]. This will have to be confirmed in
a clinical trial, presently ongoing, and will be discussed
elsewhere.
Chemotherapy compliance, similar to the results of JBR10,
showed that 73% of patients received two cycles, 61% three
cycles and 50% the planned four cycles, with a relative dose
intensity of 59% for vinorelbine and 89% for cisplatin, reflect-
ing the toxicity of the regimen with 85% grade 3–4 neutrope-
nia and 9% febrile neutropenia.
The ANITA trial established the value of adjuvant cis-
platin–vinorelbine (the first third-generation drug combined
with cisplatin) in stage II and IIIA R0 resected NSCLC.
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Within the LACE, a subgroup analysiswasperformedonpa-
tientswho received the vinorelbine–cisplatin chemotherapy in
theadjuvantsetting fromJBR10,ANITA, IALTandBLT, fora total
of 1888 patients [13]. Overall, the survival benefit was 8.9% at
5 years (HR of death 0.80, P < 0.001). Stagewas a significant pre-
dictor of efficacy on 5-year survival: 14.7% in stage III, 11.6% in
stage II andonly 1.8% in stage I. These resultswere significantly
superior to other cisplatin-based combination chemotherapy
regimens used in the LACE meta-analysis (P = 0.04).
4. The impact of adjuvant chemotherapy on
special populations
4.1. Adjuvant chemotherapy in elderly patients
The use of adjuvant chemotherapy may be an issue in clinical
practice since the life expectancy is increasing and medical
progress allows resection in the elderly population, including
for NSCLC.
The JBR.10 investigators have reported the results of their
trial on elderly patients, with a cut-off age set at P65 years,
and comparedwith patients <65 years old [14]. The two groups
differed significantly in terms of histology (more adenocarci-
noma in the younger group) and performance status (more
PS = 0 in the younger group). The benefit of adjuvant cis-
platin–vinorelbine on overall survival, reported for the overall
population, was also seen in the elderly,P65 years old (HR of
death 0.61, P = 0.04). Elderly patients significantly received few-
er doses of cisplatin and vinorelbine, and the dose intensity
was significantly reduced as well. No differences in toxicity
were observed. According to this analysis, adjuvant cisplatin–
vinorelbine seems feasible in patientsP65 years old.
Addressing the same question of the effect of age on cis-
platin-based adjuvant chemotherapy, the LACE group com-
pared the overall survival of three groups according to age
(<65, 65–69, >70 years old) [15]. The HRs of death were 0.86 for
<65-year-olds, 1.01 for the mid category (65–69 years old), and
0.90 in the oldest patients (>70). The test for trend was not sig-
nificant and the LACE concluded that ‘‘chemotherapy should
not be withheld from the elderly purely on the basis of age’’.
Similar to JBR.10, lowerdoses of cisplatinand fewer cycleswere
delivered in the elderly. No differences in toxicity were
observed.
Based on these two reports, adjuvant cisplatin-based che-
motherapy seems feasible in elderly patients and provides a
survival benefit with acceptable tolerance.
Age is not the only parameter to consider in practice,
however, and patients from clinical trials with strict inclu-
sion criteria are not always reflecting the general practice
population. Decisions should also take into account perfor-
mance status, comorbidities, compliance issues and patient
willingness.
4.2. Japanese population
In Japan, as opposed to the Western world or other Asian
countries, fluoropyrimidines are widely used to treat NSCLC.
UFT, an oral fluoropyrimidine – either as a single agent or in
combination with cisplatin – has been evaluated in random-
ised clinical trials for the adjuvant treatment of resected
NSCLC versus surgery alone. Those trials have been meta-
analysed. In the meta-analysis by Hamada et al. [16], individ-
ual patient data were collected. Among nine trials, six com-
pared surgery versus surgery + UFT; two had a third arm
with cisplatin-containing chemotherapy, but the patients for
the third arm were not meta-analysed. Most of the patients
presented with adenocarcinoma and early stage I disease.
They were treated for a period of 1–2 years with oral UFT. In
this selected population of 2003 patients, the use of UFT post-
operatively showed a significant benefit at 5 and 7 years com-
paredwith surgery alone (respectively +4.3% and +7%) with an
HR of death of 0.74 (P = 0.001).
Another Japanese meta-analysis – based on published data
of adjuvant trials performed worldwide since 1995 – included
11 trials among which six were UFT-based [2]. A separate
analysis of the UFT-containing regimen was provided. Most
of the trials were not statistically significant due to small
sample sizes. The use of UFT as a single agent on 1751 pa-
tients showed a significant benefit with an HR of death of
0.799 (P = 0.015). In the UFT-containing regimen trials the
use of UFTwas prolonged to 1 or 2 years.
The benefit of UFT in adjuvant chemotherapy is so far lim-
ited to Japanese patients since the drug is not used for this
indication outside Japan.
5. Predictive biomarkers of chemotherapy
efficacy in the adjuvant setting
The benefit of adjuvant chemotherapy in NSCLC is still recent.
Very few trials have looked at predictive biomarkers that
would allow better patient selection. The available data are
from retrospective studies with the limitations associated
with such an approach.
5.1. ERCC 1
In 2006, the IALT group reported that the level of expression of
ERCC 1 (excision repair cross-complementation group 1) by
immunohistochemistry was both predictive for the efficacy
of cisplatin-based chemotherapy on survival and prognostic
[17]. In a subsequent study from the LACE biology, looking
at the four protein isoforms of ERCC 1 in the entire population
of the LACE group, with additional antibodies mapping ERCC
1, the predictive effect of ERCC 1 was not validated [18]. Based
on these results, ERCC 1 cannot be recommended at the pres-
ent time to select patients for adjuvant cisplatin-containing
chemotherapy.
5.2. KRAS
In the JBR10 trial [10], KRAS mutational status was assessed
for its potential value as a predictive factor of resistance to
chemotherapy. No differential benefit on overall survival
was noticed between KRAS wild-type and mutant patients.
However, a trend towards a benefit was observed for dis-
ease-specific survival (DSS) with adjuvant cisplatin–vinorel-
bine in the KRAS wild-type patients (HR of DSS 0.72,
P = 0.06), with no benefit in mutant patients.
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The LACE Bio group retrospectively analysed 1543 patients
for their KRAS mutational status on codons 12, 13 and 14 [19].
Overall, KRAShasnoprognostic value according to the survival
in the surgery-alone arm. There was also no significant differ-
ence in overall survival according to the KRAS mutational sta-
tus between the control arm and the adjuvant chemotherapy
arm. Looking more specifically at the mutation type, there is
much variability in the effect of adjuvant chemotherapy
among the patients harbouring a codon 12 mutation, none of
them being significant due to the size of the samples. The co-
don 13 mutation was associated with a detrimental effect of
adjuvant chemotherapy (HR of death 5.78, P = 0.002), but this
information would require validation from a larger sample.
At the present time, KRAS should not be used for the deci-
sion for adjuvant chemotherapy in NSCLC.
5.3. Other biomarkers
The LACE Bio group has undertaken an extensive analysis of
biomarkers that could potentially act as predictive factors of
adjuvant chemotherapy efficacy. In addition to ERCC 1 and
KRAS that have been already reported, this search includes
beta-tubuline, mucine, P53, P27, P16, cyclin E, Bax, EGFR
mutation as well as histology and lymphocytic infiltration.
Another approach undertaken by several groups is to look
for a gene signature that would be associated with improved
survival and efficacy of chemotherapy. Several sets of genes
have been identified in retrospective studies, but none so far
has implications in clinical practice.
At the present time, no predictive biomarker has been
identifiedwhich could be used in clinical practice. Much hope,
however, is placed on such tools to better define selected pa-
tients who would benefit from adjuvant chemotherapy.
6. Conclusion
As in other human solid tumours, adjuvant chemotherapy for
resected NSCLC is now part of the standard of care.
It should be offered at all ages in fit patients resected with
stage II and III disease. Stage IB might be discussed, mainly
with tumours of >4 cm in diameter.
Adjuvant chemotherapy in Western countries should be
cisplatin based. Among the companion drugs to be combined
with cisplatin, vinorelbine is the only third-generation drug
that has been evaluated and that has demonstrated durable
long-termefficacy. All the otherdrugs tested – including etopo-
side, vindesine, vinblastine and paclitaxel (combinedwith car-
boplatin) – have finally failed to demonstrate a definitive
efficacy. The other third-generation drugs docetaxel, gemcita-
bine and pemetrexed havenever been evaluated in proper ran-
domised trials with overall survival as the primary endpoint.
Therefore, the only combination to be used in an adjuvant set-
ting for resected NSCLC, on evidence-based medicine, is vino-
relbine–cisplatin. Other compounds – including targeted
agents – with proven efficacy in metastatic settings have not
been evaluated in the adjuvant setting. Anti-EGFR tyrosine ki-
nase inhibitorshave failed todemonstrate abenefit in theadju-
vant setting of EGFR-mutated NSCLC in the JBR 19 randomised
trial. They cannot be recommended for such use.
Metastatic stages and early or locally advanced diseases
have different behaviours. It is known that in other tumour
types, such as colon cancer, regimens with similar efficacy
in stage IV do not translate into similar benefit in earlier
stages. Considering the possibility of cure in the majority of
patients with surgery alone, and the limited benefit of adju-
vant chemotherapy in terms of improved 5-year survival, no
added risk should be taken for the patients in a situation
where the risk/benefit ratio is rather small.
Conflict of interest statement
The author has no conflicts of interest relating to this article.
R E F E R E N C E S
[1] Stewart LA. On behalf of the non-small cell lung cancer
collaborative group. Chemotherapy in non-small cell lung
cancer: a meta-analysis using updated data on individual
patients from 52 randomized clinical trials. BMJ
1995;311:899–909.
[2] Hotta K, Matsuo K, Ueoka H, et al. Role of adjuvant
chemotherapy in patients with resected non-small-cell lung
cancer: reappraisal with a meta-analysis of randomized
control trials. J Clin Oncol 2004;22:3860–7.
[3] The International Adjuvant Lung Cancer Trial Collaborative.
Cisplatin-based adjuvant chemotherapy in patients with
completely resected non-small-cell lung cancer. N Engl J Med
2004;4:351–9.
[4] Strauss GM. Adjuvant chemotherapy of lung cancer:
methodologic issues and therapeutic advances. Hematol
Oncol Clin N Am 2005;19:263–81.
[5] Scagliotti G, Fossati R, Torri V, et al. Randomized study of
adjuvant chemotherapy for completely resected stage I, II or
IIIA non-small cell lung cancer. J Nat Cancer Inst
2003;95:1453–61.
[6] Waller D, Stephens RJ, Gower NH, et al. Chemotherapy for
patients with non-small cell lung cancer: the surgical setting
of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173–82.
[7] Strauss GM, Herndon JE, Maddaus MA, et al. Randomized
clinical trial of adjuvant chemotherapy with paclitaxel and
carboplatin following resection in stage IB non-small cell
lung cancer (NSCLC): report of Cancer and Leukemia Group B
(CALGB) Protocol 9633. J Clin Oncol 2004;22:621S.
[8] Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant
paclitaxel plus carboplatin compared with observation in
stage IB non-small cell lung cancer: CALGB 9633 with the
Cancer and Leukemia Group B, Radiation Therapy Oncology
Group, and North Central Cancer Treatment group study
groups. J Clin Oncol 2008;31:5043–51.
[9] Winton T, Livingston R, Johnson D, et al. Vinorelbine plus
cisplatin versus observation in resected non-small-cell lung
cancer. N Engl J Med 2005;352:2589–97.
[10] Butts CA, Ding K, Deymour L, et al. Randomized phase III
trial of vinorelbine plus cisplatin compared with observation
in completely resected stage IB and II non-small-cell lung
cancer: updated survival analysis of JBR-10. J Clin Oncol
2010;28:29–34.
[11] Douillard JY, Rosell R. De Lena M at al. Adjuvant vinorelbine
plus cisplatin versus observation in patients with completely
resected stage IB–IIIA non-small-cell lung cancer (Adjuvant
Navelbine Trialists Association, ANITA): a randomized
controlled trial. Lancet Oncol 2006;7:719–27.
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 3 1 –1 3 6 135
[12] Douillard J-Y, Rosell R, De Lena M, et al. Impact of post-
operative radiation therapy on survival in patients with
complete resection and stage I, II, IIIA non-small-cell lung
cancer treated with adjuvant chemotherapy: The Adjuvant
Navelbine International Trialist Association (ANITA)
randomized trial. Int J Radiat Oncol Biol Phys
2008;72:695–701.
[13] Douillard J-Y, Tribodet H, Aubert D, et al. Adjuvant cisplatin
and vinorelbine for completely resected non-small cell lung
cancer. Subgroup analysis of the lung adjuvant cisplatin
evaluation. J Thoracic Oncol 2010;5:220–8.
[14] Pepe C, Hasan B, Winton T, et al. Adjuvant vinorebin and
cisplatin in elderly patients: National Cancer Institute of
Canada and Intergroup study JBR.10. J Clin Oncol
2007;15:1553–61.
[15] Fru¨h M, Rolland E, Pignon J-P, et al. Pooled analysis of the
effect of age on adjuvant cisplatin-based chemotherapy for
completely resected non-small cell lung cancer. J Clin Oncol
2008;26:3573–81.
[16] Hamada C, Tanaka F, Otha M, et al. Meta-analysis of post-
operative adjuvant chemotherapy with tegafur-uracil in non-
small-cell lung cancer. J Clin Oncol 2005;23:4999–5006.
[17] Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC 1
in non-small-cell lung cancer and cisplatin-based adjuvant
chemotherapy. N Engl J Med 2006;355:983–91.
[18] Friboulet L, Olaussen KA, Pignon JP, et al. ERCC 1 isoform
expression and DNA repair in non-small-cell lung cancer. N
Engl J Med 2013;368:1101–10.
[19] Shepherd F, Domerg C, Hainaut P, et al. Pooled analysis of the
prognostic and predictive effect of KRAS mutation status and
KRAS mutation subtype in early-stage resected non-small-
cell lung cancer in four trials of adjuvant chemotherapy. J
Clin Oncol 2013;31:2173–81 [published online ahead of print
on April 29th 2013].
136 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 3 1 –1 3 6
Prognostic factors in resected lung carcinomas
Keith M. Kerr a,*, Marianne C. Nicolson b
a Aberdeen University Medical School, Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, UK
b Aberdeen University Medical School, Department of Oncology, Aberdeen Royal Infirmary, Aberdeen, UK
1. Introduction
A prognostic factor is one which determines or is related to
the natural history of a disease, in the absence of disease-
modifying therapy. A literature search provides innumerable
studies purporting to describe such factors prognostic for pa-
tients with lung cancer. The potential significance of virtually
every conceivable histopathological feature and molecular
biomarker has been reported in thousands of studies. Yet in
clinical practice, the only prognostic features which are regu-
larly used in clinical decision-making are the tumour stage
and the patient’s performance status. This paper will address
prognostic factors which are features of the tumour, relating
to surgically resected lung cancer. It will not discuss those
features of the individual patient which have prognostic sig-
nificance related to the outcome.
The potential value of efficient prognostication in this par-
ticular clinical setting is to enable appropriate selection of pa-
tients for adjuvant therapy, determining who should benefit
from systemic therapy, with that benefit likely to outweigh
potential toxicity. To a lesser extent, knowledge of a prognos-
tic factor before surgery may influence the type or extent of
surgery which is carried out, but related practice change is
still under trial. Adjuvant treatment is aimed at eliminating
clinically undetectable micro-metastatic disease which, if
present, may be responsible for tumour relapse. Prognostic
factors are therefore predictors of a higher or lower probabil-
ity of disease relapse and indicators of the likelihood that the
surgery alone has cured the patient. Adjuvant therapy is
therefore speculative.
Currently, adjuvant cytotoxic chemotherapy is offered to
patients with pathological Stage II–III non-small-cell lung car-
cinoma (NSCLC) and reduces the risk of death by approxi-
mately 20% [1]. Trials have demonstrated that surgery
effectively cures 64% of patients with p-Stage 1B disease
and 39% and 26% respectively of patients with p-Stage II
and III disease. Only an additional 3% of p-Stage 1B patients,
and 10%/13% respectively of p-Stage II/III patients, will be
alive as a result of adjuvant chemotherapy. Adjuvant chemo-
therapy in p-Stage 1B patients cannot be justified by this
modest gain in survival [1–3]. Despite adjuvant chemother-
apy, 33% of p-Stage IB, 51% of p-Stage II and 61% of p-Stage
III patients succumb to recurrent disease.
The implication of these figures is that current decision-
making should be improved to optimise whom and how to
treat in the adjuvant setting. Prognostic factors that predict
more accurately for postoperative disease relapse could im-
prove selection of those patients most likely to benefit from
adjuvant chemotherapy and – equally importantly – where
it should be avoided. Factors that predict for effectiveness of
individual drugs, which are outside the scope of this review,
could be used to decide how to select chemotherapy for those
who need adjuvant treatment.
1.1. Tumour stage
Tumour stage, a description of the extent of disease, is the
only tumour-related prognostic factor regularly used to in-
form treatment decisions in patients with lung cancer. The
latest iteration of the TNM (tumour, nodes and metastasis)
system, the 7th edition, is the culmination of over 80 years
of historical development and over 10 years of focused project
work by the International Association for the Study of Lung
Cancer (IASLC) [4]. This work is a ‘tour de force’ that evaluates
a large amount of emerging data, changes in imaging, thera-
peutic approach and tumour biology, and conflicts between
the need for retrospective compatibility with earlier systems
and the requirement for better separation of prognostically
divergent groups. The project involved analysis of more than
80,000 resected lung cancers, over 68,000 of which were
NSCLCs. It amalgamated many international databases, but
over half of the cases originated from Europe. Rigorous statis-
tical analysis was applied to the database to produce robust
data for all lung cancers, including evidence to support use
of the TNM staging system in bronchopulmonary carcinoid
tumours and small-cell lung cancer [5–12].
In contrast with the TNM 6th edition, the new TNM 7th
edition shows better separation of the Kaplan–Meier survival
curves for both clinical and pathological staging [8]. The main
changes are (a) the introduction of additional cut-offs of
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tumour size to refine T-status, (b) movement of tumours
>7 cm in diameter from T2 into the T3 category, (c) change
in the way additional pulmonary nodules influence T/M sta-
tus, generally recognising that this is of lesser danger to the
patient than previously thought, (d) reclassification of pleural
effusion as an M descriptor and (e) reassignment of some
T&N combinations to different stages (Table 1). The previ-
ously recognised differences in prognosis related to tumour
stage are clarified, with 5-year survival ranging from 73% in
resected pathological stage IA disease to around 10% for stage
IIIB/IV disease.
It is clear that pathological assessment of tumour stage in
the surgically resected case is at least equally important as is
full histological typing of the tumour [12] (see below). In order
to facilitate an accurate assessment of a submitted specimen,
there is an onus upon the surgeon to communicate all rele-
vant information to the pathologist. Important factors in-
clude anatomical labelling of all specimens, especially
lymph-node samples; details of surgery performed, especially
if non-standard surgery has been performed, to help assist
the assessment of margins; and information regarding any
neo-adjuvant therapy delivered. There is also a duty for the
pathologist to prepare properly the specimens in advance of
dissection, examination and block-taking since these latter
steps are key to determining adequate histological examina-
tion and pathological staging. Inflation fixation of resected
lung bearing tumour is, in the authors’ view, a critical step
in preparation. Usually this involves per-bronchial instillation
of 10% neutral buffered formalin until the lobe or lung is fully
inflated with a smooth pleura. Sub-lobar resections may be
inflated by injection. Although some pathologists prefer sec-
tioning down the bronchi, especially for central bronchial tu-
mours, parasagittal sectioning (the authors’ preference) or
coronal sections give a better view of the parenchyma, and
facilitates both examination of peripheral tumours and corre-
lation with radiology.
1.2. Pathological assessment of lymph nodes
It is clearly important to assess intrapulmonary, hilar and
mediastinal lymph nodes submitted by the surgeon at the
time of lung resection for primary carcinoma, since nodal sta-
tus is a crucial factor in pathological staging. There is, how-
ever, debate in the surgical literature regarding how to deal
with the mediastinal nodes at thoracotomy, with inspection,
node sampling or radical dissection of all tissues at each sta-
tion location being the three widely different options [13]. Im-
proved staging, better local disease control and improved
disease-free survival from more extensive surgery must be
set against longer operation times, increased morbidity and
no proven overall survival benefit. The concept of sentinel
node sampling, a procedure common in the surgical manage-
ment of other tumour sites, is poorly developed in the lung
[14]. The European Society of Thoracic Surgeons guidelines
recommend systematic nodal dissection, to include at least
three N1 nodes (inter-lobal and hilar) and three nodes from
three stations, including the sub-carinal station, in the medi-
astinum [15]. There is evidence that the number of lymph
nodes resected, the number that is positive for tumour and
the percentage of resected nodes which are positive have an
influence on postoperative outcome [16–18]. Greater clarity
is required around these data and the significance of the
number of positive lymph node stations, given that true sin-
gle-stationmediastinal lymph-nodemetastases seem to carry
a more favourable prognosis [19,20]. There are practical diffi-
culties relating to assessing lymph node number if nodal frag-
ments rather than whole nodes are delivered to pathology.
There is also evidence that inadequate pathological examina-
tion may underestimate the degree of nodal involvement
[21,22].
Does the degree of nodal involvement matter? Although it
is traditionally taught that extracapsular spread of tumour
from mediastinal nodes is a poor prognostic factor, some
studies have failed to demonstrate a survival disadvantage
[23], raising the possibility that this opinion is probably based
on assumption rather than on hard data, especially since
such spread may render the disease unresectable, rendering
information incomplete.
There has been considerably more debate regarding the
significance of micrometastatic disease in lymph nodes in pa-
tients with surgically resected NSCLC. The fact that a propor-
tion of patients with pStage I (N0) disease relapse and die of
tumour recurrence fuels a presumption of undetected micro-
metastatic disease at the time of surgery. Micrometastatic
disease has no clear definition in the context of lung cancer,
unlike in some other tumours such as breast cancer where
nodal tumour deposits of <2 mm are regarded as micrometas-
tases. Metastatic disease comprising only a few tumour cells
may not be apparent on the standard haematoxylin-and-eo-
sin-(H&E-)stained sections but could be detected on immuno-
histochemistry (IHC) [24]. Various strategies have been
employed to detect micrometastases, usually involving
immunohistochemistry with or without multiple step-sec-
tioning of lymph nodes [25,26]. Most immunohistochemistry
Table 1 – Median and five-year survivals (5YS) by stage in resected non-small-cell lung cancer under TNM7 [8].
Stage Clinical staging (cStage) Pathological staging (pStage)
Median survival (months) Five-year survival (%) Median survival (months) Five-year survival (%)
IA 60 50 119 73
IB 43 43 81 58
IIA 34 36 49 46
IIB 18 25 31 36
IIIA 14 19 22 24
IIIB 10 7 13 9
IV 6 2 17 13
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has used antibodies to a variety of cytokeratins, but p53 and
Ber-EP4 proteins have also been sought [24]. More recently,
studies have utilised reverse transcription polymerase chain
reactions (RT-PCRs) for a variety of mRNA transcripts of
numerous genes, including mucin1, carcinoembryonic antigen
(CEA), p53, KRAS, FHIT, CDKN2A, survivin and livin [24,27,28].
These markers are presumed to be sufficiently specific and
sensitive to detect metastases of any size.
The outcome of these studies will depend on the adequacy
of the ‘standard’ H&E-based initial assessment which deter-
mined N0 status. None of the IHC markers used is specific
for tumour cells, and benign intra-nodal inclusions present
the risk of a false-positive test. The same lack of specificity
applies to most (possibly all) of the mRNA-based studies,
although more recent work has used markers which are more
specific [27]. Other issues with PCR studies include the
following:
• The presence of mRNA does not necessarily mean that
tumour cells are present, only that macromolecules have
been detected.
• Studies have been based upon the homogenisation and
mRNA extraction from fresh/frozen lymph nodes; whilst
other nodes from the same location have been deemed
negative for metastatses, it is an open question as to
whether those homogenised nodes would have been his-
tologically negative if examined in that way.
• There are practical implications in basing a routine test on
fresh, frozen material; however, mRNA from formalin-
fixed, paraffin-embedded tissue can be obtained and
amplified.
Whatever the pros and cons of the technical approach, it is
the outcome that ultimately matters. Can these techniques
upstage – in a clinically significant way – patients otherwise
regarded as having pN0 disease? Such studies are prone to
reporting bias, with several using a range of approaches
‘upstaging’ 20–30% of patients who were considered to be
pN0. It has been suggested that upstaging to pN1 may not
be clinically significant, unlike upstaging to pN2 [25]. A very
detailed original study of over 4000 lymph nodes from 266
Stage I resections, plus a meta-analysis of published work
up to 2008, demonstrated that identified micrometastatic dis-
ease did not significantly decrease postoperative survival [29].
Subsequent publications, however, based upon mRNA PCR,
continue to report significantly poorer postoperative survival
in patients who are pN0 by histological examination but
molecularly N1 or 2 on those nodes examined by PCR
[27,28,30]. Notwithstanding the many technical issues around
this approach to detect metastatic disease, and the biological
significance of the findings, there is still a lack of trial evi-
dence that patients would benefit from adjuvant therapy
based upon a molecular upstaging of their tumour.
1.3. Bronchial resection margins
The status of the bronchial resection margin assessed in the
resected specimen has been a matter of some controversy,
and it is difficult to analyse due to limited and heterogeneous
data. The presence of macroscopic disease at the resection
margin (R2) is a poor prognostic factor [31]. R1 disease is also
a poor prognostic factor although there are variables which
need to be considered: the presence of extrachondral disease
at the margin, or lymphangitis carcinomatosa, seems to be
particularly poor prognostic factors, as both are associated
with N2 disease [32–34]. Invasive disease within the mucosa
also determines an R1 resection but may indicate a slightly
smaller risk of recurrence, especially in the context of Stage
I/II disease [32,34]. The significance of carcinoma in situ at
the bronchial resection margin is less clear [33,34]. Unless
the disease is extensive and involving bronchial glands as
well as the mucosal surface [33], there may be insufficient risk
of recurrence to warrant any further therapy [32,34].
2. Tumour histology
Although there is an extensive literature on the subject of tu-
mour histology and prognosis, some studies lack statistical
power, and it is difficult to determine whether any factor is
significant in multivariate analysis, especially in controlling
for Stage and rare tumour types. The use of neo-adjuvant or
adjuvant therapy may also bias the outcomes of analyses.
2.1. Squamous versus adenocarcinoma
Is there a significant difference in postoperative survival be-
tween squamous-cell carcinoma and adenocarcinoma when
controlling for Stage? Even this simple question provides is-
sues to debate, but the probable answer is either ‘very little’
or ‘no difference’ (Table 2). A large German series of 2376
cases found squamous-cell carcinoma patients had a better
5-year survival (5YS) than adenocarcinoma: 53.6% compared
with 48.2% [35]. A Japanese Lung Cancer Registry study of
13,010 cases found the opposite: 5YS for squamous carcino-
mas was surprisingly similar to that of the German study at
52.5%, but the 5YS for all adenocarcinomas was significantly
Table 2 – Five-year survivals (5YS) in resected non-small-cell carcinoma subtypes (all resected stages).
Squamous-cell
carcinoma (%)
Adenocarcinoma
(%)
Large-cell
carcinoma
Adenosquamous
carcinoma
Pfannschmidt et al., 2007 [35] n = 2376 cases 53.6 48.2 45.8 –
Asamura et al., 2008 [36] n = 13,010 cases 52.5 67.3a 45.5 42.1
Chansky et al., 2009 [12] n = 9137 cases 43 44b 41 29
a These cases would include adenocarcinoma in situ (AIS).
b This is the 5YS for adenocarcinomas excluding those diagnosed as ‘BAC’(see text). Given variations in stage distribution and other potential
confounding factors, comparison between cell types within studies are probably more meaningful than those between studies.
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better at 67.3% [36]. The likely explanation for this difference
is the inclusion of significant numbers of cases of adenocarci-
noma in situ or minimally invasive adenocarcinoma in this
cohort (see Types of adenocarcinoma, below). These lesions are
more common in Japanese studies, and until the publication
of the new IASLC/ERS/ATS recommendations of adenocarci-
noma classification [37] these cases were often classified as
well-differentiated adenocarcinoma. It is now known that
they pose no metastatic risk and show 100% 5YS. In the IASLC
staging study cohort of 9137 cases, cases reported as ‘bronchi-
oloalveolar carcinoma’ (BAC) were separated out from other
adenocarcinomas and showed a 5YS of only 61%. The low fig-
ure suggests that this was still a pathologically heterogeneous
group, comprising true ‘BAC’ i.e. adenocarcinomas in situ,
and other invasive adenocarcinomas incorrectly classified as
BAC (see below). The effect of this separation was to leave
the non-BAC adenocarcinoma group with a 5YS of 44%, not
significantly different from the 43% 5YS for squamous-cell
carcinomas [12].
2.2. Types of squamous-cell carcinoma
The WHO classification of lung tumours [38] describes a pap-
illary variant of squamous-cell carcinoma that generally has a
good prognosis, probably because it demonstrates limited
invasion and tends to be of low stage. Similarly, so-called
‘creeping’ squamous-cell carcinoma [39], an invasive tumour
confined to the mucosa, demonstrates relatively indolent
biology and a relatively good prognosis. Peripherally located
squamous-cell carcinoma, arising from third-order or greater
bronchi, may be increasing in prevalence. The growth pattern
of these tumours may be infiltrative and destructive or non-
infiltrative with preservation of lung architecture, the so-
called alveolar filling growth pattern [40–42]. When this latter
pattern is prominent, tumours tend to be of lower stage, show
less vascular invasion (see below), and patients survive for
longer [40–42]. Despite the relatively poor prognosis demon-
strated by basaloid carcinoma (see Other histological types, be-
low), the basaloid variant of squamous-cell carcinoma has
been shown to be no more aggressive than poorly differenti-
ated squamous-cell carcinoma [43,44].
2.3. Types of adenocarcinoma
The proposed changes in adenocarcinoma reporting and clas-
sification for surgically resected cases – authored by a multi-
disciplinary group of experts representing the IASLC, the
European Respiratory Society (ERS) and the American Tho-
racic Society (ATS) – are largely based upon significant differ-
ences in prognosis demonstrated by different histological
subtypes of adenocarcinoma [37]. This work acknowledged
published descriptions of bronchioloalveolar carcinoma
(BAC) and how that diagnosis is often associated with a better
postoperative outcome. It also noted that there was enor-
mous variation in type of tumour classified as BAC, in many
instances that were clearly not BAC as defined in the 1999
and 2004 WHO classification. This led to the strong recom-
mendation that the use of the term BAC be discontinued; that
cases fulfilling criteria for BAC (small, localised lesions lack-
ing invasion and showing only lepidic growth around alveolar
walls) be reclassified as adenocarcinoma in situ (AIS), since
such lesions pose no metastatic risk and have 100% 5YS
[45], and that other lesions with evidence of invasion be clas-
sified as invasive adenocarcinoma, even if there is widespread
lepidic pattern disease.
In resected invasive adenocarcinomas, the degree of inva-
sion in a lesion which is otherwise AIS with a lepidic growth
pattern may be very limited in extent. Assuming that some
(most?) adenocarcinomas arising in the lung develop in this
way, such lesions would be expected. If the focus of invasion
in such a lesion is <5 mm in maximum diameter, there is still
no metastatic risk and patients have 100% 5YS [46,47]. Such
lesions are classified as minimally invasive adenocarcinomas
(MIAs). If the focus of invasion, characterised by one or more
of the other four invasive adenocarcinoma patterns (acinar,
papillary, micropapillary, solid with mucin), is >5 mm across,
the resected tumour is classified as invasive adenocarcinoma
and a qualifier should be added to the classification when the
report is issued by the pathologist, indicating which pattern
of disease is the predominant one. This is also strongly rec-
ommended because of the notable prognostic effect: several
studies have shown that resected adenocarcinomas with a
predominantly lepidic pattern have a relatively good progno-
sis, independent of stage. Conversely, cases which are pre-
dominantly micropapillary or solid in pattern have a
relatively poor prognosis [48–52]. Some studies show poor
prognosis for papillary predominant disease [50], whilst oth-
ers do not [48], possibly due to differences in interpretation
of the papillary pattern. Although these patterns can be reli-
ably and consistently identified, some are more difficult than
others, notably papillary patterns [53].
2.4. Multiple tumours
The presence of multiple synchronous carcinomas was tradi-
tionally considered a poor prognostic factor for both squa-
mous-cell carcinomas and adenocarcinomas [54],
presumably reflecting intrapulmonary metastases in many
cases. A better understanding of carcinogenesis in these
two distinct tumour types, and recognition that multiple syn-
chronous primary tumours – especially adenocarcinoma – are
not uncommon, has modified this view. Multifocal disease
undoubtedly reflects a biologically heterogeneous group of
cases, making generalisations unhelpful. Unusual cases of
mucinous or non-mucinous multifocal, predominantly lepi-
dic pattern adenocarcinomas (the mucinous form now re-
ferred to as mucinous adenocarcinoma) were formerly
considered to be BAC, despite these cases not fulfilling the
post-1999 definition. Although demonstrating relatively indo-
lent growth behaviour, these tumours carry a relatively good
prognosis, with less propensity to spread widely outside the
thorax, although they are invasive and do represent ad-
vanced, potentially fatal disease.
2.5. Other histological types
Large-cell carcinomas and sarcomatoid carcinomas appear to
be aggressive, often large lesions [38]. Whether the associated
poor prognosis is independent of stage is less clear. In the
large studies presented in Table 2, large-cell carcinomas
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appear to have a consistently and significantly lower 5YS. Sar-
comatoid carcinomas are rare lesions which may or may not
demonstrate components of differentiated squamous-cell or
adenocarcinoma. These tumours are renowned for a poor
prognosis and aggressive behaviour, although published ser-
ies of cases are generally small [55–58]. There are two variants
of large-cell carcinoma which are notable for their poor prog-
nosis: basaloid carcinoma and large-cell neuroendocrine car-
cinoma (LCNEC). Case series of basaloid carcinomas are few,
but data suggest an aggressive tumour, often of high stage
at presentation, and a propensity for brain metastases
[59,60]. LCNEC is a high-grade neuroendocrine carcinoma
sharing many epidemiological and genetic features with
small-cell carcinoma. This is a highly invasive tumour type
prone to widespread metastases [61–63].
2.6. Other histological features
Certain histological features, independent of histological tu-
mour type, have been shown to be independent prognostic fac-
tors. Features such as vascular invasion, lymphatic invasion,
pleural invasion, tumour necrosis and poor differentiation have
beenso reported. Thefirst three featuresare intuitive, andrelate
to key factors in the TNM system which correlate with poor
prognosis.Vascular invasionwithin the tumour isa feature con-
sistently associated with early relapse featuring distant meta-
static disease [64]. Lymphatic invasion is associated with
increased risk of lymph-node metastases [65]. The poor prog-
nostic effect of pleural invasion is reflected in this feature,
upstaging tumours in the TNM classification [66]. Tumour
necrosis is usually associatedwith larger tumours, more poorly
differentiated lesions and greater proliferative activity being
indicative of an aggressive phenotype. Poor differentiation has
long been associated with aggressive tumour behaviour and
most of the other features determining higher tumour stage
[38]. Criteria for grading tumours in this way have been poorly
described and undoubtedly inconsistently applied by patholo-
gists. However, there is increasing interest in tumour grading
as an important factor in lung tumour pathology [67].
Tumour cell proliferation deserves particular consider-
ation. High mitotic activity has long been recognised as an
indicator for the presumption of relatively rapid tumour
growth, and high mitotic indices are certainly associated with
poorly differentiated tumours and tumours which have
recognised aggressive biology (small-cell and large-cell neuro-
endocrine carcinomas). It is also a diagnostic defining feature
for carcinoid versus atypical carcinoid tumour, and de facto, of
large-cell neuroendocrine carcinoma with most assessments
made on resected tumour specimens. This differential diag-
nosis carries recognised prognostic significance [38].
There are several problems in relying upon mitotic index
as an indicator of likely tumour growth rate:
• Mitoses may be difficult to recognise on pathological
specimens.
• The mitotic (M) phase of the cell cycle is relatively short so
may poorly reflect overall cell cycle activity.
• Actual tumour growth is dependent on the balance
between cell production and cell loss, the latter being very
difficult to assess in tumours.
Proteins expressed during part or all of the cell cycle have
been used as proliferation markers, although strictly speaking
they only indicate cell cycle ‘activity’ and do not provide
unequivocal evidence of cell division. These markers include
proliferating cell nuclear antigen (PCNA), Ki67, a variety of the
minichromosomemaintenance proteins (MCMs) and histone-
H3. MCMs may have an advantage over Ki67 in being evenly
expressed throughout all phases of the cell cycle, whereas
Ki67 accumulates later in G1, persisting through S, M and
G2. PCNA has not shown convincing prognostic significance
in NSCLC [68]. By far the greatest literature has been con-
cerned with Ki67 expression in both early, surgically resected
and advanced NSCLC, mostly as measured by the MIB1 anti-
body [68,69]. Two reviews, including publications up until
2006, described 46 reports of Ki67 as a prognostic factor in
NSCLC [68,69], of which only 19 (41%) show ‘over-expression’
of Ki67 as a poor prognostic marker. Most found no indepen-
dent effect on prognosis.
Actual tumour growth rates may be derived from preoper-
ative imaging measurements and expressed as a volume dou-
bling time (vDT) [70,71]. This parameter has been related to
postoperative survival, some studies demonstrating an asso-
ciation between short vDT and poorer prognosis, although
the relationship is not clear cut [72–74]. vDT is also used as
a factor in predicting malignancy during nodule follow-up, of-
ten in the context of lung cancer screening [74,75].
3. Tumour molecular pathology
There is probably more literature on the putative prognostic
effects of molecular markers in lung cancer than exists for
other prognostic features in this disease. This is not surpris-
ing since molecular changes are the fundamental factors
driving each tumour, making it behave in a unique way.
Molecular markers are perceived to be more objective assess-
ments than are some other pathological features. They are
also considered to be more easily measured, numerous and
to possess ‘scientific’ and ‘topical’ cache.
Studies have ranged from single marker investigations to
pan-genomic works using a variety of approaches. Comparing
studies of the more commonly investigated biomarkers is
hampered by enormous heterogeneity of study design, varia-
tion in techniques, case mix and interpretation of data. Con-
tradictory conclusions are frequently drawn, and perhaps
because of this – and despite the enormous amount of data
available – there is not a single molecular prognostic bio-
marker in regular clinical use for managing patients with lung
cancer. A review of the topic in 1995 identified this issue and
proposed trials of biomarkers in selecting patients for adju-
vant therapy on the basis of claimed prognostic significance
[76]. To date, very little progress has been made. It is only re-
cently that mRNA-based gene signatures have been seriously
investigated in this context (see below).‘Single gene’ studies
have tended to use immunohistochemistry (IHC) to identify
the protein product of the gene(s) of interest, although there
are many studies looking at gene mutation, fusion or amplifi-
cation using a variety of techniques. Gene transcription prod-
ucts (mRNA) have also been used, either for specific genes or
using a more global approach using array techniques. Global
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genetic studies looking for mutations, or gains and losses
using comparative genomic hybridisation (CGH), are now fre-
quent, although they have been less often studied from a
prognostic perspective.
One of the most critical issues regarding tumour biomark-
ers concerns methodology. Techniques for carrying out the
test, the reagents used, methods used to score/quantify the
result, the analysis and interpretation of the results are all
critical yet prone to variability and error. Some are more sub-
jective than others; many are simple and readily available,
others are complex, expensive and less accessible. Complex-
ity does not guarantee accuracy, greater reliability or rele-
vance. In terms of biomarker testing of tumour samples, the
handling and processing of the tissues prior to testing are of
critical importance yet difficult to standardise, but these fac-
tors are often ignored or overlooked [77,78].
A comprehensive review of prognostic biomarkers in lung
cancer is beyond the scope of this article, but there follows a
selective commentary on some important issues.
3.1. Immunohistochemistry
Following others’ methodology in reviewing the literature
[79], in 2006 Zhu and colleagues published an excellent and
extensive review of 462 original papers and 12 reviews on
immunohistochemical markers of prognosis in NSCLC pub-
lished between 1987 and 2005 [68]. These studies focused
mainly on resected NSCLC. Their data were helpfully grouped
according to Hanahan and Weinberg’s original six hallmarks
of cancer [80] and accounted for 50 different markers. They
identified five markers (EGFR, HER2, Ki67, p53 and bcl2) which
had been extensively studied and were the focus of meta-
analyses. For Ki67 and p53, higher levels of expression
showed a weak but significant poor prognostic effect whilst
high bcl2 showed a weak but significant poor prognostic ef-
fect. The authors suggested that ‘over-expression’ of cyclinE
and VEGF, and p16, p27 and beta-catenin, were ‘promising’
as poor and good prognostic factors respectively. They also
highlighted hepatocyte growth factor (HGF) and MET as
potentially important, given in vitro data. Only MET has sub-
sequently emerged as being clinically relevant due to its pro-
viding a therapeutic target and predictive factor rather than
being a poor prognostic factor [81]. One of the most telling as-
pects in the review of Zhu et al. is that for almost every mar-
ker that is the subject of more than two publications, the
prognostic effect claimed by some is absent in others. On oc-
casion there are studies claiming good, poor and no prognos-
tic effect for the same marker [68]. The authors highlight the
differences in use of antibodies and definitions of over-
expression as the probable explanation for such variation in
outcome and emphasise the need for a consistent, planned
approach to execution of such studies.
A more recent review of 111 reports took a very similar ap-
proach to that of Zhu et al. but concentrated on biomarkers
relating to three of the six hallmarks of cancer: cell cycle
activity, apoptosis and angiogenesis [82]. The authors’ conclu-
sions were similar, in that cyclin E, VEGF, p27 and p16 showed
some prognostic effect, although bcl2 did not. Cyclin B1, p21,
survivin and collagen VIII were also identified to have suffi-
cient potential as independent predictors of patient outcome.
The potential for use of combined panels of markers as prog-
nostic predictors was also emphasised in this review.
The plethora of literature and inconsistency of data were
highlighted in a further review [83] which also suggested that,
given the molecular heterogeneity of lung cancer, it was unli-
kely that a single marker would emerge as universally useful.
Essentially this is true, although a decision to treat or not
could be based upon a simple binary evaluation of a reliable
marker at a certain threshold, including patients with no
expression. Such a marker has yet to emerge. Meta-analyses
have suggested that TTF1 is a good prognostic factor in re-
sected adenocarcinoma [84], whilst COX2 may be a weak,
poor prognostic factor in stage I disease [85].
The determination of the best threshold (cut-off) for a
quantifiable biomarker is also frequently unexplained or
poorly executed. Simplistic approaches such as present/ab-
sent or above/below a median may ignore the biology of the
system under study and will fail if the effect sought varies
around a point elsewhere in the range. It is much better to
use a statistical approach to determine the most effective
threshold [86]. This is just one of the methodological factors
which requires to be standardised if real progress is to be
made with tumour biomarker testing and application [68,87].
3.2. Gene mutation and copy number
Gene mutations potentially have the same pitfalls as single
IHC biomarkers, in terms of being ubiquitous and yet ade-
quately discriminating in order to be clinically useful. Unlike
with IHC biomarkers, where NSCLC subtype has largely been
ignored, mutation studies have demonstrated prognostic ef-
fects for some mutations which are mostly found in lung
adenocarcinomas.
TP53 mutations are the commonest mutation found in
lung cancer and do appear to be associated with poor progno-
sis, but they are associated with positive smoking status,
squamous cell as opposed to adenocarcinoma histology, male
gender, poor tumour differentiation and higher stage disease
at presentation [88,89]. Analysis of the effect of the mutation,
as opposed to other associated factors, is therefore challeng-
ing. In multivariate analyses, TP53 mutations have not been
reliably independent prognostic factors in two surgical series
[88,90], despite being associated with shorter postoperative
survival in one of these studies [88].
Mutations in codons 12, 13 and 61 of KRAS are relatively
frequent in lung adenocarcinomas, being found in up to
40% of European and North American cases but in around
10% of Japanese cases [88,91,92]. Individual studies and
meta-analysis have demonstrated a poor prognostic effect
of KRAS mutation [88,90,91,93–95] but some of these associ-
ations were rather weak and have not stood up to multivar-
iate analysis [88,90,94,96]. KRAS mutation is associated with
positive smoking status, poor tumour differentiation and
higher stage, again probably confounding the prognostic ef-
fect. The presence of increased gene copy number as well
as mutation in KRAS has been associated with poor progno-
sis [95].
Mutations on the tyrosine kinase domain of EGFR occur in
around 50% of adenocarcinomas in East Asian patients and
around 15–20% of European/North American patients [92].
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EGFR mutations, associated with female gender and never
smoking, are generally perceived to be a good prognostic fac-
tor. Although some studies have shown a good prognostic ef-
fect in surgically resected adenocarcinomas [97], there are
many studies in which this effect does not survive multivari-
ate analysis [88,90,94,96,98,99]. EGFRmutations are associated
with lower stage disease [98], well-differentiated adenocarci-
nomas [88] and tumourswith a predominantly lepidic compo-
nent [100], all factors known to carry a good prognosis. In
adenocarcinomas, high copy number of EGFR was reported
as a good prognostic factor in one study [94] but another
found no effect [99]. In studies looking at ‘NSCLC’, EGFR poly-
somy/amplification has been reported as a poor prognostic
factor overall [101,102], or in squamous-cell carcinoma but
not in adenocarcinoma [103]. The overall impression is that
whilst EGFRmutations are associated with a better prognosis,
this effect is not independent of the other good prognostic
factors with which this mutation is associated.
To expand on the statement regarding HGF as a poor prog-
nostic factor, MET is the HGF receptor and increase in MET
gene copy number is associated with poorer survival through
more aggressive tumour biology, higher tumour stage and
histological grade [81,104,105]. ALK fusion genes and BRAF
mutations are targetable oncogenic drivers in advanced ade-
nocarcinomas. ALK fusion may be a good prognostic factor
in surgically resected and advanced-stage adenocarcinomas
[106–108], even although ALK fusion is associated with solid
and cribriform adenocarcinomas with signet ring cells,
aggressive histological features [37,108]. ROS1 and RET fusion
both also appear to be good prognostic factors [108]. This may
be because tumours bearing these various gene fusions are
not associated with tobacco carcinogenesis. BRAF mutations
are associated with micropapillary adenocarcinoma histol-
ogy, a poor prognostic factor [109].
3.3. Pan-genomic studies
Global chromosomal disarray, often reflected in tumour-cell
nuclear pleomorphism, has long been associated with aggres-
sive tumour behaviour. More extensive genetic gains and
losses shown by comparative genomic hybridisation (CGH)
are associated with higher tumour stage, poor differentiation
and tumour progression [110–113], and early relapse of re-
sected adenocarcinoma [114].
Oligonucleotide and cDNA expression microarrays can be
used to determine the expression of thousands of genes from
mRNA extracted from resected tumour samples [115]. This
technology has been used extensively to characterise resected
lung carcinomas. The clustering of tumours into different
groups that share patterns of gene expression has led to sub-
divisions and molecular classifications of lung adenocarcino-
mas in particular [116–120]. These subdivisions have been
associated with differential patient survival, but a closer
examination of the categories with better or worse prognosis
suggests many of these molecular subdivisions are recapitu-
lating histological factors already recognised as prognostic
[37]: well and poorly differentiated tumours, or lepidic pre-
dominant tumours [119–121].
There is also an extensive literature investigating the po-
tential for mRNA-based gene expression profiles to predict
overall survival in surgically resected lung cancer [122–129],
disease recurrence in stage I patients [130–133] and lymph-
node metastatic disease [134–136]. Panels (signatures) ranging
from 2 to 8644 genes were identified for squamous–cell carci-
noma, adenocarcinoma or all histological types, but it is strik-
ing that there is almost no overlap in the genes identified
between studies. Also, depending on the statistical methods
applied, it is possible to generate different predictive signa-
tures from the same data set [137]. The extent to which inves-
tigators undertook validation of their signature is variable.
One large study did attempt multi-institutional validation
but essentially failed to produce a robust, consistent signa-
ture, although the molecular data did appear to enhance the
prognostic value of the clinical data available [138]. One
PCR-based study did validate a ten-gene prognostic signature
for Stage I adenocarcinoma between a European and a North
American centre with 75% accuracy [139], whilst another val-
idated a 14-gene expression assay in two North American and
one Chinese institution [140], generating three risk groups in
resected stage I–III non-squamous carcinomas ranging from
74.1% to 44.6% 5YS. There is no overlap between the 10- and
14-gene sets used by these groups, and neither of these stud-
ies included squamous-cell carcinomas.
The appeal of such positive signatures is obvious, but there
are many similar and all claim more or less the same prog-
nostic power. None of these has been prospectively tested
as a means to select patients for adjuvant therapy, but trials
are ongoing and the outcomes are awaited with interest.
Whether any of these trials will risk (allow?), in case of adeno-
carcinomas, any comparison with the prognostic stratifica-
tion by histology [48–52] remains to be seen.
Other molecular signatures have been related to progno-
sis. In studies of squamous-cell carcinoma, a panel of five
microRNAs’ (miRNA) expression has been related to increased
mortality risk in squamous-cell carcinomas [141], whilst miR-
NA expression was found to be superior to an mRNA signa-
ture in predicting overall survival [142]. Lu et al. reported
two prognostic miRNA signatures in resected stage I lung can-
cers, one for all NSCLC types, and a different one for adeno-
carcinoma only [143]. Promoter methylation of the P16 gene
as a mechanism of gene silencing has been suggested as a
poor prognostic factor in NSCLC in one meta-analysis [144].
In a case–control study of resected Stage I NSCLC, promoter
methylation of P16, CDH13, RASSF1A and APC was associated
with early relapse due to tumour recurrence, an effect inde-
pendent of stage, tumour histology and patient characteris-
tics [145].
There is no specific conclusion to be reached with regard
to resected NSCLC genetics and prognosis. It stands to reason
that more aggressive tumour behaviour, with the propensity
for postoperative disease relapse, is likely to be driven by ge-
netic changes in tumours. Given the diversity of NSCLC, it
seems unlikely that any such ‘genetic signature’ will com-
prise only one or two altered genes. Combinations of genetic
alterations making an individual tumour more aggressive are
highly likely to vary from case to case, depending upon histol-
ogy, aetiology and other factors. It remains to be seen
whether clinically useful prognostic genetic signatures can
be identified, and what forms of genetic alteration these will
be.
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4. Tumour immunology
The importance of the tumour immune response in tumour
progression has been recognised by the inclusion of both tu-
mour-promoting inflammation and mechanisms to avoid im-
mune destruction in the next generation of hallmarks of
cancer [146].
Chronic inflammatory cell infiltrates (lymphocytes, plas-
ma cells and macrophages) are common in resected NSCLC
but global histological assessment of these infiltrates has
failed to show prognostic significance [147]. If, however, the
microlocation (stroma versus amongst the tumour cells) and
cell content of these infiltrates are taken into account, there
is an effect on prognostics in resected NSCLC. Intra-tumoural
infiltrates rich in CD4+ lymphocytes and S100+ Langerhans
cells are associated with better postoperative survival [147].
Uncommon examples of resected NSCLC showing marked
immune cell destruction reminiscent of immunological
regression seen in renal and skin cancers have been reported
[148]. These cases had a superior postoperative survival,
showed evidence of radiological shrinkage prior to resection,
and were characterised by infiltrates rich in Langerhans cells,
CD4+ and CD57+ lymphocytes and macrophages.
More recent studies have been better able to characterise
the nature of intra-tumoural immune-cell infiltrates, and
there are several reviews and many reports of tumour-infil-
trating lymphocytes (TIL – B cells, CD4+ and CD8+ T cells, nat-
ural killer cells), macrophages, plasma cells and others,
generally demonstrating that immunological reactions seem
to indicate a more favourable prognosis in resected NSCLC
[149–152]. There are reports, however, of certain TIL cell types,
such as FoxP3+ T cells and macrophages over-expressing IL10
or TREM-1, which seem to be pro-tumourigenic and associ-
ated with shorter survival [150]. Prognostic immune gene pro-
files have also been derived from tumour mRNA extracts
[150], supporting the histological data on intra-tumoural im-
mune-cell infiltrates. In an interesting evolution of this argu-
ment, mRNA gene signatures derived from circulating blood
mononuclear cells have been shown to be prognostic in
NSCLC patients [153,154].
5. Tumour metabolism
Tumour metabolism, as assessed by 18F-fluorodeoxyglucose
positron emission tomography (FDG-PET), has been shown
to correlate with tumour stage, lymph-node involvement
and postoperative survival [155]. Higher PET positivity
(SUVmax) indicates higher tumour metabolism and is a poor
prognostic factor which also correlates with central tumour
location, squamous-cell rather than adenocarcinoma sub-
type, poor tumour differentiation, larger tumour size, pleural
invasion, lymph-node metastases and higher stage. SUVmax
has been shown to be an independent prognostic variable in
resected NSCLC in multivariate analysis [156–158]. In resected
stage I adenocarcinomas, patients at high risk of disease
recurrence could be identified on the basis of lymphovascular
invasion and by SUVmax [158]. High SUVmax also correlates
with high tumour-cell density and high cell cycle activity
(Ki67 assay) [157]. In a meta-analysis, 11 out of 13 studies
concluded that high SUVmax was a poor prognostic factor in
resected NSCLC [159]. The threshold SUVmax described by var-
ious authors separating good from poor prognostic cases is
very variable, probably the result of case and histological
mix, but also variations in scanners used.
6. Conclusion
There is a clinical need for better prognostic markers which
more effectively identify patients with resected NSCLC who
are at most risk of disease relapse/recurrence, in the hope
that more efficient selection will lead to better outcomes from
adjuvant therapy. Many studies have identified prognostic
factors relating to the tumour type, extent, histopathological
features, individual molecular characteristics and more glo-
bal, multiplex genetic assessments as well as factors related
to tumour immune responses and metabolism. Of these, only
tumour stage is currently used in clinical decision-making,
but the relatively poor survival gains from adjuvant therapy
suggest that this approach to patient selection could be im-
proved upon. Given the multiplicity of NSCLC types, frequent
intra-tumoural heterogeneity and the biological differences
between the two major subtypes of squamous-cell carcinoma
and adenocarcinoma, it is unlikely that a single histological
feature or molecular change will provide the required finer
discrimination. It is also likely that any solution will differ be-
tween squamous-cell carcinoma and adenocarcinoma. More
complex, multiplex assessments of genetic change may prove
more effective, but we should not ignore histopathological
classification which, ultimately, is a morphological reflection
of the myriad genetic changes present in the lesion. Prospec-
tive trials to select adjuvant therapy based upon proven prog-
nostic factors are needed, but these should embrace validated
histopathological assessment as well as molecular profiles.
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The seventh tumour–node–metastasis staging
system for lung cancer: Sequel or prequel?
Jan P. van Meerbeeck *, Annelies Janssens
Oncology /MOCA, Antwerp University Hospital, Edegem, Belgium
Anatomical cancer extent is an important predictor of prognosis and determines treat-
ment choices. In non-small-cell lung cancer (NSCLC) the tumour–node–metastasis
(TNM) classification developed by Pierre Denoix replaced in 1968 the Veterans Administra-
tion Lung cancer Group (VALG) classification, which was still in use for small-cell lung
cancer (SCLC). Clifton Mountain suggested several improvements based on a database
of mostly surgically treated United States (US) patients from a limited number of centres.
This database was pivotal for a uniform reporting of lung cancer extent by the American
Joint Committee of Cancer (AJCC) and the International Union against Cancer (IUCC), but
it suffered increasingly from obsolete diagnostic and staging procedures and did not
reflect new treatment modalities. Moreover, its findings were not externally validated
in large Japanese and European databases, resulting in persisting controversies which
could not be solved with the available database. The use of different mediastinal
lymph-node maps in Japan, the (US) and Europe facilitated neither the exchange nor
the comparison of treatment results.
Peter Goldstraw, a United Kingdom (UK) thoracic surgeon, started the process of updating
the sixth version in 1996 and brought it to a good end 10 years later. His goals were to
improve the TNM system in lung cancer by addressing the ongoing controversies, to val-
idate the modifications and additional descriptors, to validate the TNM for use in staging
SCLC and carcinoid tumours, to propose a new uniform lymph-node map and to investi-
gate the prognostic value of non-anatomical factors. A staging committee was formed
within the International Association for the Study of Lung Cancer (IASLC) – which super-
vised the collection of the retrospective data from >100,000 patients with lung cancer –
treated throughout the world between 1990 and 2000, analyse them with the help of solid
statistics and validate externally with the Surveillance, Epidemiology and End Results
(SEER) database.
The ten modifications and the mediastinal lymph-node map – which were proposed in
2007 and adopted by the AJCC and IUCC in their respective seventh revision of the
TNM system – were implemented as of 2010 and were rapidly adopted by the thoracic
oncology community and cancer registries. As expected, not all controversies could be
fully addressed, and the need for a prospective data set containing more granular
information was felt early on. This data set of 25,000 consecutive incident cases will
form the base for the eighth revision in 2017 and is currently being collected. Other
threats are the role of stage migration and the increasing number of biological factors
interfering with disease extent for prognostication. The latter issue will be addressed
by the creation of a prognostic index, including several prognostic factors, of which
stage will be one.For the time being, the seventh TNM classification is considered
the gold standard for the description of disease extent, initial treatment allocation
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and the reporting of treatment results. The uniform use of the TNM descriptors and
the lymph-node map by all involved in lung cancer care is to be considered a process
indicator of quality.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
1. Introduction
1.1. Background
Prognostication of outcome is of all ages and a distinguish-
ing feature of mankind. Similarly, linking features of a tu-
mour to its natural history has been reported since
pharaonic times. Surgical resection often being the only
modality available at presentation in those days, anatomical
tumour extent was from the early days associated with out-
come and became a pivotal driver in treatment allocation
and evaluation. It was the seminal work of the French sur-
geon Pierre Denoix in the 1940s and 1950s that led to the
creation of the committee on Clinical Stage Classification
and Applied Statistics within the Union for International
Cancer Control (UICC), and the development of the tu-
mour–node–metastasis (TNM) classification which is still
the current gold standard for the anatomical staging of most
solid malignant neoplasms.
In the first edition of the UICC manual, lung cancer was
classified with ‘other sites’, although several publications
had already addressed the relationship between anatomical
extent and outcome [1–4]. The United States (US) surgeon Clif-
ton Mountain progressively introduced new denominators
and substages based on the analysis of a mostly surgical data-
base from US institutions [5–10]. Although some of his data
were externally validated in other cancer registry series, it be-
came increasingly clear by 1996, when the sixth edition of the
lung cancer TNM classification appeared, that a further
refinement had become necessary, that the revision proce-
dure had several limitations and that there was a growing
need for uniformity in the nomenclature used to describe no-
dal stations [11–13]. Globally, two nodal maps were in use: the
Mountain/Dressler [14] used in North America and parts of
Europe, and the Japanese Naruke map [15] used in Asia and
other parts of Europe.
The International Association for the Study of Lung Can-
cer (IASLC) undertook the ambitious International Staging
Project in which an international database was assembled,
consisting of more than 67,000 cases of lung cancer, treated
between 1990 and 2000 by all modalities of care and col-
lected retrospectively from 46 data sources from more than
19 countries around the world [16]. The size of this database
allowed validation, both internal and external, of the revi-
sions to descriptors and stages to a degree unprecedented
in the history of TNM. The IASLC staging project has deliv-
ered a seventh edition of the TNM classification for lung
cancer that aligns stage with prognosis more closely than
before [17]. It was enacted on January 1, 2010, and all of
its proposed revisions were subsequently accepted by
the UICC [4] and the American Joint Committee on Cancer
(AJCC) [18,19].
1.2. The seventh edition of the TNM classification of lung
cancer
The major modifications are listed in Table 1 [20,21]. Tumour
size has been given added importance [22]. New T size cut-
points were originally identified in the node-negative, patho-
logically staged patients having undergone complete resec-
tion, but were also shown to be valid in the clinically staged
patient cases: 2 cm separating T1a and T1b, 5 cm dividing
T2a from T2b and size >7 cm becoming a T3 descriptor for
the first time. If these larger tumours are node-negative, they
move to stage IIA if T2b N0 M0 and to stage IIB if T3 N0 M0;
previously these were all considered stage IB [23].
When additional tumour nodules are found synchro-
nously with a known lung cancer, the distinction between
lung metastases and multiple primary tumours has relied
on clinical and morphological criteria [24]. The distinction is
easy when tumours are of different cell types, and there is lit-
tle debate if tumours are of the same cell type but associated
with separate areas of carcinoma in situ, although in most
cases this is confirmed only after resection. The other criteria
are more problematic: the tumours should be distinct and
separate, should lie in different segments, lobes or lungs,
and should not be associated with any nodal involvement in
an area of common lymphatic drainage. Although 20 years la-
ter there was a suggestion to modify these criteria by the
addition of DNA ploidy [25], the criteria have otherwise re-
mained unchanged despite the enormous advances in imag-
ing, histopathology, immunohistochemistry, mutational
analysis and biopsy techniques since that time. In the latest
edition, the distinction between synchronous primary tu-
mours of similar histological appearance and metastases
has been clarified, and the pathologist has been given a cen-
tral role in this process, allowing the distinction to be made
on biopsy specimens before a decision is taken on the most
appropriate treatment. Multiple tumours of similar histologi-
cal appearance may now be considered to be synchronous
primary tumours if in the opinion of the pathologist – on
the basis of features such as differences in morphology,
immunohistochemistry and/or molecular studies or, in the
case of squamous cancers, on the basis of association with
carcinoma in situ – they represent different subtypes of the
same histopathological cell type. Such cases should also have
no evidence of mediastinal nodal metastases or of nodal
metastases within a common nodal drainage. Clearly, if the
management of any particular patient is dependent on this
distinction, the biopsy of more than one lesion may be neces-
sary. In other situations, or where this is considered imprac-
tical, one may fall back on a generic principle of giving the
patient the benefit of the doubt and assigning the lower T cat-
egory and/or stage. Multiple synchronous primary tumours
should be staged separately. These may be recorded sepa-
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rately, or if a single TNM category is required, the highest T
category and stage of disease should be assigned and the
multiplicity of the lesions categorised as (m), or the number
of tumours should be indicated in parentheses, for example:
T2(m) or T2(5). If the lesions are concluded to be metastases,
then the appropriate T or M category will be dependent on the
site of the nodules (Table 2). If in the same lobe as the primary
they are now classified as T3 and, when associated with node
negativity, are stage IIB. When associated with N1 or N2 dis-
ease they are now classified as stage IIIA, not IIIB. Tumours
associated with additional nodules in other ipsilateral lobe(s)
have been reclassified as T4 rather than M1. When associated
with N0 or N1, these patient cases should be designated as
stage IIIA, and with N2 or N3 as stage IIIB. Tumours associated
with additional nodules in the contralateral lung remain M1
but have been reclassified as M1a.
The T4 descriptor remained unchanged, but when associ-
ated with N0 or N1 disease, it was down-staged to stage IIIA,
not IIIB. Tumours associated with malignant pleural/pericar-
dial effusion or pleural/pericardial nodules have been reclas-
sified as M1a rather than T4 [26]. These data reflect the
algorithm previously developed to treat patients with so-
called wet IIIB disease with systemic therapy. Tumours asso-
ciated with distant metastases have been reclassified as M1b.
Analysis of the IASLC database allowed validation of the
existing N categories, which were adopted without change
[27]. Both existing lymph-node maps were unified in the IAS-
LC nodal map [28], and the precise anatomical definitions of
each nodal station are now recognised by the UICC and AJCC
as the recommended means of describing regional lymph-
node involvement for lung cancer. An important modification
to both previous maps is the observation that the anatomical
and oncological midlines in the superior mediastinum no
longer coincide. The oncological midline deviates to the left
lateral border of the trachea at the thoracic inlet and returns
to the midline at the carina. Thus, all nodes in the superior
mediastinum that lie anterior to the trachea are grouped with
right upper paratracheal station 2 and right lower paratrac-
heal station 4. Involvement of these nodes by a right-sided
tumour will now be classified as N2-disease, whereas for a
Table 1 – Ten modifications in the tumour–node–metastasis (TNM) of lung cancer in the seventh UICC classification [17–20].
Summary of change Details of new definition References
1 Subclassification of T1/2 according to
largest tumour diameter
62 cm: T1a; 2.1–3.0 cm: T1b; 3.1–5.0 cm:
T2a; 5.1–7.0 cm: T2b; >7 cm: T3
[22]
2 Reclassification of synchronous additional
tumour nodules (ATNs)
See Table 2 [22]
3 New borders for mediastinal lymph-node
stations
[28]
4 Reclassification of malignant pleural/
pericardial effusion
M1a [26]
5 Subclassification of M1 Limited to thorax: M1a; extrathoracic
spread: M1b
[26]
6 Use of TNM in SCLC and carcinoid tumours [35–37]
7 Appropriate (sub)stage regrouping (Fig. 1) T2bN0 becomes stage IIA instead of IB;
T2aN1 becomes IIA instead of IIB; T4N0/1
becomes IIIA instead of IIIB
[23]
8 Elimination of Mx descriptor The clinical assessment of metastasis can
be based on physical examination alone
(cM0/1); pM0 should be restricted to autopsy
cases. Else, the pathologist should refer to
cM
[19]
9 Optional descriptor for pleural (Pl) invasion Tumour growth under internal elastic layer:
Pl0 – through elastic layer but not abutting
pleural surface: Pl1, T upgrading to at least
T2a – abutting pleural surface: Pl2; T
upgrading to at least T2a – in parietal
pleura: Pl3; T upgrading to at least T3 –
cannot be assessed: PlX
[38]
10 Optional descriptor for perineural (Pn)
invasion
Pn0: no perineural invasion, Pn1: perineural
invasion, PnX: perineural invasion cannot
be assessed
[19]
Table 2 – The fate over time of multiple synchronous primary tumours.
UICC 5, recommendation [8] UICC 6 [11–13] UICC 7 [17–20,22]
Same lobe as primary
tumour
Tn +1 T4; at least stage IIIB T3N0: stage IIB; 3N1/2: stage IIIA; T3N3:
stage IIIB
Same lung, other lobe T4: at least stage IIIB M1: stage IV T4N0/1: stage IIIA; T4N2/3:stage IIIB
Other lung M1: stage IV M1: stage IV M1a: stage IV
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left-sided tumour, this will become N3-disease. This is in
keeping with the observations of some Japanese colleagues
[29]. In addition, the concept of nodal zones has been intro-
duced, amalgamating adjacent nodal stations into larger ana-
tomic units. An exploratory analysis of the IASLC database
studied survival after complete resection in relation to the ex-
tent of node involvement using the zonal concept. Three
groups were identified, with significant differences in sur-
vival. Those with single-zone N1 disease had the best sur-
vival, at 48% over 5 years. Patients with multizone N2
disease had the worst survival, at 20% over 5 years. The third
group, with intermediate survival, consisted of patients with
multizone N1 (35% 5-year survival) and those with single-
zone N2-disease (34% 5-year survival). This refinement is
presently under investigation, in order to make the nodal
map of greater use to oncologists and radiologists, who are
frequently tasked with classifying more bulky nodal disease
that might transgress the boundaries of individual nodal
stations.
As many as 40% of the reports on lung cancer resection
specimens contains no information on mediastinal node
involvement [30]. It is known that the greater the number of
lymph nodes removed at thoracotomy, the higher the survival
rate [31,32], even if all nodes are shown to be negative, presum-
ably by increasing the certainty of the N0 classification [33]. The
development of an internationally agreed nodal classification
has allowed the reintroduction of minimum requirements for
nodal assessment at surgery and subsequent pathological
evaluation. In the latest edition of TNM, there is now an ex-
panded definition of complete resection (R0), which recom-
mends that at least six lymph nodes/nodal stations be
removed/sampled and confirmed on histology to be free of dis-
ease to confer pN0 status [34]. Three of these nodes/stations
should be mediastinal, including the subcarinal nodes
(station 7) and three from N1 nodes/stations. It is hoped that
the setting of this basic standard will improve nodal assess-
ment and thereby the outcomes of pulmonary resection for
lung cancer.
The above mentioned modifications in T and N have led to
a migration of cases in between pre-existing (sub)stages
(Fig. 1): T2bN0 becomes stage IIA instead of IB; T2a N1 be-
comes IIA instead of IIB; T4N0/1 becomes IIIA instead of IIIB.
Small-cell lung cancer has always been excluded from the
TNM classification. However, the seventh edition is the first to
show that TNM has greater utility than the limited versus
extensive stage split commonly used in clinically staged pa-
tients as well as those treated surgically, especially as a strat-
ification factor in clinical trials of earlier-stage disease [35,36].
Although the TNM classification was already used in both the
typical and atypical variants of carcinoid tumours, the sev-
enth edition is the first to validate this practice [37].
There has never been an internationally agreed definition
of visceral pleural invasion (VPI). This created difficulties for
the IASLC staging project when attempting to define the inter-
relationship between VPI and other prognostic factors such as
tumour size. An internationally agreed definition was there-
fore developed, in which VPI is defined as ‘invasion beyond
the elastic layer including invasion to the visceral pleural sur-
face’ [38]. In addition, a comment was added recommending
the use of elastic stains when this feature is not clear on rou-
tine histology. With these refinements, VPI was carried for-
ward into the seventh edition without change, and the
IASLC proposed an optional more detailed classification of
pleural invasion, adapting the P category developed by the Ja-
pan Lung Cancer Society to create a PL classification [39,40].
The impact of visceral pleural invasion on survival according
Fig. 1 – Stage groups according to tumour–node–metastasis (TNM) descriptor and subgroups. Reprinted with permission from
Detterbeck et al [20]. >7: diameter >7 cm; Inv: invasion; Satell: satellite nodule in same lobe; Ipsi Nod: nodule in ipsilateral
lung; Contr Nod: nodule in contralateral lung; Pl dissem: pleural or pericardial dissemination.
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 5 0 –1 5 8 153
to size was reported according to the seventh UICC classifica-
tion and confirmed its proposed Pl descriptor [41].
Other changes, generic to the seventh edition of UICC, are
the elimination of Mx and the introduction of a descriptor of
perineural invasion Pn.
1.3. Implications of the 7th edition
Several authors have addressed the magnitude of the impact
of the modifications on stage grouping. Van Meerbeeck et al
estimated that in the IASLC data set of 15,952 resected pa-
tients, the change of p-TNM staging classification from UICC
6 to 7 results in the net migration of 23% of resected cases:
stage pIB (–1326), stage pIIA (+2017), stage pIIB (±730), stage
pIIIA (+701), stage pIIIB (–745) and stage pIV (+83) (Fig. 2)
[42]. The magnitude of up- and down-migration is similar.
Substage migration resulted in an increase in 5-year survival
of 4% in p-IB and a decrease of 10% in p-IIIB. This stage migra-
tion should be accounted for when comparing outcome
across surgical series using different TNM classifications. In
a Norwegian cancer registry series from 2001–2005, the con-
cordance index was 0.68 for both editions, indicating no over-
all difference in their predictive accuracy [43]. In the seventh
edition, 211 (29%) stage IB patients migrated to stage II and
161 (48%) patients migrated from stage IIB to IIA. Stage migra-
tions could change the treatment for up to 326 (17.3%) of the
patients in this series [43].
1.4. Strengths
Lung cancer stage definitions have never been subjected to
such an intense validation process [44]. Internal validity was
addressed by visually assessing the consistency of Kaplan–
Meier curves across database types and geographic regions.
External validity was addressed by assessing the similarity
of curves generated using the population-based Surveillance
Epidemiology and End Results (SEER) cancer registry data to
those generated using the project database. Cox proportional
hazards regression was used to calculate hazard ratios be-
tween the proposed stage groupings with adjustment for cell
type, sex, age and region. Validation checks were robust, dem-
onstrating that the suggested staging changes were internally
and externally stable. Several series coming from cancer reg-
istries and surgical series have confirmed some or all of the
proposed modifications, adding supplementary external vali-
dation to the classification [45,46].
Fig. 2 – (A) Stage migration from sixth to seventh tumour–node–metastasis (TNM) classification in resected cases. (B) Impact
of stage migration on overall survival. Reproduced with permission from Van Meerbeeck et al [42].
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1.5. Weaknesses
Taken together, the proposed changes are limited in number
and most are either intuitive or reflect modifications that
were already suggested in the analysis of cancer registries
or surgical series. As some of these series were included in
the IASLC database, these modifications are self-fulfilling.
With respect to the proposed boundaries for lymph-node
stations, they represent a clear improvement for surgeons,
but are not unambiguous for radiologists and echo-endosco-
pists. A recent ultrasonographic lymph-node map based on
the anatomical boundaries of the seventh UICC classification
might well resolve this issue [47]. The abovementioned
reshaping of mediastinal lymph-node borders will result in
an increase in so-called ‘minimal N2’, limited to a single sta-
tion. The magnitude of this phenomenon has not yet been re-
ported. Furthermore, stage IIIA, which used to be
heterogeneous in the sixth classification, becomes a cocktail
of six different T/N combinations.
Even a database of 67,000+ patients was not able to vali-
date all the descriptors that had accrued within previous edi-
tions of TNM. One should remember, however, that many of
these data were not originally defined for the purpose of eval-
uating the staging system, but with some other scientific
questions in mind. Their prognostic role was not always con-
firmed by multivariate analysis. Among the T descriptors that
need further study are:
(1) The best way to assess tumour size clinically: measur-
ing a single diameter, measuring the greatest diameter
or measuring two or three dimensions. Computed
tomography (CT) screening has accelerated the devel-
opment of volumetric software, adding to the debate
as to how best to determine tumour size, and whether
or not volume is preferable over size [48].
(2) The non-size-based descriptors of T2/3 as hilar atelec-
tasis, obstructive pneumonitis and the cytology-nega-
tive paramalignant pleural effusion (not considered as
a T-modifying condition) [49]. It is hoped that the use
of [18]fluorodeoxyglucose–positron emission tomogra-
phy (FDG-PET) scanning may help unravel the inflam-
matory and neoplastic elements.
(3) The split of which invasion to adjacent structures is
assigned to T3 or to T4 could not be answered because
there were too few patient cases in which the precise
descriptor justifying the T3 or T4 category was
recorded, and even fewer in which all of the other
descriptors were known to be absent.
(4) The extent of dissemination was only partly addressed
by the introduction of M1a. The recently increasing inter-
est in the outcome of oligometastatic disease could not
be translated into a separate descriptor for this entity.
Other details and areas in which ambiguities and difficul-
ties exist have been reviewed [50].
1.6. Threats
Although the data are definitely more recent than in previous
TNM editions, they still are from the past century and do not
reflect present-day staging and treatment paradigms, where-
in FDG-PET and endoscopic ultrasound are now standard
staging techniques for the M and N descriptors. It has been
shown in several series that the introduction of both tech-
niques has significantly improved the accuracy of clinical
staging and upstaged the stage distribution at diagnosis,
hence changing treatment algorithms and improved stage-
specific outcomes [51]. This process of improved stage-spe-
cific survival has been described previously at the occasion
of a previous revision of the lung cancer TNM [52]. This so-
called Will Rogers phenomenon has been observed in stage
III patients, where the outcome was significantly ‘improved’
by the occurrence of PET staging [53–55].
Whereas pathological staging has a prognostic signifi-
cance, clinical staging is meant to help the clinician in treat-
ment allocation. The interaction between better staging
techniques and improved treatment strategies does not allow
the expectation that revisions in staging classification will
necessarily translate into a better overall outcome, unless
over decades. It is controversial whether treatment should
necessarily follow a stage change, as stage should not be con-
sidered a ‘cook book’ for treatment allocation. The issue is
particularly critical for the ‘down-staged’ additional tumour
nodules, single zone N2 and T4N0 cases as described before.
The analysis of the IASLC database was heavily influenced
by surgical cases and pathological staging and cannot neces-
sarily be extrapolated to clinical staging, which has been re-
ported to be inaccurate [56]. Besides, individual patients
with more advanced stages but an inherent indolent biologi-
cal behaviour of their tumour have been reported to profit
from more ‘aggressive’ surgical or radiotherapeutic ap-
proaches, whilst others with more limited stage will be given
symptomatic care for reasons such as poor performance or
comorbidity. pT2pN0 tumours with a diameter of 5.5 cm were
previously considered pIB and hence not candidates for adju-
vant chemotherapy. The same case would now be considered
pT2bpN0 and staged pIIA and would be offered adjuvant
treatment. We should remember that the data supporting
adjuvant chemotherapy after complete resection were gener-
ated from trials using the sixth edition of the TNM classifica-
tion, and that offering adjuvant chemotherapy to ‘reclassified’
stage pIB, pII and pIIIA completely resected cases is therefore
not evidence-based [57,58]. A recent pooled analysis of pa-
tient cases from two multicentre trials using the size cut-
points of the seventh edition of the TNM classification was
unable to identify subgroups of patients who did or did not
derive significant benefit from adjuvant chemotherapy after
complete resection based on tumour size [59]. Prospective
data from large adjuvant chemotherapy trials are necessary
before clinical guidelines regarding management of surgically
resected node-negative non-small-cell lung cancer (NSCLC)
can be updated to reflect the changes introduced.
1.7. Opportunities
The aforementioned weaknesses and threats offer some chal-
lenging opportunities for further research. All unproven
descriptors and hypotheses are carried forward for close eval-
uation in a 25,000-patient prospective database being col-
lected for the future TNM- revision foreseen for 2016 [60].
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The issue of T/pT classification of ground-glass opacities
(GGOs) deserves special attention as these are increasingly
found at CT-scan screening, with or without a solid compo-
nent. By histological definition, in-situ adenocarcinoma is de-
fined only for GGOs with a diameter of <3 cm [61]. GGOs are
considered non-invasive adenocarcinoma in situ, whilst only
the associated solid component is presumed to be invasive.
Those P3 cm are no longer ‘adenocarcinoma in situ’ and re-
late to a T2 description. However, their biological behaviour
is less aggressive, suggesting that the measurement of the
GGO in the evaluation of tumour size be discarded, analo-
gously to the situation in breast cancer, where the tumour
is coded for the invasive component only.
The concept that overall burden of lymph nodal disease
(nN) might be more important than the anatomical location
of the involved nodes comes from similar observations in
oesophageal cancer. In a large retrospective series of resected
Japanese patients, it was observed that the number of lymph
nodes involved was a more precise prognostic determinant
than their location and could be considered for the nodal stage
classification as is done in other organs [62]. However, it is dif-
ficult to assess the exact number of the metastatic lymph
nodes pre-operatively, and a uniform definition for pre- and
post-operative assessment is preferable to avoid confusion. Be-
sides, fragmentation of lymph nodes produced during the
operation might result in an overestimation of the survival risk.
Pleural lavage cytology (PLC) is performed by some sur-
geons as the initial step after performing thoracotomy. In pa-
tients without overt effusion or pleural dissemination, a
recent meta-analysis confirmed that PLC shown to be positive
for cancer cells has an adverse and independent prognostic
impact after complete resection [63]. When PLC is positive,
the resection should be classified as R1(cy+). Sophisticated
immunohistochemical and genetic techniques permit the
detection of very small tumour deposits. A micrometastasis
as defined by the UICC and AJCC usually is detected by routine
haematoxylin and eosin staining, and typically mitoses and
invasion are seen [64]. Such micrometastases in nodes or dis-
tant sites are counted as positive and denoted by the symbol
(mi): for example, cN1(mi) or pN2(mi). However, the prognos-
tic impact was not evaluated in the IASLC staging analysis.
Isolated tumour cells (ITCs) are small clumps of tumour cells
typically without mitoses or vascular or lymphatic invasion.
ITCs within nodes (or distant sites) are not counted in the
stage classification and should be coded as N0 (or M0), regard-
less of node level harbouring the ITC, for example, pN0(i 1) or
pN0(mol 1). The prognostic value of ITCs has been inconsis-
tent. The same applies for circulating tumour cells [65].
A staging classification describes the anatomical extent of
a tumour, disregarding its biological behaviour. Stage is hence
only one of several prognostic factors to be accounted for in
prognostication, together with one or several biological mark-
ers which have been repeatedly linked with the outcome
regardless of the treatment established [66]. Logistic regres-
sion techniques will allow the construction of a composite
prognostic index in which different independent predictive
factors are weighted and available for use in a nomogram or
electronic outcome calculator [67,68].
Quality of health care is of increasing concern and interest.
Indicators can help to describe the structural environment,
the quality of the staging process and its outcome. The TNM
descriptors and denominators lend themselves well as indi-
cators of staging. Examples are the extent of intra-operative
lymph-node sampling as an indicator of quality of the resec-
tion, clinicopathological correlation of resected tumours as a
measure of staging accuracy and outcome according to stage.
It is expected that these and others will be increasingly used
to peer review medical practice.
2. Conclusion
The publication of the seventh edition of the lung cancer
TNM classification has been variously applauded as a ‘seis-
mic shift in staging’ by some or dubbed a laudable effort
in ‘lumping, splitting and sorting’ by others [69,70]. It is con-
sidered a quantum leap forward in patient care, being based
on an unprecedented large international database and
involving extensive analysis and validation. Inevitably, the
system is also more complex and far from perfect; with
more refined data comes greater ability to discern granular
details. This necessitates more layers of classification, man-
ifested by additional new descriptors. As with any complex
system, rules that seem clear in one context can seem awk-
ward or conflicting in another. Implementation brings ambi-
guities to light. A clear knowledge of the details and
difficulties should help to promote appropriate application
and realisation of the full benefits of the new stage classifi-
cation system.
There is much work to be done to answer these questions
before the next revision scheduled for 2016. The IASLC is
determined that over future revisions these shortcomings will
be addressed as prospective data are accrued. The seventh
edition of TNM in its present form remains, however, a surro-
gate for the anatomical extent of a tumour and a sequel to
previous revisions. Unless we succeed in the prequel of build-
ing a composite prognostic index, including an increasing
number of factors and inclusive biomarkers, ‘we might con-
sider the TNM method for lung cancer staging to be similar
to ‘brownstone’ remnants of historical interest and accept
biological markers of disease extent and behaviour as the
skyscrapers of our future’[71].
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Introduction
Optimal approach for renal cancer
Cora N. Sternberg *
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In the European Union there are some 84,400 new cases of
kidney cancer with 34,700 deaths yearly [1]. With increasing
knowledge of the mechanisms that drive renal cancer biology
and the development of agents that target angiogenesis,
growth and metastases, hope has been given to patients with
this disease. Enormous progress has been made in the last
few years for patients with advanced and metastatic renal cell
cancer (RCC). Since the era of cytokine therapy, overall sur-
vival has now doubled, with the approval of many new agents
targeting cell signalling pathways.
Six agents which target either the vascular endothelial
growth factor (VEGF) pathway or the mammalian target of
rapamycin (mTOR) pathway have been developed and ap-
proved for use in advanced and metastatic RCC. Increasing
knowledge of how to actively manage the side effects of these
agents has also greatly added to improving survival. In addi-
tion, the realistic hope of novel treatments – such as novel
immunotherapy (anti-programmed cell death protein 1 (PD-
1), anti-programmed cell death 1 ligand (PD-1L) and inhibition
of fibroblast growth factor receptor (FGFR) – may also add to
our therapeutic armamentarium.
Improvements in surgical techniques have likewise been
important. Notably, cytoreductive nephrectomy remains the
standard of care as compared with drug treatment alone,
although trials addressing this question are ongoing. Metasta-
sectomy has become common practice, as local therapy of
metastases can often be integral to the treatment of
metastatic RCC. Surgical resection has traditionally been the
preferred approach to metastasectomy, but recent data on
stereotactic radiosurgery (SRS) indicate that this treatment
modality is a valuable non-invasive alternative. Definite
guidelines for surgery of metastatic lesions do not exist, but
recommendations can be made. The available evidence for
common metastatic sites will be reviewed, including metasta-
sectomy following targeted therapy and non-invasive
approaches such as SRS.
This educational section comprises four excellent presen-
tations that review factors which guide treatment selection,
the algorithm for advanced RCC from first- to third-line ther-
apies, proper sequencing, novel immunotherapy and details
of how therapy may be individualised and surgery integrated
in the optimal approach for renal cancer.
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Individualising treatment choices in a crowded
treatment algorithm
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1. Introduction
Metastatic renal-cell cancer (mRCC) is considered incurable,
and systemic therapy is the foundation of patient manage-
ment. Historically, hormonal therapy was used for palliation
of symptoms but had little anti-cancer effect [1]; cytotoxic
chemotherapy is beneficial for only a small proportion of pa-
tients [2–7]. Immunotherapy, generally interferon-alpha
(IFNa), was standard treatment until 2005, when it was re-
placed by the first inhibitor of the vascular endothelial growth
factor receptors (VEGFRs), sunitinib [8]. Since then, another
six agents which target either the VEGF or the mammalian
target of rapamycin (mTOR) pathways have been developed
and approved for use in advanced RCC [9–15]. Notably, cytore-
ductive nephrectomy was proven in two randomised trials to
improve survival in combination with IFN, compared with
drug treatment alone [16]. Despite a significant change in
the systemic agents utilised in mRCC, this has remained an
integral aspect of the treatment approach.
The prognosis for patients with mRCC has improvedmark-
edly with the introduction of agents targeting cell signalling
pathways [17,18]. The expected survival time for an individual
patient can be highly variable, but it is standard practice to
categorise patients with mRCC into prognostic groups, origi-
nally defined by the Memorial Sloan Kettering Cancer Center
(MSKCC) in the immunotherapy era of treatment [19]. This
model, which uses clinical and pathological factors to group
patients into favourable, intermediate and poor-risk groups,
has now been updated and validated in patients treated with
VEGFR–tyrosine kinase inhibitors (VEGFR–TKIs) [20] and is an
important consideration in the current standards of care.
The treatment algorithm for mRCC in 2013 includes seven
targeted agents and cytokine therapy, used in a sequential
fashion [21]. This algorithm is becoming increasingly complex
as clinical trials attempt to define the optimal treatment reg-
imen to improve progression-free and overall survival and re-
sponse rates, and to preserve quality of life. Combinations of
targeted drug therapy remain experimental; to date, no com-
bination has proved to be superior to monotherapy, and it is
frequently poorly tolerated [22].
This educational chapter will summarise the treatment
algorithm for advanced RCC and will provide details on how
treatments may be individualised within the algorithm. The
potential impact of new agents, future trial results and devel-
opments in translational research in mRCC will also be
discussed.
2. First-line therapies
It has long been recognised that some patients with mRCC
have indolent disease biology, and a period of observation is
often recommended when metastatic disease is first diag-
nosed. This approach has clear advantages – it allows assess-
ment of the pace of metastatic disease and can spare patients
the chronic toxicities associated with drug therapy, as well as
having health economic benefits – but there is only prelimin-
ary, retrospective evidence for its safety, and it is not clear for
which patients this strategy is most suitable [23]. A deferred
drug treatment approach in mRCC is currently being evalu-
ated in a prospective, observational study [24].
Immunotherapy has largely been replaced by targeted
therapies, but is considered an acceptable treatment option
in patients with low- or intermediate-risk disease; IFN in par-
ticular remains a relevant therapy in those countries with re-
stricted or no access to high-cost drugs. A 2005 systematic
review of IFN reported modest improvements in disease con-
trol rates, 1-year and overall survival compared with non-
immunotherapy controls, with approximately 13% of patients
achieving a partial or complete response [25]. Notably, high-
dose IL-2 (HD IL-2) produces durable response rates in a small
proportion of patients with mRCC [26,27]; most recently, the
‘SELECT’ trial of HD IL-2 found an improved response rate
(29%) compared with historical results which was attributed
to improved patient selection on clinical and pathological
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grounds [28]. This remains the only systemic therapy associ-
ated with long-term remissions in mRCC, but its potential for
severe toxicity and efficacy in a restricted, molecularly unde-
fined subgroup of patients has limited its clinical application.
Sunitinib and sorafenib are kinase inhibitors with multiple
targets, including the VEGF-receptors [29–31]. They were the
first drugs developed in the VEGFR–TKI class of agents; hence
they are associated with extensive clinical experience in
mRCC. There is a stronger evidence base for sunitinib as
first-line therapy. Sunitinib was compared with IFN in a ran-
domised phase III trial and resulted in a statistically superior
response rate (47% versus 12%), and progression-free survival
(PFS) time (median 11 months versus 5 months) [8]. The med-
ian overall survival time was 26.4 months for sunitinib com-
pared to 21.8 months for IFN-treated patients, which only
became significant when those patients who crossed over
from IFN to sunitinib were excluded from the analysis [32].
The efficacy of sunitinib was confirmed in a large safety study
which enrolled a broader population of patients, including el-
derly patients, those with poor-risk disease as defined by the
MSKCC criteria and thosewith non-clear-cell RCC [33]. Sorafe-
nib was also compared with IFN treatment in 189 untreated
mRCC patients in a randomised phase II trial [34]. Although
the median PFS times for sorafenib and IFN were similar
(approximately 5.7 months), sorafenib was interpreted as
having superior clinical benefit because of improved response
rates, tolerability and quality-of-life assessments.
Pazopanib was developed as a multi-targeted kinase inhib-
itor with improved potency against VEGFR-2, thought to have
the most biological relevance of the VEGF receptors in clear-
cell RCC [35]. It was registered in the first-line treatment set-
ting on the basis of improved progression-free and overall
survival in patients who were either treatment-naı¨ve or who
had received prior cytokine therapy, in a placebo-controlled
trial [36]. Preliminary results of the COMPARZ study, compar-
ing sunitinib and pazopanib in first-line treatment for mRCC,
were presented in abstract form at the European Society of
Medical Oncology (ESMO) meeting in 2012 [37]. The median
PFS for pazopanib was 8.4 months and 9.5 months for suniti-
nib, and interim OS times were 28.4 months and 29.3 months,
respectively. This was a non-inferiority study, and although it
has been criticised for its design, it would appear to confirm
anecdotal experience that the two drugs are equivalent in
efficacy, and this is reflected in current clinical practice guide-
lines [21,38].
The intravenous monoclonal antibody to VEGF, bev-
acizumab, is an alternative first-line treatment for patients
with favourable or intermediate-risk mRCC. Two phase III tri-
als combined bevacizumab with IFN and randomised patients
to the combination or to IFN alone [12,13]. Both reported im-
proved response rates (combined analysis 28.4% versus
12.9% [18]) and PFS times (8.5 months versus 5.2 months
[12]) and 10.2 months versus 5.4 months [13]) over IFN mono-
therapy. Overall survival was not significantly improved by
bevacizumab in either study, perhaps because of subsequent
anti-VEGF systemic treatment in many patients.
Temsirolimus is an inhibitor of the mTOR complex 1 and is
the only systemic agent to be studied specifically in a poor-
prognosis group of patients with mRCC. A phase III trial of
temsirolimus or IFN or the combination enrolled treatment-
naı¨ve patients who met three of six adverse risk features: lac-
tate dehydrogenase (LDH) level of more than 1.5 times the
upper limit of normal, haemoglobin level below the lower lim-
it of normal, elevated calcium, time from initial diagnosis of
RCC to randomisation of less than 1 year, a Karnofsky perfor-
mance status of 60 or 70, or metastases in multiple organs
[15]. Notably, approximately a third of the patients in this
study had not had a nephrectomy. Median PFS in the temsi-
rolimus group was 5.5 months and median OS 10.9 months,
and temsirolimus is therefore a standard of care in this group.
3. Second-line therapies
Accepted second-line treatments for mRCC are the VEGFR–
TKIs sorafenib, sunitinib, pazopanib and axitinib, and the oral
mTOR inhibitor everolimus. Frequently, the decision is influ-
enced by which first-line treatment the patient has received;
for example, there is evidence that sorafenib, sunitinib, paz-
opanib and axitinib have clinical activity after prior cytokine
therapy [10,11,33,39].
The main controversy exists in the decision between ever-
olimus and axitinib, when patients have been previously trea-
ted with a VEGFR–TKI. The RECORD-1 study compared
everolimus to placebo in previously treated patients [14,40].
This was not strictly a second-line trial only, but patients were
stratified by the number of previous VEGFR–TKI treatments;
in patients who had received only one prior VEGFR–TKI, the
median PFS for everolimus was 5.4 months, and 1.9 months
for placebo [41]. Similar results were reported for the analysis
of sunitinib- and sorafenib-treated patients. Two further tri-
als, including the large expanded access study of everolimus
(REACT), confirmed that everolimus has meaningful clinical
activity in anti-VEGF treatment-refractory patients [42,43].
The phase III AXIS study randomised patients who had re-
ceived prior sunitinib, cytokine, bevacizumab or temsirolimus
to second-line treatment with axitinib or sorafenib [11];
approximately two thirds of the 723 patients enrolled had
had first-line anti-VEGF treatment. Overall, PFS was in favour
of axitinib, with a median time of 6.7 months, compared to
4.7 months for sorafenib. This difference was less pro-
nounced, however, in patients who had received prior suniti-
nib or bevacizumab.
Results of the RECORD-3 study were presented in abstract
form in 2013, adding further support to the efficacy of a VEG-
FR–TKI:mTOR inhibitor algorithm [44]. This phase II trial ran-
domised patients to either first-line everolimus, followed by
sunitinib on progressive disease, or sunitinib followed by
everolimus. It was designed to prove non-inferiority of PFS
with first-line everolimus compared to sunitinib, but did not
with its primary end-point (median PFS for everolimus
7.85 months and for sunitinib 10.71 months). Preliminary OS
results suggest that the current algorithm of sunitinib in the
first line followed by everolimus is superior to the opposite se-
quence. These results do not resolve the issue of whether a
VEGFR–TKI or mTOR inhibitor is superior after failure of
first-line anti-VEGF treatment, but add to the evidence base
regarding optimal sequencing of systemic agents in mRCC.
With respect to the former question, the efficacy of temsirol-
imus and sorafenib were compared in patients previously
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treated with sunitinib in the INTORSECT trial, presented at
the ESMOmeeting in 2012 [45]. Both drugs produced a median
PFS of approximately 4 months, but overall survival was sig-
nificantly better for sorafenib (16.6 months versus
12.4 months for temsirolimus). These results seem to indicate
that although VEGF followed by mTOR inhibition is an effica-
cious strategy, everolimus and temsirolimus are not necessar-
ily interchangeable, perhaps owing to their differing
pharmacokinetics [46,47].
4. Factors which guide treatment selection
It is clear that multiple choices now exist for the first- and
second-line treatment of patients with mRCC. Currently, the
choice of agent is largely determined by the licensed indica-
tion for the drug, which in turn depends on the clinical con-
text in which the drug’s registration trial took place.
However, as the clinical trial portfolio in mRCC has expanded
to include more sophisticated trial designs, and eligibility cri-
teria broadened, the decision about optimal treatment has be-
come increasingly complex. To further complicate the issue,
there are few direct comparisons between the various agents
[11,37,45] and it is therefore difficult to confidently identify a
superior drug for a given clinical situation. Nonetheless, there
are a number of factors which enable selection of treatment
to some degree, and also research initiatives aiming to move
the field towards an individualised approach to treatment.
4.1. Disease and patient factors
Clinical risk models such as the MSKCC model provide a for-
malised assessment of those features which indicate less
favourable biology in mRCC [19]. This model, now validated
by Heng and colleagues in patients treated with VEGFR–TKIs
[20] includes parameters such as haematological, biochemical
and performance status to categorise patients into favour-
able-, intermediate- and poor-risk groups, each with a distinct
survival time. However, risk stratification does not predict re-
sponse to treatment; a nomogram which utilises 11 pre-treat-
ment clinical and pathological variables predicts a 12-month
PFS with first-line sunitinib treatment [48]. A more compre-
hensive model such as this may improve decision-making
for individual patients, but it has not been validated. Recently,
an analysis of factors influencing survival in sunitinib-treated
patients was published, and this confirmed previously pub-
lished findings but also identified independent predictors of
long-term survival, including ethnic origin, bone metastases
and adjusted calcium level [49].
Features of the disease are frequently used in clinical prac-
tice to guide selection of treatment. The most obvious exam-
ple is the histological subtype of RCC. Most phase IIII trials in
mRCC enrolled only patients with the clear-cell subtype, but
approximately 25% of patients will have non-clear-cell histol-
ogy, most commonly papillary or chromophobe subtypes. The
optimal treatment for these groups has not yet been defined;
on balance it appears that the targeted agents currently in use
have activity in non-clear-cell RCC, but that the activity may
be reduced compared to that in patients with clear-cell mRCC.
However, there is evidence from some large therapeutic series
that temsirolimus, everolimus and sunitinib have similar effi-
cacy in patients with clear-cell and non-clear-cell disease
[33,50,51]. Considering the papillary subtype alone, the re-
ported range of PFS on VEGF-targeted agents varies consider-
ably (1.6–11.9 months) [52–55], but studies have not always
analysed type 1 and type 2 papillary patients (in whom there
is clearly distinct biology) separately. Response rates in the
range of 12–40% and PFS times from 4 to 14 months have been
reported for sunitinib, sorafenib, temsirolimus or everolimus
in chromophobe mRCC [52,53,55–59], although not always in
the first- or second-line setting. The presence of sarcomatoid
differentiation, which can occur in any histological subtype,
adds a considerable degree of uncertainty as to the best
choice of systemic agent (for a comprehensive review, see
[60]), because the molecular driver of sarcomatoid change is
unknown, the degree to which it is present is highly variable,
and there are limited prospective therapeutic studies. Based
on available data, the activity of sorafenib and sunitinib
seems to be superior to that of cytotoxic chemotherapy, but
outcomes are modest at best with these agents [61–64].
The burden and pattern of metastatic disease further
influences treatment choice. Patients who are symptomatic
from either a high volume of metastatic disease or disease
in critical viscera are probably best served by a multi-targeted
kinase inhibitor, because these agents are more likely to
cause tumour regression than mTOR inhibitors. Response
rates to sunitinib and pazopanib as first-line treatment, and
axitinib as second-line treatment, can be as high as 40%
[8,10,11], whereas reported response rates for temsirolimus
and everolimus monotherapy are 610% [14,15]. Decisions
about systemic treatment in those with specific metastatic
disease sites such as the brain are complex; frequently,
integration of local therapies is required, and there are no
prospective data on which to base treatment recommenda-
tions. In the example of brain metastases, sunitinib has the
strongest evidence of clinical activity [65–68].
Patient factors that should be considered when choosing
systemic treatment for mRCC include their co-morbidities,
age, expectations of and preferences for treatment and social
and pragmatic issues such as their ability to attend the hospi-
tal. The VEGFR–TKIs have multiple additional targets, and the
relative potency of these agents for different targets results in
differing side-effect profiles. The toxicities associated with
specific agents are described in detail in a separate educa-
tional chapter, but these must be balanced against baseline
organ dysfunction – including cardiovascular, endocrine, hep-
ato-biliary and haematological problems – when therapy is
chosen.
The effect of advanced age on the safety and efficacy of
targeted agents is now under careful evaluation, with the rec-
ognition that patients treated in drug development trials are
not representative of the mRCC population encountered in
the clinic. A combined analysis of 4684 patients treated with
sorafenib in six clinical trials and two expanded access pro-
grammes was recently published [69], including 599 patients
aged over 75 years. The authors reported that tolerability of
sorafenib monotherapy was similar between the four age
groups analysed, but those in the oldest group had a shorter
duration of treatment (median 3.1 months) compared to
those aged between 55 and 75 (median 4.0–4.2 months). Nota-
bly, 17% of patients aged 65–75 and 8% of those over 75 re-
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ceived sorafenib treatment for a duration of more than
12 months. Likewise, pooled retrospective data from approxi-
mately 1000 patients treated with sunitinib indicate that its
efficacy is similar in those under and over the age of 70 [70].
The overall rate of treatment-related adverse events was also
comparable between the two age groups, although particular
side-effects – such as fatigue, anorexia and weight loss,
cough, peripheral oedema and haematological abnormalities
– were noted to be higher in the older age group. The sunitinib
expanded access study included a significant proportion of
patients over the age of 65 (approximately 1/3 of the study
population, 1000 patients); the response rate of 17%, median
PFS of 11.3 months and median OS of 18.2 months were the
same as in the overall study population [33]. Finally, there is
evidence that everolimus has a similar efficacy and safety
profile in those over 65 years of age, from a retrospective anal-
ysis of the RECORD-1 study [71]. In summary, these data sug-
gest that chronological age alone should not be an influential
factor in treatment selection, rather that co-morbidities and
geriatric syndromes such as polypharmacy may need more
careful assessment and weighting in the older patient.
Preservation of quality of life is an important therapeutic
goal in mRCC. This can be difficult to achieve, because all tar-
geted agents are associated with at least some degree of tox-
icity which is chronic. Arguably, patients are best placed to
make decisions about treatment based on toxicity and quality
of life, but the latter has not been rigorously studied and/or
reported in clinical trials. For this reason, the PISCES (patient
preference study between first-line pazopanib and sunitinib)
trial, presented in abstract form in 2012 [72], has been com-
mended for its novel design. Patients were randomised to re-
ceive either drug for 10 weeks, followed by a 2-week washout
period before switching to the second drug. A clear patient
preference for pazopanib over sunitinib was displayed,
although the different drug schedules and timing of quality
of life assessments complicate the analysis and in particular
may have disadvantaged the evaluation of sunitinib. A similar
study design is employed in the TAURUS trial, a phase II trial
evaluating patient preference for the potent VEGFR–TKI tivo-
zanib for 12 weeks followed by sunitinib for 12 weeks, or vice
versa (NCT01673386). The phase III SWITCH trial will evaluate
sunitinib followed by sorafenib and the opposite sequence,
but the primary end-point is PFS (NCT00732914). Both of these
trials will be conducted in the first-line treatment setting.
4.2. Predictive biomarkers in mRCC
Predicting sensitivity to systemic therapy is the fundamental
prerequisite for the delivery of personalised treatment in
mRCC. Response to first-line targeted agents appears to be
an important indicator of longer-term outcome, with a retro-
spective analysis demonstrating that PFS below and above an
arbitrary threshold of 6 months during first-line treatment
was an independent predictor of overall survival (median OS
12.1 months versus 46.8 months, respectively, P < 0.0001)
[73]. However, when anti-VEGF treatments are used in a first-
and second-line sequence, response to the first does not pre-
dict response to the second [74,75]; this is somewhat counter-
intuitive, but is perhaps further evidence that drug response
is probably the result of complex interaction between multi-
ple tumoural, pharmacodynamic and pharmacokinetic
factors.
Clinical parameters indicative of response to VEGF-tar-
geted treatments may help to limit patients’ exposure to the
drug in the absence of benefit. Drug-induced hypertension
is a compelling example of this. A retrospective, pooled anal-
ysis of data from four clinical trials of sunitinib treatment in
patients withmRCC found that hypertensive patients, defined
by systolic blood pressure and diastolic blood pressure to a
lesser degree, had improved clinical outcomes [76]. In the
AXIS trial, diastolic blood pressure ofP90 mmHg at 12 weeks
was significantly associated with improved overall survival in
both the axitinib (20.7 months versus 12.9 months) and
sorafenib (20.9 months versus 14.8 months) arms [75], con-
firming an earlier correlation of axitinib efficacy and diastolic
blood pressure in phase II studies [77]. A prospective, random-
ised assessment of the efficacy of axitinib dose up-titration is
currently under way (NCT00835978).
The utility of hypertension in treatment selection for an
individual patient is debatable; the identification of a molecu-
lar marker that is predictive of response a priori is a key goal
of translational research in mRCC. At this time, no such bio-
marker has been established. In patients treated with anti-
VEGF agents, biomarker development efforts based on defi-
cient tumoural von Hippel Lindau (VHL) gene function and
resultant angiogenesis, the central abnormalities in clear-cell
RCC, have been unsuccessful, perhaps because the pathogen-
esis involves stromal rather than tumour cells. However,
promising discoveries have been made in relation to single-
nucleotide polymorphisms (SNPs), inherited variants in DNA
sequence, which may influence the biology underlying drug
sensitivity. Several retrospective analyses correlated SNPs in
VEGF or VEGF-receptors and drug metabolism genes (includ-
ing CYP3A5, CYP1A1, ABCB1 and 2 and NR1I3) with sunitinib
efficacy or toxicity [78–80]; a fourth study found that an SNP
in VEGF was associated with the development of sunitinib-in-
duced hypertension, but no single SNP predicted variation in
clinical outcome [81]. A prospective observational study in
which all patients received sunitinib demonstrated a signifi-
cant relationship between polymorphisms in VEGFR3 and
CYP3A5*1 with reduced sunitinib response and greater toxic-
ity, respectively [82]. Furthermore, SNPs in angiogenesis or
drug exposure genes – including IL-8 and HIF1A – may have
predictive value; the IL-8 2767TT and the HIF1A 1790AG vari-
ant genotypes were associated with reduced PFS times com-
pared to wild-type genotypes, in patients treated with
pazopanib compared to placebo [83]. This finding has biolog-
ical plausibility in that IL-8 has been identified as a potential
mediator of an angiogenic escape and thus resistance to anti-
VEGF treatment [84]. High plasma concentration of IL-8 has
also been shown to predict for shorter PFS in patients treated
with pazopanib in a retrospective analysis of the phase III
pazopanib-versus-placebo trial, whereas high concentration
of IL-6 predicted PFS benefit from pazopanib [85]. The major
issue with the studies relating to SNPs is that they have each
evaluated non-overlapping sets of SNPs, and no dominant
polymorphism or one common to different anti-VEGF treat-
ments has emerged [86]. Additionally, the frequency of iden-
tified SNPs is often low, and the biological processes which
underpin the relationship between SNPs and clinical out-
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comes, such as increased susceptibility of the tumour or nor-
mal tissue to the drug or altered drug metabolism, are not de-
scribed. However, if validated, germline genetic variants may
be very useful in drug selection, and may be particularly rele-
vant to efficacy and safety of drugs between different ethnic
groups affected by RCC.
Activation of the mTOR signalling pathway is extensively
demonstrated across grades, histological subtypes and tu-
mour sites in RCC, and alteration of some of its components
has been shown to confer a worse prognosis [87,88]. Further-
more, there is preliminary evidence that somatic mutations
in genes such as mTOR, or the tumour suppressor tuberous
sclerosis genes (TSC1 and TSC2) causing gain or loss of func-
tion, respectively, are associated with long-term response to
mTOR inhibitors [89]. Serum LDH may have a prognostic –
and possibly predictive – role in patients treated with temsi-
rolimus or everolimus [40,90,91].
Evidently, the biological relationship between tumour and
drug response is multifaceted, and recent work using ad-
vanced genomic technology has added further layers of com-
plexity to the picture. Exome sequencing of multiple tumour
regions from a small number of patients with advanced
clear-cell RCC revealed spatially separated somatic mutations
in a large number of low-frequency tumour suppressor genes;
the identification of only a small number of genes altered
ubiquitously throughout tumour regions, and the clonal hier-
archy of the mutations, points to early divergent evolution of
these tumours [92]. It is therefore contended that a single
biopsy will not represent the mutational range of the entire
tumour, and that such intra-tumour heterogeneity will hinder
biomarker discovery efforts [93,94]. It is widely recognised
that there is a critical need to identify biomarkers predictive
of response [17,95], and this is reflected by the now consider-
able number of biomarker development programmes in RCC
(reviewed in [96]). Increasingly, therapeutic clinical trial de-
sign includes a tissue collection component to facilitate sci-
entific research.
5. Ongoing trials and emerging therapies
The clinical trial portfolio in mRCC continues to expand rap-
idly, and there are several ongoing trials that may alter the
current treatment algorithm. On the other hand, there is de-
bate as to how significantly emerging agents will improve
upon current standards. For example, a phase III trial rando-
mising patients to the potent pan-VEGFR inhibitor tivozanib
or sorafenib found a PFS benefit in favour of tivozanib
(11.9 months versus 9.1 months) but no difference in overall
survival between the two drugs [97]. The AGILE study, com-
paring axitinib and sorafenib in first-line treatment of mRCC,
also found improved PFS and response rates for axitinib, but
did not meet its statistical primary end-point of PFS [98]. Both
of these trials could be criticised for their use of sorafenib as a
comparator, and the data are still immature, but in a broader
view may suggest that improvements in clinical outcomes
with the classes of agents currently available have reached
a plateau.
For this reason there is much interest in a new class of sys-
temic agents, the immune checkpoint inhibitors. An immune
checkpoint is an inhibitory mechanism whose role is to regu-
late T-cell response to pathogens and to limit autoimmunity.
Tumours can exploit these pathways to evade destruction by
the immune system, and two immune checkpoint molecules
have therapeutic relevance: the cytotoxic T-lymphocyte anti-
gen 4 (CTLA-4) and the programmed death-1 (PD-1) receptors.
Ipilimumab is a monoclonal antibody inhibiting the CTLA-4
receptor that improves survival in metastatic melanoma
[99,100]. In RCC, the most highly developed of the checkpoint
inhibitors is nivolumab (BMS-936558, MDX-1106), a monoclo-
nal antibody against the PD-1 receptor. PD-1 is an inhibitory
co-receptor that is expressed on activated T cells, particularly
regulatory T cells, as well as activated B cells and natural kill-
er cells [101]. Its two ligands, PD-L1 and PD-L2, are up-regu-
lated widely in response to inflammation; along with
activated B, T, myeloid and dendritic cells, PD-L1 is expressed
on a range of endothelial and epithelial cells [102]. As such,
the function of the PD-1 pathway appears to be in limiting
the activity of T cells in peripheral tissues during an inflam-
matory response [102]. The rationale for inhibition of this
pathway as anti-cancer therapy is strengthened by the obser-
vations that the PD-1:PD-L1 pathway is up-regulated abun-
dantly in human cancers, and that PD-1 is expressed on a
significant proportion of tumour-infiltrating lymphocytes
[103]. Expression of PD-1 in resected RCC appears to have
prognostic significance [104].
In 2012, a large phase I trial of nivolumab reported its effi-
cacy and safety results in patients with a range of previously
treated, solid tumour types [105]. Among 34 patients with
RCC, objective responses occurred in four of 17 patients
(24%) treated with a dose of 1 mg/kg and in five of 16 patients
(31%) treated with 10 mg/kg. At the time of publication, five of
eight evaluable patients had an objective response that lasted
1 year of more, and stable disease lasting at least 24 weeks
was observed in an additional nine patients (27%). Common
treatment-related adverse effects were fatigue, rash, diar-
rhoea, pruritis, anorexia and nausea, but these were usually
low-grade; however, drug-induced pneumonitis occurred in
3% of patients and was fatal in three patients (1%). Nivolumab
is currently being assessed in a phase III trial as second-line
treatment against everolimus, in patients with mRCC previ-
ously treated with one or two anti-VEGF systemic treatments
(NCT01668784), and similar anti-PD-1 antibodies are in
development.
These encouraging early results come with the promise of
a predictive biomarker. In the phase I study described, PD-L1
tumour expression was assessed by immunohistochemistry
on pre-treatment tumour specimens from 42 patients; of 17
patients with PD-L1-negative tumours, none had an objective
response, and nine of 25 patients (36%) with PD-L1-positive
tumours experienced an objective response (P = 0.006). How-
ever, these results require reproduction and validation in
other clinical settings. For example, as PD-L1 expression ap-
pears to be closely associated with the presence of tumour-
infiltrating lymphocytes and secretion of IFN-gamma [106],
the effect of multiple prior treatments is uncertain, and the
prognostic versus the predictive power of PD-L1 expression
must be determined [101].
Anti-PD-L1 agents target the same axis, and there are now
two early reports of their efficacy. Theoretically, blockade of
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the PD-1:PD-L1 but not the PD-1:PD-L2 interaction may im-
prove the safety and tolerability profile compared with anti-
PD-1 antibodies. In a phase I study, 17 patients with mRCC
were treated with the anti-PD-L1 antibody BMS 93-6559
[107]. Two patients (12%) had an objective response, one of
which lasted 17 months, and a further seven patients (41%)
remained stable for more than 24 weeks. A second phase I
trial enrolled a larger cohort of RCC patients and preliminary
results were presented at the American Society of Clinical
Oncology (ASCO) meeting in 2013 [108]; 53 patients with
mRCC, the majority of whom had received previous systemic
treatment, received MPDL3280A, an engineered human
monoclonal antibody to PD-L1. Notably, both rapid responses
and prolonged stability were observed: the response rate was
13%, and 32% of patients achieved stable disease lasting long-
er than 24 weeks. This treatment was reportedly well toler-
ated and differed in its side-effect profile from the anti-PD-1
antibodies; in particular, grade 3 or higher pneumonitis did
not occur.
6. Conclusions
There are now multiple systemic agents available for use in
mRCC, which, particularly when used sequentially, extend
the lives of patients and frequently provide effective pallia-
tive care. The ever-increasing repertoire of drugs for this
condition make decision-making for the individual patient
complex. In the absence of a predictive molecular biomarker,
treatments are selected using a combination of variables,
including the licensed indication of the drug, which in turn
can influence funding arrangements, and clinico-pathologi-
cal factors relating to the patient and the disease biology.
The algorithm will be further refined as research into the
optimal sequence of treatment, and treatments for smaller
patient groups such as those with non-clear-cell mRCC, is
completed. Statistically, the currently available drugs result
in clinical benefit for approximately 1 year at best, but clini-
cal experience suggests that the outcome for each patient is
highly variable. This emphasises the need for improved
understanding of mechanisms of resistance and, further-
more, prediction of drug sensitivity or resistance on an indi-
vidual level. A large number of biomarker initiatives have
received high-level funding, and clinical trial design is
adapting to address translational questions. The develop-
ment of novel agents, such as immunostimulatory antibod-
ies, is a further reason for optimism, with drugs such as
anti-PD-1 antibodies offering the possibility of long-term dis-
ease control.
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second-line exist?
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1. Introduction
In the 1990s, the outlook for a metastatic renal-cell carcinoma
(mRCC) patient was particularly bleak, as the disease was
resistant to conventional chemotherapy and only small sub-
sets of patients responded to immunotherapy. This outlook
improved in 2005 with the introduction of sorafenib, the first
targeted therapy; it was followed by the development of other
tyrosine kinase inhibitors (TKIs): namely, sunitinib, pazopa-
nib, axitinib, the monoclonal antibody bevacizumab (directed
at vascular endothelial growth factor, VEGF) which was used
in combination with interferon (IFN) and the inhibitors of
the mammalian target of rapamycin (mTORis) everolimus
and temsirolimus. Despite the number of available options,
sequencing questions remain key, and the choice for first-
and second-line treatment is still controversial.
However, there is a consensus that VEGF inhibition is the
standard of care for first-line treatment in most cases. The
choice of first-line treatment is informed by the results of
large randomised clinical trials which have included prognos-
tic models in their design and analysis [1–3]. Recent guide-
lines have suggested that low- and intermediate-risk
patients are candidates for sunitinib, pazopanib or a combi-
nation of bevacizumab and interferon, while temsirolimus
should be an option for high-risk patients [4].
Second-line therapy for patients with mRCC of the clear-
cell type is still an evolving field. All the targeted agents
mentioned above have activity in patients previously ex-
posed to cytokine therapy; however, only the orally admin-
istered mTOR inhibitor everolimus is approved for patients
failing prior treatment with sorafenib and/or sunitinib [5].
Recent data have shown that axitinib, a selective VEGFR
TKI, significantly improves progression-free survival (PFS)
compared to sorafenib in patients who have previously
been treated with sunitinib [6]. Based on these two studies,
both agents are currently approved and are used as stan-
dard treatment in patients failing a first-line treatment
with VEGF inhibitors; they are part of the most recent
guidelines [4].
Beyond second-line, there is no consensus and no ‘‘offi-
cially’’ approved drug. However, for the first time, the
European Society for Medical Oncology (ESMO) guidelines re-
cently opened the gate for third-line options [4]. This chapter
is intended to clarify possible options after second-line treat-
ment in mRCC.
Two sequences are currently standard of care, and approved
regimen: TKI (or VEGF inhibitor) followed by everolimus, or
TKI (or VEGF inhibitor) followed by axitinib. The proposed
third-line strategy will depend on this sequence (Table 1).
2. Treatment after TKI (or VEGF inhibitor)
followed by everolimus
There is no randomised study demonstrating the activity of
any approved agent after this sequence. However, there are
some retrospective data suggesting that another TKI can in-
duce clinical benefit in patients still eligible to receive tar-
geted agents [7,8]. In a retrospective database study, third-
line sorafenib appeared active and feasible after first-line sun-
itinib and second-line everolimus or temsirolimus in terms of
toxicity profile and median PFS [7]. Recently, 36 patients from
French sites who received a TKI after everolimus within the
RECORD-1 study have been reported [8]. The received TKI
after everolimus was sunitinib in 17 patients, sorafenib in 15
and dovitinib (TKI258) in four. The response rate with TKI
re-treatment was 8%, and the disease control rate (response
plus stable disease) was 75%. Median PFS with each compo-
nent of the TKI–everolimus–TKI sequence was 10.7 months
(range 1.8–28.5), 8.9 months (range 1.7–34.6) and 8.2 months
(95% confidence interval (CI) 5.2–11.9), respectively. Median
overall survival from the start of everolimus was 29.1 months
(95% CI 21.1 – not reached [NR]), suggesting a benefit in using
TKI in this setting.
Another option after the TKI–everolimus sequence is re-
challenge with the previous TKI [9]. Re-challenge with the
same agent has been examined in those with prior response;
for example, in a retrospective study, 23 patients who
exhibited long response with sunitinib first-line treatment
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were re-challenged with sunitinib after progression on prior
sunitinib were reported. Upon re-challenge, five patients
(22%) reached a PR. The median PFS with initial sunitinib
was 13.7 months and 7.2 months with re-challenge. Those
with >6-month interval between sunitinib treatments had a
longer PFS with re-challenge (median PFS, 16.5 versus
6.0 months, P = 0.03). Substantial new or increased severity
of toxicities was not reported during re-challenge.
Finally, newer TKIs have also demonstrated activity in this
setting. In a recent phase I/II clinical trial of dovitinib, an
inhibitor of multiple-receptor tyrosine kinases, including
fibroblast growth factor receptor (FGFr) and VEGF receptor
(VEGFr), in patients with mRCC refractory to standard thera-
pies, 8 of 10 patients previously treated with a TKI–everolimus
sequence achieved disease control, with one patient experi-
encing a partial response [10]. This has been convincing en-
ough to launch a large prospective phase III trial comparing
sorafenib and dovitinib in patients who have received one
TKI and onemTOR inhibitor (ClinicalTrials.gov. NCT identifier:
01223027). This trial, known as the GOLD trial, has completed
enrolment and will be reported shortly.
Interestingly, first-line PFS, with 6 months taken as cut-off
parameter, appears to be an important prognostic factor for
survival and thus for the likelihood of benefit of second-
and third-line treatments [11].
3. Treatment after TKI (or VEGF inhibitor)
followed by axitinib
There is currently no evidence that a third TKI after two
TKIs has activity, although axitinib has shown some effi-
cacy after sunitinib and sorafenib, with a response rate of
7% and a PFS of 7.1 months in a small number of patients
[12].
By contrast, there is level I evidence that everolimus is ac-
tive after two TKIs, as recognised in the recent ESMO guide-
lines [4]. In the aforementioned phase III RECORD-1 trial,
everolimus was compared with placebo in patients following
sorafenib and/or sunitinib [5]. Among patients who received
one previous TKI median PFS was 5.4 months versus
1.9 months (HR, 0.32; P < 0.001), and among those who re-
ceived two previous TKIs median PFS was 4.0 months versus
1.8 months (HR, 0.32; P < 0.001) [13]. Although this might sug-
gest that everolimus is more active when given in second-line
than in third-line, it more strongly demonstrates that everol-
imus is still active when given after two TKIs.
4. Future of treatment beyond second-line in
mRCC
TKIs as well as mTOR inhibitors have been shown to be active
in third-line treatment, depending on the previous sequence,
as discussed above. In the future, several other options might
be available.
Dovitinib, which is currently in phase III, might become a
new standard if the ongoing GOLD study turns out to be posi-
tive. Interestingly, this study will also demonstrate whether
sorafenib is active in a randomised study after the sequence
TKI–mTOR.
There is a lot of enthusiasm for targeted immunotherapy,
such as anti-PD1 and/or anti-PDL1, in mRCC [14,15]. There is
an going phase III evaluating the efficacy of nivolumab
(BMS-936558), a T-cell checkpoint (PD-1) inhibitor, after one
or two TKIs, in comparison to everolimus (http://clinicaltri-
als.gov/ct2/show/NCT01668784). Overall survival is the pri-
mary endpoint of this study, and this trial will eventually
change the standard of care of mRCC treatment if the out-
come is positive.
Cabozantinib, a Met and VEGF receptor-2 inhibitor, has
shown promising activity in mRCC [16]. The activity of this
new TKI will be shortly evaluated in a large phase III trial, in
comparison to everolimus, after one or two TKIs. Obviously,
this treatment might in the future become a very attractive
strategy to overcome resistance.
5. Conclusion
There is evidence that treatment beyond the second line is ac-
tive in mRCC. Depending on the previous sequence used, both
mTOR inhibitors have shown efficacy. New strategies are
emerging and might change the landscape, dovitinib being
the first drug expected to be incorporated in future guidelines.
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1. Introduction
Vascular-endothelial growth-factor (receptor) (VEGF)(R)-inhib-
iting agents – sunitinib [1–3], sorafenib [4,5], pazopanib [2,6],
bevacizumab [7,8], axitinib [5] and tivozanib [9,10] – have
changed the therapeutic landscape in metastatic renal-cell
carcinoma (mRCC). Five out of six agents have been approved
for either first-line (sunitinib, pazopanib and bev-
acizumab + interferon-alpha) or second-line (sorafenib, axiti-
nib) treatment of metastatic or advanced RCC. With these
novel strategies, the median overall survival of patients has
increased considerably, often, however, at the expense of
chronic side-effects. Common treatment-related side-effects
include: (1) general symptoms such as fatigue and asthenia,
(2) gastrointestinal symptoms such as diarrhoea and stomati-
tis, (3) skin toxicities, (4) cardiovascular toxicities and (5) a
variety of laboratory abnormalities. Some of these side-effects
are clinically highly relevant because they may jeopardise the
patient’s safety or quality of life, while others may have little
clinical relevance. Treating physicians need to be aware of po-
tential side-effects that may occur, how to prevent and/or
manage them, and the clinical implications for the ongoing
treatment. This is of paramount importance since dose
reductions and treatment discontinuations may significantly
affect the outcome [11].
2. Incidence of toxicities associated with VEGF
inhibitors
Toxicities reported from VEGFR inhibitors in mRCC are out-
lined in Table 1. Among general symptoms, fatigue (and/or
asthenia) has been most commonly reported for sunitinib
(up to 63% all grades; grade P3: 17%), followed by axitinib
(all grades 39%, grade P3: 11%) and sorafenib (all grades
37%; gradeP3: 5%). A high incidence of fatigue has also been
reported from the combination of bevacizumab + interferon-
alpha (IFNa). However, the incidence of fatigue appears to
be low in patients being treated with bevacizumab alone
[12,13]; thus, this side-effect may be attributed to IFNa rather
than bevacizumab. Interestingly, the newest VEGFR–tyrosine
kinase inhibitor (TKI) tivozanib appears to have little effect
on fatigue levels (all grades: up to 18%, grade P3: 5%).
Gastrointestinal side-effects are extremely common in pa-
tients on VEGFR–TKI treatment. In particular, sunitinib and
axitinib were shown to cause reduced appetite and/or anorex-
ia in up to 34% of the patients. In the case of sunitinib, this
may be caused partly by the high incidence of stomatitis
and/or dysgeusia (30% and 46%, respectively). Diarrhoea is an-
other frequent gastrointestinal toxicity: high incidences of all
grades of diarrhoea were reported from patients on sunitinib
(61%), sorafenib (53%), pazopanib (63%) and axitinib 55%,
again with quite a favourable profile for tivozanib (22%).
The most common skin toxicities caused by VEGFR inhib-
itors are hand–foot syndrome (HFS), skin- and/or hair-depig-
mentation and rash. The highest incidence of all grades of
HFS has been reported from sorafenib (51%) and sunitinib pa-
tients (50%), with a higher grade 3 + 4 HFS incidence in sorafe-
nib patients (16%). Similarly, sorafenib was shown to cause
rash in up to 32% of patients (all grades). Hair and/or skin
depigmentation is commonly observed in patients on pazop-
anib (up to 38%) and sunitinib (up to 27%).
Among the group of cardiovascular, lung and laryngeal
side-effects, hypertension is the most common (up to 46%).
Hypertension has been observed with all of these agents
and has been considered a fairly reliable biomarker for re-
sponse, progression-free survival (PFS) and overall survival
(OS) [14]. The highest incidence of grades 3 + 4 hypertension
has been observed with tivozanib (26%). Cardiac side-effects
include congestive heart failure (sunitinib: 13%) and ischae-
mia or myocardial infarction (sorafenib: 3%; bev-
acizumab + interferon-alpha 1%). Bleeding events, most
commonly epistaxis, have been observed in patients treated
with bevacizumab + IFN, sunitinib and sorafenib (33%, 18%
and 15%, respectively). While dyspnoea is a common side-ef-
fect of mTOR-inhibitors, the incidence is low in patients with
VEGFR inhibitors. No direct effect of these agents on lung
tissue has been reported so far; thus, the occurrence of dysp-
noea might be a secondary event due to lung metastases or
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oedema as a result of high-grade hypertension or congestive
heart failure. In contrast, dysphonia is a common side-effect
of new-generation TKIs such as axitinib (31%) and tivozanib
(22%).
The incidence of grade 3 + 4 myelotoxicity is low with VEG-
FR inhibitors when compared to classical cancer treatment
such as chemotherapy. Nevertheless, multikinase inhibitors,
particularly sunitinib, may induce grade 3 + 4 anaemia (8%),
neutropenia (18%), thrombocytopenia (9%) and lymphopaenia
(18%). Infections, however, have not been reported yet.
Various metabolic and laboratory abnormalities have been
shown to occur in patients treated with VEGFR inhibitors.
These include renal and electrolyte abnormalities such as cre-
atinine increase (up to 70%), proteinuria (71%), abnormalities
Table 1 – Toxicities reported from phase III trials (%).
(Continued on next page)
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in sodium, potassium, magnesium and calcium levels in up to
37%, 50%, 31% and 59%, respectively. In addition, pazopanib,
sunitinib and tivozanib in particular were shown to cause in-
creased levels of bilirubin, alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) in up to 36%, 60% and
61% of the patients, respectively. In the case of tivozanib,
international normalised ratio (INR) and partial thrombo-
plastin time (PTT) abnormalities were also reported (82%
and 53%, respectively). Sunitinib, sorafenib and tivozanib
were shown to increase amylase and lipase levels in approx-
imately 50% of patients. Finally, the induction of hypothyroid-
ism is an observation that may have been underreported in
the pivotal trials; in later analyses, up to 36% of patients
was shown to develop hypothyroidism [15]. As with hyperten-
sion, the occurrence of hypothyroidism has been linked to a
better outcome [15,17].
3. The severity of side-effects and their impact
on outcome
The occurrence of grade 3 + 4 toxicities, and to some extent
also toxicities of lower grades, may tempt clinicians to reduce
the dose, or to interrupt or discontinue treatment. Table 2 out-
lines the incidence of dose reductions and interruptions, the
rate and most common reasons for treatment discontinua-
tions, as well as the most common toxicities that have led
to death. Dose reductions occurred in up to 51% of sunitinib
patients, 52% of sorafenib patients, 44% of pazopanib pa-
tients, 31% of axitinib patients and 14% of tivozanib patients,
while no dose reductions of bevacizumab were permitted in
the Bevacizumab plus interferon alfa-2a for treatment of met-
astatic renal cell carcinoma: a randomised, double-blind
phase III trial (AVOREN) and CALGB bevacizumab trials. Sim-
ilarly, dose interruptions and treatment delays were required
in 38% of sunitinib patients, 80% sorafenib patients, 62% bev-
acizumab + IFN patients and 77% of axitinib patients. In con-
trast, the number of patients with dose interruptions was
considerably lower in tivozanib patients (18%). Both dose
reductions and treatment interruption may help to prevent
or manage treatment-associated side-effects. However, sev-
eral authors have shown that higher relative dose intensities
were associated with better outcome. A pharmacodynamic/
pharmakokinetic analysis including six sunitinib trials re-
vealed that response rates, time to progression and overall
survival increased with the mean daily exposure to sunitinib
[11]. Similarly, intra-patient dose-escalated sorafenib was
shown to exert promising antitumour activity and led to a
complete/partial response (CR–PR) rate of 48%, with eight
out of 44 patients achieving complete remission [18]. Finally,
Rini et al. could demonstrate in a randomised phase II study
that axitinib dose titration significantly improved overall re-
sponse rates when compared to placebo in patients eligible
Table 1 (continued)
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Table 2 – Dose reductions and treatment discontinuation due to adverse events.
Sunitinib [1–3] Sorafenib [4,5] Pazopanib [2,6] Bevacizumab [7,8] Axitinib [5] Tivozanib [9,10]
Dose reduction
due to AEs (%)
32 [1]
51 [2]
50 [3]
13 [4]
52 [5]
44 [2] Not permitted for
bevacizumab
31 8 [9]
13.9 [10]
Dose
interruptions
(treatment delays)
38 [1] 21 [4] for
dermatological
events, 80 for GI
events [5]
nr nr [7]
61.7 [8]
77 4 [9]
18 [10]
Discontinuation
due to AEs
8 [1]
19 [2]
10 [4]
8 [5]
12 [6]
24 [2]
28 [7] any
19 [7]
bevacizumab
23 [8]
4 9 [9]
4 [10]
Most common
reason
for
discontinuation
Cytopaenia [2] Constitutional [4],
gastrointestinal
[4], dermatologic
[4], respiratory
tract symptoms
[4]
HFS [5], diarrhoea
[5], asthenia [5]
Liver events [2] nr Fatigue, and
transient
ischaemic attack
nr [9,10]
AEs leading to
hospitalisation
34 [4] Nr nr nr nr [9,10]
TX-related death
or non-PD related
deaths
Renal failure [1]
n = 1
Gastric
haemorrhage [1]
n = 1
Respiratory
failure [1] n = 1
Sudden death [1]
n = 1
2 death from
cardiac
ischaemia/
infarction [4]
2 death [5] from
tumour necrosis
causing
retroperitoneal
bleeding and n = 1
GI bleeding
4 [6]
ischaemic stroke,
hepatic failure,
rectal
haemorrhage,
peritonitis and
bowel perforation
2 [7] bleeding
events n = 2, GI
perforation n = 1,
myocardial
infarction n = 1
atrial fibrillation
n = 1
pneumonia n = 1
hepatic failure
(history of active
hepatitis B)
n = 3 [8]
0 n [9]=8/272
ischaemic stroke
n = 2, acute
coronary
syndrome, acute
respiratory
failure, cerebral
vascular accident,
hypotension and
pulmonary
embolism all n = 1
nr [10]
nr, not reported.
E
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S
U
P
P
L
E
M
E
N
T
S
1
1
(2
0
1
3
)
1
7
2
–
1
9
1
1
7
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for dose titration [19]. The challenge in the management of
mRCC patients is to have a balanced approach to maintaining
both dose intensity and safety of the patient.
4. Reasons for and incidence of dose
adjustments and treatment discontinuation by
agent
4.1. Sunitinib
In the final analysis of sunitinib versus IFN-alpha [3], 51% and
19% of sunitinib patients were reported to have required dose
reductions or treatment discontinuation, respectively, be-
cause of adverse events. Causes of death apart from disease
progression included acute renal failure (n = 1), gastric haem-
orrhage (n = 1), respiratory failure (n = 1) and sudden death
(n = 1). In the COMPARZ trial, the most common reason for
sunitinib discontinuation was cytopaenia (3%).
4.2. Pazopanib
In the pivotal pazopanib trial [6] 33% and 4% of patients expe-
rienced grade 3 and 4 toxicities, respectively. The adverse
event (AE) profile was similar in treatment-naı¨ve and cyto-
kine-pretreated patients, although discontinuation rates be-
cause of AEs were higher in the cytokine-pretreated (19%)
compared with the treatment-naı¨ve patients (12%). Arterial
thromboembolic events occurred in 3% of pazopanib patients
– myocardial infarction or ischaemia 2%, cerebrovascular acci-
dent <1% and transient ischaemic attack (TIA) <1% – compared
with none in the placebo arm. The incidence of all-grade
haemorrhagic events was 13% in the pazopanib arm versus
5% in the placebo arm. Deaths from adverse events were re-
ported in 4% of pazopanib patients and in 3% in the placebo
arm. Four pazopanib patients (1%) had fatal adverse events,
including ischaemic stroke, abnormal hepatic function, rectal
haemorrhage and peritonitis/bowel perforation. In the COM-
PARZ trial [2] dose reductions and treatment discontinuations
occurred in 44% and 24% of patients, respectively. The most
common reasons for pazopanib discontinuation were liver
events (6%).
4.3. Sorafenib
In the TARGET trial [4] 10% of sorafenib patients had to dis-
continue the treatment, mostly because of constitutional,
gastrointestinal, dermatological or pulmonary upper respira-
tory tract symptoms. Dose reductions occurred in 13% of
sorafenib patients versus 3% of placebo patients (P < 0.001),
and dose interruptions because of adverse events occurred
in 21% of sorafenib patients versus 6% of placebo patients
(P < 0.001). Dose interruptions were mostly because of HFS,
rash or diarrhoea. Cardiac ischaemia occurred in 12 sorafenib
patients (3%) and two patients in the placebo groups (<1%),
(P = 0.01). Bleeding was more frequent in sorafenib than in
placebo patients (15% versus 8%, respectively). In the axitinib
phase III trial [5], the most frequent grade-3 and -4 adverse
events associated with sorafenib were HFS, hypophosphata-
emia, lipase elevation and hypertension. Two treatment-re-
lated deaths occurred in sorafenib patients and were caused
by necrosis with retroperitoneal bleeding and gastrointestinal
haemorrhage.
4.4. Bevacizumab + IFN
In the AVOREN trial [7], serious adverse events occurred in
29% of patients who received bevacizumab versus 16% of
those who did not. Similarly, AEs requiring treatment discon-
tinuation were more frequent in bevacizumab-treated pa-
tients versus placebo patients (28% versus 12%). Grade 3 and
4 AEs in patients who received bevacizumab included four
gastrointestinal perforations (1%; grade 4: n = 3) and 10
thromboembolic events (3%; grade 4, n = 4). Moreover, seven
(2%) and 5% of bevacizumab patients discontinued treatment
because of hypertension and proteinuria, respectively. Deaths
due to AEs were reported in 2% of patients who received bev-
acizumab and 2% who did not. Three deaths (<1%) among the
patients who received bevacizumab (n = 2 bleeding events and
n = 1 gastrointestinal perforation) were thought to be associ-
ated with treatment. The other causes of death of bev-
acizumab-treated patients included myocardial infarction,
atrial fibrillation, pneumonia, hepatic failure (in a patient
with a history of hepatitis B) and staphylococcal sepsis.
In the CALGB trial [8] 80% of patients receiving bev-
acizumab experienced grade P3 toxicities compared with
63% IFN patients (P < 0.001). Bevacizumab resulted in signifi-
cantly more grade P3 hypertension (11% versus 0), anorexia
(17% versus 8%), fatigue (37% versus 30%) and proteinuria
(15% versus <1%). There were four treatment-related deaths
in the IFN arm and three in the bevacizumab arm.
4.5. Axitinib
In the axitinib phase III trial [5], the most common AEs of
grade P3 were hypertension, diarrhoea and fatigue; 32% of
axitinib patients had elevations in thyroid-stimulating hor-
mone (TSH) and 27% required initiation or dose adjustments
of thyroid hormone replacement. No treatment-related
deaths occurred in the axitinib arm.
4.6. Tivozanib
In the phase II randomised discontinuation trial on tivozanib,
the most common treatment-related toxicities were hyper-
tension and dysphonia which occurred in 45% and 22% of pa-
tients, respectively. Grade 3 and 4 toxicities were rare and
included hypertension (grade 3: 11%, grade 4: 1%) and labora-
tory abnormalities (5%). Dose reductions and interruptions
were deemed necessary in 8% and 4% of patients, respec-
tively. Treatment discontinuation because of adverse events
occurred in 9% of patients. Causes of death that were not
attributed to disease progression included ischaemic stroke
(n = 2), coronary syndrome, respiratory failure, cerebral vascu-
lar accident, hypotension and embolism (n = 1 each); however,
none of these were associated with tivozanib treatment.
Understanding the pathophysiology of individual toxicities,
and developing proactive strategies for their prevention and
treatment are important aspects of disease management and
may avoid dose reductions and treatment discontinuation.
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5. Pathophysiology of selected side-effects
(involved targets) and management
Targeted agents differ regarding their side-effect profile, and
these differences may be attributed to the mode of action;
the incidence and severity of side-effects may depend on
the number of inhibited targets (single versus multikinase
inhibitors), the type of inhibited target (VEGF inhibition ver-
sus platelet-derived growth factor, PDGF, inhibition versus
Flt-3 inhibition, etc.) and the strength of target inhibition
(affinity to the tyrosine kinase, ‘on- and off-target’ toxicities).
While some toxicities have been linked to the inhibition of a
specific target, e.g. hypertension and VEGF, the association
of other side-effects with a particular target is less clear (e.g.
stomatitis, diarrhoea). Moreover, the incidence and severity
of side-effects may differ between patient populations
depending on single-nucleotide polymorphisms.
5.1. Fatigue, asthenia
5.1.1. Mechanisms
Fatigue and to a slight extent asthenia are frequent symptoms
in patients undergoing treatment with VEGF inhibitors. In
1998, Cella and colleagues described fatigue as a ‘subjective
state of overwhelming and sustained exhaustion and decreased
capacity for physical and mental work that is not relieved by rest’
[20]. Fatigue induced by VEGF inhibitors may indeed include
more symptoms than tiring easily. Patient’s description of
what their fatigue involves includes a loss of social interest,
reduced voluntariness for physical activity, cognitive disor-
ders, reduced appetite and depressive symptoms. Together,
these symptoms have been described as sickness behaviour,
a common status in patients with acute or chronic diseases
[21]. In patients treated with VEGF inhibitors, many factors
appear to contribute to fatigue and sickness behaviour. These
include several biological processes related to the patient
and/or the disease in which inflammation appears to have a
major role. Moreover, treatment-related side-effects may con-
tribute to fatigue and asthenia.
The underlying mechanisms appear to involve many as-
pects: (1) the individual genome of the patient, (2) disease-re-
lated factors, either biological or as a result of behavioural
and psychological factors that may arise during the disease,
(3) cancer treatment itself, which may induce fatigue either
on the basis of the specific mode of action or secondarily by
leading to side-effects that may be associated with the symp-
tom of fatigue.
Several studies have investigated the relationship between
genomic markers and fatigue. An association was found be-
tween functional interleukin-6 (IL-6) polymorphism and fati-
gue in patients and their relatives [22], while Aouizerat and
colleagues found evidence for a genetic association between
tumour necrosis factor alpha (TNFa) and the severity of sleep
disturbances and morning fatigue [23]. Furthermore, single-
nucleotide polymorphisms (SNPs) of several cytokines –
including Interleukin-1b, IL-1RN and IL-10 – showed associa-
tions with fatigue levels in lung cancer patients [24]. So far,
no genomic markers for fatigue have been identified in pa-
tients undergoing VEGF inhibitor treatment.
Fatigue has also been strongly correlated with depression
in cancer patients [25], and increased stress-induced inflam-
matory responses were observed in patients with major
depression and stress [26]. Moreover, acute psychological
stress was shown to influence pro-inflammatory cytokines
[27]. Finally, physical inactivity and increased body mass in-
dex have been associated with fatigue in patients with breast
cancer [28]. Again, no data have been obtained so far with re-
spect to patients treated with VEGF inhibitors.
Many tumour types have been shown to promote progres-
sion though inflammatory cells [29]. Chemokines and cyto-
kines were shown to attract immune cells to tumour cells
[30], thereby leading to immune-cell dysfunction [31]. Re-
search on neuro-immune signalling has linked pro-inflam-
matory cytokines with the development of fatigue. For
instance, sickness has been shown to be triggered by IL-1a
and b, TNFa and IL-6 [32–34]. Although no studies have been
undertaken in patients undergoing anti-VEGF-treatment, IL-
6 levels have been linked to disease progression in patients
with mRCC [35].
Cancer treatment itself is known to induce fatigue. Induc-
tion of chronic inflammation has also been recognised as a
treatment-related factor that may induce fatigue through
pro-inflammatory cytokines produced by monocytes [36].
Wang et al. measured markers of inflammation in patients
with gastrointestinal cancers undergoing chemotherapy and
their relationship with fatigue. They found that serum con-
centrations of TNF-R1 were associated with the severity of fa-
tigue [37]. Similar findings have been reported by various
other authors with regards to C-reactive protein (CRP) levels,
IL-6, etc. It is currently unknown as to whether VEGFR inhib-
itors can trigger fatigue through inflammation.
Various side-effects associated with VEGF inhibitors may
contribute to fatigue and sickness behaviour; persistent fati-
gue is a common symptom of patients with hypothyroidism
[38] and several VEGF inhibitors have been shown to induce
hypothyroidism (Table 1). Similarly, hypophosphataemia is
frequently observed in patients treated with VEGF inhibitors.
Although a low serum phosphate level does not necessarily
correlate with clinically relevant total body phosphate deple-
tion, it should be considered that hypophosphataemia may
cause muscle weakness [39]. Muscular dysfunction has also
been shown to involve the heart [40] by causing myocardial
changes and a reversible reduced sensitivity to catechola-
mines [40]. Muscle weakness may also be explained by an im-
paired muscle glucose uptake. Muscle activity involves an
increased rate of glucose uptake in the contracting muscle.
This is enabled by glucose transporter recruitment [41]. Mult-
ikinase inhibitors may interfere with signals required for this
process, such as protein kinase C, nitric oxide, etc. [42]. Fur-
thermore, TKI-induced hypoglycaemia may also contribute
to muscular weakness. Sunitinib, for instance, was shown
to decrease blood glucose levels [43]. In a clinical study that
sought to distinguish between a central and peripheral cause
of fatigue, Yavuszen et al. [44] found that patients with
cancer-related fatigue had a greater central fatigue, indicated
by shorter endurance time. Central fatigue has been linked to
a loss of voluntarily activated muscles because of mecha-
nisms proximal to the neuromuscular junction. On the other
hand, muscle fatigue may have a peripheral cause, e.g. due to
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metabolic changes within the muscles. Antoun et al. [45]
could demonstrate that treatment with sorafenib exacerbates
excessive muscle loss and that this loss increased during the
course of treatment. A possible explanation for this phenom-
enon is that VEGF inhibition leads to downstream inhibition
of AKT and mTOR, which are of paramount importance for
skeletal muscle hypertrophy and muscle protein synthesis
[46].
Finally, malnutrition as a result of VEGF-inhibitor-induced
anorexia, anaemia and dehydration caused by diarrhoea may
account for the high incidence of fatigue, asthenia and sick-
ness behaviour in patients undergoing VEGF inhibitor
treatment.
5.1.2. Management
Effective treatment for fatigue includes pharmaceutical and
non-pharmaceutical interventions.
5.1.2.1. Non-pharmacological interventions. Patterson and
colleagues [47] recently reviewed studies that looked at the
impact of eight different types of intervention on fatigue lev-
els. These interventions included (1) psycho-education, (2)
cognitive behavioural therapy, (3) exercise combined with
education and support, (4) exercise alone, (5) acupressure,
(6) energy conservation and activity management, (7) relaxa-
tion breathing exercises and (8) distraction. With the excep-
tion of cognitive behavioural therapy, all of the above-
mentioned non-pharmacological interventions were found
to effectively reduce fatigue in patients with various diseases.
In particular the impact of exercise has been well studied in
patients with cancer-related fatigue. A Cochrane analysis
[48] recently revealed that among 56 studies including 4068
participants aerobic exercise significantly reduced fatigue
while resistance training and alternative forms of exercise
did not. In contrast, Strasser et al. [49] performed a meta-
analysis on the impact of resistance training in cancer survi-
vors and found an association between resistance training
and positive effects on muscular function and body composi-
tion. Finally, a meta-analysis on exercise programmes for
cancer patients revealed an impact of these interventions
on physical functioning and quality of life [50].
5.1.2.2. Pharmacological interventions. The finding that fa-
tigue is linked to the activation of pro-inflammatory cytokines
has led to the hypothesis that agents inhibiting these cytokines
may reduce fatigue levels. In a randomised placebo-controlled
trial [51] the immunosuppressant etanercept, a recombinant
TNFa receptor fusion protein, enabled a significant improve-
ment in fatigue (mean FACIT-F improvement 5.5 versus 1.9;
P < 0.0001; 95%CI 1.6–4.5) in patients with psoriasis. Similarly,
the monoclonal antibody infliximab was shown to signifi-
cantly reduce fatigue levels in breast cancer survivors with per-
sistent fatigue [52]. Other pharmacological interventions may
include psychostimulants such as methyphenidate [53]. The
relationship between inflammation and depression has also
generated the hypothesis that the essential amino acid trypto-
phan might have a role. Tryptophan is a precursor for seroto-
nin, and patients receiving immunotherapy were shown to
have a fall in tryptophan plasma levels [54]. Another strategy
that might interfere positively with inflammation-induced
fatigue is the administration of thyrotropin-releasing hormone
(TRH). TRH was shown to be involved in the biological pro-
cesses of cytokine-induced sickness behaviour [55], and the
administration of TRH has been associated with a significant
improvement in fatigue levels, sleep disturbances and quality
of life. These effects were accompanied by a decrease in CRP
levels and an improvement in energy levels [55]. Attempts to
interfere with muscle wasting have been made with L-carnitine
supplementation, which was shown to have beneficial effects
by improving nitrogen balance via increased protein synthesis
or reduced protein degradation, inhibition of myonuclear
apoptosis and interference with inflammation. Finally, any
intervention that reduces the incidence and severity of fati-
gue-inducing side-effects may secondarily help to reduce fati-
gue levels: this includes control of anaemia, diarrhoea,
hypothyroidism, hypophosphataemia, congestive heart fail-
ure and malnutrition.
5.2. Hypertension
5.2.1. Mechanism
Hypertension is a common and dose-dependent side-effect of
all VEGF inhibitors. Classical known risk factors for hyperten-
sion failed to predict the development of hypertension in pa-
tients undergoing anti-VEGF treatment [56]. The development
of hypertension in patients undergoing anti-VEGF treatment
has mechanistically been linked to the pathophysiology of
pre-eclampsia in pregnant women. In both cases, a deficient
production of the vasodilator nitric oxide (NO) from endothe-
lial cells and/or decreased NO levels seems to play a central
role [57,58]. VEGF activates endothelial NO synthase through
AKT [59], and a VEGF antibody has been shown to inhibit this
process leading to a decrease in NO levels [58]. Inhibition of
NO may cause vasoconstriction and hypertension [56,60]. An
additional aspect of impaired NO functioning is related to
its role in the control of renal function and salt sensitivity.
NO was found to act as a regulator of pressure-natriuresis
and plays an important role in the regulation of blood flow
to the renal medulla and in the tubular regulation of sodium
excretion [56]. It has therefore been concluded that inhibition
of NO synthase may result in hypertension through its role in
the control of renal water and sodium excretion. Finally, other
mechanisms that may contribute to hypertension have been
described. High salt intake has been shown to increase lym-
phatic vessel growth through increased VEGF-C production.
Inhibition of VEGF-C by pan-VEGF inhibitors may therefore
decrease lymphatic vessel density and increase blood pres-
sure [61]. Apart from the impaired NO production, prostacyc-
lins may contribute to the development of hypertension
under anti-VEGF treatment. VEGF has been shown to activate
the production of the vasodilator prostacyclin (PGI2) [62], and
reduced levels of PGI2 metabolites were found in patients with
pre-eclampsia, suggesting a role for decreased VEGF levels.
Another mechanism that appears to trigger hypertension is
vascular rarefaction. Inhibition of VEGF signalling was found
to cause a loss of endothelial fenestration followed by regres-
sion of tumour vessels [63]. Similarly, normal capillaries in
healthy tissues were shown to regress after VEGF inhibition
[64]. Thus, a reduction in tissue microvessel density may in-
crease blood pressure through an increase in after-load. An
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involvement of an up-regulated renin–angiotensin–axis
resulting from glomerular ischaemia has also been discussed
as a potential mechanism for the development of hyperten-
sion. However, Kappers and colleagues demonstrated that a
sunitinib-induced increase in blood pressure is accompanied
by a decrease in renin [65]. The same group also showed that
sunitinib was associated with a considerable rise in endothe-
lin-1 levels. In a rat model, pretreatment with atrasentan, an
endothelin-A receptor antagonist, completely prevented a
TKI-induced rise in blood pressure [66].
5.2.2. Management
Patients undergoing VEGF inhibitor treatment should be
checked for existing blood pressure and informed about the
importance of monitoring and treating blood pressure. Home
monitoring has been recommended as a reasonable method
to closely monitor blood pressure. Recommendations regard-
ing the frequency of measurements vary between three times
daily [67] to once weekly [68]. Accepted thresholds for initiat-
ing antihypertensive treatment are blood pressures of P140/
90 mmHg and 130/80 in patients with diabetes or chronic re-
nal failure [67,69]. The selection of a specific antihypertensive
drug should be based on the general cardiovascular status of
the patient, as assessed by electrocardiogram (ECG) and echo-
cardiography before treatment [67]. According to the practice
guidelines for the management of arterial hypertension [70],
the choice of antihypertensive treatment should be based
on the underlying cardiovascular co-morbidity. Other recom-
mendations for optimal treatment may be based on consider-
ations of the underlying pathological mechanisms. As VEGF
inhibitors also induce proteinuria, angiotensin-converting en-
zyme (ACE) inhibitors may be considered appropriate: ACE
inhibitors were shown to improve nephrin expression and
to improve endothelial function [71]. Angiotensin inhibitors
as well as angiotensin-receptor blockers may have an addi-
tional advantage since they were shown to exert antitumour
activity (also discussed in section on proteinuria). Calcium-
channel blockers such as nifedipine may offer the (vascular)
advantage of VEGF secretion from coronary smooth muscles
cells [72]. In contrast, non-dihydropyridine calcium-channel
blockers such as verapamil or diltiazem should be avoided:
being Cytochrome P540 3A4 (CYP3A4) inhibitors, they may
interfere with the tumour drug metabolism. Finally, it is
important to inform the patient to withhold antihypertensive
medication in off-treatment periods, where blood pressure
mostly normalises.
5.3. Proteinuria
5.3.1. Mechanism
Although proteinuria has been understood as a classical on-
target side-effect, such as hypertension, little has been re-
ported from the pivotal RCC studies. This could be due either
to the lack of systematic assessment of proteinuria during the
trials or to a low incidence, leading to a drop-out from the tox-
icity tables. No data on proteinuria have been published in the
randomised trials of sunitinib, sorafenib, bevacizumab + IFNa
and axitinib; in contrast, proteinuria has been noted as a
common side-effect in the pazopanib and tivozanib trials tri-
als, with an all-grade incidence up to 71% and a grade 3 + 4
incidence up to 15%. As proteinuria has been linked to VEGF
inhibition, it is likely that all of these agents induce protein-
uria to a considerable extent. Several mechanisms have been
summarised in a comprehensive review on proteinuria in-
duced by VEGF signalling inhibition by Izzedine et al. [73],
and include (1) inhibition of VEGF on podocytes which results
in loss of endothelial fenestrations in glomerular capillaries,
endotheliosis, loss of podocytes and proteinuria [74,75], (2)
an anti-VEGF treatment-induced glomerular endothelial cell
detachment and hypertrophy [76], (3) a subacute glomerular
thrombotic microangiopathy [73] and (4) an adaptive hyperfil-
tration response to nephrectomy [73].
5.3.2. Management
Any abnormal proteinuria may not only trigger loss of kidney
function, it also represents a considerable risk for renal dis-
ease and cardiovascular morbidities. In patients with chronic
renal disease, structural and functional cardiac changes have
been linked to persistent pressure and volume overload [77].
Moreover, strong association between proteinuria and subse-
quent risk of coronary artery disease have been confirmed in
a meta-analysis involving 169,949 patients; in this analysis,
the presence of proteinuria was associated with a 50% in-
creased risk for coronary artery events [78]. VEGF inhibitors
have enabled many patients to live long enough to experience
such additional drug-induced diseases. Thus, both regular
monitoring for proteinuria as well as thorough management
of proteinuria appears mandatory in patients under chronic
VEGF inhibitor treatment. It has been recommended that pa-
tients should be assessed for existing kidney disease prior to
the start of the treatment [73], and that a dipstick analysis
and/or quantitative protein test analysis be performed before
each cycle of VEGF inhibitor treatment. In the case of isolated
proteinuria of <1 g/L, anti-VEGF treatment might be contin-
ued along with continued monitoring. In the case of protein-
uria P1 g/L or proteinuria with microscopic haematuria, a
nephrologist should be involved who may decide on whether
to perform biopsy. Treatment recommendations include ACE
inhibitors or angiotensin-2 receptor antagonists which were
both shown to reduce proteinuria [79,80]. Additional mea-
sures may include salt restriction and the use of dexametha-
sone, which may stabilise the podocyte cytoskeleton [81].
5.4. Cardiac toxicities
5.4.1. Mechanism
Cardiac toxicities occurring under VEGFR inhibitors may be
the result of both on-target and off-target inhibition. Several
kinases inhibited by multikinase inhibitors such as VEGF, Hy-
poxia-inducible factor (HIF), PDGF and KIT are physiologically
highly relevant for the heart, and the inhibition of these ki-
nases may impair compensatory mechanisms [82–84]. HIF
inhibition, for instance, may cause cardiac toxicity since in
the cardiovascular system HIF-related gene products are
understood as mediators of myocardial response to acute or
chronic ischaemia, myocardial remodelling, peri-infarct vas-
cularisation and vascular permeability. Thus, inhibition of
these kinases may impair the myocardial response to acute
or chronic ischaemia [82–85]. Disruption of PDGF–platelet de-
rived growth factor receptor (PDGFR) signalling may lead to
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apoptosis and necrosis of the cardiac myocyte. PDGFR is ex-
pressed on cardiac myocytes and endothelial cells. Suniti-
nib-induced inhibition of S6 kinase may lead to the release
of pro-apoptotic factor Apoptosis-regulator (BCL2) anatago-
nist of cell death, BCL2-associated X protein activation and
cytochrome C release and activation of the intrinsic apoptotic
pathway and cell death [86]. Disruption of KIT signalling may
cause cardiac damage by inhibiting repair mechanisms. KIT is
expressed on endothelial progenitor cells, and functioning of
the KIT receptor might be necessary for the mobilisation of
endothelial progenitor cells to sites of injury. Inhibition of
KIT was shown to aggravate myocardial remodelling and pre-
vent repair [87–89]. Disruption of VEGF–VEGFR signalling in
the heart may induce cardiac dysfunction by preventing com-
pensatory hypertrophy; VEGF is relevant to capillary density
in the myocardium and critical for stem-cell differentiation
into cardiomyocytes [90,91]. In the murine model, disruption
of VEGF–VEGFR signalling during imposition of the pressure
load was shown to reduce capillary density, which in turn
was associated with contractile dysfunction, fibrosis and
heart failure. Thus, inhibition of VEGF–VEGFR signalling in
the heart may become relevant to patients with poorly con-
trolled hypertension. Finally, TKI-induced changes to the thy-
roid function may cause cardiac toxicity. Triiodothyronine has
a direct effect on the cardiomyocytes. Any T3 depletion could
cause changes at the nuclear level of the myocyte level by
influencing T3-regulated transcription of genes that encode
Ca2+-ATPase exchanger, Na+/K+-ATPase and voltage-gated
potassium channels. Moreover, T3 exerts important non-nu-
clear functions on the myocyte which include ion channels
for sodium, potassium and calcium [92]. Finally, low serum
T3 levels have been shown to be the single and the most sig-
nificant predictor of cardiovascular and all-cause mortalities
in adults with heart disease [93]. Triiodothyronine also di-
rectly affects vascular smooth muscle cells, promoting relax-
ation [94]. Hypothyroidism was shown to increase vascular
resistance [94,95] and to exert endothelial dysfunction due
to reduced nitric oxide availability [96,97].
5.4.2. Management
The management of cardiac toxicities may vary among pa-
tients and may depend on the drug that has been used, poten-
tial existing co-morbidities and concomitant medications
that may trigger cardiac events. The clinical presentation
may vary as well: a decrease in left ventricular ejection frac-
tion was noticed in 13% of the patients in the sunitinib phase
III study [3]. In the target trial on sorafenib versus placebo, 3%
of patients experienced cardiac ischaemia or myocardial
infarction. Other investigators noticed arrhythmias and con-
duction disturbances, ST-segment or T-wave changes [84].
Based on the variety of clinical manifestations of cardiac tox-
icities, no general recommendation can be made. However,
this side-effect clearly requires a multidisciplinary approach
between oncologist and cardiologist. The risk of developing
a cardiac event during TKI treatment should be assessed prior
to treatment. On the other hand, patients with existing car-
diac co-morbidities should not be deprived of effective cancer
treatment. Early management of hypertension and protein-
uria appears mandatory to reduce the risk of a cardiac event
during TKI treatment. Congestive heart failure that develops
under TKI treatment is generally completely reversible but re-
quires treatment interruption and effective management [98].
TKI treatment can usually be resumed after recovery, but
should be initiated carefully with close monitoring of the pa-
tient. Cardiac ischaemia and myocardial infarction also re-
quire treatment interruption and cardiological care. Upon
recovery of the patient, the oncologist and cardiologist need
to discuss the conditions under which the patient might be
able to resume RCC treatment. The concomitant use of aspi-
rin and/or clopidrogel should not necessarily represent a con-
traindication; however, increased risks for haemorrhage need
to be carefully considered. In patients who have experienced
either congestive heart failure or myocardial ischaemia or
infarction, regular echocardiograms and electrocardiograms
should be obtained; the value of cardiac troponin T, Creatine
kinase (CK)-MB pro-B-type Natriuretic Peptide (BNP) is ques-
tionable. Many patients on TKI smay have increased serum
levels of one or all of these markers; however, for various rea-
sons, not all of them are clinically relevant. In asymptomatic
patients with increased cTNT, CK-MB and pro-BNP treatment
discontinuation should be avoided. Cardiac events under TKI
treatment may not require a different approach to that of-
fered to a patient without cancer. The only difference is that:
(1) oncological treatment should be temporarily interrupted,
and (2) treatment should be resumed upon recovery along
with permanent cardiac co-medication and close cardiac
monitoring of the patient. In this context, oncologists need
to be aware that some agents, particularly anti-arrhythmic
agents, may exert additive toxicities: e.g. some patients may
receive amiodarone after a cardiac event. Amiodarone and
sotalol are agents that prolong QT intervals, thus increasing
the risk for torsades de pointes. Sunitinib is also an agent
with a possible risk of torsades de pointes. Given together,
the risk for torsades might be higher than with each drug
alone. Changes in toxicity or activity profile may also result
from concomitant cardiac medication. Calcium channel
blockers such as diltiazem or verapamil and again amioda-
rone may be CYP3A4 inhibitors; concomitant use of these
agents with sunitinib may require reduction in the dose of
sunitinib. In most cases, patients can be effectively treated
for both the cardiac event and the oncological condition. It
is of paramount importance to inform the cardiologist about
the necessity of these agents for the patient and about the
change these agents have made to the prognosis of mRCC pa-
tients. Discontinuing RCC treatment should be regarded as
the worst-case scenario.
5.5. Diarrhoea
5.5.1. Mechanism
In contrast to pure VEGF inhibitors such as bevacizumab, diar-
rhoea is a frequent side-effect of multikinase inhibitors. The
underlying mechanism has not been elucidated so far and
may require systematic bowel biopsies and stool analyses
from patients treated with VEGF inhibitors. As both highly
selective VEGFR-TKIs as well as less selective TKIs were
shown to induce diarrhoea; it is also unclear as to whether
this toxicity should be attributed to VEGFR inhibition or off-
target inhibition (e.g. PDGFR, KIT, etc.). VEGF and VEGF recep-
tors were shown to be highly expressed in adult organs,
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including intestines [99]. Thus, VEGF inhibition may indeed
induce diarrhoea. This assumption is further supported by
data showing that the addition of VEGF(R) inhibitors signifi-
cantly reduced the capillaries network in pancreatic islets
and intestinal villi [100]. All of these findings suggest that
VEGF Inhibition may impair the function of digestive organs
such as intestines and the pancreatic gland. VEGF inhibitors
may cause changes in the bowel mucosa, thereby leading to
diarrhoea. In the intestinal mucosa, even small perturbations
of blood flow can lead to rapid metabolic changes characteris-
tic of ischaemia and hypoxia [101]. Epithelial hypoxia is clin-
ically associated with diarrhoea [102], and changes in the
bowel mucosa are consistent with ischaemic colitis [103].
Other possible mechanisms include changes induced by VEGF
inhibitors in the exocrine pancreas, where VEGF and VEGFR
are highly expressed [99]. Patients with strong VEGFR inhibi-
tor treatment frequently report on fatty stools, and VEGFR
inhibitors were shown to decrease the zymogen granules in
the pancreas (observed in animals under axitinib [2,104])
and to reduce pancreatic islets capillaries [100]. Targets other
than VEGF may be involved as well. For instance, sunitinib is
also a c-kit inhibitor, and KIT is expressed by interstitial cells
of Cajal, the pacemaker cells of the intestine [105]. Cajal cells
are adjacent to the nerve fibres of the myenteric plexus and
regulate rhythmic contractions in the muscle layer. KIT inhi-
bition in interstitial cells of the Cajal could be a potential
mechanism for diarrhoea induced by KIT inhibitors such as
sunitinib and imatinib [106].
5.5.2. Management
The management of TKI-induced diarrhoea includes dietary
measures, probiotics and drugs. Among dietary measures is
the avoidance of food and drinks that may cause bowel move-
ments, such as raw fruits, lactose-containing foods, spicy
foods, foods high in fibre and an increase in bananas, rice,
potatoes, etc. [107]. Another dietary measure is the increased
consumption of grated oxidised apples. A randomised dou-
ble-blinded trial conducted in children revealed that the oxi-
dised apples significantly reduced stool frequency in the
treatment group compared to the control group [108]. Probio-
tics have been shown to prevent diarrhoea in inflammatory
bowel disease [109]. Preclinical data yielded a similar efficacy
in chemotherapy-induced diarrhoea [110,111]. In the clinical
setting, Lactobacillus rhamnosus and fibre were shown to signif-
icantly reduce the incidence of grade 3/4 diarrhoea (37% ver-
sus 22%) in a randomised study in patients with colorectal
cancer and chemotherapy [109]. While the use of probiotics
has never been investigated in TKI patients, individual pa-
tients report considerable benefits.
Although several medical strategies have been established
to manage diarrhoea in general, none of these have been
investigated with regard to TKI-induced diarrhoea. One of
the most commonly used agents is loperamide, which slows
transit by decreasing the tone of the longitudinal muscles
and increasing the tone of circular smooth muscles of the
intestinal wall [112]. This increases the time substances re-
main in the intestines, allowing for more water to be ab-
sorbed. Loperamide also decreases colonic movements and
suppresses the gastrocolic reflux. In mRCC treatment, pa-
tient’s satisfaction with this therapeutic measure has never
been investigated and appears to vary. In clinical practice,
some patients report that loperamide successfully controls
higher grades of diarrhoea, while others complain that in
the case of watery stools a slower transit is perceived as a lar-
ger burden than an increased stool frequency. Other medical
strategies to manage or prevent diarrhoea include the use of
budesonide, a topical corticosteroid which was shown to re-
duce bowel inflammation in patients with chemotherapy-in-
duced diarrhoea. Budesonide was shown to reduce the
grade of diarrhoea in >50% in loperamide-refractory patients
treated with chemotherapy [113,114]. There are no data of
budesonide in patients on TKI-induced diarrhoea. Another
agent with unknown benefit in TKI patients is octreotide, a
synthetic somatostatin that is approved for the treatment of
diarrhoea related to vasoactive intestinal peptide (VIP)-secret-
ing tumours and symptoms due to carcinoid syndrome.
Octreotide was shown to decrease the secretion of VIP to pro-
long intestinal transit time and to reduce secretion and in-
crease the absorption of fluid and electrolytes [115]. In
patients with colorectal cancer receiving 5-Fluorouracil (FU)-
based chemoradiation, no difference from placebo was found
[116]. Finally, in patients who complain of bowel movements
during meals or right after, a pancreatic insufficiency induced
by the VEGFR inhibitor might be considered. In this case,
treatment with pancreatin might be helpful (5 meals per
day, 25,000 U pancreatin with each meal).
5.6. Anorexia
5.6.1. Mechanisms
As with fatigue, anorexia is regarded as a common and mul-
tifactorial phenomenon in tumour patients. Anorexia is part
of a syndrome often referred to as anorexia–cachexia and in-
volves metabolic and behavioural factors [117]. Anorexia–ca-
chexia has been strongly linked to an interplay between
cytokines, tumour products that induce lipolysis and/or pro-
tein degradation and neuropeptides [117–119]. TNFa was
shown to induce lipid depletion in white adipose tissue
[120]. Moreover, TNFa induces IL-6 secretion, which was
found to be significantly elevated in patients reporting weight
loss [121]. In a murine model, the cytokine IL-1 was shown to
induce body weight loss [122]. These cytokines appear to in-
duce anorexia by both their peripheral as well as their central
effects [123]. In addition, several neuropeptide dysregulations
have been associated with anorexia. Body weight was shown
to be regulated by interactions between various orexigenic
and anorexigenic central and peripheral neuropeptides
[119]. Whether these interactions are influenced by VEGF
inhibitors has not yet been elucidated.
5.6.2. Management
Several strategies have been investigated regarding their im-
pact on anorexia–cachexia. These include medroxyprogester-
one acetate, eicosapentanoic acid, L-carnitine and
thalidomide. A randomised trial that aimed to identify the
most effective among these strategies revealed the greatest
benefits with a combination of all [124]. Medroxyprogesterone
acetate (MPA) for instance was shown to increase body weight
and appetite in patients with the cachexia–anorexia syn-
drome [125]. The underlying mechanism may involve a
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down-regulation of high serum levels of IL-6 and TNFa [124].
As MPA has been shown to be increased upon the occurrence
of resistance to TKI treatment in mRCC patients [124], the use
of this agent may potentially act synergistically with TKIs by
preventing or delaying resistance.
5.7. Stomatitis
5.7.1. Mechanisms and presentation
Patients on targeted agents may frequently report changes in
the oral mucosa. The symptoms typically differ from chemo-
therapy-induced stomatitis. It also appears that changes dif-
fer between VEGF-TKIs and mTOR inhibitors. In sunitinib
patients ulcers, taste alterations and cheilitis have been de-
scribed [126]. In contrast, oral changes induced by mTOR
inhibitors appear differently as superficial ulcers similar to
aphthous stomatitis [127].
Dysgeusia or aguesia is quite common in patients under-
going sunitinib treatment. This is a taste disorder where e.g.
the taste of meat may be perceived as sweet or a salty taste
is not sensed at all. Other VEGFR-TKI patients may complain
of oral burning with or without visible signs of inflammation
[2,128,129]. Although stomatitis is completely reversible and
more or less harmless, it is considered as clinically highly rel-
evant since it often impairs the patient’s quality of life. More-
over, permanent stomatitis or dysgeusia may contribute to
chronic refusal of food intake, thereby leading to malnutri-
tion, fatigue and anorexia. As stomatitis resolves rapidly once
the drug is withheld or dose-reduced [126], physicians and pa-
tients might be tempted to accept treatment delays, dose
modifications or even a change of treatment. However, such
strategies may affect the outcome. Little is known of the
mechanism of stomatitis induced by VEGF inhibitors. Apart
from a reduction in the capillary network of the tongue, other
mechanisms may contribute to this AE. Interestingly, oral
changes – e.g. burning mouth syndrome (BMS) – have also
been linked to hypothyroidism [130]. BMS has been character-
ised by oral burning with or without inflammation, frequently
affecting women. In their study, Femiano and colleagues re-
vealed that 85 patients with BMS had thyroid alterations
when compared to 13 patients in the control group. Appar-
ently, patients with BMS are affected by dysgeusia, a phenom-
enon that occurs frequently with tyrosine-kinase inhibitors
[131]. Thyroid hormones have been shown to influence the
maturation and specialisation of the taste buds [132], and it
has been speculated that hypothyroidism could therefore
lead to a reduction in taste. Other investigators [133] have
suggested a dysfunction of the nigrostriatal dopaminergic
pathway that may account for the development of BMS. In a
study on patients with BMS, Lauria and colleagues [134] de-
tected a lower density of epithelial nerve fibres and axonal
degeneration on biopsy of the tongue and suggested that
BMS is caused by a trigeminal small-fibre sensory neuropathy.
In a randomised placebo-controlled study, the topical admin-
istration of clonazepam improved symptoms in two thirds of
BMS patients [135]. Finally, based on the assumption that BMS
involves a dysfunction of the dopaminergic central nervous
system, anti-epileptic drugs have been investigated [136]. Lo-
pez and colleagues reported on a considerable improvement
in BMS after treatment with pregabalin. Other mechanisms
that have been discussed include shifts in the oral mucosa
due to myelosupression [137], shifts in the ecological balance
of oral and gut flora [138], an up-regulation of pro-inflamma-
tory cytokines following cancer treatment [139] followed by
NF-jB and cyclooxygenase-2 up-regulation. It remains un-
clear whether and in what way VEGFR inhibitors are involved
in various processes that have been linked to stomatitis.
5.7.2. Management
Recommendations on how to treat or prevent stomatitis most
commonly stem from experiences made in patients undergo-
ing chemotherapy. General recommendations include, among
others, the avoidance of spicy food, etc., the use of soft tooth-
brushes and appropriate dental hygiene [140]. No general rec-
ommendation exists for the prevention or management of
dysgeusia. A review on drug-related taste disturbances in
the elderly [141] revealed that zinc replacement might be
helpful to enhance taste sensation for sweet, bitter and salty
flavours. Patients with dysgeusia may benefit from niacin and
vitamin A, and the use of mints, sugarless chewing gums and
bicarbonate mouthwashes has been recommended as a palli-
ative measure.
A meta-analysis on prophylactic agents to prevent stoma-
titis [142] identified 10 interventions that have positive effects
on preventing or reducing mucositis. These included amifos-
tine, Chinese herbal mixtures, hydrolytic enzymes such as
trypsin, chymotrypsin, wobe-mugo and pepsin. Moreover, a
recommendation has been made for ice chips. In patients
with haematological malignancies undergoing high-dose che-
motherapy, the use of keratinocyte growth factor-1 (palifer-
min) has been recommended [140] however, no data have
been published with regard to VEGF inhibitors. The same ex-
pert panel also recommended the use of benzydamine for the
prevention of radiation-induced mucositis in patients with
head and neck cancer receiving radiotherapy. Stomatitis in-
duced by mTOR inhibitors appears to be different since it in-
volves immune mechanisms. The management might
therefore be different, and corticosteroids might be helpful
[127].
Treatment of stomatitis may also include mouthwashes
with doxycline and/or sucralfat dissolved in water [143]. Pa-
tients who complain of inflammatory lesions may benefit
from local triamcinolonacetonide. As the management of
stomatitis can prove challenging, changes in treatment
schedules might be considered. Several authors have re-
ported on different modified sunitinib schedules: e.g. from
4 weeks on/2 weeks off to 2 weeks on/1 week off. While
such schedules may help to prevent side-effects
such as stomatitis, no changes in efficacy were observed
[144–146].
5.8. Gastrointestinal perforation
5.8.1. Mechanism and clinical presentation
Gastrointestinal perforations have been rarely reported in pa-
tients with renal cell carcinoma [7]. VEGF has been shown to
be highly important for the integrity of the intestinal mucosa.
Vasoactive agents such as prostaglandins and NO, which are
critical for mucosal defence mechanisms, are activated by
VEGF [147]. Thus, VEGF has been considered a survival factor
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for endothelial and epithelial cells in the intestines [148].
VEGF inhibition on capillary beds of intestinal villi may di-
rectly contribute to perforation by inducing the regression
of normal blood vessels [100,149]. The occurrence of gas-
trointestinal perforations with VEGF inhibitors has been
linked to the presence of bowel pathologies [148]. Diffuse
abdominal carcinomatosis is associated with a risk of bo-
wel obstruction, increased pressure on weakened bowel
areas and microperforations [150]. Other risk factors in-
clude ulcer, bowel tumour necrosis, diverticulosis, colitis
and prior abdominal or pelvic radiotherapy [151] (Gentech
Inc., Avastin prescribing information, June 2006). Finally, a
reduction in blood flow to the splanchnic vasculature by
thrombosis or vasoconstriction may further increase the
risk of bowel infarction and perforation [152]. Presentation
of gastrointestinal perforation during VEGF inhibitor treat-
ment varies in type and severity, from free air on the
abdominal x-ray which resolves without treatment to
colonic perforation with abdominal abscess and fatal
outcome.
5.8.2. Management
Patients with risk factors should be carefully monitored for
clinical signs of perforation, such as abdominal pain, obstipa-
tion, fever, vomiting and leucocytosis [149]. In patients under
suspicion of an increased risk of gastrointestinal perforation
frequent radiographic evaluations for free peritoneal air,
extraluminal contrast and abscess formation may be reason-
able [151]. Physicians should also be aware of potential risks
associated with co-medications such as non-steroidal anti-
inflammatory drugs (NSAIDS). These increase the ratio of
endostatin to VEGF and may further contribute to the occur-
rence of gastrointestinal perforations [153]. In patients who
experience gastrointestinal perforation with VEGF inhibitors,
treatment discontinuation has mostly been recommended.
5.9. Hypothyroidism
5.9.1. Mechanism
Mechanisms of hypothyroidism induced by VEGFR inhibitors
may include both on- and off-target inhibition. VEGFR is
January 2012
April 2012
Dose escalaon from 5 to 7 mg b.i.d.
Fig. 1 – Female patient after 3 months on axitinib (no response, no hypertension) and after dose escalation with onset of
hypertension.
Table 3 – Toxicity as a biomarker for outcome.
Agent Side-effect Correlation with outcome
Bevacizumab [196] Hypertension >2 DCR: 91% versus 48% and TTP: 8.1 versus 4.2
Bevacizumab + interferon [8] Hypertension >2 RR: 13 versus 9; OS:41.6 versus 16.2
Sunitinib [14] Hypertension SBP >140, DBP >90 RR: systolic: 55 versus 10; diastolic 57 versus 25%
Sorafenib [197] Hypertension all Shrinkage: 90 versus 33
Axitinib [198] Diastol BP PFS
Sunitinib [16] Hypothyroidism PFS: 10.3 versus 3.6
OS: 18.2 versus 6.6
Sunitinib [199] Hypothyroidism PFS: 575 versus 481 days
Sunitinib [200] Hypothyroidism PFS: 8.55 versus 7.03 mo
Sunitinib + sorafenib [15] Hypothyroidism PFS: 17 versus 10.8; OS: nr versus 13.9
SUN [14] Hypertension ORR: 54.8 versus 8.7%
PFS: 12.5 versus 3.8; OS: 30.9 versus 7.2
DCR, disease control rate; TTP, time to progression; RR, response rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood
pressure; PFS, progression-free survival; OS, overall survival; ORR, objective response rate.
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expressed on thyroid cells and endothelial cells of the thyroid
gland which are also able to synthesise VEGF [58,154–160].
Thus, VEGF inhibitors may induce capillary regression in the
thyroid [64,100], leading to the destruction of normal thyroid
cells. In addition, sunitinib was shown to induce hypothyroid-
ism by inhibiting iodine uptake [161] and peroxidase activity
[162]. It remains unclear whether off-target(s) inhibition
may also contribute to hypothyroidism. Multikinase inhibi-
tors such as sunitinib were shown to strongly inhibit RET/
PTC signalling, thus being potentially beneficial in the man-
agement of thyroid cancer.
5.9.2. Management
Patients treated with VEGF inhibitors should be monitored
for hypothyroidism before and at regular intervals during
treatment. Both clinically overt and subclinical hypothyroid-
ism may occur. According to the clinical practice guidelines
for hypothyroidism in adults [163], the standard treatment
is replacement with L-thyroxine in patients with persistent
TSH levels >10 mIU/L. In patients with subclinical hypothy-
roidism (defined as TSH <10 mIU/L), 92% would be consid-
ered for hormone replacement. These guidelines have
been established to prevent the long-term damage caused
by hypothyroidism in otherwise healthy patients. How rele-
vant are these recommendations in patients with mRCC,
and what are the clinical implications for the management
of TKI-induced hypothyroidism? This is particularly of inter-
est since several authors have reported on an antitumour
effect of hypothyroidism. Hypothyroidism was shown to in-
hibit tumour cell proliferation in various cancer cells and
animal models [164–167]. Moreover, hypothyroidism was
shown to inhibit neoangiogenesis and to improve outcome
in patients with head and neck cancer [168,169]. Thus, the
question arises as to whether we should tolerate TKI-in-
duced hypothyroidism to some extent. Physicians need to
be aware that hypothyroidism has considerable effects on
cardiac function, including impaired relaxation and ventric-
ular filling, increase in peripheral vascular resistance and
increased diastolic blood pressure as well as reduced ejec-
tion at exercise [170]. Therefore, hormone replacement ap-
pears to be mandatory in the majority of patients. In this
context it is important to note that triiodothyronine (T3)
is the relevant hormone for the cardiac myocyte. Interest-
ingly, T3 supplementation was shown to be 50 times less
proliferative and less pro-angiogenic than T4, the ‘bad
guy’ among thyroid hormones [171]. An advantage of T3
replacement would also be that it reduces T4 levels; how-
ever, T3 replacement is difficult in clinical practice due to
the short half-life of available formulations. This problem
could potentially be solved by the use of a combination of
T3 and T4. It has been stated recently that combined T3
and T4 replacement may represent a more personalised ap-
proach to treat hypothyroidism [172].
5.10. Hand–foot syndrome
5.10.1. Presentation and mechanism
HFS has been reported to occur between days 14 and 28 of
VEGF inhibitor treatment [173]. According to the Common
Terminology Criteria for Adverse Events (CTCAE Version
4.0, 2009), patients with grade 1 HFS present with minimal
skin changes or dermatitis (erythema, oedema or hyperker-
atosis) without pain. In contrast, patients with grade 2 HFS
complain of painful skin changes (peeling, blisters, bleed-
ing, oedema and hyperkeratosis) that may limit activities
of daily living. Finally, grade 3 HFS has been defined as
the presence of severe skin changes associated with severe
pain and limited self-care.
Several histopathological changes have been described
by Yang and colleagues [174]. The most common include
intracytoplasmic eosinophilic bodies reflecting keratinocyte
damage, keratinocyte vacuolar degeneration and confluent
keratinocyte necrosis associated with intraepidermal cleav-
age. In addition, an accelerated epidermal cell replication
and increased keratinocyte proliferation has been described
by the authors. So far, the exact mechanism of HFS with
multikinase inhibitors has not been elucidated. The sever-
ity of clinical presentation appears to be correlated with
drug exposure. Discussed mechanisms include: (1) an in-
creased drug concentration in the capillaries at the
papillary dermis, (2) interference by VEGF–PDGFR inhibition
associated with pericyte-mediated endothelial survival
mechanisms, leading to damage of the capillary endothe-
lium in hands and feet [82], (3) an impaired vascular
repair leading to keratinocyte apoptosis and inflammation
and (4) a direct effect of the drug in eccrine sweat
glands.
5.10.2. Management
The management of HFS in patients treated with VEGF
inhibitors has been reviewed by Anderson and colleagues
[175]. Prophylactic measures include pedicure before treat-
ment to remove hyperkeratosis, emollients, topical exfoliat-
ing products (urea-based and salicylic-acid-based),
protection of pressure-sensitive areas (e.g. shoes with soft
insoles) and perhaps systemic administration of pyridoxine,
glucocorticosteroids and cycloogygease-2 inhibitors. The
authors also highlight the importance of frequent and early
collaborations between oncologists and dermatologists.
Dose reductions and treatment interruptions may be tem-
porarily required. The authors recommend a dose reduction
at first occurrence of grade 2 until HFS resolves to grade 0–1
and to increase the dose afterwards; if no improvement to
grade 0–1 occurs, treatment interruption for 7 days may be
necessary. The dose may then be escalated depending on
the HFS grade. In the case of grade 3 HFS, recommenda-
tions regarding dosing include the interruption of TKI treat-
ment for 7 days (until toxicity resolves to grade 0–1) and to
resume treatment at a reduced dose. If toxicity is main-
tained at grade 0–1 at reduced dose, dose escalation may
be recommended. In the case of recurrent grade 3 HFS,
treatment should be resumed at a reduced dose after recov-
ery without further dose escalations. According to the
authors, combinations of cortisone creams and topical anti-
biotics might be recommended in cases of severe HFS.
These recommendations have been made for patients trea-
ted with sorafenib. Although they may also apply to pa-
tients with other VEGFR–TKIs, individual modifications
according to the clinical presentation, the type of drug
and the drug schedule may be reasonable.
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5.11. Myelotoxicity
5.11.1. Mechanisms
Myelotoxicity of tyrosine kinase inhibitors has been linked to
their ability to inhibit various targets. (1) They inhibit KIT sig-
nalling: KIT receptors are expressed on haematopoietic pro-
genitor cells and are involved in their growth and
differentiation. Sunitinib was shown to inhibit phosphoryla-
tion of the KIT receptor and cell proliferation [176]. (2) VEGF
inhibition may also account for myelotoxicity. Gerber and col-
leagues [177] described a regulatory loop by which VEGF con-
trols survival of haematopoietic stem cells. Interestingly,
ligands selective for VEGF and VEGFR-2 as well as VEGFR-1
agonists were shown to rescue survival of VEGF-deficient hae-
matopoietic stem cells. Moreover, VEGF was shown to be in-
volved in the formation of myeloid and erythroid colonies
from progenitor cells [178]. (3) Inhibition of FLT-3 on haemato-
poietic stem cells and PDGFR signalling has also been linked
to myelotoxicity [179,180]. (4) Finally, it has been suggested
that thrombocytopenia might be the result of hypertension
[181] or may be caused by drug-induced immune thrombocy-
topenia [182].
5.11.2. Management
In caucasian populations, myelotoxicity is seldom a dose-
or treatment-limiting toxicity. In the case of grade 2 neutro-
penia or thrombocytopenia, dose adjustments are rarely
necessary. The occurrence of grade P3 myelotoxicity has
been reported to occur more frequently in Asian patients
[183]. In the case of grade 3 neutropenia or thrombocytope-
nia temporary treatment interruptions may be required. In
the case of sunitinib, dose modifications may depend on
the day on which grade 3 myelotoxicity is observed. If ob-
served on day 28 of treatment, prior to the 2-week rest, pa-
tients may not necessarily require dose reduction in the
next course because neutropenia and thrombocytopenia
are usually short-lived and tend to resolve during the
2 weeks off treatment; blood cell counts should be repeated
on day 1 of the next course, and if neutrophils and throm-
bocytes return to normal levels, careful continuation at the
same dose level might be possible [107]. Blood cell counts
should be obtained every 2 weeks, and in the case of re-
peated grade 3 myelotoxicity, treatment should be withheld
for a few days until toxicity is grade 2 or less. In the case of
recurring grade 3 myelotoxicity, dose reduction should be
recommended after recovery [184].
6. Toxicities as biomarkers for successful
outcome
Several retrospective studies have identified specific side-
effects to be strongly associated with outcome. Table 3
summarises these findings. The most common side-effect
that has been associated with outcome is hypertension.
Additional toxicities that were shown to correlate with
the outcome are myelotoxicity [185,186], HFS [186] and fa-
tigue/asthenia [187]. What is the biological basis for this
correlation? The toxicity may reflect that (1) the mecha-
nism of action may be appropriate in the individual
patient, (2) the chosen drug has a high selectivity and ade-
quate potency to hit the target, (3) the tumour is depen-
dent on the inhibited pathway and (4) the drug exposure
is appropriate; this may also be influenced by the presence
or absence of specific single-nucleotide polymorphisms
that influence pharmacokinetic and pharmacodynamic pro-
cesses [188,189].
The potential association of toxicities and outcome has
several clinical implications and raises three major ques-
tions. (1) Should we treat the toxicity, or would this impair
the outcome? In this context, correction of hypertension
has been well studied. While the occurrence of hyperten-
sion appears to be predictive, treating hypertension does
not appear to impair the outcome. In a retrospective analy-
sis on hypertension as a predictive factor for outcome with
sunitinib treatment, Szmit and colleagues [190] reported
that patients who required at least three antihypertensive
agents had the longest PFS. Thus, managing hypertension
is not only mandatory for the patient’s safety, but it also
does not appear to affect the outcome. These findings
may, however, vary depending on the toxicity observed.
As hypothyroidism was shown to be associated with the
inhibition of angiogenesis [168,169] and cell proliferation
[164], maintaining a state of (preferably) T4-hypothyroidism
may to some extent be beneficial for the outcome. In this
context, TSH levels above the upper limit of normal and be-
low the threshold for cardiac impairments (>10 mmol/L)
may be acceptable. (2) Should we adjust the dose until tox-
icity is observed (treating according to toxicity)? In the axi-
tinib dose-titration trial, patients with dose titration and
those who did not require dose titration as assessed by
the occurrence of hypertension had a better outcome when
compared to patients without dose titration [19]. Fig. 1
shows the computed tomography (CT) scans of a female
mRCC-patient who did not experience either hypertension
(or other dose-limiting toxicities) or remission with axitinib
5 mg bid. Only upon dose adjustment to 7 mg bid did the
patient develop hypertension and a reduction in the size
of metastasis. These findings suggest that we may consider
a potential benefit of the ‘treat to toxicity’ approach. Natu-
rally, such strategies should only be considered in the ab-
sence of other dose-limiting toxicities and require careful
monitoring. (3) What is the role of agents given to manage
the toxicity? Do these agents modify the outcome? We can-
not rule out that agents given against the toxicity may have
additional benefits against tumour progression. For in-
stance, some antihypertensive agents were shown to exert
interesting antitumour properties. Beta-blockers, for exam-
ple, were shown to induce apoptosis in endothelial cells
[191] and have been established as standard of care for
infantile haemangiomas [192]. Moreover, several reports
have demonstrated that angiotensin II stimulates growth
and migration of cancer cell lines and induces angiogenesis
through up-regulation of VEGF; interestingly, this effect can
be inhibited by angiotensin-receptor blockers (ARBs) [193].
Losartan, an ARB, was shown to stimulate pro-apoptotic
signalling pathways in various tumour types [194,195]. Fi-
nally, calcium-channel blockers have been shown to reduce
the proliferation and migration of glioma cells [196].
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7. Conclusions
VEGF inhibitors have substantially improved the outcome of
patients with metastatic renal-cell carcinoma. Incidence
and severity of side-effects may vary between agents and de-
pend on the mode of action of the chosen drug as well as on
individual patient-related factors. Physicians need to be
aware of both patient- and agent-related risks that may occur
during treatment in order to choose the best individual treat-
ment and maintain the patient’s safety and quality of life. It
should be considered that the majority of side-effects are
manageable with proactive supportive measures and close
monitoring of the patient. Dose reductions, treatment inter-
ruptions and discontinuation should be avoided whenever
possible.
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Integrating metastasectomy and stereotactic
radiosurgery in the treatment of metastatic renal
cell carcinoma
Axel Bex *
The Netherlands Cancer Institute, Department of Urology, Amsterdam, The Netherlands
1. Introduction
In the European Union 60,000 patients are diagnosed annually
with renal-cell carcinoma (RCC) [1]. Synchronous metastases
are present in up to 30% of patients, with multiple sites af-
fected in 95% [2,3]. Since an additional 40% of those undergo-
ing surgery for localised RCC develop metachronous
metastasis, approximately 30,000 patients per year are diag-
nosed with systemic disease, of which an estimated 7000
have non-clear-cell histology.
In a recent population-based analysis, lung metastasis was
most frequent at 45.2%, followed by bone at 29.5%, lymph
nodes at 21.8% and liver at 20.3% [4]. Adrenal, brain and other
locations had a lower frequency. Moreover, it was found that
the proportion of patients with multiple metastatic sites was
higher in young patients, 16% and 49% of which had brain and
bone metastasis, respectively [4].
2. Rationale of metastasectomy
Selecting appropriate treatment modalities for metastatic
RCC remains a challenge. Although objective responses fol-
lowing targeted therapy are frequent, complete remissions
occur in only 1–3% [5–7]. Moreover, it has become evident
that, despite the most effective drugs in first-line treatment,
a ceiling is being reached in median overall survival (OS)
which ranges between 9 and 40 months, depending on clini-
cal risk scores [8]. Therefore, together with the occasional
durable responses achieved with high-dose interleukin-2, re-
moval of all lesions, when technically feasible, provides the
only potentially curative treatment. Traditionally, surgical
resection has been the preferred approach (metastasectomy),
but recent data on stereotactic radiosurgery (SRS) and ablative
techniques indicate that other local non-invasive or less-inva-
sive treatment modalities are a valid alternative to surgery.
However, only a minority of patients with mRCC are candi-
dates for metastasectomy. No reliable data exist on the pro-
portion of patients with mRCC who will be eligible for this
approach. It has been estimated that only 25% of patients
with metachronous metastasis are suitable candidates for
resection of metastatic disease [9,10]. For patients with syn-
chronous metastasis a recent study addressed this issue. A
whole-nation study on prevalence and potential resectability
revealed that 154 patients (16.9%) had synchronous lung
metastases [11]. However, only 11 with solitary lesions were
deemed eligible for surgical resection, and only one under-
went metastasectomy. In addition, patient selection for this
approach is difficult because of the heterogeneous course of
metastatic RCC. Metastasis may present at diagnosis or with-
in a year after nephrectomy with curative intent, whereas in
others disease-free intervals of more than 20 years have been
observed with a slow growth of lesions. In few cases sponta-
neous regression of metastases has been documented, lead-
ing to the concepts of immune modulation [12,13].
Currently, prognosis and management of mRCC depend on
a number of clinical factors such as performance status, the
length of the disease-free interval, synchronous or metachro-
nous metastasis, as well as the burden of metastatic disease
and the number and location of sites involved [14]. One of
the most commonly used prognostic models, the Memorial
Sloan Kettering Cancer Center (MSKCC) risk score, uses Kar-
nofsky performance status, time from diagnosis to treatment,
and serum haemoglobin, calcium and lactate dehydrogenase
to categorise patients as being at favourable, intermediate or
poor risk [15]. After the introduction of targeted therapy the
MSKCC risk score remains a valid tool together with the vali-
dated Database Consortium (DCM) model to assess the prog-
nosis of patients with comparable concordances of 0.66–0.65
[8,16,17]. Metastasectomy is associated with survival and
clinical benefit across these various risk groups [10,18]. In a
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retrospective analysis on 129 patients metastasectomy in the
favourable-risk group improved 5-year survival from 36% to
71%, and in the intermediate-risk group from 0% to 38%.
When adjusting for risk score, a 2.7-fold increased risk of
death remained for patients who did not undergo metastasec-
tomy. Median survival time and 2-year survival rates for low-
risk, intermediate-risk and high-risk patients were 76, 25 and
6 months, respectively, suggesting that only patients with a
favourable and intermediate risk live long enough to be can-
didates for metastasectomy. However, MSKCC and DCM
scores were primarily developed to assess prognosis in
patients receiving systemic therapies. Other clinical factors
which may have prognostic value in metastasectomy are
recognised.
Patients who are not candidates for metastasectomy are
being offered systemic targeted therapy. Following response
or substantial downsizing, metastasectomy is occasionally
reconsidered in selected individuals to achieve complete
resection and even interrupt targeted therapy. This approach
is investigational and has not been prospectively studied, but
case reports and retrospective series have been published.
A case series described three patients after complete
resection of liver, lymph node and vertebral metastases fol-
lowing absence of further progression under treatment with
sorafenib and sunitinib [19]. Patients remained disease-free
after 16, 24 and 29 months.
Targeted therapy has been discontinued after complete
resection of metastatic lesions. A series included six patients
after complete resection of residual metastases in the lungs,
iliac bone, skin and thyroid following treatment with suniti-
nib. The patients remained off treatment for 5–19 months
[20,21]. The largest study included 22 patients receiving
metastasectomy following targeted therapy [22]. Metastasec-
tomy was performed in the retroperitoneum, lung, adrenal,
bowel, mediastinum, bone and brain. Consolidative metasta-
sectomy proved feasible with acceptable morbidity, although
it resulted in a significant time off targeted therapy and
long-term disease-free interval. However, it is not known
whether this was primarily due to the complete resection of
metastatic disease, which has been identified as an indepen-
dent factor associated with prolonged survival, or the combi-
nation of surgery and targeted therapy.
Ultimately, adequate selection for metastasectomy is of
critical importance. If applied appropriately, surgical resec-
tion alone or in combination with targeted agents may result
in outcome that is superior to systemic therapy alone.
3. General prognostic factors of
metastasectomy
The bulk of literature on metastasectomy dates back to the
last century, when it was observed that patients with solitary
resectable metastasis or multiple metastases restricted to one
resectable organ site may have a survival benefit in the
absence of effective systemic therapeutic options. In the
1930s there was a report of a patient who survived 23 years
following pulmonary metastasectomy [23]. In 1978, one of
the first series on metastasectomy in 41 patients with solitary
lesions in the lungs, pleura, central nervous system and
abdomen was published. In patients with complete surgical
resection, the median disease-specific survival was
27 months, with 59% of the patients alive at 3 years [24]. Sev-
eral authors concluded similar 3-year and 5-year survival
after resection of a solitary lesion [25–27] or observed a signif-
icant difference in survival in patients with metachronous
and synchronous metastasis [28–30].
In a series involving 179 patients the 5-year survival rate
after resection of solitary lesions was 22% for synchronous
versus 39% for metachronous metastases [31]. In addition,
multiple clinical trials from the cytokine era revealed a strong
association of outcome and metastatic sites [32,33]. In a retro-
spective analysis of 101 patients with resection of a total of
152 metastatic lesions at different organ sites [34], median
survival was 28 months for the entire series. Survival was im-
proved after resection of lung metastases when compared to
other tumour locations and for patients clinically tumour-free
after metastasectomy. Again, the time interval between pri-
mary tumour resection and metastasectomy correlated posi-
tively with survival.
Others have observed similar differences in 5-year survival
rates for solitary metastases (56% for lungs, 28% for skin, 20%
visceral organs, 18% peripheral bone, 13% brain and 9% axial
bone metastases) [31]. One study evaluated 278 mRCC pa-
tients to define selection criteria for patients with solitary
metastases [35]. On multivariate analysis, factors associated
with a favourable outcome were a solitary site and single
metastasis, complete resection of the first metastasis, a long
disease-free interval and a metachronous presentation. Since
then, multiple retrospective series have been published that
support these favourable factors [32,36,37] (Table 1).
In a recent retrospective analysis of 109 patients who
underwent primary tumour resection and at least one
metastasectomy for mRCC, the following additional factors
were associated with OS [38]; primary tumour stage PT3
stage, Fuhrman grade P3, non-pulmonary metastases, mul-
ti-organ metastases and disease-free interval 612 months
were negative pretreatment prognostic factors with an accu-
racy of 0.87.
As data from Japan suggest, complete metastasectomy is a
favourable prognostic factor independent of race or geograph-
ical location [39]. No data from prospective randomised trials
on metastasectomy for RCC exist, and decision-making relies
on retrospective series. It cannot be excluded that the benefit
of metastasectomy is due largely to a lead-time bias based on
differences in tumour biology. Patients with solitary and
oligometastatic disease and a prolonged metachronous
interval are more likely to undergo metastasectomy, while
those with extensive metastatic burden, rapid progression
and reduced performance will probably never be considered
for resection. Perhaps not surprisingly, one series found
having an aggressive tumour grade to be the only adverse
factor for survival [40].
The significance of tumour heterogeneity and aggressive-
ness should not be underestimated in the interpretation of
data which extend the indication for metastasectomy to
multiple sites with the aim of achieving complete resection.
Complete resection of multiple lesions has been reported as
either a resection performed simultaneously at one or more
sites or as repeat metastasectomy of asynchronous recur-
rences after the first resection.
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Specifically, asynchronous metastases reflect a more be-
nign course of the disease. In selected cases repeat metasta-
sectomy results in exceptionally long survival lasting more
than 10 years [41,42]. In a relatively large study of 141 patients
with complete resection of solitary metastases, 5-year sur-
vival rates after complete resection of second and third
metastases were no different when compared to those of
the first metastectomy (46% and 44%, respectively, versus a
43% 5-year OS rate) [35]. This supports data from an early ret-
rospective study on repeat metastasectomy which led to im-
proved survival compared to non-surgical treatment of
recurrence after first metastasectomy [43].
Recently a large study analysed survival of patients after
complete metastasectomy for multiple synchronous metasta-
ses at one or more sites [9]. Of 887 mRCC patients, 125 were
identified who underwent complete surgical resection of mul-
tiple metastases (two to three or more metastases); 52% had
resection at two or more sites, including lungs, bone, viscera
and other locations. Patients with multiple non-lung-only
metastases had a 5-year survival rate of 32.5% with complete
resection versus 12.4% without. After controlling for perfor-
mance status and disease burden, an almost threefold in-
creased risk of death remained for patients with incomplete
resection. A scoring algorithm from the same institution to
predict survival for patients with clear-cell mRCC suggests
that complete resection of multiple metastases was associ-
ated with a 50% decrease in the risk of death [14]. It cannot
be ruled out that multiple metastasectomy benefited those
patients who would have had a favourable course of disease
regardless of surgical intervention. Collectively, these data
underscore that careful selection of patients with multiple
RCC metastases should be made according to the general
prognostic factors (Table 1).
A prominent feature of RCC is its ability to metastasise to any
anatomical location. Generally, there is little information on
how to treat rare sites. In these circumstances factors associ-
ated with a favourable outcome after metastasectomy at more
frequent sites should be considered for treatment selection
(Table 1). Individual decisions have to be taken for each case.
However, certain metastatic sites are consistent and more
frequently observed. This has led to additional information
that may guide treatment decisions. Specific management
strategies for the most frequent sites will be discussed in de-
tail. In contrast to traditional surgical metastasectomy, ste-
reotactic radiosurgery (SRS) or ablative techniques have
been largely applied to certain metastatic sites [44]. Although
treatment of RCC metastases with SRS is gaining ground and
is likely to be expanded to multiple anatomical regions, most
of the experience stems from brain and bone metastasis and
will be discussed below. While ablative techniques are mini-
mally invasive and can cause bleeding and thermal damage,
cranial and extracranial SRS involves adverse events such as
cough, fatigue, skin rash and local pain. Side effects are gen-
erally frequent, but mild (grades I–II in 96%) [45].
Table 1 – Factors associated with a favourable outcome after metastasectomy, including sterotactic radiosurgery (SRS).
General and additional reported site-specific factors for the most common sites.
Generala Pulmonary
metastasis
Skeletal
metastasis
Brain metastasis
Solitary or
oligometastatic
lesions
<7 Metastases Peripheral location
of metastases
RPA class I:
1. Karnofsky PS >70%
2. Age<65 years
3. Absence of extracranial metastases
Metachronous
metastasis and
disease-free interval
of >2 years
Absence of
mediastinal lymph-
node metastases
Wide excision After SRS: >75% decrease
of the lesion
Complete resection Metastases <4 cm Clear-cell
subtype
Single-organ site Unilateral lung
involvement
Good performance
status (Karnofsky,
ECOG, WHO)
Munich I: R0, no risk
factor
MSKCC or DCM good
and intermediate risk
Munich II: R0, P1
factor
Absence of
sarcomatoid features
Absence of nodal
metastases
Based on Munich
Score risk factors:
1. Pleural infiltration
2. Synchronous disease
3. Retroperitoneal LN
4. Metastases >3 cm
5. Mediastinal/hilar LN
6. Complete resection
ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization; MSKCC, Memorial Sloan Kettering Cancer Center; DCM,
Database Consortium model; LN, lymph node.
a Recommendations for lymph node, liver, adrenal, pancreatic and thyroid metastasis and other less frequent sites follow the general factors.
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4. Site-specific strategies
4.1. Lymph-node metastases
Data on nodal metastasectomy are difficult to interpret. They
are not regarded as distant metastasis (M) in the tumour-
node-metastasis (TNM) classification, and often occur in
association with further systemic metastatic sites. As a con-
sequence nodal metastasis can manifest as different disease
stages and is generally associated with a poor outcome that
resembles that of systemic disease in retrospective series
[46]. In few studies are locoregional and distant (mostly medi-
astinal) lymph-node metastases differentiated. There is evi-
dence that resection of isolated nodes may be beneficial in
terms of survival.
In fact, isolated lymph-node metastasis is rare. Between
58% and 95% of patients with lymph-node involvement have
associated hematogenous metastases [47,48]. Patients with
pathological N0 have a 5-year OS of 75%, versus 20% for pa-
tients with lymph-node metastases [46,49]. Despite this, pa-
tients with single lymph-node metastases and no
metastatic disease can potentially be cured by lymph-node
dissection (LND) [49].
Regional lymph-node metastases in RCC range from 13%
to over 30%. However, the true incidence of solitary nodal
metastasis without further systemic disease is unknown. In
nephrectomy and autopsy studies single nodal metastases
were observed in smaller tumours in 3–4.5% [46,49,50]. At au-
topsy, anatomical location of lymph-node metastases was
unpredictable [51]. The authors found ipsilateral renal hilar
lymph-node metastases in 7%, pulmonary hilar lymph-node
metastases in 66.2%, retroperitoneal in 36%, para-aortal in
26.8% and supraclavicular in 20.7% [51]. In addition, single
metastases in mediastinal, axillary, supraclavicular and iliac
lymph nodes without any further metastasis were described
[52,53].
In node-positive cases lymph-node dissection was associ-
ated with improved survival and a trend towards an improved
response to immunotherapy [49]. Patients with regional nodes
and distant metastases had significantly inferior survival to
those with either condition alone. However, lymph-node sta-
tus had less impact on survival than primary tumour stage,
grade and performance status. [49]. Current guidelines advise
that suspicious lymph nodes either at imaging or on palpation
should be removed during nephrectomy because LND for clin-
ically positive lymph nodes is associated with improved sur-
vival when performed in carefully selected patients [49].
A recent systemic review of the available literature con-
cluded that data from the majority of retrospective non-ran-
domised studies suggest that a possible benefit in terms of
OS exists for patients with node-positive disease [54]. In addi-
tion, LND at the time of nephrectomy may avoid symptomatic
local recurrences. As most clinically suspicious lymph nodes
are removed at the time of nephrectomy, few data exist on the
management of metachronous regional lymph-node metas-
tases and are often summarised in series reporting on local
recurrences [55], but there is a tendency to choose an investi-
gational approach and pre-treat these lesions prior to surgical
removal.
Several cases have been reported with downsizing of nodal
metastases following tyrosine kinase inhibitors. Subsequent
to sunitinib therapy, complete resection of bulky lymph nodes
with encasement of the great vessels not amenable to initial
excision was performed in a number of patients with clear-
cell histology and no evidence of further lesions [56–59].
Downsizing up to 40% was reported following 5–10 cycles.
‘Second-look’ surgery with complete retroperitoneal LND
was feasible in all cases. Despite necrosis, viable clear-cell
carcinoma was present in all cases.
4.2. Thoracic metastases
Pulmonary, pleural and mediastinal lymph-node metastases
occur frequently in RCC and are found simultaneously in
20–35% of patients [60–62]. Lung lesions are most frequent
and have a prevalence rate of 74% in autopsy studies [51].
Metastasis is mostly hematogenous, but direct lymphatic
drainage from the kidney into the thoracic duct which subse-
quently drains into the subclavian vein and pulmonary artery
has been proposed [63].
There are many retrospective series on resection of pul-
monary metastases, but most of the earlier studies were
small [33,35,64–67]. Collectively, recent series with larger pa-
tient cohorts observed a 5-year survival rate of 37–54% pro-
vided that complete resection of solitary or oligometastatic
pulmonary metastases was achieved [9,35,60–62,68–74]. Con-
sistent and robust prognostic factors were identified in multi-
variate analyses (Table 1). Incomplete resection was
associated with a poorer 5-year survival of 0–22%
[9,35,60,62,71,74,75], as was the number of pulmonary metas-
tases removed [9,35,62,68,69,75]. Thus, median 5-year survival
after complete resection of a solitary lesion was 45.6–
49 months versus 19–27 months after complete resection of
multiple metastases [68,69,75].
In a large study a significantly longer median 5-year sur-
vival was observed for patients with fewer than seven pul-
monary metastases versus those with more than seven
metastases (46.8% versus 14.5%) [62]. Furthermore, the pres-
ence of lymph-node metastasis was associated with shorter
survival [60–62,74].
Despite complete pulmonary metastasectomy, mediasti-
nal lymph-node metastases decreased median survival from
102 months to 19 months [60] and the median 5-year survival
rate from 42.1% to 24.4% [62]. A short disease-free interval
after nephrectomy or the presence of synchronous metastasis
had a poor outcome [35,62,69,71,74,75]. Disease-free interval
of > or <48 months or 23 months were associated with a med-
ian 5-year survival rate of 46% versus 26% (69) and 47% versus
24.7%, respectively [62]. The presence of synchronous pul-
monary metastasis had a particularly poor outcome, with a
median 5-year survival rate after complete pulmonary metas-
tasectomy of 0% versus 43% for patients with metachronous
disease [75].
Size of pulmonary metastasis is an additional factor
[61,74,76].A median 5-year survival rate of 70% versus 35%
was observed after complete resection of metastases either
< or >0.5 cm [76]. In an attempt to define a prognostic score,
200 consecutive patients with pulmonary metastases were re-
cently evaluated in a single centre [77]. By multivariate anal-
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ysis complete metastasectomy, metastatic size >3 cm, posi-
tive lymph-node status of the primary tumour, synchronous
metastases, pleural invasion and hilar or mediastinal
lymph-node metastases were independent prognostic fac-
tors. From these factors the Munich score was developed
which discriminates three risk groups with median OS of
90, 31 and 14 months for low, intermediate and high risk,
respectively (Table 1).
However, some investigators have found no association
with the type of resection and survival [68,73]. SRS or ablative
techniques may be an alternative to surgical resection in se-
lected patients [45,78]. In a prospective phase II trial of extra-
cranial SRS given to 82 metastases in mRCC, a total of 63 lung
lesions were treated [45]; 50% of the patients were MSKCC
favourable-risk and 46.7% intermediate-risk. In 21% of the
treated sites total regression was observed after 3–36 months,
while another 31% showed regression of >50% after 3–
12 months. Median OS was 32 months, suggesting that con-
trol and outcome can be achieved similarly to surgical metas-
tasectomy. A recent retrospective analysis including 39 lung
lesions suggests that a single fraction equivalent dose (SFED)
of P45 Gy is effective for controlling RCC metastases [79].
Isolated mediastinal lymph-node metastasis without pul-
monary or other lesions is frequently observed in RCC [80–
82]. This may be a consequence of renal lymphatic vessels
which always connect to the origin of the thoracic duct, some
directly without traversing any retroperitoneal nodes [63].
Resection of isolated mediastinal and intrapulmonary nodal
metastases has resulted in DFS of up to 5 years [83,84]. As
these lymph nodes are usually not resected at the time of
nephrectomy, these series contain mostly metachronous no-
dal metastases. As already mentioned, concurrent mediasti-
nal lymph-node and lung metastases have a poorer
prognosis [60–62]. These studies provide information on the
potential prevalence of lymph-node metastases in patients
with pulmonary metastatic disease which was 20–35%. With
a median OS of <2 years, patients with pulmonary metastases
and mediastinal lymph nodes may not be candidates for sur-
gical resection, though match paired analysis suggests a
trend towards improved survival [60].
4.3. Bone
Bone metastases occur in 16–26% of patients with metastatic
RCC and are often symptomatic [15]. The prevalence of soli-
tary bone metastasis may be low. In a series of 94 patients
with solitary metastasis, single skeletal secondaries were ob-
served in five patients (5.3%) [35]. Another retrospective series
reported a rate of 2.5% [25]. Although prolonged disease-free
survival has been reported after surgical resection of single
and even multiple bone metastases, the most frequent indi-
cation for treatment are symptoms such as pain from
nerve-root compression and pathological fractures. Exter-
nal-beam radiotherapy may be equally effective, but no ran-
domised data exist specifically for RCC. As for other
metastatic sites, outcome after surgical resection of skeletal
solitary or oligometastases has only been evaluated retro-
spectively. Early reports suggested that patients with solitary
bone lesions have a better survival after resection [85]. In a
small study analysing bone metastasis from RCC in 13 evalu-
able patients with solitary lesions, a 5-year survival rate of
55% for the entire cohort was achieved [86].
The 5-year OS rate after resection of solitary bone lesions
in other series was 40% [35] and 54%, respectively [87],
although numbers were very small. Conversely, a series
including 25 patients reported a 5-year survival rate of only
13%, despite wide resection of solitary bone metastasis [88].
A recent series evaluated 125 patients after resection of multi-
ple metastases, including 11 with bone as single site (8.8%)
and four (3.2%) with bone and lung involved [9]. The majority
(75.2%) had more than three metastases removed. For pa-
tients with extrapulmonary sites the 5-year OS rate was
32.5% when complete resection was achieved compared with
12.4% among a matched cohort without complete resection.
One of the largest studies on resection of RCC bone metas-
tases included a literature review. Five-year survival rates
were 35.8–55%, comparable to OS observed after resection of
lung lesions [86]. Patients with peripheral skeletal location
of metastases had a 75% 5-year survival rate. Collectively,
metachronous disease with a long disease-free interval,
peripheral skeletal location with wide excision and solitary
metastases were correlated with longer survival [86]. A fur-
ther prognostic factor is the presence of a clear-cell histolog-
ical subtype. Interestingly, the additional presence of
pulmonary metastases did not predict early death, some pa-
tients surviving for years after complete resection of pulmon-
ary and bone disease [9,89].
Similar predictive factors and survival rates were reported
in a number of smaller retrospective series [87,88,90,91]. Be-
cause of the retrospective data evaluation, the impact on out-
come of resection of RCC bone lesions remains controversial.
However, surgical resection of bone lesions to effectively
palliate pain and symptoms from spinal cord compression
is undisputed.
A randomised prospective trial in patients with bone
metastasis from various malignancies, including RCC,
demonstrated that immediate decompressive surgery and
postoperative radiotherapy are superior to treatment with
radiotherapy alone for patients with spinal cord compression
[92]. In addition, a prospective non-randomised study demon-
strated that spinal surgery was effective in improving quality
of life in patients with extradural spinal metastases from var-
ious cancers by providing better pain control, enabling pa-
tients to regain or maintain mobility, and offering improved
sphincter control [93]. Surgery resulted in acceptably low mor-
tality and morbidity rates.
RCC bone metastases are highly destructive vascularised
lesions. The risk of life-threatening haemorrhage poses a seri-
ous surgical challenge. The largest retrospective study on sur-
gical approach and outcome included a total of 368 RCC bone
metastases to the limbs and pelvis [89]. Surgical procedures
involved curettage with cementing and/or internal fixation,
en-bloc resection with closed nailing or amputation. The
1-and 5-year OS rates were 47% and 11%, respectively. How-
ever, 15 patients (5%) died within 4 weeks after surgery due
to acute pulmonary or multi-organ failure.
Regarding palliation, resection of painful RCC bone metas-
tases relieved pain significantly in 91% of patients. A good to
excellent functional outcome was achieved in 89%, and 94%
with metastatic lesions of the pelvic girdle and lower extrem-
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ities were ambulatory [91]. Wider resection reduced the risk of
recurrence at the same location and the need for re-interven-
tion [94]. This was a general observation made in bone metas-
tasis from a variety of cancers where wide excision resulted in
improved survival and functional outcome compared to lam-
inectomy alone [93].
Surgery for bone lesions should therefore aim at lasting
control at the treated site with a durable fixation or
reconstruction to prevent re-intervention. As the only ran-
domised trial performed included radiotherapy in both arms,
postoperative radiotherapy is advised [92].
Ablative approaches may be an alternative to surgery in
selected cases with bulky bone lesions extending to extra-
osseous regions [95,96]. As with other extracranial locations,
SRS for spinal metastasis of RCC has been shown to be effec-
tive in a series of 48 patients with 55 spinal lesions [97]. The 1-
year absence of progression rate in the spine was 82.1%. This
early series suggests that SRS to spinal metastases is effective
in palliating symptoms. At baseline, 23% of patients were
pain-free, and this increased to 44% 1 month and 52%
12 months after SRS. In a retrospective study of 24 painful
RCC bone lesions a relationship between dose and stable pain
relief was observed in patients treated with a dose of 40 Gy in
five fractions [98]. Adverse events were absent except one
grade 1 skin toxicity. These data suggest that symptomatic
and painful RCC skeletal metastases at various anatomical
sites can be effectively controlled and palliated by SRS, and
prospective non-randomised trials have been initiated.
5. Intra-abdominal organ metastases
5.1. Liver
Hepatic metastases are diagnosed in 8–30% of patients with
RCC [15]. An autopsy study reported liver metastasis from
RCC in 41% [51]. Only in 5% were these metastases solitary
metachronous lesion [99]. The simultaneous presence of mul-
tiple organ sites explains the paucity of reports on liver
metastasectomy either by surgery or by ablative techniques
[100]. In addition, in contrast to solitary pulmonary metasta-
ses, liver metastases are consistently associated with a poor
prognosis [31,32,34].
A few retrospective series with 13–68 patients suggest that
surgical resection may be beneficial in terms of survival
[99,101–104]. Earlier series reported a median survival follow-
ing resection of solitary liver metastasis of 16–48 months with
5-year survival rates of 8–38.9% [99,101,102,104]. Factors asso-
ciated with a good prognosis were disease-free interval longer
than 6–24 months, performance status and completeness of
resection. A large retrospective series analysed the outcome
of 88 patients with liver as the only metastatic site [103].
Sixty-eight patients underwent metastasectomy compared
to 20 who refused. The median 5-year OS rate after metasta-
sectomy was 62.2% versus 29.3% in the control. In both
cohorts 79% received systemic therapy, which suggests that
liver metastasectomy may be appropriate for carefully
selected patients. Patients with high-grade RCC and synchro-
nous metastases did not benefit from hepatic metastasecto-
my. Furthermore, metastasectomy is associated with
significant morbidity of 20.1% [103]. One series even reported
a mortality rate of 31% [99]. In contrast, a contemporary mul-
ti-institutional analysis of 43 patients reported a low morbid-
ity and near-zero mortality [105]. Three-year OS was 62.1%
with a median recurrence-free survival of 15.5 months. How-
ever, recurrence occurs in up to 50% after liver resection
[101,105]. Morbidity, mortality and recurrence need to be bal-
anced against a potential benefit when selecting patients. It
may be that surgery of small lesions is not superior to the
use of ablative techniques in this setting which have been ap-
plied effectively [106]. SRS has been applied in a few patients
with liver metastasis.
In a Swedish single-centre prospective study including
multiple sites three liver lesions were treated successfully
[45]. A retrospective analysis of SRS to RCC and melanoma
metastases revealed that liver lesions treated with SRS with
a SFED of P45 Gy had a local control rate at 24 months of
100% [79].
5.2. Adrenal metastases
Adrenal metastasis has been found in 3.1–5.7% in nephrec-
tomy series [107–109]. In up to 23% of adrenal lesions simulta-
neous metastasis at other sites were present. Adrenal
metastasis generally has a poor prognosis despite complete
resection of solitary ipsilateral metastases at the time of
nephrectomy. It is unknown whether this is directly due to
the adrenal involvement or a consequence of an often con-
comitant advanced locoregional tumour stage. In 347 patients
with advanced stage disease (T3-4N0-1M0-1) adrenal metas-
tases occurred in 8.1% [109]. Among 56 patients with adrenal
metastases, 82% had pT3 tumours [108]. Presence of distant
metastases, vascular invasion within the primary tumour
and multifocal growth of renal-cell cancer within the tu-
mour-bearing kidney were identified as independent predic-
tors of adrenal metastases [110].
The majority of radiographically or clinically apparent
ipsilateral adrenal metastases are resected at the time of
nephrectomy. Isolated, synchronous contralateral and
metachronous ipsilateral or contralateral adrenal metastases
are rare, and little is known about their management. They
are often included in series on the management of local
recurrences [55,111,112]. Survival with locally recurrent re-
nal-cell carcinoma is poor, with a 5-year survival rate of 28%
[111]. Patients after surgical resection had an improved 5-year
survival rate of 51% compared to 18% treated with systemic
therapy and 13% with observation alone.
Contralateral adrenal involvement, either synchronous
or metachronous, is rare. In one autopsy series of patients
after nephrectomy for RCC it was observed in 0.7% [51]. A
small series on the outcome of 11 patients after surgery
for metastatic RCC in the contralateral adrenal gland re-
ported that synchronous contralateral adrenal metastasis
occurred in two patients. The mean (median, range) time
to contralateral adrenal metastasis after nephrectomy for
nine patients was 5.2 (6.1, 0.8–9.2) years. All patients had
adrenalectomy. Despite resection, most patients in this
study died from RCC after a median of 3.7 (range 0.2–
10) years after adrenalectomy for contralateral adrenal
metastasis [113]. Collectively, not more than 60 cases are de-
scribed in the literature [114–116]. Survival ranges from 8 to
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70 months, and factors associated with outcome are uncer-
tain. Some observed an association of survival with a
metachronous interval of >18 months [115]. In summary,
adrenalectomy for isolated metachronous ipsilateral and
contralateral adrenal metastasis is recommended because
it is associated with long-term survival in individual pa-
tients. Ablative percutaneous techniques may be an alterna-
tive to open or laparoscopic adrenalectomy [117].
5.3. Pancreatic metastases
Pancreatic metastases of RCC are relatively infrequent but have
been described in 411 patients in 170 publications [118]. A sys-
tematic literature search reported the clinical outcome of pan-
creatic RCC metastases [118]. Of the metastases, 321 were
treated surgically and 73 non-surgically. In the metastasectomy
group 65.3% of the lesions were solitary and symptomatic in
57.4%. Following metastasectomy, 2-year and 5-year disease-
free survival was 76% and 57%, respectively. Interestingly, the
2- and 5-year OS rates were 80.6% and 72.6%. Further extrapan-
creatic disease had no impact on OS in the metastasectomy
group. Surprisingly, the time to pancreatic metastasis and the
number of pancreatic lesions were not associated with a worse
outcome. As expected, patients with unresected pancreatic dis-
ease had a significantly shorter 2- and 5-year overall survival
rate of 41% and 14%, respectively. These data suggest that
metastasectomy may be beneficial in patients in whom the pan-
creas is the only metastatic site and who are fit enough to under-
go pancreatic surgery. In-hospital mortality after pancreatic
metastasectomy was 2.8%, and a significant number of patients
underwent extensive surgery (pancreaticoduodenectomy in
35.8% and total pancreatectomy in 19.9%). In view of the retro-
spective quality of the data and the significant surgical morbid-
ity, patients with a short time to pancreatic metastasis following
nephrectomy may be best treated with systemic therapy first.
5.4. Brain metastases
Brain metastasis is observed in 2–17% of patients with RCC,
and is readily diagnosed by symptoms in more than 80% of
cases [119–121]. If left untreated, median survival is poor
(3.2 months) [122]. After the introduction of SRT, indications
for craniotomy have been largely abandoned except for lesions
>2–3 cm, rapid onset of symptoms and in cases of large lesions
with midline shift [123–125]. Because of their relative paucity,
therapeutic strategies for RCC brain metastases have often
been evaluated together with cerebral lesions of various pri-
mary tumours. Generally, selection of patients for therapy of
brain metastases, regardless of the primary tumour site,
involves assessment of performance status, extracranial
tumour load and the course of the disease, as summarised in
the Radiation Therapy Oncology Group (RTOG) recursive parti-
tion analysis (RPA) [126]. Unfortunately, the majority (70–80%)
of patients with RCC brain lesions belong to RPA class II – Kar-
nofsky score (KS) >70%, further extracranial metastases – who
have a poor median survival of 4.2 months [124,127].
In another study, including 4295 patients, significant prog-
nostic factors for RCC brain metastasis were KS performance
status and number of brain metastases [128]. Those with a KS
of 90–100% and a single brain metastasis had a median OS of
14.8 months versus 3.3 months for those with a KS <70% and
more than three metastases. Others have confirmed these
observations [125].
An early retrospective series of whole-brain radiation ther-
apy (WBRT) observed survival of patients with single brain
metastases from RCC of 4.4 months only, which suggested that
aggressive surgical treatment would be superior [129]. A pro-
spective randomised trial of surgery and WBRT versus WBRT
alone was in favour of the combination, although only few of
the 63 patients with brain metastases had RCC [130,131].
For patients with extracranial progressive disease WBRT
seemed sufficient. In a further study, craniotomy with resection
of brain metastases in 50 patients with RCC again proved supe-
rior to WBRT, with a median overall survival of 12.6 months
[132]. However, the addition of postoperative WBRT did not
result in a survival difference. Currently, WBRT is regarded an
adequate choice for patients with a poor performance and
multiple lesions in whom palliative control of symptoms is
the principal aim. In contrast to WBRT, SRS can provide effec-
tive local control comparable to surgery, even when multiple
lesions and recurrent metastases are present [133].
Experience with SRS in the treatment of brain lesions ex-
ceeds that at extracranial sites. This is because SRS has been ap-
plied relatively early after its introduction to brain metastases
as ‘gamma knife’ or ‘radiosurgery’ with the first series on RCC
published in 1998 [134]. In one of the larger series, 85 patients
with 376 brain metastases from RCC underwent SRS [124].
The median tumour volume was 1.2 cm (range: 0.1–14.2 cm)
although 65% had multiple brain lesions. Median OS was
11.1 months after SRS with a local tumour control rate of 94%.
Most patients (78%) died because of systemic progression. RTOG
RPA classes I, II and III survived for 24.2 months, 9.2 months and
7.5 months, respectively. Another SRS series of 69 patients ob-
served a median survival of 13 months in patients without
and 5 months in those with active extracranial disease [135].
In a recent retrospective analysis 46 patients with 99 brain
lesions were treated by SRS [136]. A single brain metastasis
was treated in 56.5%. Local tumour control was achieved in
84.7%. Median OS was 10 months, but increased to 18 months
for those with a >75% decrease in metastasis volume. It has
been argued that survival rates after SRS are inferior to those
after craniotomy, but the size of the retrospective series
involving patients with RCC brain metastases, and the fact
that more patients with a long metachronous interval and
fewer brain metastases were candidates for craniotomy
[132,137], do not allow a direct comparison.
5.5. Thyroid metastases
The thyroid gland is infrequently involved, and the first cases
were reported in the 1940s [138]. The largest retrospective study
evaluated 45 resections of solitary thyroid metastases at 15 dif-
ferent centres [139]. The 5-year overall survival rate was 51%.
Prognosis was significantly poorer in patients >70 years of age,
but no other factors were established. There was a striking coin-
cidence of thyroid and pancreatic metastases (31%).
Another group reported on seven patients with solitary
RCC metastases in the thyroid and a median OS after thyroid-
ectomy of 38.1 months [140]. In a clinicopathological study of
36 cases, 64% had documented previous evidence of RCC as
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long as 21.8 years before the thyroid lesion developed (mean,
9.4 years). After a mean follow-up of 9.1 years, 36% were alive
or had died without evidence of disease [141].
6. Conclusion
Only few and selected patients, especially those with solitary
metastases at single-organ sites, may benefit from metasta-
sectomy. Consistently, survival benefit and even cure have
been reported after complete surgical resection and SRS (Ta-
ble 2). However, available data specifically related to RCC are
from retrospective non-randomised studies. Therefore it re-
mains unresolved whether the observed survival benefit is a
consequence of surgical intervention or a selection of pa-
tients with more benign tumour biology who, owing to a mild
clinical course, were considered for metastasectomy.
The best outcome has been observed after resection of
metachronous solitary or oligometastases in the lung, but
similar survival rates were reported for other sites, including
liver, pancreas, bone and even multiple sites, provided that
complete resection was achieved.
Despite consistent prognostic factors associated with a
favourable outcome following metastasectomy, no general
therapeutic guideline can be given. Careful patient selection
is paramount, and the decision to resect metastases has to
be taken for each site and each individual patient. Perfor-
mance status, risk profiles, patient preference and alternative
techniques to achieve local control, such as SRS or ablation,
will have to be considered. After the introduction of targeted
therapy, more patients with metastatic RCC may become can-
didates for complete surgical resection; pretreatment and
multimodality concepts integrating medical and surgical
treatments are being investigated.
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Introduction
Mood disorders in cancer patients
O. Husson
Tilburg University, Faculty of Social Sciences, Tilburg, Netherlands
‘If I can’t feel, if I can’t move, if I can’t think, and I can’t care,
then what conceivable point is there in living?’
(Kay Redfield Jamison, An Unquiet Mind: A Memoir of
Moods and Madness)
Mood is a person’s subjective emotional state. According to
the DSM-IV the term mood disorder is used for a group of
diagnoses where the primary symptom is a disturbance in
mood, or in other words the experience of an inappropriate,
exaggerated or limited range of feelings. Mood disorders can
mainly be divided into two groups: (1) depressive episode(s)
characterised by feelings of sadness, hopelessness, helpless-
ness, guilt, suicidal thoughts, fatigue, appetite changes, con-
centration problems and troubles engaging in daily living
tasks; (2) manic or hypomanic episode(s) characterised by
feelings of grandiosity, extreme energy and heightened arou-
sal. Several treatment options are available for mood disor-
ders – e.g. medication, cognitive and/or behavioural therapy
– depending on the severity and the evaluation of the
health-care provider.
Several studies have shown that mood disorders are com-
mon in patients with cancer. In a meta-analysis, the point
prevalence of major depression was about 16% and that of
anxiety was 10% [1]. The exact causes of mood disorders are
largely unknown, but it is hypothesised that an imbalance
in neurotransmitters is likely to play a role. The mood disor-
der can be triggered by the cancer diagnosis on its own, or it
can be treatment-induced in cases where the aetiology can
be found in the physiological effect of a psychoactive drug
or chemical substance.
These articles provide an overview of the most common
mood disorders among cancer patients. First, Dr. Dauchy will
discuss the prevalence, predictive factors and treatment op-
tions of depression, one of the most under-diagnosed and
inadequately treated mood disorders among cancer patients.
Second, Professor Caraceni will introduce drug-associated
delirium, an altered state of consciousness with reduced
awareness of self and the environment, which may go hand
in hand with the inability to think and talk clearly and ratio-
nally, hallucinations, disorientation and cognitive impair-
ment. Third, Dr. Die Trill will discuss anxiety, one of the
most frequently reported reactions to a cancer diagnosis,
whichmay persist throughout the cancer continuum. In addi-
tion, she will shine her light on sleep disorders, which are fre-
quently associated with psychological disorders. Finally, Dr.
Schagen will describe the chemotherapy-related changes in
cognitive functioning, which can result in diminished func-
tional independence and can last throughout the survivorship
period.
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1. Introduction
Depression is frequent in cancerology. Despite its clear im-
pact on patients, it continues to be under-diagnosed and
inadequately treated. There are many reasons for this, rang-
ing from the underestimation of depressive symptoms by cli-
nicians, their widespread presence in the context of cancer,
the entanglement of depressive symptoms with those associ-
ated with the cancer and its treatment, or, indeed, the diffi-
culty of clinicians in exploring emotional symptoms [1,2].
Beyond the fact that depression causes mental suffering that
is not taken into consideration, even though it can be extre-
mely intense in nature, this situation has a major impact on
both morbidity and mortality through a number of different
mechanisms [3,4]:
• Deterioration of quality of life [5].
• Increased sensitivity to pain [6].
• Difficulties observing treatment [7].
• Difficulties communicating with carers, friends and
family.
• Significant burden placed on close relatives [8].
• Increased risk of suicide [9].
• Longer periods of hospitalisation [10].
• Reduced expectation of survival [11].
Depression also results in additional medico-economic
costs, the extent of which we are only just beginning to
understand [12,13].
There is also a risk of over-treatment, with antidepres-
sants being systematically administered for what may only
be an intense feeling of sadness, which may nevertheless be
appropriate in the context and temporary in duration.
2. What is the prevalence of depression in
cancerology?
Although depression is frequently observed in cancerology,
the figures reported by the various related studies differ owing
to the variability of the clinical forms of depressive disor-
ders – major depressive episode (MDE), dysthymia,
adjustment disorders with depressed mood, etc. – and the
way in which the diagnosis is performed: clinical interview,
questionnaires or self-report questionnaires which
may be specific to depression (BDI, CES-D and Zung scale)
or more general (HADS, POMS and SCL-90 etc.), variability
of the cut-offs, etc. The figures also vary depending on
the sample and, in particular, on the patient’s medical sta-
tus, type of cancer, location, stage, treatment during or
after cancer, etc. There may also be a bias associated
with the selection of the patients (patients who have agreed
to a clinical psychiatric assessment, convenience sample
etc.).
On average, studies report a prevalence of MDE of 5–10%,
two to three times higher than that in the general population.
In a recent meta-analysis of 70 studies (n = 10,071) conducted
by Mitchell et al. [14], the prevalence of depressions of all
types (ICD, DSM criteria) was 16.3%, with the prevalence of
MDE reaching 6%. The corresponding values rose to 24.6–
29% and 14.3–16.5% in the analysis of 24 studies (n = 4007) of
palliative-phase patients.
The way in which depressive disorders develop during the
period of cancer care is still poorly understood because of a
lack of longitudinal studies.
A depressive episode may be isolated or may have been
preceded by other such episodes. In this latter case, the disor-
der is a recurrent unipolar depression. The patient’s anteced-
ents may also include one or more phases of hypomanic or
manic excitation, or he or she may have presented a hypo-
manic reaction when under antidepressants. In this case, a
bipolar mood disorder is probable. Referral to a psychiatrist
will then be necessary for diagnosis and identification of the
relevant treatment.
3. What are the predictive factors?
Some of the risk factors for depression are known and must
be identified at an early stage [15,16].
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Personal risk factors:
• Recent personal history of negative or stressful life events
(bereavement, succession of losses).
• Personal psychiatric antecedents (depression, suicide
attempt, drug addiction and alcoholism) or familial ante-
cedents (depression, suicide attempt and suicide) [17].
• Personality traits – tendency not to express one’s emo-
tions, tendency to consider life events as uncontrollable
and inevitable, low self-esteem and poor emotional sup-
port and tendency to pessimism [18,19].
• Unlike the data obtained in the general population, the
most recent meta-analysis conducted by Mitchell et al.
[14] suggests that gender is not predictive, possibly owing
to the weight of the factors associated with the cancer
itself.
• The role of age (<50 years) remains controversial [14,20].
Social risk factors:
• Being alone (single, divorced, separated and widowed);
• Social isolation [21].
• Low socio-economic status [21].
• Belonging to an ethnic minority [22].
• Perceived lack of social support.
Risk factors associated with the cancerous disease or its
treatment:
• Type of cancer (pancreas, head and neck) [23].
• Advanced stage or metastatic disease.
• Critical phases involving the disclosure of the diagnosis,
disclosure of recurrence or aggravation (metastases) and
palliative care.
• Limitation of treatments.
• Presence of uncontrolled physical symptoms: firstly pain
(RR increased by 2–4 times) [6], as well as nausea, vomiting,
fatigue etc. [24,25].
• Functional handicap and loss of autonomy (neurological
sequelae, stomata and impairment of general condition etc.).
Treatment-related risk factors:
• Immunotherapy – interferon (IFN), interleukin 2 (IL2)
• Long-term corticotherapy [1].
• Certain antipileptics (such as levetiracetam).
• Certain neurotoxic chemotherapies (vinblastine,
procarbazine).
• The thymic toxicity of certain targeted therapies which
cross the hematoencephalic barrier has given rise to a
number of case reports.
• Despite a number of case reports, cohort studies or obser-
vations obtained during double-blind tests have not
revealed any depressogenic impact of tamoxifen [26].
Organic causes:
• Neurological anomalies (primary brain tumour or cerebral
metastases).
• Endocrine disorders (hyper- or hypothyroidism, adrenal
insufficiency).
• Metabolic disorders (vitamin B12, folate deficiency).
4. How should depression be diagnosed?
A depressive syndrome is the association of depressive
symptoms that persist over time. The diagnosis of depres-
sion is already a complex affair, even outside of the context
of physical pathology, since it consists in the lasting associ-
ation of a variety of subjective symptoms (at least five, see
below) [27], none of which is specific [28]. In most cases,
these symptoms are difficult to reveal (for example, social
withdrawal that could be explained by cancer treatments),
and the most highly visible symptoms (such as tearfulness)
are the least specific.
In the case of cancer patients, this complexity is further
aggravated by the potentially adapted nature of the depres-
sive emotion in the context of themultiple bereavements that
accompany cancer. One important area will therefore be to
differentiate between ‘normal’ sadness, on the one hand,
and adjustment disorders or depressive episode on the other.
For depression to be diagnosed, it is therefore necessary
for least five symptoms to be present nearly all day for at least
15 consecutive days. In practical terms, the diagnostic ap-
proach should consist of the following steps:
• Use of two simple questions to attempt to identify one of
the major symptoms, namely mental suffering and lack
of interest (absence of desire for anything, affective indif-
ference which can lead to social withdrawal and a loss of
commitment to contact with friends and family) [29].
• If one of these two symptoms is present, identification of
the time criterion – almost every day, almost all day, for
a minimum of 15 days.
• Then attempt to identify associated symptoms (at least
three or four from the list below).
o Feelings of worthlessness or inappropriate guilt (in partic-
ular a painful vision of the past, for example: ‘for my fam-
ily, I’m now nothing more than a burden’, ‘I’ve been a
failure with my children’).
o Recurrent thoughts of death or suicide.
o Significant weight loss or gain (>5% of body weight), or
increase or decrease in appetite.
o Insomnia or hypersomnia.
o Psychomotor agitation or retardation.
o Fatigue or loss of energy.
o Diminished concentration or indecisiveness.
A change in character with the appearance of irritability or
aggressiveness that is inconsistent with earlier behaviour is
also possible.
If five symptoms from the above list, including mental
pain and/or absence of pleasure, are present then the patient
is very probably depressed, and antidepressant treatment is
recommended.
If not, the patient is exhibiting either a temporary depres-
sive reaction (if the criterion of persistence over time is not
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met) or an adjustment disorder with depressed mood (if
insufficient symptoms are present: for example, sadness on
its own without feelings of worthlessness, sleep disorders or
anhedonia). Antidepressants are not indicated a priori.
Another difficulty affecting the diagnosis of depression is
associated with the distinction between its somatic manifes-
tations (fatigue, anorexia and/or loss of weight, cognitive or
sleep disorders, loss of libido) and the physical symptoms
associated with the cancerous disease or its treatment [30].
A number of ways of overcoming this difficulty have been
described:
• An inclusive approach in which all the symptoms are
taken into account, irrespective of whether or not they
are attributable to the cancer (which clearly leads to a risk
of over-diagnosis).
• An exclusive approach in which the somatic symptoms
are systematically excluded from the diagnostic criteria.
• A substitution method in which these very same somatic
symptoms are replaced by affective substitute symptoms
[31].
When the exclusive and substitution approaches are used,
the risk that the diagnosis may be underestimated is high, in
particular in the case of patients who conceal or repress their
emotions.
In practice, all manifestations that are not clearly linked to
another cause (physical or iatrogenic causes) should be con-
sidered as contributing to the diagnosis of the depressive syn-
drome. The chronology of the disorders is particularly useful
in this context.
It is therefore necessary to pay special attention to the cog-
nitive and affective symptoms that are not directly linked to
the somatic state, together with all their possible nuances:
• Self-devaluation and a painful vision of the past: feelings
of uselessness, worthlessness and guilt (invasive,
generalised).
• Loss of interest and pleasure: affective anaesthesia,
indifference.
• Feeling of worthlessness coupled with feelings of helpless-
ness and hopelessness.
• Desire for death and thoughts of suicide must be system-
atically explored; far from inducing suicidal behaviour,
putting such ideas into words is an opportunity for the
patient to become aware of their pathological nature and
their link, not to a rational perception of reality, but to
his or her own depressive suffering.
• Pathological pessimism.
A final difficulty lies in the fact that patients rarely sponta-
neously express those depressive symptoms that are primar-
ily purely affective in nature (emotional withdrawal, for
example), and that depressive symptoms themselves
(psychomotor retardation, social withdrawal and shame)
and lack of knowledge or minimisation of depressive symp-
toms lower this expression. Simple, open questions should
therefore be favoured during the interview (‘How’s your
mood? And everyday life? Are there some good times? etc.’).
It is important to avoid moralizing phraseology (‘face up to’,
‘keep going’) and closed questions (‘Are you in a good mood?
Are you coping?’) which risk blocking the expression of the
experienced feelings and increasing the sensation of guilt
due the patient’s perception of his or her depressed state.
The availability of the carer, whether verbal or non-verbal,
is vital for facilitating emotional expression.
The diagnosis must take into account the time of the
assessment. The assessment of depressive symptoms is diffi-
cult during the days immediately following the announce-
ment of bad news or in the case of an evolutive,
uncontrolled somatic symptomatology, in particular if this
is associated with the experience of pain. In such cases, the
patient should be reassessed at a distance or after the symp-
toms have been treated.
Finally, the idea of a break with earlier behaviour is also
important. The clinician must remain attentive to changes
in the patient’s functioning, whether this is revealed by the
patient or his or her friends and family. Helping patients be-
come aware of this change may also make it easier for them
to grasp the pathological nature of their condition.
5. How to screen for depression in cancerology?
Simple, validated tools can be used, and the aim for screening
purposes is to select short tools taking no more than 5 min to
complete. A recent review of the various potential tools for
the screening of distress undertaken by Mitchell [32,33] iden-
tified 35 short tools for the screening of depression, consisting
of 1–14 items. Although some of these specifically assess
depression and have been validated for use in cancerology,
most of them were not specifically designed for administra-
tion to patients suffering from a somatic pathology. This fact
can be problematic when the deterioration of the patient’s
general condition aggravates scores on items that evaluate
the respondent’s somatic state; this criticism has been made
with regard to the BDI (Beck Depression Inventory), for exam-
ple [34]. Others, such as HADS (Hospital Anxiety and Depres-
sion Scale), assess emotional distress at a more general level
but have the advantage of excluding somatic items. The fol-
lowing tools have been validated for use with cancer patients:
single verbal item, PHQ1, PHQ2 (and PHQ2 + help question),
two verbal items BCFD (Bried Case Find for Depression),
Edinburgh Postnatal Depression Scale (EPDS, and Brief EPDS),
Hornheide Screening Instrument (and Hornheide Short
Form), General Health Questionnaire 9, BDI Short Form, HADS
(and HADS depression subscale).
The sensitivity and specificity of the different scales vary
as a function of the cut-offs used and of the patient clinical
condition. None of the tools used today can be claimed to
be irrefutably preferable to any other. It should nevertheless
be noted that in most studies the sensitivity and specificity
of ultra-short tools (consisting of just one or two questions,
‘low mood’ and ‘loss of interest or pleasure’) have been found
to be at least as good as those of longer tools. In the meta-
analysis of screening and case-finding tools for depression
in cancer conducted by the Depression in Cancer Care con-
sensus group [29], 56 diagnostic validity studies (n = 10,009)
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were reviewed. For case-finding, one stem question, two stem
questions and the BDI-II all had level 2 evidence. For screen-
ing, two stem questions had level 1b evidence. As they are
highly acceptable, the stem questions are thus recommended
(grade B recommendation). For every 100 people screened, the
two questions would accurately detect 18 cases in advanced
cancer settings (one missed and seven falsely identified),
and 17 in non-palliative settings (two missed, and 11 falsely
identified as cases).
By contrast, clinical appraisals that are not guided by at
least one or two questions are not recommended, in particu-
lar if the clinicians are not trained [35].
In practice, it is important to remember that the diagnosis
of depression is too complex for any screening tool, used in
isolation, to be able to provide absolute certainty. Neverthe-
less, their use is recommended and can be incorporated with-
in a more global assessment of the patient’s symptoms (as in
the case of the Edmonton Symptom Assessment System,
ESAS), supportive care needs or expectations [32]. The main
value of these tools – and in particular of those which permit
an assessment based on two questions – is that they make it
possible to identify with a high degree of certainty those pa-
tients who are not depressed, and consequently focus the ef-
forts of the oncologist, carer or psychologist/psychiatrist on
obtaining a more in-depth assessment of those individuals
who have screened positively.
However, systematic screening for depression has not as
yet proved its effectiveness in significantly improving pa-
tients’ psychological outcomes [36]. Far from casting doubt
on its usefulness, this fact emphasises the vital need to in-
clude this type of screening in an overall treatment process
that extends through to the proposal and acceptance of
appropriate pharmacological and/or psychotherapeutic
care.
6. Depression and the risk of suicide
Despite the variability that can be found in the literature, ow-
ing to problems of both methodology and definition, it is pos-
sible to estimate the risk of suicide in the oncological context
at 1.95–2.8 times higher than in the general population [9,37].
The wish to die is present in 17% of patients in an advanced
phase of cancer.
Certain suicide risk factors are known [20,37]
• Poorly controlled symptoms (pain, fatigue, etc.).
• Masculine gender (relative risk of 1.7 in men and 1.4 in
women compared with the general population [38]).
• Disclosure phase (first year following the diagnosis) [37].
• Site of the tumour (head and neck, lung, gastrointestinal,
brain tumours [9]).
• Existence of a psychopathological disorder (depression,
hopelessness, delirium).
• Familial antecedents of suicide and/or psychiatric illness,
previous personal suicide attempts.
• Pathological impulsivity (personality disorder).
• Substance abuse (alcohol etc.).
• Recent loss (bereavement, for example).
• Situation of hopelessness, loss of control or
autonomy [1].
It is interesting to note that most of these factors are found
in cases where patients ask to accelerate their death (hasten-
ing death requests are associated at a significant level with
depressive states, hopelessness, low level of social support,
very poor physical condition and a lower level of recourse to
spirituality) [1]. Whenever patients make this type of request,
one should systematically and carefully search for an emo-
tional disorder that may indicate pathological suicidal
ideation.
7. Treatment plan and overall patient care
The treatment of depression has to start at an early stage [39].
It can take a long time to make patients aware of the psycho-
logical nature of their difficulties, encourage them to request
a psychological consultation or to accept the prescription of
psychotropic or, in particular, antidepressant medicaments.
The more intense the psychological distress the longer this
delay may be. It is the systematic attention paid by clinicians
to their patients’ psychological states that permits early diag-
noses and the effective elaboration of an appropriate treat-
ment plan.
The treatment of depression must form part of an overall
care context. First of all, it is necessary to take account of
the patient’s somatic condition, the associated symptoms
and any comorbidities that may be present (pain, fatigue
and sexual problems). It is not possible, for example, to treat
depression in patients with uncontrolled pain [40].
To start from the patients’ expectations – for example, by
identifying with them the symptom that causes them the
greatest distress, or discussing what they can expect from
treatment – may help them to accept depression treatment.
Certain patients, for example, who can no longer them-
selves perceive the loss of the ability to experience pleasure
or are unaware of their psychomotor retardation, may pri-
marily complain of sleep-related problems. An initial pre-
scription of drugs that are effective in combating these
sleep disorders will encourage subsequent adherence to
therapy. The patient’s habitual mode of psychological func-
tioning may also help the clinician guide him or her towards
appropriate psychotherapeutic support. It is also necessary
to try to identify the representations associated with
depression, antidepressant treatments or psychotherapies,
together with any possible prior intolerance of antidepres-
sant treatment.
Patients must be given information about their socio-pro-
fessional circumstances and psychosocial resources (family,
work and environment). What psychosocial resources can
they count on in their family or professional environments?
And, conversely, what strains or obligations are imposed on
them?
The next step is to check the level of information that pa-
tients possess regarding the cancer for which they are being
treated, their understanding of the treatment plan and their
adherence to it. The quality of the cooperation between the
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psychologist or psychiatrist, on the one hand, and the
oncologist, on the other, may if necessary make it possible
to revisit any information that has been inadequately
understood.
Finally, therapeutic care for mental distress, in particular
when drug-based treatments are used, must always be initi-
ated by a stage during which the psychological nature of the
disorders is explained and clear information about the pre-
scribed psychotropic drug – its purpose and any possible side
effects (risk of dependence associated with benzodiazepines
or hypnotic substances, for example) – is provided. Neverthe-
less, given the specific symptoms that characterise depressive
states, it can sometimes be difficult to secure the commit-
ment of depressed patients to a course of treatment, in partic-
ular when they find it difficult to acknowledge the
pathological nature of their condition or when the loss of
hope or confidence in the future is significant. Memory and
attention disorders may aggravate a patient’s reluctance to
agree to psychotropic treatment and impair compliance with
it, especially given that the anxiety that is frequently felt at
the start of treatment may be associated with an increase in
the real or feared side effects.
The discussion of the diagnosis is therefore the first step in
the administration of treatment. The information provided to
depressed patients enables them to better understand the
nature of their distress and retain their independence. The
empathy shown by carers in response to their psychological
distress also constitutes an initial vital and beneficial experi-
ence for depressed patients, who often feel isolated due to the
shame and guilt they experience (and withdraw themselves
both from their friends and family and from their oncological
team) [41].
To treat major depressive episodes it is necessary to pre-
scribe both an antidepressant and, in certain cases, a course
of psychotherapeutic care [1,15] or, at the very least, to ensure
the availability of psychosocial support to facilitate adherence
to treatment [42].
8. When and how to prescribe an
antidepressant?
It is appropriate to prescribe an antidepressant for all major
depressive episodes. This prescription does not always have
to be accompanied by treatment by a psychiatrist except in
the case of depression affecting patients with bipolar mood
disorders who should be referred to a psychologist for diagno-
sis and treatment. In a recent Cochrane review [43] it was
established that antidepressants outperform placebo level
among patients with somatic diseases (OR 2.33, IC 1.8–3,
P < 0.00001). This finding redresses a scientific shortcoming
in the field of cancerology: in 2008, only 20 studies of the
effectiveness of antidepressants had been conducted in this
field and none of them had reached a sufficient level of proof
[2]. However, we still need to gain a better understanding of
the rationale underlying the pathogenesis of depression in
the cancer field and, in particular, its links with the immune
and inflammatory mechanisms.
A preventive treatment is not recommended except in
some very specific cases, as in e.g. depression induced by
high-dose interferon alpha [44].
Generally speaking, SRIs (serotonin reuptake inhibitors)
(Table 1) tend to be the first drugs to be prescribed in the field
of cancerology [45]. There is no reason to consider the effec-
tiveness of any antidepressant to be formally superior to that
of any other [46–48]. When administered at antidepressant
dosage (which is considerably higher than the antalgic dos-
age), tricyclics (Table 1) are difficult to handle and should be
reserved for more complex cases. Escitalopram might be the
medicament with the best effectiveness-to-tolerance ratio
among patients who have no contraindication for this drug
[45]. Furthermore, the choice of an antidepressant is specific
to the patient and is determined by individual factors: the
side effects of the drug, the patient’s tolerance to it (which in-
cludes potential side effects in combination with other drugs
being co-administered or that might be used in the future),
reactions to earlier treatments, and the patient’s preferences
[49]. In particular, it is especially important to make sure that
no potential iatrogenics exacerbate the somatic or non-so-
matic difficulties that are already present (for example, sexual
difficulties or asthenia).
In the majority of cases, monotherapy is the rule; to com-
bine two antidepressants is a priori pointless and potentially
dangerous. Although exceptions exist, such prescriptions
should only be made by specialists. Accompanying prescrip-
tions – for example of anxiolytic or hypnotic drugs – should
be restricted. These may be prescribed at the start of treat-
ment but clinicians should attempt to reduce or eliminate
them as treatment progresses.
The fact that a period of 2–3 weeks is required before any
effect can be observed must be explained to the patient
who must also be alerted to the possibility of undesirable side
effects. It is important to remain vigilant with regard to the
aggravated vulnerability of cancer patients (specific metabolic
characteristics, associated treatments) and remain attentive
to the identification of secondary effects which sometimes
may not be easy to detect in a somatic context. Tolerance to
antidepressants varies depending on the drug in question,
and tolerance to tricyclic antidepressants is often poor since
these drugs frequently produce side effects (orthostatic
hypertension, weight gain, sedation, irregular heartbeat, con-
fusion, epilepsy and potentially fatal in the event of an over-
dose), which is why they are not administered as the first
line of treatment. The toxicity of serotonin reuptake inhibi-
tors is less serious and is often restricted to self-limiting dis-
orders (headaches, gastrointestinal disorders). All drugs may
also lead to an increase in anxiety. Venlafaxine and duloxe-
tine have also been reported to lead to increased blood
Table 1 – Families of antidepressants.
Family
SNRI : Venlafaxine, minalcipran and duloxetine
Nassa : Mianserine and mirtazapine
Melatonihergic : Agomelatine
Others : Tianeptine
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pressure. Mirtazapine and mianserine often lead to weight
gain and drowsiness, two effects that can lead to resistance,
particularly on the part of female patients at the end of the
period of treatment who are already exposed to weight gain
owing to other mechanisms.
There are no restrictions relating to prescriptions for pa-
tients with suicidal thoughts. According to the review con-
ducted by Mo¨ller [50], the risk that such patients will
actually take their own lives under the influence of antide-
pressants appears to be small and decreases from the age of
30 years onwards. If possible, patients who express suicidal
thoughts should rapidly be sent for psychological or
psychiatric assessment. However, if these thoughts are asso-
ciated with depression, this referral should not cause any de-
lay to treatment. A drug with only a low stimulant effect (a
pure serotoninergic drug such as citalopram or paroxetine,
but no noradrenergic products) should be preferred and
should only be prescribed for a short initial period (1 week),
after which the patient should be reassessed.
If there is a risk of suicide, the introduction of the antide-
pressant treatment is an emergency, but not such as the orga-
nisation of the care that is to be received. While awaiting the
results of psychiatric assessment, it is necessary to organise
enhanced monitoring of the patient and inform his or her
family of the suicidal risk, insofar as professional ethics per-
mit this. Ensuring that the patient is accompanied as much
as possible is an important factor in helping to prevent the
occurrence of suicide.
In all cases, it may be of value to try to limit the patient’s
impulsivity by prescribing a sedative and anxiolytic neurolep-
tic such as cyamemazine (e.g. 25–50 mg/day).
Antidepressants present no carcinogenic risk, at least in
the case of SSRIs and tricyclics [51]. Nevertheless, vigilance
is recommended in the case of the prolonged adminis-
tration (more than 10 years) of serotonin–norepinephrine
reuptake inhibitors (SNRIs), since for these recent products
it has not yet been possible to study the associated long-term
risks.
The risk of serotonin syndrome is also frequently cited.
This takes the form of excessive serotonergic stimulation
which causes motor excitation, hyperreflexia, trembling,
myoclonia and dysfunctioning of the autonomous central
nervous system and, in extreme cases, epilepsy, comas or
death. These effects are not due to any idiopathic effect but
are caused by the interaction of drugs sharing similar mech-
anisms or by overdoses [52]. It is extremely difficult to state
their frequency since minor forms are probably not recogni-
sed and still less often reported [52].
Although a treatment can start to have an effect as of the
first few days following prescription, it cannot be viewed as
ineffective until 3–4 weeks of administration at an effective
dosage level (6 weeks in the case of elderly subjects). The
effective dosage can sometimes vary considerably (by a factor
of 1–3 or even 1–4), which means that in the case of lack of
efficacy it is necessary, providing that the patient tolerates
the drug without difficulty, to progressively increase the
dosage before moving on to a new drug. If a drug appears to
be ineffective, it is also necessary to verify correct adherence
(and therefore also tolerance to the correct dosage) on the
part of the patient. The minimum period of treatment is
6 months in order to avoid any premature relapse. Treatment
must not be interrupted suddenly given the risks associated
with withdrawal which, with paroxetine, may appear in less
than 48 hours. If oral administration is impossible, it is gener-
ally possible to replace the prescribed drug with injectable
citalopram, the only SNRI available in this form. If adminis-
tration has to be performed via a tube, then drugs available
in soluble form should be preferred (citalopram, mirtazapine,
fluoxetine and paroxetine).
Table 2 lists the main limitations to prescriptions and con-
traindications. This should be updated by the clinician in the
light of the data available at the time of prescription.
There are also risks of interactions with other drugs or of
overdoses. Serotonin reuptake inhibitors are Cyt P450 sub-
strates and may accumulate in individuals with slow metab-
olism or if Cyt P450 is inhibited. The SNRIs are also CytP450
inhibitors whose effect varies from drug to drug (in contact
with different isoenzymes). There is therefore a risk of inter-
action. This is due as much to the accumulation of the sub-
strate as to its ineffectiveness when in the form of an
inactive prodrug. The important thing is to be aware of the
possibility of interactions and to be vigilant [53]. Several inter-
net sites provide regularly updated information that can be
consulted if required.
Although the prescription of psychostimulant drugs (pri-
marily methylphenidate or modafinil) may be considered in
the case of depressed patients (but in most countries remains
outside the scope of marketing authorisation), this should be
done only following a specialist assessment; in any case,
these products are nowadays subject to an initial psychiatric
prescription. Their stimulant effect on vigilance and attention
may be of particular value in cases of asthenia associated
with the prescription of opiates to overcome pain. In some
studies, these drugs have exhibited a rapid antidepressant ef-
fect which can be of value, in particular when the end of life is
near at hand and the period of action required by antidepres-
sants is therefore unacceptable or in order to obtain an imme-
diate effect during this end-of-life period. However, high-
quality studies, in particular involving adequate sample sizes,
are still required in this area. Such psychostimulants should
be prescribed only to patients for whom the experience of fa-
tigue and the functional constraints that this imposes are per-
ceived as an additional source of stress or an intolerable
limitation to their quality of life. Their prescription should
never be influenced by a desire for increased performance,
in particular when made by friends and family distressed by
the patient’s waning enthusiasm and drive and who would
be reassured to see him or her recover the roles which he is
no longer able to assume.
9. Is it necessary to prescribe a benzo-
diazepine?
These drugs should not be prescribed systematically. In prac-
tical terms, it is justifiable to prescribe a benzodiazepine or
anxiolytic:
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• In the presence of a high level of anxiety, in particular in
combination with somatic symptoms which might result
in the poor tolerance of antidepressants (attribution to
the drug of functional symptoms caused or exacerbated
by anxiety).
• If the patient is already being treated with a benzodiaze-
pine – this may subsequently be interrupted; however,
stopping it straight awaymay aggravate the clinical picture
because of drug withdrawal (which, once again, risks being
incorrectly attributed to poor tolerance of the
antidepressant).
In depressed, impulsive patients it is often preferable to
treat anxiety with low doses of a sedative neuroleptic (e.g.
cyamemazine) rather than with a benzodiazepine.
10. What are the roles of the different actors in
diagnosing and caring for depression in the field
of cancerology?
Various organisational schemas for care administration in re-
sponse to depressive disorders have been evaluated as a
function of the actors responsible for screening, diagnosing
or prescribing treatment [54].
It is not essential for the initial prescription to be made
by a psychiatrist, in particular given the facts that there
are not enough psychiatrists to provide care to all depressed
patients, and that some of these patients are reluctant to
consult a mental health specialist. Systematic screening fol-
lowed by the diagnosis and the prescription of treatment by
the oncological team itself appears to be the most efficient
way of providing effective treatment [42] if it includes the
arrangement of – at the very least – support services (coor-
dinating nurse, possibly communicating by telephone etc.)
or other psychotherapeutic services. A psychiatrist may as-
sist in the task of prescribing in the most complex cases.
This approach has been validated in North America and
seems to be suitable for use in the European context. It al-
lows issue of an initial prescription without waiting for
the psychiatrist, and emphasises the value, in addition
to the prescribed antidepressant [1], of providing to the
patient individual support by a psychologist or a non-
psychologist.
It is advisable to obtain a psychiatric opinion from the out-
set in the case of patients with schizophrenia, a unipolar or
bipolar mood disorder (manic-depressive disorder), a severe
personality disorder or suicidal thoughts.
A psychiatric opinion should also be sought as a second
line of treatment in the event of resistance to treatment even
after an increase in dose, or in the case of any doubt concern-
ing the diagnosis.
Even in the absence of a psychiatric opinion, the question
of hospitalising the patient should be discussed if there is a
risk of suicide or, in the case of refusal of treatment, agitation,
extreme anxiety or delirium. It might also be considered in
the case of extremely isolated patients.
All authors have emphasised the value of offering psy-
chological support to patients, either in the form of psycho-
social support or in the form of psychotherapy. In major
depressive disorders, combining the administration of an
antidepressant with the provision of psychotherapeutic care
improves the effectiveness of treatment. In a meta-analysis
of depression in a non-cancerological environment
(n = 1843), patients treated with a combination of psycho-
therapy (of all types) and antidepressants exhibited a consid-
erably higher level of improvement than patients treated
with drugs only (OR 1.86, 95%CI 1.38–2.52). Furthermore,
the beneficial effect of this combination increased in the
case of treatments lasting for 3 months or longer (OR 2.21,
95%CI, 1.22–4.03) [55]. In this context, initial prescription by
a psychiatrist would be ideal in order to improve the diagno-
sis and ensure, from the outset, that the prescription forms
part of a coordinated therapeutic approach, possibly accom-
panied by a psychotherapeutic element [56]. However, this
solution is only rarely available.
Table 2 – Main limitations to antidepressant prescriptions and contraindications.
Moderate renal or hepatic insufficiency SSRI, generally not contraindicated; use
the minimum effective dose and start off with half this dose
Severe hepatic insufficiency Use tianeptine or minalcipran
Conduction disorders Avoid tricyclics
Extension of QT, or co-prescription with
drugs associated with this risk
Avoid SNRIs
Cardiac disorders in general Prefer mianserine
Hyponatremia Risk of aggravation in response to SNRIs: monitor
Convulsions or risk of convulsions
(cerebral metastases)
without anticonvulsive treatment
Only tianeptine does not reduce the threshold of epileptogenesis
Arterial hypertension Avoid venlafaxine
Prostatic adenoma Tricyclics are contraindicated. Caution is necessary
with minalcipran and mirtazapine, SNRIs authorised
but possibility of urination difficulties
Administration of tamoxifen Paroxetine and fluoxetine are contraindicated.
SSRI : selective serotonin reuptake inhibitors.
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Various types of psychotherapy have been proposed,
sometimes in combination:
• Psychoeducation.
• Relaxation training.
• Problem-solving therapies.
• Cognitive behavioural therapies.
• Interpersonal therapies.
• Supportive expressive therapy.
The degree to which these therapies have been validated is
sometimes limited and, in both psycho-oncology and psychi-
atry, the question of the evaluation of psychotherapies and
psychosocial interventions continues to be a complex subject.
The differing natures of the cancer patients, the approaches
and therapeutic goals, the training and experience of the ther-
apists, and the multiplicity of assessment scales, as well as
the different periods studied during the health care circuit,
all further complicate such analyses and relativise the results
[57–59]. In this field, the very idea of randomised trials can be
called into question [60] since they do not make it possible to
appraise the subtle effects and individual benefits brought
about by psychotherapy.
Beyond the above reservations, it is accepted that psycho-
therapies have a beneficial impact on anxiety, depression,
psychological distress and quality of life [61,62]. Although it
also seems to be the most depressed patients who gain the
greatest benefits [63,64], this is at the same time the popula-
tion for which the lowest level of evidence is available in
the field of cancerology (only three well-conducted studies
Fig. 1 – Summary of the main stages during diagnosis and the prescription of an antidepressant.
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involving CBTand, in the case of metastatic patients, support-
ive–expressive therapies) [65].
It is important to identify the psychotherapeutic technique
that is best suited for each patient as a function of their per-
sonality, their expressive capacities, their psychosocial situa-
tion, their concern for others and the time at which
oncological care is administered. Thus, patients at the start
of treatment might more readily accept a cognitive or psy-
cho-educational approach, whereas those suffering from a
recurrence of the disease or confronted with a serious devel-
opment in its course might request a more existential form of
psychotherapeutic support. Psychotherapies inspired by psy-
choanalytical and/or psychocorporal techniques could ideally
be offered to all patients who request them provided that
their psychotherapists are able, during preliminary inter-
views, to assess their ability to commit themselves to such
activities and benefit from them.
Fig. 1 summarises the main stages during diagnosis and
the prescription of an antidepressant.
11. Conclusion
Depression remains highly prevalent in cancer patients, and
appears to have a great impact on their quality of life as well
as on certain cancer outcomes, even if probably by the means
of its impact on compliance, physical activity, social support
etc. This broad impact justifies carrying out systematic
screening that can be performed by standardised tools but
also by one or two simple questions. To be useful, this screen-
ing must be followed by an adequate clinical diagnosis that
relies on a precise identification of emotional and cognitive
symptoms of depression. Considering the prevalence of de-
pressed patients, the oncological teams are expected to do
the depression diagnosis and make the first antidepressants
prescription by themselves.
To be efficient, depression care must be part of a compre-
hensive care plan, including treatment of somatic symptoms,
and an adequate response to information needs and unmet
needs. When possible, and if accepted by the patient, the help
of a psychologist is highly appreciated. In all cases, patients
should benefit from an accompaniment that can be ensured
by a nurse or a social worker.
More research is still needed on factors that may cause
varying rates of depression and that predict which patients
are mostly at risk. An adequate collaborative care process
ranging from depression screening to effective treatment
has to be implemented and assessed. Longitudinal studies
are still needed to understand the evolution of depressive
symptoms. Randomised controlled trials should also help to
differentiate between the effectiveness of types of psychoso-
cial interventions. Newer antidepressants and stimulants also
should be studied in this population.
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1. Introduction
Even though most cancer patients do not meet diagnostic cri-
teria for any specific mental disorder [1], many experience
symptoms such as anxiety and sleep disturbances that may
interfere with their overall adjustment to their disease. Anxi-
ety is a common reaction to a cancer diagnosis and a normal
response to perceived threats like loss of body functions,
alterations in appearance, family disruption, death, etc. Anx-
iety may persist throughout the disease process, affecting the
patient’s quality of life significantly, and often coexists with
depression in cancer patients. Anxiety tends to appear or
worsen at critical points during the course of the illness (diag-
nosis, beginning and end of treatment, recurrence, survival
and terminal stage).
Sleep disorders are frequently associated with the psycho-
logical impact of cancer as well as with the physical illness it-
self, pain, hospitalisation and specific medical treatments.
Altered sleep adversely affects emotional wellbeing and day-
time performance, and may be an early sign of delirium in the
oncology setting. In the general population, persistent insom-
nia has been associated with a higher risk of developing clin-
ical anxiety or depression [2].
To effectively adjust patient needs to optimal treatment
interventions, health-care professionals must be able to dis-
tinguish normal adjustment to cancer from altered reactions
to the disease. This paper will focus on anxiety and sleep dis-
orders in the oncology setting and will describe their clinical
presentation, assessment, aetiology and treatment.
2. Anxiety in the cancer setting
2.1. Description and prevalence
Anxiety is defined as the apprehensive anticipation of future
danger or misfortune accompanied by feelings of dysphoria
or somatic symptoms of tension [3]. Classification systems
used in psychiatry – such as the World Health Organization
International Classification of Disorders [4] – require (a) a core
of anxiety symptoms such as palpitation or tremor, manifest-
ing the presence of autonomic overactivity, and (b) anxiety to
be abnormal, in order to fulfil a diagnosis of anxiety disorder
[5].
While anxiety is a normal reaction to threats such as can-
cer, some patientU:/ES/DTD520/EJCSUP/204s exhibit an over-
whelmingly anxious response that impairs their day-to-day
functioning. Frequently, anxiety increases as the disease pro-
gresses or as treatment becomes more aggressive [6], as well
as at transition points that represent threatening events
throughout the course of the disease. Patients receiving a can-
cer diagnosis, learning about a recurrence, or hearing that
treatment has been ineffective usually experience initial
shock or disbelief followed by emotional turmoil, anxiety
and depressive symptoms [7]. Inability to concentrate, dimin-
ished sleep, loss of appetite, irritability and intrusive thoughts
about the future are also frequent at these times. However,
these symptoms tend to decline gradually and resolve within
the first 7–10 days after confirmation of cancer diagnosis [8].
Anxiety may affect a person’s behaviour regarding his/her
health, contributing to a delay in or neglect of measures that
might prevent or treat cancer adequately. Anxiety can lead to
an overestimation of negative prognosis. For example, wo-
men with high levels of anxiety who learn that they have a
genetically higher level of risk of breast cancer than they
had previously believed might perform breast self-examina-
tions less frequently [9]. A longitudinal study of women with
breast cancer found that anxiety was the factor that wasmost
consistently and strongly associated with an inaccurate per-
ception of and an overestimation of future breast-cancer-re-
lated risk [10]. Anxiety may also delay or interfere with the
seeking of medical care once symptoms have developed, ad-
versely influencing – in this case – prognosis.
As mentioned already, in most cases the anxious reactions
are time-limited and may motivate patients and families to
take steps to reduce the reactions, such as seeking medical
advice, which may assist in adjusting to the illness. Anxiety
may also be part of a normal adaptation to cancer. Normal
or successful adjustment is indicated in patients who are able
to minimise disruptions to life roles, regulate emotional dis-
tress and remain actively involved in aspects of life that con-
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tinue to hold meaning and importance for them [11]. Clinical
practice shows that anxiety may also decrease as patients ac-
cept and come to terms with their medical situation, despite
disease progression.
In the United States (US), 1-year prevalence for all anxiety
disorders among adults in the general population exceeds
16% [12], and in the United Kingdom (UK) reported prevalence
is between 3% and 16% [13]. Anxiety occurs to varying degrees
in patients with cancer. Our limited understanding of anxiety
in cancer care is illustrated by the wide range of prevalence
estimates of abnormal anxiety in cancer patient populations
[5]. Estimated current prevalence of anxiety disorders in
oncology is within a range 15–28% [14], with variations being
due to differences in research methodology. In large studies
using standardised psychiatric interviews and applying re-
search diagnostic criteria, estimates of abnormal anxiety in
cancer populations ranged from 10% to 30% [4]. Some
researchers have found that up to 44% of patients with cancer
reported some anxiety, and 23% reported significant levels of
anxiety [5,15]. Variation in reported prevalence is due largely
to limitations in research methodology: differing study popu-
lations (single versus mixed cancer diagnosis, differing tu-
mour sites, early- versus late-stage disease, outpatient
versus inpatient; etc.), varying diagnostic criteria and assess-
ment instruments and studies failing to separate anxiety
from depression, etc.
Some researchers suggest that anxiety disorders are also
prevalent in medically ill patients in general [16]. However,
rates of anxiety disorders among primary care outpatients
have ranged from 7% to 15% [17], and among general medical
inpatients rates of 20% have been reported [18]. In both cases,
reported rates seem to be lower than those reported in cancer
patients. However, populations studied have varied widely in
disease severity and prognosis [16].
In cancer patients symptoms of anxiety often coexist with
depression and mixed states, and are perhaps more common
than anxiety alone [1,19].
2.2. Clinical presentation and pathological anxiety
In order to understand anxiety we need to differentiate be-
tween anxiety as a state and anxiety as a relatively stable per-
sonality characteristic or trait (state versus trait anxiety).
Patients with high levels of trait anxiety will carry their pre-
disposition throughout the disease course, and thus it is
important to identify it in an early phase.
Symptoms are similar in most patients, regardless of
whether they represent acute responses to cancer or its treat-
ment, or are part of a pre-existing anxiety disorder, exacer-
bated by the diagnosis of cancer [16]. Acute anxiety
symptoms include:
• uneasiness, unpleasant feeling of arousal, restlessness;
• irritability;
• inability to relax; tendency to startle;
• difficulty falling asleep (leads to fatigue and low tolerance
to frustration);
• recurring, intrusive thoughts and images of cancer;
• occasionally, sense of impending doom;
• distractibility;
• helplessness and a sense of loss of control over one’s own
feelings;
• symptoms of autonomic arousal: rapid or forceful heart-
beat, sweating, unpleasant tightness in stomach, short-
ness of breath, dizziness;
• vegetative disturbances: loss of appetite, decreased sexual
interest;
• parasympathetically-mediated symptoms: abdominal dis-
tress, nausea, diarrhoea.
Pathological anxiety can be identified because it tends to
be out of proportion to the level of threat; it persists or dete-
riorates when no intervention is administered, the intensity
of symptoms is unacceptable regardless of the intensity of
the threat (these include panic attacks, severe physical symp-
toms, abnormal beliefs such as thoughts of sudden death),
and the patients experience a disruption of their usual or
desirable functioning [3,4]. However, such criteria are difficult
to apply to cancer patients given that cancer is always associ-
ated with some form of threat: the threat of loss, death, body
functions, roles, body image, etc. In addition, while the dura-
tion of symptoms is important in identifying abnormal anxi-
ety, the natural history of anxiety in oncology is uncertain.
Disruption of functioning is also common in cancer patients
and is frequently associated with anxiety (i.e. intrusive and
unpleasant thoughts regarding recurrence, disability or death
can disrupt the ability to concentrate, decision-making, sleep
patterns, etc.) [4].
Massie and Shakin [20] have categorised anxiety in cancer
patients into three groups: reactive anxiety, pre-existing anx-
iety disorders and anxiety related to medical illness.
Reactive anxiety: Adjustment disorders are emotional reac-
tions to an identifiable stressor, in this case the disease, with
a degree of psychopathology that is less severe than diagnos-
able mental disorders such as generalised anxiety. The pa-
tient experiences significant distress that is in excess of
what would be expected from exposure to the stressor and
a significant impairment in functioning.
CASE: Ms E, a 56-year-old woman recently diagnosed
with colon cancer, was referred to the Psycho-Oncology
Unit because of increased anxiety that interfered with
her ability to decide whether to receive treatment with
chemotherapy (CT) or not. Ms E had cared for her
mother, who had died of ovarian cancer 2 years earlier
after suffering severe treatment toxicity. Psychotherapy
focused, among other things, on improving coping skills,
deconstructing myths about cancer and its treatment,
strengthening supports and introducing the patient to
others that had successfully undergone cancer treat-
ment, as well as practicing relaxation techniques in
the oncology clinic where treatments were adminis-
tered. Once her anxiety was significantly reduced, the
patient decided to undergo treatment, which ended
successfully.
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Of hospitalised and ambulatory cancer patients, 32% were
found to meet diagnostic criteria for an adjustment disorder
[1]. In patients with advanced cancer, prevalence ranges from
14% to 35% [21], and in terminally ill patients rates range from
11% to 16%. Variability in prevalence rates is due to different
factors such as differences in stage of disease, type of cancer
or diagnostic procedures used for anxiety. The difference
between an adjustment disorder and a normal reaction to
cancer is based primarily on the duration and intensity
of symptoms, as well as on the degree of functional
impairment.
Pre-existing anxiety disorders: Panic disorders, phobias,
generalised anxiety disorders and post-traumatic stress dis-
order are distinguished from other anxiety disorders as
being long-lasting, often preceding the diagnosis of cancer.
They are characterised by the extreme fear of losing
control and of being overwhelmed by various
circumstances:
Panic attacks are sudden, extreme anxiety reactions accom-
panied by sympathetic nervous system arousal and an over-
whelming urge to escape. Intense anxiety is usually
accompanied by severe somatic symptoms such as shortness
of breath, dizziness, palpitations, trembling, diaphoresis,
nausea, tingling sensations and fears of going crazy or having
a heart attack. Panic attacks may be re-experienced when the
patient is exposed to medical procedures, treatment toxicity,
etc.
CASE: Ms. A, a 35-year-old woman diagnosed with
breast cancer requested psycho-oncological consulta-
tion for recurring panic attacks that developed shortly
after ending cancer treatment. Ms A described herself
as a very controlling, perfectionist, anxious and self-
demanding woman for whom the disease was not a
logical consequence of her previous behaviour, which
had focused on healthy eating habits, reduced alco-
holic intake, no smoking and almost daily exercise.
She was experiencing between one and three panic at-
tacks per week. Psychotherapy focused on helping the
patient regain a sense of control over her life, focusing
on the here-and-now while accepting her cancer risk,
and developing more efficient ways of handling her
anxiety, together with cognitive-behavioural tech-
niques (i.e. training in relaxation, deep breathing tech-
niques, etc.). Pharmacological treatment with
benzodiazepines contributed to making the panic at-
tacks disappear.
Phobias are persistent fears, intense anxiety or avoidance
of a circumscribed object or situation. Phobias are experi-
enced by cancer patients in a number of ways, the most com-
mon of which are fears of witnessing blood or tissue injury
(also known as needle phobia) or claustrophobia (fear of
closed places). Phobias may interfere with the administration
of cancer treatment with patients refusing medical treatment
or necessary tests [22], and may lead to anticipatory anxiety
[16].
Mr E was a 28-year-old male with testicular cancer
who had a needle phobia. Each time the patient had to
undergo blood tests or receive IV chemotherapy treat-
ment, his anxiety escalated to the point where, on one
occasion, his treatment had to be postponed to the fol-
lowing day. Training in relaxation as well as in deep
breathing techniques alternated with techniques to help
him regain control over the situation. For example, it
was himself who counted to three before the nurse
administered the procedure, which increased his per-
ception of control over the situation. Mr E was trained
to do breathing exercises with the use of a party blower.
In addition, he learned to identify a positive thought for
each negative thought he had, prior to the procedure.
For example, ‘This is really going to hurt’ was accompa-
nied by ‘Feeling the needle is not going to be very pleasant,
but it will help cure my disease’. Mr E was able to undergo
treatment with reduced levels of anxiety.
Generalised anxiety disorder is characterised by ongoing,
unrealistic and excessive anxiety and worry that the patient
finds difficult to control. The worry is pervasive and does
not respond to either reassurance or contrary evidence.
Symptoms do not have either the sudden onset or intensity
of panic attacks and include restlessness, muscle tension,
being easily fatigued, irritability, difficulty concentrating and
sleep disturbance. Cancer patients with generalised anxiety
disorder may, for example, worry or fear that no one will care
for them, even though they have adequate social support, or
they tend to anticipate medical complications.
Post-traumatic stress disorder (PTSD) developswhen a person
is exposed to a mentally stressful event that involved actual
deathor the threat of death, serious injuryor a threat to oneself
or others, and respondswith intense fear, helplessness or anx-
iety. The personwith PTSD re-experiences the traumatic event
persistently in the way of recurrent and intrusive distressing
images or thoughts, dreams of the event, avoids situations
associatedwith the trauma, and experiences persistent symp-
toms of increased arousal that were not present prior to the
trauma. To be diagnosedwith PTSD, these symptomsmust last
for at least 1 month and cause significant problems in the pa-
tient’s personal relationships, employment or other important
areas of daily life [3]. For the person who has experienced a
diagnosis of cancer, the specific trauma that triggers PTSD is
unclear. It may be the actual diagnosis of a life-threatening ill-
ness, certain aspects of the treatment process, test results,
information given about recurrence or some other aspect of
the cancer experience. Because the cancer experience involves
somanyupsetting events, it ismuchmoredifficult to single out
one event as a cause of stress than it is for other traumas, such
as a natural disaster or rape. PTSD has been studied in long-
term non-Hodgkin’s lymphoma survivors who had partici-
pated in an earlier survey and were at least 7 years post-diag-
nosis [23]. Although half of the respondents reported no
PTSD symptoms and 12% reported a resolution of symptoms,
more than one third (37%) reported persistence or worsening
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of symptoms over 5 years. Thosewho had a low income, more
advanced illness at diagnosis (stage P2), aggressive lym-
phoma, having received chemotherapy and greater impact of
cancer at the initial survey had more PTSD symptoms at fol-
low-up. Cancer survivors with PTSD may relive the cancer
experience in nightmares or flashbacks and by continuously
thinking about it; they may avoid places, events and people
associatedwith the cancer experience, andmay tend tobe con-
tinuously overexcited, fearful, irritable and unable to sleep.
Mr K was a war veteran who underwent a bone mar-
row transplantation for leukaemia. During hospital iso-
lation, Mr K started re-experiencing the time when he
was imprisoned and placed in a cell, isolated for a pro-
longed period of time, during the war. In the hospital
he had recurrent and intrusive images and thoughts
about the war episode, frightening dreams of the event,
and flashback episodes that gave him a sense of reliving
the traumatic event. Other symptoms he exhibited in-
cluded hypervigilance, insomnia, difficulty concentrat-
ing and avoidance of conversations related to the war
episodewhen hewas imprisoned. Benzodiazepineswere
administered. In addition, he was trained in different vi-
deo games that provided him with cognitive distraction.
In the evenings, when other patients were asleep and
visitors had left the hospital, Mr K had to be walked in
a wheelchair, the appropriate protective measures hav-
ing been taken, up and down the hallways of the hospi-
tal floor to alleviate his sense of being ‘locked up’.
Obsessive-compulsive disorder is characterised by: (a) recur-
rent, persistent thoughts, ideas or images (obsessions) that
causemarked anxiety or distress, and are experienced as intru-
sive and inappropriate, and (b) repetitive, purposeful and inten-
tional behaviours (compulsions) that the patient performs in
response to an obsession in an attempt to reduce his/her dis-
tress. In order to diagnose an obsessive-compulsive disorder,
the obsessions or compulsions should cause marked distress,
should be time-consuming (take more than an hour a day) and
interfere with the person’s normal routine or functioning [3].
Ms Twas a 34-year-old woman who had been treated
for skin melanoma. Her skin was extremely white and
full of freckles all over her face, body and extremities.
Ms T was referred to the Psycho-Oncology Unit by her
dermatologist, whom she visited frequently and unnec-
essarily. The patient would spend more than 2 h daily
observing her freckles and trying to identify changes in
any one of them. She involved her husband in helping
her with this task, as she couldn’t view her back. This
habit became increasingly incapacitating for the patient,
and a source of irritation for her husband. The patient
was treated with antidepressant medication and initi-
ated psychotherapy sessions that helped reduce her dis-
tress as well as confront her underlying fear of death
and other internal conflicts she had.
Anxiety related to medical illness uncontrolled pain, meta-
bolic causes, medication side effects, withdrawal states and
hormone-producing tumours may result in increased anxiety
levels in the cancer patient. Patients with severe pain are usu-
ally anxious, and anxiety in turn can potentiate the pain sen-
sation. Consequently, it is important to treat anxiety in order
to adequately manage pain [24]. Anxiety may be the first sign
of a change in metabolic state. Sepsis accompanied by chills
and fever is often associated with anxiety. Delirium may
cause symptoms of anxiety, restlessness and increased agita-
tion. Certain drugs used in cancer, such as corticosteroids, are
frequently a cause of anxiety symptoms such as restlessness
and agitation. Akathisia is a side effect of several neuroleptic
drugs that are frequently used for control of emesis. With-
drawal states from alcohol, narcotic analgesics and sedative
hypnotics are often overlooked as causes of anxiety [20]. This
is an especially important issue in head and neck cancer pa-
tients who often have histories of heavy alcohol and tobacco
consumption that place them at increased risk for withdrawal
states. Hormone-secreting tumours such as thyroid and para-
thyroid tumours may be associated with anxiety symptoms.
2.3. Variables associated with anxiety in the cancer
setting
Cancer is usually an emotionally stressful event in the lives of
patients. In addition to physical discomfort, patients typically
face dysfunction, alterations in appearance, changes in fam-
ily and social roles, disruption of work activities and other
complex situations. Various factors have been associated
with anxiety in cancer patients. Among them are:
• history of anxiety disorders: premorbid anxious tenden-
cies such as elevated trait anxiety and obsessive personal-
ity traits [25,26]; helplessness, fatalism and anxious
preoccupation have also been correlated with anxiety in
breast cancer patients [27];
• psychological variables such as anxiety at the time of diag-
nosis [28] and history of trauma [29].
Previously discussed factors have been associated with
anxiety in cancer patients and include history of anxiety dis-
orders [25–27] and psychological variables such as anxiety at
the time of diagnosis [28] and history of trauma [29]. In addi-
tion, medical/physical variables such as functional limita-
tions, pain (described earlier) and advancing disease [6]
have been associated with increased levels of anxiety in can-
cer patients. Cancer treatments, specifically the type of treat-
ment administered and tumour response, have also been
associated with elevated anxiety [30]. Anxiety is experienced
by patients with anticipatory nausea and vomiting (ANV), a
phenomenon that results from a classical conditioning pro-
cess by which stimuli repeatedly associated with chemother-
apy end up producing nausea and emesis prior to treatment
administration. Anxious patients seem to develop anticipa-
tory nausea and vomiting more frequently than non-anxious
patients [31]. In these cases, patients may feel nauseous or
vomit the week/day before treatment, as they approach the
clinic, or even just thinking about chemotherapy.
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2.4. Screening and assessment
Optimal management of anxiety disorders requires a compre-
hensive assessment and an accurate diagnosis. The distinc-
tion between normal fears and more severe fears that reach
criteria for an anxiety disorder is not always clear in the can-
cer setting. According to Nicholas [32], patients with normal
worry compared to those with more serious symptoms of
anxiety disorders have only some difficulty concentrating,
are able to ‘turn off thoughts’ most of the time, have occa-
sional trouble falling asleep, and crying spells that seem to
provide relief, and have few, if any, physical symptoms such
as dry mouth, restlessness or racing heart. Worry comes
and goes in this group of patients. On the other hand, patients
with severe anxiety symptoms are unable to concentrate and
to ‘turn off thoughts’ most of the time, have sleep problems
most nights as well as crying spells that interfere with daily
activities, experience constant worries and have few ways
of reducing anxiety. It is important to understand the extent
to which anxiety interferes with daily living and quality of
life.
Psychometric instruments may be used to complement
the clinical interview when assessing anxiety. The scales
most frequently used with cancer patients include:
• hospital anxiety and depression scale (HADS) [33], which is
a 14-item scale measuring symptoms of clinical depres-
sion and anxiety;
• brief symptom inventory (BSI) [34], which is an 18-item
scale measuring somatisation, depression, anxiety and
general distress;
• profile of mood states (POMS) [35], which is a 65-item scale
measuring six mood states: anxiety, fatigue, confusion,
depression, anger, vigour;
• state-trait anxiety inventory (STAI) [36], which is a 40-item
measure that indicates the intensity of feelings of anxiety;
STAI differentiates between state anxiety (a temporary
condition experienced in specific situations) and trait anx-
iety (a general tendency to perceive situations as
threatening);
• distress thermometer and problem list, which consists of a
0–10 scale to measure distress that is accompanied by a
problem list in which patients are asked to note the nature
and source of their distress (physical, social, psychological
or spiritual) [37].
Self-report screening instruments must be scored, evalu-
ated and discussed with each patient, and are useful in pro-
viding the oncology team with notions of how anxious the
patient is.
2.5. Treatment of anxiety disorders
Psychosocial adjustment to cancer is an ongoing process in
which the patient tries to manage emotional distress, solve
specific cancer-related problems, and gain control over can-
cer-related events [38]. The purpose of treatment for anxiety
in cancer patients is to facilitate successful adjustment to
the disease: i.e. to help them minimise disruptions to life
roles, regulate emotional distress and remain actively in-
volved in aspects of life that continue to hold meaning and
importance to them [11]. The average patient receiving psy-
chosocial intervention for anxiety is less anxious than those
not receiving the intervention. The overall positive benefit
for psychosocial interventions seems to be greater with those
who seem to need it most [39].
Treatment of anxiety should be multimodal, including a
combination of pharmacotherapy and different psychothera-
peutic interventions. Holland et al. [40], in a randomised
study, compared relaxation with alprazolam in the treatment
of anxiety and distress in cancer patients. Findings demon-
strated both treatments to be equally effective for mild to
moderate degrees of anxiety or distress. Alprazolam was
more effective for greater levels of anxiety or distress, and
had a more rapid onset of the beneficial effect.
Medication is only considered when patients experience
severe symptoms, when their anxiety does not respond to
psychological intervention and/or when there are no psycho-
social services available or the patient refuses to use them.
Massie and Shakin [20] describe clear guidelines for the use
of pharmacotherapy to treat anxiety in the oncology setting.
The choice of benzodiazepine depends on the desired half-
life, route of administration available, route of metabolism
and the presence or absence of active metabolites. They sug-
gest that drugs with shorter half-lives, multiple routes of
administration and no active metabolites are preferable in
the medically ill patient, as well as the use of low-dose anti-
psychotic medications in patients with severe anxiety when
treatment with benzodiazepine has not been effective. Benzo-
diazepines are not indicated in patients with medical condi-
tions such as delirium, because they may exacerbate
confusion and disorientation. In any case, use of these agents
should be closely monitored and anxiety symptoms re-evalu-
ated, medication being tapered off as symptoms subside [41].
Psychological approaches in the treatment of anxiety in-
clude combinations of cognitive behavioural therapy (for
example, calming self-talk), insight-oriented and supportive
psychotherapy, crisis intervention, support and self-help
groups, and relaxation-based interventions such as hypnosis,
meditation, progressive relaxation, guided imagery and bio-
feedback. All have been proven to be effective in reducing
anxiety in the cancer patient [42–46].
Different psycho-educational interventions are equally
useful. They have aimed at replacing the sense of helpless-
ness with a sense of control, and in the process, reducing psy-
chological distress [16]. For example, a booklet with disease-
related information was provided to patients with Hodgkin’s
disease, and these patients experienced more reductions in
their levels of anxiety than those who did not receive the
booklet [47]. Psychoeducational interventions might be pro-
vided by the physician and/or nurse, through accurate medi-
cal information and support. Anxiety related to medical
procedures may be reduced by adequate preparation by a staff
member, such that the patient will most likely have more
realistic expectations about the procedure.
Regardless of the treatment modality employed to reduce
anxiety in the cancer setting, organic causes of symptoms
must be discarded prior to initiation of the intervention,
and if detected, their correction should be a priority.
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2.6. Sleep disorders
Sleep disorders are a common symptom of anxiety, one of the
most prominent concerns of cancer patients [48], and one of
the main reasons for consultation in oncology [49]. In the gen-
eral population, people with insomnia report more medical
problems than those without insomnia [50]. Altered sleep
usually has a profound adverse effect on emotional, cognitive
and physical functioning.
Sleep consists of two phases: rapid eye movement (REM)
sleep and non-REM (NREM) sleep [51]. REM sleep is the active
or paradoxical phase of sleep in which the brain is active. It is
also known as dream sleep. NREM sleep is the restful phase of
sleep. Both phases alternate in a repeated pattern or cycle of
NREM followed by REM, with each cycle lasting approximately
90 min. The sleep–wake cycle is dictated by an inherent bio-
logical clock or circadian rhythm. Disruptions in individual
sleep patterns can disrupt the circadian rhythm and impair
the sleep cycle [52].
2.7. Categories of sleep disorders
The American Academy of Sleep Medicine [53] has defined
five categories of sleep disorders:
• disorders of initiating and maintaining sleep: insomnias;
• sleep-related breathing disorders: sleep apnoea;
• disorders of excessive somnolence: hypersomnias;
• disorders of the sleep–wake cycle: circadian rhythm sleep
disorders;
• dysfunctions associated with sleep, sleep stages, or partial
arousals: parasomnias.
2.8. Sleep disorders in cancer patients
Sleep disturbances occur in about 10–15% of the general pop-
ulation [54] and are often associated with situational stress,
disease, ageing and drug treatment [55]. Between one third
and one half of cancer patients experience sleep disorders
[56]. These are usually associated with pain, hospitalisation,
medication, recurring thoughts about the disease and can-
cer-related fears. Anxiety and depression have been found
to be highly correlated with insomnia [56]. Alterations in the
sleep–wake cycle can be early signs of delirium.
However, insomnia is often under-recognised and under-
treated, partly because it has been seen as a normal and tran-
sient reaction to cancer and cancer treatment, and partly be-
cause sleep disturbances are under-reported by patients [57].
Patients with cancer report insomnia, poor sleep quality and
short sleep duration [58]. Sleep disturbances can persist in
time, with a significant number of cancer survivors reporting
them as one of the most pervasive problems they face.
Reports over the past 20 years have begun to shed light on
the putative relationship between cancer-related sleep disor-
ders and cancer-related fatigue. While most of the studies in
this area are correlative in nature, it is generally the case that
sleep disturbance is: (a) positively correlated with fatigue, (b)
more severe in fatigued than in non-fatigued patients and
(c) a significant predictor of fatigue [58–60]. Current under-
standing of the possible link between cancer-related fatigue
and sleep disturbances suggests that interventions targeting
sleep disorders and daytime sleepiness could provide promis-
ing potential treatments for cancer-related fatigue. Targeted
treatment of either symptom may possibly affect the other,
given the emerging data suggesting that sleep disturbance is
common in patients with cancer and that it may be both a
cause and an effect of fatigue [58].
The following risk factors have been described for sleep
disorders in cancer patients [61]:
• disease factors, including paraneoplastic syndromes with
increased steroidproduction, andsymptomsassociatedwith
tumour invasion (i.e. pain, fever, shortness of breath) [62];
• treatment-related factors, including symptoms associated
with surgery (i.e. pain, use of opioids and frequent moni-
toring) [62];
• chemotherapy administration (i.e. exogenous
corticosteroids);
• medications such as opioids, sedatives/hypnotics, ste-
roids, some antidepressants and dietary supplements [63];
• environmental factors (i.e. hospital routines and room-
mates, environmental noise) [64];
• physical and/or psychological stressors [57];
• anxiety and depression [56];
• delirium.
In addition to considering the above risk factors, an ade-
quate assessment of sleep disorders should evaluate the usual
patterns of sleep, including usual bedtime, routine before retir-
ing, length of time before onset of sleep and duration of sleep
(waking episodes during the night, ability to resume sleep and
usual time for awakening). Characteristics of disturbed sleep
(changes following diagnosis, treatment and/or hospitalisa-
tion), perception of significant others as to quantity and qual-
ity of patients’ sleep, and family history of sleep disorders
should be taken into account, together with emotional status,
exercise and activity levels, diet and care-giver routines [53].
Some studies link sleep with natural killer cell activity [65]
and conclude that sound sleep may be important for immune
defence against tumour cells [66].
2.9. Treatment of sleep disorders
Multiple psychological interventions – ranging from individ-
ual supportive psychotherapy to cognitive behavioural tech-
niques (biofeedback, hypnosis, progressive muscle
relaxation) – have proven to be effective in the control of anx-
iety and sleep disorders [67], and may be combined with phar-
macological interventions. Several large randomised trials
and meta-analysis have demonstrated the efficacy of cogni-
tive behavioural therapy for insomnia in patients without
cancer [68,69] as well as in the cancer population [70–72].
Components of cognitive behavioural therapy (CBT)
include:
• cognitive restructuring, such as restructuring negative
thoughts, beliefs and attitudes related to sleep, and pre-
venting excessive monitoring or worrying about getting
enough sleep [68];
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• behavioural strategies including stimulus control and
sleep restriction in order to limit the time spent in bed dur-
ing which the patient does not sleep [68];
• relaxation techniques that can be combinedwith both cog-
nitive and behavioural interventions are quite useful when
accompanied by visual imagery;
• basic sleep hygiene education includes suggesting the fol-
lowing to the patient: sleeping and waking up at regular
times, relaxing at least 90 min before going to bed; creating
a dark, comfortable sleep environment with a cool temper-
ature, avoiding watching television, using a laptop, or
working in bed, getting ample daylight during non-sleep
hours, avoiding day naps, avoiding stimulants such as
caffeine, nicotine and cigarettes 2–3 h before bedtime,
avoiding intake of liquids 2 h prior to sleeping, and
getting regular exercise but no closer than 3 h before
bedtime.
In one study, 30 cancer patients were assigned to either a
three-session relaxation programme or no treatment. Pa-
tients receiving relaxation training reported reductions in
sleep latency [70]. Espie et al. [72] found CBT to be associated
with mean reductions in wakefulness of 55 min per night
compared with no change for the care as usual group for per-
sistent insomnia in patients with cancer. Results were sus-
tained 6 months after treatment. Standardised relative
effect sizes were large for complaints of difficulty initiating
sleep, waking from sleep during the night and for sleep effi-
ciency (percentage of time in bed spent sleeping). CBT was
associated with moderate to large effect sizes for five of seven
quality-of-life outcomes, including significant reduction in
daytime fatigue. No significant interaction was found be-
tween any of these outcomes and baseline demographic, clin-
ical or sleep characteristics. Savard et al. [71] studied 57
women with insomnia caused or worsened by breast cancer.
Patients in the treatment group participated in CBT group ses-
sions during eight weekly sessions of 90 min duration each,
led by a psychologist. Sustained reductions in sleep latency
and wakefulness were observed after CBT compared with
controls. There was no increase in total sleep, but increases
in sleep efficiency (proportion of time in bed spent asleep)
averaged 15%.
Long-term pharmacological treatment is not desirable,
especially when fatigue is an issue [73,74]. Despite this, 25%
of cancer patients have been reported to take sleeping pills
on a regular basis [66], and approximately 25–50% of all pre-
scriptions written for patients with cancer are for hypnotics
[75]. In cases where CBT is not available, has not been suc-
cessful, or when patients have comorbidities contributing to
sleep disturbances (i.e. pain, hot flashes, depression, etc.),
then pharmacological treatment will be necessary. Several
types of medication are used to treat disturbed sleep [61]:
non-benzodiazepine benzodiazepine receptor agonists, ben-
zodiazepines, melatonin receptor agonists, antihistamines,
antidepressants and antipsychotics that have sedative ef-
fects, and melatonin. Most of the approved sleep aids have
not been studied in cancer populations; therefore the risk/
benefit profiles of these drugs are not delineated in this
setting.
3. Conclusion
Patients with cancer report elevated levels of anxiety and
sleep disturbances that may intensify throughout the disease
course. Symptoms are frequently underestimated, despite the
enormous adverse impact they have on patients’ quality of
life. Adequate assessment of symptoms is imperative and
should identify medical as well as non-medical variables
influencing or causing anxiety or sleep disturbance, in order
to obtain optimal symptom management. Psychotherapeutic
techniques such as CBT have proved to be effective in control-
ling both anxiety and sleep disturbances. However, the most
effective intervention for both anxiety and sleep disorders is
that which combines psychotherapeutic techniques with
pharmacological treatment, when necessary.
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1. Introduction
The potentially detrimental effects of cancer and related
treatments on cognitive functioning are emerging as a key fo-
cus of cancer survivorship research. Many patients with cen-
tral nervous system (CNS) or non-CNS tumours develop
cognitive problems during the course of their disease that
can result in diminished functional independence and can
continue well into the survivorship period.
In recent years, growing attention is being paid to the po-
tential adverse effects of chemotherapy on brain and cogni-
tive function. This central neurotoxicity may manifest as
both acute and delayed complications. Virtually all categories
of chemotherapeutic agent have been associated with ad-
verse neurological effects, including both acute and chronic
encephalopathy. More subtle cognitive dysfunction has also
been demonstrated and frequently manifests as diminished
memory, executive function, attention and information pro-
cessing speed.
In this article on chemotherapy and cognitive functioning
we will summarise knowledge on the incidence of cognitive
deficits, the neuropsychological pattern and structural brain
changes associated with chemotherapy, risk factors identified
for developing neurotoxicity and underlying mechanisms as
well as current treatment options to prevent or diminish the
adverse effects of chemotherapy on cognition.
We will focus on chemotherapy-associated cognitive
problems in breast cancer patients, as these symptoms
have been particularly well studied in this patient group.
In addition, studies on chemotherapy and cognition in
adult CNS cancer patients will also be discussed. In this
group of patients chemotherapy may be associated with
stabilisation or improvement of cognitive function due to
better disease control, but may at the same time go hand
in hand with CNS toxicity as a consequence of
chemotherapy.
2. Neuropsychological studies in breast cancer
patients
Over the last 10–15 years, increasing evidence has revealed
the occurrence of acute and long-term cognitive problems
for a subset of patients following chemotherapy applied in
the treatment of non-CNS malignancies. In breast cancer pa-
tients alone, over 60 neuropsychological studies have been
published that have investigated whether adjuvant chemo-
therapy is associated with cognitive impairment [1–3]. In the
early years most of these studies had a cross-sectional design
and provided us with a snapshot of the prevalence of cogni-
tive impairment and the characteristics associated with this
impairment at specific moments post-chemotherapy. In re-
cent years, prospective neuropsychological studies on the
incidence of cognitive problems arising from pre- to post-che-
motherapy supported the previous observed relationship be-
tween chemotherapy exposure and cognitive problems by
demonstrating cognitive decline post-treatment relative to
pre-treatment cognitive performance.
Thoseprospective studieswithapre-treatmentassessment
also indicated the importance of a baselinemeasure, as several
studies observed lower than expected cognitive performance
in breast cancer patientswhoare about to undergo chemother-
apy in comparison to reference data of non-cancer subjects or
cancer patients with lower disease stages who will not need
chemotherapy. Up till now, no explanation has been found
for thesedecreasedcognitive scoresat baseline. Surgery (under
general anaesthesia), distress, fatigue or disease-associated
immune responses cannot yet clarify this observation.
3. Frequency and pattern of cognitive
dysfunction
The vast majority (70%) of the neuropsychological studies
demonstrated cognitive impairment and/or cognitive decline
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in breast cancer patients who have been treated with
cytotoxic agents compared to breast cancer patients without
chemotherapy or compared to non-cancer controls, regard-
less of the design of the study.
Patients show deficits on a wide range of standardised
neuropsychological tests, but core impairments are related
to learning new information and accelerated forgetting of
information. Impairment in executive functions – such as
planning and implementing strategies, flexible shifting and
working memory – is also common, as are deficits in psycho-
motor speed (indicative of a frontal–subcortical profile).
Despite the accumulation of knowledge on the cognitive
side-effects of chemotherapy, the actual incidence of this
impairment is still a subject of research. Estimates of affected
patients vary from 17% to 78% across studies, because of dif-
ferences between treatment regimens and between individ-
ual patients, but also owing to variations in study measures,
assessment times and criteria applied to define cognitive
impairment and deterioration. When the magnitude of the
cognitive deficits as expressed in sizes of effects is studied,
a large variation between studies is also observed.
4. Course over time
The literature has shown that cognitive changes can arise
during treatment and can persist up to several years after
completion of treatment. Studies have largely followed pa-
tients up to 1–2 years post-treatment. Only a few studies have
investigated the very late (i.e. P5 years post-treatment) ef-
fects of chemotherapy, but those that have show long-term
cognitive problems in chemotherapy-exposed breast cancer
survivors. A recent large study showed that breast cancer sur-
vivors who received CMF chemotherapy (cyclophosphamide,
methotrexate, 5-fluorouracil) on average 20 years previously
were more likely to have lower performance on memory,
information processing speed and psychomotor speed com-
pared with women without a history of cancer. The magni-
tude of the effects was comparable to approximately 6 years
of age-related decline in cognitive function [4].
The influence of cancer and cancer treatment on the pro-
cess of cognitive ageing is a topic that is increasingly receiv-
ing attention. There is concern that chemotherapy may
induce accelerated ageing and that it can increase an individ-
ual’s susceptibility to late-emerging cognitive decline or
dementia. The underlying development of cognitive impair-
ment in ageing appears to begin at mid-life. Genetic signa-
tures of brain ageing (i.e. from transcriptional profiling in
post-mortem brains) can be identified in subjects as early as
their 40s. Substantial evidence demonstrates that a wide vari-
ety of variables in early life are determinants of cognition in
later life. Furthermore, both lifestyle and health-related risk
factors in mid-life are associated with poor cognition decades
later. It is plausible that damage to brain health in young to
middle-aged women becomes even more clinically evident
many years later when the brain is extra vulnerable. There-
fore it is essential to investigate how chemotherapy in earlier
life may influence cognition in later life.
Different trajectories for chemotherapy-associated cogni-
tive problems have been proposed in the literature. It could
be that long-term cognitive problems result from lack of
recovery from the acute effects of treatment. It could also
be that the initial effect of treatment may produce a cascade
of biological events that cause continued cognitive decline
with ageing. Alternatively, chemotherapy may not be suffi-
cient to cause enough redundancy loss to immediately affect
cognitive function, but may produce a delayed effect as age-
ing continues, with the slope of change being influenced by
a variety of factors [5].
Prospective studies with a very long-term follow-up or
studies focusing on older cancer survivors are almost ab-
sent. A study on the effects of chemotherapy and cognition
in patients P65 years of age showed that these subjects
experienced more cognitive decline than unexposed coun-
terparts. Incidence of dementia was not explored in this
study, and even though these subjects were of older age,
their mean time since treatment was still relatively short
[6,7]. A few retrospective studies have been published
examining the risk of dementia in breast cancer survivors
up to 15 years after completion of cytotoxic treatment;
these studies used data from the linked Surveillance, Epide-
miology and End Results (SEER)–Medicare database. None of
these studies showed any clear evidence for the existence
of such a relationship, although several methodological is-
sues limit the validity and interpretation of the studies [8–
11].
5. Risk factors
Several factors have been identified that generally increase
the risk of developing neurotoxicity associated with chemo-
therapy. These include: (1) exposure to higher doses due to
planned use of high-dose regimens, or to high concentrations
of the parent drug and/or its metabolite due to impaired sys-
temic clearance and/or pharmacogenetic modulation of drug
pharmacokinetics; (2) additive or synergistic effects of multi-
agent chemotherapy; (3) additive or synergistic effect of mul-
timodality therapy that includes administration of chemo-
therapy either concurrently with or subsequently to cerebral
radiation; (4) intra-arterial administration with blood–brain
barrier disruption; and (5) intrathecal administration [12–17].
From the literature it is clear that not all patients are af-
fected equally by chemotherapy. The finding that a subgroup
of patients experience persistent post-treatment cognitive de-
cline has led to the examination of patient- and disease-re-
lated risk factors for cognitive change. Candidate predictors
of cognitive dysfunction frequently studied include age, edu-
cation and pre-morbid IQ; however, no consistent predictors
have been identified. Most studies failed to identify a relation-
ship between treatment-related cognitive decline and age, IQ,
education, baseline cognitive function and a host of other fac-
tors such as depression, anxiety, stress, fatigue, disease stage,
haemoglobin levels and treatment-induced menopause.
When an association between a sociodemographic or clinical
predictor and cognitive dysfunction has been found the rela-
tionship is generally weak [3]. However, given the small sam-
ple sizes in nearly all studies, exploration of any
sociodemographic or clinical predictors is likely to be
underpowered. This is also the case for genetic factors (e.g.
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vulnerable alleles of genes such as APOE and COMT) that have
been examined as potential risk factors for cognitive
decline [5].
Risk factors – endocrine treatment: a treatment-related risk
factor for cognitive decline in breast cancer patients that is
of particular clinical relevance is the combined use of endo-
crine therapy. Breast cancer patients undergoing chemother-
apy often receive endocrine therapy as well. These therapies
commonly consist of treatment with selective oestrogen
receptor modulators (SERMs) such as tamoxifen and/or aro-
matase inhibitors (AIs) such as exemestane, anastrozole or
letrozole. Evidence derived from basic as well as clinical re-
search indicates that estradiol, within a time window of
opportunity, can stimulate neuroplasticity in brain areas in-
volved in cognitive behaviour leading to improved perfor-
mance [18–20]. Since SERMs and AIs also target brain areas
involved in the regulation of cognitive behaviour, it is plausi-
ble that these substances may contribute to cognitive deteri-
oration in breast cancer patients. Blocking estradiol synthesis
with AIs deprives the brain of modulation via estradiol and
therefore theoretically results in decreased neuroplasticity
and impaired cognitive functioning. However, surprisingly,
studies in breast cancer patients seem generally to indicate
that AIs less consistently adversely influence cognitive func-
tioning compared with SERMs [21]. Studies specifically
addressing the interaction between chemotherapy and endo-
crine therapy are sparse and the majority of studies have
been too small to adequately investigate this interaction. Ab-
sence of oestrogen neuroprotective action in the brain – in the
natural, surgical or chemotherapy-induced postmenopausal
brain – makes the brain possibly extra vulnerable to neural
damage by chemotherapy [22].
Particularly in older breast cancer patients, treatment with
SERMs seems to have a potentially detrimental effect on cog-
nitive functioning [23]. Basic research is rather conclusive on
the neuroprotective properties of SERMs in the absence of cir-
culating estradiol, but the effects of chronic SERM administra-
tion on cognitive behaviour are more ambiguous. Cleary more
research is needed, particularly on the effects of SERMs on the
brain and behaviour in relation to age and the length of depri-
vation of endogenous estradiol.
Risk factors – information: information on chemotherapy-
associated cognitive problems is more and more accessible
to patients. The reporting of cognitive problems may also be
influenced by strictly cognitive mechanisms that are not
rooted in psychological distress or negative affect, but simply
in the extent to which a patient is informed about the possi-
bility of cognitive problems following chemotherapy. Several
studies on cognitive deficits in breast cancer patients showed
that mere information about the association between chemo-
therapy and cognitive problems resulted in lower memory
performance and higher complaint reporting [24,25]. These
effects occurred independently of negative affect and pre-
existing knowledge. The notion that mere information can
add to the occurrence andmaintenance of cognitive problems
is derived from a large body of social psychological research
on stereotype threat and priming. Stereotype threat – i.e. fear
of confirming a stereotype – has been researched extensively,
and evidence shows that activation of a stereotype or schema
unconsciously leads to behaviour that is in correspondence
with that stereotype [26,27].
Concepts of stereotype threat and priming are important
for explaining the effects of treatment-related information
on complaint reporting and neuropsychological test scores.
Furthermore, it may be that some individuals are particularly
vulnerable to these effects. Research shows that stereotype
threat effects are stronger among people who are especially
cognizant of the particular stigma, and that participants
who self-identify more strongly with a stereotyped group
show stronger stereotype threat effects on cognitive function
[28]. A recent study showed that receipt of stereotypical infor-
mation about the occurrence of medical problems experi-
enced by cancer patients primed the cognitive accessibility
of the cancer patient stereotype and differentially affected
women’s cognitive complaints and test scores, depending
on their level of consciousness of cancer patient stigma [29].
It is not suggested that these psychological processes
should be viewed as alternative explanations for biological
influences. Rather, the possibility is raised that, for certain pa-
tients, self-regulatory and expectancy processes may also
play a role – as a contributing, additive or meditational influ-
ence – in cognitive functioning. The next steps for clinical
practice include the determination of the severity and dura-
tion of priming effects and to further understand the individ-
ual variation in these effects. In addition there is a need to
explore the possibilities of diminishing or preventing these
effects.
6. Neuropsychological studies in patients
with central nervous system tumours
Evaluating adverse effects of chemotherapy on cognitive
function in CNS cancer patients is often challenging because
of the variety of other factors that can impact cognition in
this population, most notably treatment with radiation and
tumour progression. Both radiation and chemotherapy have
been reported to share at least one common mechanism for
their adverse effect on brain and cognition: disruption of
the neural stem and precursor cell function [30]. Only recently
clinical trials have incorporated cognitive testing into their
study design, providing the opportunity to address these is-
sues in large samples of homogeneously treated patients.
Radiation therapy has been demonstrated to adversely im-
pact brain and cognition through vascular damage and
inflammation, and via damage to neuronal progenitor cells
affecting hippocampal neurogenesis and oligodendroglial for-
mation [31]. Impairment in processing speed, attention, exec-
utive function and memory is commonly seen in brain
tumour survivors previously treated with radiation therapy
[32]. Several recent retrospective studies have examined the
effects of radiation dose on different areas of the brain and
cognitive outcomes. These studies provide evidence of a
dose–response relationship between radiation to the bilateral
hippocampal region and memory function [33], in addition to
other brain regions and more heterogeneous cognitive out-
comes [34]. Trials are currently under way in many centers
to explore the use of technological advances in radiation
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delivery to spare normal tissues from radiation exposure, and
to explore different forms of radiation such as proton therapy
that may similarly achieve reduced-dose exposure to the nor-
mal brain and other critical structures.
The standard of care for glioblastoma patients has in-
cluded concomitant chemoradiation and adjuvant chemo-
therapy with temozolomide since 2004 [35]. A small single-
institution study with standard-dose temozolomide reported
cognitive decline in three out of 13 progression-free patients
after concurrent chemoradiation and three cycles of adjuvant
chemotherapy [36]. Declines were evident in psychomotor
speed, attention and executive function, but not in verbal
memory or working memory span. The results of a larger
multi-institutional cooperative group trial comparing adju-
vant standard-dose temozolomide and dose-dense temozolo-
mide have also been reported [37]. In patients that were
clinically and radiographically progression-free after concur-
rent chemoradiation and three cycles of adjuvant chemother-
apy, 30% demonstrated cognitive decline, with no differences
between arms. Cognitive decline was evident in all domains
assessed – including verbal learning and memory, executive
function and processing speed – and was prognostic of pro-
gression-free and overall survival. A recent study using tem-
ozolomide-administered rodents has demonstrated reduced
hippocampal neurogenesis, decreased theta activity as mea-
sured by electromyography during an eye blink conditioning
task and disrupted learning [38].
Due to the importance of angiogenesis in the growth and
spread of cancer, there has been a great interest in inhibitors
of vascular endothelial growth factor (VEGF), such as bev-
acizumab. Anti-VEGF agents have been demonstrated to pro-
duce rapid radiological improvement, ostensibly due to their
ability to reduce tumour and blood–brain barrier permeability
associated with leaky blood vessels. There is concern that this
represents a ‘pseudoresponse’ which complicates the inter-
pretation of traditional imaging end-points [39]. A phase II
non-comparative study of bevacizumab in a recurrent glio-
blastoma multiforme (GBM) population included tests of cog-
nition to characterise changes in brain function associated
with bevacizumab therapy. In patients who achieved an
objective radiographic response or who were clinically and
radiographically progression-free at 24 weeks, the majority
(75% and 70%, respectively) demonstrated stable or improved
cognitive function relative to their pretreatment baseline [40].
Two placebo-controlled phase III trials with cognitive end-
points in newly diagnosed GBM patients are currently under
way and will provide more information on the impact of bev-
acizumab on cognitive function.
The long-term outcomes and associated reanalysis from
the RTOG 9402 trial recently reported [41] a doubling of overall
survival rates in pure or mixed anaplastic oligodendroglioma
patients with 1p/19q co-deletion who received procarbazine,
CCNU and vincristine (PCV) chemotherapy. This trial did not
assess patient-oriented outcomes such as cognitive function
to help determine the net clinical benefit of this survival
advantage. However, two single-institution studies assessed
cognition in anaplastic glioma [42] and GBM [43] patients trea-
ted with regimens that included PCV. Of patients with ana-
plastic glioma, 35% who were re-evaluated at a median of
8 months after initiation of treatment demonstrated cognitive
decline. In GBM patients retested at a mean of approximately
8 months after initiating treatment, decreased cognitive func-
tion (in 44–52% of patients) was most commonly observed in
the domains of psychomotor speed, executive function and
memory. Unfortunately, these studies were not designed to
distinguish the effects of chemoradiation from adjuvant che-
motherapy and did not control for tumour progression, com-
plicating the interpretation of these results as evidence of
chemotherapy-related neurotoxicities.
Cognitive dysfunction is a frequent presenting/occurring
sign in patients with primary CNS lymphoma (PCNSL). How-
ever, unlike patients with primary brain tumours, many
PCNSL patients who receive chemotherapy with or without
radiation therapy show evidence of improvement in cogni-
tive function [44]. For example, Correa et al [45] reported
improvements in executive function and verbal memory up
to 2 years after treatment in newly diagnosed PCNSL pa-
tients who were treated with induction rituximab, metho-
trexate, procarbazine and vincristine followed by reduced-
dose whole-brain radiation and consolidation high-dose
cytarabine.
7. Neural substrate and underlying
mechanisms
Despite evidence of cognitive changes associated with che-
motherapy in cancer patients, the pathophysiology of these
changes needs further elucidation.
Neuroimaging studies in breast cancer patients indicate
structural changes in the brain associated with certain che-
motherapeutic agents, and have started to shed light on the
brain alterations that may be part of the mechanisms under-
lying the observed cognitive dysfunction in patients following
administration of chemotherapeutic compounds without tar-
geted CNS delivery.
8. Imaging studies
Several structural imaging studies have been conducted
among breast cancer patients treated with adjuvant regi-
mens, with assessments generally occurring from months
to 3 years after completion of treatment [46–50], although
two studies examined patients 10 and 20 years after comple-
tion of treatment [51,52]. Nearly all of these studies are indic-
ative of structural brain differences between patients that
received chemotherapy and either healthy controls or breast
cancer controls that did not receive chemotherapy. White-
matter pathology has been observed within months up to
10 years post-treatment, after both high-dose and standard-
dose regimens. Studies using voxel-based morphometry have
reported volume reductions in white and grey matter 1 year to
20 years after completion of chemotherapy. A prospective
study observed focal grey matter volume decrease 1 month
after the cessation of chemotherapy, which recovered in some
but not all regions at 1 year post-treatment.
The cerebral white matter seems particularly vulnerable to
the effects of chemotherapy. Studies investigating cerebral
white matter integrity using diffusion tensor imaging (DTI) re-
ported lower fractional anisotropy (FA) in the genu of the cor-
pus callosum, lower FA in frontal and temporal white matter
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and higher mean diffusivity in frontal white matter of breast
cancer patients who received standard-dose anthracycline-
based regimens compared with breast cancer controls and
healthy controls. In a study conducted 10 years after comple-
tion of high-dose chemotherapy, DTI also showed lower FA in
several white-matter tracts compared with breast cancer pa-
tients who never received chemotherapy [53]. In a large study
conducted on average 20 years after completion of treatment,
it was shown that in the absence of significant group differ-
ences in white matter integrity, time since treatment was in-
versely associated with lower global and focal white matter
integrity within the breast cancer group [54]. This cross-sec-
tional indication of affected white matter integrity was sup-
ported by a prospective study showing that breast cancer
patients who received chemotherapy displayed significant de-
creases in FA in frontal, parietal and occipital white-matter
tracts from pre- to post-chemotherapy, whereas for both a
healthy control and a breast cancer control group, FA values
were the same between baseline and follow-up [55].
Moreover there seems to be a link between the abnormal
microstructural properties in white-matter regions and the
cognitive impairments seen in breast cancer patients treated
with chemotherapeutic agents; several studies observed cor-
relations between abnormal diffusion properties and cogni-
tive problems on neuropsychological testing [53].
The observed changes in DTI parameters may be related to
demyelination of white matter axons or axonal injury after
chemotherapy. Although caution is warranted in directly
translating changes on structural imaging measures into bio-
logical changes, a rapidly increasing number of preclinical
animal studies are helping define potential mechanisms
underlying chemotherapy-induced cognitive dysfunction,
and their results relate to a significant extent to the observa-
tions in human studies.
9. Animal studies
Valuable insights have come from preclinical studies on the
potential pathogenic mechanisms involved in cognitive
impairment related to systemic administration of chemother-
apeutic compounds without targeted CNS delivery, although
the precise mechanisms remain insufficiently understood.
Many factors have been proposed to play a role in chemother-
apy-induced neurotoxicity, including the directly toxic effects
of chemotherapeutic agents on various brain cells, vascular
injury and the indirect immune-mediated inflammatory pro-
cesses. It is unlikely that a single mechanism can explain
much of the major cognitive problems observed in cancer pa-
tients following chemotherapy.
Experimental studies have shown that many chemothera-
peutic agents, when administered peripherally and in clini-
cally relevant dosages, are associated with adverse effects
on neurobiology and cognition (including 5-fluorouracil,
methotrexate, doxorubicin, paclitaxel, cisplatin, BCNU and
cyclophosphamide). In behavioural studies in animals, che-
motherapy-related deficits have been observed in rodents
on tasks that require involvement of the hippocampus and
frontal systems. Toxicity is observed in multiple CNS cell
types and multiple CNS regions [56]. Specifically, chemother-
apy-induced damage of mature post-mitotic oligodendrocytes
and immature progenitor cell populations required for ongo-
ing neurogenesis, gliogenesis and maintenance of white mat-
ter integrity seems to be an important aetiological factor in
the development of neurotoxicity [57].
Research focusing on the development of strategies to in-
hibit specific transporters to enable drugs to cross the blood–
brain barrier (BBB) in sufficient amounts is also relevant for
understanding the mechanisms by which chemotherapeutic
agents not targeted to reach the CNS cause cognitive and
brain changes. Gong et al. [58] propose in their stem-cell
hypothesis that differential sensitivities of glioma stem cells
and neural stem cells to alkylating agents, temozolomide, cis-
platin and targeted agents such as erlotinib and bortezomib
hold the key to the resistance of primary brain tumours and
the occurrence of chemotherapy-associated neurotoxicity in
non-CNS disease.
The development of modalities that enhance delivery of
drugs to brain tumours will also increase the drug exposure
of the normal brain tissue, and may place patients at risk
for treatment-induced cognitive decline. Until now, several
preclinical studies have investigated pharmacological preven-
tion strategies that further underscore the relevance of sev-
eral hypothesised mechanistic pathways underlying the
effects of chemotherapeutic agents on the brain and behav-
iour. Konat et al. [59] showed that N-acetyl cysteine, an anti-
oxidant, ameliorated cognitive impairment in Wistar rats
after combined administration of cyclophosphamide and
doxorubicin. Two recent studies further explored potential
candidates for interventions. A study by Lyons et al. [60] dem-
onstrates that fluoxetine, when administered before and dur-
ing treatment with 5-FU in rats, may prevent cognitive
impairment and the loss of normal cell proliferation in the
hippocampus observed after administration of 5-FU. Vijaya-
nathan et al. [61] demonstrated that treatment with a gluta-
mate receptor antagonist improved cognition after
intrathecal administration of methotrexate in rats.
10. Interventions
Cognitive dysfunction is a common consequence for many
cancer patients, and it does not always fade away. As indi-
cated, pharmacological interventions to prevent or intervene
against cognitive symptoms are in an early stage of develop-
ment. Agents that have been examined or that are currently
under investigation in patients include erythropoietin, meth-
ylphenidate, modafinil, donepezil and melatonin [62,63].
Some of these agents are promising, but the need for their rig-
orous testing with appropriate study designs and sufficient
sample sizes precludes translation and implementation in
daily practice.
Within the area of neuropsychological rehabilitation
roughly two models can be distinguished: the restoration
model and the compensation model [64]. The restoration
model is directed at restoring damaged cognitive functions
through function training, often using a so-called repeated
practice approach, based on the assumption that specific
stimulation induces plasticity. But evidence is still lacking
that the benefits of training on specific tasks will transfer to
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other untrained tasks or lead to any general improvement in
the level of cognitive functioning. Compensation techniques,
on the contrary, are proven to be successful. Improvement in
daily life functioning can be achieved using intact cognitive
abilities and strategies. Neuropsychological rehabilitation
based on the compensation model together with psycho-edu-
cation and coping strategies can be offered to cancer patients
confronted with cognitive problems to maximise their ability
to function [65].
11. Conclusion
Evidently, people with (a history of) cancer constitute an
increasing group in our community. From this viewpoint,
we have an obligation to obtain information on the cognitive
effects of chemotherapy from a descriptive and preventive
standpoint, and from an individual as well as a societal per-
spective. Chemotherapy is a necessary component in the
management of many types of cancer, and the choices be-
tween different regimens in terms of adequate cancer control
and minimal side-effects are restricted. Many cancer patients
are returning to employment or other activities that may be
affected by cognitive functioning. It is critical to identify cog-
nitive effects of cancer treatment, to explore the mechanisms
underlying these cognitive effects and to explore possible
interventions that follow from these mechanisms and that
may minimise cognitive side-effects and their severity and
impact.
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1. Delirium definition and clinical
characteristics
Delirium is a disorder of consciousness and attention; it is
one of the most common neurological complications seen
in general in the medically ill hospitalised patient, and is also
common in the medical oncology ward [1,2]. Delirium seen in
different settings contributes to defining the diagnoses of di-
verse specificities: postoperative delirium, delirium in the
ICU, withdrawal delirium or delirium tremens, terminal rest-
lessness and others.
Before considering specific clinical contexts or diagnoses it
is necessary to recognise the general characteristics of delir-
ium as a syndrome and its clinical implications. There is
now almost universal agreement on the definition of delir-
ium, or acute confusional state, according to the DSM. How-
ever, acute confusional state is a synonym of delirium and
is still a useful clinical definition, particularly in non-
English-speaking countries. Delirium is a syndrome and not
a disease, and its pathophysiology has not been fully eluci-
dated. Different theories have favoured alternatively the fail-
ure of a common final pathway – mainly regulating the
cholinergic projection to the cerebral cortex – or a more dif-
fused or multifocal impairment of different areas in the
CNS which contribute to maintaining the normal level of vig-
ilance and attention.
Clinically, delirium is an altered state of consciousness
with reduced awareness of self and of the environment,
which may present with inability to think and talk clearly
and rationally; at times there are hallucinations, delusions,
disorientation with respect to time and space, altered sleep–
wakefulness cycle and cognitive impairment. Psychomotor
agitation can be present in the hyperactive deliria, but hypo-
active deliria will show psychomotor retardation and somno-
lence. One extremely important clinical aspect of delirium is
fluctuation of the clinical presentation; symptoms can
change suddenly, often under repetitive conditions (such as
in the classic nocturnal worsening often described in the el-
derly with cognitive impairment and called in the past ‘sun-
downing’). These sudden changes from a near-to-normal
mental state to frank delirium often surprise nursing and
medical staff and find them unprepared in front of the patient
and a distressed family.
The clinical presentation of delirium varies, and no de-
fined association of symptoms and signs can be considered
specific [3]. For the purposes of diagnosis and clinical evalua-
tion it is easier to use the DSM criteria as they give a system-
atic approach to the core clinical elements [4]. All four of the
following criteria have to be fulfilled to make a diagnosis.
Disturbance of consciousness (i.e. reduced clarity of
awareness of the environment) with reduced ability to focus,
sustain and shift attention; to fulfil this criterion the levels of
both consciousness and attention need to be affected.
Change in cognition (such as memory deficit, disorienta-
tion and language disturbances) or perception disturbances
that are not better explained by a pre-existing established or
evolving dementia. Testing cognitive function with simple
bedside examinations such as the Minimental test is often
enough to describe disorientation with respect to time and
space, difficulties in performing calculations and in writing
and simple memory tests. In the elderly with previous cogni-
tive failure or being already demented it may be difficult to
distinguish a failure in cognition as part of a chronic condi-
tion from a newly developing delirium (Table 1). Perceptual
disturbances are illusions and hallucinations. Most often
hallucinations are visual, but they are present only in a
percentage of delirious patients and their absence is not a
determinant for the diagnosis [3].
The disturbance develops over a short period of time
(usually hours to days) and tends to fluctuate during the
course of the day. This criterion specifically aims to distin-
guish delirium from chronic conditions, particularly from
dementia (Table 2), but in elderly patients with longstanding
medical complications it may be difficult to differentiate the
contribution of pre-existing neurological factors and inci-
dent acute factors. This distinction may be academic in
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many cases but it is relevant, as described below, to explain
many complex cases. Also in the case of advanced cancer
patients, with multiple clinical problems and polypharmacy,
delirium can be a long-lasting complication either character-
ising the final phase of the disease or being a reversible con-
dition [5].
There is evidence from the history, physical examination,
or laboratory findings that the disturbance is caused by the di-
rect physiological consequences of a general medical condi-
tion. This last criterion conceptually distinguishes delirium
from primary psychiatric disease (mainly acute psychosis)
(Table 1). In the old taxonomy this criterion was included in
the construct of organic brain disorder or of recognising an or-
ganic cause of psychiatric symptoms. This terminology is no
longer accepted by the latest DSM versions, but it can be used
to clarify the scope of criterion 4.
Based on the clinical presentation, delirium is distin-
guished into hypoactive, hyperactive and mixed types. The
hyperactive deliria are usually associated with delusions
and hallucination, disruptive or agitated behaviour and often
worsening of symptoms during the night. Hypoactive deliria,
in contrast, show a somnolent detached state of conscious-
ness and may be missed or mistaken for depression if the pa-
tient is not assessed more carefully with formal mental task
testing. Mixed hyper- and hypoactive presentations are most
frequent and the transition from hyperactive to hypoactive
delirium, stupor and coma can be seen as one of the ways
of dying.
2. Frequency and assessment
The frequency of delirium is high in the acutely hospitalised
patient population, with a prevalence which may be around
10% in the medical ward (excluding the cases of postoperative
delirium). The most relevant patient populations seen by
oncologists are summarised in Table 2, which shows that
the frequency of this complication can not only increase in
more advanced disease, but also that it is common in the el-
derly and as well as in the general oncology ward [6,7].
The diagnosis of delirium should be based on clinical
observation and examination, and can be aided by the sys-
tematic use of screening tools to detect cognitive failure, such
as the Minimental state examination, or tests specifically
Table 1 – Main differential diagnoses of delirium.
Clinical features Delirium Dementia Acute psychosis
Onset Acute Slow Acute
Circadian course Fluctuating Stable Stable
Level of consciousness Affected Spared unless in severe cases Spared
Attention Impaired Initially spared Can be impaired
Cognition Impaired Impaired Can be impaired
Hallucinations Usually visual Often absent Often auditory
Delusions Poorly systematised
and fleeting
Often absent Sustained and
systematised
Psychomotor activity Increased, reduced
mixed with alternating
course
Often normal Can vary, with
bizarre behaviour
depending on the psychosis
Involuntary movements Asterixis, myoclonus
or tremor can be present
in some subtypes
Absent in most forms Absent
EEG Abnormala Abnormala Normal
EEG, electroencephalogram.
*See text for more details.
Table 2 – Frequency of delirium in different patient populations admitted to hospital, hospice or home palliative care
programme.
Population Prevalence (%) at admission Incidence (%) during admission
Elderly P65 admitted to acute hospital unit 10.5 31.3
Elderly P70 admitted to acute hospital unit 25.0
Elderly P70 admitted to acute hospital unit 18.0
Medical oncology unit 18.0
Medical oncology unit 16.5
Hospice 28.0
Hospital palliative care unit 42.0 45.0
Palliative care programme including home care 28.0 –
Dying cancer patients in specialised palliative care unit 80
Modified from Caraceni and Grassi [2].
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designed to screen potential delirium cases, such the Nursing
Delirium Screening Test (NuDESC). In the validation study by
Gaudreau et al [8], the NuDESC proved sufficiently sensitive to
be used as a screening tool in oncology, although recently a
study on the detection of postoperative delirium in the elderly
showed that sensitivity was too low in this population [9].
Still, a more careful and systematic approach [10] adopted
by the nursing staff is a reasonable strategy and is to be rec-
ommended in oncology and particularly in palliative care set-
tings such as a hospice. The diagnosis finally relies on the
DSM criteria and requires specific expertise. The main differ-
ential diagnoses and their characteristics are listed in Table 1.
3. Diagnostic procedures
As with any new neurological sign or symptom, in a patient
with cancer a change in mental status requires a neurological
examination and, if available, neurological consultation. In
the case of neurological findings suggesting a structural brain
lesion, imaging should be performed. In a patient with cancer,
depending on the stage of the disease, it is not rare for delir-
ium, even without focal neurological signs, to be an initial
presentation of brain or meningeal metastases, as demon-
strated in 15% of patients in one case series [11].
Encephalitis of infectious origin can occur particularly in
immunocompromised patients and occurs not infrequently
after bone-marrow transplantation conditioning
chemotherapy.
Cancer patients are at increased risk of posterior reversible
encephalopathy syndrome (also known as posterior revers-
ible leukoencephalopathy), a syndrome that is probably
caused by damage to the brain vasculature and is found in
association with immunosuppressive therapies (cyclosporine,
tacrolimus), as a complication of transplant, high-dose multi-
drug chemotherapy (cytarabine, cisplatin, gemcitabine, vino-
relbine, FOLFOX regimen and methotrexate) and of the new
biological therapies such as anti-angiogenetic antibodies
and others (bevacizumab, rituximab, bortezomid andmotesa-
nib) [12]. The syndrome usually includes seizures, cortical vi-
sual deficit and headache, but at presentation changes in
mental status, or delirium, can dominate the clinical picture.
When seizures are not associated with obvious general-
ised or focal convulsions, the differential diagnosis of delir-
ium can be difficult. In fosfamide encephalopathy
obtundation of consciousness and myoclonus reflect a con-
tinuous seizure-like activity in the electroencephalogram
(EEG).
Patients with a history of psychiatric disorders can develop
acute psychotic reactions, especially when confronted with
serious medical illness such as cancer, with clinical presenta-
tions such as unresponsiveness and catatonia that can be
confused with delirium. These patients are usually young,
and the clinical context helps to exclude the most common
causes or risk factors of delirium.
True paraneoplastic neurological syndromes presenting
with alteredmental state (limbic encephalitis) are indeed very
rare; specific expertise is required for their diagnosis and they
are usually found in association with initial cancer with the
onset of the neurological syndrome preceding the diagnosis
of cancer [13].
Table 3 summarises the elements which can guide clinical
reasoning and a diagnostic strategy when faced with a cancer
patient with delirium that is not occurring after surgery and
general anaesthesia. The clinical context, risk factors, prog-
nosis, associated symptoms and goals of care will influence
the diagnostic path and completeness or futility of any inter-
ventions eventually required.
4. Pathophysiology, risk factors and aetiology
The complex pathophysiology of delirium is beyond the scope
of this chapter [14], but it is important to remember that the
brainstem, thalamic and hypothalamic projections into the
cortex are implicated in the regulation of normal vigilance
and in modulating the level of consciousness between the
physiological states of wakefulness and sleep. This system
has a neurotransmitter organisation, including acetylcholine,
dopamine, serotonin, histamine and c-aminobutyric acid
Table 3 – Diagnostic and etiological directions in case of delirium in the oncological patient (excluding postoperative
delirium).
Action Assessment
Rule out structural brain lesions Oncological history, neurological examination, brain imaging if unclear
Rule out seizures, non-convulsive
status epilepticus
When brain lesions are known or suspected EEG may be necessary
Rule out acute psychotic reactions History of psychiatric disease, young age, psychogenic unresponsiveness or
catatonia
Identify potentially toxic agents
Consider posterior reversible
encephalopathy (MRI required)
Reduce the risk of drug interactions
Specific (chemotherapy toxicity, brain RT, high-dose ifosfamide, antivirals,
immunosuppressive agents)
All generic psychoactive drugs
Any drug can be involved; check metabolic pathways in the hepatic microsomal
oxidising system
Checkmetabolic factors and vitamin
deficiency
Renal failure, hepatic failure, electrolyte imbalance, hypoxia, acidosis,
B1 (thiamine) deficit
Think of rarer conditions Paraneoplastic neurological syndromes (usually associated with unknown
or initial neoplastic disease)
EEG, electroencephalogram; MRI, magnetic resonance imaging; RT, radiotherapy.
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(GABA). An imbalance in some of these neurotransmitters is
thought to have a primary role in delirium pathophysiology.
An impaired cholinergic transmission from the brainstem
and enhanced dopaminergic tone are also thought to play a
causal role in delirium [14]. All drugs with anticholinergic
activity are sedating and can cause delirium. The cholinergic
hypothesis can also explain the increased susceptibility to
delirium of the elderly and of patients with cognitive impair-
ment or dementia, considering that all these situations are
characterised by a reduced function of the cholinergic central
activating system.
Delirium may have many causes, but in most cases a mul-
tifactor model can best explain its pathophysiology, with the
combination of some predisposing conditions and incident
noxious factors. This model was suggested by clinical obser-
vation in early studies on the syndrome [15] and has been
confirmed by well-conducted cohort studies demonstrating
that the combination of specific baseline conditions – such
as advanced age, cognitive impairment, dementia and sever-
ity of illness – was associated with an increased incidence of
delirium when combined with new factors, occurring during
the hospital stay, in elderly patients [16]. Among incident fac-
tors, infections and medications were noted. The results,
summarised in Table 4 [17], can be interpreted by classifying
the associated factors such as structural lesion or functional
abnormalities potentially impairing specific CNS functions
(brain metastases, previous cognitive failure), being direct or
indirect indicators of progression of the disease (metastases),
or of poor general condition and toxic factors (benzodiaze-
pines, opioids and steroids).
4.1. The role of drug toxicity
Drug toxicity, in the setting of medical therapy or abuse, is an
extremely frequent cause of delirium (Table 5). The ability to
identify one drug as a cause for delirium depends on anec-
dotal clinical observation, pharmacological knowledge and
clinical studies. One recent systematic review of the literature
supports the association of psychoactive medications, con-
sidered together, and use of opioids, which have an indepen-
dent increased risk of developing delirium in cancer patients
[18]. Another review focusing on patients at risk of developing
delirium (elderly patients admitted to hospital for medical
reasons or in the postoperative period) suggests avoiding
the use of benzodiazepines in this population [19].
Experimental human studies demonstrated that anticho-
linergic drugs such as scopolamine, ditran and atropine can
cause delirium depending on dosage [20]. Lower doses usually
produce somnolence (scopolamine 0.3–0.8 mg), higher doses
(atropineP5 mg, scopolamine = 1 mg) agitated florid delirium;
paradoxical effects of low doses have also been demonstrated.
In fact the list of drugs with anticholinergic activity is very
long (Table 6), and such drugs should be used with caution,
especially in the elderly with poor general conditions, multi-
ple medical problems and polypharmacy. Unfortunately all
these conditions are commonly found in cancer patients of
advanced age, with progressive disease and who need appro-
priate palliative therapy for symptom control. Appropriate
selection of drugs with simplified metabolic pathways and
lack of interference would reduce the risk of adverse
reactions.
4.2. Opioids
Opioids are very important drugs for the quality of life of can-
cer patients, and their role in the management of pain and
other symptoms cannot be underestimated. Opioids have
CNS side-effects which include sedation, impairment of cog-
nitive functions [21] and delirium. The central side-effects of
opioids are usually dose-related and can be the main dose-
limiting side-effects in dose titration to obtain better pain
control. High doses of opioids are associated with myoclonus,
delirium, hyperalgesia and eventually seizures [22,23]. Symp-
toms of CNS toxicity can also occur at low doses in individual
cases [24,25]. Recently an independent statistical association
with the use of doses P90 mg of oral morphine per day was
found to be associated with an increased risk of developing
delirium [18]. This means that we have to carefully monitor
the mental status of patients on significant opioid doses
and seek for signs or symptoms of CNS toxicity such as myoc-
lonus and hallucinations. Conversely, the mistake should not
be made of blaming opioids for any complication. Most cases
of delirium will be recognised in complex situations and with
multiple factors together with, if not alternative to, opioid
toxicity alone.
Renal failure can make more difficult the choice of an opi-
oid and increase the risk of delirium due to the accumulation
of toxic metabolites. Drugs which exhibit the safest pharma-
cological profile, when renal failure occurs, are buprenor-
phine, fentanyl, alfentanil, remifentanil and sufentanil [26].
However, simple clinical measures include the choice of an
opioid with least pharmacological interactions (morphine is
the first choice), providing hydration if metabolite accumula-
tion occurs because of reduced renal clearance, reduction of
the dose and substitution of the opioid if toxicity is suspected.
A palliative care consult is helpful to optimise opioid pharma-
cotherapy in these cases.
Table 4 – Factors associated with the risk of developing
delirium resulting from multivariate analysis in cancer.
Modified from Caraceni and Simonetti [17].
Potentially specific predisposing factors:
Advanced age
Previously impaired cognition
History of delirium
Metastatic CNS lesion
Non-specific factors associated with disease progression/
deterioration of general function:
Functional impairment
Severity of illness
Low albumin
Bone metastases
Liver metastases
Haematological malignancies
Potentially specific incident factors:
Metabolic abnormalities
Metastases to brain or meninges
Opioids (dose-related)
Benzodiazepines
Corticosteroids (dose-related)
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4.3. Steroids
The use of steroids is very common in cancer patients. High
doses and prolonged administration can induce delirium, also
called in the past steroid psychosis [27]. Also sudden discon-
tinuation of steroids can cause hypocortisol syndrome and
delirium. It is very important that steroids are given for a lim-
ited amount of time and tapered slowly when no longer nec-
essary. Usually at least a week or two of therapy is needed to
develop psychiatric complications [28]. The symptoms can
range from depression to mania and psychosis. The true inci-
dence of mental changes related to steroid administration in
palliative care is unknown. High doses are often reported to
cause euphoria.
Table 6 – Drugs with anticholinergic activity in each
category. The agents are listed from the more pronounced to
less pronounced anticholinergic potency.
Prototypical anticholinergics:
Belladonna alkaloids
Atropine
Scopolamine
Hyoscine butylbromide
Robinul
Antidepressants:
Amytriptiline
Imipramine
Desimipramine
Nortriptyiline
Paroxetine
Trazodone
Mirtazapine
Antihistamines:
Marzine
Diphenhydramine
Promethazine
Biperidene
Trihexyphenidyl
Cimetidine
Ranitidine
Neuroleptics:
Chlorpromazine
Flufenazine
Clozapine
Prochlorperazine
Trifluorperazine
Olanzapine
Thioridazine
Haloperidol
Quetiapine
Risperidoone
Ziprasidone
Anti-Parkinsonian:
Amantadine, Levodopa
Other:
Metoclopramide
Baclofen
Entacapone
Table 5 – Case reports of delirium associated with drug
toxicity. Modified from Caraceni and Grassi [2].
Pychotropics:
Clozapine
Diphenydramine
Fluoxetine
Mianserin
Promethazine
Lithium
Risperidone
Antibiotics, antimalarials and antivirals:
Ciprofloxacin
Clarithromycin
Mefloquine
Ofloxacillin
Acyclovir
Gamcyclovir
Drug combinations:
Benzodiazepine/clozapine combination
Flecainamide/paroxetine combination
Diphenhydramine/linezolide combination
Paroxetine/benztropine combination
Lithium/neuroleptic combination
Tacrine/ibuprofen interaction
Ethanol/niacin coingestion
Sertraline/haloperidol/benztropine combination
H-2 receptor blockers:
Famotidine (six cases)
Ranitidine
Ranitidine and cimetidine
Opioids:
Fentanyl
Oxycodone
Morphine
Hydromorphone
Antiblastic:
Paclitaxel
Vincristine
Ifosfamide
Cytosine arabinoside
Cisplatin
Methotrexate
Thiotepa
Etoposide
Nitrosurea
Biological drugs used in cancer:
Bevacizumab
Rituximab
Other:
Diet pills (phentermine)
Amiodarone
Cyclosporin
Donepezil
Herbal medicine loperamide, theales and valerian
Levodopa
Nizatidine
Omeprazole
Paclitaxel
Steroids
Tacrine
Ziconotide
Zolpidem
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4.4. Serotonin syndrome
This significant toxic reaction becamemore frequent with the
spread in the use of serotonin selective inhibitors (SSRIs, e.g.
paroxetine) such as antidepressants. It is usually seen after
the addition of a serotonergic drug to a drug regimen already
containing serotonin-enhancing drugs, and it combines signs
of encephalopathy (confusion, restlessness, myoclonus, hy-
per-reflexia, rigidity and coma) and of autonomic instability
(fever, diaphoresis, diarrhoea, flushing, tachycardia, tachyp-
nea, blood-pressure changes, midriasis, shivering and tre-
mor). It may be fatal or may have a more benign course.
Interactions of different drugs, often used in cancer patients,
should be monitored (SRRI with tramadol, ketobemidone and
venlafaxine). Table 7 lists a number of cases reported in the
literature of drug combinations leading to serotonin syn-
drome. Caution should therefore be exercised not only in
the use of the drugs reported but with all agents with seroto-
nergic action, such as duloxetine and tapentadol, in particular
when considering their use in combination with other seroto-
nergic agents.
4.5. Drug pharmacological interactions
The role of metabolic interactions as a cause of toxicity is
more and more likely as the number of drugs increase and
the general patient condition deteriorates. The induction or
inhibition of hepatic enzyme metabolism is an important
source of variability in drug effects and can lead to unex-
pected toxic reactions. The P450 system comprises a family
of more than 20 isoenzymes, among which the CYP 2D6 and
the CYP 3A4 metabolise 80% of known drugs. A relatively re-
cent review [29] reports on a number of examples of drugs
commonly used in oncology and palliative care that have high
or moderate probability of interacting with the same meta-
bolic pathways and of leading to unexpectedly high or low
levels of a drug, with the consequence of under- or over-dos-
ing; examples of such drugs include methadone, codeine,
oxycodone, haloperidol, tricyclic antidepressants (TCAs),
SSRIs, monoamine oxidase (MAO) inhibitors, benzodiaze-
pines, macrolides, azoles, rifampin and antifungals. Table 8
shows a list of interactions that can be particularly relevant
in the management of symptoms in cancer patients.
However, the clinical role of drug interaction in producing
specific effects may be very difficult to ascertain; laboratory
in vitro data may not be applicable to the clinical situation,
while in vivo other circumstances may be operating to change
the effect that was expected on the basis of laboratory data.
For instance, in dogs the co-administration of ketoconazole
and midazolam resulted as expected in a reduced elimination
of midazolam but did not affect the elimination of fentanyl
[30]. Case reports suggest that these interactions are indeed
at times important [31,32].
Table 7 – Serotonin syndrome reported in cases of admin-
istration of serotonin reuptake inhibitors alone or in com-
bination with other serotoninergic substances.
Drug Combinations
Fluoxetine Carbamazepine
Pentazocine
MAOIs
Moclobemibe
Nefazodone
Tramadol
Mirtazapine
Fluvoxamine Alone
Nefazodone
Paroxetine Risperidone
Moclobemide
Sertraline Isocarboxazide
Nortriptyline
Tranylcypromine
Erythromycin
Buspirone
Loxapine
Tryptopan Fluoxetine
Non-selective MAOIs
Clomipramine
Venlafaxine Alone
Trazodone Buspirone
Nefazodone
Moclobemide Citalopram
Imipramine
Meperidine Iproniazid
MAOIs
Moclobemide
Phenelzine 3,4-Methylenedioxy-
methamphetamine
Dextrometorphan Non-selective MAOIs
Dothiepine Alone
MOAIs, monoamine oxidase inhibitors.
Table 8 – Potential drug interactions with potential elevation
of blood plasma levels of central nervous system active
agents.
CYP2D6 inhibitors Drugs metabolised by CYP2D6
whose plasma levels can
increase when combined with
inhibitors
Cimetidine
Desimipramine
Fluoxetine
Paroxetine
Haloperidol
Sertraline
Oxycodone
Tramadol
Haloperidol
Risperidone
Fluoxetine
Paroxetine
Venlafaxine
Desimipramine
CYP3A4 Inhibitors Drugs metabolised by CYP3A4
whose plasma levels can
increase when combined with
inhibitors
All imidazole
antifungals
Fluoxetine
Norfloxacine
Fentanyl
Alfentanyl
Methadone
Alprazolam
Midazolam
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The number of potential pharmacological interactions is
extremely large and variable according to clinical conditions
and antineoplastic, supportive and combined therapies.
Dexamethasone, anticonvulsants and cisplatin or asparagi-
nase have specific interactions, to give only one example. In
cases of delirium, a specific review of drugs and their metab-
olism is mandatory. Conversely the choice of drugs with the
least metabolic interference potential is to be recommended.
Guidelines to treat pain and depression, for instance, should
recommend as first choice morphine, mirtazapine or citalo-
pram, while TCAs should not be used as first choice in combi-
nation with morphine because of their strong anticholinergic
effects and also because they increase morphine bioavailabil-
ity [33]. However, oral gabapentin has been shown to increase
oral morphine bioavailability [34], but the clinical impact of
this observation has never been clarified.
4.6. Alcohol and drug withdrawal
Patients with known alcohol and or drug abuse, in particular
chronic use of benzodiazepines, should be considered at risk
ofwithdrawalinthecaseofreducedorsuspendedintakeofalco-
hol when admitted to the hospital or hospice. Alcohol with-
drawal delirium should be treated with benzodiazepines; in
severe cases (delirium tremens) this can be life-threatening
and requires specialist advice or intensive care. More subtle
casescanresult fromthesuddendiscontinuationof thechronic
useofbenzodiazepines inpatientswith reducedability to swal-
low when admitted to a care facility, which may go unnoticed
without a very careful assessment of the patient history.
4.7. Delirium as a complication of the terminal phase of
advanced cancer
In patients with advanced cancer undergoing palliative care
and admitted to a hospice, delirium episodes are particularly
frequent; this can be expected from the progressive accumu-
lation of the risk factors described, and indeed the prevalence
of delirium tends to increase as the terminal phase of illness
approaches, reaching 80% in the last days of life, and it is per
se a prognostic factor of shortening life expectancy [7,35]. On
the other hand, in palliative care units and in hospices delir-
ium episodes can be reversible – owing to modifiable etiolo-
gies, such as drugs and infections – in as many as 50% of
the cases [5,36]. It is therefore of extreme importance to as-
sess delirium reversibility in advanced disease, to direct treat-
ment goals and family counselling. When a single drug
toxicity can be identified the probability of reversing toxicity
is also high [36], but on the other hand when the clinical sit-
uation is complex – due to multiple concurrent factors, organ
failure and in an advanced phase of the disease – reversibility
is less likely and delirium can be viewed as one aspect of the
terminal phase of the illness. In this last case, not only can it
be impossible to modify the eventual contribution of drugs to
the delirious state, it could also be futile or even inappropriate
if comfort and quality of dying is the goal of care. Interven-
tions directed at dealing with and managing the impact of
delirium on family distress and anxiety are particularly
appropriate at this time [37].
5. Delirium management
Screening of potential etiologies, starting with an accurate
medication list, is the first step in deliriummanagement; con-
sequently a first recommendation is to withdraw all medica-
tions that are not absolutely necessary. Very often finding the
aetiology is delayed, and the time to recovery after modifying
etiological factors can be significant. In a number of cases, as
already discussed above, the multifactor pathophysiology can
be part of a complex clinical picture which does not allow for
recovery or is even part of the dying process. All of these con-
ditions require symptomatic management – in particular to
control hallucinations, delusions and psychomotor agitation
– be it temporary until recovery or continuously until death.
The first-line pharmacological intervention for delirium is
neuroleptics, and haloperidol is the first-choice drug accord-
ing to all clinical guidelines [38–41]. In patients with mild to
moderate delirium, oral medication may be indicated, but
more difficult cases will require parenteral administration.
Haloperidol initial dose can vary from 0.5 to 1 mg, orally or
parenterally b.i.d., according to patient age, and should be ti-
trated in the following hours depending on the severity of
delirium symptoms. Titration of the dose is a fundamental
step before a real lack of clinical response can be docu-
mented, as many treatment failures are failing this recom-
mendation. Parenteral haloperidol can be used via
intramuscular administration. This can be necessary in pa-
tients without an IV line and with very disruptive behaviour,
otherwise an IV infusion can also be adopted. The use of hal-
operidol should be preceded by cardiac monitoring with elec-
trocardiography (ECG), according to some national
regulations, while its intravenous infusion is not officially ap-
proved, although commonly used in different settings of care.
Prolongation of the Q–T interval on the ECG may contraindi-
cate the use of haloperidol. This caveat is based on reports
of cases of fatal cardiac arrhythmia following haloperidol
administration.
Pharmacological treatment of delirium aims at patient
tranquilisation, abolishing hallucinations and delusions,
reducing psychomotor agitation, and improving night-time
sleep. Haloperidol, risperidone or olanzapine, while sharing
a strong tranquilising action, are not primarily sedating
drugs and haloperidol has the least sedating properties
among all the neuroleptics. If required, more sedating neu-
roleptics can be used: for example quetiapine (25–50 mg
b.i.d.), eventually giving a higher dose at bed-time. If this
approach fails, more specific drugs can be added to control
symptoms by keeping the patient sedated, including anti-
histamines, benzodiazepines and eventually alfa-2 agonists
(clonidine, dexmedetomidine). All these regimens require
specialist advice, be it from the neurologist, psychiatrist or
palliative medicine consultant, depending on the clinical
conditions and setting [17].
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Introduction
Lung cancer in non-smokers
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The decrease in lung cancer mortality in many Western
societies is being attributed to a large extent to smoking pre-
vention measures. However, lung cancer also occurs in non-
smokers, with an estimated frequency of 10–25%. The identi-
fication of oncogenic driver alterations which are successfully
targetable, being more prevalent in lung cancer in non-smok-
ers, has encouraged interest in these tumors. The current
knowledge on the molecular alterations in lung tumors of pa-
tients who have never smoked is summarised in the article of
Drs. Subramanian and Govindan. Smoking prevention is of
particular importance for pregnant women. The effect of in-
utero exposure to tobacco smoke is a growing area of research
in the field of passive smoking. Current knowledge on its po-
tential health consequences is summarised by Dr. Nawroth
and colleagues.
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1. Introduction
Epidemiological studies have demonstrated that tobacco smoke
is a major cause of both cancer and vascular diseases. More
than 3800 chemicals are present in tobacco smoke, which
may cause oxidative stress via biotransformation or by macro-
phage activation. In 1954, Richard Doll and Bradford Hill pub-
lished the first prospective evidence on cigarette smoking and
lung cancer [1,2]. In 1962, Framingham investigators published
data showing that smoking increased the risk of heart disease
[3]. Nevertheless, despite the strong evidence, uncertainty was
manufactured and enlarged. This strategy is a common practice
to reduce the public health implications from epidemiological
findings and was used not only by tobacco companies but also
by other industrial arms, including asbestos and lead factories
[4]. For almost half a century, the tobacco companies hired sci-
entists to dispute first that smokers were at greater risk of dying
of lung cancer; second, the role of tobacco use in heart disease;
and finally, the evidence that environmental tobacco smoke in-
creased disease risk in non-smokers [5,6].
The effect of in-utero exposures on health in childhood
and later in life is a growing area of research interest, with
major public health implications. Children are vulnerable to
the adverse effects of environmental tobacco smoke as their
lungs and immune system are undergoing further develop-
ment. The first publications of detrimental health effects of
parental smoking on children’s respiratory health were pub-
lished in the early 1970s [7]. Exposure to environmental tobac-
co smoke in the first 2 years of life has been estimated in
some European countries by Pattenden et al. [8] and ranged
from 19% in Germany to 70% in Bulgaria.
2. Meta-analytical evidence of early-life
effects
There is pooled evidence that constituents of cigarette smoke
cross the placenta, induce pregnancy complications, reduce
intrauterine foetal growth and increase the risk of preterm
delivery (Table 1) [9,10]. Meta-analytical evidence has also
shown increased risk of respiratory and ear infections
[11–13], overweight [14]and an increase in blood pressure
[15] in early life and/or childhood, suggesting that maternal
smoking in pregnancy influences the foetal development of
different organ systems. Indeed, low birth weight and pre-
term delivery are also determinants of health risks later in
life, including childhood asthma [16,17]. A cross-sectional
study of 11,500 participants of 8–11-year-old children showed
that prenatal exposure to cigarette smoke has a stronger ef-
fect on childhood asthma compared with postnatal smoke
[18]. Prenatal exposure to maternal smoking without subse-
quent postnatal exposure to environmental tobacco smoke
was related to the presence of asthma at school age with an
odds ratio (OR) of 1.8 (95%CI: 1.1–2.9) [18].
Parental smoking increases the risk of acute lower respira-
tory tract diseases in children [12,13]. The pooled estimates
showed a higher risk in association with smoking by the
mother (OR: 1.56, 95%CI: 1.51–1.62) than with smoking by
the father (OR: 1.31, 95%CI: 1.20–1.42) [12]. The higher risk re-
lated to the mother’s smoking could be explained by the fact
that young children usually spend more time with their
mother or by the interplay with maternal smoking during
pregnancy. In addition to lower respiratory tract infections
(OR: 1.51 95%CI: 1.44–1.52), exposure to environmental tobac-
co smoke has been associated with an increased risk of otitis
media (OR: 1.32, 95%CI: 1.14–1.52) [12].
Exposure to prenatal tobacco increases the level of genetic
damage in newborns and children. A meta-analysis per-
formed in children exposed to environmental tobacco smoke
showed that children and newborns had, respectively, 1.3 and
6.7 times higher levels of haemoglobin adducts compared
with non-exposed newborns [19]. Available meta-analytical
evidence of an association between in-utero exposure to to-
bacco smoke from the parents and childhood cancer seems
weak. Maternal smoking was estimated as an increased risk
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Table 1 – Meta-analytical evidence of early-life exposure to cigarette smoke.
Disease Author/Year (population) Design N articles N Pooled Estimate
Placenta previa Castles et al. [9]
(North America, Western Europe)
Case–control
Cohort
6 50.695 Patients 1.58 (1.04–2.12)a
Abruptio placenta 8 57.302 1.62 (1.46–1.77)a
Ectopic pregnancy 9 10.632 1.77 (1.31–2.22)a
Preterm PROMc 6 34.668 1.7 (1.18–2.25)a
Pre-eclampsia 5 4.451 0.51 (0.38–0.64)a
Preterm delivery
(>32 weeks but
<37 weeks of gestation)
Shah et al. [10] (Europe, North
America)
Case–control 20 Cases: >100.000 1.27 (1.21–1.33)a
0-10 Cig/Day: 1.25 (1.12–1.38)a
11-20 Cig/Day: 1.38 (1.23–1.55)a
>1 Pack/Day: 1.31 (1.19–1.45)a
Acute lymphoblastic
Leukaemia (Childhood)
Boffeta et al. [20] (Europe, North
America)
Case–control 4 Primary Not Given Paternal smoking during pregnancy1.17 (0.96–
1.42)b
Milne et al. [23] (Europe, North
America, Australia)
11 Cases: 1994 Paternal smoking around the time of
conception1.15 (1.06–1.24)a
Acute otitis media Moritsugu et al. [12] (Europe, North
America, Australia, Asia, Africa)
3 Primary Not Given Smoking by Either Parent0.99 (0.70–1.40)a
Asthma Moritsugu et al. [12] (Europe, North
America, Australia, Asia, Africa)
31 Primary Not Given Asthma
Smoking by Either Parent: 1.23 (1.14–1.33)a
Smoking by Both Parents: 1.42 (1.30–1.56)a
Maternal Smoking: 1.33 (1.24–1.43)a
Paternal Smoking: 1.07 (0.97–1.18)a
Bladder cancer Van Hemelrijck et al. [51] (Asia,
Europe, North America)
Case–controlCohort 8 223.000 Participants Childhood Exposure1.19 (0.88–1.62)b
Blood pressure Brion et al. [15] (Primary not given) Cohort 9 16.690 Participants Maternal Smoking During Pregnancy
Systolic Blood Pressure:0.67 mmHg (0.31 to
1.04)
Breast cancer Pirie et al. [52] (Asia, Europe, North
America)
Case–controlCohort 25 220.000 Participants Childhood Exposure: 0.98 (0.88–1.08)b
Childhood cancer
(overall)
Boffeta et al. [20] (Europe, North
America)
Case–control Cohort 12 900 participants
6351 cases
6253 controls
Maternal smoking during pregnancy1.10
(1.03–1.19)b
Cough Moritsugu et al. [12] (Europe, North
America, Australia, Asia, Africa)
39 Primary not given Cough
Smoking by either parent: 1.35 (1.27–1.43)a
Smoking by both parents: 1.64 (1.48–1.81)b
Maternal smoking: 1.34 (1.17–1.54)a
Paternal smoking: 1.22 (1.12–1.32)a
Cancer of the nervous
system (childhood)
Boffeta et al. [20] (Europe, North
America)
Case–control 12 Primary not given Maternal smoking during the pregnancy
1.04 (0.92–1.18)b
Case–control 10 1627 cases
2974 controls
Paternal smoking during pregnancy
1.22 (1.05–140)b
Genetic damage in
children
Neri et al. [19]
(Australia, Europe, USA, South
America)
Case–control
Cohort
6 Primary not given HB adducts
Children exposed to environmental tobacco
smoke: 1.38 (0.98–1.96)
5 Prenatal Exposure: 6.67 (2.56–17.24)
SCEe:prenatal exposure: 1.02 (0.94–1.10)d
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Lower respiratory
illnesses
Moritsugu et al. [12] (Europe, North
America, Australia, Asia, Africa)
Case–control
Cohort
38 Primary not given Lower respiratory illnesses
Smoking by either parent: 1.51 (1.44–1.59)a
Maternal smoking: 1.56 (1.51–1.62)a
Paternal smoking: 1.31 (1.20–1.42)a
Lower respiratory tract
infection
Li et al. [11] (Asia, Europe, North
America)
Case–control Cohort 13 32,945 cases Hospitalisation for respiratory illness
1.93 (1.66–2.25)a
Serious infections0–2 years: 1.71 (1.33–2.20)a
3-6 years: 1.25 (0.88–1.78)a
Lymphatic and
haematopoietic
Neoplasm (childhood)
Boffeta et al. [20]
(Europe, North America)
Case–control 9 Cases: 3610
Controls: 5054
Maternal smoking during pregnancy 1.03
(0.90–1.17)
Kidney cancer
(childhood)
Boffeta et a. [20]
(Europe, North America)
Case–control 5 Cases: 442
Controls: 2536
Maternal smoking during pregnancy
0.95 (0.76–1.19)
Middle ear effusion Moritsugu et al. [12]
(Europe, North America, Australia,
Asia, Africa)
6 Primary not given Middle ear effusion
Smoking by either parent: 1.20 (0.90–1.60)a
Maternal smoking: 1.84 (1.54–2.20)a
Paternal smoking: 1.49 (1.13–1.96)a
Non-Hodgkin
lymphoma (childhood)
Boffeta et al. [20]
(Europe, North America)
Case–control 4 Primary not given Paternal smoking during the pregnancy
2.08 (1.08–3.98)b
Overweightf Oken et al. [32]
(Australia, Europe, North America)
Cohort 14 84,563 Participants Maternal smoking during pregnancy
1.50 (1.36–1.65)a
Recurrent otitis media Moritsugu et al. [12]
(Europe, North America, Australia,
Asia, Africa)
9 Primary not given Recurrent otitis media
Smoking by either parent: 1.32 (1.14–1.52)a
Maternal smoking: 1.37 (1.19–1.59)a
Paternal smoking: 0.90 (0.70–1.15)a
Respiratory tract
infections
Peat et al. [13] (Asia, Australia, Chili,
Europe, New Zealand, USA)
Case–control Cohort 14 Primary not given Parental smoking
Hospitalisation for respiratory illness: 2a
Lower respiratory tract infection: 1.7a
Early respiratory illness: 1.6a
Sudden infant death
syndrome
(after prone-sleep-
position intervention
programs)
Mitchell et al. [24]
(Europe, New Zealand, US)
Case–control
Cohort
24 Cases: 15,694
Controls: 3,592,021
Cases: 719
Controls: 4885
Maternal smoking during pregnancy
3.93 (3.78–4.08)b
Paternal smoking, mother does not smoke
1.49 (1.25–1.77)b
Wheeze Moritsugu et al. [12] (Europe, North
America, Australia, Asia, Africa)
45 Wheeze
Smoking by either parent: 1.26 (1.20–1.33)a
Smoking by both parents: 1.41 (1.23–1.63)a
Maternal smoking: 1.28 (1.21–1.35)a
Paternal smoking: 1.22 (1.12–1.32)a
a Odds ratio.
b Relative risk.
c PROM, premature rupture of membranes is a rupture (breaking open) of the membranes (amniotic sac) before labour begins. If PROM occurs before 37 weeks of pregnancy, it is called preterm
premature rupture of membranes (PPROM).
d MR is a point estimate of the relative effect of the exposure on biomarker level detected in each study taking the value 1 when there is no effect, values >1 when exposure is associated with a
decreased level of the investigated biomarker.
e SCE: sister chromatid exchange is the exchange of genetic material between two identical sister chromatids. The reason for the SCE is not known but it is required and used for mutagenic testing of
many products. Four to five sister chromatid exchanges are in the normal distribution, 14–100 exchanges are not normal and present a danger to the organism.
f Primary analysis of overweight has been chosen, defined as BMI P85th percentile or P90th percentile for age and sex.
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of 10% (95%CI: 1.03–1.19) for childhood cancer, yet no signifi-
cant elevated risk was found for lymphomatic and haemato-
poietic neoplasm, or for cancer of the central nervous system
or kidney cancer (Table 1) [20]. When considering maternal
and paternal in-utero exposure to genotoxic compounds, a
difference in the mode of action is implied in the direct trans-
placental effects versus the preconception alterations. Car-
cinogens in tobacco can induce DNA damage in sperm:
male smokers have higher levels of 8-oxo-2-deoxyguanosine
in their semen than non-smokers, which may result in oxida-
tive damage to sperm DNA [21,22]. Paternal smoking during
conception and acute lymphoblastic leukaemia are related
with a pooled odds of 1.15 (CI: 1.06–1.24), paternal exposure
during pregnancy is not [20,23]. Furthermore, meta-analytical
work suggests an increased risk after paternal exposure to to-
bacco smoke with childhood non-Hodgkin lymphoma and tu-
mors in the central nervous system [20].
Based on pooled evidence of 25 studies [24], maternal
smoking was associated with almost a 4-fold time increase
in risk of sudden infant death syndrome. The corresponding
risk of paternal smoking with absence of maternal smoking
was 1.49 (Table 1). While the effect of smoke exposure in utero
seems to be stronger, postnatal environmental tobacco smoke
has been found to increase the risk of sudden infant death
syndrome even after controlling for prenatal exposure. How-
ever, in most cases this is difficult to distinguish as most chil-
dren that have been exposed in utero are also exposed during
their first months of life.
3. Smoking ban and health gains
The positive effect of smoking cessation suggests a causal asso-
ciation between active smoking and cardiovascular disease [25].
Evidence from observational studies shows a decrease in cardio-
vascular events in progression of atherosclerosis in those who
quit smoking compared with those continuing to smoke ciga-
rettes. Along with this, evidence from cohort studies and ecolog-
ical evidence on recent smoking bans (introduced by law)
consistently shows a rapid decrease in hospitalisation for myo-
cardial infarction (MI). The pooled aggregated data showed that
the rate of acute MI hospitalisation in countries that imple-
mented a smoking ban law, decreased 12months after its imple-
mentation, on average by 17% (95%CI: 20–13%) [26]. The rapid
decrease in MI after introduction of bans suggests an interplay
between chronic and acute processes, including triggers. A trig-
ger can be defined as an external stimulus that produces acute
physiological or pathophysiological changes. The idea of the
pathophysiological relevance of triggers leading to the onset of
acute myocardial infarction (MI) has been proposed [27]. In gen-
eral, ageing leads to functional and structural abnormalities of
the arterial wall, which are amplified by hypertension and ath-
erosclerosis [28]. A vulnerable atherosclerotic plaque might lead
to an occlusive thrombus which is more likely to be formed if
other factors come into play to narrow homoeostasis and in-
crease vasoconstriction. The role of triggers such as alcohol
[29], anger [30,31], physical exertion [31,32]and use of marijuana
[33] in the onset of MI is recognised [34].
Recently gained evidence supports the notion that prema-
ture birth is also a syndrome which might have trigger com-
ponents, including ambient temperature and smoking
[35,36]. Recent Scottish [36] and Belgian [35] data support
reductions in the rate of preterm births after the implementa-
tion of smoking bans, whereas no such decrease was evident
in the years or months before these bans.
In Belgium, smoke-free legislation was implemented in dif-
ferent phases (in public places and most workplaces in January
2006, in restaurants January 2007, and in bars serving food Jan-
uary 2010). Wewere able to demonstrate a consistent pattern of
changes in preterm delivery with stepwise reductions over the
different enforcements. In an analysis using a birth register
comprising 606,877 live-births, we observed an immediate
change in the risk of spontaneous preterm delivery of 3.13%
(95%CI: 4.37% to 1.87%; P < 0.01) on 1st January 2007 (ban
on smoking in restaurants), and an annual slope change of
2.65% (5.11% to 0.13%; P = 0.04) after 1st January 2010
(ban on smoking in bars serving food). In 716,941 Scottish new-
borns, the risk was decreased by 11.72% (95% CI: –15.87 to –7.35)
3 months prior to the introduction of the comprehensive smok-
ing ban in 2006. Similarly to Belgian findings, a study on the im-
pact of the Irish workplace smoking ban on birth weight and
preterm birth found a protective effect only on the latter out-
come [37]. Although their analysis was limited to a comparison
of rates 1 year before and after the ban, they even found an in-
crease in the risk of low birth weight.
The smoking ban studies must be viewed as an investiga-
tion of the possible impact of a ‘population intervention’
rather than an investigation of changes in individual behav-
iour. It is possible that unmeasured confounders were respon-
sible for the observed changes. Nevertheless, it is hard to
conceive of a factor that could change the population risk of
preterm births after the introduction of the different succes-
sive smoking bans. It is unlikely that our observations could
be explained by abrupt changes in therapeutic strategies coin-
ciding with the smoking bans. Nevertheless, the Belgian study
collected data on the prescription of atosiban and on cervical
cerclage treatment from a social security organisation cover-
ing 42% of the population. Atosiban is an inhibitor of oxytocin
and vasopressin and is specifically used to halt premature la-
bour. Cervical cerclage is used for the treatment of cervical
incompetence, a condition where the cervix has opened
slightly and there is a risk of miscarriage.
Given that even a mild reduction in gestational age has
been linked to adverse health outcomes in early and later life,
these population interventions have important public health
implications. Indeed, a Swedish study found that, even
among those born late preterm (34–36 weeks), preterm birth
was associated with a 31% (13–50%) increase in mortality in
young adulthood [38].
4. Molecular epidemiological aspects
The human placenta forms the interface between foetal and
maternal circulation, and by controlling nutrient supply plays
a critical role in the regulation of foetal growth and develop-
ment. Maternal smoking causes perturbations in this utero-
placental exchange as it increases the risk of low birth weight
[39,40] and preterm delivery [35,41]. The mechanisms under-
lying these observed effects remain unclear, but emerging
data suggest that biochemical, genetic and epigenetic activi-
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ties respond to and are modified by in-utero tobacco expo-
sure. Nutrients and potential pollutants are metabolised,
making the placenta a molecular ‘footprint’ to which the foe-
tus has been exposed in utero.
Mitochondria are abundant in placental cells, they provide
energy for the functioning of this metabolically active organ.
Each cell contains approximately 200–2000 mitochondria, car-
rying between two and ten copies of mitochondrial DNA
(mtDNA). Recently, by assessing the relative mtDNA content
(a marker of mitochondrial damage and dysfunction), its
functioning has been linked to various disease mechanisms
[42,43]. The placental mtDNA content has been shown to be
very adaptive to environmental insults, including maternal
smoking [44] and air pollution [45]. The relative mtDNA con-
tent is decreased by 37% (P < 0.02) in placentas of mothers
who smoke [44] compared with a decrease of 17.4% (P = 0.05)
for each 10-lg/m3 increase in PM10 exposure during the third
trimester of pregnancy [45].
Important questions remain concerning how mitochondrial
biogenesis and maintenance are regulated as a response to to-
bacco exposures, and how these relate to placental functioning.
An attractive link between adverse insults and altered foetal
development is gene regulation. Maternal smoking during preg-
nancy can lead to changed placental gene expression levels,
which is epigenetically regulated by DNA methylation, histone
modifications or non-coding RNAs. Epigenetic changes can occur
throughout the course of life as a result of environmental condi-
tions. Much of the epigenome is already established in germ cells
and embryos as it appears to be particularly important for the
regulation of embryonic growth and placental development
[46]. Recently, studies investigating cord blood and placental tis-
sue showed that the epigenetic system is sensitive to tobacco
exposure in utero. Global DNA methylation levels in cord blood
is lower among newborns with smoking mothers
(mean = 15.04%; 95%CI: 8.4–21.7) compared with second-hand
smokers (21.1%; 95%CI: 16.6, –25.5) and their non-smoking coun-
terparts (mean = 29.2%; 95%CI: 20.1–38.1) [47]. An epigenome-
widemethylation study in cord blood of newborns exposed to to-
bacco smoke during pregnancy showed that genes that play an
important role in detoxifying components of tobacco smoke
(AHRR and CYP1A1) are differentially methylated [48]. Accord-
ingly, Suter and colleagues reported site-specific changes in
DNA methylation of the CYP1A1 promoter, and this hypomethy-
lation correlated with an increase in CYP1A1 gene expression in
the placenta [49]. They showed in an epigenome-wide methyla-
tion study on placental tissue that methylation levels of 623
genes are deregulated in a CpG site-specific manner [50].
Despite a limited number of (epi)genomic studies in cord
blood and placental tissue, we are getting a better picture of
how maternal tobacco smoke can alter placental functioning
and contribute to adverse pregnancy outcomes. Therefore the
potential health consequences of changes in mitochondrial
functioning, gene expression and epigenetics in early life
should be further elucidated.
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A R T I C L E I N F O
Tobacco smoking is the most common cause of lung cancer, but approximately 10–25%
of patients with lung cancer are life-long never smokers. The cause of lung cancer in
never smokers is unknown, although tobacco-smoke exposure may play a role in some
of these patients. Lung cancer that develops in the absence of significant tobacco-smoke
exposure appears to be a unique disease entity with novel genomic and epigenomic
alterations and activation of molecular pathways that are not generally seen in
tobacco-smoke-induced lung cancer. These molecular alterations are very likely respon-
sible for the unique clinico-pathological features of lung cancer in never smokers
(LCINS), and some of these molecular alterations – such as the activating EGFR TK muta-
tions and EML4–ALK fusion – significantly influence therapeutic choices and treatment
outcomes. In the last few years there has been a number of studies exploring the molec-
ular characteristics of LCINS, and some of them have reported new and significant find-
ings. Here we review the key findings from these studies and discuss their potential
therapeutic implications.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
1. Introduction
Globally, over a million patients are diagnosed with lung can-
cer each year, making it the most common type of cancer in
the world [1]. Even though tobacco smoking is considered to
be the most common cause of lung cancer, it is estimated that
10–25% of all patients diagnosed with lung cancer are never
smokers [2]. Never smokers with lung cancer are more likely
to be women, have adenocarcinoma histology and are of East
Asian ethnicity when compared to tobacco smokers with lung
cancer [3–5] Apart from these now well-established epidemi-
ological differences, recent research has uncovered several
key molecular alterations that are more frequently detected
in never smokers with lung cancer. Some of these molecular
alterations – such as activating mutations in the tyrosine ki-
nase (TK) domain of the epidermal growth factor receptor
(EGFR) gene and the EML4–ALK fusion – have therapeutic rel-
evance in the treatment of patients with advanced-stage lung
cancer [6–10]. Comprehensive genomic analysis by whole
genome sequencing has also identified significant differences
between the tumour genome of lung cancer in never smokers
(LCINS) and tobacco smokers with lung cancer [11] (Table 1).
In this review we will discuss the genomic and epigenomic
findings that characterise LCINS.
2. Inherited susceptibility to LCINS
Despite the fact that tobacco smoking is the primary cause of
lung cancer, identification of familial clustering of patients
with lung cancer is suggestive of an inherited risk factor. Sev-
eral studies have reported that patients with LCINS are more
likely to have a family member diagnosed with lung cancer
than a tobacco smoker with the same disease [12–15]. A sys-
tematic review of 11 studies identified that a positive family
history of lung cancer increases the risk of developing lung
cancer by 1.5-fold in never smokers [16]. A linkage study of
52 families with two or more members diagnosed with lung
cancer identified the 6q23–25 region to be a major
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susceptibility locus for lung cancer [17]. In addition, three
large genome-wide association studies (GWASs) identified
the 15q24–25.1 locus as the site harbouring genetic polymor-
phisms associated with lung cancer risk [18–20]. However, a
pooled analysis of data from all three studies did not find
the 15q24–25.1 locus to be associated with increased risk for
LCINS [21].
Studies have also examined whether polymorphisms of
genes involved in carcinogen metabolism, DNA repair and
inflammation are associated with increased risk for develop-
ing LCINS. Pooled analysis of studies evaluating CYP1A1 and
GSTM1 polymorphisms identified that CYP1A1-I462V poly-
morphism was associated with two- to three-fold increased
risk for developing LCINS. Interestingly, the CYP1A1-I462V
polymorphism was associated with increased risk for LCINS
only in Caucasians, not in Asians [22]. However, these find-
ings are limited by the small sample size of patients with
LCINS in each individual study, and they were focused on a
limited number of molecular alterations. Individual studies
have shown specific polymorphisms involving DNA repair
genes (XRCC1 and ERCC2) and genes involved in interleukin
production (IL1, IL6 and IL10) to be associated with increased
risk for LCINS [23–25]. These studies are limited by their rela-
tively small sample size and require independent validation
to ascertain that these polymorphisms are associated with in-
creased risk for LCINS.
3. Markers of tobacco exposure
Significant differences have been reported in the frequency
and patterns of gene mutations between LCINS and lung can-
cer in tobacco smokers (reviewed in [26]). Some of the earliest
studies identified that mutations in the tumour suppressor
gene TP53 were less frequent in LCINS (8–47%) when
compared with tobacco smokers with lung cancer (26–71%)
[27–29]. Also a significant dose–response relationship be-
tween tobacco smoke and TP53 mutations has been reported
in patients with non-small-cell lung cancer (NSCLC) [27]. In a
sample of 30 resected NSCLC tumor samples the odds of hav-
ing TP53 mutations in a patient smoking 20 cigarettes per day
for 30 years were 5.3 when compared with a patient with
LCINS. Tobacco-smoke exposure was also associated with a
distinct mutational spectrum in the TP53 gene, with
increased frequency of G ! T transversion mutations when
compared to LCINS [30,31].
Mutations involving the KRAS oncogene are rare in pa-
tients with LCINS and are more frequently reported in tobacco
smokers with lung cancer [32–36]. In a sample of 106 patients
with adenocarcinoma, the incidence of KRAS mutations was
significantly higher in the smokers cohort versus the never
smokers (43% versus 0%, P = 0.001) [35]. Similarly KRAS muta-
tions are more frequently identified in tobacco smokers and
are predominantly G ! T transversion mutations [31].
4. Fusions and mutations involving kinase
genes
Analyses of tumor samples from patients with excellent re-
sponse to treatment with EGFR TK inhibitors led to the dis-
covery of activating mutations involving the EGFR TK gene
[6,7]. At around the same time it was also discovered that pa-
tients with LCINS had a better response to EGFR TK inhibitors
such as gefitinib [37]. Several retrospective studies subse-
quently established that patients with LCINS were more likely
to harbour the EGFR TK mutation than tobacco smokers with
lung cancer [8,38,39]. One of the largest studies (n = 1082) con-
firmed that activating EGFR TK mutations were more frequent
in patients with LCINS than in tobacco smokers with lung
cancer: 54% versus 16% [40]. The higher incidence of EGFR
TK mutations in LCINS has been a consistent finding across
different ethnic and geographical divisions. In addition, the
frequency of EGFR TK mutations is inversely related to tobac-
co-smoke exposure. The proportion of EGFR TK mutations in
patients with less than 20 pack year exposure was 55% versus
27% for 20–50 pack years and 22% for >50 pack years
(P < 0.001) [38]. Pham and colleagues reported similar findings:
decreasing incidence of EGFR TK mutations with increasing
pack years [39]. The difference was significant when exposure
was >15 pack years (9%) versus never smokers (51%); P < 0.005.
In addition, EGFR TK mutations were not detected in tobacco
smokers with more than 75 pack year exposure.
The EGFR TK inhibitor erlotinib was initially approved for
the treatment of all patients with advanced NSCLC in the
second- and third-line settings. The discovery of activating
EGFR TK mutations led to several randomised trials compar-
ing EGFR TK inhibitors with chemotherapy in the front-line
Table 1 – Characteristic molecular variations in lung cancer in never smokers (LCINS).
Markers Lung cancer in tobacco smokers LCINS
Genomic changes Point mutations in protein coding regions Primarily G ! T
transversions
Primarily G ! A
transitions
KRAS mutation Common, 30–43% Rare, 0–7%
EGFR mutation Rare, 0–7% Common, 45%
TP53 mutation; G ! T to G ! A ratio Ratio = 1.5 Ratio = 0.23
STK11 mutations 14% 3%
EML4-ALK fusion 2–3% 5–11%
ROS fusion <1% 1.5–6%
RET fusion <1% 2%
Epigenomic changes Methylation index (MI) High MI Low MI
p16 and APC methylation Common Rare
Loss of protein expression in hMSH2 Less common, 10% More common, 40%
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setting in patients with EGFR TK mutations [41–43]. Results
from these trials have now established EGFR TK inhibitors
as the standard front-line treatment for patients with ad-
vanced-stage NSCLC that is positive for EGFR TK mutation.
Mutations involving the HER2 gene have been shown to be
more frequent in never smokers with adenocarcinoma [9]. In
a sample of 671 NSCLC tumours, the overall frequency of
HER2 mutations was low at 1.6% (11/671), but they were more
frequently identified in never or light smokers (8 of 248, 3.2%;
P = 0.02). The HER2 mutations were not detected in tumours
harbouring either the activating EGFR-TK or KRAS mutations.
The STK11 gene encodes a serine–threonine kinase and
plays an important role in cell proliferation and survival.
Mutations involving the STK11 gene have been reported in
8% of all patients with lung cancer. In addition, they are more
frequently present in tobacco smokers with lung cancer than
in patients with LCINS (14% versus 3%; P = 0.007) [44].
EML4–ALK is a novel fusion gene present in approximately
5% of patients with NSCLC and is associated with an excellent
therapeutic response to treatment with an Alk kinase inhibi-
tor [10,45,46]. The fusion gene was more frequently identified
in never smokers and younger patients with lung cancer. In
addition, it appears to be mutually exclusive to EGFR TK and
KRAS mutations.
Two new transforming fusions involving the RET and ROS1
kinase genes at the 3 0 end have been identified in patients
with lung cancer [47]. In one study, tumour samples from
936 patients with surgically resected NSCLC were tested for
RET fusion genes by the reverse transcriptase polymerase
chain reaction (PCR). The RET fusion was detected in 13 pa-
tients (1.4%), and these patients predominantly had adeno-
carcinoma histology (84.6%), were never smokers (82%) and
many of them were younger: age 6 60 years at the time of
diagnosis (73%) [48]. RET fusions have been shown to promote
cell proliferation, and treatment with vandetanib, a multi ki-
nase inhibitor with activity against RET kinase, was able to in-
hibit RET-induced cell proliferation [47]. Fusions involving the
ROS1 gene in lung cancer were first reported in 2007 [49] and
in a subsequent study, a fluorescent in situ hybridisation
(FISH) based assay of 1000 NSCLC tumour samples identified
ROS1 fusions in 18 (1.7%) samples [50]. Similar to patients
with ALK or RET fusions, ROS fusions were found primarily
in younger patients who were never smokers and had adeno-
carcinoma histology. Cell lines expressing ROS fusion were
sensitive to treatment with the ALK inhibitor crizotinib. Over-
all, fusion genes involving the ALK, RET and ROS kinases are
relatively rare molecular events in patients with NSCLC.
These patients have similar clinico-pathological features,
including that of being a never smoker. In addition, these fu-
sions appear to be mutually exclusive to each other and to
other known driver mutations in lung cancer, such as EGFR
TK and KRAS mutations.
5. Epigenetic alterations
Methylation of tumour suppressor genes – including p16INK4a,
DAPK, RASSF1A, RARb, APC, CDH13, MGMT, hMLH1, hMSH2 and
GSTP1 – leading to epigenetic silencing has been reported in
lung cancer (reviewed in [51,52]). Studies have reported that
methylation of the tumour suppressor gene p16 is less fre-
quent in LCINS in comparison to lung cancer in tobacco
smokers [53–57]. In a sample of 514 NSCLC tumours, which
included 112 never smokers with adenocarcinoma, p16
(P = 0.007) and APC (P = 0.0007) methylation rates were signif-
icantly lower in never smokers than tobacco smokers with
adenocarcinoma [54]. There was no significant difference in
the methylation rate of the other tumour suppressor genes
RASSF1A, RARb, CDH13, MGMT and GSTP1 between the two
groups. The methylation index (total number of genes meth-
ylated/total number of genes examined) was significantly
higher in tobacco smokers with lung cancer when compared
to LCINS. In a follow-up study of 383 NSCLC tumours, the
authors confirmed that the p16 methylation rate and the
methylation index were significantly lower in LCINS
(P < 0.0001) [55]. The methylation rate for APC was signifi-
cantly lower (P < 0.0001) in never smokers when the analysis
was restricted to adenocarcinoma. Subsequent studies have
also reported a low p16 methylation rate in never smokers
with adenocarcinoma [56,58]. There was no significant differ-
ence in the methylation rates of RASSF1A and DAPK between
tobacco smokers with lung cancer and LCINS [56].
The loss of protein expression in protein mismatch repair
genes hMLH1 and hMSH2 was reported to be more frequent in
LCINS than in lung cancer in tobacco smokers [59]. In a sam-
ple of 77 resected NSCLC tumours, the loss of protein expres-
sion for hMLH1 (70% versus 46%) and hMSH2 (40% versus 10%)
was more frequent in LCINS. The authors also reported that
promoter methylation was the predominant mechanism for
the loss of protein expression in both genes.
6. Next-generation sequencing in LCINS
The advent of next-generation sequencing technologies now
allows us unprecedented access to the tumour genome. Re-
cently, next-generation sequencing of several tumour–normal
pairs from patients with NSCLC was reported, and some of
these patients were never smokers. Whole genome and tran-
scriptome sequencing was performed in 17 patients with
NSCLC, including five never smokers and 12 tobacco smokers
[11]. The total number of mutations involving genes in protein
coding regions was significantly higher in smokers than in
never smokers; median 209 versus 18. In addition, the muta-
tions in tobacco smokers were primarily G ! T transversions,
whereas in LCINS they were G ! A transitions. For the first
time this study identified that the G ! A transition point
mutations in never smokers is a genome-wide phenomenon
and is not restricted to KRAS and TP53 genes.
Genomic and epigenomic profiling of tumour–normal
pairs from six Korean patients with LCINS with exome seq,
RNA seq, micro RNA seq and methylated DNA immunopre-
cipitation-sequencing (MeDIP-seq) confirmed the low muta-
tion rate in LCINS [60]. They reported a total of 47 somatic
mutations from the six LCINS tumour samples. In addition,
they identified several novel fusion genes, including CCDC6–
RET fusion which has been previously reported and could be
a potential therapeutic target. Pathway analysis identified
that genes involved in cell cycle regulation – particularly in
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G2/M transition – are very likely to have played a significant
role in the development of these tumours.
7. Conclusion
Cancer is a disease that is characterised by genomic and epi-
genomic alterations that result in malignant transformation
of normal tissue. Such transforming genomic and epigenomic
alterations are considered the drivers of the malignant dis-
ease and determine the clinical behaviour of the disease. In
the case of lung cancer, tobacco-smoke exposure appears to
be an important factor in determining the type of oncogenic
drivers associated with the disease. This is well exemplified
by findings from several studies showing that mutations
involving TP53 and KRAS genes are more frequent in tobacco
smokers with lung cancer, whereas LCINS is characterised by
EGFR TK mutations, ALK, RETand ROS fusions. The differences
between LCINS and lung cancer in tobacco smokers are not
restricted to a few genes. Recent next-generation sequencing
studies have found that the genome of LCINS is significantly
different from the tumour genome of a tobacco smoker with
lung cancer (Fig. 1). Overall, the number of mutations is sig-
nificantly lower in LCINS, and the point mutations are primar-
ily G ! A transitions.
The higher number of genomic alterations seen in smok-
ers with lung cancer is very likely due to the mutagenic field
effect of tobacco-smoke exposure. The vast majority of these
genomic alterations in tobacco smokers with lung cancer are
believed to be passengers that do not have any role in the
malignant transformation or progression. In contrast, in
LCINS the absence of tobacco-smoke exposure and the
relatively smaller number of identified genomic alterations
suggest that most if not all of them play a role in its malignant
transformation. Hence the LCINS genome may provide us
with a relatively enriched and easily identifiable set of
oncogenic drivers for lung cancer. In addition, the relatively
small number of genomic alterations in LCINS also presents
better opportunities for the development of targeted thera-
pies against LCINS. With the advances in sequencing technol-
ogy and decreasing costs it is possible that, in the near future,
advanced-stage LCINS may be primarily treated with molecu-
larly targeted therapy, and it would be possible to achieve pro-
longed periods of disease control similar to the treatment of
chronic myeloid leukaemia (CML) and gastrointestinal stro-
mal tumour (GIST).
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1. Introduction
Although the skeleton is a common site of metastasis for
many solid tumours, metastatic bone disease is particularly
relevant in prostate and breast cancers. Thus, bone is the
most frequent – and often the only – location of metastasis
in patients with advanced prostate cancer. Moreover, up to
70% of patients with metastatic breast cancer develop bone
metastases over the course of their disease.
Metastatic bone involvement usually results in multiple
skeletal complications leading to a significant deterioration
in the quality of life for cancer patients. Pain, hypercalcemia
and skeletal-related events (SREs) – such as the use of
radiotherapy or surgery of bone, pathological fractures and
spinal cord compression – are problems typically derived
from bone metastases [1].
The pathogenesis of bone metastases is a complex process
involving many interactions between tumour cells and osteo-
clasts and osteoblasts. Receptor activator of nuclear factor-jb
(RANK) ligand (RANKL), which is expressed by osteoblasts and
marrow stromal cells, is a potent inducer of osteoclast forma-
tion. In bone metastases, cytokines and growth factors
secreted by tumour cells (interleukins 1 and 6, parathyroid-
hormone-related peptide, tumour necrosis factor, prostaglan-
din E2, and macrophage-colony-stimulating factor, amongst
others) increase the expression of RANKL on marrow stromal
cells and osteoblasts [2]. Following this, RANKL binds to its
receptor, RANK, on the surface of osteoclast precursors and
stimulates the differentiation of these cells to mature osteo-
clasts. This excessive RANKL-induced osteoclast activity
results in increased bone resorption and local bone destruc-
tion, leading to the release of growth factors from the bone
matrix that subsequently promotes tumour progression. This
relationship between tumour and bone cells constitutes the
vicious cycle of bone metastases.
For all these reasons, patients with metastatic bone
involvement who show higher levels of bone turnover mark-
ers have a particularly high risk for SREs in addition to worse
clinical outcomes [3].
Treatment of bone metastases requires a broad strategy
with different therapeutic options, including both local and
systemic therapies. External-beam radiotherapy remains the
mainstay of treatment for symptomatic bone metastases.
However, considering that osteoclast-mediated bone resorp-
tion plays a critical role in the development of metastatic
bone disease, its inhibition represents an attractive target
for treating bone metastases. Below, some of the major man-
agement approaches are very briefly summarised.
2. Bisphosphonates
Bisphosphonates are chemically stable derivatives of inor-
ganic pyrophosphate. These compounds are potent inhibitors
of osteoclast-mediated bone resorption through two
well-recognised mechanisms of action. On the one hand,
first-generation non-nitrogen-containing bisphosphonates
(i.e. clodronate) are metabolised by osteoclasts to cytotoxic
ATP analogues; on the other hand, second- and third-genera-
tion nitrogen-containing bisphosphonates, such as zoledron-
ic acid and pamidronate, act by inhibiting farnesyl
diphosphate synthase, a key enzyme of the mevalonate
pathway.
Over the last two decades these agents – in particular
zoledronic acid and pamidronate – have been the most effec-
tive treatments in delaying or preventing SREs in patients
with bone metastases from solid tumours, as well as in pa-
tients with multiple myeloma [4].
3. Denosumab
Denosumab is a fully human monoclonal antibody that binds
to RANKL in order to inhibit osteoclast activity. Denosumab
has been evaluated in three identically designed, randomised,
double-bind, phase III clinical trials [5–7]. Patients were
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randomly assigned to receive either subcutaneous denosu-
mab 120 mg and intravenous placebo or intravenous zoled-
ronic acid 4 mg and subcutaneous placebo every 4 weeks.
The primary endpoint was time to first on-study SRE (defined
as pathological fractures, the use of radiotherapy or surgery of
bone, or spinal cord compression). These studies are summa-
rised in Table 1.
Overall, adverse events and serious adverse events were
similar with both treatments, although more acute-phase
reactions and renal adverse events occurred in the zoledronic
acid group, whereas hypocalcemia was more frequent with
denosumab. Additionally, the rate of osteonecrosis of the
jaw was low in both arms (2%).
4. Other agents
4.1. Mammalian target of rapamycin (mTOR) inhibitors
mTOR inhibition decreases osteoclast maturation and in-
creases osteoclast apoptosis, resulting in reduced bone
resorption in animal models [8].
In the randomised phase III trial with everolimus in meta-
static breast cancer (BOLERO-2), a total of 724 postmeno-
pausal women with oestrogen-receptor-positive breast
cancer refractory to non-steroidal aromatase inhibitor ther-
apy were treated with exemestane and randomised (2:1) to
everolimus or placebo. The addition of everolimus signifi-
cantly improved median progression-free survival, the pri-
mary endpoint of this study (6.9 months versus 2.8 months;
HR = 0.43; P < 0.001) [9]. An exploratory endpoint also included
the evaluation of changes in bone turnover marker levels and
the rate of progressive disease in bone, defined as unequivo-
cal progression of a pre-existing bone lesion or the appear-
ance of a new bone lesion [10]. Everolimus added to
exemestane significantly decreased bone turnover marker
levels at 6 and 12 weeks. Moreover, the cumulative incidence
rate of progressive disease in bone was lower in the combina-
tion arm.
5. Novel compounds
Other bone-targeting agents are currently under investiga-
tion, although the clinical development of SRC- and C-MET
inhibitors is further along. Both have shown important
bone-specific activity in patients with breast or prostate can-
cer, as well as in preclinical models [11,12].
6. Conclusions
A better understanding of the biology of bone metastases is
establishing an exciting scenario in the treatment of this dis-
ease. This explosion of data has led to a large increase in
knowledge and the subsequent introduction of new bone-tar-
geted therapies in daily practice.
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Table 1 – Phase III studies with denosumab in patients with bone metastases or myeloma multiple.
Number of patients Type of tumour Time to first
on-study SRE
Overall
survival
Time to disease
progression
Refs.
1904 Prostate cancer HR = 0.82 (P = 0.0002
for non-inferiority analysis;
P = 0.008 for superiority analysis)
HR = 1.03
(P = 0.65)
HR = 1.06(P = 0.3) [5]
1776 Myeloma multiple;
solid tumours
(except breast and prostate)
HR = 0.84 (P = 0.0007 for
non-inferiority analysis)
HR = 0.95
(P = 0.43)
HR = 1(P = 1) [6]
2046 Breast cancer HR = 0.82 (P < 0.001 for
non-inferiority analysis;
P = 0.01 for superiority analysis)
HR = 0.95
(P = 0.49)
HR = 1(P = 0.93) [7]
SRE, skeletal-related event; HR, hazard ratio.
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1. Introduction
Androgen deprivation therapy (ADT) is standard for advanced
prostate cancer and is now increasingly used as adjunct ther-
apy in high-risk or locally advanced disease and for the treat-
ment of recurring disease based on rising prostate-specific
antigen levels. Testosterone stimulates bone formation di-
rectly by stimulating the osteoblast proliferation, inhibiting
the apoptosis of both osteoblasts and osteoclasts, and indi-
rectly by being a precursor of oestrogen which is also involved
in inhibiting osteoclastic function (bone resorption). The ef-
fects of testosterone on preserving bone health are lost in
the hypogonadal state induced by ADT [1]. The impact of
ADTon bone loss and osteoporosis is well established through
multiple studies. In one of these studies, non-metastatic
prostate cancer cases were followed for 10 years; none of
the patients on ADT had normal bone mass density (BMD)
at the end of the study, and the prevalence of osteoporosis
(T score < 2.5) was approximately 50% by 4 years and 80%
by 10 years in men on ADT [2].
Bone metastases will occur in over 90% of men with lethal
castration-resistant prostate cancer (CRPC). Due to the com-
bined effect of bone fragility due to ADT and the presence of
bone metastases, almost all patients will experience some
form of morbidity related to bone metastases prior to suc-
cumbing from the disease. Complications go beyond pain
and include pathological fracture, the need for palliative radi-
ation or surgery, and spinal cord compression. These events
impair quality of life and place a significant burden on
health-care resources.
2. Management options
2.1. Life style modification and supplementation
Regular exercise, smoking cessation, lowering alcohol and
caffeine intake, as well as oral vitamin D (800 IU daily) and
calcium (500–1500 mg daily) supplementation are helpful in
attenuating ADT-related bone loss, but they are insufficient
to prevent or treat ADT-induced bone loss [3].
2.2. Bone targeted therapy (anti-resorptive agents)
Bisphosphonates are the first and most widely used of the
anti-resorptive agents. Due to their structural similarity to
pyrophosphate, a normal component of bone matrix, they
are integrated in the bone matrix by binding to hydroxyapa-
tite crystals, resulting in inhibition of osteoclast-mediated
bone resorption. Non-nitrogen-containing bisphosphonates
are metabolized by osteoclasts to cytotoxic compounds, while
nitrogen-containing bisphosphonates exert their effects on
osteoclasts and tumour cells by inhibiting a key enzyme in
the mevalonate pathway and by inducting osteoclast apopto-
sis. Nitrogen-containing bisphosphonates (e.g., pamidronate,
zoledronic acid) are more potent than non-nitrogen-contain-
ing bisphosphonates (e.g., clodronate). Zoledronic acid is un-
ique in that it contains two nitrogen groups, and it has been
shown to be 40–850-fold more potent than other bisphospho-
nates [4].
In the setting of non-metastatic prostate cancer, bisphos-
phonates have consistently been found to reduce BMD loss
associated with ADT in multiple randomized controlled trials,
but none have had sufficient power or duration to demon-
strate a reduction in fractures [5].
Zoledronic acid is the only bisphosphonate and the first
osteoclast-targeted agent that has shown a protective effect
against skeletal-related events (SRE) in patients with meta-
static castration-resistant prostate cancer. The phase 3 study
showed a 48% reduction in the mean annual incidence of SRE
(P = 0.005), 5 months prolongation in the median time to first
SRE (P = 0.009) and 36% reduction in the ongoing risk of SREs
at 24 months [6,7].
Bisphosphonate-induced nephrotoxicity is a major con-
cern, especially with intravenous bisphosphonates. Renal
function monitoring and dose adjustment according to creat-
inine clearance are crucial to prevent significant deterioration
in renal function. Other side effects include self-limiting flu-
like symptoms occurring with the first infusions, hypocalca-
emia and osteonecrosis of the jaw (ONJ) [8].
The zoledronic acid bone metastases prevention study
recently reported their results. The Zometa European Study
[ZEUS] reported that there was no difference in the
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metastases rate after 4 years in high-risk non-metastatic
prostate cancer. Of note, the incidence of new metastases
was very low at approximately 13% [9].
Denosumab is a receptor activator of nuclear factor kappa B
(RANK), a member of the tumour necrosis factor (TNF) recep-
tor superfamily expressed by osteoclast precursors, and its li-
gand (RANKL) plays an essential role in regulating the
osteoclast life cycle at different levels. Binding of the RANKL,
secreted by osteoblasts and bone-marrow stromal cells, to its
receptor RANK leads to differentiation, activation, and sur-
vival of osteoclasts which induce bone resorption [10].
Denosumab is a fully human monoclonal antibody that
specifically targets RANKL, thus effectively inhibiting osteo-
clastic function and bone resorption, In a randomised pla-
cebo-controlled study in patients with non-metastatic
prostate cancer receiving ADT, denosumab (60 mg subcutane-
ously every 6 months) was associated with significant
improvements in BMD at the lumbar spine (6.7%), the total
hip (4.8%) and distal one third of the radius (5.5%). Denosu-
mab was also the first agent to show a reduction in the inci-
dence of new vertebral fractures (1.5% versus 3.9%; P = 0.006)
in patients on ADT [11].
In the setting of metastatic CRPC, denosumab (120 mg sub-
cutaneously every 4 weeks) compared to zoledronic acid
(4 mg intravenously every 4 weeks) significantly improved
the time to first SRE (20.7 versus 17.1 months; P < 0.001 for
non-inferiority; P = 0.008 for superiority). Overall survival
and progression-free survival were similar for both drugs.
Hypocalcaemia was more common with denosumab (13%)
than with zoledronic acid (6%) (P < 0.0001) and a non-signifi-
cant trend towards higher osteonecrosis of the jaw was seen
with denosumab (2.3% versus 1.3%; P = 0.09) [12]. Calcium and
vitamin D supplementation and monitoring of calcium levels
while on therapy are essential to reduce the risk of
hypocalcemia.
In another placebo-controlled trial in non-metastatic
CRPC, denosumab (120 q monthly) significantly increased
the bone-metastasis-free survival in patients with non-meta-
static CRPC by a median of 4.2 months (29.5 versus 25.2
months; HR, 0.85; 95%CI, 0.73–0.98; P = 0.028) [17]. Although
hypocalcaemia was much lower in the setting of non-meta-
static CRPC, the risk of ONJ was higher given the longer expo-
sure time to denosumab [13].
2.3. Osteonecrosis of the jaw (ONJ)
Osteonecrosis of the jaw is defined as exposed necrotic bone
in the maxillofacial region that persists for more than 8
weeks. The incidence of ONJ in patients with CRPC receiving
denosumab was similar to that in patients receiving zoled-
ronic acid [12]. Although the aetiology is unclear, duration
of therapy, poor dental hygiene, invasive dental surgery or
ill-fitting dentures, concomitant corticosteroid use, radiother-
apy and chemotherapy are identified risk factors. A conserva-
tive approach to the management of ONJ is recommended
and includes oral rinses, antibiotics, pain control and mini-
mal surface bony debridement to reduce sharp or rough bone
surfaces. Biopsies are not recommended unless metastasis to
the jaw is suspected. Good oral hygiene, baseline dental eval-
uation for high-risk individuals and avoidance of invasive
dental surgery during therapy reduce the risk of ONJ [14–16].
Most of the cases that were reported had had a tooth extrac-
tion or some other form of trauma that may have contributed
to the development of ONJ. Most cases were treated conserva-
tively, and less than 10% required bone resection. It is esti-
mated that the risk is approximately 1–2% per year of
exposure to bone-targeted therapies such as zoledronic acid
and denosumab. Although bone-targeted therapy is benefi-
cial, one must consider the risk of ONJ after 2 years of therapy
when deciding whether to continue therapy.
2.4. Radiopharmaceuticals – (radium-223)
In a recently completed phase III study of patients with met-
astatic CRPC, patients were randomized on a 2:1 basis to
either radium-223 (an alpha-emitting bone seeker) or placebo.
To be eligible for the study patients had to have bone metas-
tases and to have progressed after chemotherapy or were not
eligible to receive chemotherapy. Patients received either ra-
dium-223 or placebo every 4 weeks intravenously. Overall sur-
vival (OS) was the primary endpoint. Median survival was 14
months for the treated patients as opposed to 11.2 months
for those who received a placebo, conferring approximately
a 30% improvement in OS (HR = 0.699, P = 0.0022). The up-
dated analysis involving 921 patients confirmed the radium-
223 survival benefit (median, 14.9 months vs. 11.3 months;
hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P < 0.001). The study
also showed a 5-month delay in time to skeletal-related
events. This agent has recently been approved by the FDA
and is the first bone-targeted agent to demonstrate a survival
advantage.
3. Conclusion
Patients with metastatic prostate cancer are at high risk for
skeletal complications, including debilitating bone pain often
requiring palliative radiation therapy, pathological fractures,
and spinal cord compression. These complications impair
quality of life and place a significant burden on health-care
resources. They are due to the combined effects of bone
metastases and ADT-related bone loss. The use of bone-tar-
geted therapy (denosumab and zoledronic acid) has been
shown to significantly delay and reduce the risk of these skel-
etal complications. Studies have also suggested that introduc-
tion of these therapies prior to PAIN or SREs may further
improve efficacy. Denosumab (60 mg every 6 months) has re-
cently been approved for prevention of bone loss related to
ADT. Most recently the radiopharmaceutical, radium-223,
was shown to delay skeletal complications and also to im-
prove overall survival in patients ineligible for or having failed
chemotherapy. The combination of early bone-targeted ther-
apy followed by radium-223 later in the disease continuum
appears to lead to further improvements in the management
of bone metastases in CRPC.
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Current role of human papillomavirus in head
and neck oncology
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Tobacco and alcohol were, until recently, considered to be
the major risk factors in carcinogenesis of head and neck can-
cer (HNSCC). However, during the past decade a causal asso-
ciation between infection with human papillomavirus (HPV)
and HNSCC has been established [1], and this ‘new’ aetiolog-
ical factor has changed the conventional understanding of
HNSCC because of the extensive influence of the virus on
the epidemiology, clinical presentation and treatment out-
come for patients with HNSCC.
Association with HPV is predominantly a matter of con-
cern in tumours of the oropharynx, especially in tonsillar can-
cer [2,3], and a dramatic increase in the incidence of
oropharyngeal cancer (OPC) has been reported in several Wes-
tern countries over the past 30 years [4–8]. Based on the obser-
vations that, simultaneously, there has been an increase in
the frequency of HPV-positivity among OPCs [4,9], infection
with HPV seems to be the dominant cause of this develop-
ment. Moreover, in the same time period a decrease in tobac-
co-smoking seems to be responsible for a reduction in the
incidence of HNSCC outside the oropharynx [6], at least in
Western countries. The natural history of oral HPV infection
remains to be fully elucidated, and although the exact mech-
anism is not known, oral–genital contact is assumed to be the
primary mode by which HPV is transmitted to the oral muco-
sa, and several case–control studies have shown an associa-
tion between HPV-related HNSCC and sexual behaviour
(reviewed by Gillison et al. [3]). The optimal method for
detecting HPV in tumours is controversial, and both in-situ
hybridisation and the polymerase chain reaction (PCR) are
commonly used; p16-immunohistochemistry has gained
broad acceptance as a surrogate marker and is also widely
used in the clinical setting [10,11].
HPV-related HNSCC constitutes a clinically distinct sub-
group of cancers in terms of molecular biology, patient char-
acteristics and sensitivity to treatment, and this on the
whole differentiates it markedly from HPV-negative tu-
mours. The molecular profile of HPV-related HNSCC is dis-
tinct, with P53 degradation, retinoblastoma RB pathway
inactivation and p16 up-regulation. By contrast, HPV-negative
tumours are characterised by TP53 mutation and down-
regulation of p16 [12,13]. Patients with HPV-related HNSCC
tend to be younger, have less comorbidity and a better per-
formance status [14–16], and are less declined to be abusers
of tobacco and alcohol [6,15] compared with HPV-negative
patients.
Tumour HPV status has a major impact on outcome for pa-
tients with HNSCC, and compared with HPV-negative pa-
tients, tumour-control and survival are highly significantly
better for patients with HPV-positive tumours. This has been
shown repeatedly in several clinical trials and with the use of
a variety of different treatment schedules [17–22] and is be-
lieved to be caused in part by a higher sensitivity to radiother-
apy of HPV-positive tumours, presumably because of the
distinct molecular profile [23], combined with a better general
health status in this group of patients. Smoking negatively af-
fects survival in HNSCC, and the accumulated lifetime num-
ber of pack years independently impacts prognosis for both
HPV-positive and -negative tumours [21,24]; implementation
of smoking history in the risk stratification of HNSCC is under
consideration.
As a consequence of this profound impact of HPV in
HNSCC, this ‘new’ type of cancer has attracted a lot of
attention, and separate therapeutic treatment strategies
based on tumour HPV status are in the pipeline. In light
of the enhanced sensitivity to treatment of HPV-related
HNSCC, de-intensification of present treatment strategies
in order to avoid excessive toxicity has been proposed for
selected patients with minimal risk of distant metastasis
[25]. On the other hand, patients with HPV-negative tumours
have a very poor prognosis, and efforts should be made to
improve treatment efficacy and compliance in this group
of patients.
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Novel therapeutic targets in diffuse large B-cell
lymphoma
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Diffuse large B-cell lymphoma (DLBCL) represents the most frequent lymphoma subtype
and is considered a heterogeneous diagnostic category [1]. Using gene expression profiling,
two major molecular subtypes termed germinal centre B-cell-like (GCB) DLBCL and acti-
vated B-cell-like (ABC) DLBCL can be distinguished [2]. Their gene expression profiles sug-
gest that they arise from B-cells at different stages of differentiation. The GCB DLBCLs
appear to originate from germinal centre B-cells, whereas the ABC DLBCLs may arise from
post-germinal-centre B-cells that are in transition to being differentiated into plasma cells.
Intriguingly, these two subtypes differ not only with respect to the expression of thousands
of genes, but also utilise different oncogenic pathways and have significantly different sur-
vival rates following therapy [3,4]. ABC DLBCLs are characterised by inferior survival com-
pared with GCB DLBCL patients when treated with a combined approach of the anti-CD20
antibody rituximab and CHOP chemotherapy [5].
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.
Recent advances in the understanding of the biology of
these entities lead to the identification of a variety of poten-
tially novel therapeutic targets for the treatment of affected
patients. ABC DLBCLs are characterised by constitutive activa-
tion of the oncogenic nuclear factor-jB (NF-jB) pathway,
which promotes cell proliferation and differentiation and
suppresses apoptosis [6]. NF-jB signaling is mediated by a
family of transcription factors that are normally kept inactive
in the cytoplasm by binding to inhibitory IjB proteins. The
constitutive activation of NF-jB in ABC DLBCL is caused in
the vast majority of cases by somatically acquired mutations
that affect positive (CARD11, CD79B and MYD88) and negative
(TNFAIP3) NF-jB regulators [7–10]. Inhibition of NF-jB was
toxic to preclinical models of ABC DLBCL [6]. Therefore, tar-
geting the NF-jB pathway seems to be an attractive therapeu-
tic approach. Such a strategy was taken by Dunleavy and
colleagues in a recent phase II study in which the efficacy of
bortezomib was investigated in DLBCL [11]. Preclinical data
suggest that bortezomib inhibits NF-jB by blocking IjBj
degradation. The efficacy of bortezomib in combination with
chemotherapy was evaluated in relapsed/refractory ABC and
GCB DLBCL patients [11]. Interestingly, the response rates
were significantly higher in ABC compared with GCB DLBCL,
and even more importantly, patients with ABC DLBCL had a
significantly superior overall survival. These results poten-
tially suggest that inhibition of NF-jB might be a promising
approach in ABC DLBCL. This hypothesis was further sup-
ported by recently presented data on the efficacy of the Bru-
ton agammaglobulinemia tyrosine kinase (BTK) inhibitor
ibrutinib [12]. BTK plays an important role in activating NF-
jB following B-cell receptor stimulation. Using this inhibitor,
impressive response rates in relapsed and refractory ABC
DLBCL could be achieved. Collectively, these data indicate
that inhibition of the oncogenic NF-jB pathway might be a fu-
ture option to overcome the adverse prognosis of patients af-
fected by ABC DLBCL.
While patients with GCB DLBCL are characterised by supe-
rior prognosis compared with ABC DLBCL [5], a substantial
proportion of GCB DLBCL patients are not cured by standard
treatment. GCB DLBCLs frequently express the transcriptional
repressor BCL-6 that plays an important role in the germinal
centre reaction. BCL-6 therefore might represent a novel
target for GCB DLBCLs. In preclinical models, specific BCL-6
inhibitors showed impressive efficacy [13,14]. GCB DLBCLs
are furthermore frequently characterised by deregulation of
the phosphatidylinositol 3-kinase (PI3K)/AKT signaling path-
way [4]. The PI3K signaling cascade is initiated with the phos-
phorylation of phophatidylinositol 4,5-bisphosphate (PIP2) to
phophatidylinositol 3,4,5-trisphosphate (PIP3), resulting in
cellular processes such as proliferation, cell survival and cell
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growth. Various PI3K inhibitors are currently being evaluated
in different cancer types and might represent a promising
therapeutic approach in GCB DLBCL.
In summary, ABC and GCB DLBCL represent molecular
subtypes that are dependent on different oncogenic signaling
pathways. In clinical reality this biological diversity is still
insufficiently taken into account. Efforts to distinguish these
entities using gene expression profiling or next-generation
sequencing will pave the way to more specific and less toxic
treatment strategies.
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Novel teatment options in early-stage non-small-cell lung
cancer
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1. Introduction
Early-stage lung cancer refers to patients presenting with
clinical stages I and II non-small-cell lung cancer (NSCLC)
according to the TNM classification. They represent approxi-
mately 20–25% of incident cancer cases in most population-
based cancer registries, and radical surgical resection is con-
sidered the treatment of choice in operable and fit patients [1].
Although no prospective, randomised trial exists to compare
surgery versus radiotherapy in the treatment of early-stage
NSCLC, surgical resection has traditionally been considered
the treatment of choice. Markedly improved survival rates
are reported in surgical series in comparison to patients
who did not undergo surgical resection for a variety of rea-
sons [2]. This abstract will address some of the challenges
of novel treatment options in these patients.
With low-dose computed tomography (CT) scan screening
becoming the new standard of early detection of lung cancer,
physicians and surgeons will be confronted with an increase
in T1a lung cancer, disguised as non-calcified nodules.
Although it is tempting to proceed to a parenchyma-sparing
resection for issues of functional operability, the risk of local
recurrence and inadequate intraoperative lymph-node stag-
ing should not be neglected. Whether some of these lesions
can be treated by so-called sublobar resection – consisting
of either anatomical segmentectomy or wedge excision – is
currently the subject of intensive investigation by appropriate
randomised trials. For a limited resection to be oncologically
valid, a precise pre- and intraoperative diagnosis is impera-
tive. In terms of preoperative diagnosis, specific criteria on
chest CT as percentage ground-glass opacity (GGO), tumour
shadow disappearance rate and histogram analysis have been
shown to have a high predictive value[3]. Three similar trials –
JCOG 0802 in Japan, CALGB 140503 in North America and IEO
S638/311 in Italy – are currently enroling patients, and collab-
oration is highly regarded [4,5].
More tailored, personalised surgical therapy has recently
been introduced. Quality-of-life parameters and surgical
quality indicators become increasingly important to deter-
mine the short-term and long-term impact of a surgical pro-
cedure. International databases currently collect extensive
surgical data, allowing more precise calculation of mortality
and morbidity according to predefined risk factors. Centrali-
sation of care has been shown to improve results [6].
Functionally inoperable patients are nowadays proposed
stereotactic ablative body radiotherapy (SABR), in which hyp-
ofractionated doses are administered over a short period of
time [7,8]. Although lung-cancer-specific time-to-event out-
come data seem very promising, unusual late toxicity is
increasingly being reported, and there is concern regarding
the inclusion of variable fractions of non-pathologically pro-
ven non-calcified nodules [9]. Clearly, before extrapolating
these results to functionally operable patients, large random-
ised trials with an unequivocal non-inferiority design should
be carried out [10]. Other radiotherapeutic techniques in
development to improve local control with minimal pulmon-
ary toxicity are the application of different breath control de-
vices and the introduction of hadron/proton therapy.
Radiofrequency ablation is another way of tackling pul-
monary masses and nodules whereby a transthoracic radiop-
robe is inserted under CT guidance, allowing for a subsequent
‘cooking’ with electromagnetic energy. The technique is well
known in the treatment of primary liver cancer and metasta-
ses, and several uncontrolled series have been reported in a
mixed series of patients with primary lung cancer and lung
metastases [11]. However, the technique lacks standardisa-
tion and long-term results, but is promising for centres which
cannot afford SABR. There are currently no ongoing random-
ised trials [12]. An endobronchial application is certainly
promising.
Adjuvant chemotherapy is the present standard of care in
completely resected stages pII and III NSCLC, albeit toxicity is
considerable and the observed improvement in outcome
modest. Patient selection using molecular and biological bio-
markers and signatures is likely to increase the fraction of pa-
tients benefiting from it. The large BIO-IALT study has
described a number of prognostic and predictive factors,
although recent reports challenge the accuracy of the
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techniques used [13,14]. One of the most critical issues
regarding tumour biomarkers concerns methodology. Tech-
niques for carrying out the test, the reagents used, methods
used to score/quantify the results, the analysis and interpre-
tation of the results are all critical yet prone to variability and
error. Some are more subjective than others; many are simple
and readily available, others are complex, expensive and less
accessible. Complexity does not guarantee accuracy, greater
reliability or relevance. In terms of biomarker testing of tu-
mour samples, the handling and processing of the tissues
prior to testing is of critical importance yet difficult to stan-
dardise, but these factors are often ignored or overlooked [15].
Biomarkers might be selected for patients preferably trea-
ted with agents targeted at hallmark pathways of oncogene-
sis: e.g. sustained proliferation, angiogenesis and avoiding
immune destruction. Trials investigating the efficacy of adju-
vant epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors, vascular endothelial growth factor (VEGF) inhibi-
tors or vaccines against melanoma antigen (MAGE) are cur-
rently ongoing, and their results are expected to alter
clinical practice [16,17].
Although neoadjuvant chemotherapy is better tolerated
and its added value to outcome is similar to that of adjuvant,
its widespread use suffers from a low rate of pathological
remission, which is a precondition for a lesser resection to
be carried out. Window-of-opportunity trials with neoadju-
vant targeted agents and biological imaging are promising
[18]. They have so far not been conducted in a biomarker-se-
lected population.
The role of postoperative radiotherapy is currently limited
to non-radically resected cases, although there are uncon-
trolled observations of its efficacy in subgroups of completely
resected patients. In the ongoing randomised LUNGART trial,
its role is explored in patients with clinical or pathological N2
disease [19].
An important handicap in present-day patient selection is
the inaccuracy of clinical staging. Half or more of clinically
staged patients are up- or down-staged at surgery [20]. Posi-
tron emission tomography–CT (PET–CT) scan and minimally
invasive mediastinal ultrasound techniques are expected to
improve on this figure and result in a stage shift.
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Oncoplastic surgery – Standard of care
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1. Introduction
Over the last decade the whole approach to breast cancer sur-
gery has changed radically from its ‘general surgery’ roots.
There are few surgical specialties that have changed so much.
The initial phase was the attention to wide local excision sur-
gery, employing a more sensitive take on breast conservation,
with scar placement and parenchymal reshaping. Then the
concept of avoiding mastectomy by means of more extensive
wide tumour excision together with partial breast reconstruc-
tion led to a flurry of innovations involving volume replace-
ment and displacement techniques [1]. Oncoplastic breast
surgery as a specialty now encompasses all elements of
breast cancer surgery: appropriate cancer resection, skin-
sparing mastectomy and immediate breast reconstruction,
the full elements of total and partial breast reconstruction
and adjustment for breast asymmetry by augmentation,
reduction mammaplasty or mastopexy for the contralateral
unaffected breast [2].
The legacy of historical surgical training has meant that
until recently few surgeons have been equipped to offer this
cancer surgery/cosmetic/reconstructive breast surgery hybrid
approach. This is changing with training initiatives. Over the
last decade approximately 90 surgeons in the United King-
dom have undergone 1-year-long senior fellowships in onco-
plastic breast surgery in nine tertiary centres, trained by both
breast and plastic surgeons seamlessly. This approach is
changing the quality of surgical care for the benefit of women.
It has also led to a rejuvenation of breast surgery away from
purely resection-based operations that had remained un-
changed for many decades, to an innovative specialty with
creative concepts and aesthetic detail. In turn, the result in
the UK has been marked interest amongst trainee surgeons
to enter breast surgery as a career, and applications for the
national fellowships are highly competitive.
Nevertheless much breast cancer surgery is still delivered
by general surgeons, so care for individual women may in-
volve surgeons from general as well as plastic/reconstructive
surgery backgrounds now working together in an ‘oncoplastic
multidisciplinary team’.
In 2007 extensive guidelines were developed in the UK
to address inequalities in surgical provision. Oncoplastic
Breast Surgery – a guide to good practice was a joint venture
between the Association of Breast Surgery at BASO, the
British Association of Plastic, Reconstructive and Aesthetic
Surgery (BAPRAS), and the Breast Surgery Interface Train-
ing Committee at The Royal College of Surgeons of Eng-
land [3]. This was intended to be for women with breast
cancer, and all those involved in their care, to ensure the
highest standards in setting up and delivering an onco-
plastic breast service.
In 2012 the guidelines were revised and newly published,
and constitute a fully comprehensive document describing
high standards of care for all aspects of oncoplastic and
reconstructive breast surgery. They also cover aspects of the
processes, the patient’s journey and arrangements for both
equipment needs and team participants. The advantage of
the revision is that the 5 years’ experience in developing mod-
els of care has been incorporated by the multispecialty team
of writers into the 2012 document. The UK document is un-
ique in its ambition to raise surgical quality nationally, to en-
sure that patients are aware of what is available, and to
inform surgeons, allied professionals and hospital adminis-
trators about what is required to provide a modern high-
quality standard of care for women with breast cancer.
These guidelines can be accessed online through either the
Association of Breast Surgery or BAPRAS websites: ‘Oncoplas-
tic breast reconstruction – Guidelines for Best Practice,
2012, Eds Dick Rainsbury and Alexis Willet’ (http://www.asso-
ciationofbreastsurgery.org.uk/media/23851/final_oncoplastic_
guidelines_for_use.pdf).
The role of surgery in the management of women
with breast cancer remains all important and fundamental.
Its role in the prevention of breast cancer for women
at high risk by virtue of family history or gene mutation is
increasing.
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Role of aggressive surgery for peritoneal metastases
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1. Peritoneal cavity: a particular site of
metastasis
The spatial conformation and the poor prognosis of perito-
neal metastases (PM) make it an original entity. Once contam-
inated by tumour cells, disease spread is rapid and
multidirectional over a surface that is equal to the body sur-
face area in m2. The prognosis of PM is poorer than that of
metastatic spread elsewhere; patients with colorectal metas-
tases treated with chemotherapy and targeted therapies have
a median survival of 15 months with PM versus 21 months
without PM (P < 0.001) [1]. The presence of PM is thus tradi-
tionally deemed a fatal event.
Complete cytoreductive surgery (CCRS) resects all visible
peritoneal deposits, and the remaining invisible disease is
subsequently treated with a high local concentration of che-
motherapy potentiated by hyperthermia (HIPEC) in one ses-
sion. This aggressive surgery can therefore be proposed only
for disease confined to the peritoneum. According to the ori-
gin of the disease, such treatment is administered in two out
of three colorectal carcinomas, one out of three gastric carci-
nomas, seven out of ten ovarian carcinomas, nine out of ten
pseudomyxomas and eight out of ten mesotheliomas.
2. Aggressive surgery as a state of the art:
pseudomyxoma and mesothelioma
CCRS + HIPEC is considered the gold standard treatment for
these two peritoneal malignancies. In a retrospective multi-
centric registry, including 2298 patients with pseudomyxoma
from 16 specialised units using this combined approach [2],
median survival was 16.3 years and 10-year survival was
63%. Mortality was 2%, and major complications occurred in
24%. The main prognostic factors in the multivariate analysis
were the histological subtype, a high extent score and no HI-
PEC. CCRS achieved the best outcome. Similar conclusions
were drawn for malignant mesothelioma in a multi-institu-
tional registry including 405 patients [3] in which only 46%
underwent CCRS. Median survival was 53 months and 5-year
survival was 47%.
3. Aggressive surgery as a new therapeutic
approach: colorectal carcinoma
3.1. Long-term results after CCRS plus HIPEC
Ten years ago the results of a randomised study [4] – which in-
cluded 105 patients treated for colorectal PM (systemic che-
motherapy versus with surgery plus HIPEC) – demonstrated
significantly prolonged survival in patients treated with sur-
gery plus HIPEC, with a median survival twofold higher
(P = 0.03), although CCRS was achieved in only 38% of cases.
This was confirmed in another study [5] comparing two sim-
ilar groups in terms of the main patient characteristics. All
patients underwent a laparotomy and had resectable PM; 48
patients were treated with CCRS + HIPEC in one centre, and
48 were treated in five other centres without HIPEC. After a
minimal follow-up of 63 months, 5-year overall survival was
51% in the CCRS + HIPEC group and 13% for patients in the
no-HIPEC group (P < 0.05).
Long-term results of primary CCRS + HIPEC demonstrated
that definitive cure of PM was possible in 16% of the 93 pa-
tients treated between 1995 and 2004 [6], a rate which is close
to that obtained with a similar long follow-up after hepatec-
tomy for liver metastases (LM). Median survival was
36 months at that time, but attained 48 months in 2011 [7],
emphasising a learning-curve effect and better patient
selection.
CCRS + HIPEC is wrongly reputed to cause excessive mor-
bidity, but in specialised centres and in selected patients mor-
tality is lower than 5% and grade 3–4 morbidity is lower than
30%.
Aggressive surgery plus HIPEC is also considered costly,
but its clear superiority over the usual palliative therapies in
terms of QALY (cost-efficacy) has been demonstrated.
Regarding prognostic factors, the results of the French Reg-
istry – which analysed 523 patients treated with CCRS + HIPEC
– showed that the extent of PM (scored with the peritoneal
cancer index, PCI) is the main prognostic factor [8]. There
were no survivors when the PCI exceeded 20, and we now
consider a PCI above 20 to be a contraindication.
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3.2. Role of complete cytoreductive surgery alone
No randomised study has compared CCRS to systemic che-
motherapy. The results of four retrospective series provide
some elements of response: median survival was 28 months,
with 5-year survival at 24%, showing clear but limited superi-
ority over systemic chemotherapy alone. In contrast, an
incomplete resection (R2) afforded no advantage, with sur-
vival rates similar to those reported with chemotherapy alone
[8]. In conclusion, CCRS benefits patients with limited PM and
a good general status.
3.3. Role of hyperthermic intraperitoneal chemotherapy
No randomised study has been published to date. We are
awaiting the results of Prodige 7, the French randomised trial
comparing the survival of patients treated with CCRS + HIPEC
to that of patients treated with CCRS alone, whose accrual
was recently completed (n = 260). This study will define the
real impact of HIPEC.
3.4. Future
As this aggressive surgery gives far better results for limited
PM, it should be used mainly to treat patients at a very early
stage, but early diagnosis of PM cannot be done by clinical
or imaging examinations. Only systematic second-look sur-
gery (SLS) can detect PM early, but this aggressive approach
should be proposed exclusively in patients at high risk of
PM. In such patients (limited PM resected with the primary,
a history of ovarian metastases and a perforated primary tu-
mour) with no preoperative evidence of PM, SLS has allowed
us to find macroscopic PM in 55% of cases [9], and to treat
PM earlier with CCRS + HIPEC. A randomised multicentric
trial (Prophylochip) comparing the standard treatment (fol-
low-up) in these high-risk patients to the new one (second-
look + HIPEC) is ongoing.
4. CCRS + HIPEC to treat PM of other origins
Indications are in progress for ovarian-, gastric-, NET- and
rare disease-derived PM. The initial results of CCRS + HIPEC
were disappointing, but progress in techniques and in indica-
tions in ongoing prospective trials is giving promising results.
5. Conclusion
CCRS + HIPEC yields long-term survival in patients with PM.
No clear and widely accepted definition of resectable PM ex-
ists. However, we postulate that when the patient has a good
general status and when the extent of PM is limited, without
extraperitoneal disease, this approach is beneficial.
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Successful clinical translation of preclinical
combinations of radiation and immunotherapy
Silvia C. Formenti *, Sandra Demaria
New York University School of Medicine, New York University Cancer Institute, USA
1. Introduction
Ionising radiation (IR) can induce immunogenic cell death in
tumours, an effect likely to contribute to the success associ-
ated with radiotherapy (RT) for cancer. Recent studies suggest
that radiotherapy can be applied as a powerful adjuvant to
immunotherapy, and can even contribute to converting the
irradiated tumour into an in situ vaccine, resulting in specific
immunity against metastases [1].
Importantly, preclinical models of syngeneic tumours
have reliably predicted clinical success in several distinct tu-
mour settings and with several different immunotherapy/
radiation combinations. As a proof-of-principle trial, we have
translated the preclinical evidence of a successful combina-
tion with Flt3 ligand and RT to a protocol of granulocyte–
monocyte colony-stimulating factor (GM-CSF) and IR, and
demonstrated out-of-field objective responses in 27% of pa-
tients with multiple metastases of solid tumours, defined as
an abscopal effect [2]
In-parallel mechanistic studies in the laboratory were
conducted in the syngeneic mouse models of metastatic
breast cancer. Results showed that radiation was synergistic
with anti-CTLA-4 treatment, a strategy to break immune tol-
erance to the tumor. Multiple mechanisms contributed to
thus synergy, including the RT-induced upregulation of a
chemokine that promoted homing of effector T cells to the
tumor. Intravital microscopy demonstrated that while both
IR and CTLA-4 blockade given as monotherapy enhanced
the motility of activated CD8 T cells infiltrating 4T1 tumours,
IR with anti-CTLA-4 increased the arrest of T cells in contact
with tumour cells, promoting the formation of an immune
synapse between cytotoxic T cells and their targets. The lat-
ter required interaction between NKG2D on CD8+ T cells and
its ligand, retinoic acid early inducible-1 (Rae-1), on the tu-
mour cells, which was up-regulated by IR. Blocking
NKG2D–Rae-1 interactions markedly increased the motility
of anti-CTLA-4 treated T cells within irradiated tumours,
inhibiting their contact with tumour cells and also abrogated
immune-mediated tumour rejection [4].
The preclinical success of the combination of anti-CTLA-4
antibody and IR was mirrored by abscopal responses seen in
metastaticmelanoma and non-small-cell lung cancer (NSCLC)
patients irradiated in one lesion during ipilimumab therapy.
These clinical observations strongly suggest that the effects
of IR identified in experimental models are relevant to
patients. IR can stimulate the anti-tumor immune response,
increasing the proportion of patients who respond to check-
point blockade treatment, an hypothesis currently being
tested in clinical trials. The same pattern of abscopal re-
sponses has been observed in preclinical models was also
demonstrated in clinical cases of lymphomas and breast can-
cers treated by combinations of RT and toll-like receptor ago-
nists. Finally, blocking tumour growth factor beta (TGF-beta)
during RT preclinically has demonstrated abscopal effects that
have been confirmed in one patient accrued to a trial of anti-
humanTGFb antibody fresolimumab andRT.While promising,
this evidence remains preliminary and warrants more re-
search to define the optimal combinations of immunotherapy
and RT, to best exploit this novel role of ionising radiation [3].
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At what price do we treat patients with testicular
cancer?
Gedske Daugaard *
Copenhagen University Hospital, Department of Oncology, Rigshospitalet, Copenhagen, Denmark
In 2013 testicular cancer (TC) represents the most curable
solid tumour. The high cure rate is associated with a signifi-
cant long-term morbidity. Long-term effects after TC treat-
ment can be divided into life-threatening (e.g. secondary
tumours and cardiovascular disease) or effects on single or-
gans (e.g. nephro-, neuro- and pulmonary toxicity, hypogo-
nadism or decreased fertility). Psychosocial effects are also a
major issue, with fatigue, influence on sexuality, work, cogni-
tive function, quality of life, lifestyle factors, etc. Some of
these side effects are discussed below, with a focus on future
studies. Testicular cancer survivors are at significantly in-
creased risk of solid tumours for at least 35 years after treat-
ment, with a higher incidence in patients who have had a
seminoma compared to non-seminoma [1,2]. However, pub-
lished studies lack detailed information concerning treat-
ment or refer to formerly used treatments.
Several studies have demonstrated increased risk of car-
diovascular disease [3–7]. A Norwegian study found a 5.7-fold
higher risk for coronary artery disease after bleomycin, etopo-
side and cisplatin (BEP) treatment, with a median observation
time of 19 years [3]. Hypogonadism, hyperlipidaemia [4] and
metabolic syndrome [4,7] have been mentioned as risk fac-
tors. Metabolic syndrome in particular could be linked to sub-
clinical testosterone deficiency.
It is necessary to increase our knowledge concerning the
impact of cisplatin-based chemotherapy, lifestyle factors
(diet, tobacco, physical activity), hypogonadism, family his-
tory concerning cardiovascular disease (CVD), alcohol, abnor-
mal blood samples and gene changes on the development of
cardiovascular disease in TC patients. Given the increased
incidence of CVD in TC patients it would be relevant to look
at genetic markers which in the general population have been
found to predispose to these diseases. To develop risk models
that include the above-mentioned factors, international coop-
eration is needed. This could make it possible to stratify TC
patients into risk groups and develop evidence-based inter-
vention according to the risk factors.
Testicular cancer patients should be tested for subclinical
hypogonadism. We know that after treatment, the serum tes-
tosterone concentration is in the lower part of the normal
range [8] and that 12–16% of long-term survivors have devel-
oped hypogonadism. Most younger TC patients exhibit some
dysfunction of the Leydig cells, which is compensated by an
increase in luteinising hormone (LH) levels. Whether this
compensation is adequate in elderly TC patients is not
known. The clinical significance of low testosterone levels is
under discussion, but most people believe that a sustained
reduction in testosterone is a contributing factor in the devel-
opment of metabolic syndrome, type-2 diabetes, osteoporo-
sis, decreased quality of life and premature ageing [9].
Hypogonadism could be a significant and independent pre-
dictor for the development of CVD, and if this is the case, tes-
tosterone replacement should be examined.
All TC patients treated with cisplatin will experience a de-
cline in glomerular filtration rate (GFR). This reduction will in
some patients be reversible, whereas in others GFR shows a
permanent decrease of up to 30% or more [10,11]. There is
no long-term monitoring of renal function in TC patients
treated with cisplatin. Experimental and clinical data suggest
that hypomagnesaemia is important for the development of
nephrotoxicity [12]. There are several unanswered questions
related to nephrotoxicity in this group of patients. It is un-
known whether the natural age loss in GFR is accelerated in
TC patients treated with platinum or whether the nephrotox-
icity is exacerbated in older platinum-treated TC patients. An-
other important issue to clarify is the influence of a decline in
GFR on the development of cardiovascular disease and death
from all causes.
The high survival rate and young age of patients with TC
entails that the treatment effect on reproductive function, fer-
tility and offspring health is a very significant factor. Affected
Sertoli-cell function and impaired Leydig-cell function in a
subset of TC patients result from testicular dysgenesis syn-
drome [13] which may explain the increased incidence of oli-
go-and azospermi in TC patients both before and after
orchiectomy, but before further treatment.
Most long-term survivors after treatment for TC can be-
come biological fathers without medical assistance [14]. Yet
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the 10-year paternity rate is reduced by 30% compared with
the normal population. All studies concerning gonadal func-
tion in TC patients is based on data from a single department,
with a limited number of patients and few details about the
treatment.
With the development of modern assisting reproductive
techniques, even men with significant gonadal dysfunction
will be able to have children. Cryopreservation of semen, opti-
mally performed before orchiectomy, is offered in most places
in order to increase the likelihood of subsequent fatherhood.
In view of the increased opportunity and use of frozen semen
for later artificial insemination, it is important to clarify
whether pregnancies obtained with frozen semen of low
quality are subject to more abortions, stillbirths or deformed
children. These data will be essential in order to advise the
TC patients. Larger-scale data concerning fertility in patients
with TC treated with either surveillance or chemotherapy
(three or four cycles of BEP) are needed.
Data regarding the factors leading to long-term side effects
of treatment remain scarce. Molecular testing methods might
help in identifying patients at high risk for therapy-related
complications and guide risk-adapted screening and inter-
vention strategies. In recent years, screening for variations
in polymorphisms has proved to be a valuable tool to investi-
gate the genetic predisposition for late effects. There is a rel-
atively high incidence of single-nucleotide polymorphisms
(SNPs) in genes which affect the cellular response in relation
to the cytotoxic treatment for TC [15].
In order to gain further knowledge on the development of
late effects in TC patients we need to have detailed informa-
tion about treatment, to include genetic research methods,
and to study side effects over time. The hope is that increased
knowledge can lead to interventional studies with reduction
or prevention of late effects.
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Collaborative international oncology nursing
research is improving but still has a long way to go!
Experiences, possibilities and challenges
Carol Tishelman *
Karolinska Institutet, Department of Learning, Informatics, Management and Ethics, Medical Management Center, Stockholm, Sweden
In this interactive teaching lecture I will draw on my
experiences from a variety of successful and less successful
international research projects, with roles as researcher, col-
laborator and advisor. Topics that will be addressed include
the process from vision to collaboration, benefits of collabora-
tion, the need for and qualities of leadership in driving such
projects, key components of collaborative endeavours and
challenges faced in forming and carrying out research
collaborations. Discussion of these topics will be based on
ongoing and completed collaborative projects. Reflections
from the participants are welcome throughout the session.
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Epidermal growth factor receptor targeting and its
role for individualisation in radiation oncology
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Because of its over-expression in many human tumours
and its association with a poor prognosis, the epidermal
growth factor receptor (EGFR) is used as a therapeutic target
in clinical routine and in clinical trials. Two major classes of
inhibitors are used: anti-EGFR antibodies and EGFR tyrosine
kinase inhibitors (TKIs). On simultaneous application of the
anti-EGFR antibody cetuximab with radiotherapy in head
and neck squamous-cell carcinoma (HNSCC) patients, an
improvement in locoregional tumour control and survival
has been shown as compared with radiotherapy alone, lead-
ing to the approval of this drug as the first molecular targeted
agent in a curative radio-oncological setting. However, so far
there is no hint of a superiority of this combination over
simultaneous cisplatin-based radiochemotherapy; thus, both
treatments are used today as alternative schedules.
While it is evident from preclinical as well as from clinical
data that a major heterogeneity exists among the responses
of individual patients to the combined treatment, apart from
skin reactions under cetuximab treatment, there is so far no
validated biomarker predicting response to cetuximab-based
combined treatment, nor to cisplatin-based radiochemother-
apy. Establishing predictive biomarkers would highly increase
efficacy of the treatment due to the positive selection of pa-
tients. Some conclusions can currently be drawn from trans-
lationally oriented studies: at least for HNSCCs (others have
not been well investigated), cetuximab application during
radiotherapy improves locoregional tumour control in many
but not all individual tumours, with individually impressive
responses. For EGFR–TKI all local tumour control studies have
been negative so far, whereas palliative effects have been
shown in most HNSCCs. A promising candidate biomarker
for the effect of combined radiotherapy and cetuximab in
HNSCC is genetic EGFR over-expression measured by the fluo-
rescence in situ hybridization (FISH) test. This marker has to
be further validated in clinical settings, as well as for other tu-
mour entities or combination schedules. Because of interac-
tions between the treatment modalities, such biomarkers
can be different between single-modality and combined-
modality treatments.
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From novel insights inmolecular biology to targeted
treatment approaches in head and neck cancer
Kevin J. Harrington *
The Institute of Cancer Research, London, United Kingdom
Squamous-cell carcinoma of the head and neck is the fifth
commonest neoplasm worldwide. Over 50% of patients pres-
ent with stage III/IV disease: so-called locally advanced head
and neck cancer (LAHNC). For LAHNC, the treatment para-
digm has shifted from mutilating, ablative surgery towards
organ-preserving concomitant cisplatin-based chemoradio-
therapy [1]. Compared with surgery, chemoradiotherapy
delivers equivalent or better locoregional control and dis-
ease-free survival with significantly better functional out-
comes [1]. Nonetheless, 5-year disease-free and overall
survival (30–40%) rates are suboptimal [2]. Strategies to im-
prove outcomes by escalating conventionally delivered radio-
therapy and/or cytotoxic chemotherapy are appealing, but
they pose unacceptable risks of severe acute and late normal
tissue damage and threaten chronic structural, cosmetic and
functional deficits that negatively impact quality of life [3].
Recent technical developments in physical targeting of
radiation delivery, including intensity-modulated and im-
age-guided therapy, offer a way of safely escalating tumour
dose without exceeding normal tissue tolerances. Also, a
clearer understanding of the radiation-induced DNA damage
response (RIDDR) opens up the possibility of developing tu-
mour-selective biological response modifiers to enhance the
effect of radiotherapy/chemoradiotherapy. The potential va-
lue of such therapies has been proven by the translation of
therapy targeted to the epidermal growth factor receptor
(EGFR), cetuximab, from preclinical studies to a positive phase
III trial in combination with radiation [4]. In addition, small-
molecule tyrosine kinase inhibitors have been tested [5,6].
Recently, biological studies have characterised LAHNC as a
disease spectrum, divisible into different prognostic groups
on the basis of demographic (tobacco exposure), clinical/
radiological (T and N stage) and molecular pathological (hu-
man papillomavirus (HPV) status) variables [7]. In addition,
we are beginning to understand the molecular landscape of
LAHNC more clearly [8]. As a result, we can escape the stan-
dard model whereby all patients receive treatment according
to a ‘one size suits all’ philosophy. Instead, we are moving to-
wards treatment individualisation according to prognostic
risk group.
Until recently, it was accepted that the standard of care for
patientswithLAHNCwasconcomitant cisplatin-basedchemo-
radiotherapy. However, recent data on prognostic subgroups
suggest that this is a significant oversimplification: patients
with poor prognosis disease may receive suboptimal treat-
ment, while those with good prognosis disease may be over-
treated with unnecessary risks of toxicity. Therefore, there
has been a realignment towards developing effective, molecu-
larly targeted strategies that offer personalised treatment to
individual patients based on prognostic factors. The clearest
viewof prognosis comes from post hoc analysis of patientswith
oropharyngeal cancers treated in the RTOG-0129 phase III trial
[7]. This study defined prognostic groups using specific demo-
graphic, clinical/radiological andmolecular pathological char-
acteristics: (1) poor-risk disease affected 27% of patients with
heavy tobacco use, T4 tumours andHPV/p16INK4a-negative sta-
tus; (2) low-risk disease occurred in 43%with HPV-positive sta-
tus and little prior tobacco exposure (or, if >10 pack-year
smoking history, by N0–N2a nodal status) and (3) intermedi-
ate-risk disease was represented by the 30% with either HPV-
positive tumours and >10 pack-year tobacco exposure and
N2b/N3 neck disease or HPV-negative tumours and <10 pack-
year tobacco exposure and T2/T3 tumours.
A particularly attractive approach to targeted therapy fo-
cuses on developing combinations of radiotherapy or chemo-
radiotherapy with targeted agents that modulate RIDDR to
exploit differences between malignant and normal tissues.
Mutations in p53 have been reported in many LAHNC and cor-
relate with exposure to tobacco/alcohol. p53-mutant LAHNC
show relative resistance to radiation, as evidenced by in-
creased locoregional recurrence rates after radical or adjuvant
irradiation [9], and reactivation of p53 has been shown to in-
crease responses to radiation/chemoradiation. In addition,
abnormalities in DNA repair signalling involving ataxia-telan-
giectasia mutated (ATM) and meiotic recombination 11
(MRE11) upstream of p53 are associated with radioresistance.
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In contrast, HPV-positive LAHNC does not harbour disruptive
p53 mutations but, rather, p53 is inactivated by HPV-E6 [10]. In
both situations, functional loss of the p53 pathway renders
tumour cells reliant on effective G2/M cell cycle checkpoint
control (Fig. 1). Also, the importance of repair of single-strand
DNA breaks, especially in the context of deficiencies in
homologous recombination, is well recognised, and targeting
this pathway has been shown to increase the response of
head and neck cancer cells to radiation in vitro and in vivo [11].
There is now significant experience in translational pre-
clinical/clinical studies of small molecules and biological
agents in LAHNC. In newly-diagnosed LAHNC, agents that tar-
get cell cycle checkpoint kinase 1 (Chk1) and heat shock pro-
tein-90 (HSP90) have provided proof-of-principle for the
potential radiosensitising effects of modulating DNA damage
responses at the G2/M checkpoint. Chk1 is key in cellular re-
sponses to DNA damage and replication stress. It is phosphor-
ylated in an ataxia telangiectasia-mutated- and Rad3-related-
(ATR-)dependent manner that is required to trigger the G2/M
checkpoint and promote homologous recombination. Studies
have demonstrated enhancement of radiation-induced cyto-
toxicity through Chk1 inhibition, but none has been with
drugs that have yet entered the clinic [12,13]. HSP90 is a ubiq-
uitously expressedmolecular chaperone that exists in a larger
complex including HSP70 and co-chaperones (Cdc37, p23,
AHA1, Hip and Hop) [14]. HSP90 maintains the conformation
of a pool of client proteins that regulate many cell functions.
Critically, this includes several signallingmolecules and onco-
genic proteins that play key roles in cell cycle arrest, DNA
damage repair and apoptosis in response to radiotherapy,
and a potential advantage of HSP90-targeted therapies lies
in their simultaneous combinatorial depletion of many com-
ponents of the RIDDR. Preclinical HSP90-mediated radiosensi-
tisation has been reported with geldanamycin, its derivatives
(17-N-allylamino-17-demethoxygeldanamycin (17-AAG), 17-
dimethylaminoethylamino-17-demethoxygeldanamycin (17-
DMAG)), the PU3 purine scaffold derivative BIIB021, and with
NVP-AUY922 [15]. In the context of relapsed/metastatic dis-
ease, EGFR-targeted therapies have been shown to yield im-
proved outcomes. In addition, a new class of therapies
based on replication-competent, oncolytic viruses has en-
tered clinical trials and shown significant promise [16].
In summary, our improved knowledge of the molecular
biology of LAHNC has revealed that specific disease subtypes
may be amenable to personalised treatment approaches. The
challenge for the next decade is to optimise these treatments
to improve antitumour effects and to minimise toxic effects
in normal tissues.
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Fig. 1 – Mechanistic basis for targeting S and G2/M checkpoint control in locally advanced head and neck cancer (LAHNC). In
human papillomavirus (HPV)-negative, intermediate-/poor-risk disease, p53 mutations render tumour cells reliant on S and
G2/M checkpoints to repair radiation-induced DNA damage. HPV-positive, low-risk disease will also rely on this checkpoint
(due to viral E6-mediated degradation of p53). Chk1 inhibition, either by relatively specific Chk1 inhibitors or multi-targeted
agents (heat shock protein (HSP90) inhibitors), is likely to exert potent radiosensitisation in both prognostic subgroups.
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Metastatic melanoma: New paradigms of treatment
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1. Introduction
Metastatic melanoma was historically designated the ‘‘drug
killer cancer’’ because for decades no drug had demonstrated
any benefit in terms of overall survival (OS) for patients with
metastatic melanoma. This situation has radically changed
over the last 2 years. Melanoma appears today as a ‘‘pilot’’dis-
ease for which the most innovative therapeutic strategies
have demonstrated significant efficacy. The two strategies
are immunotherapy on the one hand and targeted therapy
on the other. These two significant breakthroughs led to the
authorisation in the United States (US) and in Europe of two
drugs: the anti-BRAF agent vemurafenib and the anti-CTLA-
4 monoclonal antibody ipilimumab. More recently, two addi-
tional targeted agents, dabrafenib and trametinib, were
authorised in the US. Moreover, the field continues to improve
with the exciting development of new drugs following these
two new approaches.
2. Immunotherapy: anti-CTLA-4 and
anti-PD-1
The anti-CTLA-4 monoclonal antibody ipilimumab was the
first drug ever to demonstrate a significant OS benefit in the
context of a randomised phase III trial [1]. This pivotal trial
showed that ipilimumab at the dose of 3 mg/kg, alone or in
combination with a peptidic vaccine and compared with vac-
cination alone, prolonged the survival of patients with pre-
treated metastatic melanoma. Median OS of patients was
around 10 months with ipilimumab versus 6.4 months with
the vaccination. A second pivotal trial evaluated ipilimumab
at 10 mg/kg, combined with the standard chemotherapy
dacarbazine (DTIC), compared with dacarbazine alone in
first-line treatment. The ipilimumab-containing arm demon-
strated a significant survival benefit compared with dacarba-
zine alone (HR = 0.72; P < 0.001) with a median OS of
11.2 months versus 9.1 [2]. This trial did not suggest that the
combination of DTIC with ipilimumab added any benefit,
but rather added toxicity, especially in terms of
hepatotoxicity.
Clinical results with ipilimumab are characterised by low
objective response rates, usually below 20%, but frequent
long-term responses. Responses are often delayed, being ob-
served after at least 4 months following initiation of therapy,
and can even occur after an initial tumour progression or the
appearance of new lesions.
As expected for a new mechanism of action, blocking
CTLA-4 is associated with a new spectrum of adverse events.
These are frequent, occurring in 40% of the patients and are
mostly immune-related, as expected for an immunostimula-
tory agent. The most frequent side effects are skin rashes,
diarrhoea and colitis resembling Crohn’s disease, hypophysi-
tis and hepatitis. Adverse effects usually resolve spontane-
ously or after steroid therapy. High-dose steroids have to be
prescribed in cases of severe immune-related adverse events;
rarely, stronger immunosuppressive agents, such as anti-
TNF-alpha (infliximab), can be needed.
Challenging questions remain to be answered to opti-
mise the efficacy of this new treatment. Indeed, the survival
benefit concerns few patients, and we currently lack predic-
tive clinical or biological markers of response. Furthermore,
the two pivotal trials have explored two different doses, 3 or
10 mg/kg, and two schedules of follow-up treatment de-
signs. Thus, the optimal administration schedule is still
unknown.
Programmed death-1 receptor (PD1) and its ligand (PD-L1)
are new, highly promising targets in immunotherapy. PD1
protein is another immune checkpoint expressed on many
T cells in response to inflammation. The engagement of PD1
on the lymphocyte surface by one of its ligands, PD-L1, that
can be expressed on melanoma cells, delivers inhibitory sig-
nals resulting in T-cell function down-regulation [3].
In contrast to CTLA-4/CD28 interaction that down-regu-
lates T-cell activation in lymphoid organs during naı¨ve T-cell
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priming, PD-1/PDL-1 interaction mostly contributes to
exhaustion of T cells in peripheral tissues afterwards. Reacti-
vation of T cells that are already present on tumour sites is
thus an alternative and potentially complementary strategy
to improve cancer immunosurveillance.
Very compelling results of phase I trials evaluating two
anti-PD1 antibodies nivolumab and lambrolizumab were re-
cently published [4,5]. Various dose and schedule regimens
were evaluated in phase I trials. Response rates were around
30–40% for both antibodies, with the vast majority of respond-
ing patients still in response after median follow-up dura-
tions of more than 1 year. The safety profiles of these new
anti-PD-1 agents seem tolerable, with 10–12% of grade 3 or 4
adverse events, usually manageable except in rare cases of se-
vere pneumonitis.
Combined blockade of PD-1 and CTLA-4 has also been ex-
plored in a phase I trial in 86 patients, and also gave extre-
mely promising clinical results with tolerable adverse events
[6].
Combination of nivolumab and ipilimumab was associ-
ated with a 53% rate of treatment-related adverse effects that
most frequently corresponded to changes in biological
parameters (lipase, transaminase elevation) with no clinical
manifestation.
3. The second strategy relies on the use of
targeted drugs: anti-BRAF and anti-MEK agents
BRAF and MEK are protein kinases involved in the MAP-kinase
pathway that is activated in the vast majority of melanomas
due to BRAF, NRAS, MEK and KIT mutations in (respectively)
about 50%, 15%, 8% and 3% of the cases [7].
Among BRAF mutations, the most frequent one – account-
ing for more than 90% of the somatic mutations of this onco-
gene – results in the V600E amino acid replacement.
Small kinase inhibitors directly targeting the mutated
BRAF protein have been developed. The first one, vemurafe-
nib, was recently approved as a first-line treatment for pa-
tients with unresectable or metastatic melanoma
harbouring the V600E BRAF mutation, based on the results
of a randomised phase III trial showing a significant improve-
ment in overall survival with vemurafenib (HR: 0.37, P < 0.001)
and a median progression-free survival (PFS) of 5.3 months
versus 1.6 months (HR: 0.26, P < 0.001) with dacarbazine and
a high response rate around 50% [8]. Dabrafenib, another
BRAF inhibitor, showed similar results in term of PFS and
objective response rate (ORR), but could not demonstrate OS
benefit because the design of the phase III trial included a
cross-over [9].
BRAF inhibitors are usually well tolerated, the most com-
mon adverse events being arthralgia (56% of the patients), fa-
tigue (46%) and cutaneous manifestations such as rash (41%),
photosensitivity (41% for vemurafenib only) and squamous-
cell carcinoma of the keratoacanthoma-type (10–25% of the
patients depending on the type of BRAF inhibitor used).
However, two major concerns are associated with all spe-
cific BRAF inhibitors evaluated so far. The most challenging
is the short median duration of the clinical responses, with
most of the patients relapsing in the 4–12 months after initi-
ation of therapy. Numerous distinct resistance mechanisms
have been identified that can reactivate the MAPK pathway
(ERK-dependent) or use additional proliferation pathways
[10].
The second issue when using these agents is that they
paradoxically activate the MAPK pathway in cells devoid of
BRAF mutation, especially in the presence of an additional
somatic event occurring in this pathway, such as a RAS
mutation. This explains the appearance of squamous-cell
neoplasia (keratoacanthomas and squamous-cell carcino-
mas) as well as new melanomas in a subpopulation of pa-
tients [11].
One strategy to decrease secondary resistance as well as
neo-tumourigenesis associated with anti-BRAF monotherapy
is to combine it with an inhibitor of MEK1 and MEK2 down-
stream from BRAF. Indeed, several MEK blockers are in devel-
opment, and one of them, trametinib, has shown a
significantly increased PFS in patients with V600E metastatic
melanoma in a phase III randomised trial, and was recently
approved by the FDA [12]. Another MEK inhibitor, selumetinib,
also demonstrated an improvement in PFS when combined
with dacarbazine compared with dacarbazine plus placebo
in a randomised phase III trial [13]. Anti-MEK drugs are asso-
ciated with numerous skin side effects, as are most antican-
cer targeted agents, but potentially serious adverse events
involving the retina and myocardia are rare and mostly
reversible.
The most promising approach at present is the combina-
tion of BRAF and MEK inhibitors. Indeed, this approach not
only seems to give higher response rates and longer PFS but
is also associated with a significantly decreased incidence of
neo-skin-derived proliferation [14].
4. Conclusion
A revolution in the metastatic melanoma treatment paradigm
is going on. We now have several effective weapons via both
the immunotherapy and the direct targeted therapy ap-
proaches. Our challenges are to optimise the design of treat-
ments in terms of combination and/or sequences and to
optimise safety regarding the new adverse events that are
occurring.
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Pharmacogenetics in the clinic
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Pharmacogenetics is one of the first clinical applications of
the postgenomic era; it studies the role of heritability of drug
responses. It promises personalised medicine rather than the
established ‘one size fits all’ approach to drugs and dosages.
This should ultimately lead to more efficient and safer drug
therapy. In recent years, pharmacogenetic information has
been included in drug labels (especially for oncology drugs),
and commercially available pharmacogenetic tests have been
approved by the Food and Drug Administration (FDA), but
their application in routine patient care remains limited. In-
deed, the implementation of pharmacogenetics in routine
clinical practice presents significant challenges. The clinical
value and the interpretation of pharmacogenetic tests are
found difficult. Now, pharmacogenetics-based therapeutic
(dose) recommendations, based upon the systematic review
of the literature, are available for 53 drugs associated with
genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-
methyltransferase (TPMT), dihydropyrimidine dehydrogenase
(DPD), vitamin K epoxide reductase (VKORC1), uridine
diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-
B44, HLA-B*5701, CYP3A5 and factor V Leiden (FVL). These
two large initiatives are made available through the pharmac-
ogenomics knowledge base and may help clinicians to make
use of current pharmacogenetic knowledge. In the teaching
lecture specific clinical examples of challenges for implemen-
tation of pharmacogenetics are discussed, and best practices
for implementation will be presented.
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Radiotherapy for rectal cancer: Short course versus
long course – When and how
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Prior to the introduction of improved surgical techniques
such as total mesorectal excision, local recurrence rates after
resection were unacceptably high with surgery alone. Phase
III trials were designed to determine the benefit of the addi-
tion of radiotherapy to radical surgery, and these have re-
ported significant reductions in local recurrence.
Two different strategies were evaluated in the preoperative
setting. Initially in Scandinavia the approach of a hypo-frac-
tionated 1-week course of radiotherapy performed prior to
radical surgery was evaluated in a series of phase III trials.
In contrast, the strategy of integrating fluoropyrimidine che-
motherapy with long-course fractionated radiotherapy in
the postoperative setting was then evaluated preoperatively.
Two key trials determined that the addition of fluoropyrimi-
dine to neoadjuvant radiotherapy compared with radiother-
apy alone significantly reduced the risk of local recurrence.
Following the increasing use of total mesorectal excision
and the associated lower rates of local recurrence, in the
Netherlands and in the United Kingdom (UK) two phase III tri-
als were conducted. The Dutch TME and MRC CR07 trials
showed a reduction in local recurrence from the addition of
short-course preoperative radiotherapy but without any im-
pact on overall survival.
The two strategies (short-course and long-course treat-
ment) have developed in parallel. This leads to a number of
questions:
• When preoperative radiotherapy is combined with radical
surgery to reduce the risk of local recurrence, is there any
difference in the efficacy of the two approaches?
• Is there any difference in the acute toxicity of the two
approaches?
• Is there any difference in the late toxicity between the two
approaches?
Two phase III trials have directly compared short-course
preoperative radiotherapy followed by immediate surgery ver-
sus long-course concurrent chemoradiotherapy followed by a
delay in surgery. The Polish trial was designed to determine
whether long-course chemoradiotherapy would increase the
chance of sphincter preservation, whereas the TROG trial
was designed to compare local recurrence rates between the
two approaches.
Given the relatively low rates of local recurrence seen in
routine clinical practice and within the trials, both studies
are underpowered for a formal comparison of efficacy. How-
ever, neither trial has reported a significant difference in local
recurrence between the two approaches.
With respect to acute toxicity, long-course chemoradio-
therapy is associated with the concomitant administration
of fluoropyrimidine chemotherapy. The acute toxicity is high-
er with this approach compared with short-course hypo-frac-
tionated radiotherapy. In terms of long-term toxicity, neither
the Polish nor the TROG trials have reported any evidence of
any significant difference in late toxicity between the two
approaches.
The trials that have compared these two approaches have
focused on the neoadjuvant use of radiotherapy combined
with radical surgery. The current evidence does not suggest
any major differences in efficacy and long-term outcome in
patients with resectable disease. However, where the margin
of excision is threatened or involved, current consensus is
that long-course chemoradiotherapy is the preferred ap-
proach. There are limited non-randomised studies that have
reported the use of short-course preoperative radiotherapy
followed by an elective delay to surgery from both Sweden
and Leeds. There are also comparative interim data from
the Stockholm III trial. Short-course preoperative radiother-
apy followed by an elective delay to surgery is a treatment op-
tion that could be considered in patients who are considered
unsuitable for concurrent chemoradiotherapy.
The use of these two radiotherapy strategies needs to be
considered within the changing landscape of rectal cancer
management. There is increasing interest in organ-preserving
approaches where surgery is deferred or avoided. In this
context dose escalation of the radiation dose is likely to
increase the complete response rates. This approach is more
easily and safely obtained by dose-escalating long-course
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concurrent chemoradiotherapy. Dose escalation of short-
course radiotherapy should be approached with caution and
within the context of a clinical trial. The efficacy of short-
course radiotherapy and delay in early rectal cancer is the
subject of an ongoing study within the UK (TREC). The Dutch
CARTS study has evaluated chemoradiotherapy followed by
local excision.
A further area of interest is the use of neoadjuvant chemo-
therapy that is integrated closely with neoadjuvant radiother-
apy. In this context the use of short-course radiotherapy may
have some advantages and needs to be tested in clinical trials.
This will be illustrated by discussion of both the European
RAPIDO and the North American PROSPECT trials.
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State of the art in neoadjuvant therapy of breast
cancer
Gunter von Minckwitz *, Caterina Fontanella
GBG Forschungs GmbH, Neu-Isenburg, Germany
1. Introduction
Neoadjuvant therapy is no longer an option just for locally ad-
vanced operable cancers in order to facilitate breast-conserv-
ing surgery, but also for all early breast cancers when an
indication for chemotherapy is given [1]. Pathological com-
plete response (pCR) – defined as the absence of residual inva-
sive or sometimes even in-situ cancer on breast and lymph
nodes after preoperative therapy – has been shown to predict
long-term outcome in patient-based analyses of several ran-
domised clinical trials [2–4]. Achieving pCR is important
mainly for those patients with an unfavourable initial progno-
sis, such as HER2-positive/hormone-receptor- (HR-)negative,
triple-negative breast cancer (TNBC) and some luminal-B-like
tumours. In contrast, the survival benefit of patients with pCR
was less pronounced in luminal-A-like tumours (HR-positive,
HER2-negative, grade 1–2) [2,4].
Because of the different behaviours of breast cancer sub-
types, a neoadjuvant strategy tailored on clinicopathological
criteria should be considered the optimal option (Table 1).
2. HR-positive disease
The GeparTrio trial [5] investigated a response-guided ap-
proach based on early response assessment; the treatment
was either intensified with two additional cycles in the case
of an early response, or changed to a different chemother-
apy in the case of no response. Response-guided strategy
led to a higher pCR rate in patients with HR-positive tu-
mours, without a significant improvement in disease-free
survival. These discordant results might be explained by
the established weak prognostic impact of pCR in HR-posi-
tive disease [2,4]
3. HER2-positive disease
In studies adding trastuzumab to neoadjuvant chemother-
apy, patients with HER2-positve/HR-negative tumours
achieved the highest pCR rate across subtypes [3]. Other-
wise, in the German neoadjuvant trial experience, an
increasing number of chemotherapy cycles might be related
to a higher pCR rate in patient with HER2-positive/HR-posi-
tive disease [4]. Moreover, results from the Tryphaena study
showed that six to eight cycles of a taxane-based chemo-
therapy, including either an anthracycline or carboplatin,
plus trastuzumab and pertuzumab lead to an increased
pCR rate of >60% [6].
Currently, a sequential chemotherapy approach contain-
ing anthracycline–cyclophosphamide and a taxane plus trast-
uzumab is the better choice for patients with HER2-positive
disease. The addition of pertuzumab to this sequence, or to
a taxane–carboplatin combination, could be a future option
when it becomes available.
4. TNBC
The simultaneous application of docetaxel, doxorubicin and
cyclophosphamide (TAC) for six cycles accounts for the high-
est pCR rates in TNBC patients in the German neoadjuvant
studies, particularly for patients with an early response after
only two cycles [7].
As shown in the GeparQuinto study, the treatment effect
might be further improved by adding bevacizumab to neoad-
juvant chemotherapy [8]. However, even considering the non-
confirmatory results of the NSABP B40 trial [9], the use of this
anti-angiogenic drug in the neoadjuvant setting should be
further investigated.
In the near future the role of bevacizumab and carboplatin
will be better defined by the GeparSixto study [10] which is
investigating bevacizumab given simultaneously to weekly
carboplatin, paclitaxel, and pegylated doxorubicin in TNBC
and HER2-positive patients; and by the CALGB 40603 study
[11] which is evaluating three weekly carboplatin and bev-
acizumab in a 2 by 2 factorial design in patients treated with
weekly paclitaxel followed by dose-dense doxorubicin/
cyclophosphamide.
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5. Conclusion
In conclusion, considering that HER2-positive/HR-negative
and TNBC patients who achieve pCR showed a prognosis
comparable to that of patients with luminal-A-like tumours
[2], a neoadjuvant strategy tailored to different breast cancer
subtypes can completely change the natural history of some
cancers.
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Table 1 – Different neoadjuvant approaches according to breast cancer subtypes.
Subtype Neoadjuvant treatment Reference
HR-positive disease EC–Pw Meta-analyses of several neoadjuvant studies2–4
TAC · 2! response-guided chemotherapy GeparTrio5
HER2-positive disease EC(H)–TH Meta-analyses of several neoadjuvant studies2–4
FECHP–TH or TCH (plus P if available) Tryphaena6
TNBC TAC Meta-analysis of seven German neoadjuvant studies7
EC–Pw Meta-analyses of several neoadjuvant studies [2–4]
Role of bevacizumab is uncertain GeparQuinto8 and NSABP 409Waiting for GeparSixto10
and CALGB 4060311
Role of carboplatin is uncertain Waiting for GeparSixto10 and CALGB 4060311
E, epirubicin; C, cyclophosphamide; Pw, paclitaxel weekly; T, docetaxel; A, doxorubicin; F, 5-fluorouracil; H, trastuzumab; P, pertuzumab; TNBC,
triple-negative breast cancer.
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Surgical management of neuroendocrine tumour
(NET) liver metastases
Per Hellman *
University Hospital, Department of Surgery, Uppsala, Sweden
Neuroendocrine tumours (NETs) usually have an indolent
course, developing slowly over many years, and when there
is a lack of overt hormonal symptoms they may have been
present for a considerable period of time before diagnosis.
Therefore, NETs are commonly found with metastatic disease
at diagnosis, especially in the most common variant small-
intestinal NETs (SI-NETs). Surgical treatment of NETs varies
somewhat according to site of origin and extent of disease.
Surgical treatment of liver metastases is generally indicated
if there are less than about five tumours, if they are confined
to one lobe or in the case of large tumours as a debulking op-
tion to reduce hormonal release.
However, there are several alternative options. First of all,
stabilisation of disease is important, usually achieved by offer-
ing biotherapy (SI-NETs) or chemotherapy (pancreatic or
pulmonary NETs). In addition, treatment with 177luthetium-la-
belled somatostatin analogues in tumours expressing somato-
statin receptors has emerged as a possible option for initial
treatment. After stabilisation of the disease, or even reduction
of the tumour burden, often achieved by these treatments,
surgery may become an option. A likewise targeted metasta-
sis-directed therapy is ablation by radiofrequency (RFA), micro-
wave (MW) or recently also irreversible electroporation (IRE).
Another available option is hepatic artery embolisation.
Therefore, surgical management of liver metastases may
be offered at different stages of the disease. In some cases
the goal is total eradication of metastases from the liver, in
other cases as anothermethod to keep the disease ‘under con-
trol’ or as a debulking procedure to reduce hormonal levels.
RFA or MW for SI-NETs has been evaluated and found to be
safe, to reduce hormonal levels, and to reduce symptoms
such as diarrhoea and abdominal pain. However, there seems
to be no improvement on survival, although no randomised
trial to test this has yet been conducted.
Surgery has classically involved standard resections such
as segmentectomies or hemihepatectomy, but recently a
more local approach has been utilised as an alternative to
the likewise local RFA or MW. No studies have compared liver
surgery for NETs with the alternatives, but studies have
demonstrated the safety of – and clear benefit as a result of
– surgery as a debulking procedure.
Studies in SI-NET have shown that the recurrence rate of
liver metastases is very high. In careful microscopic evalua-
tions of resected liver specimens it is clear that there are al-
most always several previously unrecognised metastases
present, perhaps indicating the impossible goal of reaching
microscopic R0.
In pancreatic NETs the situation may be different. Unless
diffusely spread, R0 may be achieved in the liver, and if com-
bined with proper chemotherapy an impressively stable dis-
ease may be achieved compared with previously.
Liver transplantation has been advocated in patients with
pancreatic NETs, Ki67 < 10% and lack of extrahepatic disease.
In practice, however, this situation is rather rare, since
lymph-node and skeletal metastases are often present,
nowadays visualised with the more sensitive tools of today
(Ga-DOTATOC/TATE PET). For SI-NET, liver transplant would be
theoretically preferable considering the high rate of unknown
liver metastases, but the survival for such patients has a
median of >20 years, raising doubts about whether liver trans-
plant is anoption. Indeed, themetastases inSI-NETs commonly
also occur at other sites than in the liver – but may still be con-
trolled with the appropriate biotherapy treatment, as well as
with 177Lu in certain cases. Indeed, there are reports of very suc-
cessful liver transplant case series, but also cases with recur-
rence of disease in the new liver associatedwith short survival.
Overall, no comparative or randomised studies are avail-
able to support any evidence-based recommendations. There
are several patient case series describing long survival and
improvement of symptoms after liver surgery, but these are
of small value because of lack of comparisons. On the other
hand, liver surgery or ablative procedures may still be chosen
by the individual patient when offered, as a variant of per-
sonalised medical care.
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Application of sentinel nodes in gynaecological
cancer therapy
M.H.M. Oonk, A.G.J. van der Zee *
University Medical Centre Groningen, Department of Gynaecologic Oncology, Groningen, The Netherlands
The sentinel-node procedure was introduced in cancer
therapy in order to reduce the morbidity that is associated
with full lymphadenectomy without compromising survival
rates. In gynaecological cancer the application of the senti-
nel-node procedure has been investigated in vulvar, cervical,
and endometrial cancer.
In vulvar cancer, the Groningen International Study on
Sentinel nodes in Vulvar cancer (GROINSS-V) showed that it
was safe to omit inguinofemoral lymphadenectomy in pa-
tients with a negative sentinel node. Eligible patients who
underwent the procedure had unifocal squamous-cell cancer
of the vulva, with a maximum diameter of 4 cm and no suspi-
cious groin nodes at palpation. In the case of a negative sen-
tinel node, no inguinofemoral lymphadenectomy was
performed, and patients were followed up regularly. Both
short-term and long-term treatment-related morbidities were
significantly lower when only the sentinel node was removed.
Groin recurrences were observed in 2.3% of the patients with
a negative sentinel node [1]. An analysis of the patients with a
positive sentinel node showed an increasing risk for involve-
ment of non-sentinel nodeswith increasing size of themetas-
tasis in the sentinel node. Furthermore, the prognosis was
significantly worse for patients with sentinel-node metasta-
ses >2 mm [2]. More recently Levenback and colleagues
published the results of the Gynaecologic Oncology Group
study on the sentinel node procedure in vulvar cancer
(GOG-173). They included 452 patients; all patients underwent
inguinofemoral lymphadenectomy after sentinel-node detec-
tion. They found a false-negative predictive value of 3.7%. In
women with a tumour <4 cm, the false-negative predictive
value was 2.0%, a result resembling that of GROINSS-V [3]. Pit-
falls of the sentinel-node procedure are gross nodal involve-
ment that may obstruct lymph flow and thereby cause
bypassing of the sentinel node and confusion about the num-
ber of sentinel nodes [4]. Preoperative groin imaging with
computed tomography (CT), magnetic resonance imaging
(MRI) or ultrasound (US) is mandatory to exclude gross nodal
involvement, while preoperative lymphoscintigraphy gives
adequate information on the number of sentinel nodes per
groin and presence of unilateral or bilateral sentinel nodes.
Controversies remain regarding the method of preoperative
imaging, the therapeutic benefit of inguinofemoral lymphad-
enectomy in case of micrometastases in the sentinel node,
and alternative treatment options in patients with a positive
sentinel node. An ongoing second observational study, GRO-
INSS-V-II, is investigating the safety of radiotherapy instead
of inguinofemoral lymphadenectomy in patients with a posi-
tive sentinel node. Preoperative imaging is mandatory in this
study to exclude gross nodal involvement. The GOG has
joined GROINSS-V-II; this international collaboration will help
shorten the duration of studies in rare malignancies like
vulvar cancer.
In cervical cancer single-institution case series had
already demonstrated the feasibility of the sentinel-node
concept, when Altgassen and colleagues in 2008 published
the results of their multicentre study on the detection rate
and diagnostic accuracy. The detection rate of pelvic senti-
nel nodes was 88.6% in 590 patients. They also showed a
significantly higher detection rate when blue dye and a
radioactive tracer were combined. The sensitivity was
77.4% overall, but 90.9% in women with tumours 62 cm.
They concluded that the sensitivity of the sentinel-node
concept was low, but that patients with tumours 62 cm
might profit from this concept [5]. The results of the SENTI-
COL study, by Le´curu and colleagues, showed that in 139
stage IA1 with LVSI-IB1 cervical cancer patients the senti-
nel-node procedure yielded a sensitivity of 92.0% and a neg-
ative predictive value (NPV) of 98.2% for detection of nodal
metastasis. No false-negative results were observed in those
patients in whom the sentinel node was identified bilater-
ally. They concluded that the sentinel-node procedure has
a high sensitivity and NPV, and is especially reliable in pa-
tients in whom the sentinel node is detected bilaterally [6].
These results were confirmed in a recent study by Cibula
and colleagues in their study in 645 patients [7]. The same
authors showed that the presence of micrometastases in
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the sentinel node was associated with a significant reduc-
tion in overall survival, which was equivalent to that in pa-
tients with macrometastasis. No prognostic significance was
found for isolated tumour cells [8]. Recently a single-institu-
tion study showed that when comparing a prospectively
collected patient cohort (in whom a pelvic lymphadenec-
tomy was omitted in the case of a negative sentinel node)
with historic controls in whom a full lymphadenectomy
was performed, the sentinel-node technique yielded a
higher proportion of patients with lymph-node metastases,
indicating a higher sensitivity of the sentinel-node tech-
nique [9]. However, the clinical impact of sentinel-node
biopsy in cervical cancer needs to be further evaluated in
observational or preferably randomised studies comparing
sentinel-node biopsy with sentinel-node biopsy plus
lymphadenectomy (NCT01157962).
Finally, in endometrial cancer the sentinel-node procedure
is still in a preliminary stage of evaluation. Different tech-
niques of tracer injection have been proposed; however, there
is no consensus about the most accurate method for identify-
ing the sentinel node. Cervical and intramyometrial subsero-
sal injections are safe and simple, but probably do not reflect
the expected endometrial cancer lymphatic drainage. Also
the detection rate is low. Hysteroscopical injection might bet-
ter reproduce the drainage of the tumour; however, this is
complex, costly, and also shows a high variability in detection
rate. Different studies showed identification rates varying
from 45% to 100% [10]. Recently transvaginal ultrasound-
guided myometrial injection of the radioactive tracer was
suggested as a safe, feasible method for sentinel-node
detection [11].
In conclusion, GROINSS-V and GOG173 have provided ade-
quate evidence for the safety of sentinel-node detection in se-
lected early-stage vulvar cancer patients. The sentinel-node
procedure is now part of standard therapy in vulvar cancer
patients with a unifocal tumour <4 cm with no palpable
lymph nodes. Only in the hands of an experienced multidisci-
plinary team should the procedure be considered safe. In cer-
vical cancer, the sentinel-node procedure seems a promising
tool, especially in patients with tumours 62 cm and when
bilateral drainage is found. The results of a large randomised
trial comparing sentinel-node biopsy to sentinel-node biopsy
plus lymphadenectomy are expected in a few years. In endo-
metrial cancer, studies are still evaluating the best diagnostic
method.
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Best management of locally advanced inoperable
breast cancer
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Locally advanced breast cancer (LABC) is a heterogeneous
disease; it includes disease which is either extensive within
the breast and/or in ipsilateral nodal areas. These cancers
vary widely in biological characteristics and clinical behavior,
ranging from locally aggressive but systemically ‘‘indolent’’, to
de novo generalised disease. LABC includes: (1) large breast tu-
mours (>5 cm in diameter); (2) cancers that involve the skin of
the breast or the underlying muscles of the chest; (3) cancers
that involve multiple local lymph nodes (those located in the
arm pit or the soft tissues above and below the collar bone)
and (4) inflammatory breast cancer (IBC). The clinical man-
agement of LABC is complex and should be tailored to the
individual patient, according to the biological features of the
disease. A multidisciplinary approach is recommended com-
bining systemic therapy (chemotherapy and/or hormone
therapy and biological agents) and in some cases radiother-
apy. LABC is reported to occur in 10–15% of all new primary
breast cancer diagnoses [1]. At least 20–30% of women with
breast cancer wait more than 8 weeks from the initial symp-
tom(s) until they seek clinical assessment [2,3]. Richards et al
reported a 12–19% decrease in 5-year survival in those women
with delays of 3 months or more versus those with a shorter
time to diagnosis [4]. The following factors have been cited
as causes of patient delay: poor access to health care, lack
of preventive health-care habits, increasing age, having child-
care/elder care obligations, notion that the symptoms are be-
nign, poor education, misperception of risk, embarrassment,
fear of chemotherapy and breast loss and concern about
being a hypochondriac and pessimist about survival [3–5,6].
IBC is an aggressive disease that progresses rapidly and car-
ries a very grim prognosis. It is characterised by erythema, ra-
pid enlargement of the breast, skin ridging and a
characteristic ‘‘peau d’orange’’ appearance of the skin sec-
ondary to dermal lymphatic tumour involvement. Although
a palpable tumour may not be present, about 55–85% of pa-
tients will present with metastases to the axillary or supracla-
vicular lymph nodes. Accurate diagnosis is critically
important, as multimodal therapy can significantly improve
outcomes if instituted early enough. The treatment of LABC
is complex, and to complicate matters further, when it ap-
pears as a recurrent disease it can be considered as a ‘‘moving
target’’ since previous treatment delivered in the adjuvant set-
ting may affect treatment choice at recurrence.
Patients with stage IIIB or IIIC disease – including those
with IBC and those with isolated ipsilateral internal mam-
mary or supraclavicular lymph-node involvement – are often
inoperable. Patients with stage IIIB or IIIC disease who re-
spond to primary chemotherapy should be treated until the
response plateaus or to a maximum of six cycles (minimum
four cycles), after which several case series have demon-
strated that locoregional control is improved [7–12]. The loco-
regional management of patients with stage IIIC disease who
respond to chemotherapy is unclear and should be individu-
alised. In the absence of evidence on this subgroup of pa-
tients, it is reasonable that they receive locoregional
radiotherapy (including nodal irradiation). The role of com-
pletion mastectomy should be individualised and based on
technical and disease factors. Following the completion of
chemotherapy, pre- or postmenopausal patients with locally
advanced (operable and inoperable) hormone-responsive tu-
mours should receive endocrine therapy according to their
menopausal status. Patients with HER2-positive breast cancer
who received chemotherapy in combination with trast-
uzumab should receive trastuzumab maintenance therapy.
In the case of inflammatory breast cancer the role of anti-
angiogenic agents has been explored in either HER2-positive
or -negative disease. Inflammatory breast cancer is character-
ised pathologically by high vascularity and increased micro-
vessel density because of the high expression of angiogenic
factors such as vascular endothelial growth factor (VEGF).
Use of bevacizumab, a VEGF-targeting monoclonal antibody,
resulted in substantially improved progression-free survival
and response in patients with advanced breast cancer and
showed neoadjuvant activity in patients with previously un-
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treated locally advanced breast cancer or IBC. In a recent
study, neoadjuvant treatment with bevacizumab, trast-
uzumab and chemotherapy was efficacious and well tolerated
in patients with previously untreated primary IBC [13–15].
Treatment of LABC and IBC requires a coordinated multidisci-
plinary approach that should be individualised depending on
tumour characteristics and response to treatment. The treat-
ment may include a combination of chemotherapy, endocrine
therapy, biological therapy and radiotherapy. While the prog-
nosis in these cases is poor compared with that for other pre-
sentations of breast cancer, a reasonable survival and quality
of life can be obtained with a team approach to treatment. All
patients with LABC and IBC should be considered candidates
for clinical trials to evaluate the most appropriate fashion in
which to administer the various components of multimodal-
ity regimens.
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Cancer invasion and resistance
Anna Ha¨ger a, Stephanie Alexander b, Peter Friedl a,b,c,*
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Preclinical microscopy has greatly enhanced our mecha-
nistic understanding of cancer invasion and metastasis,
the contribution of the tumour microenvironment to meta-
static progression, and how invasion and the microenviron-
ment jointly support cancer cell survival and resistance.
Using organotypic models in vitro, live-cell imaging in
three-dimensional (3D) tissue culture has identified how
cytoskeletal, adhesion and protease systems drive invasion
and metastasis [1]. When altered at the molecular level,
these pathways underlie the unexpected diversity of the
invasive process [2]. The recent use of intravital microscopy
has further suggested that cancer invasion into interstitial
stroma in vivo: (1) occurs mostly as collective invasion in
which cells remain coupled to neighbouring cancer cells,
(2) is guided by and responsive to signals delivered by con-
nective tissue structures and (3) that invasion pathways
cross-talk with pathways of cancer cell survival and resis-
tance to anticancer therapy [3].
1. Principles of collective cell invasion
Collective cell migration is defined as the movement of multi-
ple cells that retain cell–cell contacts, coordinate their actin
dynamics and intracellular signaling, and thereby form a
structural and functional unit for joint translocation [1,4]. In
contrast to single-cell migration, moving cell masses remain
mechanically coupled by cell–cell adhesion receptors, most
notably of the cadherin and integrin families, and form a
coordinated cortical structure of the actin cytoskeleton, occa-
sionally referred to as a ‘super-cell’ [4]. Besides cancer inva-
sion and metastasis, collective cell movement contributes to
cell migration in morphogenesis and tissue repair [5], sug-
gesting homologous underlying mechanisms.
As in all known types of actomyosin-based cell migration,
collective migration is plastic, i.e. it undergoes modification
with altered intracellular signaling or an altered environment
[2]. Interference with molecules that maintain or regulate
collective cell behaviour can lead to single-cell detachment.
Depending on the type of single-cell migration obtained after
dissociation, two types of conversion are currently known:
the epithelial–mesenchymal transition (EMT) and the collec-
tive–amoeboid transition (CAT). EMT is a well established
molecular process that leads to the down modulation of
cell–cell adhesion, whereby the migration machinery remains
intact, which induces cell detachment and scattering from
multicellular groups [1] (and references therein). Mechanisms
that enable single-cell detachment include reduced cadherin
expression, loss-of-function mutations in cadherin and cate-
nin [mit Leerzeichen ersetzen] signaling pathways, and
deregulated function of proteases degrading cadherins and
other cell–cell adhesion molecules [4]. In vivo, EMT corre-
sponds to the loss of differentiated epithelial morphology in
usually small regions towards a sarcomatous, stromal and,
hence, invasive and likely metastatic phenotype. CAT is the
transition from collective invasion to amoeboid single-cell
crawling after simultaneous weakening of cell–cell and cell–
ECM interactions, such as after EMT-independent down-regu-
lation of cadherins (data not shown) or inhibition of b1 inte-
grins in collectively invading melanoma explants [5] and in
tumour xenografts in vivo (data not shown). Detached cells
then survive, continue to move via amoeboid shape change
(similarly to interstitial migration of amoeboid leukocytes
[6]), and eventually cause distant metastasis (S. Alexander,
MD Anderson Cancer Center). These findings suggest that
collective migration represents an invasion mode of high cel-
lular and molecular order that, after loss of function of partic-
ular adhesion pathways, interconverts to single-cell
dissemination and metastasis. The understanding of the sig-
nals maintained by simultaneous cell–cell and cell–matrix
communication during collective invasion and secondary
plasticity will be important in defining the cross-talk between
strategies of invasion and resistance signaling [3].
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2. Intravital multiphoton microscopy of
collective cancer invasion in vivo
Multiphoton microscopy (MPM) has become the method of
choice for investigating cell structure and function in tissues
and organs, including the invasion and progression of cancer
lesions [7]. Particularly suited for cancer research is infrared
multiphoton microscopy, which enables deep tissue penetra-
tion and detects multicellular, collective invasion of mela-
noma and soft-tissue sarcoma lesions in vivo [8]. Recent
evidence from intravital microscopy further suggests that col-
lective invasion is strongly associated with resistance to radi-
ation therapy and chemotherapy.
3. Joint mechanisms of cancer invasion and
resistance
Based on the multiple inputs from the tumour microenviron-
ment and their overlapping signaling pathways, invasive tu-
mour-cell migration and resistance are now considered as
interconnected cell functions. To gain deeper insight into
the steps and niches of concurrent resistance and dissemina-
tion, preclinical animal models followed by time- and space-
resolved molecular imaging are necessary to detect tumour
responses to therapy at a cellular level. The signals required
for both single-cell and collective cancer invasion include
the activation of integrins, cadherins, small GTPases Rac
Fig. 1 – Signaling pathways controlling tumour cell growth, survival and invasion. Example pathways of p53, Ras GTPase,
small Rho GTPases, integrins, growth factor receptors and cadherins with a dual role in controlling cell growth (upper row)
and survival as well as cell migration and invasion (lower row). Migration effectors are marked in pink, survival effectors in
purple, signaling hubs in bright green. Arrows indicate signaling direction. Bound to DNA, transcription factors. Figure taken
from Ref. [3]. a-Act., a-actinin; cat, catenin; Cdc42, cell division cycle 42; CREB, cAMP response element-binding; CyclD1, cyclin
D1; eIF, eukaryotic initiation factor; ERK, extracellular signal-related kinase; ETS, erythroblast transformation specific
(transcription factor); FAK, focal adhesion kinase; GEF, guanine nucleotide exchange factor; GFR, growth factor receptor; GRB2,
growth factor receptor-bound protein 2; ILK, integrin-linked kinase; Integ., integrin; JNK, Janus-kinase; MEK, mitogen-
activated protein kinase/extracellular signal-regulated kinase kinase; MEKK, MEK kinase; mTOR, mammalian target of
rapamycin; MLC, myosin light chain; MLCPtase, MLC phosphatase; MRCK, myotonic dystrophy kinase-related Cdc42-binding
kinase; NFjB, nuclear factor ‘kappa-light-chain-enhance’ of activated B cells; PAK, p21-activated kinase; PINCH, particularly
interesting Cys–His-rich protein; PKC, protein kinase C; PLCc, phospholipase c; PI3K, phosphoinosid-3-kinase; PTEN,
phosphatase and tensin homologue; ROCK, Rho-activated kinase; STAT, signal tranducer and activator of transcription;
TIAM1, T-cell lymphoma invasion and metastasis 1; Vinc, vinculin; WASP, Wiskott–Aldrich syndrome protein; WAVE; WASP
family Verprolin-homologous protein. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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and Rho, as well as Ras pathways, and the engagement of
intracellular signaling networks that include PI3K, mTOR,
Src and Map kinases (Fig. 1). Consequently, druggable signal-
ing hubs that may serve to target both tumour invasion and
resistance include growth factor and chemokine signaling,
integrin engagement, as well as downstream Ras/MAPKs,
PI3K and mTOR signaling. Thereby, the residual niches that
withstand targeting of conventional therapy can consist of a
limited number of cells which, after surviving cycles of thera-
pies, regrow, initiate migration and thereby re-establish an
invasive tumour.
4. Outlook
Collective invasion types contribute and provide particular
challenges to the progression and therapy of cancer disease.
The cell mass likely produces high autocrine concentrations
of promigratory factors and matrix proteases. Because many
cells move as one functional unit, cells of different clonal ori-
gin or different biological abilities may be linked and invade
together (‘mixed clone’ behaviour). Furthermore, it can pro-
tect inner cells from immunological assault through cytotoxic
lymphocytes. As a particular challenge, the joint signaling
from tissue structures and cell–cell junctions may activate
survival pathways not engaged in quiescent, non-invading tu-
mour regions. Thus, preclinical in vivomicroscopy will enable
both fascinating insight into the basic mechanisms of cancer
biology as well as advance preclinical validation of drugs and
the identification of resistance mechanisms.
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1. Background
Much development in nursing care is not based on research
but is created from the ideas of health-care professionals,
for instance, about benefit for patients. One example is case
management (CM), where newer models focus on transitions
in the health-care system and have a holistic and empower-
ing approach to information, coordination and other kinds
of support needed by the patients [1]. Within CM, nurse nav-
igation (NN) is an innovation in which availability also charac-
terises the model [2,3].
2. Aims
We were keen to investigate who could benefit from the help
on offer and what significance female cancer patients attach
to NN.
3. Methods
A longitudinal phenomenological–hermeneutical study was
carried out among 21 consecutively included women. They
were referred on suspicion of gynaecological cancer and were
followed by first author form the referral had reached a uni-
versity hospital in Denmark and 3 months ahead. The women
were offered help from one of two female NNs from a surgical
department, from the time of referral and until they were re-
ferred further or hospitalised for cancer surgery. The method
has been thoroughly described elsewhere [4–6] and includes
patient diaries, observational studies and semi-structured
interviews, where women made graphical representations
of their emotions over time as visual aid to their memory
[6]. From verbatim transcriptions, an open-minded analysis
on three analytical levels, inspired by Riceour [7], leads to a
comprehensive understanding.
4. Findings
An overlap was found between women’s experiences of their
relationship with the health-care professionals before com-
municating with the NN, and the subsequent significance an
NN had for the women. Important themes were trust and
guarded trust [4]. Moreover, although the women said that
they were anxious, and to various degrees felt ignorant and
feared death, an NN could have or not have a special mean-
ing, and this meaning could be either positive or negative
[5] (Table 1).
5. Comprehensive understanding and
discussion
Each woman had benefit of having a specific health-care pro-
fessional, whom she trusted could and would help her
through the course of her cancer. If the woman did not have
such a relationship with a health-care professional at the time
of referral, the woman could use the trusting relationship the
NN offered. Trust, guarded trust or distrust towards another is
created primarily from our interpretations of the other’s non-
verbal signals, where we judge whether the corresponding
person behaves as expected [8]. A health-care professional’s
efforts to maintain or gain patient’s trust therefore requires
a kind of cultural sensitivity, which is tested every day and
the test is not always passed, if trusting patients are the goal.
On the one hand, offering an NN in cancer care can therefore
be seen as a patch on a system which is not functioning opti-
mally, but on the other hand we can ask whether optimising
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communication by health-care professionals can remove all
the patient’s needs for extra help from an NN.
When help from the NN became useful for the women, the
women’s descriptions were similar to those of close providers
(see Table 1). The women were aware of the period of avail-
ability of the NN, but nonetheless they still expected her
attention. When this was in vain, the patients became disap-
pointed and felt rejected and let down. This cannot be ex-
plained solely by patients’ wishes for continuity in care.
Bowlbys’ attachment theory [9] explains that in a period
where death was felt as a possible close event, the NN offered
herself as a special caring figure – an attachment figure – with
high levels of availability, knowledge and help. The referred
woman without a health-care professional attachment figure
started making emotional bonds with the NN. Therefore, a
further referral, for instance, which changed the NN’s mode
of action, would feel very harsh, although the woman ratio-
nally knew that the NN was no longer available. Cancer pa-
tients have various degrees of critical periods in the course
of their cancer [10], and should emotional bonds to an NN
have to be terminated, we recommend that health-care pro-
fessionals consider both the timing and ways to do this.
Our results cannot be generalised but are rather trans-
ferred to similar places.
6. Conclusion
Women’s trust and guarded trust in health-care professionals
are key points in relation to the use of an NN, but we do not
know how to find those who need the extra effort. Moreover,
the NN might become an attachment figure for the individual
woman, and sustain special importance. Therefore, it must be
considered whether health-care professionals in general
should increase their focus on communication, in combina-
tion with offering an NN to the patients for a longer duration
of time, if possible in a never-ending attachment.
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Table 1 – Significance of women who choose or do not choose help from a nurse navigator (NN), and the significance they
attach to the NN.
Awoman’s experience of the relationship with the health-
care professionals before communication with an NN4
The significance female cancer patients attached to an NN
Trusting that a health-care professional among the close
relatives can and will help
No special meaning. The NN was a nurse in the crowd of
nurses and her help was not useful outside the outpatient
setting
Trusting that a known physician can and will help
Not fully trusting that a known health-care professional
can and will help. The women felt guarded trust in one or
more health-care professionals of special importance
Guarded trust followed the women’s interpretation of non-verbal
signals from a physician they counted on in relation to their own
health. Such interpretations were always told as the women’s
latest experiences with an important physician before the contact
to the NN
A special person providing useful help, also after the initial
outpatient setting [5]
In the periodwith an available NN the women felt a special
affinity with the NN and the women felt that the NN was:
– Trustworthy, knowledgeable and someone special, who
as an easily accessible health-care professionalwas nice
and helpful to act immediately, inform, support, reas-
sure and provide an overview and empowermentIn the
period after an available NN thewomen felt the NN was
– Disappointing, failing and repelling
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Nutritional status in relation to treatment
modalities
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1. Influence of nutritional status on
chemotherapy and radiotherapy
The prevalence of disease-related malnutrition in patients
with cancer ranges from 40% to 80%, which is the highest of
all hospital groups. This variation in prevalence is the result
of the different definitions of malnutrition used, and it also
depends on tumour type, stage and anticancer treatment.
Malnutrition is associated with negative outcome, including
increased morbidity, poor prognoses and tolerance to treat-
ment, decreased quality of life and increased health-care
costs [1]. Head and neck cancer patients who experience a
weight loss >20% of their total body weight during or
following radiotherapy are at an increased risk of toxicity
and mortality. Stage 3 or 4 disease and smoking more than
20 cigarettes a day should be reason enough for early enteral
feeding. A prophylactic percutaneously placed endoscopic
gastrostomy (PEG) feeding tube is also beneficial when there
is pretreatment weight loss [2].
Nutrition screening is the process of identifying patients
with characteristics commonly associated with nutritional
problems that may require full nutritional assessment.
Screening can be applied to all patients. The malnutrition
screening tool (MST) is a validated, quick and simple nutrition
screening tool. The patient-generated subjective global
assessment (PG-SGA) can be applied for a full nutritional
assessment [1].
The identification of baseline risk factors to assess a
patient’s fragility or ability to tolerate treatment is desirable
to predict outcome of chemotherapy toxicity, not only for
medically unfit patients but also amongst patients with an
apparently good medical condition, since the high inter-indi-
vidual variability in drug exposure remains an unresolved
issue. Chemotherapy-induced DNA damage might become
more cytotoxic to normal tissue in the presence of perturba-
tions of the cellular immune response because of high protein
catabolism and stimulation of acute-phase protein responses
(APPRs). The nutritional and inflammatory status (NIS)
appears to correlate with increased risk of severe haematolog-
ical toxicity following anticancer chemotherapy. This status
takes in account (1) C-reactive protein, (2) alpha-1-acid
glycoprotein, (3) albumin and (4) prealbumin: NIS = (1 · 2)/
(3 · 4) [3].
Malnutrition has been associated with changes in drug
disposition, including changes in absorption, protein binding,
hepatic metabolism and renal elimination. In malnourished
patients reduced concentrations of plasma proteins may
significantly increase the likelihood of toxicity from the
administrations of agents that are highly protein-bound, such
as prednisolone, etoposide, teniposide, cisplatin, paclitaxel
and SN-38 [4].
Anticancer treatment can induce a poor nutritional
status by inducing nausea, vomiting and anorexia and
gastrointestinal disorders as mucositis and diarrhoea [4].
Reversible lactose intolerance – associated with diarrhoea,
flatulence and poor nutritional status – is not infrequent
in patients treated with chemotherapy based on 5-fluoro-
uracil (5-FU). Hypolactasia can easily be diagnosed with a
lactose tolerance test. Dietary lactose restriction might
improve tolerability of treatment [5]. Malabsorption may
be caused not only by fluorouracil but also by other drugs
affecting cell proliferation such as thioguanine, methotrex-
ate, vinca’s alkaloid, actinomycin D, hydroxyurea and
daunomycin [6].
2. Influence of nutritional deficiencies on
chemotherapy and vice versa
Trace elements consist mostly of metal ions which act mainly
as basic components of essential enzymatic systems or pro-
teins that play major roles in the physiology of the gastroin-
testinal tract (Jackson, 1989). Studies suggest that trace
elements serve as cofactors in several metabolic pathways,
and a decrease in their concentration may facilitate the mal-
nutrition process that takes place in cancer patients. Negative
acute-phase reactants such as selenium and zinc are de-
creased in cancer patients, whereas serum levels of copper
are increased. Selenium deficiency may interfere with
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free-radical-mediated damage. Zinc regulates the function of
cytochromes, stabilizes plasma membranes, reduces lipid
peroxidation and has a role in the detoxification of ammonia.
A deficiency in zinc potentiates the toxicity of other metals
and decreases the plasma values of vitamin A. Supplementa-
tion of these trace elements can delay cachexia with its con-
sequent depression of the immune system, influencing the
neoplastic process and the success of chemotherapy [7].
Cetuximab, a monoclonal antibody against the epithelial
growth factor receptor (EGFR), can induce an inappropriate
urinary excretion of magnesium through the inhibition of
reabsorption of magnesium in the ascending loop of Henle,
since EGFR is strongly expressed in the kidney [8]. This leads
to symptomatic hypomagnesaemia, a side effect also com-
monly known to be associated with the use of cisplatin.
Cachectic patients with decreased dietary carnitine uptake
may develop carnitine deficiency when treated repeatedly
with chemotherapies that include cisplatin. They have a ten-
fold increase in renal carnitine excretion [9].
Pemetrexed, a multitargeted antifolate, is associated with
life-threatening toxicity, especially myelosuppression, if not
administrated after supplementation with folic acid and vita-
min B12. One week prior to commencing pemetrexed, folic
acid (0.5 mg by mouth each day) and vitamin B12 (1 mg by
intramuscular injection every 9 weeks) should be given [10].
3. Influence of nutritional supplements on
chemotherapy
More than 80% of the patients with cancer surveyed in 2000 in
the United States reported using complementary and alterna-
tive medicine (CAM) [11]. While the body of literature related
to the use of CAM is growing, the extrapolation and applica-
tion to patient care remain complex. Clinicians must estab-
lish whether the supplement is an antioxidant, is an
anticoagulant or procoagulant, has immunosuppressive or
immunomodulatory properties, has hormonal properties,
has known safety issues and has known or theoretical drug
interactions [12].
Antioxidants represent one of the largest categories of die-
tary supplements. Reactive oxygen species (ROSs) are a natu-
ral consequence of living in an aerobic environment.
Oxidative stress occurs when natural defence systems are
inadequate to combat the production of ROSs. Antioxidants
could be protective against the adverse effects of chemother-
apy, but some of these agents rely for their antineoplastic
activity on the production or interaction with ROSs. Agents
with a high reliance on ROSs for their antineoplastic activity
are alkylating agents and mitomycin C. Mitoxanthrone is less
likely to be dependent on ROSs.
The use of dietary supplements with anticoagulant proper-
ties, alone or concomitantly with conventional anticoagulants
or antiplatelet medication, may pose a risk for bleeding due to
additive or synergistic effects on the coagulation pathway.
Agents with coumarin constituents – such as angelica root,
agents that inhibit platelets such as panax ginseng, agents
with salicylate constituents such as black cohosh, garlic, gink-
go, saw palmetto – may increase the risk of bleeding. Supple-
ments with procoagulant properties should be avoided with
hormonal treatments such as tamoxifen, andwith erythropoi-
etic growth factors, estramustin or thalidomide.
4. Conclusion
Nutrition and nutritional status are influenced by the pres-
ence of cancer but also have an important influence on anti-
cancer treatment and treatment outcome. It is important that
the oncologist has an insight into the possible interactions
and complications that nutritional agents may havewith che-
motherapeutic agents.
The ability to identify and locate reliable information
regarding dietary supplements is vital.
The use of more than one reference is necessary to com-
plete the analysis of dietary supplements for a patient. Coun-
selling patients with cancer about dietary supplements
requires a systematic thought process that considers the
available theories and data, as well as the patient’s views
about these agents [13]. More attention should be paid to pa-
tient nutritional status, and cooperation with a dietician is
essential in the care of the cancer patient.
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1. Introduction
One of the biggest risk factors for the development of breast
cancer is age, and over 40% of all breast cancers diagnosed
are in women aged 65 years or older [1]. Despite this, there
are few standardised guidelines for the management of older
breast-cancer patients, primarily due to the lack of level-I evi-
dence and the lack of representation of older women in adju-
vant therapy trials. Thus clinicians are often required to make
treatment decisions for elderly patients in the face of uncer-
tainty. This often leads to undertreatment, or less frequently,
overtreatment of elderly patients, with resultant poorer
outcomes.
In order to address this issue, a task force created by the
International Society of Geriatric Oncology (SIOG) and the
European Society of Breast Cancer Specialists (EUSOMA) has
developed a set of evidence-based guidelines for the manage-
ment of breast cancer in elderly individuals [2]. It is important
to note that these guidelines are predominantly applicable
only to elderly patients who are fit, rather than those who
are less fit or frail, due to the scarcity of data relating to treat-
ment of this latter group. Key recommendations are summa-
rised as follows.
• For an older individual with breast cancer it is critical that
all management decisions take into account physiological
age, life expectancy, potential risks versus absolute bene-
fits, treatment tolerance, patient preference and potential
barriers to treatment.
• Elderly breast-cancer patient management should involve
collaboration between geriatricians and oncologists.
Elderly patients are at higher risk for competing comorbid-
ities, which may not be evident on oncological assess-
ment. Comprehensive evaluation of functional status
with a multidomain geriatric assessment (CGA) is ideal,
although this may not be possible in all patients. Alterna-
tively, it is reasonable to perform a functional screening
assessment to identify which patients are at increased risk
for functional deficits on the extended CGA. In patients in
whom reversible functional deficits are detected, proactive
management of these can improve quality of life and sur-
vival. Similarly, identification of interval decrease in func-
tional status through the use of repeated geriatric
assessments allows appropriate intervention and poten-
tially improved outcomes.
2. Early breast cancer
• Surgical options for patients 70 years or older should be
equivalent to those of younger patients, with age itself
not an indication for less-than-standard surgical manage-
ment. In some older patients it might be reasonable to
omit either sentinel lymph-node biopsy or completion
axillary lymph-node dissection, though this is an area of
ongoing debate.
• All elderly patients undergoing breast-conserving surgery
should be offered whole breast irradiation as a means to
significantly reduce local relapse rates. Elderly patients
with high-risk tumour (T3–4 or at least four lymph nodes
involved) should be considered for post-mastectomy
radiotherapy.
• Treatment of estrogen-receptor (ER) positive breast cancer
with endocrine therapy alone is a suitable treatment strat-
egy only in an elderly individual who has a limited life
expectancy (less than 3 years), who is considered unfit
for surgery after optimisation of medical conditions, or
who refuses surgery. Geriatrician input to guide the man-
agement of comorbidities and to accurately assess life
expectancy is strongly recommended.
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• Tamoxifen and aromatase inhibitors have similar efficacy
in older as in younger patients and are recommended as
initial adjuvant hormone therapies. The choice between
tamoxifen or aromatase inhibitors should be made by bal-
ancing the slightly higher efficacy of aromatase inhibitors
with the increased vulnerability of elderly patient to their
toxicities. For patients who commence on tamoxifen, a
switch from tamoxifen to aromatase inhibitor after 2–
3 years should be considered on the basis of treatment tol-
erability. Similarly, for healthy elderly patients, extended
endocrine therapy with an aromatase inhibitor after
5 years of tamoxifen is reasonable. In elderly patients with
very low-risk tumours (pT1aN0) or severe comorbidities,
the risks and toxicities of endocrine therapy may outweigh
the benefits; in these circumstances it may be reasonable
to omit adjuvant endocrine therapy.
• Fit elderly patients gain as much benefit as younger
patients from adjuvant chemotherapy. Chemotherapy
decisions should be made based on potential benefits,
which are highest in node-positive, hormone-negative dis-
ease, compared with risks and toxicities. Four cycles of an
anthracycline-containing regimens are usually preferred
over cyclophosphamide methotrexate 5-fluorouracil
(CMF). Substitution of anthracycline with taxane is also a
reasonable option to reduce the risk of cardiac toxicity.
• Adjuvant trastuzumab in combination with chemotherapy
should be offered to all elderly patients with HER2-positive
breast cancer, without cardiac disease, and who are suit-
able for chemotherapy treatment. Use of single-agent
trastuzumab in patients not suitable for chemotherapy
might be an option, although limited outcome data are
available in support of this approach.
3. Metastatic breast cancer
• Chemotherapy is indicated for ER-negative, hormone-
refractory, or rapidly progressing disease.
• Single-agent chemotherapy is generally preferred,
although oral combination chemotherapy is also a reason-
able option in elderly patients. There is no good evidence
in support of routine dose or schedule modifications in
elderly patients. However, this may be appropriate in cer-
tain circumstances, based on the known toxicities and
pharmacology of the chemotherapy agents coupled with
comorbidities in the patient.
• All patients with human epidermal growth factor receptor
2 (HER2) positive disease should be offered HER2-targeted
therapy. In fit elderly patients, anti-HER2 therapy should
be given in combination with chemotherapy. Anti-HER2
therapy plus endocrine therapy is a reasonable treatment
option in patients with HER2-positive ER-positive disease
in whom chemotherapy is contraindicated. Similarly
patients with HER2-positive ER-negative disease who are
not suitable for chemotherapy may be candidates for trast-
uzumab monotherapy.
• While bevacizumab has demonstrated benefit in terms of
improved progression-free survival in both elderly and
younger patients alike, concerns regarding both toxicities
and cost efficacy make its place in elderly breast cancer
management uncertain.
Increased comorbidities and polypharmacy are both more
common in elderly patients. Additionally, physiological age-
ing can be associated with altered pharmacokinetics (drug
absorption, distribution, metabolism and excretion). Each of
these factors can affect the efficacy and toxicity of anti-can-
cer agents, making it critical that drug prescription in elderly
patients be done with care. Eliminating or reducing the risk of
drug interactions is best achievedwith a thoroughmedication
review before making any treatment decisions.
Poor compliance or non-compliance with oral anti-cancer
medications is not uncommon in older breast-cancer patients
[3–5] and can lead to reduced efficacy of therapy. It is impor-
tant to consider causes of non-compliance, which may often
include poor tolerability of treatment. Thus, close adverse-
event monitoring and addressing specific toxicity concerns
and side-effects are crucial to improve compliance, treatment
tolerability and efficacy.
Older breast-cancer patients often rely more strongly on
the recommendation of the cancer specialist regarding breast
cancer management decisions; however, it is important to
recognise that some older patients may wish to take a more
active role in decision-making. While older patients are as
likely to accept therapy as younger patients, they may be less
willing to risk deterioration in quality of life for a potential
improvement in survival [6]. For this reason, careful and clear
discussions regarding diagnosis, prognosis and treatment op-
tions, as well as expectations of treatment and potential tox-
icities, are essential.
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Mechanisms of treatment-related symptoms in
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Despite significant gains in our understanding of cancer
biology, this progress has not matched what we know about
the biology underlying the symptoms and toxic effects that
therapies produce. These adverse symptoms can cause sub-
stantial discomfort, functional loss and distress to patients;
they limit treatment tolerability, and can persist indefinitely
in post-treatment survivorship [1]. Effective control of treat-
ment-related symptoms could enhance therapeutic out-
comes by improving patient health status, minimising
toxicities that impair function, increasing adherence to cura-
tive treatments, maintaining health-related quality of life and
potentially increasing survival. A mechanistic understanding
of treatment-related symptoms would be of benefit in drug
development, drug evaluation and early integration of appro-
priate supportive care in treatment planning. This presenta-
tion will present steps in a translational pathway for
understanding and controlling treatment-related symptoms
Cytotoxic therapies (chemotherapy, radiation) are ex-
pected to produce symptoms, because normal tissue and
function are disrupted as cancer cells are killed. Targeted
anticancer therapies were expected to destroy cancer cells
specifically and therefore to cause less general toxicity, yet
different and often severe toxicities have emerged, with each
novel agent having its own unique toxicity profile
1. A translational pathway for treatment-
related symptoms
The difficulties inherent in translating laboratory findings
into patient benefit are widely recognised in every disease
area. In 2005, the National Cancer Institute created a Transla-
tional ResearchWorking Group to speed the application of the
findings of molecular oncology to patient care [2]. In response,
the working group developed a model for a translational re-
search pathway. Although the model was developed for new
curative therapy, a similar model might be used to conceptu-
alise how to move the collective basic and clinical symptom
research into the clinic. A schematic illustrating such a trans-
lational pathway for symptom research is presented in Fig. 1,
using fatigue as an example [3].
Early components of the pathway include discovery re-
search steps and decision points based on longitudinal obser-
vational studies of patients, including patient interviews and
determination of specific symptoms associated with disease,
stage or treatment. Correlational studies showing the co-var-
iation of biomarkers (such as inflammation) and symptom
expression, although an important step, do not provide suffi-
cient information on the mechanistic basis of symptom pro-
duction for the development of potential agents targeted at
symptom control. Instead, hypotheses about mechanisms
underlying symptom expression are developed through
examination of longitudinal symptom data, clinical corre-
lates, biomarkers (genes, proteins) and brain imaging data ob-
tained from patients. These hypothesised mechanisms are
then tested in animal models. Candidate agents that may af-
fect these mechanisms are developed in the laboratory, then
applied in animal models of the specific disease. Agents that
give some signal of effectiveness in preventing or reducing
the specific cancer without excessive toxicity then move for-
ward into patient research.
For some symptoms, such as bone-related pain, sufficient
progress has been made in animal models to provide a basic
understanding of the mechanisms involved and to test agents
that might have a clinical benefit. In contrast, much less is
known about the development of animal models of such
symptoms as treatment-related cognitive impairment, fati-
gue and treatment-related distress. Animal models of cogni-
tive impairment and reduced motivation are available, but
the effects on these models of having cancer and being trea-
ted for cancer have not been assessed.
Biomedical research is largely dependent on having ani-
mal models of the targets of interest. The same applies to
symptom science, where exploratory and confirmatory stud-
ies in humans can be conducted in parallel in animal models
of symptom translational research in a bedside-to-bench and
bench-to bedside collaboration. Fatigue research is an excel-
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lent example: many of the components of fatigue that pa-
tients describe—lack of motivation, increased cognitive prob-
lems and decreased motivation to be social—can be modelled
in animals, and many are typical components of what is stud-
ied in animals as ‘sickness behaviour’ [4]. Animal models of
disease and treatment-induced cancer pain have suggested
both potential mechanisms of pain development and novel
ways of treating cancer pain. Animal models also are neces-
sary for preclinical testing of symptom agents. Generating
hypotheses about symptom expression can lead to early
phase trials in patients. Animal models that reflect symptom-
atic behaviours in a way that ‘makes sense’ to both patients
and clinicians need to be developed on the basis of patient
self-report of symptom severity and linked to animal behav-
ioural, central nervous system (CNS) and systemic changes
that reflect these symptoms. A critical step throughout the
process is to determine the interaction between pathways
that modulate disease and those that modulate symptoms,
to ensure that symptom control does not compromise cura-
tive benefit.
Cancer-related symptoms are affected not only by treat-
ment but also by individual host characteristics. There is sub-
stantial variation in the degree to which symptoms will
impair patients, much like there is variance in the ability of
a given drug to control cancer. Being able to predict this risk
would benefit personalised cancer care. Potential predictors
of high behavioural toxicity can be studied using advanced
molecular genetic technologies. Analysis of genetic predictors
for symptom occurrence and severity during treatment will
help us to understand the biological basis of symptoms, iden-
tify susceptible individuals, develop tests with prognostic
power, design novel drug targets and predict therapeutic
outcomes.
Finally, methods to reduce treatment-related symptoms
will require early clinical investigation. Too many large-scale
phase III symptom-focused clinical trials have been per-
formed with negative results. Potential reasons for this in-
clude (a) lack of knowledge of the potential mechanisms
producing the symptoms, (b) inadequate preclinical testing
and (c) small early trials in patients to detect a signal. Just
as with curative therapies, early use of adaptive clinical trial
design could be employed to sort among agents that show
promise for mitigating symptoms and to quickly cull those
that do not [5].
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1. Introduction
Multidisciplinary management is the standard of care for
common cancer subtypes, and it is particularly important
for rare cancers such as penile cancer. Often clinical expertise
may have to be concentrated into defined regional or supra-
regional cancer centres; thus patients may have to be treated
at centres distant from their home town. For comprehensive
management of the needs of penile patients, close communi-
cation is needed between the specialist cancer teams and lo-
cal medical services, including community support services,
particularly in the aftercare of surgery, for follow-up and in
the palliative management of end-stage disease.
2. Background (epidemiology, incidence, path
and biology)
Penile cancer is relatively rare, representing about 0.5% of
male cancers. It has an incidence in Western societies esti-
mated at 1:100,000 [1]; a higher incidence is reported in
non-Western societies such as South America, Africa (partic-
ularly Uganda) and Asia. Whilst it is more prevalent in older
men, about 25% of cases are found in men younger than
40 years of age and about 10% in men under 30 years of age
[2].
Predisposing factors include both cultural and religious
practices as well as social and hygienic habits [3]. Of these,
circumcision in newborns and before puberty, together with
good hygiene, is associated with a reduced risk (by 3–4-fold)
of penile cancer. Other risk factors include smoking [4], phi-
mosis, inflammatory conditions such as lichen sclerosus or
balanoposthitis, ultraviolet radiation [5] and the presence of
human papilloma virus (HPV) that is related to sexual
promiscuity. However, there is no clear evidence yet that the
presence of HPV in penile cancer confers a worse prognosis
[6], but rather that it may predict a favourable outcome [7].
The major histopathological subtype is squamous-cell car-
cinoma (SCC), and this entity represents 95% of penile can-
cers. Other subtypes include melanoma and basal-cell
carcinoma. Herein we will concentrate on malignant SCC of
the penis. It has been reported that penile SCC may demon-
strate four different patterns of growth [8] differing in natural
history and prognosis [9]: superficial spreading, vertical
growth, verrucous growth and multicentric growth. This will
be relevant to surgical management to ensure that any surgi-
cal resection adequately encompasses the potential patterns
of spread.
3. TNM (primary tumour, regional nodes and
metastasis) classification
The 2009 TNM classification listed in Table 1 has provided an
update for the T1 category but still suffers from limitations
in the T2 category, where corpus spongiosum involvement
has been reported to be associated with a better prognosis
than corpora cavernosa involvement [10]. Another limitation
of the current TNM system is the lack of differentiation be-
tween T2 and T3 disease. One improvement is that the iden-
tification of retroperitoneal nodal disease is now accurately
regarded as extra-regional disease or distant metastasis
(M1).
4. Prognostic factors
Early diagnosis and adequate staging is crucial to ensure that
management is organised appropriately. Full examination of
thepenisandparticularlyof thesurroundingnodaldrainagere-
gions is needed, as the primary drainage of thepenis is into the
inguinalnodes.Intheclinicallynegativeinguinaltheuseofultra-
sound may identify suspicious nodes suitable for fine-needle
aspiration (FNA). Recent advances and improved techniques
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for sentinel-node biopsy have provided better identification of
the relevant inguinal node(s) and have permitted extraction of
the node for full histological evaluation compared with the
limitationsofusingFNA.
5. Clinical presentation and diagnosis
It is important to make a detailed examination of the penis
with attention to the dimensions and location of the lesion
and its relationship to the musculature of the penis. A deep
biopsy is needed in equivocal cases, with dorsal slitting if
there is a tight phimosis. Full assessment of the regional
drainage regions, i.e., inguinal, is mandatory. If there are pal-
pable nodes, then an FNA with or without ultrasound guid-
ance should be undertaken. Further staging of the pelvis
and abdomen will be needed using a computed tomography
(CT) scan of the thorax, abdomen and pelvis. The role of mag-
netic resonance imaging (MRI) and positron emission tomog-
raphy (PET) staging has not been fully established and
remains under investigation. In clinical cases of negative
inguinal nodes, where there is moderate to high risk of nodal
involvement (PT1 G2), then dynamic sentinel node examina-
tion should be undertaken. The management schema de-
scribed herein provides the policy guidelines followed
within our supra-regional centre, one of the largest services
within the United Kingdom.
6. Management of primary disease
Ta lesions are treated conservatively, usually with circumci-
sion for lesions located over the prepuce, whilst lesions on
the glans can be treated using a wide local excision for smal-
ler lesions, or for larger lesions a total glans resurfacing or
glansectomy.
T1 lesions of the prepuce are treated with circumcision,
while lesions on the glans can be managed by either penis-
preserving surgery or radiotherapy. Penis-preserving surgery
may utilise a wide local excision that may include skin graft-
ing or glansectomy and skin grafting. Radiotherapy may be
delivered using external-beam irradiation or brachytherapy
which is the implantation of radioactive wires within the
vicinity of the extent of the lesion.
T2/T3 lesions of the penis can also be treated conserva-
tively with surgery if there is only distal involvement of the
glans and/or corporal heads, but frozen sections of the resec-
tion margins are needed to ensure adequacy of surgical clear-
ance. The penis-preserving surgical methods include
glansectomy and skin-graft reconstruction, or glansectomy
and distal corporectomy and reconstruction. If clinically
appropriate, penis preservation may also be considered for
proximal lesions. In these cases, delayed reconstruction with
a penile lengthening procedure may be considered. If penis
preservation surgery is not possible, then another alternative
Table 1 – TNM classification of penile cancer.
T Primary tumour
T0 No evidence of primary tumour
Tis Carcinoma in situ
Ta Non-invasive verrucous carcinoma, not associated with destructive invasion
T1 Tumour invades subepithelial connective tissue
T1a Tumour invades subepithelial connective tissue without lymphovascular invasion and is not poorly
differentiated or undifferentiated (T1G1-2)
T1b Tumour invades subepithelial connective tissue without with lymphovascular invasion or is poorly
differentiated or undifferentiated (T1G3-4)
T2* Tumour invades corpus spongiosum/corpora cavernosa
T3 Tumour invades urethra
T4 Tumour invades other adjacent structures
N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No palpable or visibly enlarged inguinal lymph node
N1 Palpable mobile unilateral inguinal lymph node
N2 Palpable mobile multiple or bilateral inguinal lymph nodes
N3 Fixed inguinal nodal mass or pelvic lymphadenopathy, unilateral or bilateral
M Distant metastases
M0 No distant metastasis
M1 Distant metastasis
pN Regional lymph nodes
pNX Regional lymph nodes cannot be assessed
pN0 No regional lymph node
pN1 Intranodal metastasis in a single inguinal lymph node
pN2 Metastasis in multiple or bilateral inguinal lymph nodes
pN3 Metastasis in pelvic lymph node(s), unilateral or bilateral or extranodal extension of regional lymph node metastasis
G Histopathological grading
GX Grade of differentiation cannot be assessed
G1 Well-differentiated
G2 Moderately differentiated
G3–4 Poorly differentiated/undifferentiated
* Ref. [20]
304 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 3 0 3 –3 0 6
is to use radiotherapy as described above, or radical penec-
tomy with perineal urethrostomy.
T4 lesions of the penis often require multimodal therapy
for adequate local control. Down-staging with neo-adjuvant
chemotherapy should be considered. The standard chemo-
therapy is usually a platinum-based regimen, often in combi-
nation 5-fluoro-uracil (5-FU) or capecitabine. The surgery is
a penectomy with perineal urethrostomy. Alternatively,
radiotherapy can be considered for local control in selected
cases.
7. Management of the regional nodes
7.1. Clinically node negative at presentation
G1 Ta to T1 disease: in these cases, those patients with a neg-
ative ultrasound and FNA are at very low risk of nodal disease
and they can safely be observed.
G2 T1 lesions and above or T2 lesions G1-3: those patients
with both a negative ultrasound FNA and dynamic sentinel
node study are managed with surveillance. The surveillance
programme involves clinical 2-monthly follow-up for the first
year, 3-monthly follow-up for the second year and 4-monthly
follow-up for the third year. During each follow-up visit, a full
physical examination of the region is conducted, with ultra-
sound examination of the inguinal regions. A CT scan is
undertaken only where there are specific clinical indications.
For patients in whom the ultrasound FNA or dynamic sentinel
node study is possible, then a modified radical inguinal node
dissection will be performed on the ipsilateral side, with
observation of the contralateral inguinal region. In these
cases, all patients should have a staging CT scan of the tho-
rax, abdomen and pelvis as a baseline, and this should be re-
peated every 6 months for 3 years.
7.2. Clinically node positive at presentation
Those patients with clinically positive nodal disease should
receive a modified radical inguinal-node dissection on the
ipsilateral side and a dynamic sentinel-node study on the
contralateral side. Baseline CT staging is also needed, with
any other imaging based on clinical indications.
Those patients who have been found to have extracapsular
disease involvement should be offered postoperative radio-
therapy to the ipsilateral region. For patients with multiple
or bilateral superficial nodes, then bilateral inguinal-node dis-
section should be performed with consideration of pelvic no-
dal dissection. Postoperative radiotherapy should be offered
in the presence of extracapsular disease involvement of the
inguinal or pelvic nodal regions. Alternatively, if pelvic-node
dissection cannot be undertaken, then external-beam radio-
therapy can be used to cover the regions of risk together with
the inguinal regions of extracapsular disease involvement. If
there is large-volume pelvic disease then consideration
should be directed towards combination therapy using che-
mo-radiation to the pelvis followed by consolidation chemo-
therapy or initial chemotherapy followed by chemo-
radiation to the pelvis. There are currently no evidence-based
data on the most suitable management course or sequence of
therapies in these cases.
Chemotherapy for node-positive or high-risk disease is not
given routinely. Where possible, recruitment into clinical tri-
als of adjuvant therapy is strongly encouraged.
7.3. Fixed or fungating inguinal nodes
In this situation, palliative inguinal-node dissection with
appropriate covering flaps undertaken by a supporting plastic
surgery team should be considered. External-beam radiother-
apy may also be used postoperatively if there is extensive
residual disease or as monotherapy for symptomatic pallia-
tive intent.
7.4. Metastatic disease
The common sites of metastatic penile cancer disease are in
the lungs, liver or nodal regions outside of the pelvis. The
aim of palliative chemotherapy is to limit disease progression
and to improve symptomswith the aim of maintaining a good
quality of life for a good duration. Chemotherapy regimens
are usually platinum-based (cisplatin or carboplatin, depend-
ing on renal clearance) in combination with either capecita-
bine or 5-fluorouracil. Other regimens include the
combinations of carboplatin, methotrexate and bleomycin if
fluoropyrimidines are contraindicated for cardiovascular dis-
ease. Alternatively taxane-containing regimens have been
used. For localised metastatic lesions, palliative radiotherapy
is effective in reducing painful symptoms.
8. Palliative care
Palliative care is an important aspect of management that re-
quires multidisciplinary input as outlined in the introduction.
Integrated coordination between cancer teams and local sup-
port teams is vital and should be initiated early in the course
of management.
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Practical tips and tricks with recently approved
molecular targeted agents in non-small-cell lung
cancer
Stefan Zimmermann, Solange Peters *
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The detection of driver mutations in the epidermal growth
factor receptor (EGFR), the rearrangement of anaplastic lym-
phoma kinase (ALK) genes and the subsequent development
of targeted therapy have transformed the treatment of lung
cancer. In a Caucasian population, as illustrated by the Bio-
marker France database, these alterations represent 9.4%
and 4.0%, respectively, in 10,000 samples of non-small-cell
lung cancer (NSCLC) [1]. Of these patients, 56.9% received
treatment according to their molecular profile, either with la-
belled drugs or in a bio-guided trial. Similarly, the Lung Can-
cer Mutation Consortium, after testing more than 1000
patients with lung adenocarcinoma, found 15% to harbour
an EGFR mutation and 8% an ALK rearrangement [2]. An
actionable driver alteration was detected in 62% of these tu-
mours. The use of targeted therapies has raised practical
questions related to therapy sequences and durations, the
role of chemotherapy, the role of combination with chemo-
therapy, the validity of Response Evaluation Criteria in Solid
Tumours (RECIST) criteria, utility of therapeutic rechallenge
with the same drugs and several additional issues that arise
in the wake of all significant medical progress. This article
will address some of these questions and highlight some
areas of controversy.
2. Whom and when to test?
The College of American Pathologists recommends testing for
EGFR mutations and ALK rearrangements in all patients with
lung adenocarcinoma, irrespective of clinical characteristics.
In the setting of lung cancer resection specimen availability,
EGFR and ALK testing is recommended for adenocarcinomas
andmixed lung cancers with an adenocarcinoma component,
but is not recommended in lung cancer that lacks any adeno-
carcinoma component. In the setting of more limited lung
cancer specimens (biopsy, cytology) where an adenocarci-
noma component cannot be excluded, EGFR and ALK testing
may be performed in cases showing squamous- or small-cell
histology, with clinical criteria such as young age and lack of
smoking history being useful in selecting the subset for test-
ing. Primary tumours or metastatic lesions are considered
equally suitable for testing, and testing of many different
areas within a single tumour is not necessary. For patients
with multiple, apparently separate, primary lung adenocarci-
nomas, each tumour should be evaluated. Testing should be
ordered at the time of initial diagnosis of advanced-stage dis-
ease (stage IV according to the tumour-node-metastasis
(TNM) staging system 7th edition) or at the time of recurrence
or progression in patients who originally presented with low-
er-stage disease. Testing for EGFR should be prioritised over
other molecular markers, followed by ALK, and only later
other molecular markers in lung adenocarcinoma, for which
published evidence is insufficient to support the development
of testing guidelines at the present time [3].
3. When to start treatment?
First-line EGFR tyrosine kinase (TKI) therapy in patients
whose tumour harbours an activating mutation of the EGFR
gene has not translated into prolonged overall survival in four
randomised trials with mature overall survival (OS) data [4–7],
owing to the fact that the vast majority of patients receiving
chemotherapy as first-line treatment received EGFR TKI as
salvage therapy upon disease progression [4–9].
Why do guidelines advocate use of first-line over chemo-
therapy [10]? To start with, EGFR mutational status may be al-
tered under first-line chemotherapy, and selection of patients
for targeted therapy on the basis of molecular testing on the
initial biopsy may be inadequate [11]. Furthermore, in the
randomised trials, up to 41% of patients treated with initial
chemotherapy did not receive second-line EGFR TKI, mostly
because of rapid tumour progression leading to death or re-
duced performance status, thus excluding these patients
form the opportunity to receive the most efficient treatment
[5–7]. Quality-of-life data also favour use of EGFR TKI over
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chemotherapy in first-line treatment. Finally, the high intra-
cranial response rate of EGFR TKIs may defer use of cerebral
radiotherapy in patients with central nervous system meta-
static disease.
ALK TKIs such as crizotinib are being studied for first-line
treatment. Their use is restricted to second and further lines
at the present time. OS has not been reported, and is unlikely
to be improved as the study design allowed for cross-over to
crizotinib in the control arms upon disease progression.
4. Which TKI to choose?
Gefitinib, erlotinib and afatinib have shown significant pro-
longation of progression-free survival (PFS) in the first-line
setting as compared with a platinum doublet. No adequately
powered trial has compared these TKIs. Gefitinib and erlotinib
are both appropriate as first-line treatment, afatinib being
commercially unavailable at the present time with a possible
slightly higher gastrointestinal toxicity.
5. When to stop treatment?
All patients on EGFR TKI ultimately develop acquired resis-
tance, which translates into progressive disease as per RECIST
criteria. However, only a fraction of tumour clones might car-
ry a resistance mechanism, and interruption of TKI therapy
may result in tumour flares. The ASPIRATION trial
(NCT01310036) currently compares PFS evaluated by RECIST
criteria with PFS until ‘progressive disease according to the
investigator’, defined as symptomatic progression, multiple
progression or threat to a major organ. A randomised phase
II trial compared chemotherapy plus erlotinib with chemo-
therapy alone in EGFR TKI-responsive NSCLC that subse-
quently progresses [12]. No improvement in PFS or OS could
be detected, although the number of enrolled patients was
low and the trial terminated early. Improvement in RR but
not in PFS or OS could be shown in a recent retrospective trial
[13]. However, the controversy about continuing EGFR TKI be-
yond progression is ongoing, with promising retrospective re-
sults reported against the switch to chemotherapy [14,15] or
by adding local treatment to TKI [16], or combining TKI with
chemotherapy [17]. The IMPRESS trial is an ongoing phase
III trial expected to clarify the role of TKIs beyond progression.
For progression limited to the brain, local therapy to the area
of progression may lead to prolonged disease control.
6. What to do upon disease progression?
Despite initial activity of EGFR TKIs, all patients eventually de-
velop acquired resistance. The most common mechanism of
resistance is the EGFR T790M secondary mutation, which ac-
counts for 50–60% of cases, and results in increased kinase
affinity for adenosine triphosphate [18]. Second-generation
EGFR TKIs – such as neratinib, afatinib and dacomitinib –
are effective in preclinical gefitinib- and erlotinib-resistant
EGFR T790M models, but to date their delivery in EGFR TKI-
resistant patients have shown disappointing results in the
clinic. Combination of afatinib with cetuximab in EGFR TKI-
resistant patients resulted in a 30% response rate and 75%
disease control rate, with significant gastrointestinal toxicity
[19]. Other mechanisms of resistance include MET amplifica-
tion, with no commercially available inhibitor, HER2 amplifi-
cation potentially amenable to treatment with anti-HER2
monoclonal antibodies or histological transformation to
small-cell lung cancer, which requires cytotoxic chemother-
apy. Additional potential mechanisms of acquired resistance
to EGFR TKIs may develop, including altered EGFR trafficking,
amplification or activation of downstream or overlapping
pathways and expression of drug-efflux transporters. Stan-
dard treatment upon progression on EGFR TKI remains cyto-
toxic chemotherapy. Later rechallenge with EGFR TKI may
result in some modest degree of response (range 4–24%) and
a significant disease control rate (range 45–67%) [20–22].
Resistance mechanisms to crizotinib are multiple, and in-
clude ALK-dominant mechanisms such as resistance muta-
tions and copy number gain, and ALK non-dominant
mechanisms through the outgrowth of clones containing a
separate activated oncogene. In contrast to the EGFR setting,
where the T790M mutation predominates, the spectrum of
ALK resistance mutations is broad. Several distinct second-
generation ALK inhibitors which are potentially efficient in
preventing/overcoming TKI resistance are under develop-
ment. A response rate of 80% has been observed during treat-
ment with LDK378 in patients who had experienced disease
progression after crizotinib treatment [23]. Similarly to EGFR
TKIs, successful later rechallenge with ALK inhibitors has
been reported in case reports [24].
7. What toxicity to expect?
Grade 3 or 4 toxicities occur infrequently with EGFR TKIs, with
the exception of skin rash, fatigue and diarrhoea (13%, 6% and
5%, respectively in the Caucasian European Randomised Trial
of Tarceva versus Chemotherapy (EURTAC) cohort). Grade 1 or
2 toxicities, however, occur in most patients, with rash, fati-
gue and diarrhoea bothering the majority of patients (67%,
51% and 52%, respectively), and with appetite loss, alopecia,
anaemia and arthralgia occurring in a minority of patients
(31%, 14%, 11% and 10%, respectively). Rare but potentially
fatal interstitial pneumonitis occurs in 1% of patients. Overall,
one third of patients require dose reduction or treatment dis-
continuation because of adverse effects [9]. Topical skin care
is mandatory. Systemic antibiotics and anti-diarrhoeal drugs
may be necessary to manage higher-grade toxicity.
Frequent toxicities of the ALK inhibitor crizotinib include
vision disorders (62%), nausea (53%) and diarrhoea (43%). Pa-
tients are less frequently affected by oedema (28%), constipa-
tion (27%), fatigue (20%) decreased appetite (19%), dizziness
(16%) and dysgeusia (12%). Potentially dose-limiting, in-
creased alanine aminotransferase levels occur in 13% of pa-
tients, with less than 5% being of grade 3 or 4. Rapid-onset
low testosterone is common in male patients. Renal cysts
and pneumonitis have been described, but their frequency
is unknown [25,26].
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Role of expert centres in the management
of sarcomas
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1. Introduction
Sarcomas are rare tumours of the connective tissue which
may resemble a variety of tissues – such as muscle, nerve
and bone – although many sarcomas have no normal tis-
sue counterpart. The annual incidence of soft-tissue sarco-
mas (STSs) in England and Wales between 1990 and 2007
was 2300, which equates to about 40 per million per an-
num. Bone sarcomas are significantly less common, repre-
senting only 0.2% of all malignancies. Treatment within
specialised multidisciplinary teams (MDTs) is crucial since
a body of expertise in all areas of diagnosis and treatment
is required to manage them appropriately. Studies have
shown that conformity to approved treatment guidelines
is improved when patients are treated by an MDT in a ref-
erence centre [1].
2. Diagnosis – histopathology, radiology
The risk of a tumour being metastatic at diagnosis, and
of subsequent death, is directly related to tumour size
[2]. Earlier diagnosis could have a huge impact, and guide-
lines are now in place in the UK to encourage early refer-
ral of suspicious lumps (or X-rays in the case of bone
tumours).
Once a tumour is suspected, the two key diagnostic
tools are radiology and histopathology. The initial assess-
ment of suspicious lumps will be by physical examina-
tion and probably ultrasound, followed by core needle
biopsy. Core needle biopsy has an accuracy of >90% as
well as the ability to distinguish high-grade from low-
grade lesions and in most cases the specific sarcoma
subtype [3].
Cross-sectional imaging is required prior to surgery,
in order to plan treatment and for staging. This is
usually in the form of magnetic resonance imaging
(MRI) for the primary disease site and computed
tomography (CT) for staging purposes. It is common
for the diagnosis of patients referred with a diagnosis
of sarcoma to be revised to another subtype, another
disease, or even a benign condition [4]. Reported dis-
crepancy rates between referring and expert patholo-
gists are generally in the order of 25%, with a
benign to malignant discrepancy of 5%.
3. Sarcoma surgery
The primary management of most sarcomas is surgical
excision. Unplanned operations, performed on the
assumption that the ‘‘lump’’ is benign, can make the
eradication of disease much more difficult. A study dem-
onstrated that patients who had unplanned surgery had
a much higher local recurrence rate and poorer long-
term disease control, in spite of definitive surgery and
radiotherapy [5]. All sarcoma operations should be per-
formed in specialised centres in order to ensure opti-
mum outcomes. For retroperitoneal surgery, where
multivisceral resections are common, guidance is avail-
able [6]. The NICE (National Institute for Health and
Care Excellence) Improving Outcomes Guidance (IOG) for
people with sarcoma recommended that specialised cen-
tres should treat a minimum of 100 STS a year and 50
in the case of bone sarcomas. The IOG, which also ad-
dresses wider issues concerning the sarcoma MDT, can
be obtained using the following URL: http://guid-
ance.nice.org.uk/CSG
4. Radiation oncology
Adjuvant radiotherapy improves the local control of high-
grade extremity soft tissue sarcomas [7]. Research continues
into the appropriate timing, dose and field size of adjuvant
irradiation. The complexity of pre- and post-operative radio-
therapy for sarcomas is such that specialised centres are best
placed to offer the appropriate expertise, in the context of the
MDT.
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5. Medical oncology
Chemotherapy for most sarcomas is palliative, but never-
theless valuable. Recent years have seen a significant in-
crease in treatment options and tailoring of treatment to
the individual disease subtype. The standard agents, doxo-
rubicin and ifosfamide, remain useful, but other drugs are
now in routine use, including gemcitabine plus docetaxel
for leiomyosarcoma and pleomorphic sarcoma [8,9], tra-
bectedin for leiomyosarcoma and liposarcoma [10] and
paclitaxel for angiosarcoma [11]. The management of gas-
trointestinal stromal tumour (GIST) was transformed by
the introduction of imatinib [12,13], and subsequently sun-
itinib [14]. More recently another tyrosine kinase inhibitor,
pazopanib, has been licensed for treatment of STS [15].
Certain rarer diseases require special approaches: e.g. the
use of rapamycin analogues for PEComa, imatinib for
chordoma, tamoxifen for fibromatosis and aromatase
inhibitors for endometrial stromal sarcoma.
6. Clinical trials and data collection
Clearly, for such a rare group of diseases it is essential that
care be concentrated in specialised centres which can treat
patients in appropriate clinical trials. These will not be avail-
able in smaller centres, putting patients at a disadvantage.
The cumulative experience of the MDT together with the
amalgamation of clinical and laboratory data also represent
a major resource for research and the opportunity to use
these data directly for the benefit of patients.
7. The wider multidisciplinary team
In addition to surgeons, radiation and medical oncologists,
radiologists and histopathologists, the MDT will have clinical
nurse specialists, physiotherapists, dieticians, palliative care
physicians and site-specific specialists.
As described, the management of sarcomas is truly multi-
disciplinary, increasingly complex and, as more molecular
targets are identified, more likely to be treated with highly
specific targeted therapy. The need for specialised centres
has been recognised in the UK, and a process, informed by
the NICE IOG, is leading to the concentration of care in a lim-
ited number of centres. We hope that earlier diagnosis, fewer
unplanned operations and better integrated care will lead to a
significant improvement in outcomes, which have not chan-
ged over the last 20 years (http://www.ncin.org.uk/publica-
tions/data_briefings/soft_tissue_sarcoma). We can only hope
to do better.
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Therapeutic procedures in liver metastases:
Conventional and future measures
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1. Background
Resection of liver metastases from colorectal carcinoma (CRC)
is associated with 5-year survival rates of 30–40%, with the
possibility of cure, even in the absence of systemic therapy.
This demonstration of a local therapy improving outcomes
for ‘oligo-metastatic’ CRC is well accepted. Long-term survi-
vors have also been reported following resection of liver
metastases from sarcoma, renal-cell carcinoma, breast can-
cer and melanoma, with 5-year survival rates of 23–36% in a
series of non-CRC liver metastases. Resection of neuroendo-
crine liver metastases has also been associated with favour-
able survival.
Stereotactic body radiation therapy (SBRT) is an attractive
option for patients with liver metastases. Liver SBRT re-
quires a planning computed tomography (CT) simulation
scan with intravenous (IV) contrast for target definition.
Multimodal imaging with contrast-enhanced magnetic reso-
nance imaging (MRI) or positron emission tomography (PET)
may improve target delineation. Breathing-related liver mo-
tion should be assessed by respiratory-correlated (or 4D) CT,
cine-MRI or 2D kV fluoroscopy to determine appropriate
planning target volume (PTV) margins. Highly conformal
dose distributions are desirable using multiple beams or
arcs in coplanar or non-coplanar geometries. The nominal
prescribed dose should reflect the isodose that encompasses
the PTV (or 95% of the PTV) with hotspots within the PTV.
Immobilization of the liver using controlled breath holds,
shallow breathing, abdominal compression and gating of
the RT (radiation therapy) beam during specified phases of
the respiratory cycle, medications and tumour tracking of
implanted fiducial markers may help reduce the adverse ef-
fects of breathing motion. Image-guided RT (IGRT) based on
orthogonal imaging, ultrasound or volumetric imaging such
as MV or kV cone beam CT, is required at every fraction in
order to reduce PTV margins for setup uncertainty. MR IGRT
is an area of active research that may benefit patients
requiring liver SBRT.
Advantages of SBRT include increased convenience for
patients. Furthermore, there are preclinical data demon-
strating dose-per-fraction effects (e.g. endothelial and
immune effects), with a threshold of approximately 8 Gray
(Gy). Clinical experience in SBRT for liver metastases is
rapidly increasing.
2. Methods
Updated results from Princess Margaret Cancer Centre
phase I/II studies of SBRT for liver metastases are
presented, as well as a review of previously published
SBRT studies and consensus statements of radiation ther-
apy for liver metastases.
3. Results
In our centre in Toronto, a phase I/II study of individua-
lised IGRT-guided SBRT was conducted in 107 patients
with 172 unresectable or medically inoperable liver metas-
tases from CRC, breast cancer or other primary sites [1].
The median tumour volume was 75 ml. Extrahepatic dis-
ease was present in 40 patients (43%), and 75% had re-
ceived prior systemic therapy. Patients were treated with
six-fraction SBRT (median dose 42 Gy, range 24–48 Gy).
No radiation-induced liver toxicity was observed. Median
survival was 18.1 months. The presence of extrahepatic
disease was associated with worse survival. Prognostic
factors for improved local control included breast primary
site, dose and tumour volume. Some patients with CRC or
breast cancer liver metastases are alive with no progres-
sive disease more than 5 years post-SBRT.
In a subset of patients from the Toronto cohort with
unresectable liver metastases who had kV cone-beam CT
scans at each fraction, the cone-beam CTs were used in
combination with deformable image registration to deter-
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mine the accumulated delivered dose (versus the pre-
scribed dose). Accumulated minimum doses to the GTV
(gross tumour volume) of <35 Gy, 35–45 Gy and >45 Gy, in
six fractions were associated with 18-month local control
of 33%, 55% and 83%, respectively. The dose–response rela-
tionship was steeper for accumulated dose compared with
prescribed dose.
Most published SBRT studies have prescribed doses in the
range 30–60 Gy in 1–6 fractions, for <5 metastases, with max-
imal tumour sizes 66 cm. CRC liver metastases are the most
frequent tumour type. However, an increasing number of pa-
tients with liver metastases from breast and lung cancer are
being included in recent SBRT series. In the published series,
survival rates have been better than those expected following
systemic therapy alone. Toxicity is uncommon as long as en-
ough uninvolved liver can be spared from radiation therapy
(e.g. >700 ml receiving 15 Gy in three fractions or mean liver
dose <18 Gy in six fractions). Local control of the irradiated li-
ver metastases at 1 year ranges from 67% to 100%. The med-
ian survival of patients treated with SBRT ranges from 18 to
37 months, with the best outcomes seen in a more recent
series.
A dose response has been observed in most series, with an
increased chance of sustained local control (80–90% at
2 years) when doses >42 Gy in three fractions are used. Local
control is also improved in patients with metastases <3 cm in
maximal size and in breast cancer metastases compared to
colorectal cancer metastases.
In a pooled analysis of SBRT for CRC metastases [2], dose
was the only significant prognostic factor for local control
and extra-hepatic disease and local recurrence were associ-
ated with impaired survival. A dose of 48–51 Gy in three frac-
tions was estimated to be associated with a 1-year local
control rate of 90%.
An international subcommittee – with members from the
American Society for Radiation Oncology (ASTRO), the Euro-
pean Society for Therapeutic Radiology and Oncology (ES-
TRO), the Canadian Association of Radiation Oncology
(CARO) and the Trans-Tasman Radiation Oncology Group
(TROG) – led by Hoyer et al [3] developed a consensus state-
ment of liver metastases radiation therapy. Ideal candidates
for SBRT were described as patients with good performance
status (ECOG 0–1), possessing adequate hepatic function, with
no extrahepatic disease, having ideally 65 liver metastases
and an uninvolved liver volume P700 ml. As outcomes are
best following higher-dose SBRT, most suitable patients in-
clude those with a focal distribution of metastases, at least
1 cm from luminal gastrointestinal organs. Breast cancer
metastases appear more sensitive than CRC metastases.
The consensus statement described uncommon toxicity in
the liver, with increased risk in patients re-irradiated and/or
with prior liver disease. Luminal gastrointestinal toxicity
and chest wall and rib fractures have also occasionally been
seen. Of note, the consensus statement briefly reviewed
non-SBRT methods of delivering high-dose radiation therapy
to liver metastases, including conformal radiation therapy,
selective internal radiation therapy (e.g. hepatic arterial deliv-
ery of yttrium) and interstitial or intraluminal brachytherapy.
In addition, patients with diffuse symptomatic liver metasta-
ses were highlighted as a population largely understudied, in
whom low-dose palliative whole-liver radiation therapy may
be of benefit. In a pilot study of 20 patients with symptoms
from diffuse liver metastases at the Princess Margaret Cancer
Centre, approximately 50% of the patients had a patient-re-
ported benefit in pain or discomfort at 1 month following
8 Gy in one fraction. Based on this, a phase III study of simple
palliative radiation therapy compared to best supportive care
is planned (HE.1, through the National Cancer Institute of
Canada Clinical Trials Group).
4. Conclusions
SBRT is a promising treatment for patients with focal ‘oligo’
liver metastases. The most suitable patients with liver metas-
tases are those with three or fewer metastatic tumours, each
<6 cm, with no extrahepatic disease and with metastases at
least 2 cm from the luminal gastrointestinal tissues. More re-
search is required regarding optimal dose-per-fraction and
mechanisms, as well as the most appropriate patient
selection.
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Together we are better: Establishing a community
oncology nursing programme to improve cancer
care through shared working
Janice P. Richmond *,1
Letterkenny General Hospital, Co. Donegal, Ireland
1. Background and introduction
One in three people in Ireland will develop cancer during their
lifetime, and over 29,000 new cases of cancer are diagnosed
each year [1]. Due to an aging population and improved
screening/detection of cancer, the incidence is expected to
rise exponentially to over 40,000 per year by 2020 [1] with an
estimated 100% increase in cancer incidence over the next
20 years [2].
Many, if not all, of these people will require nursing care
during their cancer experience. Currently, 42% of the men
and 50% of the women diagnosed with cancer survive for
5 years and longer [1,2] and require ongoing follow-up, sup-
port and/or treatment(s). The increasing number of individu-
als with cancer receiving potentially life-threatening
treatments which have significant side-effects causes a con-
siderable challenge for acute hospital services.
2. Community care
Most individuals receiving treatment for cancer attend a
treating cancer unit for therapies and are then discharged
home; thus most side-effects are experienced within the
community setting. This model of cancer care has the aim
of retaining the patient in their own environment, yet oncol-
ogy health professionals are cognisant of the requirement to
provide continuous, safe and efficient cancer care.
3. Development of a training programme
The National Cancer Strategy (2006) for Ireland recognised the
need for improved integration between specialist and primary
health-care services. Since 2007, specialist oncology person-
nel in a district general hospital in a rural county in Ireland
(County Donegal) have collaborated with community nursing
colleagues to provide specific procedures in the community to
patients undergoing systemic therapy.
Following discussions between the national department
for cancer care in Ireland (National Cancer Control Pro-
gramme), the local oncology hospital and community nursing
staff, it was agreed that this initiative could be formalised and
developed to provide a more holistic shared care approach.
This programme could then be accredited by educational
authorities to make it available nationally.
4. Delivery of the community training
programme
In 2010, the National Cancer Control Programme developed
the Community Oncology Nursing Programme. Its aim was
to build capacity, confidence and competence in community
professionals to provide integrated seamless care throughout
the patient journey. The course was delivered over a 6-month
period and involved local staff delivering appropriate educa-
tion on cancer care relevant to community nurses. The
training was theoretical and skill-based and was approved
by the Irish Nursing Board (An Bord Altranais).
National and local governance structures and processes
were established through a local implementation group.
Ethical approval was sought and obtained through the lo-
cal hospital ethics committee. Project design, implementa-
tion, data collection, analysis and evaluation involved
collaboration with relevant nursing, medical and manage-
ment representatives from community, hospital and nurse
education.
A key safety feature built into the programme included
assessment of community nurses’ knowledge, skills and com-
petence upon completion of training. A designated referral
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form and a Community Oncology Nursing Resource Book [3]
were developed to support the Community nurses’ extended
roles.
A full evaluation of this educational initiative was per-
formed by the National Cancer Control Programme and is cur-
rently in press [4]. The evaluation involved patient interviews,
focus groups with community and hospital staff and analysis
of longitudinal data obtained from patient interventions in
both hospital and community.
5. Evaluation of patient outcomes
This programme reduced the patient’s burden of travel and
the additional pressures on their family of having to make re-
peated journeys to the hospital. For the majority of patients in
the study, the return hospital trip was 1½–2 h. Patients appre-
ciated not having to travel for all of their care, particularly at
times when they were weak and unwell. Patients valued hav-
ing aspects of their care delivered at home, and they reported
that it improved their quality of life. Most importantly the pa-
tients expressed confidence in the community nursing ser-
vice and no adverse patient events occurred throughout the
evaluation period.
6. Evaluation of nursing outcomes
A benefit for nursing included an increased scope of practice
for the community nurses involved, but the additional work-
load, particularly within an already stretched service, was
identified as a challenge. By its nature, the timelines and
immediacy of some cancer interventions resulted in resched-
uling of other non-cancer patient visits and clinics. There was
a dramatic decrease in hospital attendances for defined clin-
ical procedures that were then performed in the community.
Consequently hospital capacity was improved and no adverse
patient events occurred.
7. Future plans
The collaborative approach offered by local hospital oncology
specialists, community nurses and educational leaders
helped to develop the required skills and attitudes to provide
innovative and safe patient care. University accreditation is
currently being sought for this educational programme, and
once this is obtained it will then be expanded nationally. In
addition, the service is a good example of patient-centred
integrated care and could be further developed as a model
for other chronic diseases.
To ensure continued safety, auditable systems and forma-
lised policies/standard operational procedures are vital for
shared care between the hospital and the community. It is
hoped that these will be developed in the future.
The evaluation highlighted that for community nurses
there is great variability in the interventions performed since
they have been trained. Consequently ongoing training con-
tinues to be made available locally (up to four times a year)
in a theoretical and skills-based workshop format to ensure
maintenance of competence.
8. Conclusion
This programme has been successful in terms of quality of
life for patients. By taking an integrated approach to patient
care and delivering appropriate care in the community, the
potential exists to meet the growing demands of oncology
care. The community nursing service has adapted and ex-
panded to embrace this new initiative, has increased its scope
of practice and has increased its partnership with hospital
staff in the care of individuals with a cancer diagnosis.
This programme demonstrates that safe, seamless and
efficient nursing care can be delivered so long as there is prior
and extensive planning, detailed collaboration and efficient
leadership. Shifting oncology care to the community can have
a positive impact on the patient’s quality of life and can im-
prove hospital capacity through shared working.
In line with the national cancer nursing strategy [5], this
programme will be offered again and extended nationally
once third-level educational accreditation is obtained. It will
require ongoing evaluation and local planning and develop-
ment with clinical leaders who are cognisant of appropriate
utilisation of resources. The potential for improvement for
cancer care in Ireland through shared working between hos-
pital and community staff will continue to be promoted and
maximised in the future.
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